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Part 1 
Myocardial metabolic changes during acute ischemia in man. 
Relation to coronary flow and potential for evaluating pharmacological 
interventions. 
A. Introduction and rationale for the studies. 
INTRODUCTION. 
For many decades, myocardial ischemia has been 
at the root of cardiovascular medicine. Prevention 
as well as treatment of this syndrome has been two 
of its major tasks and, consequently, certain 
improvements have been achieved in this area. 
Through a substantial reduction in primary risk 
factors, the incidence of coronary artery disease 
has declined. Also, preliminary reports indicate, 
that regression of coronary atherosclerosis, 
through pharmacological or dietary interventions, 
may actually become possible. 
Furthermore, rapid technical developments in the 
area of mechanical, catheter-based interventions, 
aimed at improving coronary artery patency, have 
certainly added to the therapeutic achievements 
already afforded by cardiovascular surgery. 
Both in this respect and on the prevention side, our 
recent, rapidly growing understanding of the 
important role of the vascular endothelium in the 
regulation of vasotone, in vascular growth and 
atherosclerosis, and in their interrelationship, will 
have a major impact on future management and 
prevention of ischemic heart disease. 
At present, however, the incidence of ischemic 
heart disease still ranks high, despite a decline in 
coronary artery disease. 
In the majority of patients, particularly those with 
so-called stable angina and ischemia, the 
therapeutic approach will be conservative for a 
number of reasons; the cost-effectiveness of non-
pharmacological approaches being of major 
importance. 
It is interesting to note, that despite its long 
standing history, the pharmacological "treatment" 
of ischemic heart disease is still very limited. 
Platelet-active agents aside, only three groups of 
drugs are officially recognized in this respect. 
Compounds, which are certainly not uniformly 
effective and often give rise to significant side 
effects. As such, there is a constant need for new 
cardiovascular drugs and, in particular, for 
alternative forms of pharmacological therapy. 
Consequently, sensitive and precise methods to 
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analyse the mode of action and efficacy of these 
agents in man are greatly needed also. As the vast 
majority of anti-ischemic drugs act through their 
hemodynamic properties, invasive methods 
generally afford these to be better appreciated, in 
particular when fast sequential changes in and 
interaction of a multitude of cardiovascular 
parameters have to be studied. 
Likewise, invasive screening allows for more 
precise as well as fast sequential monitoring of 
those markers of ischemia, which are otherwise 
inaccessible, e.g. specific myocardial metabolic 
indicators, such as lactate and the nucleosides. 
This thesis reflects our efforts in this field. 
In sequential order, animal and human studies on 
the usefulness of nucleosides as markers of 
ischemia are discussed, followed by reports on the 
sensitivity of myocardial lactate metabolism in this 
respect in man and the reproducibility of lactate 
changes during short, repetitive periods of 
ischemia. Next, the relation of regional coronary 
bloodflow changes with these metabolic alterations 
will be considered. In subsequent chapters, the 
acute antiischemic properties of different vaso-
active compounds are assessed through their effect 
on metabolism, both in patients with ischemic 
heart disease with and without left ventricular 
dysfunction. 
Finally, a new area will be highlighted, that of the 
changes in systemic and transcardiac neuro-
hormones during myocardial ischemia and the 
potential usefulness of specific therapy, e.g. 
converting enzyme inhibition, as anti- ischemic 
treatment, again demonstrated through their effect 
on cardiac metabolism. 
To facilitate understanding the importance of these 
investigations, these specific chapters will be 
preceded by introductory notes on the normal 
regulation of cardiac metabolism, coronary flow 
and neurohormones, on the changes herein during 
ischemia and on those methodologies, which apply 
metabolic markers to detect myocardial ischemia. 
Chapter I 
CARDIAC METABOLISM. 
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I.l.Regulation of nonnal cardiac metabolism. 
Oxydative phosphorylation. 
Owing to the ever continuing sequence of 
contraction and relaxation, cardiac muscle, in 
contrast to other types of muscle, is not allowed an 
oxygen debt. The heart is in constant need of 
energy, locally generated and stored as adenine tri-
phosphate (ATP) and, to a lesser extent, as 
creatinine phosphate (CrP). Under normal 
conditions, these high-energy phosphates are 
formed exclusively by oxydative phosphorylation, 
only 1% being generated through anaerobic 
pathways. In contrast, during extreme workloads, 
~Glycogen 
anaerobically-derived ATP-production may 
increase up to 7%(1). 
Which substrates the heart prefers for its energy 
production depends on a number of variables, such 
as plasma substrate concentration, (neuro)humoral 
activity, e.g. insulin, glucagon and catechol-
amines, and the instantaneous metabolic rate of the 
heart. Besides extracellular substrates, e.g. free 
fatty acids (FFA), glucose, lactate and ketone 
bodies, there are endogenous cardiac stores of fuel, 
such as triglycerids and glucagon. 
FFA 
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Fig. I: Myocardial substrate metabolism under normal, aerobic conditions. In declining order of 
prevalence FFA, glucose and lactate are taken up by the cell and metabolized, eventually to form 
acetyl-GoA, which enters the Krebs cycle. During the latter process I mol ATP is generated directly 
(substrate phosphorylation). However, more important is the formation of the reduced co-enzymes 
NADH and FADH2, which subsequently are oxydized in the respiratory chain, eventually to form 33 
mol of ATP. FFA enters the cell by diffusion or carrier-bound, where the majority is stored as glycerol. 
Only a small portion is metabolized in the fi-oxydation pathway after binding to acetyl-GoA and 
entering the mitochondria via the carnitine shuttle system. During fi-oxydation acetyl-CoA fragments 
are formed as well as the reduced co-enzymes NADH and FADH2, which are then oxydized in the 
respiratory chain. (From reference II with permission). 
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FFA metabolism. 
In the resting, fasting state, FFA will be 
predominantly utilized for oxydative metabolism 
(2), providing up to 60-70% of substrate (2-6), 
although this may depend on concomitant plasma 
lactate levels (7,8). FFA uptake by the cell depends 
on instantaneous blood levels, on the ratio of total 
FF A to high-binding sites on albumen and on 
chain length and degree of saturation. During first 
passage through the heart, approximately 40-50% 
of labelled FFA are extracted C4), membranal 
transport being both carrier-bound and through 
diffusion (9). Once intracellular, FFA are mainly 
esterified to lipids and stored as glycerol. To a 
lesser extent, they partake in membrane function 
after transformation to phopholipids (10). A small, 
but rapidly replenished soluble portion of the FFA 
is activated by acyl-CoA synthetase and, sub-
sequently, translocated by carnitine-dependent 
transferases to the mitochondrial matrix space, 
where they are oxydized. During B-oxydation, 
acyl-CoA is stepwise degraded to form acetyl-
CoA fragments, which, subsequently, enter the 
citric acid or Krebs cycle (Fig. 1). 
ATP ADP 0 ~ ------...... 
Glucose Glucose. --=-•--Glucose- 6 - P ~ Glycogen 0 (insulin 1 1]\ • f6\ 
cotecholamines \V t V 
p02) Fructose- 6 - P 
0) CATP ADP 
Fructose- 1,6- DIP 
Dihydroxyacetone- P __ j G lycera Ide hyde - 3 - P 
0 ~c:::H 
1,3 DiP-Giycerate c2 ADP ~ 2 ATP 
NAD."----••"NADH f 
Lactate 0::""'1--~-Lactate; _,__ __ 0=:4::=~----- Pyruvate 
Fig. 2: Glucose and lactate metabolism under normal aerobic conditions. Glucose uptake by the cell is 
carrier-bound and dependent on insulin and adrenalin stimulation. Once inside it is phosphorylated by 
hexokinase (I) to glucose-6-P. It then enters the glycolytic pathway or is transformed to glycogen by 
the enzyme glycogensynthetase (5). The glycolytic flux is mainly governed by the enzymes 
phosphofructokinase (2) and glyceraldehyde-3-P-dehydrogenase (4). fVhen there is sufficient 0 2 
supply glycolysis is regulated mainly by the instantaneous ATP content at the phosphofructokinase 
level. Although ATP is utilized at 2 steps a net gain of 2 mol ATP per mol of glucose is achieved at the 
end of glycolysis. Pyruvate, formed both by the glycolytic pathway as well as from lactate is thereupon 
converted to acetyl-CoA and enters the Krebs cycle. (From reference I I with permission). 
-17-
Glucose metabolism. 
Under normal workloads and in combination with 
other substrates, the rate of glucose utilization is 
generally low (10-30%). In the presence of insulin 
the rate-limiting step for glycolysis in aerobic 
tissue is formed by the enzyme phosphofructo-
kinase, the activity of which, under normal condi-
tions, is limited by the tissue levels of high energy 
phosphates and citrate C12,13). In the absence of 
insulin, glucose transport into the cell becomes 
rate-limiting C14). When, however, glucose is the 
only fuel available, glycolytically -derived acetyl-
CoA may increase with 70% during extreme work-
loads C1). 
Sarcolemmal transport of glucose is carrier-
bound, its activity stimulated by insulin, epine-
phrine and intracellular hypoxia. Next, it is trans-
formed to glucose-6-phosphate by the enzyme 
hexokinase. From here, it may enter the glycolytic 
pathway to pyruvate, subsequently entering the 
citric acid cycle via acetyl-CoA, or it may be 
converted to glucagon and stored (Fig. 2). 
Of importance, during its passage through the 
glycolytic pathway, a net yield of 2 mol ATP per 
mol glucose is gained anaerobically. 
Lactate metabolism. 
Under normal, non-ischemic conditions, lactate is 
always extracted by the heart (15) although, as a 
result of relatively low arterial levels (in man 
varying between 0.39 and 1.0 mmol/1 in the 
supine, fasting state, personal communication), 
this does not provide sufficient energy for 
myocardial muscle function C8). Hence, it only 
functions as an additional substrate for oxydative 
metabolism. The latter is achieved after transfor-
mation to pyruvate and to acetyl-CoA and subse-
quent processing in the K..rebs cycle. The net 
extraction pattern of lactate varies between 0% and 
46% (chapter V), depending on the arterial lactate 
level, substrate competition and catecholamine 
stimulation. It therefore follows, that when the 
heart produces lactate, there is bound to be some 
form of abnormality, the most common by far 
being myocardial oxygen deprivation (15). 
Substrate and O:l..')'dative phosphorylation and 
energy production. 
Although some A TP is produced during anaerobic 
glycolysis, this is largely insufficient for normal 
cardiac mechanical function. Of the total yield of 
36 mol A TP per mol glucose, virtually all is 
generated aerobically by respiratory chain -linked 
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oxydative phosphorylation. 
Aerobic metabolism is dominated by the citric acid 
cycle, the primary function of which is to oxydize 
acetyl groups that enter the cycle in the form of 
acetyl-CoA molecules. Mter condensation of 
acetyl-CoA with oxaloacetate to citrate, the energy 
made available when the c-H and c-c bonds in 
citrate are oxydized, is captured in different ways 
during passage in the citric acid cycle. At the 
succinyl-CoA level, a high-energy phosphate link 
is created by a mechanism, which resembles that 
which operates during glycolysis, yielding 1 mol 
ATP (Fig. 3) (1 6). 
The remaining energy from oxydation is channel-
led into the conversion of the co-enzymes NAD+ 
and FAD to their reduced forms NADH and 
FADH2• Under aerobic conditions, NADH and 
FADH2 are subsequently oxydized during respira-
tory chain-phosphorylation, in which process the 
high-energy electrons, initially carried by these 
co-enzymes, are finally transferred under the 
influence of mitochondrial membrane-bound 
enzymes (cytochromes and co-enzyme Q) to 
oxygen. The energy, released during this process, 
is used to pump protons across the inner membrane 
of the mitochondrial matrix into the intermem-
branal space. This creates an electrochemical 
proton gradient across the mitochondrial inner 
membrane. The backflow of H+ down this 
gradient in tum activates another membrane-
bound enzyme, ATP synthetase, which catalyzes 
the conversion of ADP + inorganic phosphate to 
A TP, thus completing the process of oxydative 
phosphorylation. 
The energy, thus produced, may be stored as ATP 
or CrP or used for a large variety of chemical 
processes including enzyme regulation, membrane 
function, contractility and relaxation. To this 
purpose, ATP has to be transported from the 
mitochondrion to the cytoplasm, a process which 
is carried out by the adenine nucleotide system. 
The role of L-camitine in aerobic metabolism. 
Adenine nucleotide translocase is an exchange-
diffusion transport protein, localized at the inner 
mitochondrial membrane, which catalyzes the 
exchange of ATP versus ADP on a mol per mol 
basis. Hence, it constitutes a key factor in linking 
mitochondrial energy production and cellular 
energy need. The activity of this transport system 
is regulated by the ratio long-chain acyl-CoA 
versus carnitine, indicative of the significance of 
myocardial cellular carnitine levels (17). 
0 
Acetyl-GoA 
+ 
Oxaloacetate 
Fig. 3: Pathways of acetyl-
CoA oxydation. 
r~NADH ~ CoA-SH /"( - ,, Citrate 
a. Tricarboxylic acid cycle or 
Krebs cycle. Citrate is formed 
after condensation of acetyl-
CoA with oxaloacetate and 
eventually transformed in the 
Krebs cycle to oxaloacetate, 
during a process of oxydation 
and decarboxylation, where a 
number of reduced co-enzymes 
are formed. 
Malate NAD 
Fumarate 
\c::::· "j"ls \ocitrate 
\: NADH -A \... C02 
Succinate 
b. Substrate level phosphory-
lation. Each mol of enzyme-
bound CoA released from 
succinyl-CoA provides for the 
generation of a single' mol of 
ATP. (From reference 16, with 
permission). 
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Moreover, L-carnitine is critically involved in the 
translocation of long-chain fatty acids from the 
extramitochondrial space to the mitochondrial 
matrix through the activity of carnitine acyltrans-
ferases. As these enzyme systems are both under 
hormonal and nutritional control, this carnitine-
dependent process allows for a controlled access of 
long-chain fatty acids to their oxydation site, at the 
same time modulating the ratio of acyl-CoA and 
freeCoA. 
In view of the important regulatory role of 
L-carnitine in oxydative metabolism it is of 
interest that two of the major organs in need of 
L-carnitine, i.e. skeletal and cardiac muscle, are 
unable to synthesize this molecule, despite a high 
abundance of its primary precursor, E-N -trime-
thyllysine, the reason being, that they lack the final 
enzyme in this process, deoxycarnitine hydroxyl-
ase. As a result, the direct precursor of carnitine, 
deoxycarnitine, has to be converted into carnitine 
in other organs, such as liver or kidney, and then 
transported back to the heart and skeletal muscles. 
Here, carnitine and deoxycarnitine are exchanged 
in a specific bidirectional exchange-diffusion 
pathway, which is only partially energy-related 
and depends on a membrane bound carrier system, 
which, like other transmembranal transport pro-
teins, is sensitive to thiol reagents. 
Besides raising several interesting questions which 
relate to genetic information and (changes in) gene 
expression of the various components of carnitine 
formation in the heart, this peculiarity of nature 
with respect to carnitine and the heart, also under-
lines the delicate position of this key control factor 
in aerobic metabolism and the critical dependency 
of normal carnitine supply to the heart. 
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Amino acids, citrate and the malate-aspartate 
cycle. 
Another component of the metabolic complex in 
the heart, which deserves some consideration in 
view of its potential significance in myocardial 
ischemia, is the malate-aspartate cycle. Amino 
acids have been proposed as an additional source of 
fuel both during aerobic (18) and anaerobic 
conditions C19,20). However, energy production 
derived from amino acid fermentation is minimal 
compared with that of glycolysis C21). A more 
important function of several amino acids, such as 
aspartate and glutamate, is to enable the uphill 
transfer of reducing equivalents by the malate-
aspartate cfcle against an NADH-NAD+ potential 
gradient (2 ) (Fig. 4). 
In addition, the malate-aspartate cycle is required 
to coordinate mitochondrial and cytosolic 
metabolism in the heart (23). Direct feedback and 
inhibition of glycolysis by citrate has, amongst 
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others, generally been accepted as a · primary 
mechanism for its control. However, as mito-
chondrial citrate is virtually unable to cross the 
mitochondrial membrane, the latter can only be 
accomplished through indirect means by way of 
the malate-aspartate cycle, which links the activity 
of the mitochondrial citric acid cycle with com-
parable isoenzymes in the cytosol. Thus, the gly-
colytic flux is made responsive to the redox state of 
pyridine nucleotides, to phosphorylation of 
adenine nucleotides and, in general, to the energy 
state of the heart. 
The malate-aspartate cycle is dependent on the 
presence of glutamate, actively taken up by the 
heart. Changes in this uptake mechanism, together 
with alterations in alanine release, may reflect a 
malfunctioning of the cycle, such as occurs in 
ischemia, and may be used to indicate the severity 
of the latter. 
Fig. 4: Schematic display of the malate-aspartate 
cycle and uphill transfer of reducing equivalents 
against and NADHINAD+ potential gradient over 
the mitochondrial membrane. After reduction of 
oxaloacetate (OAA) to malate (MAL), malate is 
transferred into the mitochondrion, where NADH 
and oxaloacetate are regenerated. Transfer of the 
latter to the cytosol is accomplished by trans-
amination with glutamate (GLU), whereby a-
ketoglutarate (a- KG) and aspartate (ASP) are 
formed, which are transported to the cytosol. 
Here oxaloacetate and glutamate are regenerated 
by reverse transamination. 
LAC=lactate, PYR=pyruvate and TRIOSE-P=gly-
ceraldehyde-3-P and a-glycerophosphate. 
(From reference 23, with permission). 
1.2. Myocardial metabolism during ischemia. 
FFA metabolism. 
With the occurrence of myocardial ischemia and 
the consequent unavailability of oxygen, aerobic 
metabolism and oxydative phosphorylation will 
quickly slow down and may even come to a com-
plete stop, depending on the severity of ischemia. 
Secondary to diminished electron transport, as the 
ultimate acceptor oxygen is not available, and as a 
result of the subsequent rise in mitochondrial 
NADH/NAD+ and FADH2/FAD ratios, inhib-
ition B-oxydation, the most rate-limiting step of 
aerobic metabolism in ischemia, quickly 
follows (24). This is accompanied by impaired 
utilization of fatty acids in the citric acid cycle. 
Also, during ischemia, membrane phospholipids 
are broken down with subsequent accumulation of 
non-esterified fatty acids and lysophospho-
lipids (25-27). Consequently, intracellular fatty acid 
amphiphiles of long-chain acyl-CoA and acyl-
carnitine rapidly increase. These fatty acid 
intermediates may affect the stmctural conform-
ation and function of ionic channels, rroteins and 
lipid bilayers in cellular membranes (2 ,29). More-
over, they may inhibit important enzyme systems, 
such as adenylate cyclase (30), Na+fK+-ATP-
ase (30,31) ca2+-ATP-ase C32) and adenine nucleo-
tide transl~case (33,34). As such, FFA accumulation 
may add to the derangement in myocardial con-
tractile function, observed in ischemia. 
Incorporation of lipid intermediate amphiphiles in 
the membrane, either resulting in an insertion or 
exchange with the lipid bilayer or in a depletion 
through a detergent-like action, may alter the sur-
face charge or permeability of the membrane with 
subsequent changes in ionic movements and cell 
swelling C35,36). It has also been suggested that 
increased mitochondrial levels of long-chain fatty 
acids are directly involved in the uncoupling of 
electron transport (37). Recent studies indicate the 
presence of a fatty acid binding protein (FABP) in 
the heart, that binds with high affinity to intracel-
lular fatty acids and their thio-esters (38-40). It has 
been suggested, that FABP's, which constitute 4-
8% of the soluble proteins in the heart, may 
temporarily sequestrate FFA, thereby modulating 
their detrimental effects( 41-42). Alternative! y, 
FABP may help !transfer the poorly soluble fatty 
acids and fatty acyl-CoA from their site of entry 
into the cell to the site of oxydation or 
esterification (43). Interestingly, these FABP's are 
lost from the heart during ischemia (44). Also, a 
recent study has suggested that supplementation of 
these- ·proteins may protect against myocardial 
ischemia, and may result in a significant preserv-
ation of high-energy phosphates and/or membrane 
phospholipids during ischemia and 
reperfusion (45). 
FFA and carnitine in ischemia. 
The long-chain acyl-CoA/free carnitine ratio 
increases rapidly during ischemia (46). Also, 
during ischemia, the ratio of long-chain acyl-
CoA/CoA rises significantly with accumulation of 
long-chain CoA. This ratio modulates the activity 
of the enzyme pymvate dehydrogenase, essential 
for the entry of pymvate into the citric acid cycle. 
An increase in the ratio acyl-CoA/CoA inhibits 
enzyme activity. Through acyl removal from CoA 
as a consequence of the action of carnitine and 
carnitine-CoA acyltransferase, carnitine directly 
improves the flux of pymvate in the Krebs cycle. 
Also, elevated levels of long-chain acyl-CoA 
inhibit adenine nucleotide translocase activi~, 
whereas carnitine reverses this inhibition C17, 4 ) . 
This again suggests that the level of myocardial 
free carnitine is important during ischemia. More-
over, free carnitine is instmmental in the removal 
of long-chain acylcarnitines through an acylcam-
itine-carnitine exchange process, equivalent to that 
between deoxycarnitine and carnitine (48). 
Thus, the level of free carnitine in the heart is 
essential in reducing long-chain acylcarnitine and 
acyl-CoA levels during ischemia, removing their 
inhibitory effect on adenine translocase activity 
and, by diminishing the acyl-CoA/CoA ratio, 
modulating the inhibitory effect of the latter on 
pymvate dehydrogenase during ischemia. 
Our recent observation of significant free carnitine 
loss from the acutely ischemic myocardium in man 
(49) may be important therefore, and may indicate a 
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role for carnitine and its derivatives as an alter-
native way of limiting ischemia-induced myo-
cardial functional changes. 
Myocardial ischemia and anaerobic glycolysis. 
When oxydative phosphorylation is reduced during 
myocardial ischemia, glycolytic flux will be acti-
vated through increased activity of the enzymes 
phosphofructokinase and glyceraldehyde-3-P-de-
hydrogenase, secondary to accumulation of A TP 
metabolites and reduced feedback by citrate and 
ATP C23,50) (Fig. 5). 
Also, cellular uptake of glucose increases as well 
as the formation of glucose-6-phosphate by hexo-
kinase. However, this supply of substrate is 
critically dependent on the level of ischemia and 
the possibility of blood to reach the ischemic area. 
Glucose 
0 
Glucose.---- Glucose- 6- P 
(insulin 
catecholamines 
I 
' 
Hexokinase 
((±)Pi) 
An additional substrate for glycolysis is derived 
from glycogenolysis. However, the latter reserves 
are limited and will be exhausted within minutes 
during severe anoxia (51). Also, it has been 
suggested that glycolytic flux, derived from glyco-
genolysis, is less beneficial than that derived from 
exogenous glucose during ischemia, in spite of 
similar rates of glycolytic ATP production (52). 
Maintenance of cardiac contractile function and 
prevention of ischemic changes in diastolic tension 
may depend more on the source of A TP, e.g. 
glycolysis via glucose uptake, than on the concen-
tration of A TP (53-55), at least during prolonged 
periods of ischemia. In contrast, in early ischemia, 
such as would be encountered in stress- or pacing-
induced ischemia, the relative contribution of 
glucose flux in glycolytic ATP production and 
protection of function depends on available high-
energy phosphates from other sources (52). 
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Fig. 5: Stimulation of anaerobic glycolysis during myocardial ischemia and subsequent inhibition of 
oxydative phosphorylation due to enhanced activity of phosphofructokinase and glyceraldehyde-3-P-
dehydrogenase in combination with increased cellular uptake of glucose. As a result, lactate is 
produced by the cardiocyte, instead of the usual extraction. (From reference 11 with permission). 
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Lactate. 
As lack of oxygen will prevent normal functioning 
of the citric acid cycle, pyruvate is not further 
processed in the latter but, instead, will be trans-
formed to lactate. 
Thus, myocardial lactate production, rather than 
the normal extraction pattern, is found in an early 
stage during the ischemic process. The potential of 
this metabolic marker to indicate the presence of 
ischemia has been widely recognized (14,56,57), 
despite evidence, that lactate does not equilibrate 
freely over the cell membrane C58•59) and despite 
the fact that significant tissue-coronary venous 
lactate gradients are found in ischemia (57,60). 
Although, theoretically, any kind of malfunc-
tioning of aerobic metabolism will increase glyco-
lysis, the specificity of myocardial lactate produc-
tion to indicate ischemia in patients with coronary 
artery disease, is widely accepted. 
Still, the concept may not be as simple as it looks 
at first sight. Cultured adult ventricular myocytes 
release lactate, despite optimal oxygenation (61). 
Also, in non-ischemic canine and porcine models, 
lactate release from the heart has been clearly 
shown with isotope techniques in situations, 
where, using conventional methods, net chemical 
lactate extraction is found (62,63). This observation 
is difficult to explain. Preferential usage of glyco-
lytically derived ATP for sarcoplasmatic function 
and myocardial relaxation has been suggested. 
Also, some evidence indicates, that the subendo-
cardial layers may be hypoperfused in the working 
heart during peak systolic pressures and, hence, 
may rely on anaerobic glycolysis to a greater 
extent than the subepicardial regions (64,65). 
Besides some recent dispute on the specificity of 
myocardial lactate as a marker of ischemia, its 
sensitivity compared with other clinical markers, 
such as electrocardiographic or hemodynamic 
parameters, and with angina has also been debated 
(chapter V of this thesis). Part of this thesis relates 
to methods to improve the sensitivity of myocar-
dial lactate production as indicator of ischemia in 
man (chapter V). 
Inhibition of glycolysis does affect its usefulness 
as marker of ischemia. 
Whereas, as will be demonstrated in chapter V, 
myocardial lactate is a sensitive marker during 
short periods of ischemia, its effectiveness in this 
respect becomes progressively less during 
prolonged periods of ischemia. Due to inhibition 
of glycolysis, particularly at the glyceraldehyde-
3-P-dehydrogenase level (66,67), myocardial lac-
tate production eventually diminishes when the 
ischemic period is sustained. The latter is pre-
dominantly caused by proton and lactate accumul-
ation (6S) due to reduced venous efflux from the 
ischemic area. This results in pH changes and in a 
rise in the NADH/NAD+ and FADH2/FAD 
ratios. Glycolysis is predominantly regulated by 
phosphofructokinase activity during early 
ischemia (69,70), whereas inhibition of glycolysis 
during prolonged periods of ischemia occurs at the 
level of glyceraldehyde-3-P-dehydrogenase (67). 
Both enzymes are sensitive to pH changes and are 
inhibited by high-energy phosphates. Thus, 
glycolysis is dependent on the ratio of ATP versus 
ADP and AMP C68). Consequently, the reduction 
in glycolytic flux leads to a decrease in anaerobic 
ATP production. Moreover, lactate production 
diminishes. Sustained inhibition of glycolysis after 
an ischemic event may explain why myocardial 
lactate production values are not reproducible 
when only short intervals are allowed between 
repeated periods of ischemia (chapter VI). 
Adenine nucleotide breakdown and myocardial 
ischemia. 
In the absence of oxydative phosphorylation, 
synthesis of ATP from ADP cannot take place. As 
a result, ATP (and CrP) levels fall and ADP, AMP 
and inorganic phosphate (Pi) rapidly accumulate. 
The degree to which intracellular high-energy 
phosphate levels change, clearly depends on the 
severity of ischemia. 
After complete coronary occlusion, CrP levels 
decrease by 75% during the first minute, accom-
panied by an equivalent rise in lactate levels (7l). In 
contrast, ATP content changes relatively little 
during the first 3 minutes following occlusion 
(Fig. 6). 
During the subsequent 30 minutes, ATP falls 
progressively to approximately 50% of baseline 
values during severe (10% of control) coronary 
flow limitation and to 66% during moderate (20-
70% of control) flow reduction C72). When flow 
reduction is continued over 5 hours, a further de-
crease in ATP content to 6% of control in severe 
and to 52% in moderate ischemia follows. Also, 
repetitive short (3 minute) occlusions over 3 hours 
induce a 50% drop in ATP content of the ischemic 
tissue, but only during the first 20 episodes (73). 
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Fig. 6: Immediate changes of intracellular high 
energy phosphate and lactate content after 
complete coronary occlusion in dogs. During the 
first 15 sec there is little change. However, a 
marked increase in lactate and decrease in CrP 
occurs during the following 15 sec, indicating 
both the appearance of anaerobic glycolysis and 
the immediate effect of depression of aerobic 
metabolism on high energy phosphate metabo-
lism. Note that ATP content decreases relatively 
little during the first 3 min (from reference 71, 
with permission). 
Simultaneous with the decrease in A TP, an early 
rise in AMP levels is observed. As resynthesis to 
ADP is not possible in ischemia, AMP is either 
dephosphorylated to adenosine or deaminated to 
inosine monophosphate (IMP) (Fig. 7). 
As the latter reaction will be inhibited by the 
concomitant rise in P· levels, this results in an 
increase in adenosine Juring ischemia. Changes in 
the myocardial purine nucleoside content have 
long been known to occur in anoxia and 
ischemia (74,75) with elevations in adenosine levels 
of 5-6 fold after only 15 seconds of coronary 
occlusion C76). 
In well-oxygenated hearts, a substantial portion of 
adenosine is formed intracellularly by hydrolysis 
of S-adenosylhomocysteine C77) and reincorporated 
in the adenine nucleotide pool by adenosine kinase. 
Only a small portion is washed out by the coronary 
circulation. 
During ischemia, adenosine is predominantly 
formed by dephosphorylation. In contrast, in well 
oxygenated hearts a substantial portion is derived 
from the transmethylation pathway (77). Adenosine 
is the first ATP catabolite, able to pass the-intact 
cell membrane into the interstitial space. 
Subsequent breakdown to inosine is under the . 
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influence of adenosine deaminase, an enzyme 
predominantly located in endothelial cells of blood 
vessels in the heart and adjacent pericytes, but not 
in myocytes or fibroblasts (78). 
After cellular entry, adenosine, at low concen-
trations, is preferentially phosphorylated. At 
higher concentrations, above the phosphorylation 
potential of the endothelium, adenosine is broken 
down via inosine and hypoxanthine/xanthine to 
uric acid by the sequential actions of adenosine 
deaminase, nucleoside phosphorylase and xanthine 
oxydase (Fig. 7). Theoretically, hypoxanthine may 
be reincorporated into the myocytes in the form of 
inosine monophosphate through the action of 
hypoxanthine phosphoribosyltransferase. Thus, 
regeneration of adenine triphosphates is possible, 
but only with low efficacy (79,80)_ 
Adenosine modulates a variety of physiologic 
effects in different tissues. Through coupling to 
adenosine-1 receptors it induces negative chrono-
tropic, dromotropic and inotropic effects (81-84), 
whereas binding to adenosine-2 receptors results 
in its well-known vasodilator properties C85-87). 
In addition, adenosine induces anti -adrenergic 
effects on the His-Purkinje system (88), reduces 
impulse formation in the sinus node (89) and 
inhibits high -affinity beta -adrenergic agonist 
binding in myocardial membranes (83). Moreover, 
it modulates platelet aggregation and inhibits 
superoxyde anion generation by neutrophils, thus 
attenuating neutrophil-mediated endothelial 
injury (90). 
Fig. 7: Adenine nucleotide breakdown during 
myocardial ischemia. In the absence of oxydative 
phosphorylation resynthesis of ATP from ADP is 
inhibited which results in the accumulation of 
AMP and Pi. AMP can either be dephos-
phorylated to adenosine or deaminated to IMP. 
The latter reaction, however, will be inhibited by 
the accumulating Pb resulting in an increase of 
adenosine which is the first ATP catabolyte 
capable to pass the cell membrane into the 
interstitial space. It then may combine with 
specific adenosine receptors on the arterioles and 
induces vasodilatation. Adenosine is easily and 
quickly deaminated to inosine and is only found in 
very small amounts in the venous effluent. Its 
breakdown products inosine and especially 
hypoxanthine can be detected more easily and 
may be used as biochemical markers of 
myocardial ischemia. 
1. 5 '-nucleotidase 
2. adenosine deaminase 
3. nucleoside phosphorylase 
4. xanthine oxidase 
5. adenylic acid deaminase 
(From reference 11 with permission). 
Finally, exogenous adenosine, administered intra-
coronary in humans, may provoke angina -like 
pain, which diminishes after aminophyllin, 
suggesting that purinergic receptor stimulation by 
adenosine may be responsible, at least in part, for 
ischemia-induced anginal pain (91). 
Thus, adenosine may have a multiple role in cardi-
ovascular functions, apart from its central role as 
metabolic regulator of (coronary) flow. For 
instance, one may speculate on the effect of adeno-
sine during early ischemia on myocardial contrac-
tility. However, from a diagnostic point of view, 
its importance in ischemic heart disease relates 
predominantly to the fact, that, after sarcolemmal 
passage, it is easily and quickly deaminated to 
inosine. 
Although the half-life of adenosine varies in 
different species from 3 minutes in the dog to 10 
seconds in man (92), it is sufficiently short to 
prevent adequate detection of adenosine in the 
venous effluent during anoxia or ischemia (93,94), 
despite the accumulation of appreciable intracel-
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lular amounts (95). In contrast, its immediate 
breakdown, inosine and hypoxanthine, are 
detectable. 
Following preliminary data (96) in guinea pigs and 
in cats, which indicated that other nucleosides than 
adenosine could be useful as markers of ischemia, 
we embarked on a series of studies, investigating 
the sensitivity of these metabolites as indices of 
ischemia. A porcine model was used, as this better 
reflects the human situation than the commonly 
used canine, feline and rodent models of ischemia. 
In these studies, inosine and hypoxanthine were 
compared with other metabolic and with hemo-
dynamic parameters. Next, these investigations 
were extended to patients with coronary artery 
disease. The results of these studies are presented 
in chapter VI.2. Moreover, the temporal relation 
of changes in myocardial nucleoside (hypo-
xanthine) release with alterations in regional myo-
cardial perfusion, changes in different metabolites 
as well as electrocardiographic and hemodynamic 
markers of ischemia, are given in chapter VII. 
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Effect of myocardial ischemia on other 
metabolites. 
Inorganic phosphate. 
As a byproduct of adenine nucleotide breakdown 
during ischemia, inorganic phosphate accumu-
lation and subsequent release from the ischemic 
area has received appropriate attention. 
We and others have clearly shown that in the 
animal experiment, a significant rise in inorganic 
phosphate is found early after ischemia is 
induced (97-100), at least when determined from the 
direct effluent of the ischemic area. In fact, it has 
been suggested, that changes in inorganic phos-
phate are more pronounced than those of lactate 
and electrolytes, such as potassium (101). 
However, in man, ischemia-induced changes are 
small when measured in the coronary 
sinus (102,103), which suggests that this parameter 
is of limited importance in the clinical assessment 
of ischemia. Nevertheless, we have attempted to 
relate ischemia-induced alterations in inorganic 
phosphate with simultaneous changes in nucleo-
sides and lactate in patients with coronary artery 
disease, with and without angina, during pacing-
induced stress, results of which are presented in 
chapter IV.2. 
Blood pH, pC02 and p02. 
Myocardial ischemia results in a significant reduc-
tion in pH and in an increase in pC0.2, presumably 
secondary to enhanced hydrogen IOn formation 
during activated anaerobic glycolysis (57,104). 
Similar to the observations with inorganic phos-
phate, changes are readily detected in the local 
venous effluent. However, detection in coronary 
sinus blood depends on the severity of ischemia. 
In the studies by Opie et al., neither coronary sinus 
pH nor pC02 changed when ischemia was moder-
ate, in contrast to significant alterations during 
severe ischemia (57). 
For similar reasons we have never been able to 
detect any such changes with coronary sinus sam-
piing during short periods of ischemia in man (see 
chapter IV and personal communications). 
Potassium. 
Electrolyte changes during ischemia are likely to 
occur as a result of functional and conformational 
membranal alterations as a result of ischemia. 
Clearly the most important are alterations in 
potassium fluxes. Myocardial potassium loss 
during ischemia has been known for a long time 
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and attention has focussed primarily on its relation 
to ventricular arrhythmias in this setting (105-110). 
In animal experiments with direct access to the 
venous effluent from the ischemic area, an imme-
diate and sharp rise in potassium efflux is 
found (51,111), persisting throughout the ischemic 
period (111). Again, in humans, the situation is far 
less clear. 
Although early studies did claim excessive potas-
sium loss during pacing-induced ischemia, an 
equally significant, albeit smaller egress of potas-
sium from the heart has also been observed in 
patients who did not become ischemic during the 
test (1I2S. As the latter observation suggested, that 
potassium loss during pacing was not specific for 
ischemia but rather dependent on the increase in 
heart rate per se, we compared changes in this 
electrolyte to more specific metabolic parameters 
of ischemia, applying an identical form of stress 
testing. In these studies (see chapter IV.2.) signifi-
cant potassium loss from the heart in anginal 
patients was observed, however, at an early stage, 
before the development of angina. 
Ketone bodies. 
Ketone bodies, e.g. beta-hydroxybutyrate and 
acetoacetate, formed in the liver, have been propo-
sed as an alternative substrate for oxydative meta-
bolism. It is unlikely, however, that they are 
significant in this respect. Theoretically of more 
importance is the fact, that the ketone bodies may 
form a redox couple, which is in equilibrium with 
the mitochondrial NADH/NAD+ ratio. Acute 
ischemia may manifest itself by a rise in the ratio 
beta-hydroxy butyrate/acetoacetate in the coronary 
venous effluent and a diminished cardiac uptake of 
beta-hydroxybutyrate. Unfortunately, ketone body 
concentrations in the heart are very low and, 
although small changes in the latter ratio can be 
found during ischemia (57, 113), they are presum-
ably of limited value as metabolic marker of 
ischemia. 
Glucose. 
Glucose uptake by the hypoxic heart increases as 
oxydative phosphorylation slows down. Thus, the 
degree of extraction may serve to indicate presence 
and degree of myocardial ischemia. However, 
different stimuli, such as stress, work, neurohor-
mones and insulin, may similarly affect glucose 
uptake. Also, utilization of endogenous glucagon 
stores during the early phase of ischemia will 
affect glucose uptake. Finally, the rate of exog-
enous glucose is primarily determined by the 
amount of arterial blood eventually reaching the 
ischemic area. 
For these reasons, the identification of glucose 
metabolism in the heart has been of limited clinical 
value (see chapter IV), although the concept is still 
in use in non-invasive radionuclide techniques 
(chapter ill). 
Amino acids. 
The main amino acids, transported in and out of 
the heart, are alanine, aspartate, glutamic acid and 
glutamine. Of these, alanine and glutamine are 
released whereas glutamate and aspartate are taken 
up. Alanine formation in the heart results from 
transamination of pyruvate (114)_ As glutamate is 
the main amino acid for transamination in this 
process, a correlation between f:lutamate uptake 
and alanine release is present ( 15). Interference 
with the glycolytic pathway may reverse this 
uptake-release pattern (114)_ 
Alternatively, hypoxia and ischemia enhance 
alanine release from the heart and, concomitantly, 
glutamate uptake (114,116-118). Hence, these amino 
acid fluxes may theoretically be useful as indices 
of ischemia. 
The clinical significance of amino acid changes 
during ischemia are several. First, by shtmting 
pyruvate away from lactate production to alanine 
formation, intracellular acidosis is reduced. 
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ll.l. Regulation of coronary blood flow. 
Regulation of vascular control is one of the areas in 
medicine, which bas seen quite significant 
conceptual changes during the last decade. 
Besides their conduit function, blood vessels are 
now known to be active synthetic and secretory 
organs, encorporating a number of intracrine, 
autocrine and paracrine systems, involved in the 
autoregulation of vessel size and function. In this 
respect, quite a variety of vascular growth promo-
ting and inhibiting factors have been discovered, 
apart from novel vasoconstrictor and -dilator 
substances. 
Of particular interest, several of these factors share 
properties relating to growth and vasotone. Thus, 
endothelin, a strong vasoconstrictor (1), bas mito-
genic activities (2), whereas the vasoconstrictor 
peptide angiotensin II not only promotes (3,4), but 
also inhibits vascular smooth cell growth (S). Also, 
serotonin may stimulate smooth muscle cell mito-
genesis C6). In contrast, pure vasodilators, such as 
bradykinin and certain prostaglandins, have 
minimal mitogenic effects, although they stimulate 
protooncogene expression in fibroblasts to a 
similar degree as observed with typical growth 
factors, such as platelet-derived growth factors (7). 
Besides vessel growth regulation, of which our 
knowledge is still in its infancy, regulation of 
vascular tone has seen considerable conceptual 
changes during the past decade. 
Thus, the concept of endothelium-dependent 
vasodilatation, not appreciated until Furchgott and 
Zawadki's description of the obligatory role of 
intact endothelial cells in vasorelaxation induced 
by acetylcholine (S), has rapidly claimed its (im-
portant) place in the multitude of factors involved 
in the regulation of coronary flow. 
Has it changed our thinking of how coronary flow 
is regulated? To a certain extent the answer is 
affirmative. 
The concept of alterations in vasotone as a result of 
abnormal endothelial function in diseased coronary 
artery segments, has added to the picture of 
coronary vascular tone being regulated by 
metabolic, myogenic, autonomic and hemo-
dynamic factors, such as we had before endothelial 
regulation of flow became known. 
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Now, a more complex but certainly more exiting 
pattern emerges, where not only the original 
hypotheses are better understood but also the 
interaction between endothelium, vascular smooth 
muscle cell and extravascular factors, implicated in 
vascular control, is gradually recognized. 
The coronary artery system. 
The coronary arterial system can be subdivided in 
the large epicardial or conduit vessels, from which 
smaller arteries branch off to penetrate the 
myocardial wall at an approximate 90% angle and 
eventually form the arterioles and capillaries. 
Resistance to coronary flow is determined mainly 
by the arterioles (the resistance vessels) which, 
under maximal pharmacological vasodilatation, 
have the capacity to increase coronary blood flow 
by a factor 4 to 5. 
Normally, in the epicardial arteries, the conduit 
vessel resistance to flow is relatively low. In 
contrast, in the smaller intramyocardial vessels, an 
additional resistance to flow is created through the 
compressive forces of the tension developed in the 
ventricular wall. 
This will be particularly noticeable in the 
subendocardial region, where wall tension is 
highest (Fig. 1). As a result, subendocardial resist-
ance vessels are already dilated to some degree in 
the normal, non-ischemic situation. This merely 
ensures sufficient blood flow to the subendocardial 
cells, in which, due to the higher loading condi-
tions, myocardial oxygen consumption is always 
greater than in the subepicardial cells. 
Consequently, during progressive coronary artery 
narrowing and the subsequent increase in conduit 
vessel resistance, the potential to vasodilate will be 
more readily exhausted in the subendocardial than 
in the subepicardial area. 
Thus, when no other mechanisms interfere, 
myocardial ischemia, resulting from progressive 
epicardial coronary artery narrowing, will begin in 
the subendocardium, only to progress in an 
epicardial and lateral direction during more severe 
and more prolonged episodes of coronary flow 
reduction. 
Subepicardium Subepi cardium Subepicardium 
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Fig 1: Schematic representation of the various resistances in the coronary arterial bed and their effect 
on flow (F) in a normal coronary artery (fig. 1a) and in the situation of a moderate and severe stenosis 
(fig. 1b and fig. 1c, resp.). Due to higher wall tension and compressive forces (R3) in the subendo-
cardial region, vasodilatation with decreased arteriolar resistance (R2) is already present in the normal 
situation (fig. 1 a). During progressive coronary stenosis and hence increase in conductance vessel 
resistance (R1), a compensating vasodilatation and a decrease in arteriolar resistance is found, which 
in moderate lesions results in unchanged regional flow (fig. 1b). However, with a severe stenosis 
subendocardial arterioles eventually cannot further dilate and local coronary flow will diminish 
resulting in ischemia, even at rest (fig. 1 c). (From reference 9 with permission). 
Regulation of coronary flow. 
With equal myocardial performance, coronary 
blood flow will remain constant in spite of varying 
perfusion pressures. The continuous adjustment of 
coronary resistance and flow to meet the 
instantaneous oxygen need of the myocardium, 
exists strictly on the basis of local mechanisms, 
which are mainly metabolic. This process is 
known as autoregulation (10,11) and occurs on a 
beat to beat basis at the microvascular level (12). 
Besides metabolic control, myogenic regulation is 
also present. This old concept of vasoconstriction 
in response to increasing intraluminal pressures 
was recently investigated in subepicardial versus 
subendocardial arterioles of 80-100 micron (13). 
This in vitro study clearly confirmed, that 
coronary arterial myogenic activity indeed exists 
and is capable to contribute to autoregulation. 
Furthermore, this study showed that myogenic 
control is more prominent in subepicardial than in 
subendocardial arterioles at all levels of perfusion 
pressure. 
Under control conditions, 40-45% of coronary 
vascular resistance resides in small arterioles, 
which are 100 micron in diameter or less (14,15)_ 
An additional 7-10% of vascular resistance is 
derived from the venous side. As a result, vessels 
over 100 micron in diameter are responsible for 
the remaining resistance under control conditions. 
However, microvessels respond heterogeneously 
to changes in perfusion pressure with 
vasodilatation in small (<100 micron) vessels, as 
opposed to either no alterations or vasoconstriction 
in larger size microvessels during progressive 
reduction in perfusion pressure (16). 
Of the metabolites involved in autoregulation, 
adenosine is one of the most important and 
instantaneous regulators of coronary flow. 
Through binding with A2 receptors on the peri-
vascular myocytes, it directly influences arterial 
tone (17). This provides for an immediate 
metabolic link between energy production and 
oxygen delivery. 
In order to explain work-induced vasodilatation, it 
has been hypothesized, that relative decreases in 
pOz are sensed by chemoreceptors on specific 
pencyte type cells, which then may increase local 
activity of the enzyme 5-nucleotidase and thus 
stimulate adenosine production (18). Other 
metabolic factors, which influence coronary 
vascular tone without direct autoregulatory effects 
are pH, pC02 and osmolarity changes. Although a direct autoregulatory effect of pH or 
pC02 is unlikely on quantitative grounds, e.g. 
non-physiological, large changes are needed to 
adapt coronary flow to instantaneous 0 2 demand, 
changes in pH and pCO') presumably modulate the 
sensitivity of the autoregulatory (adenosine?) 
receptors. In general, metabolic acidosis will 
enhance coronary blood flow while, on the other 
hand, alkalosis induces vasoconstriction, 
accompanied by a (small) decrease in flow. 
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Endothelium-dependent control ofvasotone. 
A novel concept in autoregulation? 
Endothelium-derived relaxing factor( s). 
Since the introduction of the concept of endo-
thelium-dependent vasodilatation in 1980 (8), it 
has been demonstrated that the endothelium 
produces several potent vasodilator as well as 
vasoconstrictor substances. Of these, the endo-
thelium-derived relaxing factor (EDRF), a labile 
humoral substance formed in the endothelium 
from L-arginine (19-21), is one of the more potent, 
albeit short-lived vasodilator agents in nature. 
EDRF is presumably identical to nitrous oxyde 
(NO) (22-2"5)_ However, recent data on different 
responsiveness patterns of basal EDRF compared 
with EDRF, which is released by acetylcholine or 
compared with NO in proximal versus distal dog 
coronary arteries, have suggested that basal EDRF 
may not be analogous to NO and that more than 
one form of endothelium-dependent relaxing 
factors are present (26). 
Various stimuli, mechanical, humoral or platelet-
derived of nature, accelerate basal EDRF 
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Recently, flow-mediated vasodilatation was 
shown to be dependent on an intact endo-
thelium <33-36), suggesting that increased blood 
flow and shear stress on endothelial cells result in 
enhanced basal release ofEDRF. 
Alternatively, transmission of a hyperpolarizing 
current from the endothelium to the vascular 
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production or NO (Fig. 2). This then diffuses to 
the vascular smooth muscle cell to cause vasa-
relaxation through increased production of soluble 
guanylate cyclase <27,28), subsequently elevating 
cyclic guanosine 3,5' monophosphate (cGMP) and 
activating cGMP-dependent protein kinase C29). 
It has been suggested, that EDRF, through 
stimulation of cGMP, inhibits (norepinephrine-
induced) inositol triphosphate formation and hence 
modulates transsarcolemmal and intracellular 
calcium fluxes (30). This effect is not specific, but 
is also observed with sodium nitroprusside and 
ANF in de-endothelialized vessels. In addition, 
and just as likely not a specific effect, EDRF, 
through cGMP-production, may inhibit 
norepinephrine release from adrenergic nerve 
endings (31). As such, the endothelium can act as 
an endogenous inhibitor of sympathetic neuro-
transmitter release. The phenomenon of flow-
mediated vasodilatation has been known for some 
time. It had already been observed in 1970, that 
this was indeed dependent upon flow and not upon 
pressure. Also, it was demonstrated, that 
neurogenic stimuli could not account for the 
observation C32). 
Fig. 2: Schematic representation of different 
factors involved in control of vascular tone. A 
large number of circulating or platelet-derived 
factors may act on the endothelium through 
endothelial receptors. Several will be involved in 
formation of endothelial-derived relaxing factors 
(EDRF-1 and -2), which induce vasodilation 
through increased production of soluble guanylate 
cyclase, subsequent elevation of cGMP and 
interaction with transsarcolemmal and 
intracellular calcium fluxes. In addition, 
different vasodilator - and constrictor systems 
are indicated, acting on the endothelium or on the 
smooth muscle cell. By necessity, the figure is not 
meant to demonstrate all, vasodilating - or 
constricting presently known mechanisms (jor this 
the reader is referred to the text in this chapter), 
but solely to indicate the multitude of factors, 
involved in vascular control. Even so, recent 
concepts, such as the endothelins, are not 
mentioned. 
smooth muscle cell, through activation of specific 
ionic (potassium) channels following mechanical 
deformation of the endothelial membrane, has 
been proposed to explain flow-dependent 
vasodilatation C37,38). Recent data from Cooke and 
coworkers clearly indicate, that flow activates a 
potassium channel (possibly the calcium-activated 
potassium channel) on the endothelial cell mem-
brane, which leads to the release of the endothe-
lium-derived relaxing factor (39)_ The latter 
observations did not exclude participation of the 
hyperpolarizing current or different endothelium-
derived factors, e.g. the endothelium-derived 
hyperpolarizing factor (40,41)_ However, as 
ouabain did not block the flow response, an 
additional effect of the hyperpolarizing factor, if 
present, must be limited. In contrast, specific 
EDRF blockers such as L-NMMA, abolished 
vasodilatation, unmasking an underlying vasocon-
strictor tone. 
Besides flow, a large number of exogenous 
substances also induce vasorelaxation by enhanc-
ing EDRF production, such as acetylcholine, 
adrenaline/noradrenaline, ADP, thrombin, 
vasopressin, substance P, leukotriene D4, brady-
kinin and serotonin C42). 
Recent observations suggest, that acetylcholine 
may trigger the release of two chemically different 
relaxing factors through stimulation of muscar-
inic-1 and -2 receptors, at least in canine 
arteries (43). Stimulation of endothelial muscari-
nic-1 receptors induces EDRF (NO) release, 
whereas activation of the muscarinic-2 receptor 
results in the formation of the endothelium-
derived hyperpolarizing factor (or EDRF-2). To 
complicate matters further, a recent report sug-
gested, that superoxide-dependent relaxing 
factor(s) are released from the endothelium (44) and 
may induce vasodilatation by a different 
mechanism, other than obtained by EDRF stimu-
lation. 
Endothelium-dependent vasodilatation is not 
confined to the large conduit arteries (45). It is also 
observed in resistance vessels following the 
administration of several (although not all) of the 
stimuli, which induce vasodilatation in conduit 
vessels (46). However, the response to humoral 
agents in arterioles may not be similar to that 
observed in large arteries. For instance, serotonin 
appears to have differential effects at different 
levels of the coronary artery system, constricting 
larger coronary arteries (>90 micron), while 
smaller arterioles dilate when exposed to 
5-hydroxytryptamine C46). These contrasting ac-
tions of the same compound on the various levels 
of one arterial system may be explained by 
differential receptor populations. More likely, 
however, it is an expression of autoregulation with 
secondary endothelium-dependent dilation in 
down-stream microvessels, which compensates 
for upstream vasoconstriction following activation 
of 5-HT2 receptors in the larger arteries. Also, 
endothelium-dependent relaxations may vary with 
the type of vessel and drug dosages used C47). 
The observation, that basal EDRF production is 
under the influence of shear stress and is mediated 
by changes in ionic currents through potassium 
channels, may alter our concept of autoregulation 
to the extent, that different forms of autoregu-
lation, not only metabolic or myogenic, but also 
hemodynamic of nature, may be operative side by 
side on the microvasculature. 
Prostanoids. 
In the endothelial cell, arachidonic acid, released 
from membrane phospholipids by the enzyme 
phospholipase A2, is converted via the cyclo-
oxygenase pathway and endoperoxyde formation 
into prostaglandin H2 (48). Subsequently, prostacyclin is formed, a potent 
vasodilator that enhances vascular cAMP produc-
tion (49,50), or its counterpart, the potent vaso-
constrictor thromboxane A2 , as well as other 
prostaglandins (PGEz, PGF2_a, PGD2). Whereas prostacyclin is the major product of the cyclo-
oxygenase pathway of the vascular wall, throm-
boxane is predominantly formed in platelets. Other 
prostanoids, which are also formed in the endo-
thelium, although in small amounts, such as pros-
taglandin F2-a and prostaglandin Ez , may result in 
vasoconstrictory or dilatory responses depending 
on the experimental conditions used (51). 
Phospholipase A2 activation is observed after 
mechanical or chemical actions on the endothelial 
membrane. This may explain, to a certain extent, 
why prostacyclin release is flow-dependent and 
why pulsatile flow results in a significantly greater 
prostacyclin production than constant flow. 
Prostacyclin release is also triggered by hypoxia-
induced calcium influx in the endothelial cell (52). 
Besides, several of the substances that induce 
EDRF release, such as acetylcholine, histamine or 
thrombin, may also release prostacyclin (53). 
Interestingly, angiotensin II stimulates prosta-
cyclin production in the canine renal, but not in the 
femoral artery (54). 
Despite the high level of prostacyclin synthetase in 
the intima and the potential to synthesize the 
prostanoid after various stimuli, the role ofprosta-
cyclin as an endogenous vasodilator is not quite 
clear. Inhibition of this autocoid does not result in 
substantial effects on blood flow in many 
organs C48), in contrast to marked effects after 
inhibition of nitrous oxyde synthesis (55,56). 
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Endotheliwn-dependent vasoconstriction. 
Until recently, considerably less attention has been 
paid to endothelial-related vasoconstriction than to 
vasodilatation. Although several stimuli, including 
arachidonic acid, have been demonstrated to 
induce endothelium -dependent contractions, 
presumably mediated by the release of eicosanoids, 
these could not account for all conditions under 
which vasoconstriction took place(57 ,58). 
During recent years, attention has focussed on a 
family of peptides, endothelins, 25 amino acids 
long, with strong vasoconstrictor properties and 
produced in normal functioning vascular endo-
thelium. Endothelin induces long lasting vasocon-
strictor effects of relatively slow onset in most 
vascular beds(S9). Its mechanism of action may 
involve acceleration of intracellular calcium 
fluxes, a conclusion predominantly based on the 
inhibitory actions of several calcium anta-
gonists<60-62). However, high-affinity binding 
sites for endothelin- 1, the endothelin derived from 
human endothelial cells, are not affected by 
calcium antagonists. Thus, although the level of 
extracellular calcium may modulate contractions 
by endothelin, a distinct functional pathway, 
which involves phospholipase C-mediated 
phosphoinositide breakdown has been proposed. 
This results in intracellular mobilization of Ca2+ 
and activation of protein kinase C, with subsequent 
inositide triphosphate and diacylglycerol forma-
tion(63-65). These intracellular actions are directly 
related to other biological effects of endothelin~ 
such as an impairment of myocardial relaxation(66J 
or the induction of vascular (and myocardial?) 
growth(67-69). 
Whether endothelin is involved in acute autoregu-
lation is unknown. Its long lasting effect and 
relatively slow onset of action would argue against 
this. On the other hand, endothelin production, 
like nitrous oxyde, is regulated by shear stress(70). 
Most likely, the peptide institutes a continuous 
baseline vasoconstrictor tone, easily overridden by 
dilator mechanisms, such as prostacyclin and 
nitrous oxyde. 
Under pathological conditions, where endothelial 
function is compromised, the vasoconstrictor 
actions of endothelin may, however, take the 
overhand. 
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Non-endothelium-mediated regulator 
mechanisms of coronary flow. 
Vascular smooth muscle cell receptor modulation 
of vascular tone. 
The vascular smooth muscle cell (VSMC) ulti-
mately controls its own contractile state and, 
hence, vasotone. Vascular tone is regulated by the 
cytosolic Ca2+ level, by the interaction of calcium 
with other second and third messenger systems 
(calmodulin) and, subsequently, by myosin light-
chain phosphorylation, which enables the interac-
tion of the contractile elements and, hence, 
contraction. 
Important regulators, besides calcium, are the 
G-proteins, the inositol-phosphatidyl pathway and 
Na/H antiporter systems. The signals for vaso-
regulation either induce direct intracellular actions 
in the VSMC or act through one of the numerous 
receptors on the cell membrane. Examples of 
direct stimuli are NO and prostacyclin from the 
endothelium. Also, various agents may act directly 
on intracellular guanylate cyclase (nitrates and 
sodium nitroprusside) or on adenylate cyclase 
(forskolin and phosphodiesterase inhibitors) to 
induce vasodilatation (Fig. 3). 
Fig. 3: Endothelium-independent vasodilator 
mechanisms. Several agents may act directly on 
cAMP and cGMP, thereby inducing vasodila-
tation (see the text of this chapter). (From 
reference 71 with permission). 
However, the majority of stimuli for vasodilat-
ation or vasoconstriction act through receptor 
coupling. 
For instance, binding of endothelin -1 to high-
affinity receptors, as a first step to vasocon-
striction, has already been mentioned. Several 
compounds, which induce endothelium-dependent 
vasodilatation, may actually behave as vasocon-
strictors through direct interference with specific 
receptors on the VSMC, when the endothelium is 
absent or is functionally impaired to such an 
extent, that protection against these actions is not 
possible anymoreC72) (Fig. 4). 
An example here is acetylcholine, which will 
directly induce vasoconstriction through its M2 
BLOOD VESSEL WITH INTACT ENDOTHELIUM 
Smooth 
muscle cells 
receptor on the vascular smooth muscle cell 
membrane, either by reducing adenylate cyclase 
activity or by enhanced turnover of the phos-
phoinositide cycle. 
BLOOD VESSEL WITH DAMAGED ENDOTHELIUM 
Thromboplastin Aggregating /platelets 
/ 
Fig. 4: Schematic representation of the role of the endothelium to protect against vasoconstriction by 
several products of aggregating platelets, such as vasopressin (VP), serotonin ( 5- HT), thromboxane 
(TBAJ), platelet-activity factor (PAF), adenine nucleotides (ATP, ADP) and thrombin. The intact 
endothelium (left figure) provides the vasodilator prostacyclin (PGI -;), degrades serotonin and, through 
activation of specific endothelial receptors by most other products, forms vasodilating substances. 
Also, it prevents platelet aggregation (PGI2, EDRF). In contrast, when the endothelium is damaged (right figure), platelets aggregate and several derived substances may induce vasoconstriction, 
depending on the blood vessel. (From reference 72 with permission). 
In contrast, when the endothelium is intact, acetyl-
choline releases EDRF with subsequent vasodila-
tation. Receptor-linked vasodilatation may result 
from inhibition of the postsynaptic alpha -1 
Prazosin 8 
Phentolamine 
Adenosine 
® 
receptor with prazosin, whereas calcium 
antagonists attenuate postsynaptic alpha-2 
receptor-mediated vasoconstrictionC73) (Fig. 5). 
Fig. 5: Vascular smooth muscle cell receptor-
linked vasoregulation. Activation of specific 
receptors by several stimuli interfere with the 
contractile apparatus through modulation of 
adenylate- and guanylate-cyclase, G-proteins, 
the inositol-phosphatidyl pathway, Ca2+ and 
Na!H antiporter systems (see text on page 38). 
Ail = angiotensin receptor; ANF = atrial natriur-
etic peptide; CLMDN = calmodulin; MLC = 
myosin light-chain; P1 = purinergic receptor; SR 
= sarcoplasmatic reticulum. (From reference 7 I 
with permission). 
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Vascular angiotensin II receptor(74) blockade may 
have similar effects on intracellular calcium fluxes, 
reducing vascular tone. 
Alternatively, receptor-dependent vasodilatation 
may be achieved by beta-2 stimulation and 
subsequent cAMP production, which inhibits the 
activation of myosin light-chain kinase by calcium 
and calmodulin. 
Likewise, purinergic (adenosine A 1) stimulation 
promotes cAMP production and, besides, impedes 
Ca2+ entry into the cell. 
Atrial natriuretic peptides, after activation of their 
specific receptor(s)C75), result in an increase in, 
particularly, (membrane-bound) cGMP(76), which 
presumably has a dual effect on Ca2+ kinetics, 
restricting ca2 + entry into the cell and promoting 
its sequestration from the cytosol into the sarco-
plasmatic reticulum; effects, which are also 
achieved through cAMP activation(77). 
Both in the heart and the arterial system, calcitonin 
gene-related peptide binding sites have been 
identified. CGRP binding may stimulate adenylate 
cyclaseC78, 79). Both peptides I and II, present in the 
peripheral nervous system in heart and blood ves-
sels, induce vasodilatation, apart from positive 
inotropic and chronotropic effectsCSO). 
Moreover, activation of specific dopamine-1 
receptors will result in vasodilatation in various 
arterial systems, including coronary vessels(Sl). 
Presynaptic modulation of vasotone. 
An additional, important but indirect way to 
induce receptor-dependent vasodilatation is 
through presynaptic modulation of neurotrans-
mitter release (Fig. 6). 
Besides its direct effect on postsynaptic adrenergic 
receptors, norepinephrine, when released into the 
synaptic cleft, also stimulates the presynaptic 
alpha-2 receptor, thereby inhibiting further nor-
epinephrine release. 
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In addition, stimulation of other presynaptic 
receptors, such as the serotonergic, histaminic 
(H2), purinergic (A1), dopaminergic (DA.z) and 
muscarinic receptors, also results in dimmished 
norepinephrine release and vasodilatation. 
Conversely, presynaptic beta-adrenergic and 
angiotensin II receptor activation leads to enhanced 
neurotransmitter release and vasoconstriction. 
Thus far, alpha-adrenergic vasoconstrictor mecha-
nisms have been mentioned in particular. 
However, it should be realized, that from the same 
nerve endings, neuropeptide Y and ATP are 
coreleased with norepinephrine(82,83) and may in 
tum affect vasotone. 
Besides, A TP is also released from sensory motor 
nerves and from non-sympathetic purinergic 
nerves. Depending on which subtype of the purin-
ergic-2 receptor is activated it may induce oppos-
ing effects on vessel toneCSO). Moreover, adenine 
nucleotides are instrumental in eliciting EDRF 
formation via endothelial P2 receptor stimulation, 
which suggests a complex mode of action of the 
purine nucleotides on overall flow regulation. 
However, the relative importance of these various 
effects of ATP on coronary flow is as yet specula-
tive. 
Neuropeptide Y, although predominantly a neuro-
transmitter, which modulates noradrenaline 
release, may by itself induce coronary vasocon-
strictionC85), either directly or by facilitating 
alpha-adrenergic vasocontrictionC86). 
Adrenergic control of coronary flow. 
Whether an alpha-adrenergic vasoconstrictor tone 
is present under absolute resting conditions, is still 
a matter of debateC87-90). 
Studies in cardiac transplant patients suggest, that 
resting coronary resistance is less than in normally 
innervated individualsC91), at least when overall 
Fig. 6: Presynaptic modulation of neurotrans-
mitter (norepinephrine: NE) release and indirect 
receptor- mediated vasodilatation. AI I 
angiotensin; ACH = acetylcholine; DA2 = dopaminergic receptor; H 2 = histaminic receptor; 
M = muscarinic receptor; P1 = purinergic 
receptor; S = serotinergic receptor. (From 
reference 7 I with permission). 
coronary sinus flow (measured by thermodilution) 
and resistance is compared between transplant 
patients and normal individuals. It has been 
suggested, that a constant degree of neurally-
induced vasoconstriction exists under normal 
conditions, continuously reflex- modulated and 
limiting metabolic coronary dilatation by 
30% (92,93). 
Vasoconstriction follows alpha-adrenergic stimu-
lation and is opposed, to a certain extent, by beta-
adrenergically-induced relaxation. The latter is the 
primary adrenergic resr-onse to endogenously 
released norepinepbrineC9 ) . Although early studies 
have suggested, that adrenergically-induced 
changes in resistance are low (30-40%) compared 
with metabolically-induced alterations, which can 
be 5-6 fold from baseline, later investigations have 
indicated, that norepinephrine administration 
increases coronary resistance and is able to 
compete with metabolic vasodilatationC95-97). 
Also, in conscious dogs on beta-blockade, alpha-
adrenergic coronary vasoconstriction limits exer-
cise-induced metabolic coronary dilatation and the 
subsequent increase in coronary flowC98). 
This alpha-adrenergic effect on vascular tone 
during exercise is exerted predominantly by 
circulating catecholamines and not by endogenous 
amine release from cardiac sympathetic nerves. 
Both alpha- 1 and -2 adrenoceptors are present in 
the coronary system, including that of 
humansC99-103). Although the relative distribution 
of the 2 types may vary in conduit and resistance 
vessels, both types are present in the large epicar-
dial as well as in the resistance vesselsCI04,105)_ 
However, as with autoregulation, the response to 
alpha-adrenergic stimulation varies with vessel 
size, i.e. constriction of microvessels greater than 
150 micron but dilatation of vessels less than 100 
micronCI04)_ Under control conditions, resistance 
vessels respond equally with vasoconstriction to 
specific stimuli(l03). In contrast, alpha -adrenergic 
vasoconstriction opposing exercise-induced vaso-
dilatation is Jlredominantly achieved by alpha-1 
stimulationCI 6). Whereas during exercise alone, 
adrenergic vasoconstriction appears transmurally 
homogeneousCI07), during ischemia following 
coronary flow restriction, alpha-adrenergic vaso-
constriction has been claimed to redistribute coro-
nary blood from the epicardium to the endocar-
dium and, hence, may be beneficial in alleviating 
transmural steal during coronary hypoper-
fusionCI08). 
The question arises whether this implies that 
alpha-adrenergic stimulation is actually beneficial 
in myocardial ischemia or whether it increases 
ischemia through enhance vasoconstriction in the 
post-stenotic coronary vessels. 
Also, how do the numerous regulator mechanisms 
of coronary vasomot.Jr tone behave during 
ischemia? 
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II.2. 
Coronary blood flow regulation and myocardial ischemia. 
The classic concept of coronary insufficiency. 
The classic concept of coronary insufficiency is 
that of a pathophysiological disturbance in coron-
ary perfusion and therefore of oxygen and sub-
strate supply to the myocardium in relation to its 
instantaneous demand. In most instances, coronary 
insufficiency results from significant luminal nar-
rowing of a large coronary conduit artery and 
subsequent inability to increase coronary flow 
sufficiently to meet instantaneous oxygen demand 
during exercise or stress. This "stenosis" may be 
more or less fixed, following atherosclerotic 
thickening of part of the arterial wall or dynamic, 
as a result of abnormal, regional vaosconstriction. 
Alone, these mechanisms may not appreciably 
reduce coronary flow. When they are operative in 
concert, however, as often happens, coronary 
insufficiency may become sufficient to induce a 
PER CENT LESION BY DIAMETER (x) 
Whether, in the latter situation, coronary flow will 
be sufficient to prevent ischemia, depends not only 
on the remaining vasodilator reserve, but also on 
direct myocardial oxygen demand. Hence, the 
occurrence of myocardial ischemia becomes critic-
ally dependent on the instantaneous 
supply/demand ratio. 
Myocardial oxygen demand is determined to a 
small extent only by the basic cellular functions 
needed for cell viability. Whilst the beating 
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relative or absolute shortage of oxygen and sub-
strates in the post-stenotic area as well as reduced 
drainage from it, culminating in the clinical picture 
of myocardial ischemia. 
The vasodilator reserve of the coronary vasculature 
prevents flow reduction in the presence of moder-
ate coronary artery diameter narrowings of 40-
50% or less. 
In contrast, a progressive decrease of coronary 
flow with only minimal or no vasodilator reserve, 
is observed when the coronary artery diameter is 
acutely reduced by 85% or more(109). In the inter-
mediate range, blood supply improves but only to 
a certain extent, depending on the remaining coro-
nary vasodilatory reserve (Fig. 7). 
Fig. 7: Coronary artery flow and vasodilatory 
reserve. The relation between percentual coronary 
artery diameter constriction to resting mean flow 
(- - - - - - - -) and the hyperemic response (---:1 
to intracoronary contrast injections in dogs is 
shown. Flows are expressed as ratios to control 
resting mean values at the beginning of each 
experiment. The shaded area indicates the limits 
of the relation plotted for individual dogs. (From 
reference 109 with permission). 
(canine) heart consumes 8-15 m1 0 2/min/100 gr 
myocardial tissue, only 2 ml is needed in the 
quiescent, non-beating heart(llO). 
Wall tension, heart rate and, to a lesser extent, 
contractility are the major determinants of 
myocardial oxygen consumption. The occurrence 
of myocardial ischemia in the event of a critical 
stenosis will depend on these hemodynamic 
variables. However, this is often not the only 
cause and it may not even be the determining 
factor, as to the possible occurrence of ischemia. 
Coronary vasoconstriction and spasm. 
The concept of the myocardial supply/demand 
ratio for the development of ischemia is of less 
importance when spasm occurs in normal or near 
normal epicardial arteries. Although the original 
concept considered vasospasm as a form of in-
creased smooth muscle tone surrounding a critical 
stenosisC111,112), it has subsequently been shown, 
that coronary vasospasm may occur on top of any 
kind of lesion, but also in normal or subnormal 
coronary arteriesC113,114). 
Significant coronary vasospasm in patients with 
normal or near-normal coronary arteries, is pre-
sumably of less clinical importance than moderate 
reductions in artery diameter as a result of corona-
ry vasoconstriction, when superimposed on a fixed 
stenosis, at least not in terms of incidence. 
In recent years we have seen an explosion of 
evidence for abnormal coronary artery narrowing 
in lesion vessels, following a multitude of stimuli, 
including acetylcholine, sympathetic stimulation, 
exercise and fast atrial pacingCllS-119). Even rela-
tively small luminal reductions, due to increased 
vasotone, may alter a moderate lesion into a criti-
cal stenosis without any coronary flow reserve. 
Such examples of a 20% reduction in coronary 
diameter as a result of vasoconstriction, as presen-
ted in Fig. 8, are clinically relevant. 
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Fig. 8: Theoretical example of the effect of a 
relatively small reduction in diameter by 
increased vasomotor tone on the severity of an 
underlying coronary artery lesion. A 20% 
narrowing due to vasoconstriction can change a 
moderate lesion with sufficient coronary reserve 
into a critical stenosis without any reserve left or 
with even a decrease in resting coronary flow 
(From reference 9 with permission). 
In humans, both excerciseC119) and intracoronary 
acetylcholineCllS) induce similar reductions in 
diameter in stenotic coronary vessels. When these 
constrictions occur superimposed on lesions of 
70% or greater, the resultant reduction in overall 
coronary flow could be sufficient to induce 
ischemia without the need to alter myocardial 
oxygen demand as well. Thus, our concept of the 
supply/demand ratio should take into account the 
dynamic behaviour of the large conduit vessels 
over and beyond the lesion area. Assuming that the 
stenosis is sufficiently eccentric to allow for 
vasomotion, this certainly means an addition to the 
old concept. 
Due to the variability of dynamic changes in 
vasotone superimposed on an existing fixed lesion, 
different degrees of ischemia may be found in the 
same patient despite similar changes in myocardial 
oxygen demand. 
Alternatively, similar changes in coronary 
perfusion may occur in an individual but resulting 
from entirely different stimuli. An example of the 
latter is given in Fig. 9, where, in the same 
patient, a comparable reduction in regional 
coronary flow is observed during spontaneous 
angina at rest and during pacing-induced ischemia, 
at a heart rate of 120 beats/minute. 
Mechanisms of abnormal vasomotor regulation 
Evidence is accumulating, that abnormal vascular 
behaviour, e.g. a diminished or absent dilator 
response following stimuli, which normally would 
induce vasodilatation, is not restricted to severely 
stenotic arteries, but is also observed in vascular 
regions with only minimal atherosclerosisC116-118) 
(Fig. 10). Moreover, recent data suggest, that in 
hypercholesterolemia per se, without athero-
sclerosis, endothelium-dependent relaxation is 
already impaired, even after a short exposure to 
cholesterolC120). Also, several studies indicate, that 
the vasoconstrictor response to calcium and 
norepinephrine is increased in hypercholes-
terolemic animals before the development of 
atherosclerosisC121-123). 
A disturbance in endothelial function in 
atherosclerosis and hypercholesterolemia with 
subsequent inappropriate EDRF or NO 
production, has been implicated to explain the 
abnormal vasodilator response after certain 
stimuli. Likewise, a persistent dysfunction of 
regenerated endothelium after angioplastv and 
reperfusion injury has been reportedCl24,125). In 
the first model, a sustained, abnormal vasodilator 
response to acetylcholine and aggregating platelets 
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Fig. 9: Reduction of regional coronary flow during spontaneous angina pectoris at rest in the same area 
as during atrial pacing-induced ischemia. In this patient Krypton-81m is continuously infused into the 
left circumflex artery which has a 70-90% stenosis (arrow). During pacing-induced anginal pain 8lmKr 
distribution is decreased over the post-stenotic area with an increase over the normal area. 5 min after 
pacing the krypton changes have nearly returned to the control situation after angina has subsided for 
several minutes. However, thereafter, during spontaneous anginal pain Krypton-81m again 
diasappears in the same area with an increase over the normal region suggesting a reduction in coronary 
flow due to spasm of the artery at the site of the stenosis. (From reference 9 with permission). 
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was found(l24) . In contrast, in the second model 
with reperfusion injury, provided that such a 
pathophysiogical condition does indeed existC126), 
this was only due to aggregating plateletsC125). 
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Fig. 10: Abnormal vasomotor response of 
atherosclerotic coronary artery segments 
following the cold pressure test (CPT). Whereas 
smooth segments dilate, severely stenotic artery 
diameter decreases significantly. However, also 
minimal atherosclerotic segments (irregular) 
behave abnormally with vasoconstriction. (From 
reference 116 with permission). 
Enhanced platelet aggregation, not counteracted by 
EDRF, could favour platelet adhesion, aggregation 
and the release of platelet-derived contractile (and 
growth-promoting) agents, favouring coronary 
vasoconstriction, spasm and ischemia. 
It is interesting to note, that besides a persistent 
abnormal endothelial response to certain stimuli, 
the effect of others, such as bradykinin, becomes 
impaired only after a long time following denu-
dation and regeneration of the endothe-
lium(l27,128). This observation and the relatively 
high frequency of restenosis following angioplasty 
strongly indicates the need for extensive research 
in the area of restenosis and endothelial changes at 
the molecular and cellular level. 
The endothelium, although popular, is not the only 
culprit when it comes to abnormal vasodilator 
behaviour during ischemia or clinical situations 
related to ischemia. Despite arguments to the 
contrary from most in vitro workers, preliminary 
data on the vasodilator response of non-endothe-
lium-dependent vasodilator stimuli suggest, that in 
hypercholesterolemic humans abnormalities in 
both endothelial and smooth muscle function are 
present (M.Creager: personal communication). 
Moreover, several studies suggest an important 
role for alpha-adrenergic vasoconstriction in 
ischemia, either by initiating or by amplifying the 
ischemic process. During progressive reduction of 
coronary flow, intracoronary norepinephrine or 
cardiac sympathetic nerve stimulation reverses 
metabolic coronary vasodilatation to alpha-adren-
ergic vasoconstriction(l29-131). Whether specific 
adrenoceptor subtypes are preferentially involved, 
is not yet clear. 
The bulk of the evidence, coming from one 
research group, suggests, that vasoconstriction is 
predominantly caused by alpha-2-linked mecha-
nisms, whereas alpha-1 adrenergic vasoconstric-
tion actually diminishes during ischemia(132,133). 
Besides specific alpha-2-blocking agents, 
calcium-antagonists are shown to antagonize adre-
nergically-induced coronary vasoconstriction 
during ischemiaC134,135). In contrast, in anes-
thetized open-chest dogs, where baseline sympa-
thetic tone is likely to be elevated, alpha-
adrenergic vasoconstriction during ischemia is 
alleviated by alpha-1 but not by alpha-2 blocking 
agentsC136). 
This, together with the observation, that alpha-1 
adrenergic vasoconstriction specifically limits the 
increase in coronary flow during exercise(l06), 
again a situation where overall sympathetic tone is 
equally enhanced, suggests a differential alpha-
subtype interference with vascular resistance, 
which depends on the instantaneous level of 
overall sympathetic tone. 
Relative contribution of abnormalities in 
vasodilator control to the clinical picture of 
myocardial ischemia in man. 
The relative contribution of the multitude of 
factors, which govern the instantaneous 
myocardial oxygen demand/supply ratio and 
regional coronary vasotone to occurrence and 
severity of myocardial ischemia in man, will vary 
considerably from one clinical setting to the other. 
The origin of myocardial ischemia in conditions, 
such as Prinzmetal-type variant angina, or occur-
ring as a result of abnormal microvascular 
behaviour in syndrome X, hypertrophic or dilated 
cardiomyopathy, will be clearly different from that 
in the patient with coronary artery disease, the 
subject of this thesis. Even in the latter it is im-
possible, however, to create a uniform picture. 
One factor, which may be rather consistent 
although difficult to determine sequentially in 
vivo, is the "coronary steal phenomenon", e.g. the 
propensity of coronary arterial blood to be shunted 
away from high to low resistance areas. 
Thus, oxygen and substrates are preferentially 
transported to normal regions with unaffected 
vasodilator reserve capacity, away from the 
coronary lesion area with its increased stenosis 
resistance. Furthermore, if coronary artery lesions 
are severe and eccentric, further downstream 
vasodilatation, as a result of stress or vasodilator 
mechanisms, may actually increase stenosis 
resistance and reduce coronary flow(l37-139). 
Proposed mechanisms here include a collapse of 
the normal compliant part of the arterial wall as a 
result of pressure loss in the stenosis area or 
enhanced outflow turbulence and subsequent 
increased resistance. In addition, turbulent flow 
and, as a consequence, abnormal flow patterns 
along the endothelial wall, might affect basal 
EDRF release. 
To what extent an abnormal regulation of vaso-
motor tone by the various mechanisms outlined 
above, really contributes to the onset and 
propagation of ischemia over and above the factors 
given before, is as yet unknown. Largely, because 
sufficient human data are not yet available. ' 
Sympathetic activation by isometric exercise may 
induce significant coronary artery narrowing, 
followed by objective and subjective clinical signs 
of ischemiaC140,141). 
Also, the cold pressure test may result in increased 
coronary vascular resistance, mediated by alpha-
adrenergic vasoconstriction and, subsequently, in 
ischemiaC142,143). However, the latter patient 
studies only examined overall coronary flow and 
not stenosis resistance. 
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In contrast, several recent angiographic investi-
gations do indeed indicate, that abnormal vasomo-
tor tone and vasoconstriction are present in lesion 
areas during exercise or fast atrial pacing. 
However, the underlying mechanisms are not clear 
from these studies. Neither do they provide insight 
as to whether these alterations in coronary 
diameter and in flow do result in ischemia and, if 
so, what the temporal relation is to myocardial 
ischemia. 
We have tried to establish this relation in a model 
of pacing-induced myocardial ischemia, where 
regional coronary blood flow was continuously 
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Chapter ill 
METABOLITES AS MARKERS OF ISCHEMIA. 
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m.t. 
Usefulness and applicability of myocardial metabolic markers as indicators of 
myocardial ischemia in man. 
Myocardial ischemia results in early and profound 
metabolic alterations in the heart, predominantly 
in the ischemic area. Consequently, the 
identification of myocardial ischemia in man by 
way of these metabolic alterations has been one of 
the diagnostic goals in cardiovascular medicine 
since the introduction of coronary sinus 
catheterization in man by Bing et al in 1947C1). 
Although, in theory, a sensible approach when 
defining the presence and magnitude of ischemia, 
several questions arise, e.g. how useful are 
changes in metabolites for the assessment of 
myocardial ischemia; which metabolites are 
particularly useful in humans and how applicable 
are the methods to determine these metabolic 
changes in man? Moreover, are they sufficiently 
reproducible to allow for (pharmacological) inter-
ventions to be tested? And finally, are there 
specific metabolic alterations, which allow us to 
define specific interventions? 
Currently existing methods to identify ischemia-
induced metabolic alterations consist of invasive 
and non-invasive techniques (Table I). 
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Invasive techniques are best categorized as: 
- methods, which identify ischemia through 
chemical evaluation of metabolites in arterial 
and coronary venous blood. 
tracer methods, which apply radiolabelled 
substrates in the setting of arterial and coronary 
venous catheterization 
- techniques, which use specific catheter tip 
electrodes positioned in the coronary venous 
effluent. 
Non-invasive techniques consist of radionuclide 
methods, in particular positron or single photon 
emission tomography with labelled fatty acids, 
glucose or amino acids as substrates. In addition, 
nuclear magnetic resonance spectroscopy, 
although still in its infancy where the human heart 
is concerned but very promising in smaller species 
as well as in peripheral human tissue, should also 
be mentioned. 
Table 1: Methods to identify ischemia-induced metabolic alterations in humans. 
Method 
Arterial/coronary sinus 
catheterization 
Radionuclide methods 
Magnetic resonance 
spectroscopy 
Technique 
INVASIVE 
Biochemical evaluation 
(arterial and coronary venous 
blood) 
Radio-labelled substrates 
Catheter tip electrodes 
NON-INVASIVE 
Planar/SPECT 
PET 
PET 
PET 
PET/SPECT 
PET 
- Rotating frame technique 
- Depth-resolved surface coil 
spectroscopy 
- Image-selected in-vivo 
spectroscopy 
- Spectroscopic imaging 
Substrates 
lactate, pyruvate, inorganic 
phosphate, potassium, citrate, 
alanine, glutamate, FFA, 
carnitine, nucleosides, 
prostaglandins, neurohormones 
14C-glucose 14C-lactate 
3H -norepin~phrine, 13c-'Iactate 
pH, 0 2, potassium 
123I -phenylpentadecanoic acid 
1231-hexadecanoic acid 
lie-palmitate 
18F-deoxyglucose 
13N -glutamate 
lie-acetate 
P-31, H-1, N-14, C-13, 
Na-23,F-19 
Abbreviations: PET= positron emission tomography; SPECT = single photon emission computed 
tomography 
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ID.2. Non-invasive techniques. 
As emphasis in this thesis is on the evaluation of 
myocardial metabolism through invasive methods 
in humans, non-invasive techniques, important as 
they are, will be reviewed only briefly. 
NMR -spectroscopy. 
Nuclear magnetic resonance spectroscopy is a 
new, non-invasive technique to study myocardial 
metabolism. Using the spin properties of certain 
nuclei, such as P-31, H-1, N-14, C-13, Na-23 
and F-19, specific metabolic steps in the heart 
have been evaluated in vivo. The technique now 
allows reproducible experiments with a temporal 
resolution of several seconds to minutes. Thus, in 
animal experiments, relatively fast changes in 
high-energy phosphates, inorganic phosphate and 
pH are noted during ischemia and reperfusion(2,3). 
The technique enables the determination of 
intracellular free calcium concentrations using 
F-19(4)_ Moreover, C-13 NMR spectroscopy has 
been used to identify certain aspects of glycogen 
metabolism and citric acid fluxesC5,6). Also, direct 
detection of free radicals with NMR spectroscopy 
has been described(?). Although promising, the 
applicability of nuclear magnetic resonance 
spectroscopy in the human heart has been limited 
thus far b~ issues such as sensitivity and 
localization( ) . 
Radionuclide techniques. 
The radionuclide techniques, employed in the 
detection of myocardial metabolism, consist 
primarily of positron (PET) or single photon 
(SPECT) emission tomography with labelled fatty 
acids, acetate, deoxyglucose and glutamate as 
substrates. Earlier studies predominantly 
employed planar scintigraphy. With this technique 
the half-life of disappearance from the heart of 
phenylpenta-, hexa- and heptadecanoic acids, 
labelled with gamma-emitting iodine isotopes can 
be determined, which supposedly reflects their 
metabolic turnover in the 13-oxydation pathway. 
Moreover, a recent study applied planar 
scintigraphy with 13N -glutamate during 
symptom-limited bicycle exercise testing in 
patients with single-vessel coronary artery 
disease. In this investigation, glutamate 
accumulation as a marker of ischemia in reversible 
ischemic areas was compared with with thallium-
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201 kinetics, which reflect myocardial perfu-
sion(9). 
Labelling of medium -chain FFA with iodine-123 
in the omega position does not significantly alter 
their normal biological behaviour(lO,ll). Apart 
from visualization of areas with diminished 
uptake, e.g. infarct areas, abnormal turnover rates 
of FFA labelled with iodine-123 in ischemic or 
infarcted regions may be determined(l2,13). 
However, some doubt has arisen, as to whether the 
measured changes in radioactivity really reflect the 
metabolic turnover of FFA or merely the kinetics 
of free iodineC14,l5). Moreover, beside other 
limitations inherent in the use of single photon-
emitting radionuclidesC16,l7), planar scintigraphy 
also precludes precise delineation of regional and 
transmural metabolic changes. The latter, 
however, does improve considerably with 
tomography. 
Whereas with SPECT similar fatty acid isotopes 
are used as with planar scintigraphy(!&), 
cyclotron-produced positron emitters, such as 
oxygen-15, nitrogen-13, carbon-11 and fluorine-
18, are employed with PET for metabolic 
studies(19-24). 
Moreover, with the latter technique, myocardial 
perfusion can be monitored simultaneously with 
metabolic imaging, using oxygen-15(25), 
nitrogen-13C26), or the generator-produced 
rubidium- 82(27-28). 
Thus, regional glucose uptake (labelled with 
fluorine-18) can be compared with llc-palmitate 
turnover and myocardial perfusion (13N -ammo-
nia)(23) during pacing- or exercise-induced 
ischemia(29,30) (Fig. 1). As such, the methodology 
allows for a useful approach towards the detection 
of regional alterations in metabolism and flow and 
is one which is applicable in man. 
In general, non-invasive methods are preferable to 
invasive techniques, at least to a certain extent. 
Besides obvious advantages for the patient, as well 
as being less vigorous for the investigator, these 
methods do allow for long term, sequential 
investigations to be carried out in the same patient. 
Moreover, the technical advancements of some of 
the techniques, e.g. positron and single photon 
emission tomography, enable us currently to 
identify regional as well as transmural changes in 
myocardial metabolism, coupled to changes in 
regional coronary flow. In no way is this possible 
Control 
8 min 
40 min 
Pacing 
. 
. 
. 
. 
' ... 
with any of the invasive methods available. 
Obviously, these are very significant advantages of 
the non-invasive techniques. 
On the other hand, a number of important limita-
tions are present as well, which make these 
methods less attractive than would appear at first 
sight (Table II). 
First, tracer uptake in the heart depends on several 
mechanisms, which are difficult to control, such as 
local perfusion, the integrity of active transport 
mechanisms and the overall metabolic state of the 
heart. For instance, extraction and turnover of 
fatty acids, such as palmitate, are clearly depen-
dent on substrate availabilityC3I). In contrast, a 
recent study<32) indicates, that myocardial fuel 
supply and selection have only limited effects on 
acetate kinetics, supporting previous suggestions 
that the early rapid clearance phase of llC-acetate 
truly reflects tricarboxylic acid cycle flux without 
much influence by changes in substrate 
supply(33,34). Secondly, the quantitative delinea-
tion of tracer distribution may be complicated by 
wall motion, partial volume effects and spillover 
of the isotope. 
In addition, in the case of planar scintigraphy, 
tracer activity uptake by non-myocardial struc-
tures or the overlapping of ischemic and normal 
areas, may be a significant complicating factor. 
Fig. 1: Myocardial 11C-palmitate acttvtty at 
control and during atrial pacing in a patient with 
a 90% proximal stenosis in the left anterior 
descending coronary artery. Midventricular 
images are shown with the anterior wall at the 
upper left, septum at the upper right and lateral 
wall at the lower left. Images at the top (8 min) 
reflect llC-palmitate uptake and bottom images 
(40 min) clearance. Uptake is normal and 
homogenous both during control and pacing. At 
rest, clearance is also homogenous. However, 
during pacing, clearance became heterogenous 
with retarded clearance in septum and anterior 
wall, indicative of impaired fatty acid oxydation 
during pacing in the area at risk (from reference 
29, with permission). 
However, most importantly, the relatively long 
half-life of most tracers, used for metabolic 
imaging, as well as the long duration of tomo-
graphic imaging time, do preclude the fast sequen-
tial determination of metabolic changes, which is a 
prerequisite for monitoring of myocardial metabo-
lism during (the early phases ot) myocardial 
ischemia. 
In addition, the various substrates used as tracer, 
may induce specific problems in the interpretation 
of ischemic metabolic changes. Labelled fatty 
acids, extracted by the ischemic myocardium, may 
back-diffuse in a considerable amount in unaltered 
chemical formC35). Also, that part of the tracer 
time-activity curve that primarily reflects the 
oxydation process may be overshadowed by re-
tarded wash-out curves, particularly during 
ischemia, thus obscuring the real metabolic rate. 
Glucose, labelled with fluorine-18 as fluoro-2-
deoxyglucose(36) is trapped after being converted 
to ISF-2-deoxyglucose-6-P and does not enter the 
glycolytic pathway. It therefore only indicates the 
rate of cellular uptake of glucose and subsequent 
phosphorylation. 
Although the latter is related to glycolysis, it also 
depends on glycogenolysis. Moreover, the half-
life of this tracer (109.7 min, fi+ 97%) makes its 
value rather dubious, particularly in the event of a 
progressive reduction in coronary flow. 
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Table II: Metabolic imaging techniques in myocardial ischemia - limitations. 
Tracer uptake 
Tracer clearance 
Imaging 
Tracer distribution quantification 
Imaging duration/tracer half-life 
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perfusion, integrity active transport systems, 
overall metabolic state 
back-diffusion 
tracer uptake myocardial tissue - overlapping 
normal areas 
wall-motion, partial volume effect, tracer spill-
over 
fast sequential determination metabolic changes 
not possible 
ID.3. Invasive methods. 
Catheter tip electrode techniques. 
In contrast to the long lasting procedures generally 
encountered with non-invasive radionuclide 
metabolic imaging, catheter tip electrodes enable 
both very fast as well as accurate determinations of 
specific metabolic changes in blood passing by the 
catheter tip. 
Thus, in patients with coronary artery disease, 
significant, albeit small changes in coronary 
venous pH or potassium are readily detected 
during ischemic episodes with the catheter 
postioned in the coronary sinus. During angio-
plasty procedures, the coronary venous pH is 
shown to fall transiently, 4 to 6 seconds after 
deflation of the balloon, returning to control values 
within 65 secondsC37). As to be expected, the peak 
pH change is related to the duration of coronary 
artery occlusion. However, at least 15 seconds of 
balloon inflation is needed for coronary venous pH 
to change. 
Similar changes in coronary venous potassium are 
observed during angioplasty, again not during, but 
following balloon deflation, with increments up to 
0.6 mmol/1(38). In a different set-up, but by the 
same investigators the effect of fast atrial pacing on 
coronary venous pH was studied in patients with 
coronary artery disease. In all but one patient, who 
developed ischemia during the test as shown by 
characteristic electrocardiographic changes, a 
significant increase in coronary venous pH (>0.02 
units) was observed(39)_ Interestingly, maximum 
changes were not found during, but at 20 seconds 
post-pacing (Fig. 2). This coincides with 
maximum changes in coronary venous lactate 
levels under identical circumstances, e.g. 15 
seconds post-pacing, in patients with ischemic 
heart disease, as reported by us in the same 
yearC40). 
The catheter tip electrode technique allows for a 
continuous and sensitive assessment of the 
metabolic parameter under study. 
With chemical analysis of coronary venous blood, 
significant pH changes have never been established 
in man, neither during nor directly after pacing 
(unpublished observations). Although, early 
studies using biochemical methods did indicate, 
that coronary venous pH 
pacing 
~ 777777/J 
-0·04 
-0·02 
L>.pH 0 
+0·02 o ischaemic 
o non- ischaemic 
-120 -60 0 -120 -60 0 60 120 180 
Time (s) 
Fig. 2: Sequential changes in coronary venous pH 
during and after atrial pacing, measured by 
catheter tip electrode technique. In ischemic 
patients a maximal decrease in pH is observed at 
approximately 20 seconds after pacing. 
increased during (pacing-induced) ischemia, 
arterial pH rose also and to a greater extent. 
Consequently, the difference between arterial and 
coronary venous pH actually increased signifi-
cantly<41). 
Also, significant potassium release as a result of 
ischemia has never been consistently established 
using biochemical methodologiesC42,43), indicative 
of the sensitivity of the catheter tip electrode 
technique. 
Moreover, the method should allow for repro-
ducible recordings to test interventions, providing 
that the usual precautions, necessary with coronary 
sinus catheterization studies, are taken care of and 
that sufficient time is allowed between tests for 
restoration of metabolism. 
The main disadvantage of the technique, apart 
from being invasive, is that it does not allow for 
concomitant determinations of coronary flow and 
metabolites, and like all other invasive methods, is 
not wei suited for the determination of regional 
changes in metabolism. 
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Biochemical evaluation of metabolites in the 
coronary venous effluent. 
The inability to determine regional alterations in 
metabolism is a major disadvantage of all invasive 
catheter-based techniques, particularly those, 
which rely on coronary venous blood being 
sampled for subsequent chemical analysis. To 
determine coronary flow by the latter method, to 
collect blood at short intervals and, at the same 
time to ensure reproducible measurements after 
lengthy intervals, the coronary venous catheter is 
optimally positioned in the mid-portion of the 
coronary sinus. The collecting orifice, usually at 
or near the tip of the catheter, should be at least 
2-3 em away from the ostium of the coronary 
sinus, to prevent reflux of atrial blood interfering 
with the coronary venous sampleC44). Even then, 
the presence of atrial reflux should be excluded by 
measuring the effect of bolus infusions of saline in 
the right atrium on the coronary sinus thermo-
dilution curve. 
Atrial reflux is a major concern in invasive studies 
of the coronary sinus, particularly when right 
atrial pressure becomes elevated following ven-
tricular pacing or atrial cannon waves, such as may 
occur during fast atrial pacing. 
On the other hand, when coronary sinus flow is 
measured and blood is sampled for metabolic 
determinations, the catheter should not be posi-
tioned too high up in the coronary sinus, as then 
the combined procedure of sampling blood and 
measuring flow over relatively long periods will 
become virtually impossible. Repetitive fast 
sampling of blood from a restricted area such as 
that drained by the great cardiac vein through 
thermodilution flow-type catheters, is usually very 
difficult and unpredictable. If, in the latter situa-
tion, atrial pacing is carried out to produce 
ischemia, failure to capture or the occurrence of 
ventricular instead of atrial pacing may be an 
additional problem. 
Thus, the preferred and commonly used position 
of the catheter will be somewhere in between these 
two extremes, in the mid-portion of the coronary 
sinus. 
In this position, the venous admixture from the 
anterior, high-mid septal and lateral part of the left 
ventricle will usually contain blood from areas 
with and without significant coronary lesions. 
Hence, during ischemia, blood from non-ischemic 
regions will invariably dilute the effluent from the 
ischemic area(s). As during a procedure, such as 
exercise or atrial pacing, post-stenotic blood 
inflow falls and, subsequently, venous outflow 
diminishes, coronary sinus samples may mainly 
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reflect blood from normal, non-ischemic regions, 
thus obscuring the main event to be studied. 
Sensitivity and usefulness of metabolic 
markers of ischemia. 
A host of metabolites, eicosanoids and neuro-
hormones have been assessed, using coronary 
sinus catheterization, in patients with coronary 
artery disease in an attempt to better identify the 
ischemic event. Of these, lactate, pyruvate, 
inorganic phosphate, blood gases, potassium, 
citrate, alanine, glutamate, FFA, carnitine, 
nucleosides, prostanoids and neurohormones have 
been studied using various forms of stress testing. 
With respect to the first, the parameters to be 
studied, lactate, nucleosides and the neuro-
hormones will be addressed in particular, as they 
are the key targets of this thesis. With respect to 
the second, the preferable stress tests in a setting, 
where emphasis is on myocardial metabolic 
changes, are fast atrial pacing and coronary 
balloon occlusion. 
Coronary angioplasty has provided for a unique 
model of myocardial ischemia in man. The 
potential of the technique to induce ischemia has 
already been referred to on page 59. With respect 
to reproducibility, both coronary hemodynamics 
and myocardial metabolites have been reported to 
be comparable following the first 2 occlusions but 
not thereafterC45,46). In contrast, more recent 
studies have expressed concern about the unpre-
dictable effect of partial obstruction by the deflated 
balloon before the first inflation, which may 
render the subsequent occlusion period less 
reliableC47). 
Besides questions concerning reproducibility, 
ethical considerations may interfere with the use-
fulness of the model, as they may prohibit a strict 
adherence to the study protocol in terms of occlu-
sion times. 
Ethical considerations are generally less of a 
problem where the atrial pacing stress test is 
concerned. Although the majority of patients will 
experience anginal pain during pacing-induced 
stress, as with all other procedures aimed at 
inducing myocardial ischemia, this rapidly 
diminishes immediately after pacing in nearly all 
patients. Often, angina diappears during the first 
30-second period following pacing, which is in 
sharp contrast with the relatively slow regression 
of pain after exercise. Although the latter may be 
an argument against exercise, an even stronger 
argument is the fact that reproducible measure-
ments of coronary flow and metabolites, using a 
coronary sinus catheter, are in fact impossible. 
Although reproducible flow measurements during 
supine exercise have been claimedC48), the inherent 
movement of the catheter with exercise and hence 
the probability of sampling different venous out-
flow beds in the course of the study, precludes 
usage of the method other than in very selected 
cases. Moreover, arterial levels of metabolites and 
of neurohormones change significantly during 
exercise, irrespective of ischemia, interfering with 
myocardial extraction patterns and invalidating a 
proper evaluation of small ischemia-induced 
changes herein. In contrast, alterations in arterial 
levels generally do not occur during pacing. 
Other forms of stress, such as the hand grip test, 
do not result in a similar degree of myocardial 
ischemia and ischemia-induced metabolic changes 
as fast atrial pacingC49). The cold pressure test is 
also relatively insensitive in the diagnosis of ische-
mia, both compared with exercise testingCSO) and 
atrial pacing (unpublished observations). 
Hence, atrial pacing has been the preferred mode 
of stress in studies of coronary hemodynamics and 
cardiac metabolism, since its introduction in 1967 
by Sowton et alC51). 
Likewise, we have used the test intensively over 
the past 17 years. As a result, the patient studies, 
mentioned in this thesis, have all been carried out 
with incremental atrial pacing, using a standard 
pacing protocol, as described in chapter V. 
Myocardial lactate metabolism as indicator of 
ischemia. 
During fast atrial pacing and ischemia, there is a 
relative prevalence of venous admixture from non-
ischemic regions, as a result of reduced arterial 
inflow and diminished venous outflow from ische-
mic areas. This, presumably, is the major reason 
for the relatively low sensitivity of metabolites, 
such as lactate, to indicate myocardial ischemia in 
humans, at least when measured directly, through 
chemical analysis of coronary sinus blood. More-
over, where lactate is concerned, several other 
factors interfere with its normal extraction pattern. 
During exercise, arterial lactate levels increase, 
accompanied by markedly enhanced cardiac 
extraction. This already suggests, that this 
parameter is not well suited as indicator of 
ischemia in this setting, besides the near impos-
sibility to conduct meaningful investigations by 
way of coronary sinus catheterization during exer-
cise. In contrast, conditions such as 
hyperventilation, alternative substrate availability 
(FFA) and catecholamines, all reduce cardiac 
lactate extraction by affecting either glucose uptake 
or several key enzymes in the glycolytic 
processCS2-SS). As a result, a reduction of lactate 
extraction alone under a certain level, e.g. 10%, as 
has been used in human studies to indicate 
ischemiaC45,56-58), cannot be taken as an objective 
sign of ischemia (chapter V)C59). Neill and 
KremkauC60) compared the second largest group of 
patients with and without a significant (> 70%) 
coronary diameter narrowing reported in the 
literature (see chapter V for comparison) and 
observed that during fast atrial pacing average 
values +I- 2 SD for lactate extraction in the normal 
group ranged between 46% and 0%. A similar 
range during pacing was reported by Gertz et al. in 
normal subjectsC59). Hence, the stringent criterion 
of lactate production should be adhered to, to 
obviate false positive results. If so done, the 
sensitivity of lactate as marker of ischemia in 
patients with coronary artery disease indeed 
appears lowC61) as suggested by the majority of 
studies in humansC4l,60-66). However, this 
information is derived from studies where changes 
in myocardial lactate metabolism were only 
assessed during the stress test. In Table III (next 
page) the percentage of patients with significant 
coronary artery disease, who developed 
myocardial lactate production during pacing are 
compared to those with significant electrocardio-
graphic or hemodynamic criteria or ischemia. In 
contrast to a variable but rather high incidence of 
anginal pain and to relatively low but consistent 
frequencies for ischemic ST -changes, the 
occurrence of lactate production is also more 
variable and, at the same time, relatively low, 
varying between 35% and 69%. Likewise, 
abnormal elevations in left ventricular end 
diastolic pressure are also inconsistent, ranging 
between 39% and 76%. Does this mean, that we are 
restricted to a relatively non-specific and 
subjective marker as anginal pain as the primary 
indicator of ischemia in this modelC64) or are there 
ways to increase the sensitivity of objective 
indices? More specifically, can we improve the 
potential of abnormal myocardial lactate 
metabolism to indicate ischemia in man? This 
particular question will be addressed in this thesis. 
How to improve identification of myocardial 
ischemia through lactate determination. 
All data considered, in patients with coronary 
artery disease myocardial lactate production av-
erages 50% during specific stress tests, such as fast 
atrial pacing, which is not encouragingC41,60-66). 
However, it should be realized, that available 
human data are derived from relatively small 
patient populations (Table III). 
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Table ill: Percentage of patients with metabolic, electrocardiographic, hemodynamic and 
symptomatic signs of ischemia during pacing. 
Parker 1969 [41] 21 62 90 76 81 
Linhart 1972 [63] 31 55 39 55 
Neill/Kremkau 1974 [60] 
submax: pacing 89 28 51 
max pacing 24 35 71 
Chiong 1974 [61] 23 69 52 78 
Thadani 1979 [62] 12 58 58 58 100 
Ihlen 1983 [65] 40 54 100 
Markham 1983 [64] 18 50 56 44 67 
Thomassen 1988 [66] 64 62 73 100 
Abbreviations: LVEDP = left ventricular end diastolic pressure; N =number of patients 
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Also, the relative presence of proximal versus 
distal left coronary artery disease or right coronary 
artery disease has generally been given little 
attention. More importantly, the assessment of 
lactate metabolism was always carried out during 
pacing. As far back as in 1981 we reported, that 
the sensitivity of measurements of myocardial 
lactate metabolism as a definitive marker of 
ischemia, significantly improves when the cardiac 
extraction values of this metabolite are not only 
determined during maximal pacing rates, as is 
customary, but in particular when they are 
assessed during the immediate post-pacing period, 
e.g. at 15 seconds after pacing<40). Several years 
later, this observation was confirmed by Ihlen et 
al(65). These authors observed that, whereas 
average lactate extraction values were still positive 
during maximal pacing heart rates, they became 
negative and significantly different from control at 
15 seconds after pacing. However, in their study 
also, only 13 out of 20 patients had signs of 
abnormal lactate metabolism at some point during 
the test, which is little different from the values 
from other studies, given in Table III. 
This predominant increase in lactate release from 
the heart at this particular point of time after 
pacing has subsequently been observed in all our 
published material dealing with ischemic 
metabolic changes in man. The potential of im-
proved assessment of myocardial lactate meta-
bolism as indicator of ischemia has not been given 
further official attention. Instead, working on the 
hypothesis, that relatively large numbers of 
patients would be needed to underscore our initial 
observations and to better understand the relative 
impact of lesion location and size on ischemia-
induced metabolic changes,a prospective study 
was carried out in approximately 450 patients, all 
undergoing the same form of stress testing under 
identical circumstances. Of these, patients with 
and without coronary artery disease, with and 
without pre-existing signs of myocardial 
ischemia, and with single left or right versus 
multivessel disease were studied, all undergoing 
myocardial lactate determinations at prefixed time 
points during and after pacing. Moreover, 
coronary flow was also measured in a 
subpopulation. 
As the data analysis has only recently been 
completed, two of the most important questions 
have been addressed and are presented in this 
thesis. 
One compares the sensitivity and specificity of 
lactate versus other markers of ischemia in patients 
with and without significant left coronary artery 
disease (see chapter V), the other investigates the 
reproducibility of lactate changes following 
variable intervals between the pacing stress test 
(chapter VI.2). Preliminary data indicate, that the 
optimal time point to assess myocardial lactate 
production is between 15 and 30 seconds after 
pacing and not at any other point of time during or 
following the test. Moreover, by concentrating on 
this particular period after pacing, the sensitivity 
of the method significantly improves and becomes 
superior to commonly used markers as angina, 
ST-segment changes or alterations in left 
ventricular end diastolic pressure. 
Evaluation of myocardial lactate 
metabolism: radionuclide tracer technique 
versus chemical evaluation. 
Can we further improve the sensitivity of 
myocardial lactate metabolism as an index of 
ischemia in man? 
It has been suggested, that when only chemical 
changes in lactate are measured, regional altera-
tions in lactate release and their contribution to the 
instantaneous, overall lactate extraction pattern, 
may be underestimated or may remain unnoticed. 
Gertz and coworkers assessed myocardial lactate 
metabolism in patients with coronary artery 
disease, measuring arterial and coronary venous 
levels through simultaneous biochemical and 
radionuclide techniques, using 14C-1-lactate as 
tracer for the latter method(67). At rest, they 
clearly showed labelled lactate release from the 
heart during net chemical extraction, thereby 
underscoring the suggestion, that, in fact, chemical 
analysis may significantly underestimate regional 
ischemia. Moreover, in a later study, they 
observed, that during atrial pacing, the 
radioisotope release, already present at rest, 
increased markedly and more significantly than 
chemical lactate release(68). 
However, they also demonstrated, that in a greater 
percentage of patients myocardial lactate release, 
as indicated by the tracer technique but not by the 
chemical method,apparently occurred in the 
complete absence of other objective or subjective 
symptoms of ischemia. More disturbingly, 
significant radioisotope lactate release was also 
present in patients without coronary artery lesions, 
under resting conditions(67) (Fig. 3). Without the 
latter observation, it could be argued, that silent 
ischemia is apparently present (continuously or 
transiently?) in patients with significant coronary 
artery disease. Transient perfusion effects have 
been documented with thallium scintigraphy in 
resting patients without further obvious signs of 
ischemia. Likewise, we have observed resting 
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Fig. 3: Myocardial lactate release, as determined 
by a tracer technique, using 14c -]-lactate. 
Already at rest, myocardial lactate is released as 
a function of the degree of coronary artery 
disease. However, lactate release, not 
appreciated by conventional biochemical 
techniques, is also present in patients without 
coronary lesions (from reference 67, with 
permission). 
abnormalities in myocardial perfusion with 
Krypton-8Jm, distal to significant coronary 
lesions in patients without chemical lactate 
production or other objective signs of ischemiaC69) 
(chapter IV). However, the abnormal tracer release 
of lactate in patients without coronary lesions, 
without any sign of ischemia, is far more difficult 
to explain. Both in vitro studies and animal studies 
have indicated, that lactate release from the heart 
may occur despite normal oxygenationC?0,71), 
which suggests that under certain conditions, some 
background efflux of lactate from specific areas of 
the heart may be "physiologic" (see chapter I, page 
23 for further discussion) or, at least, not directly 
related to hypoxia of cardiac tissues, as already 
suggested by HuckabeeC72). 
To further confound the issue, Hanet and 
coworkers recent!~ reported the opposite in 
silent ischemiaC7 ) . These authors observed a 
significant increase of labelled lactate extraction 
and of myocardial lactate uptake in non-anginal 
patients, in whom, in contrast, chemical lactate 
production and cardiac release was present, taken 
to indicate the presence of asymptomatic 
myocardial ischemia (Fig. 4). 
To date, more data are obviously needed to settle 
this issue. However, it certainly underscores the 
necessity to accept only net chemical production 
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values for lactate as a definite sign of ischemia. 
Can we improve the sensitivity of lactate 
through the determination of additional 
metabolites? 
Pyruvate. 
The ratio of lactate to pyruvate has been proposed 
to improve the sensitivity of the first in the 
assessment of hypoxia. A number of early workers 
in the field reported that this ratio increased in the 
coronary venous effluent during myocardial 
hypoxiaC74-76) .However, Henderson et al. 
observed that lactate and pyruvate do not 
equilibrate freely across the cell membrane and 
that the pyruvate efflux from the isolated rat heart 
exceeds that of lactate by the factor 10(77). This 
suggests, that although potentially more sensitive, 
the ratio of lactate to pyruvate might also be less 
reliable. Besides, on theoretical and mathematical 
grounds, the original concept of "excess lactate" 
presumably does not hold. In addition, later 
animal and human studies during ischemia have 
indicated that pyruvate measurements do not 
improve the sensitivity of lactate as a metabolic 
marker of ischemiaC78). 
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Fig. 4: Net chemical lactate release during fast 
atrial pacing in asymptomatic patients with 
coronary artery disease, indicative of silent 
ischemia. In contrast, a simultaneous tracer 
method with L-(+)[1 - 14C]lactate suggests the 
opposite, i.e. net cardiac lactate uptake (adapted 
from reference 73). 
Alanine and glutamate. 
Besides lactate, the concomitant determination of 
glutamate and alanine fluxes may provide a more 
sensitive means to assess ischemia in man. The 
hypothesis being, that to alleviate lactate 
accumulation during ischemia and the subsequent 
inhibition of various enzymes of the glycolytic 
chain, transamination of glutamate with pyruvate 
occurs. This, subsequently, results in the 
formation of a -ketoglutarate, as a potential fuel 
for the Krebs cycle, and of alanine, which is then 
released from the heart and can be measured. In 
order to maintain the redox state of the 
NADH/NAD+ system, aspartate needs to be 
converted to succinate through the malate-
aspartate cycle (see chapter I, page 20, for more 
detailed discussion). 
Hence, alanine release or enhanced glutamate 
uptake, besides lactate production, should theo-
retically improve the assessment of anaerobic 
glycolysis. 
Thomassen and coworkers recently compared 21 
normal individuals and 64 patients with coronary 
artery disease(79)_ Of the latter, 40 did produce 
lactate during and after atrial pacing, Their data do 
not support the theory that, in humans, glutamate-
alanine changes have a significant impact on the 
overall assessment of metabolism during ischemia. 
Although, as shown in Fig. 5, some extra alanine 
production was present in the group with lactate 
production and some enhanced uptake of glutamate 
in both lactate and non -lactate producers in the 
recovery phase, these effects were relatively 
moderate when compared with the significant 
changes in lactate metabolism. 
Citrate. 
In the same study, Thomassen and coworkers 
stressed, that cytosolic citrate release may be more 
relevant as an additional marker of ischemia than 
the amino acids glutamate or alanine. Previous 
studies by the same group already demonstrated 
citrate release in both normal individuals and 
patients with corona~ artery lesions during 
pacing-induced stress<8 )_ As such, this parameter 
discriminated between groups during the period 
after pacing. Of importance, a significant 
augmentation of citrate release from the control 
situation was also observed in patients who did not 
produce lactate during pacing (79). However, as no 
data were provided to show that this group did 
really develop ischemia during pacing, the real 
value 
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Fig. 5: Myocardial fluxes of lactate, glutamate 
and alanine during and after pacing in patients 
without ischemia and ischemic patients with (LP) 
and without lactate production (NLP) during 
pacing. Despite evidence for some extra alanine 
production and enhanced glutamate uptake in LP, 
compared with other groups, changes are 
moderate and variable, compared with the 
significant effects in lactate metabolism (from 
reference 79, with permission). 
of citrate release as marker of ischemia over and 
above lactate production remains obscure. Also, in 
the study by Thomassen, absolute changes in 
citrate kinetics were minimal. Moreover, they 
occurred in all groups with changes all pointing in 
the same direction. At present, the real 
significance of citrate as a marker of ischemia 
awaits further clarification, preferably from 
different centres as well. 
Nucleosides. 
The determination of cardiac nucleoside release 
provides for an entirely different approach to 
assess myocardial ischemia and one, that is not as 
dependent on substrate delivery as lactate. 
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Contrary to observations in various animal species, 
such as the dog, hypoxanthine efflux, rather than 
adenosine or inosine release, is found in humans 
during ischemia, due to specific differences in 
nucleoside degradating enzyme activity (see 
chapter I). 
We have been the first to report on inosine and 
hypoxanthine release during ischemia in the 
porcine heart and of hypoxanthine, in particular in 
patients with coronary artery disease(43,81-8S)_ The 
results strongly suggest the usefulness of these 
nucleosides as indicators of myocardial ischemia. 
Some are presented in chapter IV. 
In man, our observations were recently confirmed 
by Edlund et al(86). Like us, these authors were 
also unable to detect inosine in appreciable 
quantities or find significant changes in adenosine 
release during ischemia. As such, our results 
contrast with the original publication by Fox et al., 
who reported a significant increase in coronary 
venous adenosine in patients who during atrial 
pacing, became lactate producers<S7). The latter 
study should be considered with some 
reservations, though. First, only coronary venous 
blood levels and not arterial values for adenosine 
were reported. Secondly, the separation in lactate 
versus non -lactate producers was not exact. 
Thirdly, the amount of blood needed for one 
adenosine determination (90 cc) precludes fast and 
easy sampling with the inherent danger of 
erythrocyte damage during the procedure. Our 
results are in even sharper contrast to the 
observations by Kugler(88), who did not find 
significant changes in coronary venous or arterial 
hypoxanthine during pacing-induced ischemia in 
man, although myocardial extraction changed to 
production. Moreover, in his study, ischemia 
significantly affected coronary venous inosine 
levels and changed cardiac extraction of this 
nucleoside to production. 
The main difference between Kugler's 
experimental design and ours is the immediate 
inhibition of blood element metabolism with 8% 
perchloric acid after blood sample collection in our 
studies. Also, the amount of blood needed in our 
studies was significantly less than in Kugler's 
experiment, which must have had an important 
impact on the results. Clearly, Kugler's results 
may have suffered from the additional 
measurement of nucleosides from non-cardiac 
origin. 
In our earlier studies on myocardial nucleoside 
efflux during ischemia in man, cardiac 
hypoxanthine release was compared in anginal 
versus non-anginal patients, as was customary in 
those days. In fact, by so doing, a significant 
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difference was observed between these groups. 
Hypoxanthine release occurred predominantly in 
anginal patients and was apparently more 
pronounced than lactate production in these 
patients (Fig. 6). 
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Fig. 6: Pacing- induced changes in arterial and 
coronary venous lactate and hypoxanthine levels 
in patients who developed angina versus non-
anginal patients. Coronary venous hypoxanthine 
levels rise markedly in anginal patients, more so 
than coronary venous lactate (from reference 55, 
with permission). 
In later studies, patients were never grouped as 
anginal or non-anginal. Instead, patients with 
significant coronary artery lesions were studied as 
one group. Even so, significant hypoxanthine 
efflux again could be demonstrated during pacing-
induced stress in patients who became ischemic, 
also in individuals without angina. 
Two important procedural differences exist 
between our early studies and later experiments, 
the results of both periods given in chapters IV and 
VII. 
First, the biochemical analytical technique 
improved markedly by introducing high-pressure 
liquid chromatography(89,90)_ Subsequently, much 
higher levels of coronary venous hypoxanthine 
were observed during ischemia<91). Also, the new 
technique allowed separation of hypoxanthine and 
xanthine, which before then was not possible. 
Secondly, later studies focussed on the post-pacing 
period. Thus, we found that hypoxanthine efflux 
was most marked after pacing, in analogy with the 
results obtained with lactate. However, the 
maximum for hypoxanthine was at 1 minute post-
pacing and not at 15 seconds, as with lactate. 
Moreover, hypoxanthine efflux was more 
prolonged than lactate production, still being 
present at 5 minutes after pacing. Data are 
presented in chapter VII. 3. 
Also, the temporal relation of these metabolic 
changes with myocardial perfusion, electrocar-
diographic changes and hemodynamic alterations 
are reported. 
Other metabolic markers of ischemia. 
The usefulness of several other metabolites as 
indicators of ischemia have been studied in man, 
using invasive techniques and, generally, by 
applying fast atrial pacing as stress test. 
In contrast to the metabolic changes mentioned 
before in this chapter, most other metabolites have 
not really added in improving the diagnostic 
armamentarium of the invasive cardiologist in this 
area. 
Substances, which are potentially important have 
already been described in detail in chapter I and 
will not be rediscussed here in view of their 
limited or absent applicability·and/or sensitivity in 
man. Moreover, a number have been investigated 
in concert with lactate and hypoxanthine in our 
patient studies and will be duly commented upon 
in the respective manuscripts (chapter IV). 
The effect of ischemia on cardiac prostaglandins 
we believe falls outside the scope of this thesis, 
although we have reported on them in patients 
with silent ischemia at rest as well as during 
pacing-induced ischemia(92,93). 
Furthermore, neurohormones and myocardial 
ischemia will be considered separately in part II of 
this thesis. 
As an exception, however, the effect of ischemia 
on cardiac carnitine fluxes deserves some atten-
tion. 
Camitine. 
The role of carnitine in normal cardiac metabolism 
and during ischemia has been commented upon in 
chapter I. It has been suggested, that the level of 
free carnitine in the cardiac myocyte is essential 
for a number of transport functions, linked with 
free fatty acid flux into the B-oxydation pathway 
and transport of high-energy phosphates over the 
mitochondrial membrane. 
Ischemia-induced loss of free carnitine from the 
heart may therefore have important implications. 
Reduction of cardiac free carnitine levels has been 
demonstrated in animal studies of acute as well as 
relatively long lasting and severe ischemia 
proportional to the reduction in blood flow(94-97). 
We have recently shown, that relatively short and 
moderate episodes of myocardial ischemia in man 
also result in a significant efflux of free carnitine 
from the heartC98) (Fig. 7). 
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Fig. 7: Significant increase of coronary venous 
free camitine levels during pacing- induced 
ischemia without changes in arterial free camitine 
or in total camitine levels. Concomitantly, 
cardiac free camitine uptake changes into release. 
Moreover, our data suggest, that this release is 
from the ischemic area. In contrast, total carnitine 
levels do not change, which implies an increased 
uptake of acyl-carnitines. Whether specifically 
long-chain acyl-carnitines accumulate is unknown 
at present, but is the subject of further studies. 
Animal studies have indicated, that L-carnitine 
suppletion may protect against myocardial 
ischemiaC99). Whether, in man, free carnitine 
release during ischemia is affected by carnitine 
suppletion is unknown. However, Ferrari et al., in 
1984, have suggested that the administration of 
intravenous L-carnitine may have beneficial 
effects on metabolites during pacing-induced 
ischemia, reversing lactate production to extrac-
tion with a simultaneous decrease in glucose 
uptake and enhanced FFA extraction(100)_ 
Moreover, Thomsen and coworkers reported 
improved paciny tolerance after administration of 
DL-carnitineC10 )_ However, as the interval 
between pacing with and without the drug was 
only 15 minutes, the general lack of reproduc-
ibility of objective variables of ischemia (see 
chapter VI.2.) does not allow for such a conclu-
sion. In contrast, several non-invasive exercise 
studies in patients with angina do suggest an 
antiischemic effect of L-carnitine (102-104). 
On theoretical grounds, not L-carnitine but instead 
propionyl- L-carnitine may be the preferred 
substance to reverse changes in myocardial 
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carnitine content during ischemia, as myocardial 
extraction of this derivative is better than that of 
the mother compound. 
Moreover, propionyl-L-carnitine may have 
additional beneficial effects in ischemia through an 
anaploretic effect of propionyl itself. A recent 
placebo-controlled trial did indeed indicate a 
significant improvement with long term propio-
nyl- L-carnitine(IOS). Unfortunately, L-carnitine 
was not investigated in this study. 
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ill.4. 
Usefulness of metabolic markers in delineating the effectiveness of pharmacological 
interventions. 
Reproducibility. 
The first requirement of any method to test 
interventions is reproducibility. In view of the 
invasive nature of the metabolic techniques, dis-
cussed in this thesis, any study, designed to 
delineate the effectiveness of pharmacological 
interventions during ischemia in humans, will 
usually be performed only once. Likewise, such 
studies have to be completed within a reasonable 
time frame. 
The question therefore will be whether metabolic 
changes, induced during repetitive periods of 
ischemia, are reproducible within a time span, 
which is acceptable both in logistical and ethical 
terms. 
Unfortunately, this aspect has received very little 
attention thus far. As a result, the bulk of invasive 
metabolic studies has been performed in an 
uncontrolled way, using various metabolites, in 
particular lactate, to identify the effect of 
interventions on myocardial ischemia. 
Often, the interval between tests has been short, 
presumably too short, to allow cardiac metabolism 
to recover from ischemia before embarking on the 
second episode of ischemia. 
Reproducibility of myocardial metabolic 
markers of ischemia using atrial pacing as 
stress test. 
With respect to the pacing stress test model, which 
is central in this thesis, only a few reports can be 
found in the literature, dealing with the objective 
of reproducibility of metabolic alterations during 
repetitive periods of pacing-induced stress. Of 
these, all but a few have only considered changes 
in cardiac lactate extraction. 
Jackson and coworkers, in 1978, performed a few 
placebo tests in the context of studies on the effect 
of propanolol on cardiac ischemia(106)_ Based on 
observations in 5 patients, of whom only 2 
produced lactate, they concluded, that an interval 
of 45 minutes was needed for reproducible lactate 
production values. In contrast, 3 patients, in whom 
shorter, albeit unspecified intervals were applied, 
had variable lactate production values. In a 
preliminary report, a few years later, we could 
confirm their observations, albeit in a definitely 
larger patient population. Our studies suggested, 
that an interval of 15 minutes resulted in 
significantly less average lactate production 
values. In contrast, when the interval was 
lengthened to 30 minutes, mean values were 
comparable but individual values did vary 
considerably. This was less after 45 minutes. 
Although the results of subsequent studies by 
different groups generally tended to agree with our 
preliminary observations, there is as yet no 
consensus as to the optimal interval between atrial 
pacing stress tests and the reproducibility of 
metabolic values. Thus, whereas with an interval 
of 45 minutes excellent reproducibility of 
individual lactate values were found by Ferrari et 
al. C107), Bagger et al. reported a large variability 
after exactly the same J§eriod(108). Also, whereas 
Drobinsky et al. (1 9) and Pouleur and 
coworkers(llO) reported significantly less lactate 
production after an interval of 20 minutes, which 
agrees with our observations, Ihlen and coworkers 
found good reproducibility in lactate extraction 
values following a similar period(111)_ Although 
the latter discrepancy may relate to different 
pacing protocols it still reflects the absence of a 
consensus as to the resting period needed between 
stress tests. Moreover, dissimilar results have been 
reported with respect to FFA levels after intervals 
varying between 20 and 45 minutes(107,108,110)_ In 
addition, the determination of FFA in conditions 
where heparin has to be administered does not 
make much senseC112). In contrast, cardiac 
exchange of amino-acids and citrate may be more 
reproducibleCl 08-11 O). 
In general, these results do not depend on the 
model used, e.g. whether pacing is incremental or 
at a continuous high rate. However, the duration 
of pacing may have an effect. In this respect, the 
study by Ihlen(lll) is interesting, which implicates 
that very short periods of pacing may allow for 
lactate changes to be reproducible, whereas longer 
periods result in a suppression of lactate 
production. This suggests, that in the latter 
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instance, glycolysis becomes depressed. 
Besides the fact, that very little information exists 
concerning the model, i.e. the reproducibility of 
pacing-induced ischemia, available data stem from 
small patient groups. Also, the number of intervals 
studied between tests is limited and generally not 
performed by the same investigators. 
Hence, we have carried out a prospective, 
comparative study in a larger patient population. 
All patients were investigated at the same time of 
day, fasting and without premedication, submitted 
to a similar type of pacing protocol, the only 
difference being the interval between tests, which 
ranged from 15 minutes to 1 hour. Results on the 
reproducibility of lactate values are given in 
chapter VI.2. 
At present, insufficient data ara available on the 
reproducibility of other metabolites, in particular 
of the nucleosides. However, an early study in the 
ischemic pig model suggests, that during a second 
30-minute period of 60% flow reduction, 
following 35 minutes of reperfusion, cardiac 
nucleoside release is similarly reduced as lactate 
production when compared with the first ischemic 
period (see chapter VI.1). 
These data indicate, that this model of relatively 
severe and protracted ischemia is not suited for the 
study of interventions. Moreover, they suggest 
that the reproducibility of metabolites, such as the 
nucleosides, should be carefully checked before 
embarking on intervention trials using these 
metabolites to indicate antiischemic effects. 
In general, whenever new parameters, whether 
metabolic, prostanoid or neurohumoral of origin, 
are being used to delineate the effectiveness of a 
therapeutic intervention, their reproducibility 
ought to be investigated in a double-blind, 
placebo-controlled manner. Moreover, when 
changes in metabolites, such as lactate, are used 
routinely, each laboratory should establish the 
reproducibility of this parameter in their particular 
setting. We have carried out a number of 
investigations on the effect of different vasoactive 
compounds, primarily based on lactate as marker. 
These investigations were performed after we had 
established the minimum interval for its 
reproducibility (see chapter VI). 
Our studies were carried out under very specific 
conditions, with the patient supine and resting and 
the stress applied in the form of an increase in 
heart rate. This has a number of advantages from 
the model point of view. With pacing, only the 
heart is stressed under very controlled and 
reproducible conditions without general systemic 
effects, which may interfere with ischemia-
induced cardiac alterations. On the other hand, it 
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may be argued, that the model is not very 
physiologic, ischemic attacks usually being evoked 
by different stimuli, e.g. exercise or cold. 
The arguments against the latter forms of stress, 
where metabolic monitoring is concerned, have 
already been mentioned. 
It may also be suggested, that interventions, which 
act mainly by their effect on heart rate, cannot be 
studied in this set-up. This, however, is not 
entirely true, as the agent, which strictly acts by a 
negative chronotropic effect, has yet to be 
discovered. Thus, several studies, using pacing-
induced stress, have been carried out with different 
beta blocking agents, nearly all showing a 
reduction in ischemia following this intervention, 
despite artificially preventing the agent's negative 
chronotropic properties(I06,l13). Likewise, in a 
small, early study we have observed a significant 
reduction in myocardial lactate production 
following 5 mg intravenous atenolol, a selective 
beta-1 blocking drug, in patients with coronary 
artery disease, being studied during repetitive 
atrial pacing stess tests, 1 hour apart (unpublished 
observations). In the latter instance, these effects 
could be explained by an acute, drug-induced 
reduction in arterial pressures as well as in 
contractility and, hence, in myocardial oxygen 
demand. Unfortunately, no data were available at 
that time on coronary flow. 
It has been suggested that beta blocking agents, 
even the selective types, may diminish coronary 
flowC114), either by an autoregulatory effect 
secondary to a reduction in myocardial oxygen 
demand or by an unopposing effect on alpha-
adrenergic tone. 
Indeed, by using the model of pacing-induced 
stress we have observed that a direct vasocon-
strictory effect of beta blockade may be important 
in limiting its antiischemic activity, at least in the 
resting patient. These studies were carried out with 
low- and high-dose intravenous administrations of 
labetalol, thereby altering the relative effects of 
alpha versus beta blockade on systemic and 
coronary hemodynamics(! IS). 
Normotensive patients with coronary artery 
disease either received 0.5 mg/kg, or 2 mg/kg 
labetalol intravenously. Studies were carried out at 
rest, measuring coronary and systemic hemo-
dynamic effects of labetalol for 15 minutes after 
drug administration. Next, its effect on myocardial 
ischemia was investigated during two successive, 
identical atrial pacing stress tests, one hour apart. 
At rest, only the high dose reduced coronary 
vascular resistance, despite a proportionally 
greater decrease in coronary perfusion pressure, 
reflecting more pronounced alpha-adrenergic 
blocking properties of the high dose compared 
with the low dose. In contrast, during pacing, 
coronary vascular resistance increased significantly 
less following the high dose, compared with the 
pretreatment pacing test (Fig. 8). 
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Fig. 8: Effect of high dose (2 mg/kg, HL) or low 
dose (0.5 mglkg, LL) intravenous labetalol on 
coronary vascular resistance (CVR) during 2 
successive, identical atrial pacing stress tests, I 
hour apart (APST I and II, resp.). 'Whereas the 
decrease during maximal heart rates (MAX) is 
similar in low dose patients, the reduction in 
coronary vascular resistance is significantly less 
following the high dose. 
With the low dose, comparable increases were 
seen during, before and after pacing. This 
difference in effect can be explained in two ways. 
One, the more pronounced, unspecific beta 
blocking properties of the higher dose labetalol 
may limit coronary vasodilatation following the 
increase in myocardial oxygen demand, enabling 
alpha-adrenergic coronary vasoconstriction to 
become the limiting factorC116-118). In this respect, 
our recent observation of enhanced norepinephrine 
uptake in the ischemic myocardiumC119), may be 
relevant. Apparently, the more pronounced alpha-
adrenergic blocking effects are not able to 
counteract the effect of the beta blocking part of 
labetalol at this stage. The second explanation for 
the reduction in coronary vascular resistance 
relates to the equally more pronounced reduction 
in myocardial oxygen demand, also observed in 
the high dose group. Consequently, there might be 
less need for coronary flow. However, if this were 
true, one would also expect myocardial oxygen 
consumption to be less, which did not occur. 
Moreover, pacing-induced myocardial ischemia 
should be less in the high dose group. This again 
did not occur. Objective signs of myocardial 
ischemia were reproducible in the high dose group 
(Fig. 9). In contrast, the low dose patients 
demonstrated a significant improvement in 
myocardial lactate metabolism, whereas ST-
segment depression was less, indicating anti-
ischemic effects with the low but not with the high 
dose. 
LACTATE-
UPTAKE 
(.umol/min) 
ST-SEGMENT 
DEPRESSION 
mV 
-0.2 
-0.1 
X±SEM 
* p < .05 APST I vs. APST II 
i p < .05 HL vs. LL 
- HL,n= 14 
~/. LL, n = 13 
Fig. 9: Antiischemic effects of low dose labetalol 
(LL) during 2 successive pacing tests (APST I and 
II, resp.), indicated by significant improvement of 
myocardial lactate metabolism. In contrast, no 
such effects are observed with the high dose 
patients (HL). 
This observation favours the concept that beta 
blocking agents may limit the necessary decrease 
in coronary vascular resistance during pacing-
(and possibly exercise-)induced stress in the post 
stenotic area. 
This example identifies one of the major 
advantages of the atrial pacing stress test protocol, 
its potential to examine the underlying 
pathophysiologic mechanisms of ischemia in a 
well defined and controlled manner. 
By using this technique we have been able to 
identify mechanisms, through which different 
types of vasoactive agents and specific neuro-
humoral modulators may result in acute anti-
ischemic effects in the resting patient. 
In this respect amiodarone, bepridil and diltiazem 
have been studied. Results are presented in chapter 
VIII. Moreover, we have differentiated the effects 
of some of these compounds in patients with a 
normal versus depressed cardiac pump function 
(see chapter IX). 
-71-
The latter may be clinically important as it helps 
identifying the responsiveness to and tolerability of 
these drugs in patients with severe ischemia at rest, 
in whom ventricular function usually is depressed. 
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J. W. DEjONG, P. D. VERDOUW AND W.J. REMME. Myocardial Nucleoside and Carbo-
hydrate Metabolism and Hemodynamics During Partial Occlusion and Reperfusion of 
Pig Coronary Artery. :Journal qf Molecular and Cellular Cardiology (1977) 9, 297-312. The 
effect of local ischemia on myocardial metabolism and hemodynamics was studied in 
open-chested pigs. Coronary artery flow was reduced by 74% with a screw clamp for one 
hour, after which period the clamp was released. Arterial and local coronary venous 
samples were taken repeatedly during control, occlusion and reperfusion. During control, 
the myocardium extracted lactate (20%) and inosine (24%). No or minor arteriovenous 
differences were measured for glucose, potassium, inorganic phosphate and hypoxanthine. 
During ischemia, the heart consumed glucose (about 25%); lactate and inosine extraction 
decreased to minimal values of -126% and -642%, respectively. Hypoxanthine, 
potassium and inorganic phosphate showed relatively small changes in arteriovenous differ-
ence. Extraction patterns approached control values during release. Myocardial oxygen 
uptake decreased by 68% after occlusion. Immediately following release, uptake returned 
to control value, but subsequently it fell again by 20 to 30%. Extensive and long-lasting 
reactive hyperemia was observed during reperfusion. However, flow debt was only 
partially repaid. Throughout the experiment heart rate increased, and cardiac output and 
mean aortic pressure decreased. During occlusion, the peak derivative ofleft ventricular 
pressure decreased about 24%; peripheral resistance and left ventricular end-diastolic 
pressure increased 20 to 30%. These changes were only partially reversed during reper-
fusion. !tis concluded that, in addition to changes in lactate metabolism, myocardial inosine 
production is a good marker for myocardial ischemia in the pig, because it correlates well 
with carbohydrate extraction and ventricular function, and the occlusion-induced changes 
are relatively large. 
KEY WoRDs: Myocardial ischemia; Inosine; Hypoxanthine; Lactate; Glucose; Inorganic 
phosphate; Potassium; Left ventricular pressure; Cardiac output; Peripheral resistance; 
Coronary constriction; Flow and oxygen debt; Contractility. 
I. Introduction 
Electrocardiographic and hemodynamic measurements have not been able to 
quantitatively delineate functional changes due to ischemic heart disease. Ab-
normalities of myocardial lactate metabolism can indicate the severity of this 
disease [20, 27]. However, the usefulness of the latter has been questioned [17, 19]. 
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Brachfeld [2] and Cohen [5] summarize a number of conditions in which lactate 
changes were not associated with hypoxia. At a symposium of the World Health 
Organization [24] a search for other metabolic indicators of myocardial ischemia 
was suggested. 
Catabolites of adenine nucleotides accumulate in the ischemic heart [I, 7, 14, 
25]. Also the release of these compounds during ischemia has been demonstrated. 
Coronary venous and coronary sinus levels of inorganic phosphate increase after 
coronary artery occlusion in dogs [II, 23, 28-30]. Phosphate [4], adenosine [12] 
and hypoxanthine [ 32] release could be found from human hearts during angina 
induced by rapid atrial pacing. Pig hearts released some inosine and hypoxanthine 
after partial occlusion of a coronary artery [ 8, 15]. The present study was under-
taken in order to compare the myocardial release of several ATP-catabolites and 
other metabolites, and relate these to changes in hemodynamic parameters during 
ischemia and reperfusion. Myocardial inosine release seems to be useful as a marker 
for ischemia of the pig heart.* 
2. Materials and Methods 
Animal preparation 
Male or female Yorkshire pigs (20 to 25 kg) were fasted for about 24 h. The animals 
were sedated with 120 mg azaperone (Stresnil, Janssen Pharmaceutica, Beerse, 
Belgium) i.m. Subsequently 150 mg metomidate (Hypnodil, Janssen Pharmaceu-
tica) was administered via a vein on the dorsal surface of the ear [ 21]. The animals 
were intubated and connected to a Pulmonat respirator for artificial respiration 
with a mixture of 33% oxygen and 67% nitrous oxide, at a frequency of 12/min 
(tidal volume about 20 mlfkg). Ventilation was controlled by continuous moni-
toring of expired carbon dioxide (kept at about 4%) with a Capnograph (Jaeger, 
Wiirzburg, GFR) and intermittent measurement of arterial blood gases. Oxygen 
saturation was measured with an in vitro hemoreflectometer (American Optical 
Company, Framingham, Mass.). Arterial oxygen saturation was maintained above 
95%. The temperature of the animals was kept between 35 ° and 37 °C with a heating 
pad and infrared lamps. ECG leads I, II and III were recorded throughout the 
experiment. A single SF Cournand catheter was positioned in the thoracic aorta 
via the left femoral aretery. The lumen was used for central aortic pressure measure-
ments by connecting it to a P23Db Statham pressure transducer, and for the with-
drawal of blood samples for the determination of blood gases and biochemical 
parameters. Through the right femoral vein a 7F triple lumen balloon-tipped 
thermodilution catheter (Edwards, Santa Anna, Ca.) was positioned in the pul-
* Part of this work has been presented at the 25th Annual Scientific Session of the American 
College of Cardiology, New Orleans, La., 1976 [9]. 
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monary artery for the determination of cardiac output [ 13]. Through the left caro-
tid artery an 8 MMC Dallons-Telco catheter (Thomson, Paris, France) with a 
frequency response flat to 1000 Hz was placed in the left ventricle for the recording 
of left ventricular pressure. From the right jugular vein an SF Cournand catheter 
was placed in the right atrium for the administration of anesthetics consisting of a 
mixture of 2 mg kg-1 h-1 azaperone and 8 mg kg-1 h-1 metomidate [21]. The 
catheter was connected intermittently to a P23Db Statham transducer for the 
determination of right atrial pressure. 
Surgical procedure 
The left ventricle was exposed by means of a midsternal incision and sufficient parts 
of the cleaved fourth and fifth ribs were removed to get easy access to the left an-
terior descending coronary artery (LAD) and accompanying vein. The LAD was 
then dissected free from its origin to its first branch. This allowed for about 1 
em of free artery around which an electromagnetic flow probe (Skalar, Delft, 
The Netherlands; 20 to 25 mm in diameter) was applied. Distal to this flow 
probe, but before the first branch, a ]-shaped screw clamp was placed. Zero flow 
was obtained by occluding the LAD with an atraumatic forceps. In 12 pigs the 
accompanying cardiac vein was cannulated with a polyethelene catheter (internal 
diameter 1.0 mm) with its tip in the zone expected to become ischemic. Care was 
taken for a free runoff of cardiac venous blood. The blood was collected and re-
turned to the animal. Mter dissection of the vessels a total of 3 ml lidocaine was 
applied to prevent spasm. The system was flushed with about 3000 units heparin. 
Three sham-operated animals served as control. Blood sampling and hemody-
namic measurements were carried out as in the other animals. 
In a third group of six animals also the ramus circumflex was dissected and a 
flow probe was placed around the vessel. Mechanical interference prevented can-
nulation of the vein accompanying the circumflex, when flow probes were placed 
around the left anterior descending and the circumflex. No biochemical data were 
obtained from these experiments. 
Hemodynamic measurements 
All tracings were recorded on a Siemens Oscillomink B recorder. Cardiac output 
recordings were made in duplicate. Between the cardiac output determinations, 
left ventricular pressure, its first derivative (LVdPJdt) and aortic pressure were 
recorded at high speed. During this recording the ventilator was switched off to 
avoid baseline drift due to respiratory assist. From the tracings the following para-
meters were obtained: left ventricular end-diastolic pressure (LVEDP), maximum 
rate of rise ofleft ventricular pressure (peak LVdPJdt) and mean aortic pressure. 
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For an accurate assessment ofLVEDP, the gain of the left ventricular pressure sig-
nal was magnified five times during part of the recording. Heart rate was counted 
from the EGG, while peripheral resistance was calculated from: 
. h 
1 
. mean aortic pressure-right atrial pressure 
penp era resistance = eli · 
car ac output 
Biochemical measurements 
Blood samples were taken and handled as described earlier [ 8]. Plasma glucose [ 36], 
potassium [ 37] and inorganic phosphate [ 38] were assayed on an AutoAnalyzer II 
(Technicon, Tarrytown, NY) with Technicon SMA reference serum/CPK as the 
standard. The following determinations were performed in duplicate. Lactate was 
assayed enzymically in deproteinized acid samples on the AutoAnalyzer [8]. 
Standard curves were made with lithium lactate in 4% HCl04. Inosine and hypo-
xanthine were detennined at room temperature (22 °C) in neutralized samples as 
described before [ 8]. Samples containing less than 5 [.LM inosine were assayed 
according to Olsson [ 25]. 
Experimental protocol 
After a stabilization period of 30 min control hemodynamic measurements were 
performed and simultaneously blood samples drawn from the descending aorta 
and the local coronary vein. Subsequently the mean LAD blood flow was reduced 
to about 25% of control by tightening of the screw clamp. The clamp was adjusted, 
when needed, to control the flow at a stable level during the entire ischemic period 
of 60 Inin. During ischemia, the same parameters were recorded and samples 
collected as during the control run. Subsequently the clamp was released. All 
hemodynamic measurements were carried out again and blood samples were col-
lected for 50 min. 
Statistical anafysis 
Student's paired t-test (two-tailed) was used. P > 0.05 was considered to be not 
significant (N.s.). P-values are given for comparison with the mean control value, 
unless otherwise indicated. 
3. Results 
Ventricular arrhythmias 
Ventricular arrhythmias were observed frequently in the first half hour after the 
flow was reduced by about 75%. After 30 Inin ventricular arrhythmias became 
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rare. Ventricular fibrillation occurred in 25% of the pigs, all within the first half 
hour. No attempts were made to defibrillate these animals and they were excluded 
from the study. Complete occlusion of the left anterior descending coronary artery 
always causes ventricular fibrillation of pig heart within 30 min [see also ref. 33], 
which excludes complete ligation in the open-chested anesthetized pig as a model 
for the study oflonger periods of ischemia. 
Coronary blood flow 
In all six animals in which the flows through the left anterior descending coronary 
artery and the ramus circumflex were measured simultaneously, the LAD flow 
was dominant: it was 2 to 2.5 times the circumflex flow. During the LAD occlusion 
period (up to one hour) there was no increase in circumflex flow. Also no change in 
LAD flow and in the oxygen saturation of its accompanying vein was found, when 
the circumflex was occluded for as long as one hour. 
Figure 1 shows the time course of LAD flow during the experiment. Partial 
occlusion of this artery resulted in a decrease in coronary blood flow from 26.5 ± 
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FIGURE 1. Time course of coronary blood flow and heart rate during control, partial occlusion 
of the LAD, and release. Mean values± s.E. are presented (n = 6-9). < indicates P < 0.05. The 
shaded areas during occlusion and release represent the flow debt and reactive hyperemic flow 
("repayment"), respectively. 
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2.3 (mean ± s.E.) to 7.0 ± 0.4 mlfmin (P < 0.001). Mter release of the clamp, 
extensive and long-lasting reactive hyperemia was observed. Peak hyperemic flow 
was reached after about 2 min (58.8 ± 8.7 ml/min, P < 0.01). Flow debt [26] 
during the occlusion period was 1170 ml, while the reactive hyperemic flow tumed 
out to be 375 ml. Consequently there was no total repayment of the flow debt as 
(reactive hyperemic flow) f (flow debt) was only 0.32. 
At the end of the experiment the flow values approached the control level. 
Heart rate 
Heart rate (Figure 1) increased gradually from 113 ± 7 to 142 ± 13 beats/min 
(P < 0.05) during ischemia and continued to rise during the release period to 155 
± 11 beats/min (P < 0.01). 
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FIGURE 2. Coronary venous oxygen saturation (02 sat) and myocardial oxygen uptake during 
control, occlusion and reperfusion (X ± s.E., n = 4-9). Oxygen uptake was calculated as (A-V) 
Oz sat X coronary flow X [hemoglobin] X hemoglobin-bound 02. No correction was made for 
physically dissolved oxygen. Mean arterial 02 sat was 97% throughout the experiment, and mean 
hemoglobin concentration was 120 gfl. Hemoglobin binding capacity was taken to be 1.34 ml 
0 2 /g hemoglobin. < indicates P < 0.05. The shaded area during occlusion represents the oxygen 
debt, which is not repaid during release. 
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Myocardial oxygen uptake 
Local venous oxygen saturation during control was 47.1 ± 3.2%. This was re-
duced to 35.9 ± 2.0% (P < 0.005) after 2 min of occlusion an<l remained decreased 
during ischemia (Figure 2). Mter release, oxygen saturation increased to 71.3 ± 
4.1% (P < 0.001) and dropped gradwilly to 57.5 ± 5.9% (P < 0.05) at the end of 
the experiment. 
Oxygen uptake decreased from 1.91 ± 0.09 ml/min during control to 0.62 ± 
0.03 ml/min (P < 0.001) during the ischemic period (Figure 2). During reperfu-
sion, there was a return to control value in the first minutes, but subsequently 
oxygen uptake dropped somewhat. Thus no repayment of oxygen debt was ob-
served. 
Pressures, cardiac output and peripheral resistance 
Peak LVdPJdt decreased about 24% during ischemia. The decrease was only 
statistically significant during the first half hour of occlusion (Figure 3). During 
reperfus~on, 90% of control value was found (N.s.) A few minutes after occlusion 
LVEDP increased from 6.8 ± 0.9 to 8. 7 ± 1.0 mmHg (N.s.). L VEDP remained at 
that level during the ischemic period. Mter release, LVEDP dropped to 5.8 ± 1.3 
mmHg (N.s. versus control, P < 0.05 versus ischemic values). Mean aortic pressure 
decreased gradually during ischemia by 11% (Figure 3). Mean aortic pressure 
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FIGURE 3. Changes in peak L VdP(dt and mean aortic pressure during the experiment (X ± s.E., 
n = 6-9). < indicatesP < 0.05. 
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continued to decrease during release: At the end of the experiment it was 76% 
of control. 
A gradual decrease in cardiac output was observed during occlusion (Figure 4). 
The values remained decreased during reperfusion (64% of control). Peripheral 
resistance (Figure 4) increased gradually during occlusion. The resistance exceeded 
at the end of occlusion control values by 28% (P < 0.005); during release, it 
levelled off, but remained elevated. 
Biochemical changes 
The control value of arterial lactate (3.84 ± 0.52 mM) rose gradually to 6.29 ± 1.03 
mM (P < 0.001) at the end of the experiment (Figure 5). Occlusion-induced changes 
in myocardial carbohydrate extraction were observed. Lactate extraction during 
control (20.4 ± 2.9%) decreased immediately, with minimal values ( -126 ± 
16%, P < 0.001) during the first lO min of occlusion (Figure 5). During control, 
myocardial glucose consumption was of minor importance. Mter occlusion, 
however, the heart extracted about 25% (P < 0.001) of glucose (Figure 5). Both 
lactate and glucose extraction approached their control values at the end of re-
lease. 
During control, inosine is extracted by the heart (Figure 6). The average venous 
control value (14.3 ± 2.5 fLM) is different from the arterial one (17.9 ± 2.5 fLM, 
P < 0.001). This inosine extraction (24.4 ± 6.1 %) decreases, with a minimal 
value of -642 ± 116% (P < 0.001) at lOminofischemia. 
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FIGURE 4. Cardiac output and peripheral resistance (Rp) during the experiment (X ± S.E. 
n = 6-9). < indicatesP < 0.05. 
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Figure 6 also shows release of hypoxanthine from the heart during ischemia. At 
the end of release the coronary venous levels of both ATP-catabolites approach the 
arterial levels (which increase gradually during the experiment). 
Figure 7 shows the changes in potassium and inorganic phosphate. The venous 
levels of both electrolytes exceed the arterial values somewhat during control. 
During occlusion, venous potassium increases rapidly by 50% (P < 0.001) followed 
by a return towards the arterial level. The elevation in venous inorganic phosphate 
is most pronounced during the first 15 min of occlusion (up to 35%, P < 0.001); a 
gradual decrease is observed thereafter. Venous electrolyte levels approach arterial 
values during release. 
Correlations 
In Table 1 correlations between several parameters are given. High correlations 
(r = I 0.94-0.971) were observed for the arteriovenous difference of inosine and 
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FIGURE 5. Lactate production and glucose consumption by the ischemic heart. The arterial ( e - - e) and coronary venous ( e--e) concentrations of whole blood lactate and plasma glucose 
are indicated (mean with one s.E., n = 6-9). < indicates P < 0.05 for comparison of coronary venous 
with arterial levels. 
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hypoxanthine with lactate and glucose extraction. Figure 8 shows the correlation 
between coronary venous inosine and myocardial lactate extraction (r = -0.93). 
Lactate and glucose extraction correlated significantly less with the arterio-venous 
difference of potassium (r = 0.74 and -0.52, respectively, Table 1). The same 
table shows the correlation between several biochemical parameters and LVdP/dt. 
Relatively high degrees of correlation were found for expressions of carbohydrate, 
inosine or inorganic phosphate utilization versus LVdPfdt. Such a correlation was 
absent versus peripheral resistance. 
4. Discussion 
Left anterior descending flow exceeds circumflex flow 2 to 2.5 times. This is in 
agreement with the findings of Schaper [33], who injected pig coronaries with an 
epoxy-polymer; the LAD cast weight was double the circumflex cast weight. Thus, 
the LAD provides more blood to the pig left ventricle than the circumflex does. The 
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FIGURE 6. Inosine and hypoxanthine release from the ischemic heart. Whole blood arterial 
(e-- e) and coronary venous (e-e) levels of both ATP-catabolites are shown (mean with 
one s.E., n = 7-9). < indicates P < 0.05 for comparison of venous with arterial levels. 
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TABLE 1. Correlation between changes in myocardial metabolite levels with lactate and 
glucose extraction and the first derivative ofleft ventricular pressure, LVdP/dt. 
Correlation coefficients (r) were calculated for the mean values (n = 20, obtained 
during control, occlusion and release) in 9 pigs, of extraction or arterio-venous 
difference (A-V) of several biochemical parameters with lactate and glucose 
extraction and LV dP/dt 
Versus Versus Versus 
lactate extraction glucose extraction LVdPjdt 
r p r p r p 
Lactate extraction -0.87 <0.001 0.86 <0.001 
Glucose extraction -0.87 <0.001 -0.75 <0.001 
A-Vinosine 0.94 <0.001 -0.94 <0.001 0.77 <0.001 
A-V hypoxanthine 0.94 <0.001 -0.97 <0.001 0.58 <0.005 
A-V potassium 0.74 <0.001 -0.52 =0.001 0.65 <0.001 
A-V inorganic phosphate 0.94 <0.001 -0.77 <0.001 0.74 <0.001 
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FIGURE 7. Release of potassium and inorganic phosphate from the ischemic myocardium. 
Plasma arterial ( e - - e) and coronary venous ( e--e) concentrations are shown (mean with one 
s.E., n = 7-9). < indicates P < 0.05 for comparison of venous with arterial levels. 
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right coronary artery is of the same size as the left anterior descending coronary 
artery. These distributions resemble more closely the situation in man than the dog 
heart does [ 3, 33]. 
A number of investigators emphasized that the metabolic consequences 9f coro-
nary artery occlusion are best studied by assay of samples draining the zone of 
ischemia [see, for instance, refs. 6, 11, 30]. In an earlier study [8] we reduced the 
peak flow in the LAD by 50%, which caused an average initial increase in coronary 
venous inosine of 70%. However, in 7 out of these 14 pigs h1creases in coronary 
venous inosine were below 35%. In the present study mean flow in the LAD was 
reduced by 74% resulting in a remarkable increase in the release of inosine (Figure 
6). Within 5 min of partial occlusion coronary venous inosine exceeded the arterial 
level by more than 230% in all pigs. This release of inosine is accompanied by 
excessive production oflactate (Figure 5). Coronary venous inosine levels and myo-
cardial lactate extraction correlate very well, except for the values found within 2 
min of occlusion: the initial change of lactate extraction to lactate production is 
more pronounced than that of inosine (Figures 5, 6 and 8). This difference during 
the first few minutes of ischemia could be due to the fact that lactate is an end-
product (of anaerobic glycolysis), whereas inosine can be catabolized. Inosine and 
lactate production reach a maximum at about 10 min of ischemia and gradually 
level off thereafter. It is doubtful that the decrease of inosine and lactate production 
Myocardial lactate extraction 
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FIGURE 8. Correlation between the mean values of lactate extraction and venous inosine 
concentration during control, partial occlusion and reperfusion. (.) Value found 2 min after 
occlusion. r = 0.93, P < 0.001, n = 20 (9 pigs). 
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is due to the mobilization of collateral flow in the myocardium. The pig heart has 
a very poorlyfunctioning collateral system; it has the ability to develop a sizable 
functional collateral circulation [18], but this is not likely to occur within one hour 
[34]. Measurements of microspheres or by casts are necessary to obtain more in-
formation on the collateral system under our experimental conditions. 
It can be speculated that the extraction of inosine observed during control (24%) 
reflects an active salvage pathway of purine nucleosides in pig heart, via hypoxan-
thine, IMP andadenylosuccinate [22]. 
During control, lactate is the main substrate for the pig heart under these ex-
perimental conditions. If one assumes that the lactate extracted by the pig myo-
cardium is converted to carbon dioxide and water, more than 70% of the myocar-
dial oxygen consumption is accounted for. The extraction of glucose is only im-
portant during ischemia; during control, insignificant amounts of glucose (and 
free fatty acids, unpublished observations) are extracted. Myocardial utilization of 
carbohydrates depends on the arterial concentration of a variety of substrates of the 
heart (fatty acids, ketone bodies, lactate, glucose). The concentration of substrates 
may vary considerably: for instance, under azaperone-metomidate anesthesia 
arterial lactate levels are 3 to 4 times higher than those observed under pento-
barbital [8], fentanyl [10] or halothane [10] anesthesia. Brachfeld [2] pointed out 
that despite great care, one may still fail to obtain evidence of ischemia by reliance 
on evidence of anaerobic glycolysis alone. Throughout the study coronary venous 
inosine or its arteriovenous difference correlates very well with lactate extraction 
and glucose extraction (Table 1, Figure 8). Change in arteriovenous inosine 
difference appears to be useful as a (additional) parameter for myocardial ischeinia 
in the species used in this study. Changes in myocardial inosine metabolism also 
were found to correlate with changes in LVdPfdt (Table 1). In earlierstudies [8, 
16] a correlation between local venous inosine and the degree of myocardial wall 
thickening was observed during ischemia. In this study the myocardial ATP con-
tent was not measured. It is speculated that the nucleosides released during occlu-
sion reflect depletion of ATP from a compartment involved in contraction. 
Opie et al. [28, 29] and Mathur and Case [23] occluded the LAD in the dog, 
which results in a reduction in flow to 12% of control [ 34]. Potassium and inorganic 
phosphate releases were much less evident than changes in lactate metabolism 
after LAD occlusion [23, 28, 29]. Also in the present study in which the LAD was 
partially occluded, release of these ions was small compared to changes in the 
myocardial metabolism of carbohydrates and nucleosides. 
Arterial lactate, inosine and hypoxanthine rose gradually by 60 to 70%. At the 
same time heart rate increased throughout the experiment, whereas cardiac output 
and mean aortic pressure decreased. These changes indicate that the condition of 
the pigs deteriorated in the course of the experiment. This is further evidenced by 
our control studies with sham-operated animals in which these biochemical and 
hemodynainic parameters remained at their initial value. Peripheral resistance, 
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LVdPJdt and LVEDP did not return to control values after the occlusion period, 
which also indicates that irreversible changes took place. As was shown recently 
[31, 35], after (total) occlusion of longer duration, reperfusion failed to restore 
contractility to any significant extent. 
During 50 min of reperfusion flow debt was only partially repaid and oxygen 
debt was not repaid (Figures 1 and 2). This contrasts findings with occlusions 
lasting up to minutes that oxygen and flow debt are invariably overpaid [see 
review, ref. 26]. Sharma et al. [35] reported that the severe myocardial damage 
induced by total occlusion of canine LAD for 60 to 90 min was not reversed by 
reperfusion for one hour. They stated that longer periods of reperfusion may be 
beneficial. In our experiments no biochemical evidence was found for anaerobic 
myocardial metabolism after 50 min of reperfusion. Lactate was again utilized by 
the heart, and glucose extraction was nil. At the end of the experiment oxygen and 
lactate uptake were not significantly different from control values. 
It is concluded that, in addition to changes in lactate metabolism, myocardial 
nucleoside production is a good marker of myocardial ischemia, because it corre-
lates well with carbohydrate extraction and the occlusion-induced changes are 
relatively large. Changes in contractile properties of the heart correlate with changes 
in myocardial lactate and inosine metabolism. 
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Inosine and hypoxanthine are useful markers of early myocardial ischemia 
in pigs. In this study the applicability of the products of adenosine tri-
phosphate (ATP) breakdown as markers of myocardial ischemia in man 
was investigated in 25 patients undergoing diagnostic cardiac catheter-
ization for suspected coronary artery disease. Pacing-induced myocardial 
ischemia resulted in elevated coronary sinus hypoxanthine levels only 
after the onset of angina in 18 patients (from 1.2 ± 0.2 p.molar [mean± 
standard error of the mean] during the control period to 2.4 ± 0.5 p.molar 
during ischemia, P <0.05), whereas lactate production often occurred 
before angina was noted. Neither hypoxanthine nor lactate levels changed 
in seven patients without angina. No significant pacing-induced alterations 
were found in plasma potassium, inorganic phosphate, glucose or oxygen 
saturation in either group of patients. No hemodynamic variable, except 
postpacing left ventricular end-diastolic pressure, served as a useful di-
agnostic marker separating patients with and without myocardial isch-
emia. Significant S-T changes during maximal heart rates occurred in only 
12 of the 18 patients with angina and in none of those without angina. We 
conclude that release of hypoxanthine is a useful indicator of pacing-
induced ischemia in the human heart. 
Protection of the ischemic myocardium with pharmacologic, mechanical 
or surgical interventions has been a major goal of cardiac research in 
recent years. Sensitive markers of the degree of ischemia are needed to 
evaluate the effects of subsequent interventions. Sudden hypoxia at the 
cell level results within seconds in increased anaerobiosis accompanied 
by a precipitous decrease in the high energy compound creatine phos-
phate and followed by a breakdown of adenosine triphosphate (ATP).1•2 
This enhanced degradation of ATP causes increased efflux of the 
breakdown products that are able to pass the cell membrane-inorganic 
phosphate, adenosine, inosine and hypoxanthine.3 In the pig heart a 
sudden reduction of coronary blood flow is associated with release of 
myocardial inosine and hypoxanthine4 that reaches a maximum at 5 
minutes of ischemia. Because lactate production reaches its peak value 
somewhat earlier,5•6 lactate appears to be preferable as an early metabolic 
indicator of ischemia and has been used in many clinical studies to 
quantitate the amount of ischemia. However, its usefulness for this 
purpose has been questioned7 because lactate extraction or production 
patterns may depend on the nutritional status of the patient, the blood 
levels of free fatty acids and the existence of diabetes mellitus or alka-
losis. 8•9 Especially in studies of several hours' duration, in the first hours 
of myocardial infarction, for example, lactate metabolism may be af-
fected by extracardiac factors. Thus metabolic markers that are less 
susceptible to extracardiac influences are needed. 
Fox et aL 10 have shown that small amounts of adenosine are produced 
during pacing-induced ischemia in the human heart. However, no ex-
periment~ have been reported on the release during myocardial ischemia 
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of the other products of ATP degradation such as in-
osine and hypoxanthine. We have extended our studies 
in the pig heart and investigated the release of hypo-
xanthine during pacing-induced ischemia in the human 
heart, comparing the possible value of hypoxanthine as 
an indicator of myocardial ischemia with that of other 
metabolic, hemodynamic and electrocardiographic 
variables. 
Materials and Methods 
Twenty-five adults underwent cardiac catheterization for 
evaluation of coronary artery disease. In all patients the only 
manifestation of cardiac disease was angina pectoris for which 
they were taking nitroglycerin or beta adrenergic blocking 
TABLE I 
Summary of Clinical and Catheterization Data 
Case Age (yr) 
Rl 
no. & Sex 
Site of 
Old Ml Vessel Involved 
FIGURE 1. The pacing protocol. After control (C) deter-
minations, pacing was started at a rate of 10 beats/min 
higher than control rhythm. The pacing rate was in-
creased every 2 minutes by 10 beats/min until pacing had 
to be stopped (because of anginal pain or atrioventricular 
block). Samples obtained during the control period and 
during pacing (P1, P2 and P3) and recovery (R1 and R2) 
periods were analyzed. 
drugs. The latter drugs were withheld 1 week before cathe-
terization. No patient had clinical diabetes mellitus. Studies 
were carried out after an overnight fast and without pre-
medication. No drug, other than 45 to 60 mg of heparin, was 
administered during the study. 
Right heart catherization was performed with a no. 7F 
Swan-Ganz thermodilution catheter inserted by way of an 
antecubital vein. Measurements included pulmonary arterial 
and pulmonary wedge pressures, right ventricular and right 
atrial pressures and duplicate cardiac output measurements. 
After the measurements were completed the thermodilution 
catheter was replaced with a no. 7 bipolar Zucker catheter, 
which was positioned with its proximal electrode just inside 
the coronary sinus orifice, where it remained throughout the 
study. Its position was checked regularly with fluoroscopy. 
Col· S-T Segment 
lateral Depression (mv) 
Vessels LV Contraction During Pain 
Group With Angina (no. ~ 18) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
58M 
46M 
46M 
49M 
49M 
40M 
52M 
41M 
56M 
44M 
511\il 
51M 
38F 
45M 
53M 
40M 
46F 
58M 
49M 
50M 
42M 
46M 
34M 
34M 
40M 
Ant 
lnf 
Post 
Ant 
Ant, lnf 
Ant, lnf 
lnf-Post 
Ant 
Ant 
Post-In! 
LAD, RCA + + 0.2 
LAD, LCx +Ant 
LAD, RCA + +Apex 0.1 
LAD, I_Cx, RCA + Normal 
LAD, LCx, RCA + + lnf 0.1 
LCx, diag, RCA Normal 
LAD, LCx, RCA + + lnf 0.2 
LAD +Ant 
LMCA, LAD,LCx,RCA ++ Apex, Ant 
LAD, diag, LCx, RCA + Normal 0.1 
LAD, LCx, RCA + ++ Apex 0.2 
LAD, LCx, RCA +U 0.5 
LAD, marg, LCx, RCA + Normal 0.1 
LMCA, LAD, LCx + Normal 0.2 
LAD, LCx, RCA + + + Apex, Ant 0.1 
LAD, LCx, RCA + U Ant 
LAD + +Apex 0.2 
LAD, LCx, marg, RCA + Normal 0.1 
Group Without Angina (no.~ 7) 
Normal 
Normal 
LCx, RCA + lnf 
Normal 
LAD I Apex 
Normal 
Normal 
Ant= anterior; diag =diagonal branch; lnf =inferior; LAD= left anterior descending coronary artery; LCx =left circumflex coronary artery; 
LMCA::;: left main coronary artery; marg =first marginal branch; Ml =myocardial infarction; Post= posterior; RCA= right coronary artery. 
+=present;- =absent; +, + +, + + + indicate increasing degrees of abnormality of the left ventricular contraction pattern. 
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This catheter was used for atrial pacing and sampling of cor-
onary sinus blood. Through a right brachial arterial cutdown 
procedure a tip micromanometer catheter (Dallons-Telco 
MMC no. SF or Millar Instruments no. 7F) was positioned in 
the left ventricle for left ventricular pressure recording and 
sampling of arterial blood. 
Pacing procedure: A 15 minute stabilization period was 
allowed after the catheters were positioned. For control 
measurements arterial and coronary blood samples were si-
multaneously drawn, three electrocardiographic leads (I, a VF 
and V 2), were recorded and left ventricular pressure and its 
first derivative (dP/dt) were determined. Subsequently atrial 
pacing was started at a rate 10 beats/min higher than the pa-
tient's own control rate. Every 2 minutes the pacing rate was 
increased by 10 beats/min until patient had anginal pain or 
the occurrence of atrioventricular (A-V) block made further 
pacing impossible. Blood samples and hemodynamic and 
electrocardiographic measurements were taken at 4 minute 
intervals after the onset of pacing. The last determination 
during pacing (P3 in Fig. 1) was always made when cessation 
of pacing was thought necessary and thus might be obtained 
within 4 minutes after collection of the previous data (P2 in 
Fig. 1). After 5 and 10 minutes of recovery (R1 and R2, re-
spectively) these determinations were repeated. Cardiac 
catheterization was completed with left ventriculography and 
selective coronary angiography. 
Biochemical measurements: Blood (1.5 ml) for hypo-
xanthine and lactate measurements was rapidly deproteinized 
with an equal volume of cold 8 percent perchloric acid (HC104 ) 
and centrifuged. In the supernatant, lactate was assayed11 
enzymatically in duplicate on an AutoAnalyzer II (Technicon, 
Tarrytown, New York). (Standard curves were made with 
lithium lactate in 4 percent HC104.) Hypoxanthine was de-
termined according to the method of Olsson. 2 Approximately 
2.5 ml of blood was collected for the assay of plasma glucose, 
potassium and inorganic phosphate12 on the AutoAnalyzer 
II with Technicon SMA reference serum/creatine kinase as 
the standard. Oxygen saturation was determined in duplicate 
on a hemoreflectometer (American Optical Co., Framingham, 
Massachusetts). 
TABLE II 
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Hemodynamic measurements: During each recording 
period left ventricular pressure tracings of 12 successive beats 
were used to determine left ventricular systolic pressure, left 
ventricular end-diastolic pressure and maximal rate of rise and 
decline of left ventricular pressure (maximal and minimal 
dP/dt, respectively). A modified tension-time index, the 
product of heart rate and left ventricular systolic pressure, was 
used as an indication of myocardial oxygen consumption. 
Electrocardiogram: S-T segment depression of 0.1 mv or 
more was considered indicative of myocardial ischemia. 
Statistical analysis: Values are expressed as mean values 
±standard error of the mean. Comparisons between the dif-
ferent periods were evaluated in each patient using Student's 
t test for paired data (two-tailed). The significance of differ-
ences between the groups with and without angina was de-
termined using Student's t test for unpaired data. A value of 
P >0.05 was considered not significant. 
Results 
In 18 of the 25 patients studied, atrial pacing was 
discontinued because of progressive chest pain (group 
with angina, Table I). AlliS of these patients had sig-
nificant obstruction (more than 50 percent of luminal 
diameter) in one or more coronary vessels; none had 
single right coronary artery disease. Left ventriculog-
raphy (single plane determinations in the right anterior 
oblique projection) showed hypokinetic or akinetic 
segments of the left ventricular wall in 10 patients; an 
aneurysm was observed in 2 others (Cases 3 and 9). No 
patient had mitral insufficiency. In the seven patients 
without angina pacing was stopped before angina de-
veloped because of the occurrence of A-V block. One of 
the seven (Case 21) had significant two vessel disease 
and one (Case 23) had one vessel disease. The remaining 
five patients had a slight narrowing (25 to 50 percent) 
of one or more vessels. The pattern of ventricular con-
traction was abnormal in the two patients with signifi-
cant vessel disease and normal in the other five. Thus, 
Hemodynamic Data During Atrial Pacing and Recovery (mean± standard error of the mean) 
HR LVSP TTl X 10-3 LVEDP LV dP/dt max LV dP/dt min 
Group With Angina (no.= 18) 
c 78 ± 4 134 ± 4 10.5 ± 0.6 13.4 ± 1.3 1560 ±50 1720 ± 120 
P, 110 ± 11 123 ± 10 14.5 ± 0.7 7.0 ± 1.0:1: 1810 ± 80* 1980± 160* 
P, 123 ± 5 130 ± 4 15.8 ± 1.0 9.7 ± 1.9:1: 1840 ± 80* 1880 ± 160 
P, 133 ± 4 131 ± 5 17.1 ± 0.8 12.0 ± 2.0 1910±110* 1820 ± 160 
R, 77 ± 4 134 ± 5 10.3 ± 0.7 11.8 ± 1.5 1630 ± 90 1680 ± 140 
R, 77 ± 5 136 ± 4 10.3±0.7 12.6 ± 1.5 1590 ± 80 1650 ± 140 
Group Without Angina (no.= 7) 
c 70 ± 3 136 ± 8 9.4 ± 0.5 12.3 ± 1.2 1710 ± 150 1790± 100 
P, 107 ± 4 129 ± 10 13.2 ± 0.8 5.7 ± 1.8t 1850±170 1810 ± 110 
P, 129 ± 5 126 ± 9 16.0 ± 0.8 5.5 ± 2.4t 2000 ± 200* 1820± 120 
P, 143 ± 7 127 ± 12 16.6 ± 1.2 8.7 ± 2.6t 2300 ± 200* 1920 ± 160 
R, 73 ± 4 136 ± 12 9.8 ± 0.6 12.9 ± 2.3 1710 ± 140 1860 ± 130 
R, 75 ± 3 137 ± 12 11.2 ± 1.0 12.6 ± 3.0 1750± 140 2000 ± 200 
•p < 0.05; t P < 0.02; :j:p < 0.001, versus control. 
C =control; HR =heart rate (beats/min); LVdP/dt max and LVdP/dt min= peak positive and negative value of the first derivative of left ven-
tricular pressure (mm Hg/sec); LVEDP = left ventricular end-diastolic pressure (mm Hg); LVSP =left ventricular systolic pressure (mm Hg); 
P1, P,, P3 =three levels of pacing rates; R1, R 2 =recovery, 5 and 10 minutes after cessation of pacing (see Fig. 1); TTl= modified tension-time 
index (heart rate X left ventricular systolic pressure [mm Hg/min] ). 
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FIGURE 2. Arterial and coronary (cor.) sinus lac-
tate levels (mmolar) during control (C), pacing 
(P,P2,P3) and recovery (R 1,R2) periods. In the 
group without angina the arteriovenous difference 
in lactate remained unchanged, whereas in the 
group in whom pacing was stopped because of 
angina lactate extraction changed to lactate pro-
duction. Probability (P) values indicate a significant 
difference between coronary sinus levels and 
control values. 
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these seven patients had less coronary arterial ob-
struction than the group with angina. 
Hemodynamic findings (Table II): There were no 
significant differences between the groups with and 
without angina in the control values for any hemody-
namic variable. Heart rates in the two groups of patients 
were similar in each of the three pacing periods. Left 
ventricular systolic pressure did not change throughout 
the study. Therefore the changes in the modified ten-
sion-time index merely reflect the changes in heart rate. 
Left ventricular end-diastolic pressure was decreased 
in both groups during pacing. Immediately after pacing 
was stopped there was an abrupt increase in left ven-
tricular end-diastolic pressure to values that were dif-
ferent (P <0.05) for the patients with (20 ± 2 mm Hg) 
and without (12.0 ± 1.6 mm Hg) angina. However, after 
5 minutes of recovery, values returned to control level 
in both groups. Maximal left ventricular dP/dt in-
creased in both groups during pacing. Although the 
increments were less in the group with angina, the dif-
ferences were not significant. The maximal rate of de-
cline of left ventricular pressure (minimal dP/dt) re-
mained unchanged in the group without angina but 
Anginal 
..,l p < 0.05 
/ ..... 
/ ..... 
increased during pacing period P 1 in the group with 
angina (Table II). 
Metabolic findings: Lactate: Arterial lactate levels 
were the same in both groups of patients and remained 
constant throughout the study (Fig. 2, Table Ill). 
During the control period there was lactate extraction 
in both groups. Lactate extraction remained constant 
throughout the pacing and recovery periods in the 7 
patients without angina. In the 18 patients with angina, 
there was a progressive increase in coronary sinus lac-
tate levels during pacing, giving rise to lactate produc-
tion in some patients during pacing period P 1. During 
period P 2 (Fig. 2) coronary sinus lactate levels of the 
group with angina were significantly elevated when 
compared with control values, but not when compared 
with the coronary sinus levels of the patients without 
angina. However, during angina (P3) coronary sinus 
lactate increased to values that were different from 
those in the group without angina. Recovery values were 
not different from control values. A relatively large 
number of patients produced lactate before pain caused 
a cessation of pacing: Four of the 6 patients with lactate 
production during P 1 and 7 of the 11 patients who pro-
2 // ..... ..... p < 0.02 
T./ ' 
._ _____ 1.--- _ _.. ~-- ----
• • i i i i 
·---
cor. sinus 
arterial 
Non-Anginal 
c 
FIGURE 3. Arterial and coronary (cor.) sinus hy-
poxanthine levels (,umolar) during control (C), 
pacing (P,.P2,P3) and recovery (R 1,R2) periods. In 
the group without angina there were no arterio-
venous differences. In the group with angina there 
was a sharp rise in coronary sinus levels during P3. 
Probability (P) values indicate a significant dif-
ference between coronary sinus levels and control 
values. 
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duced lactate during P 2 were free of pain. The other 
patients felt some slight discomfort that was not con-
sidered severe enough to discontinue pacing. 
Hypoxanthine: Arterial levels of hypoxanthine re-
mained unchanged throughout the study in both groups 
(Fig. 3, Table iii). Coronary sinus levels in the group 
without angina also remained unchanged and did not 
differ from arterial levels. Consequently no arteriove-
nous difference in hypoxanthine was observed at any 
time in the group without angina. By contrast, coronary 
sinus hypoxanthine concentrations increased gradually 
during pacing in the group with angina, differing sig-
nificantly from the control value during the last pacing 
period (P3, Fig. 3). At this time the coronary sinus levels 
in the group with angina were much higher than in the 
group without angina (2.4 ± 0.5 versus 0.8 ± 0.2 ~molar, 
respectively, P <0.05). During recovery there was are-
turn toward control levels, although during the first 
recovery period (R1) coronary sinus concentrations in 
the group with angina were still significantly higher than 
TABLE Ill 
HYPOXANTHINE RELEASE DURING MYOCARDIAL ISCHEMIA-REMME ET AL. 
control levels. A large number of patients produced 
lactate before the occurrence of pain. However, only 
three patients had elevated coronary sinus hypoxan-
thine levels (2 ~molar or more) before pain caused ces-
sation of pacing. 
Potassium: The arterial potassium levels of both 
groups showed small but significant fluctuations (Fig. 
4). This was especially true for the group without an-
gina, who had significantly elevated levels during pac-
ing. In the group with angina, the fluctuations were less 
marked and only became significant when the pacing 
had to be stopped because of pain. In spite of an initial 
increase in the potassium content of the coronary sinus 
blood in the group with angina there were no significant 
differences from the group without angina. Arteriove-
nous potassium differences did not provide any infor-
mation that would aid in separating patients with and 
without angina. 
Glucose: In both groups of patients small continuous 
increases in arterial and coronary sinus levels of glucose 
Metabolic Data Obtained in 25 Patients During Atrial Pacing 
Case no. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
Mean 
±SEM 
P value 
vs c 
Art vs CS 
19 
20 
21 
22 
23 
24 
25 
Mean 
±SEM 
P value 
VS C 
Art vs CS 
c 
Art cs 
0.42 0.40 
0.40 0.39 
0.36 0.25 
0.53 0.52 
0.71 0.87 
0.75 0.60 
0.61 0.56 
0.52 0.48 
0.68 0.62 
0.54 0.56 
0.57 0.57 
0.98 1.33 
0.50 0.57 
0.47 0.34 
0.47 0.45 
0.99 0.50 
0.53 0.44 
0.54 0.50 
0.58 0.55 
0.04 0.05 
NS 
0.62 0.48 
0.59 0.46 
0.54 0.44 
0.44 0.33 
0.71 0.74 
0.40 0.30 
0.70 0.64 
0.57 0.48 
0.05 0.06 
<0.01 
Lactate (mmolar) Hypoxanthine IMmolar) 
P, c P, 
Art cs Art cs Art cs Art CS Art CS Art cs 
Group With Angina (no.~ 18) 
0.47 0.41 0.38 0.47 0.42 0.38 1.0 0.9 
0.48 0.52 0.45 0.53 0.48 0.42 1.6 1.6 
0.30 0.37 0.36 0.46 0.25 0.41 1.2 1.2 
0.58 0.50 0.52 0.56 0.58 0.60 1.4 1.5 
0.70 1.01 0.70 1.14 0.71 0.94 1.6 1.1 
0.75 0.72 0.76 0.73 0.75 0.71 1.3 1.5 
0.60 0.59 0.57 0.69 0.48 0.64 0.6 1.3 
0.51 0.53 0.39 0.62 0.46 0.55 0.6 0.9 
0.66 0.64 0.68 0.84 0.64 0.61 0.6 0.8 
0.52 0.55 0.55 0.63 0.54 0.56 0.8 1.1 
0.60 1.15 0.62 1.04 0.62 0.75 0.9 0.6 
1.09 1.53 1.03 1.60 0.98 1.25 1.8 4.0 
0.53 0.66 0.55 0.68 0.48 0.55 1.0 1.3 
0.52 1.21 0.64 1.58 0.60 0.48 0.6 0.5 
0.44 0.47 0.46 0.31 0.47 0.37 0.4 1.1 
0.89 0.71 0.89 0.42 0.5 0.5 
0.68 0.67 0.59 0.74 0.58 0.60 0.8 0.9 
0.54 0.59 0.55 0.71 0.55 0.53 0.6 0.7 
0.59 0.71 0.59 0.78 0.58 0.60 1.0 1.2 
0.04 0.07 0.04 0.08 0.04 0.05 0.1 0.2 
NS <0.02 NS <0.005 NS <0.05 
<0.05 <0.01 NS NS 
Group Without Angina (no.~ 7) 
0.60 0.50 0.63 0.50 0.62 0.38 0.7 1.2 
0.57 0.53 0.59 0.54 0.63 0.67 2.0 1.0 
0.59 0.41 0.59 0.37 0.56 0.39 0.6 1.0 
0.47 0.37 0.50 0.46 0.55. 0.33 0.6 0.9 
0.76 0.71 0.72 0.70 0.85 0.68 0.2 0.2 
0.33 0.33 0.37 0.35 0.37 0.37 0.9 0.6 
0.68 0.58 0.53 0.54 0.69 0.64 1.3 1.2 
0.57 0.49 0.56 0.49 0.61 0.49 0.9 0.9 
0.05 0.05 0.04 0.05 0.06 0.06 0.2 0.2 
NS NS NS NS NS NS NS NS 
<0.01 NS <0.05 NS 
0.8 0.7 
1.3 1.5 
1.1 1.2 
1.1 1.3 
1.5 1.9 
1.1 1.4 
0.5 1.0 
1.1 0.7 
0.7 0.6 
1.0 1.0 
0.8 1.3 
1.3 2.1 
0.9 1.5 
0.8 3.8 
0.6 1.2 
0.8 1.2 
1.0 1.6 
1.0 1.4 
0.1 0.2 
NS NS 
<0.025 
0.8 1.1 
1.1 1.3 
0.8 1.4 
0.7 0.9 
0.5 0.2 
0.6 0.8 
1.3 1.2 
0.8 1.0 
0.1 0.2 
NS NS 
NS 
1.0 1.4 
1.2 3.6 
1.2 1.4 
0.5 1.1 
1.5 2.7 
1.4 1.5 
0.8 2.2 
0.8 2.0 
0.6 2.0 
1.1 1.2 
0.9 2.4 
2.3 3.7 
0.9 2.4 
1.2 10.6 
1.0 0.8 
0.4 1.6 
0.9 1.2 
0.9 1.4 
1.0 2.4 
0.1 0.5 
NS <0.05 
<0.02 
1.2 1.0 
1.2 1.0 
0.6 0.7 
1.0 1.1 
0.2 0.2 
0.5 0.4 
1.2 1.0 
0.8 0.8 
0.2 0.2 
NS NS 
NS 
Art cs 
0.8 1.3 
1.2 1.8 
1.1 1.8 
1.2 1.3 
1.8 1.8 
1.2 1.5 
0.6 0.9 
0.7 1.6 
0.4 0.8 
1.0 1.1 
1.0 1.3 
1.2 3.7 
0.9 1.4 
1.2 1.8 
0.8 1.0 
0.5 0.8 
0.7 1.2 
0.7 1.3 
0.9 1.5 
0.1 0.2 
NS <0.02 
<0.001 
0.8 1.3 
1.2 0.8 
0.8 1.0 
0.8 1.0 
0.2 0.2 
1.0 0.4 
1.3 0.7 
0.9 0.7 
0.2 0.0 
NS NS 
NS 
Art= arterial; C =control heart rate; CS =coronary sinus; NS =not significant; P~ and P, =two levels of pacing rates (see Table I); P = proba-
bility; R 1 = 5 minutes after cessation of pacing; SEM =standard error of the mean. - -
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i==l/--7-----1-----1---- j FIGURE 4. Arterial and coronary (cor.) sinus po-tassium levels during control (C), pacing (P1,P2,P3) and recovery (R1,R2) periods. In spite of significant 
arteriovenous differences in the group with angina, 
there were never significant differences in the 
potassium levels of the two groups. Probability (P) 
values indicate a significant difference between 
coronary sinus levels and control values. 
c 
were found during the pacing and recovery periods (Fig. 
5). However, arteriovenous differences remained very 
small and were not different in the two groups of pa-
tients. 
Oxygen extraction: This variable remained un-
changed for both groups (60 ± 2 percent) throughout 
the pacing and recovery periods. 
Inorganic phosphate: Determinations were carried 
out in the first eight patients (Fig. 6). No significant 
changes in inorganic phosphate levels were observed. 
Electrocardiographic measurements: No patient 
in the group without angina had 8-T changes during 
pacing. Twelve of the 18 patients with angina showed 
8-T segment depression of 0.1 mv or more during pain 
when values were compared with control values (Table 
I). 
Discussion 
This study was designed to determine whether isch-
emia induced by atrial pacing would result in the release 
Sl 
8 
" 
7.0 
6.0 
6 7.0 
6.0 
• - .... cor. sinus 
e----e arterial 
Non-Anginal 
of breakdown products of adenosine triphosphate from 
the human heart. The production of other metabolites 
and hemodynamic as well as electrocardiographic al-
terations were measured. The patients were separated 
into groups with and without angina; in 18 patients 
atrial pacing was stopped when angina occurred and in 
7 patients it was stopped when A-V block occurred 
without angina. 
Electrocardiographic measurements: 8-T changes 
during atrial pacing have not been proved useful as a 
discriminant factor13 in angina. Our study confirms this 
as only 12 of 18 patients manifested significant 8-T 
segment changes during pain. 
Hemodynamics: The hemodynamic findings in our 
patients compare very well with those reported by 
others. Maximal pacing heart rates and modified ten-
sion-time index values are comparable with those found 
by others, although heart rates were increased at various 
intervals.14- 18 Immediately after pacing a significant 
j 
FIGURE 5. Arterial and coronary (cor.) sinus glu-
cose levels (mmolar) during control (C), pacing 
(P1,P2 ,P3) and recovery (R 1,R2 ) periods. 
-105-
HYPOXANTHINE RELEASE DURING MYOCARDIAL ISCHEMIA-REMME ET AL. 
0.81 
Anginal 
0.7 
0.6 
2 
0 0.8 
-a. 
R- - ... cor. sinus 
.__... arterial 
0 
..c 
c.. 
Non-Anginal 
FIGURE 6. Arterial and coronary (cor). sinus 
inorganic phosphate levels (mmolar). The 
differences between the groups with and 
without angina were not significant. Abbre-
viations as in Figure 5. 
0.7 
0.6 
c 
difference in left ventricular end-diastolic pressure was 
observed between patients with and without angina. In 
the group with angina end-diastolic pressure increased 
above the control value, whereas in the group without 
angina it did not differ from the control value. This 
confirms the findings of others.l4•19 McLaurin et al.2° 
reported a decrease in the maximal rate of decline of left 
ventricular pressure (minimal dP/dt) in patients with 
angina and suggested that this variable could be used 
as an index for impaired ventricular relaxation. By 
contrast, we found no change in minimal dP/dt in pa-
tients with or without coronary artery disease; this 
finding is in agreement with the data of Schwarz et 
al.21 
Metabolic markers: Increases in coronary sinus 
hypoxanthine concentrations to values exceeding 
control up to 20-fold (Table Ill) were found during 
anginal pain, whereas there were no appreciable changes 
in the group without angina. Because arterial levels for 
both groups remained constant throughout the exper-
iment, hypoxanthine production must have increased 
during pain in the group with angina. This increased 
hypoxanthine efflux probably reflects ATP degrada-
tion.2·3 Inosine, although a very good marker of myo-
cardial ischemia in the pig heart,4- 6 was not produced 
in measurable amounts in this study. Even during 
ischemia the inosine concentration was less than 0.4 
,umolar. This may indicate a quick turnover from 
adenosine by way of inosine to hypoxanthine. 
Adenosine efflux was observed by Fox et aP0 in 
coronary sinus blood during pacing-induced ischemia, 
although the nucleoside usually was not detectable 
during control situations. Adenosine was a relatively 
insensitive marker of ischemia (only 10 of their 15 pa-
tients had significant differences during angina). In our 
study only 3 of the 18 patients with angina failed to show 
increases in venous hypoxanthine levels (more than 0.2 
,umolar) during angina. Because the method of Fox et 
al. for measuring adenosine requires 90 ml of blood 
compared with only 1.5 ml for hypoxanthine measure-
ments, the latter method is obviously preferable. 
The data on lactate metabolism show increased an-
aerobic glycolysis in the course of atrial pacing in the 
group with angina. There was extraction during the 
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control period, although somewhat less than in the 
group without angina because some patients were al-
ready producing lactate. During the pacing periods 
there was progressive lactate production. All but one 
patient with angina showed significant lactate abnor-
malities during the last pacing period (P3). Because this 
patient (Case 6) also had unchanged venous hypoxan-
thine levels it is possible that he did not have true angina 
or that his coronary artery disease lay outside the area 
sampled by the catheter. He was the only patient in the 
group with angina who had no significant obstruction 
in the left anterior descending coronary artery. The 
presence of abnormal myocardial lactate metabolism 
before angina suggests that anaerobic glycolysis occurs 
very early in the course of developing myocardial isch-
emia and that angina is experienced somewhat later in 
the process.13 Significant hypoxanthine production also 
developed later than lactate production. This finding 
is in agreement with the results of our experiments in 
the ischemic pig heart,5·6 in which sharp increases in 
local coronary venous nucleoside concentrations were 
preceded by relatively larger lactate concentrations. 
None of the other metabolic variables proved useful 
in identifying myocardial ischemia. There was no 
change in oxygen saturation in either group during 
pacing; this finding has been reported before.l4•22•2:l 
Dagenais et al.24 found no significant differences in 
myocardial glucose extraction in patients with and 
without angina. A difference was found by Most et al.,25 
but they concluded that glucose extraction could not be 
used as an indicator of myocardial ischemia because of 
a wide variability in individual subjects. No significant 
arteriovenous differences in glucose levels were found 
in our patients, although small but steady increases in 
arterial and venous levels were observed. The latter 
increases may have been the result of catecholamine 
stimulation in response to the stress situation, but it is 
doubtful that such small increases in glucose concen-
trations interfered with lactate metabolism in our 
study. 
Inorganic phosphate production by the ischemic 
myocardium has been reported in dog26-29 and pig6 
preparations. Changes depended on the extent of 
myocardial ischemia27 and were usually small when 
HYPOXANTHINE RELEASE DURING MYOCARDIAL ISCHEMIA-REMME ET AL. 
compared with changes in other metabolites.6 Chiong 
et al.3° studied the effects of pacing-induced ischemia 
on inorganic phosphate balance of the human myocar-
dium. Small but significant changes were found in lac-
tate producers. Ho"'(.ever, inorganic phosphate pro-
duction was found in only 55 percent of their patients 
with angina. In our first eight patients no significant 
changes could be found (see also Ref 24) and further 
determinations were not carried out. 
Potassium egress induced by atrial pacing from both 
the nonischemic and (to a greater extent) the ischemic 
heart was reported by Parker et al.31 They suggested 
that the negative potassium balance was rate-dependent 
and apparently aggravated in the presence of myocar-
dial ischemia. Our findings partly support these ob-
servations because early rises in venous potassium levels 
occurred in both groups, and were more pronounced in 
the group with evidence of ischemia. Changes in venous 
potassium were always small and accompanied by 
similar fluctuations in arterial potassium levels. Thus 
potassium efflux was an unreliable indicator of myo-
cardial ischemia. 
Clinical implications: Abnormal myocardial lactate 
metabolism occurs early in the course of developing 
myocardial ischemia. Therefore it remains a very im-
portant, but not always necessarily specific, metabolic 
marker of myocardial ischemia. In these situations the 
simultaneous measurement of hypoxanthine could 
provide additional information about abnormal myo-
cardial metabolism. 
Acknowledgment 
We acknowledge the expert technical assistance of Mrs. E. 
M. Eijsbroek-Sipman. We thank Professor P. G. Hugenholtz 
for advice and Mrs. C. Viool-Kegge for typing the manu-
script. 
References 
1. Kubler W: Myocardial energy metabolism in patients with ischemic 
heart disease. Basic Res Cardiel 69:105-112, 1974 
2. Olsson RA: Changes in content of purine nucleoside in canine 
myocardium during coronary circulation. Circ Res 26:301-306, 
1970 
3. Starn H, De Jong JW: Sephadex-induced reduction of coronary 
flow in the isolated rat heart: a model for ischemic heart disease. 
J Mol Cell Cardiol, in press 
4. DeJong JW, Goldstein S: Changes in coronary venous inosine 
concentration and myocardial wall thickening during regional 
ischemia in the pig. Circ Res 35:111-116, 1974 
5. DeJong JW, Remme WJ, Verdouw PD: Myocardial arteriovenous 
difference in carbohydrates, purine nucleosides and electrolytes 
following occlusion and release of pig coronary artery (abstr). Am 
J Cardiol37:130, 1976 
6. De Jong JW, Verdouw PD, Remme WJ: Myocardial nucleoside 
and carbohydrate metabolism and hemodynamics during partial 
occlusion and reperfusion of pig coronary artery. J Mol Cell Cardiel 
9:297-312, 1977 
7. Gudbjarnason S: The use of glycolytic metabolism in the assess-
ment of hypoxia in human hearts. Cardiology 57:35-46, 1972 
8. Brachfeld N: Characterization of the ischemic process by regional 
metabolism. Am J Cardiel 37:467-473, 1976 
9. Scheuer J, Berry MN: Effect of alkalosis on glycolysis in the iso-
lated rat heart. Am J Physiol 213: 1143-1148, 1967 
10. Fox AL, Reed GE, Glassman E, et al: Release of adenosine from 
human hearts during angina induced by rapid atrial pacing. J Clin 
Invest 53:1447-1457, 1974 
11. Apstein CS, Puchner E, Brachfeld N: Improved automated lactate 
determination. Anal Biochem 38:20-34, 1970 
12. Technicon AutoAnalyzer procedures, Tarrytown, NY 11-02 (March 
1972), 11-07 (October 1971) and 11-04 (December 1970) 
13. Parker JO, Chiong MA, West RO, et al: Sequential alterations in 
myocardial lactate metabolism, S-T segments, and left ventricular 
function during angina induced by atrial pacing. Circulation 40: 
113-131,1969 
14. Linhart JW: Atrial pacing in coronary artery disease. Am J Med 
53:64-76, 1972 
15. Helfant RH, Forrester JS, Hampton JR, et al: Coronary heart 
disease. Differential hemodynamic, metabolic, and electrocar-
diographic effects in subjects with and without angina pectoris 
during atrial pacing. Circulation 42:601-610, 1970 
16. Balcon R, Maloy WC, Sowton E: Clinical use of atrial pacing test 
in angina pectoris. Br Med J 3:91-92, 1968 
17. O'Brien KP, Higgs LM, Glancy DL, et al: Hemodynamic accom" 
paniments of angina. A comparison during angina induced by ex-
ercise and atrial pacing. Circulation 39:735-743, 1969 
18. Chiong MA, West R, Parker JO: The protective effect of glu-
cose-insulin-potassium on the response to atrial pacing. Circulation 
54:37-46, 1976 
19. Khaja F, Parker JO, Ledwich RJ, et al: Assessment of ventricular 
function in coronary artery disease by means of atrial pacing and 
exercise. Am J Cardiel 26:107-116, 1970 
20. Mclaurin LP, Rolett EL, Grossman W: Impaired left ventricular 
relaxation during pacing-induced ischemia. Am J Cardiel 32: 
751-757, 1973 
21. Schwarz F, Thormann J, Winkler B: Frequency potentiation and 
postextrasystolic potentiation in patients with and without coronary 
arterial disease. Br Heart J 37:514-519, 1975 
22. Gorlin R: Evaluation of myocardial metabolism in ischemic heart 
disease. Circulation 39, 40:SuppiiV: IV-155-IV167, 1969 
23. Gorlin R: Assessment of hypoxia in the human heart. Cardiology 
57:24-34, 1972 
24. Dagenais GR, Marquis Y, Moisan A: Valeurs du glucose, potassium 
et phosphate inorganique comme indicateurs metaboliques d'is-
chemie myocardique chez l'humain. Arch Mal Coeur Vaiss 68: 
169-177, 1975 
25. Most AS, Gorlin R, Soeldner JS: Glucose extraction by the human 
myocardium during pacing stress. Circulation 45:92-96, 1972 
26. Owen P, Thomas M, Young V, et al: Comparison between meta-
bolic changes in local venous and coronary sinus blood after acute 
experimental coronary arterial occlusion. Am J Cardiol 25: 
562-570, 1970 
27. Opie LH, Thomas M, Owen P, et al: Increased coronary venous 
inorganic phosphate concentration during experimental myocardial 
ischemia. Am J Cardiol30:503-513, 1972 
28. Opie LH, Owen P, Thomas M, et al: Coronary sinus lactate mea-
surements in assessment of myocardial ischemia. Comparison 
with changes in lactate/pyruvate and beta-hydroxybutyrate/ace-
toacetate ratios and with release of hydrogen, phosphate and po-
tassium ions from the heart. Am J Cardiol 32:295-305, 1973 
29. Mathur PP, Case RB: Phosphate loss during reversible myocardial 
ischemia. J Mol Cell Cardiol 5:375-393, 1973 
30. Chiong MA, West R, Parker JO: Myocardial balance of inorganic 
phosphate and enzymes in man: effects of tachycardia and isch-
emia. Circulation 49:283-290, 1974 
31. Parker JO, Chiong MA, West RO, et al: The effect of ischemia and 
alterations of heart rate on myocardial potassium balance in man. 
Circulation 42:205-217, 1970 
-107-
-108-
Chapter V: 
MYOCARDIAL LACTATE METABOLISM AND ISCHEMIA. 
-109-
v. 
Assessment of Myocardial Ischemia in Man. Reevaluation of the Usefulness of 
Myocardial Lactate Monitoring 
W.J. Remme, M.P. Look, P.A. Remme, M.D. van den Berg, X.H. Krauss, H.A.C.M. Kruyssen, 
D.C.A. van Hoogenhuyze. 
Zuiderziekenhuis and Sticares Foundation, Rotterdam, The Netherlands. 
Submitted for publication in abbreviated format 
-110-
v. 
Assessment of Myocardial Ischemia in Man. Reevaluation of the Usefulness of 
Myocardial Lactate Monitoring 
W .J. Remme, M.P. Look, P .A. Remme, M.D. van den Berg, X.H. Krauss, H.A.C.M. Kruyssen, 
D.C.A. van Hoogenhuyze. 
Zuiderziekenhuis and Sticares Foundation, Rotterdam, The Netherlands. 
Abstract. 
Anaerobic glycolysis is a primary event in 
myocardial ischemia and has provided for a 
valuable tool in defining ischemia under 
experimental conditions. However, the usefulness 
of myocardial lactate production as ischemic 
marker in man has been debated. To reexamine 
sensitivity and specificity of this metabolic 
indicator of ischemia, 232 patients, 161 with 
significant ~70%) left coronary artery disease (gr 
LC), 48 with ~25% coronary lesions (gr MC) and 
23 patients without coronary disease (gr N) 
underwent an incremental atrial pacing stress test, 
which focussed on the direct post-pacing phase. 
Groups MC and N had no backgrotmd of cardiac 
disease. Hemodynamic changes during pacing 
were comparable between groups, except for heart 
rate which was less in LC (141±2 beats/minute, 
versus 151±3 and 154±4 beats/minute in MC and 
N, resp.). In contrast, left ventricular systolic 
pressure fell with 5% and 12% in groups MC and N 
resp., but not in group LC. Consequently, the 
double product was similar in all groups. Pacing 
resulted in angina-like pain in 52% (N), 69% (MC) 
and in 80% (LC). Also, maximal ST -segment 
depression was comparable, i.e. 0.16±0.02, 
0.14±0.02 and 0.16±0.01 mV in groups N, MC 
and LC, resp. By contrast, left ventricular filling 
pressure only increased in group LC. Baseline 
lactate extraction values were comparable between 
groups. Also, arterial lactate levels were similar 
and did not change during the test. Moreover, in 
groups MC and N coronary venous lactate and, 
hence, lactate extraction remained unaltered. By 
contrast, in patients with significant coronary 
disease coronary venous lactate rose early but 
progressively with marked elevations at 15 
seconds post-pacing (0.82±0.03 mmol/1, 
compared with 0.53±0.02 mmol/1 at control, 
p<0.05), resulting in lactate production during and 
for 2 minutes after pacing. Abnormal coronary 
venous levels persisted until 5 minutes post-
pacing. Additional lactate measurements at 0, 30 
and 45 seconds post-pacing in a subgroup of LC 
indicated maximal, comparable lactate production 
values at 15 and 30 seconds post-pacing. In 28 
patients in group LC, lactate production was only 
observed after pacing, increasing its overall 
incidence from 60% to 78%, which compared 
favourably to ST-segment depression (60%) and 
left ventricular filling pressure changes (50%). 
Alternatively, in groups N and MC lactate 
production only occurred in 9% and 10% of 
patients, in contrast to ST -segment depression in 
57% and 29% and abnormal left ventricular filling 
pressures in 46% and 39%, resp. Thus, myocardial 
lactate production is highly specific and more 
sensitive than commonly applied criteria, such as 
ST -segment changes or angina, in identifying 
functionally significant coronary disease, provided 
that lactate metabolism is evaluated between 15 
and 30 seconds post-pacing. 
Introduction. 
A derangement of oxydative phosphorylation is 
among the first intrinsic cardiac cellular alterations 
to follow the onset of myocardial ischemia and the 
subsequent lack of oxygen supply. As a result, 
anaerobic glycolysis is activated early during 
ischemia through enhanced activity of the 
glycolytic enzymes phosphofructokinase and 
glyceraldehyde-3-P-dehydrogenase. The latter 
follows the accumulation of A TP catabolites, such 
as ADP, AMP and inorganic phosphate(!). 
Simultaneously, glucose uptake in the cell may 
improve, depending on blood supply to the ische-
mic area, whereas glycogenolysis will increase, 
both in an effort to enhance substrate availability 
for glycolysis and anaerobic ATP production. As 
the endproduct of the glycolytic pathway, 
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pyruvate, cannot enter the Krebs cycle, it will be 
transformed into lactate. Thus, a change from 
myocardial lactate extraction to production is 
found early during ischemia, enabling this 
metabolite to function as a potentially sensitive 
marker of this ;;ondition(2-4)_ 
Moreover, as primary metabolic event, it may be 
more consistent as marker than secondary events, 
such as electrophysiologic alterations, changes in 
(local) contraction or relaxation or subjective 
symptoms, such as angina or dyspnoe. However, 
the usefulness of myocardial lactate production as 
indicator of myocardial ischemia in humans has 
been disputed(5,6). Much of this depends on the 
model of ischemia used. Exercise increases arterial 
lactate levels and myocardial extraction in normal, 
non-ischemic areas. As a result, changes in the 
ischemic region may be entirely overshadowed 
when myocardial lactate metabolism is assessed 
from coronary sinus blood, as is common practice. 
In the resting patient, efforts to induce ischemia, 
for instance by rapid atrial pacing, do not 
invariably result in myocardial lactate production. 
Reported percentages of patients with lactate 
production in this model range between 50 and 
60% in the majority of studiesC6-13). This may be 
explained, to a certain extent, by technical 
problems, concerning the position of the sampling 
catheter in relation to the ischemic area, by atrial 
reflux(l4) or by inappropriate admixture of blood 
from non-ischemic areas with that from the 
ischemic region. Alternatively, this parameter may 
have been underestimated. Available data on 
myocardial lactate production during pacing-
induced ischemia are derived from small patient 
populations. Also, the relative presence of 
proximal versus distal left coronary artery disease 
or right coronary lesions has generally been given 
little attention. More importantly, lactate 
determinations are typically carried out during the 
test only, i.e. during pacing. We have previously 
suggested that the sensitivity of lactate as marker 
of ischemia may significantly improve when 
determined in the immediate post-pacing 
period(lS). 
In the present study the results of a large 
prospective investigation of the potential of 
myocardial lactate metabolism, determined in this 
way, and other objective and subjective parameters 
to delineate ischemia are reported in patients with 
significant left coronary artery disease compared to 
individuals without coronary lesions or with only 
minimal disease. 
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Methods 
Patients 
After the study protocol was approved by the 
Institutional Ethical Review Board and informed 
consent was obtained, 457 consecutive patients 
were studied prospectively. Patients were 
scheduled to undergo elective cardiac 
catheterization for the evaluation of stable, 
exercise-inducible angina-like symptoms and/or a 
previous myocardial infarction or for the presence 
of atypical, but persistent complaints of chest 
discomfort. Objective signs of myocardial 
ischemia were not required as the aim of this study 
was to acquire data on patients with coronary 
artery disease and individuals without coronary 
lesions. Eligible patients had to be normotensive 
without symptoms of heart failure (NYHA class 
III and IV). Exclusion criteria comprised the 
presence of conduction disturbances, clinically 
significant valvular disease, pulmonary 
hypertension or a recent myocardial infarction 
(less than one month old). Furthermore, patients 
with unstable angina, defmed by the occurrence of 
recent episodes of angina, increased duration 
and/or frequency of anginal episodes during the 
preceding 4 weeks or recent prolonged episodes at 
rest, were also excluded. Moreover, patients with 
predominant angina at rest and/or ECG changes 
suggestive of variant angina were not included. 
Antianginal therapy was stopped at least one day 
prior to the study but usually for longer periods, 
i.e. 36-72 hours pre-study, depending on the 
plasma half- life of the respective medication. Oral 
anticoagulants were withheld 2-3 days before the 
investigation and NSAIDs, if present, 10 days. 
Diuretics were not given on the day of investiga-
tion, whereas patients on digitalis therapy were 
excluded. Only short-acting nitroglycerin was 
allowed up to 6 hours pre-study. 
Of the 457 patients studied, 232 patients were 
selected, who represented the 3 subgroups chosen 
for this investigation, i.e. patients with significant 
left coronary disease (group LC, n=161), 
individuals with normal coronary arteries (group 
N, n=23) and those with only minimal coronary 
lesions (group MC, n=48). Significant left coro-
nary disease was defined by the presence of at least 
one >70% coronary diameter narrowing in either 
the left anterior descending, a diagonal branch, the 
proximal part of the left circumflex artery or a 
proximal marginal branch. Normal coronary 
arteries were considered present if the epicardial 
system was entirely smooth without luminal 
irregularities. Minimal coronary lesions were 
defined as one or more coronary diameter narrow-
ings of 25% or less. 
The decision whether to include patients based on 
these criteria was made after catheterization 
following analysis of the coronary angiogram by 2 
independent angiographers, experienced in the 
qualitative assessment of over 600 coronary angio-
grams annually. In case of disagreement, a third 
party would be involved or the patient discarded 
from further participation. Moreover, several pre-
cautions were taken to ensure that the groups with 
minimal coronary lesions or without coronary 
disease really represented individuals without 
ischemic or other forms of heart disease. Thus, 
patients with a history of myocardial infarction or 
objective signs of ischemia during stress testing 
were not included in these groups. Also, those 
with an abnormal left ventriculogram or valvular 
disease (mitral prolapse) were excluded. Clinical 
and angiographic characteristics of the 3 patient 
groups are given in Table I. 
Table I. Clinical and angiographic characteristics. 
Sex (male/female) 
Age (average/range), yrs 
Previous infarctions 
(anterior/inferior) 
Positive exercise test (n) 
Medication: 
nitrates 
calcium-antagonists 
B-blockers 
Coronaxy angio (n) 
(2:70% diameter stenosis) 
1-vessel (L-CAD only) 
2-vessel 
3-vessel 
LV ejection fraction (%) 
LV e~ diastolic volume 
(mllm ) 
LV wall motion 
abnormalities (n) 
Abbreviations: 
Gr.LC 
(n=161) 
147/14 
54±0.8f/30-72 
45/39 
82 
86 
84 
103 
52 
54 
55 
50±1.2f 
78±2.2 
70 
Gr.MC 
(n=48) 
29/19 
46± 1.4/18-62 
10 
22 
18 
62± 1.8 
78±3.3 
Gr.N 
(n=23) 
14/9 
49±2.1/24-63 
4 
6 
9 
59±2.4 
77±4.5 
LC = patients with _2:70% left coronary artery disease; L-CAD = left coronary artery disease; LV = left 
ventricular; MC = patients with <25% coronary artery disease; N = patients without coronary artery 
disease; n =number of patients; yrs= years; f p<.05 vs other groups. 
Valuesare~±SEM. 
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By design, groups N and MC had no appreciable 
abnormalities. In contrast, in group LC, previous 
myocardial infarctions were present in 63% of 
patients, objective signs of ischemia during stress 
testing (ST-segment depression >0.1 mV) in 50%. 
In the group with significant coronary lesions 
(LC), 52 patients had single-vessel, 54 double-
vessel and 55 triple-vessel disease. Left ventri-
cular ejection fraction was significantly lower in 
patients with coronary disease (50±1.2%, compa-
red with 59±2.3% and 62±1.8% in patients with 
normal coronary arteries and minimal disease, 
resp.). Also, 70 patients in group LC had abnor-
mal left ventricular wall motions, whereas, by 
design, patients in the other 2 groups had a normal 
ventriculogram. Furthermore, pre-existing cardiac 
medication differed between groups with signifi-
cantly more patients on antianginal medication in 
group LC than in the other 2 groups. Finally, the 
average age in group LC was slightly, but signifi-
cantly higher than in the other 2 groups. 
Study procedures 
Studies were carried out at approximately the same 
time in the morning without premedication. 
Patients had been fasting since midnight and had 
been supine for approximately 1.5 hours. Instru-
mentation was carried out after local anaesthesia 
with 1% lidocaine. First, coronary angiography 
was performed using the Seldinger technique, 
usually including 6 to 7 left and 3 right coronary 
angiograms with a total of 60 to 80 ml Renografin 
or Iopamidol administered. 
Then, a no 7 Fr Millar microtip manometer cathe-
ter, an 8 Fr Sentron microtip manometer pigtail or 
a 7 Fr Cordis pigtail catheter was introduced into 
the left ventricle through a Desilet introducer sys-
tem in a femoral artery. Next, a 7 Fr thermodilu-
tion pacing catheter (Wilton Webster Laboratories) 
or a 7 Fr Zucker bipolar pacing catheter was 
advanced into the mid portion of the coronary sinus 
from a right antecubital vein, such that the proxi-
mal thermistor was at least 3 em beyond the orifice 
of the coronary sinus. The catheter position had to 
be stable and allow for repetitive, fast sampling of 
coronary venous blood. The absence of right atrial 
reflux was confirmed by a bolus injection of 10 ml 
of saline into the right atrium under study condi-
tions. The position of the catheters was subse-
quently recorded on video disc to allow re-
checking of their position during the study. 
After instrumentation, the fluid-filled catheters 
were calibrated using Statham or Bentley pressure 
transducers with zero reference levels set at mid-
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chest. The micromanometer pressure was balanced 
to zero and superimposed on the conventional 
pressure curves. 
Hemodynamic and electrocardiographic 
measurements: 
Measured hemodynamic parameters in this study 
included left ventricular systolic and end diastolic 
pressures (mmHg), left ventricular pressure-
derived contractility and relaxation parameters [LV 
peak positive dP/dt (mmHg/sec), dP/dt/P at 40 
mmHg, Vce40 (sec-1), Vmax (sec-1) and peak 
negative dP/dt (mmHg/sec), resp]. 
After calibration, left ventricular pressures and the 
first derivative of left ventricular pressure were 
recorded on paper at different paper speeds, i.e. at 
10, 25 and 100 mm/sec, using a CGR 1000 cath 
lab system. Moreover, left ventricular pressures 
and pressure-derived indices were also determined 
and displayed on -line by a Mennen cath lab 
computer system. In a beat-to-beat analysis over 
15-20 consecutive beats, the system averages out 
respiratory fluctuations. Representative beats may 
be chosen by the operator for further analysis. 
A 3 -lead electrocardiogram (leads I, II and V5) 
was recorded continuously on paper to determine 
heart rate and ST-segments. The latter were 
measured from 3 consecutive beats, at 80 msec 
after the J -point using a calibrated magnifying 
glass. 
Blood sampling technique and assay of lactate 
For lactate determination, simultaneous sampling 
of arterial and coronary venous blood was carried 
out. Before each sample, residual blood in the 
catheters was first discarded. Then, 1 ml of blood 
was directly transferred into chilled glass tubes, 
containing 2 ml of ice-cold 0.6 M HC104, vor-
texed and kept on ice. Immediately after the study, 
samples were weighed and centrifuged for 20 
minutes at a speed of 2000xg and the supernatant 
frozen for subsequent determination. Lactate assay 
was carried out in triplicate by the enzymatic tech-
nique described by Guttman and Wahlefeld(16)_ In 
our laboratory, the standard deviation of this assay 
carried out in approximately 2500 samples annual-
ly, is 0.012 mmol/1(17)_ 
Scoring of angina-like pain 
Before the study, patients were instructed to 
indicate any kind of chest discomfort or related 
pain as soon as this occurred. They were then 
familiarized with a pain scoring system according 
to a simplified Borg scale. Also, they were asked 
to indicate the time of disappearance of these 
complaints following cessation of pacing. 
--PACING-
HR+so 
PACING STOP 
(ANGINA ± BLOCK) 
APST L L L 
0" 30" 45" 
"' "' "' )'-rff-r-
c c 100/ 120/ 140/ MAX 15" 1' 2' 5' 
min min min p-p p-p p-p p-p 
H H H H H H H H H 
ST ST ST ST ST ST ST ST ST 
L L L L L L L L L 
Fig 1: Schematic representation of the atrial 
pacing stress test protocol. Repetitive baseline 
measurements are carried out at least 20 and 40 
minutes after instrumentation and coronary 
angiography resp. Pacing is then performed with 
increments of 10 beats/2 minutes until significant 
angina-like pain, atrioventricular block or a 
maximal heart rate of 170 beats/minute. 
Hemodynamic (H), electrocardiographic (ST) 
and metabolic (lactate, L) variables are assessed 
at fixed rates during pacing, at maximal rates 
(MAX) just before cessation of pacing, followed 
by repeated measurements at 15 seconds, 1,2 and 
5 minutes post-pacing (P-P). In addition, in a 
subgroup lactate was also assessed at 0, 30 and 
45 seconds P-P (arrows). 
The study was carried out following a stabilization 
rest period of at least 20 minutes after instrumen-
tation and 40-50 minutes after coronary angio-
graphy. Before pacing was initiated, multiple 
control hemodynamic measurements were perfor-
med and analysed on-line to ascertain stable base-
line conditions. Also, the ECG was compared with 
recordings made at entry in the catheterization 
laboratory to record baseline changes. Next, lacta-
te sampling was carried out in duplicate. This was 
followed immediately by the pacing stress test. 
The pacing protocol consists of increments in heart 
rate of 10 beats/2 minutes until significant angina 
is present, atrioventricular block occurs or a maxi-
mum pacing rate of 170 beats/minute is reached. 
Significant angina was deftned as the level, at 
which the patient would usually rest or take nitro-
glycerin. Atrioventricular conduction disturbances 
were accepted as an endpoint. Atropine was not 
administered during the test. All measurements 
were repeated at ftxed intervals during pacing, i.e. 
halfway the 100, 120, 140 and 160 beats/minute 
period, if applicable. All determinations were 
repeated at maximal heart rates, just before cessa-
tion of pacing. Next, variables were reassessed at 
1, 2 and 5 minutes after pacing. In addition, left 
ventricular end diastolic pressures were deter-
mined at 10 seconds post-pacing. Moreover, 
lactate was also assessed at 15 seconds post-
pacing, together with heart rate and left ventricular 
systolic pressure. 
In a subgroup of 38 patients, lactate measurements 
were carried out as well at different periods after 
pacing, i.e. direct after cessation at 0 seconds, at 
30 and/or at 45 seconds after pacing (Fig. 1). As 
the full procedure of sampling, including clearing 
of the catheters and transfer of blood, usually took 
10-15 seconds, it was not always possible to 
evaluate all time points in the post-pacing phase in 
each patient in this subgroup. 
Statistical analysis 
Data are presented as averages and 1 standard error 
of the mean. Group differences at baseline as well 
as for calculated changes from control were 
examined using a one-way analysis of variance. 
Within groups, the change in values between 
measurements during and after pacing versus base-
line were calculated. Comparisons with control 
values were evaluated using a two-tailed paired t-
test. Coefficients of correlation were calculated 
where appropriate. A p-value of <0.05 was con-
sidered significant. 
Results 
At control, none of the patients in groups N and 
MC had clinical signs of myocardial ischemia, e.g. 
no anginal complaints or electrocardiographic 
abnormalities. Also, in group LC, none of the 
patients had anginal complaints at rest. However, 
asymptomatic ischemia at rest was documented by 
ST-segment depressions in 5 patients and by 
myocardial lactate production in 14 patients. 
Baseline hemodynamic, electrocardiographic 
and metabolic variables 
Baseline hemodynamic, electrocardiographic and 
metabolic parameters were comparable between 
the 3 study groups. Only left ventricular end dias-
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tolic pressure was significantly lower in patients 
without coronary (group N) disease compared with 
group LC (12±1.4 mmHg versus 16±0.5 mmHg, 
resp.). Baseline heart rates and double products 
were similar in all groups, as well as control ST-
segment levels. Also, control lactate extraction 
values were identical, i.e. 17±3%, 19±2% and 
19±1% in groups N, MC and LC, resp. 
Table II. Hemodynamic variables before and during pacing. 
l••····~~t;Q••······•••••••• .. i••·,~(~~·~l•• / ~ ················· < <.t~t••<••·•····· ··•~w~ ......... 
•··•· ·····•···• ·······•·•• >• ·~W I 'IS > · ..•. 
HR (b/min) LC 75±1.0 101±0.2* 121±0.3* 140±0.4* 141±1.7*+ 
MC 74±1.8 101±0.5* 122±0.5* 140±0. 9* 151±3.0* 
N 75±2.4 100±0.4* 121±0.8* 140±0.8* 154±4.3* 
LVSP (mmHg) LC 140±2.2 138±2.1 137±2.4 134±3.3 138±2.0 
MC 133±3.5 133±3.5 131±3.6 123±4.2 127±3.7* 
N 132±2.7 131±2.1 129±3.1 128±3.4 116±3.1*+ 
DP LC 10.6±0.2 13.8±0.2* 16.6±0.3* 18.7±0.5* 19.3±0.3* 
(HRxLVSPx10-3) MC 9.8±0.3 13.3±0.4* 16.0±0.4* 17.2±0.6* 19.0±0.6* 
N 10.0±0.4 13.1±0.2* 15.6±0.4* 17.8±0.5* 17.9±0.7* 
LVEDPCmmHg) LC 16±0.6 12±0.6* 10±0.7* 10±1.0* 13±0.8* 
MC 15±1.0 11±1.0 8.5±0.9* 7±1.1* 9±1.3* 
N 12±0.8 8±0.8 6±0.9* 7±1.3* 10±2.4 
LV dp/dt pos. LC 1767±47 1983± 56* 2150± 67* 2130± 98 2169± 68* 
(mmHg.sec-1) MC 1788±84 1944±108 2066±116* 2050±135 2153±120* 
N 1614±91 1805± 75* 2008±110* 2134±159 2009±111* 
VCE40 LC 33±0.8 39±1.1* 42±1.2* 43±2.1 41±1.3* 
-1 (sec ) MC 33±1.3 38±1.8* 42±1.9* 43±2.4 41±2.1* 
N 33±1.9 39±1.4* 44±2.0* 45±3.0 43±2.3* 
Vmax LC 48±1.1 56±1.6* 59±1.7* 60±2.5 57±1.9* 
-1 (sec ) MC 51±2.0 57±2.6* 62±3.1* 63±3.9 60±3.2* 
N 50±2.6 59±2.2* 65±2.6* 67±4.1 65±3.5* 
LV dp/dt neg. LC 1690± 51 1802± 60* 1843± 61* 1890±111 1799± 62 
-1 (mmHg.sec ) MC 1826± 87 1930± 98 2031±101* 1951±118 1932±129 
N 1809± 92 1905± 97* 2012± 99* 1968±135 1556±113* 
Abbreviations: 
b/min = beats/minute; DP =double product; HR = heart rate; LC =patients with ~70% Left coronary artery 
disease (n=161); LVEDP = Left ventricular end diastolic pressure; 
LVSP =Left ventricular systolic pressure; MAX= maximal pacing rate; MC =patients with ~25% coronary 
artery disease (n=48); N = patients without coronary artery disease 
(n=23); p-p =post-pacing; " =seconds; ' =minutes. ALL values x±SEM; *p<.05; + p<.05 vs other groups; 
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Changes in hemodynamic Variables during pacing (Table n and lla) 
Pacing-induced hemodynamic changes were 
comparable in patients without or with only 
minimal disease, but differed in several aspects 
from patients with significant coronary disease. 
First, groups N and MC could be paced to a 
significantly higher heart rate than group LC, i.e. 
Table IIa. Hemodynamic variables before and after pacing . 
. ·•••••cori~·f:P·t························ r••·•··•··~•S•"g~·••••••••••••••••••••·•••• lr i 1 •·•~e . L••••••••• ·•••••··· )~~~~········ ·····. \ ········•· i... •.< 1•••••••••s·p--5\ } < HR (b/min) LC 75±1.0 76±1.8 79±1.5 78±1.7 79±2.2 
MC 74±1.8 78±3.1 80±2.4 81±3.0 78±4.2 
N 75±2.4 86±4.8 86±3.2 84±3.6 85±3.4 
LVSP (mmHg) LC 140±2.2 150±3.6 145±2.8 143±3.5 137±3.8 
MC 133±3.5 127±6.2 132±4.2 130±4.5 135±6.4 
N 132±2.7 133±3.8 125±2.8 123±4.0 120±4.9 
DP LC 10.6±0.2 11.8±0.4 11.4±0.3 11.2±0.4 10.9±0.4 
(HRxLVSPx1 0-3) MC 9.8±0.3 9.7±0.8 10.6±0.5 10.2±0.5 10.8±0.9 
N 10.0±0.4 12.1±0. 9 10.7±0.4 10.1±0.6 10.2±0.6 
LVEDP (mmHg) LC 16±0.6 21±1.1*+ 16±0.8 14±1.0 14±1.2 
MC 15±1.0 14±1.6 14±1 .4 12±1.1 15±1.9 
N 12±0.8 13±2.7 11±1.6 10±1.2 11±1.8 
LV dp/dt pos. LC 1767±47 1980± 70* 1902± 67* 1964± 93* 1661± 65 
(mmHg.sec-1) MC 1788±84 1903±210 1795±105 1857±123 1706±161 
N 1614±91 1786±190 1665± 83 1658± 95 1580±115 
VCE40 LC 33±0.8 33±2.2 34±1.0 36±1.5 32±1.2 
(sec_,) MC 33±1.3 35±2.7 34±1.4 36±1.8 33±2.4 
N 33±1.9 37±3.2 36±1.4 35±1.6 30±2.0 
Vmax LC 48±1.1 52±3.5 49±1.4 52±1.8 48±1.4 
-1 (sec ) MC 51±2.0 51±3.6 50±2.1 53±2.5 47±2.4 
N 50±2.6 55±4.2 53±1.9 54±1.5 50±2.5 
LV dp/dt neg. LC 1690± 51 1690±130 1702± 63 1634± 74 1625± 75 
(mmHg.sec-1) MC 1826± 87 1870±161 1907± 98 1893± 96 2010±190 
N 1809± 92 1880±154 1853± 60 1932±110 1856±120 
Abbreviations: 
b/min = beats/minute; DP = double product; HR = heart rate; LC = patients with ~70% Left coronary artery 
disease (n=161); LVEDP = Left ventricular end diastolic pressure; 
LVSP =Left ventricular systolic pressure; MAX= maximal pacing rate; MC =patients with ~25% coronary 
artery disease (n=48); N = patients without coronary artery disease 
(n=23); p-p =post-pacing; " =seconds; ' =minutes. ALL values x±SEM; *p<.OS; + p<.OS vs other groups; 
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154±4.4 and 151±3.0 beats/minute (groups Nand 
MC, resp.) versus 141±1.6 beats/minute 
(group LC). 
Consequently, the change from control levels was 
different. However, this did not result in different 
double products as left ventricular systolic pressure 
fell progressively and significantly during pacing 
in groups Nand MC by 12% and 5%, resp., but not 
in group LC. Following the greater reduction in 
left ventricular systolic pressure, the peak negative 
value of LV dP/dt decreased sharply at maximal 
heart rates in group N, but not in MC and LC. 
Contractility parameters improved similarly in all 
groups. At maximal pacing rates, Vmax increased 
by 30%, 19% and 20% in groups N, MC and LC, 
resp. Thus, no significant differences were present 
in the various determinants of myocardial oxygen 
demand between groups. 
Pacing-induced myocardial ischemia. 
Comparison of subjective and objective criteria 
(Table ill and IDa) 
Angina-like pain 
Angina -like pain, chest discomfort or related 
complaints were indicated by 12 patients without 
coronary disease (52%), by 32 patients (67%) with 
only minimal disease and by 129 patients (80%) 
with significant coronary lesions. The degree of 
discomfort was comparable between groups. 
Following pacing, angina usually subsided within 
the first minute in each group. 
Left ventricular end diastolic pressure 
Left ventricular end diastolic pressure decreased 
during the initial phase of pacing in all patients. At 
120 beats/ minute, pressures were significantly 
lower than control in each group and decreased 
further in groups MC and LC during maximal 
pacing rates, but not in group N. Immediately 
following cessation of pacing, left ventricular 
filling pressures returned to control levels in 
groups N and MC. In contrast, they increased in 
group LC (21±1.1 mmHg versus 16±0.6 mmHg at 
control, p<0.05) (Fig. 2). 
ST- segment depression 
Significant electrocardiographic changes occurred 
in all groups with comparable values for ST-
segment depression during maximal pacing, i.e. 
1.58±0.22, 1.42±0.19 and 1.60±0.11 mV in 
LVEDP 
25 mmHg 
D L-CAD > 70%, n = 161 
~CAD < 25%, n = 48 
- NO CAD, n = 23 
* p < .05 vs. CONTROL 
t p < .05 
15" p-p 1' p-p 
Fig 2: Pacing-induced changes in left ventricular filling pressure. An abnormal rise immediately (10 
secondsj post-pacing (P-P) is only observed in patients with significant coronary disease. MAX = 
maximal pacing heart rates; '=minutes;"= seconds. Values are x±SEM. 
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ST-SEGMENT 
mV 
CONTROL 120/min 140/min MAX 
CJ L-CAD 2 70%, n = 161 
m CAD ::;;: 25%, n = 48 
-NO CAD, n = 23 
* p <.05 vs. CONTROL 
1' p-p 
Fig 3: Pacing-induced electrocardiographic changes. A significant and equal ST-segment depression is 
observed in all groups, although they persist somewhat longer after pacing (P-P) in patients with 
significant coronary disease. MAX= maximal pacing heart rates; '=minutes; " =seconds. Values are 
x±SEM. 
groups N, MC and LC, resp. (Fig.3). 
Lactate 
Pacing-induced alterations in myocardial lactate 
metabolism differed significantly between groups 
N and MC on the one band and group LC on the 
other. Whereas arterial lactate levels did not 
change during the study and were comparable 
during and after pacing between groups, coronary 
venous levels were not In groups MC and N, 
coronary venous levels and, consequently, lactate 
extraction did not change and were comparable 
during and after pacing. In contrast, in patients 
with significant left coronary artery disease, 
coronary venous levels progressively increased 
during pacing. At 100 beats/minute they were 
already elevated (p<0.05 versus control) (Fig. 4). 
Consequently, in this group myocardial lactate 
extraction decreased and changed into production 
at maximal heart rates ( -2±2% versus 19±1 % at 
control, p<0.001). At 15 seconds post-pacing a 
marked rise in coronary venous levels was observ-
ed with an additional increase in lactate production 
(extraction -23±4%, p<0.05 versus maximal 
rates )(Fig .5). 
Hereafter, coronary venous levels gradually de-
clined. Lactate production values at 1 minute post-
pacing were comparable to those during maximal 
pacing rates and returned to control values at 5 
minutes post-pacing. 
Assessment of lactate metabolism after pacing 
In a subgroup of patients with :?,70% left coronary 
artery disease, additional sampling was carried out 
at 0 sec (n=37), at 30 sec (n=22) and at 45 sec post-
pacing (n=15). Data are displayed in Fig. 6, which 
shows the additional increase in coronary venous 
lactate and lactate production values, relative to the 
levels observed during maximal rates. As the latter 
were comparable both in the subgroup and the 
main study group, the additional measurements are 
compared to the 15-second evaluation in the latter. 
Results indicate that lactate production is maximal 
at 15 and 30 seconds post-pacing with little differ-
ence in between these two time-points. However, 
values are less at 0 and 45 seconds. Although lac-
tate production at 0 seconds post-pacing differed 
from values observed during maximal pacing, it 
was significantly less than the levels at 15 and 30 
seconds post-pacing. 
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TABLE III: Electrocardiographic and metabolic changes during pacing. 
ST-segment LC -0.4±0.05 -0.6±0.9 -0.8±0.08* -1.1±0.13* -1.6±0.1 * 
mV MC -0.5±0.10 -0.7±0.11 -0.9±0.12* -1.0±0.16* -1.4±0.19* 
N -0.6±0.16 -0.7±0.13 -0.8±0.12 -0.8±0.13 -1.6±0.22* 
Lactate, LC 0.67±0.02 0.69±0.02 0.68±0.02 0.67±0.03 0.69±0.02 
Arterial MC 0.62±0.02 0.58±0.02 0.58±0.02 0.56±0.03 0.60±0.03 
mmol/L N 0.69±0.03 0.72±0.04 0.68±0.04 0.64±0.03 0.70±0.03 
Lactate, LC 0.53±0.02 0.60±0.03* 0.60±0.02* 0.64±0.09* 0.70±0.03* 
Coronary venous MC 0.51±0.02 0.46±0.03 0.46±0.02 0.44±0.02 0.49±0.02 
mmol/L N 0.57±0.03 0.56±0.03 0.54±0.03 0.52±0.04 0.56±0.03 
Lactate extractio LC 19±1.4 14±2.3 11±1. 9 4±2.5 * -2±2.2 * 
% MC 19±2.1 21±2.4 22±2.1 20±3.1 18±2.2 
N 17±3.2 22±4.8 19±2.8 19±5 .1 20±3.0 
Abbreviations: 
LC =patients with >70% Left coronary artery disease Cn=161); MAX= maximal pacing rates; Min= minute; MC = 
patients with ~25% coronary artery disease (n=48); N =patients without coronary artery disease (n=23); p-
p = post-pacing; " = seconds; ' = minutes; * p<.05 vs control. 
Incidence of objective criteria for ischemia 
To investigate sensitivity and specificity of the 3 
objective criteria for ischemia used in this study, 
patients were categorized according to the presence 
or absence of abnormal changes in left ventricular 
filling pressure, determined as an increase of 
~5 m.mHg above control values, ST -segment 
depression of ~0.1 mV from baseline or by the 
occurrence of myocarial lactate production. In the 
group without appreciable coronary lesions, 
pacing induced abnormal elevations in left ventri-
cular filling pressure in 46%, an abnormal ST-
depression in 57%, but myocardial lactate produc-
tion only in 9% of patients. Likewise, in the group 
with minimal disease, pacing resulted in abnormal 
left ventricular filling pressures in 36% of patients, 
in significant ST-segment depression in 29% and 
in lactate production in 10%. In contrast, myocar-
dial lacate production was observed in 78% of 
patients with left coronary artery disease, a sig-
nificantly higher incidence than that of ST-
segment depression (60%) or abnormally elevated 
left ventricular filling pressure (50%) in this group. 
The pronounced sensitivity score of lactate in 
determining functionally significant coronary 
artery disease related to the fact that 28 patients in 
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this group only demonstrated lactate production 
during the 15-second post-pacing sampling phase. 
Without these patients, sensitivity would have 
been reduced to 60%, equal to electrocardiographic 
changes. 
Pacing-induced changes in heart rate as well as in 
maximal pacing rates and double products were 
significantly less in non -lactate as compared to 
lactate producers in group LC. No such discrimi-
nation was present for the other variables. 
Discussion 
On theoretical grounds, the evaluation of myocar-
diallactate metabolism should be useful in assess-
ing occurrence and degree of myocardial ischemia. 
Although a valuable tool in animal models of 
regional ischemia with the inherent easy 
accessibility of metabolites in the coronary venous 
effluent, its applicability in this respect is less 
obvious in man. Changes in substrate availability 
make lactate unsuitable as a research tool during 
exercise, even apart from the inability to perform 
sensible catheter-based metabolic studies in this 
model. 
TABLE Ilia: Electrocardiographic and metabolic changes after pacing. 
· .. : ..... ····:• .. ~-:·· ~< .. ... · . ..·· 
Contro.l. :•• .•.••..•. 15"p,-p• . ·: 2'p-p 5'p-p 
····< . ··: ·• •• 1/' , ... .......... .. 
ST-segment LC -0.4±0.05 -0.9±0.12* -0.8±0.10* -0.8±0.11* -0.6±0.11 
mV MC -0.5±0.10 -0.8±0.15 -0.6±0.11 -0.5±0.10 -0.5±0.10 
N -0.6±0.16 -0.9±0.21 -0.8±0.20 -0.6±0.20 -0.3±0.12 
Lactate, LC 0.67±0.02 0.68±0.02 0.69±0.02 0.70±0.02 0.71±0.03 
Arterial MC 0.62±0.02 0.63±0.04 0.64±0.04 0.64±0.03 0.63±0.05 
mmol/L N 0.69±0.03 0.72±0.04 0.68±0.03 0.69±0.04 0.69±0.05 
Lactate, LC 0.53±0.02 0.82±0.03i 0.73±0.03* 0.66±0.03* 0.61±0.03* 
Coronary venous MC 0.51±0:02 0.50±0.03 0.48±0.03 0.49±0.03 0.50±0.03 
mmol/L N 0.57±0.03 0.55±0.04 0.55±0.04 0.56±0.04 0.58±0.05 
Lactate extractior LC 19±1.4 -23±4.5 * -4±2.8 * 7±2.6 15±2.4 
% MC 19±2.1 20±2.7 24±2.5 23±3.0 19±3.5 
N 17±3.2 23±4.1 20±3.7 19±2.9 16±3.5 
Abbreviations: 
LC =patients with >70% Left coronary artery disease Cn=161); MAX= maximal pacing rates; Min= minute; MC = 
patients with ~25% coronary artery disease (n=48); N =patients without coronary artery disease (n=23); p-
p = post-pacing; " = seconds; • = minutes; * p<.05 vs control. 
However, also in the resting patient, available data 
from human studies do not seem to favour this 
metabolite as a sensitive indicator of functionally 
significant coronary disease. In the latter situation, 
nearly aU studies have been based on pacing-
induced stress. 
Of these, the majority indicate that the incidence of 
myocardial lactate production ranges between 50% 
and 60%(6,7,9-11,13,16). However, it should be 
noted that other objective parameters of myocar-
dial ischemia also score relatively low in these 
studies, including ST-segment changes, the "gold 
standard"_, which was reported to vary between 50 
and 60%(t>,l1,13). 
Data on ischemia-induced lactate changes are 
mainly derived from studies in relatively small 
patient populations, which do not uniformly 
discriminate between type and location of vessel 
stenosis or compare the results from patients with 
significant coronary artery disease with normal 
individuals. Above all, these studies usually only 
concentrate on lactate changes during pacing. 
The present study re-exaq:tines the usefulness of 
myocardial lactate production as marker of ische-
lnia by taking these considerations into account in 
a large patient population. It clearly indicates, that 
by extending lactate assessments into the immedi-
ate post-pacing period, the sensitivity to indicate 
functionally important coronary artery lesions 
improves significantly and becomes superior to 
other objective markers, including ST-segment 
changes. Also, in so doing, the number of patients 
with demonstrable lactate production values 
increases significantly. Alternatively, the inci-
dence of myocardial lactate production in patients 
with minimal coronary lesions or in individuals 
without coronary disease is low, i.e. 9-10%. In 
view of the relatively high incidence of other 
markers in these latter patient groups, this suggests 
that myocardial lactate production, besides being 
more sensitive, is also more specific in the evalua-
tion of ischemia than commonly used objective 
criteria. 
Usefulness and applicability of myocardial 
metabolites as indicators of ischemia in man 
As myocardial ischemia results in early and 
profound metabolic alterations in the heart, 
identification of these changes has been one of the 
diagnostic goals in cardiovascular medicine since 
the introduction of coronary sinus catheterization 
in man by Bing et al in 1947(19). Although 
conceptually a sensible approach, several questions 
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Fig 4: Pacing-induced changes in lactate levels. 
Arterial values are comparable between groups 
and do not change during pacing. Also, coronary 
venous levels remain unaltered in patients without 
and with only minimal coronary disease. In 
contrast, in patients with significant lesions, 
coronary venous levels rise early [at I 00 
beats/minute (b/min)] with a marked increase at 
I 5 seconds post-pacing (P- P). Levels are still 
elevated, compared with control, at 5 min P-P. 
MAX= maximal pacing heart rates; '= minutes; 
" = seconds. Values are x±SEM. 
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arise concerning the usefulness of specific metabo-
lites as markers of ischemia, their reproducibility 
during repetitive periods of ischemia and the 
applicability of invasive techniques in general. 
With respect to the latter, non-invasive metabolic 
imaging techniques have certain apparent advan-
tages, but, alternatively"' may be limited by several 
technical shortcomings~.t.O). In general, they are not 
suitable for fast, sequential determination of meta-
bolic changes, due to the relatively long half-life 
of applicable radio-isotopes. Fast and accurate 
determinations of metabolic alterations can be 
accomplished with catheter tip electrodes, sensi-
tive for pH, oxygen or potassiumCZl-23)_ The main 
disadvantage of this technique is, that it does not 
allow for the concomitant measurement of other 
metabolites or coronary flow. This does not apply 
to conventional methods where coronary venous 
blood is sampled through catheters, positioned in 
the coronary sinus, such as in the present study. 
Consequently, a host of metabolites have been 
assessed in humans in an attempt to better identify 
the ischemic event. Of these, citrate, alanine, 
glutamate and the adenine nucleoside, hypoxan-
thine, seem potentially useful candidates as 
markers of ischemia, besides lactateC16,18,24). 
However, whether they are superior to lactate or 
whether they may improve the assessment of 
ischemia in addition to lactate, remains to be 
evaluated. In contrast, changes in pyruvate, glu-
cose, free fatty acids, inorganic phosphate, potas-
sium or in blood gases are either absent or 
insufficient to mark the ischemic event in 
manC12,16,24-26)_ Hence, when invasive metabolic 
studies are considered, lactate would still seem the 
substrate of choice. In addition, as studies are 
preferentially carried out in the resting patient, the 
atrial pacing stress test <l,f-f.ears the method of 
choice to induce ischemiaC2 - 9). 
Potential limitations of lactate as marker of 
ischemia 
A potential limitation of myocardial lactate 
metabolism as a marker of ischemia is its 
dependency on substrate availability. During 
exercise, arterial lactate levels increase, accom-
panied by enhanced extraction in non-ischemic 
areas. This is bound to affect the evaluation of 
lactate levels in the overall coronary effluent. In 
contrast, during pacing, arterial levels remain 
unaltered, as shown in the present study. Also, 
myocardial lactate extraction does not change as a 
result of pacing per se. Thus, this aspect may not 
apply to this test. In contrast, conditions of 
Fig. 5: Lactate extraction patterns during and 
after pacing (P-P). Lactate extraction remains 
unchanged in patients without or with minimal 
disease. Early changes occur in patients with 
significant lesions with production at maximal 
rates (MAX), followed by a significant increase in 
production values at 15 seconds (") post-pacing 
(P-P), returning to control levels thereafter. 
Values are x±SEM. 
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hyperventilation and neurohumoral activation, e.g. 
of catecholamines, may reduce lactate extraction, 
which may be one of the reasons that a reduction 
of lactate extraction under a certain level, i.e. 10%, 
as sometimes used in human studies, cannot be 
taken as an objective sign of ischemia(8,30,31)_ As 
ischemia-induced stimulation of circulating 
catecholamines bas been demonstrated in similar 
type patients and an identical study design as in the 
present investigation<32), the latter also emphasizes 
the necessity to adhere to the stringent criterion of 
myocardial lactate production during the 
evaluation of ischemia. 
The major limitation in the invasive assessment of 
ischemia by way of metabolites, such as lactate, 
from coronary sinus blood in humans, lies in the 
inability to measure regional alterations in meta-
bolism. To obviate atrial reflux on the one hand 
and sampling as well as capture problems during 
pacing on the other, the coronary sinus catheter 
should neither be too high up in the coronary sinus 
nor too near its orifice. Consequently, in the 
preferred position, the midportion of the coronary 
sinus, blood will invariably be sampled from 
ischemic and non-ischemic areas. As, during a 
procedure as fast atrial pacing, blood inflow in the 
post-stenotic area decreases and, subsequently, 
venous outflow diminishes, coronary sinus sam-
pies may mainly reflect blood from normal, non-
ischemic regions, thus obscuring the main event to 
be studied. 
Improved assessment of lactate metabolism 
The present study clearly indicates that alterations 
in myocardial lactate metabolism, due to pacing-
induced ischemia, are optimally assessed in the 
post-pacing period, more precisely between 15 
and 30 seconds post-pacing. The latter procedure 
significantly enhances the sensitivity of this 
marker of ischemia, making it superior to other 
objective indicators. In so doing, the number of 
patients in whom lactate production is demon-
strable also increases significantly. Moreover, our 
studies indicate that the collection of blood 
immediately after cessation of pacing (i.e. at 0 
seconds) or at a later interval, e.g. at 45 seconds, 
does not lead to similar results. Already in 1981, 
in a preliminary report, we suggested that abnor-
malities in lactate metabolism during pacing-
induced ischemia are optimally assessed at 15 
seconds post-pacing(33)_ Our findings were later 
confirmed by Ihlen et al. (7) Also, a study into the 
effect of pacing-induced ischemia on coronary 
venous pH, did indicate that maximal changes in 
pH occurred in the immediate post-pacing 
phase<21). 
It may be speculated that the enhanced lactate 
release from the heart after pacing results from a 
diminution in coronary flow through non-ische-
mic areas together with a concomitant improve-
ment in flow in the ischemic area upon cessation of 
pacing. As the determinants of myocardial oxygen 
demand are back to control levels soon after 
pacing, as can be seen from our data, a quick 
return to baseline values of coronary flow appears 
-123-
.1MAX 
COR. VEN. LACTATE 
(mmol/1) 
.1MAX 
LACTATE 
EXTRACTION 0" 15" 30" 45" p-p 
0.20 
0.16 
0.12 
0.08 
0.04 
n = 22 
* 
(%) 
n = 15 
n =128 
n = 22 
* p < .05 vs. MAX PACING 
t p < 0" vs. 15" p-p 
Fig. 6: Additional evaluations of lactate in the post-pacing (P- P) phase in a subgroup of patients with 
::_70% left coronary artery disease. Although at 0 seconds (") P-P lactate production values have 
increased compared with values at maximal pacing (MAX), maximal changes are found at 15 and 30 " 
P-P. Values are x±SEM. 
likely in the non-ischemic areas. However, it is 
doubtful whether this also holds true for the 
ischemic regions. We have demonstrated that 
myocardial perfusion remains disturbed for a 
relatively long period after pacing, at least for 5 
minutes, persisting after lactate metabolism has 
normalized(18,34). Also, sustained reductions in 
perfusion for periods up to 20 minutes after ische-
mia have been reportedC35). Hence, a rearrange-
ment of coronary flow immediately after pacing is 
unlikely and cannot explain the pronounced 
increase in coronary lactate levels at this point in 
time. 
Coronary venous flow occurs predominantly in 
systole. During pacing, the duration of systole 
progressively declines and so does the time for 
venous outflow. In contrast, immediately after 
pacing, systolic periods lengthen considerably. 
Moreover, there is a general tendency that left 
ventricular peak systolic pressure also improves in 
the post-pacing phase. We would propose that a 
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prolonged systolic squeezing effect is the main 
mechanism underlying the observed increase in 
coronary venous levels in the early post-pacing 
interval. 
Comparison of lactate production with other 
markers of ischemia 
Lactate production, in the present study, proved to 
be a better indicator of ischemia than the other 
variables tested, both with respect to sensitivity 
and specificity. In patients with a normal coronary 
artery system and no background of ischemic heart 
disease, lactate production occurred in only 9% 
compared with 52%, 57% and 46% of patients with 
angina, electrocardiographic and hemodynamic 
abnormalities, respectively. Similar differences 
were present in patients with only minimal coro-
nary diasease, but also without a background of 
ischemic heart disease. 
The selection procedure of these study groups 
makes it very unlikely that ischemic heart disease 
was present, but does not provide absolute proof. 
After all, patients were catheterized for the evalua-
tion of angina -like chest-pain or equivalent symp-
toms, typical or atypical of nature. Also, as coro-
nary flow measurements in this study were only 
carried out in a very limited group of patients, we 
have no information on coronary vascular reserve. 
Some patients may have had small vessel disease 
or the so-called syndrome X. However, these 
patients generally have objective signs of ischemia 
during exerciseC:r6,37), which our patients had not. 
Thus, the absence of lactate production in the two 
study groups without significant coronary lesions 
probably did correctly indicate the absence of 
ischemic heart disease. It is interesting to note, that 
angina and ST-segment depressions apparently 
were less specific. Artifactual ST -segment 
depression during pacing in our study is unlikely 
as all electrocardiograms were also assessed during 
the first 5 complexes following cessation of 
pacing. 
Also, it is interesting that there was no appreciable 
difference between patients without lesions and 
those with minimal disease. It has been suggested, 
that coronary vasomotion is disturbed already in 
arterial segments with minimal lesions as it is in 
stenosed arteries with an abnormal response to 
pacingC38•39). For this reason, patients with coro-
nary lesions and those with only minimal disease 
were considered separately in our study, although 
the response of fast atrial pacing was comparable 
in these two study groups. 
Besides a better specificity, lactate production was 
also more sensitive than other markers in detecting 
functionally significant coronary artery disease. Its 
occurrence was only equalled by angina -like pain, 
which, as we have shown, is a very unspecific 
symptom. Our observation is particularly relevant 
in relation to (the lack of) changes in ST-segment. 
Not only was the incidence of lactate production 
greater, there was also a significant correlation 
between the absence of lactate changes and myo-
cardial oxygen demand, which was not present for 
ST-segment changes. Patients in the coronary 
disease group, in whom myocardial lactate meta-
bolism was not affected by pacing, were stressed 
to a significantly lower heart rate and double 
product than the patients with lactate production, 
suggesting that the sensitivity of this marker might 
have been significantly greater when appropriately 
high pacing rates were applied to all patients. In 
contrast, such discrimination could not be made 
for the other variables. Furthermore, lactate 
production persisted longer than ST-segment 
depressions following pacing. In earlier studies we 
suggested that certain metabolic changes, i.e. 
adenine nucleoside release, may be sustained after 
the ischemic eventC18). The present study indicates 
that this also holds true for lactate. 
Ischemia-induced abnormalities in left ventricular 
ejection fraction and in regional wall motion may 
precede lactate r:roductionC40) and may also be 
more sensitiveC4 ) . However, these studies only 
considered lactate production during pacing. 
Preliminary data from our laboratory indicate that 
the occurrence of new wall motion abnormalities 
is comparable to myocardial lactate abnormalities, 
when assessed as suggested in this report (Bartels, 
unpublished observation). 
Implications 
Our data indicate that myocardial lactate produc-
tion is a useful marker of myocardial ischemia in 
man and sensitive as indicator of functionally 
important coronary artery disease. Alternatively, 
the parameter appears very specific. As such, it 
does appear more optimal than uniformly applied 
criteria with the exception perhaps of regional wall 
motion abnormalities. Also, although angina did 
occur slightly more often in patients with sig-
nificant coronary lesions, this parameter, on the 
other hand, is highly unspecific. To obtain optimal 
information on myocardial lactate metabolism, it 
is necessary to assess lactate between 15 and 30 
seconds post-pacing. As myocardial lactate 
production, assessed in this way, is both sensitive 
and specific, it should be useful in delineating the 
antiischemic effects of interventions. 
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Summary 
The effect of repeated local ischemia and reperfusion on myocardial metabolism 
and ventricular performance was studied in 12 open-chested pigs fasted overnight. 
Myocardial ischemia was induced by reduction of the flow in the left anterior 
descending coronary artery to 40% of control during 30 min. After 35 min of 
reperfusion a second 30-min occlusion period was started, again followed by a 35-
min reperfusion period. At the end of both reperfusion periods coronary flow and 
coronary resistance had returned to control values. During control there was lactate 
uptake, but no significant uptake of glucose, free fatty acids CFF A), triglycerides, 
glycerol and inosine. During the first occlusion period the heart released lactate and 
inosine, and used glucose and FF A. At the end of the first reperfusion period lactate 
uptake approached control values, but inosine was still released by 10 of the 12 
animals. In the second ischemic period, glucose and FF A were again taken up. 
Lactate and inosine were released, but the production was much smaller than 
during the first occlusion period. Depletion of myocardial glycogen and high-
energy phosphates could be responsible for this quantitatively different response. 
Necrosis may have played a role, although enzyme release was minimal and only 
observed after the second occlusion period. 
Heart rate, peripheral resistance and ventricular filling pressure were virtually 
unchanged throughout the course of the experiments. Maximum rate of fall of left 
ventricular pressure (min LV dP /dt) decreased during ischemia and did not recover 
during reperfusion. Changes in min LV dP/dt and cardiac output were more closely 
related than changes in max LVdP/dt and cardiac output. 
This model cannot be used for the study of interventions during myocardial 
ischemia in which the animal serves as its own control: 
A large number of experimental studies dealing with the consequences 
of acute myocardial ischemia or infarction have been carried out in the 
dog. However, the coronary vasculature and the collateral circulation of 
*)This investigation was supported by a grant from the Dutch Heart Foundation. 
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the dog is quite different from that found in man (14). The pig may be more 
suitable for these studies, since striking similarities exist between the 
hearts of man and pig (4, 7, 13, 28 and 29). Consequently different aspects 
of myocardial ischemia have been studied in the pig heart (1, 7, 8, 11, 18, 23, 
31, 34 and 36). In an earlier report from our laboratory (10), we compared 
myocardial lactate release with the release of the ATP-catabolites inosine 
and hypoxanthine, during severe ischemia and reperfusion. In a large 
number of investigations multiple occlusions are carried out in order to 
evaluate the capability of drugs to modify the degree of ischemia. ST-
segment changes are frequently used as an indicator of the degree of 
ischemia in such studies. However, little attention has been paid to 
myocardial metabolism, although alterations in the oxygen demand/sup-
ply ratio is often the prime target of such interventions. We therefore 
studied myocardial metabolism during two periods in which the flow in 
the left anterior descending coronary artery (LAD) was reduced to 40% of 
its control value for 30 minutes. After the first partial occlusion period the 
LAD was reperfused until flow and coronary vascular resistance resumed 
control values. Subsequently the second occlusion period was started. In 
our previous communication (10) nucleoside and carbohydrate metabol-
ism were evaluated. In this study considerable attention has been paid to 
the role of free fatty acids. 
Materials and methods 
The experiments were performed on 12 Yorkshire pigs fasted overnight. The 
animals were sedated with 120 mg azaperone i. m. (Stresnil®, Janssen Phar-
maceutica, Beerse, Belgium). Subsequently 150 mg metomidate (Hypnodil®, Jans-
sen Pharmaceutica, Beerse, Belgium) was administered via a vein on the dorsal 
surface of the ear. The animals were intubated and connected to a Bird Mark 4 
respirator for assisted ventilation with a mixture of 33% oxygen and 67% nitrous 
oxide. Ventilation was controlled by intermittent measurement of arterial blood 
gases (ABL1, Radiometer, Copenhagen, Denmark). The temperature of the animals 
was kept between 36.5 and 37.5 oc with a heating pad. ECG leads I, II and III were 
monitored throughout the experiment. The animals were kept anesthetized with a 
mixture of 2 mg · kg-1 · hour-1 azaperone and 8 mg · kg-1 · hour1 metomidate, adminis-
tered through the lumen of an 8 F Cournand catheter placed in the right atrium 
from the right jugular vein. A single 8 F Cournand catheter with its tip positioned in 
the thoracic aorta, was used for central aortic pressure measurements and for the 
collection of blood samples for the determination of blood gases and biochemical 
parameters. Through the left carotid artery a high fidelity 8 MMC Telco tip-
manometer catheter (Thomson, Paris, France) was placed in the left ventricle for 
pressure measurements. Cardiac output was measured using the thermodilution 
technique. To this end a 7 F triple lumen balloon-tipped catheter was inserted in a 
femoral vein and its tip was positioned in the pulmonary artery. A 7 F Cournand 
catheter was positioned in the vena cava inferior for infusion purposes. 
Surgical procedure 
The left anterior descending coronary artery (LAD) was exposed by means of a 
midsternal thoracotomy. Parts of the fourth and fifth ribs were removed to get easy 
access to the LAD and its accompanying vein. The LAD was prepared free from its 
origin to its first branch and an electromagnetic flow probe (Skalar, Delft, The 
Netherlands, 20-25 mm in diameter) and a screw clamp were placed around the 
artery. 
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The accompanying vein was cannulated and a polyethylene catheter was 
inserted with the tip in the area to become ischemic. Care was taken for a free run-
off of the myocardial venous blood, which was collected and returned to the animal 
via the catheter in the vena cava superior. Heparin (3000 units) was administered to 
prevent clotting. 
Hemodynamic measurements 
All tracings were written out on a Siemens Oscillomink B recorder. Cardiac 
output (CO) determinations were made in duplicate. Between the cardiac output 
measurements, the ECG, left ventricular pressure (L VP), its first derivative (LVdP/ 
dt), central aortic and right atrial pressures were recorded. 
Biochemical measurements 
Arterial and local coronary venous pH, P 0 , and Pco, were determined with the 
ABL1 blood gas analyzer (Radiometer, Copenhagen, Denmark). Oxygen saturation 
was measured with an in vitro hemoreflectometer (American Optical Company, 
Framingham, Massachusetts). 
Lactate was assayed enzymically in deproteinized samples on a Technicon 
AutoAnalyzer II (Tarrytown, New York, USA) as described by Apstein (2). Inosine 
was determined in neutralized samples (11). Samples containing less than 5 !1M 
inosine were analyzed according to Olsson (24). Plasma glucose was assayed with 
the AutoAnalyzer II, using Technicon methodology. Serum free fatty acids were 
measured according to Dole and Meinertz as modified by Trout et al. (33); titration 
was carried out on a Titrigraph (Radiometer, Copenhagen, Denmark). Biochemica 
test combinations (Boehringer, Mannheim, Germany) were used to determine 
plasma glycerol, triglycerides, lactate dehydrogenase-1-isoenzyme (aHBDH, EC 
1.1.1.27) and creatine kinase (CK activated, EC 2.7.3.2). Lactate dehydrogenase 
(LDH, EC 1.1.1.27) was assayed according to·Bergmeyer (3). Blood gases at 30 oc 
were determined immediately after withdrawal of the blood samples. The other 
samples were stored at -30 oc until determinations were carried out. 
Experimental protocol 
After completion of surgery, a stabilization period of thirty minutes was allowed 
before control measurements were made. Subsequently the LAD flow was reduced 
to 40% of control by tightening the screw clamp. When necessary, the screw was 
adjusted to keep the flow at its reduced value. After 30 minutes the clamp was 
released and the LAD was reperfused. Thirty-five minutes later the LAD flow was 
again reduced to 40% of control for a period of 30 min and the LAD was subse-
quently reperfused. At fixed time intervals, arterial (a) and local coronary venous 
blood (cv) samples were drawn for the determination of biochemical parameters 
and the hemodynamic state of the animal was evaluated. 
Only the anesthetics mentioned before, pancuronium (2 mg, when necessary to 
suppress muscle tremor) and saline (154 mM NaCl, to compensate for blood loss) 
were given throughout the study. 
Statistics 
The paired Student t-test (two tailed) was employed to determine probability 
levels. Only p < 0.05 was considered to be significant. 
Results 
Ventricular arrhythmias 
Ventricular ectopic activity was rare during both the flow reduction 
and reperfusion periods. In one animal a short lasting ventricular fibrilla-
tion was induced by the catheter in the ischemic myocardium during one 
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of the blood sampling periods. The results of this experiment were not 
different from the others and were therefore included in the study. 
LAD blood flow and myocardial 0 2 consumption 
LAD blood flow was 47 ± 4 ml/min (mean ± SEM) during the first 
control period. This was reduced to 18.3 ± 1.7 ml/min (39% of control) 
during the first occlusion. After the clamp was released, at t = 30 minutes, 
there was considerable reactive hyperemia with a peak of 70 ± 5 ml/min (p 
< 0.001, compared to control) after 2 minutes of reperfusion (fig. 1). The 
flow gradually decreased and 35 minutes after release of the clamp LAD 
flow was not different from control. The coronary resistance of the vascu-
lar bed perfused by the LAD was not calculated during the occlusion 
period because the post-stenotic pressure was not measured. However, 
calculation of the resistance immediately after reperfusion was started, 
indicated vasodilatation had occurred (fig. 1). After 35 min of reperfusion, 
the coronary resistance had also returned to control values. At this time 
the second partial occlusion was started. In the second reperfusion period 
again a reactive hyperemic flow was found with a peak of 60 ± 4 ml/min 
after two minutes. At the end of the second reperfusion period, the LAD 
flow as well as the coronary vascular resistance values were not different 
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Fig. 1. From top to bottom are shown the left anterior descending coronary artery 
(LAD) flow, myocardial 0 2 consumption and the resistance of the vascular bed 
perfused by the LAD. Because the post-stenotic pressure was not measured during 
flow reduction, the coronary resistance immediately after the beginning of the 
reperfusion was considered to be a measure of the vasodilatation occurring during 
the occlusion period. * stands for p < 0.05 vs. control. 
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from control and from the values found at the end of the first reperfusion 
period. Myocardial 0 2 consumption which had decreased with 50% during 
occlusion, returned to control only in the early reperfusion period. There-
after there was a gradual decrease and after 35 min of reperfusion 0 2 
consumption was only 80% of control. During the second occlusion and 
reperfusion periods a similar pattern was found. 
Hemodynamics 
No significant changes from control occurred during the course of the 
experiments in the following parameters: heart rate (115 ± 6 beats/min), 
right atrial pressure (5.1 ± 0.6 mmHg) and peripheral resistance (1900 ± 
200 gcm-4sec-1) while only a transient increase in left ventricular end-
diastolic pressure was observed in the first minutes after the first flow 
reduction (11.5 ± 1.0 mmHg vs. 9.0 ± 0.6mmHg, p < 0.025).MaxLVdP/dt 
decreased by 25% during the first occlusion, but control values were 
restored during reperfusion (fig. 2). A small decrease in max LVdP/dt was 
seen in the second occlusion period, but recovery was incomplete in the 
following reperfusion. The most sensitive hemodynamic parameter was 
the maximum rate of fall of left ventricular pressure (min LV dP I dt), which 
showed large increases during both occlusions (20-25%), without any 
recovery during reperfusion (fig. 2). Cardiac output (CO) also decreased 
during both occlusions without improvement during reperfusion. The 
correlation between CO and min LVdP/dt (r = -0.88, p < 0.001) was much 
better than between CO and max LVdP/dt (r = 0.40, p < 0.05). 
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Fig. 2. From top to bottom are shown the maximum rate of rise (max LVdP/dt), and 
fall (min LVdP/dt) of left ventricular pressure and the cardiac output. Cardiac 
output and min LVdP/dt did not improve during the reperfusion periods.* stands 
for p < 0.05 vs. control. 
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Blood gases 
Arterial blood gases were in the normal range throughout the entire 
experiments in all animals: pH: 7.35-7.45, Pc02: 35-45 mmHg and 0 2 
saturation > 95%. Arterial-coronary venous difference (a-cv) in pH was 
0.048 ± 0.005 during control and incre;3.sed to 0.214 ± 0.021 after 5 minutes 
of LAD obstruction (p < 0.001, fig. 3). In the following 20 minutes (a-cv) pH 
gradually dropped. Control values had resumed at the end of the first 
reperfusion period. The second occlusion period gave rise to a new 
increase of (a-cv) pH. After 5 minutes a difference of 0.137 ± 0.016 was 
observed; this is smaller (p < 0.005) than the value measured at the 
comparable time in the first occlusion period. As in the first ischemic 
period (a-cv) pH started to decrease after 5 minutes of ischemia in the 
second period and after 25 minutes (a-cv) pH was again significant lower 
than after 5 min (p < 0.001). During the second reperfusion period control 
values returned. The (ev-a) Pco2 response to ischemia and reperfusion 
correlated very closely with that of (a-cv) pH (r = 0.99, p < 0.01, fig. 3). 
Lactate 
Arterial lactate levels increased gradually throughout the occlusion 
and reperfusion periods (fig. 6). This increase correlated with the decrease 
in cardiac output (r = -0.92, p < 0.001). 
Lactate uptake (31 ± 8 fLinOles/min) during control changed to lactate 
release in the first occlusion period, reaching a peak of 48 ± 9 f.lmoles/min 
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Fig. 3. Myocardial C02 (top) and proton (bottom) balance during control, flow 
reduction to 40% and reperfusion. Control and reperfusion values did not differ 
significantly. Large arterio-coronary venous differences in pH and Pcoz were found 
during the flow reduction periods. Proton and C02 release during the second 
occlusion period were significantly smaller than at comparable times during the 
first period. * stands for p < 0.05 vs. controL 
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Fig. 4. Arterial lactate levels (bottom) increased gradually during the experiments. 
Myocardial lactate balance (top) shows that lactate release after 25 min in the first 
occlusion period was significantly smaller than after 15 min. The figure also 
indicates that at any time during the second occlusion period, a much smaller 
release was found than at comparable times during the first occlusion period, 
despite the same LAD flow (see fig. 2). Control and reperfusion values did not differ 
significantly. * stands for p < 0.05 vs. control. 
(p < 0.001) after 5 minutes. Subsequently lactate release started to 
decrease and after 25 minutes a value of 15 ± 4 !J.moles/min was found 
(p < 0.005 when compared to 5 minutes of ischemia). 
Uptake at the end of the first reperfusion period was not significantly 
different from control. However, myocardial lactate release in the second 
occlusion period was much less than that at comparable times during the 
first occlusion period (fig. 4). 
After 5 minutes in the second occlusion period, no significant lactate 
release took place (3 ± 11 !J.moles/min, compared to 48 ± 9!-tmoles/min 
after 5 minutes of the first occlusion, p < 0.002). Uptake by the heart at the 
end of the second reperfusion period was not different from control. 
Inosine 
Arterial inosine levels (13.3 ± 1.8 !J.M during control) did not change 
significantly during the experiments (fig. 5), which is at variance with the 
increase in the arterial lactate levels. Myocardial inosine uptake (0.047 ± 
0.022 !J.moles/min) changed into release during the first occlusion period 
reaching a peak of 0.923 ± 0.243 !J.moles/min after 5 minutes of occlusion. 
Inosine release after 25 minutes of occlusion was significantly smaller 
than after 5 minutes (p < 0.005). At the end of the first reperfusion period, 
there was still a significant inosine release (0.128 ± 0.046 !A-moles/min, p < 
0.01 vs. control), indicative for the presence of ischemia. A remarkable 
observation is that 10 out of 12 animals had still inosine release, whereas 
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Fig. 5. Arterial inosine levels (bottom) did not change during the experiments. 
Myocardial inosine balance showed a similar pattern during the occlusion periods 
as myocardial lactate balance (see fig. 6). At the end of the first reperfusion period 
there was still a significant inosine release. * stands for p < 0.05 vs. control. 
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Fig. 6. Arterial glucose levels (bottom) did not change during the experiments. 
There was no glucose uptake during control and at the end of reperfusion but there 
was a similar glucose uptake at the end of both occlusion periods. * stands for p < 
0.05 vs. control. 
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only 2 of the animals released lactate. During the second occlusion period 
inosine release increased to a maximum of 0.236 ± 0.100 ~-tmoles/min after 
15 minutes, which was again much less than that at the comparable time 
during the first period (p < 0.005). At the end of the second reperfusion (at t 
= 140 min), the arterial as well as the venous levels were not different from 
those found at the end of the first reperfusion period. 
Glucose 
Arterial glucose levels did not alter during the experiments. During 
control as well as at the end of the reperfusion periods, the heart did not 
use glucose. However, during the occlusion periods, there was a signifi-
cant and comparable uptake (fig. 6). 
Free fatty acids 
The myocardium did not use any free fatty acids (FF A) during control 
as arterial and coronary venous levels were identical (0.77 ± 0.15 mM). 
Arterial levels increased gradually during the experiment. This increase 
became significant during the first reperfusion period (1.04 ± 0.13 mM, p < 
0.05, fig. 7). After 25 minutes of flow reduction a significant (p < 0.005) 
uptake of FFA .by the ischemic myocardium was observed: 1.8 ± 0.5 
1-tffiOles/min. Uptake at the end of reperfusion (t = 65 min) was not 
significant, whereas during the second occlusion period FF A uptake was 
the same as during the first occlusion period. No significant FF A uptake 
was found during the last reperfusion period. 
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Fig. 7. Arterial free fatty acid (FFA) levels showed a slight increase during the 
experiment. FFA was not used by the heart during control and at the end of the 
reperfusion periods, but there was a significant and similar uptake during the 
occlusion periods. * stands for p < 0.05 vs. control. 
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Table 1. Triglyceride, glycerol and potassium release after repeated 30 min partial 
occlusion and after 35 min reperfusion of a coronary artery in pigs. 
Control 
First occlusion 
First reperfusion 
Second occlusion 
Second reperfusion 
Triglycerides 
Arterial 
0.118 ± 0.019 
0.149 ± 0.012 
0.188 ± 0.023* 
0.166 ± 0.019 
0.186 ± 0.019* 
Venous 
0.113 ± 0.010 
0.156 ± 0.008* 
0.170 ± 0.030 
0.143 ± 0.013 
0.177 ± 0.014* 
Glycerol 
Arterial 
0.20 ± 0.02 
0.24 ± 0.03 
0.31 ± 0.04* 
0.37 ± 0.06* 
0.40 ± 0.05* 
All values are expressed in mM; * p < 0.05 vs. control. 
Triglycerides and glycerol 
Venous 
0.19 ± 0.02 
0.26 ± 0.03* 
0.34 ± 0.04* 
0.39 ± 0.05* 
0.41 ± 0.05* 
There was an increase in the arterial and coronary venous levels of 
triglycerides (up to 60%) and glycerol (up to 120%). However, no signifi-
cant arterio-venous differences were observed (table 1). A significant 
correlation (r = 0.61, p < 0.05) between the arterial levels of FFA and 
glycerol was found during control. The correlation between FF A and 
glycerol improved gradually during the course of the experiments and at 
the end of the second reperfusion period (t = 140 min) rwas 0.90 (p < 0.001) 
for the same twelve animals. 
Enzymes 
No changes in the arterial levels of total CK were oberserved during the 
course of the experiments (table 2). However, there was a gradual increase 
in the coronary venous levels and at the end of the second reperfusion 
period, a small but significant myocardial CK release was found. Arterial 
and coronary venous levels of LDH and aHBDH did not alter (table 2). 
Discussion 
The effects of reperfusion of occluded coronary arteries are not fully 
understood. Reperfusion after a total occlusion for more than 15 minutes 
in pigs did not result in improvement of hemodynamic function or 
myocardial metabolism (1). Reperfusion after a one hour partial occlusion 
(flow reduced to 25% of control) resulted in arterio-venous lactate differ-
ences which were not different from control (10). However, the same 
authors also reported that myocardial oxygen uptake and hemodynamic 
function did not recover within one hour of reperfusion. In the dog, partial 
(15, 19) as well as complete (21) recovery have been described after com-
plete ligation of coronary artery for more than 15 minutes. In the same 
species two hours of reperfusion after an one hour reduction of the LAD 
flow to 50% resulted in only partial recovery of contractility in the 
ischemic area (26). It may be expected that shorter periods of partial 
coronary artery occlusion may lead to a complete return towards preocclu-
sion values. Therefore we studied myocardial metabolism and hemody-
namics during 30 minutes in which coronary blood flow was held at 40% of 
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Table 2. Enzyme release after repeated 30 min partial occlusion and after 35 min reperfusion of a coronary artery in pigs. I ~ 
CK LDH aHBDH 
Arterial Venous Arterial Venous Arterial Venous 
Control 0.40 ± 0.04 0.37 ± 0.03 0.56 ± 0.03 0.53 ± 0.04 0.276 ± 0.014 0.270 ± 0.017 
First occlusion 0.41 ± 0.04 0.40 ± 0.04 0.55 ± 0.05 0.57 ± 0.07 0.271 ± 0.019 0.276 ± 0.016 
First reperfusion 0.41 ± 0.03 0.44 ± 0.04 0.54 ± 0.03 0.47 ± 0.05 0.260 ± 0.014 0.272 ± 0.014 
Second occlusion 0.45 ± 0.03 0.47 ± 0.04* 0.57 ± 0.04 0.53 ± 0.04 0.278 ± 0.018 0.282 ± 0.014 
Second reperfusion 0.44 ± 0.03 0.48 ± 0.04+* 0.54 ± 0.04 0.51 ± 0.03 0.267 ± 0.020 0.271 ± 0.015 
All values are in units/ml plasma. Abbreviations: CK, creatine kinase; LDH, lactate dehydrogenase; aHBDH, a-hydroxybutyrate 
dehydrogenase (LDH-1-isoenzyme). 
+ = p < 0.05 vs. arterial level; * = p < 0.05 vs. control. 
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control. After 35 min of reperfusion, coronary flow and resistance had 
resumed control values. 0 2 consumption of the LAD perfused area was 
still slightly depressed (80% of control). 0 2 consumption of the entire heart 
was not measured in this study, thus no conclusive data are available 
about the course of the 0 2 consumption of the area which was not subject 
to coronary flow reduction. An indirect way of estimating myocardial 0 2 
demand is by calculation of the double product, heart rate times left 
ventricular systolic pressure. Control data were (10.5 ± 0.9) 103 mmHg/ 
min. At the end of the first reperfusion it was (9.9 ± 0.6) 103 mmHg/min, 
which was not statistically different from control. On the basis of these 
data, it is assumed that the previously underperfused area was not able to 
use as much 0 2 as the normal part of the myocardium. 
During control the heart preferred lactate as substrate over glucose and 
free fatty acids. The choice of the anesthetics could explain this unex-
pected finding, because the combination of azaperone/metomidate 
yielded rather high arterial lactate levels (4 mM). This enhances myocar-
dial lactate uptake (16), which could be at the cost of free fatty acid 
oxidation. This hypthesis is also supported by the findings that in pigs 
anesthetized with halothane, lower arterial lactate levels (1.0 mM) and 
uptake of free fatty acids were found (22, 35). During the course of the 
present experiments a gradual rise in arterial lactate levels was observed, 
while arterial inosine concentrations did not change. This increase in 
arterial lactate levels may be partially responsible for the discrepancy in 
the lactate and inosine data at the end of the first reperfusion period. At 
that time inosine is still released (an indication of ischemia), whereas 
lactate is extracted by the heart in amounts not different from control. 
Thus, lactate data in addition to coronary flow and resistance data suggest 
that at the end of the first reperfusion period the heart has returned to its 
control state. Inosine, on the other hand, reveals that return yet is incom-
plete. The increase in arterial lactate concentrations may have further 
promoted lactate uptake and consequently disturbs a proper evaluation of 
the metabolic state of the myocardium (6). 
Lactate uptake changed into lactate release during the first occlusion 
period, with a peak value after 15 minutes. After 25 minutes a smaller 
amount of lactate was released by the ischemic heart, despite unchanged 
coronary inflow and unchanged hemodynamic determinants of myocar-
dial 0 2 demand. A decrease in lactate release after a longer period of 
ischemia has also been reported in the isolated rat heart (27) and could be 
explained by an inhibition of glyceraldehyde-3-phosphate dehydrogenase 
(EC 1.2.1.12) by decreased intracellular pH and increased cytosolic NADH 
levels (32). This would reduce the formation of lactate via a reduced 
glycolytic flux. It is attractive to adopt this explanation also for our data. 
However, this does not explain why inosine release exhibited a similar 
pattern as lactate release during the first occlusion period. Nucleotide and 
nucleoside contents, determined in biopsy specimen, are needed to elim-
inate a number of possible explanations: (i) decreased ATP content due to 
inhibition of glycolysis; (ii) reduced AMP catabolism; (iii) reduced nuc-
leoside transport across the membrane; (iv) increased intracellular hypox-
anthine conversion to AMP via inosine 5' -monophosphate. 
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Lactate and inosine release were smaller during the second ischemic 
period than in the first period at comparable times. This may be due to 
either reduced intracellular production or (and) to reduced removal. A 
number of mechanisms could be responsible for reduced production. 
First, the occurrence of necrosis. This would reduce the mass of ischemic 
myocardium involved in the metabolic processes. Reperfusion after coro-
nary artery ligation in dogs results in an earlier appearance of CK in 
coronary sinus (5) and in arterial blood (15). In our experiments some CK, 
but no LDH or aHBDH was released at the end of the second reperfusion 
period (table 2). This could indicate that during the second occlusion a 
small part of the myocardium was irreversibly damaged. A second expla-
nation might be the functioning of collateral vessels. Although collateral 
vessels in young swine have been observed (14) it is very unlikely that they 
start functioning within a couple of hours (28). Thus it is doubtful that the 
decrease in myocardial lactate and inosine release in the second ischemic 
period could be explained by activation of a collateral circulation. A third 
explanation could be the activation of other metabolic pathways due to 
depletion of glycogen and possibly ATP (17, 20, 25 and 30). The existence 
of such pathways is also suggested by the (a-cv) differences in pH and P co2 
during the second occlusion period. These differences reached values of 
60-70% of the differences found during the first occlusion period, whereas 
lactate release in the second occlusion period was only 6-33% of that in the 
first occlusion period. Thus, while the close relation between lactate and 
pH changes in the first occlusion period suggests that the increase in the 
H+ concentrations in the coronary venous effluent is associated with 
anaerobic glycolysis, the less strong relationship in the second period 
indicates that other factors than anaerobic glycolysis play a role in the 
formation of H+. 
Glucose extraction as well as (a-cv) differences were the same during 
the two occlusion periods (fig. 8). Therefore it must be assumed that 
during the second occlusion period, in view of the decreased lactate 
release, another pathway than glucose ~ lactate was preferred. This could 
be the conversion from glucose to glycerol-3-phosphate and subsequently 
esterification with fatty acids, leading to triglyceride and phospholipid 
formation. If this would be the case a larger FFA extraction during the 
second than during the first occlusion should be expected. However, such 
an increase was absent during the second occlusion. The possibility of an 
altered transport mechanism rather than a reduced intracellular lactate 
and inosine production can also not be excluded. 
The changes in the hemodynamic parameters during the first occlusion 
period were minimal as heart rate, left ventricular end-diastolic pressure 
and systemic vascular resistance did :riot change appreciably, while car-
diac output decreased slightly. During the reperfusion period cardiac 
output did not return to control values but decreased further (10-25%). In 
the second occlusion period the above mentioned parameters behaved 
very similar as during the first occlusion period. In this study the most 
sensitive hemodynamic parameter was the maximum rate of fall of the left 
ventricular pressure (min LV dP I dt), which changed with 57% against max 
LVdP/dt with 23% and cardiac output with 26% during the course of the 
experiment. Relatively little attention has been given to this parameter, 
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although its significance has been noticed before (9, 37). Another striking 
feature of min LV dP/dt is the finding that it did not even recover partially, 
during the first reperfusion period. Consequently min LVdP/dt and CO 
behaved more similarly (r = -0.88) than max LVdP/dt and CO did (r = 
0.40). It is obvious from the results in this study that multiple coronary 
flow reductions to 40% of control, each of which lasts 30 minutes are not 
very well suited for the evaluation of interventions which aim to limit the 
degree of myocardial ischemia, despite a reproducible coronary flow and 
resistance. 
The slightly elevated CK levels in the coronary venous effluent may 
indicate some necrosis during the second occlusion period, although 
arteriovenous differences were minimal. A less severe or a shorter lasting 
coronary artery obstruction probably prevents any necrosis. Both 
approaches have distinct disadvantages, when biochemical markers are 
used to describe the degree of ischemia. A minor obstruction could lead to 
undetectable changes in the metabolites (38). Since lactate and inosine 
release reach peak values after 15 minutes of ischemia, a shorter occlusion 
period appears to be unwanted. In order to establish if an initial slower rise 
in lactate (inosine) release after onset of ischemia is due to decreased 
anaerobic metabolism or due to an effect of the intervention on the 
transport mechanism of the metabolite across the cell membrane, a longer 
occlusion period appears to be desirable. 
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Zusammenfassung 
Der Effekt von wiederholter lokaler Ischii.mie und Reperfusion auf den myokar-
dialen Energiestoffwechsel und Ventrikelfunktion wurde bei 12 narkotisierten 
Schweinen mit geoffnetem Thorax studiert. Die Schweine hatten 24 Stunden 
gefastet. Die myokardiale Ischamie wurde verursacht durch eine Reduktion der 
Blutdurchstromung in der linken Anterior Descending Koronar Arterie bis 40% 
vom Anfangswert wahrend 30 Minuten. Eine zweite Reduktion wurde nach 35 
Minuten Reperfusion angefangen. Die zweite Reduktion folgte wieder durch eine 
35 Minuten dauernde Reperfusion. Am Ende der beiden Reperfusionen der 
Koronardurchstromung und Koronarwiderstand hatten sie wieder Anfangswerte 
angenommen. Wahrend der Kontrolle gab es Laktat-Aufnahme, aber keine 
Aufnahme von Glukose, Freie Fettsaure (FFA), Triglyzeride, Glyzerol und Inosine. 
Wahrend der ersten Okklusions-Periode wurde aus dem Herzen Lactat und Inosine 
freigemacht, es wurde Glukose und FFA aufgenommen. Am Ende der ersten 
Reperfusion wurde Laktat wieder aufgenommen, aber Inosine wurde noch immer 
an 10 von 12 Schweinen freigemacht. In der zweiten Okklusions-Periode gab es 
wieder Glukose und FFA-Aufnahme. Laktat und Inosine wurden freigemacht, aber 
die Produktion war viel kleiner als in der ersten Okklusions-Periode. Erschopfung 
von myokardialen Glykogen und energiereichen Phosphaten konnen daffu verant-
wortlich sein. Nekrose konnte auch eine Rolle gespielt haben, obschon Enzym-
Abgaben sehr gering waren und nur nach der zweiten Okklusions-Periode gefun-
den wurden. Herzfrequenz, Peripherewiderstand und ventrikularer Fiillungsdruck 
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blieben so gut wie unverandert. Wahrend der Experimente wurde die maximale 
Druckabfallgeschwindigkeit (minL V dP/dt) weniger, wahrend Ischamie sich bei 
Reperfusion nicht herstellte. Veranderungen in minLVdP/dt und Herzminuten-
volumen hatten einen hoheren Korrelations-Koeffizient als maxLVdP/dt und Herz-
minutenvolumen. Dieses Modell kann nicht fUr die Studien von Interventionen 
wahrend myokardialer Ischamie benutzt werden. 
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ABSTRACT 
Despite widespread use of myocardial metabolic 
markers to define the efficacy of antiischemic 
interventions in myocardial ischemia in man, their 
reproducibility during successive ischemic epi-
sodes has not been evaluated consistently. 
Reproducibility of myocardial lactate production 
was studied during repeated, incremental atrial 
pacing stress tests, separated by intervals of 15, 
30, 45 and 60 minutes (min) in 14, 15, 12 and 14 
patients with left coronary artery disease, resp. By 
design, duration and maximal heart rates (MAX) 
were identical in both first (P1) and second (P2) 
pacing test in each group. Also, left ventricular 
systolic pressures and double products were 
similar and comparable between groups. In 
contrast, contractility improved significantly less 
during P2 compared to P1 after intervals of 15 and 
30 min. Arterial lactate levels did not change 
during pacing. In contrast, coronary venous levels 
increased in each group. However, following 
intervals of 15 and 30 min, changes were signi-
ficantly less during P2 compared to Pl. Conse-
quently, myocardial lactate production was 53% 
and 58% less during P2, compared to P1 (p<0.05). 
In contrast, average coronary venous lactate and 
lactate extraction values were similar following 
intervals of 45 min or more. Also, individual 
values were comparable. In only two patients in 
the 45-minute and in one in the 60-minute group 
was lactate production 2:10% less during P2. Other 
indices of ischemia were less reproducible. Angina 
was significantly less in 35% (15 min) or 50% 
(other groups) of patients during P2. Also, left 
ventricular filling pressure increased after Pl, but 
not after P2 with 15 and 60 minutes intervals. 
Furthermore, ST-segment depression was either 
more extensive (15 min) or less (30 min) during P2 
compared with Pl, whereas individual values 
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became comparable after 60 minutes only. Thus, 
the efficacy of interventions in (pacing-induced) 
ischemia should not be tested with angina or left 
ventricular filling pressure as criterion. Also, indi-
vidual variability in ST-segment changes with 
intervals less than one hour, does not favour the 
use of this parameter. In contrast, good reproduc-
ibility of myocardial lactate production after 
recovery periods between ischemic episodes of 45 
minutes or more allows interventions to be tested 
by this objective criteria within an acceptable time 
frame. 
INTRODUCTION 
Myocardial ischemia is characterized by early and 
extensive metabolic alterations. Animal studies 
indicate that of these, anaerobic glycolysis is a 
consistent component, observed soon after onset of 
a critical reduction in myocardial oxygen sup-
ply(l). Also, in humans, coronary flow reductions 
are quickly followed by myocardial lactate pro-
duction together with other metabolic manifes-
tations of ischemia, such as cardiac nucleoside 
release and electrocardiographic changes, but 
before angina occurs<2). Thus, the determination of 
myocardial lactate production in the coronary 
venous effluent may serve as an early and, possibly 
sensitive marker of ischemia in man. However, as 
myocardial lactate metabolism is influenced by 
changes in arterial lactate levels, such as may occur 
during exercise, this assumption appears predomi-
nantly true for the assessment of ischemia at rest. 
Moreover, as studies on myocardial lactate 
changes by necessity will be invasive of nature, the 
atrial pacing stress test has been recognized as a 
useful tool to this purpose. With pacing, identifi-
cation of abnormal myocardial lactate metabolism 
significantly improves when measurements are 
carried out in the direct post-pacing period, e.g. at 
15 seconds post-pacing(3,4). In so doing, the 
sensitivity of lactate as marker of ischemia exceeds 
that of other objective indices of ischemiaCS). 
Consequently, both the variable, i.e. lactate, and 
the technique, i.e. pacing, have been frequently 
applied to identify ischemia in man and to assess 
the consequences of different interventions. The 
latter requires, that the metabolic changes studied 
during ischemia are reproducible within a time 
frame which in view of the invasive nature of the 
method is acceptable, both in logistical and ethical 
terms. Although myocardial lactate production is a 
sensitive indicator during short periods of ische-
mia, its effectiveness becomes less when myocar-
dial ischemia is sustained as a result of inhibition 
of glycolysis, in particular at the glyceraldehyde-
3-P-dehydrogenase level(6-8). Consequently, the 
reduction in glycolytic flux leads to a decrease in 
lactate production, which may explain why myo-
cardial lactate production values are not reproduc-
ible after a short interval between moderate 
ischemiaC3,9) or more prolonged intervals when 
ischemia has been more severeCl O). 
Thus far, this aspect has received little attention in 
human studies. The vast majority of invasive 
metabolic investigations into the effect of inter-
ventions on ischemia have been uncontrolled. 
Also, the few studies on the reproducibility of 
ischemia-induced alterations in myocardial lactate 
metabolism, all carried out during pacing-induced 
stress, have invariably been conducted in small 
patient groups. Moreover, studies have focussed 
on only a limited number of intervals between 
pacing testsC4,9,ll). Usually one interval was 
tested. Also, different stress test protocols may 
affect the reproducibility of lactate productionC4). 
At present, there is no consensus on the obligatory 
time period between tests to allow for myocardial 
lactate metabolism to recover. As a result inter-
pretation of the effect of interventions, based on 
so-called "historical" controls from the literature, 
are clearly not possible. 
The present study addresses this aspect in a pro-
spective investigation in 55 patients with left 
coronary artery disease, undergoing repetitive 
incremental atrial pacing with intervals ranging 
from 15 to 60 minutes. 
METHODS 
Patient characteristics 
After the sn1dy was approved by the institutional 
Ethical Review Committee and informed consent 
was obtained, 55 patients, 51 men and 4 women, 
aged 57 years (range: 42 to 68 years) entered the 
trial. All patients were scheduled for elective 
cardiac catheterization because of stable, exercise-
induced angina pectoris in conjunction with objec-
tive signs of myocardial ischemia and/or a pre-
vious myocardial infarction. To be eligible, 
patients had to be normotensive without signs of 
heart failure. Moreover, patients with conduction 
disturbances, valvular heart disease, unstable 
angina or a myocardial infarction of less than one 
month old were excluded. Antiischemic therapy, 
including beta-blockers, calcium-antagonists and 
long-acting nitrates were withheld 36-72 hours 
pre-study, depending on plasma half-life of the 
respective medication. Digoxin and diuretics, if 
present, were stopped 24 hours before the trial. 
Oral anti-coagulants were also withheld 2-3 days, 
and anti-platelet therapy and NSAIDs at least 10 
days prior to the study. Only, short-acting nitro-
glycerin was allowed until 6 hours before onset of 
the investigation. 
To participate in the study, patients had to have 
significant coronary artery disease ~ 70% diameter 
narrowing) in at least one of the major epicardial 
coronary arteries draining the anterior, antero-
septal and lateral part of the heart, e.g. either the 
left anterior descending, diagonal, proximal cir-
cumflex or proximal marginal branches. Eligibil-
ity for the study, based on this criterion, was first 
assessed on videorecordings of the left coronary 
angiogram during catheterization. However, the 
final decision regarding participation was made 
after two independent angiographers, experienced 
in qualitative assessment of over 600 coronary 
angiograms annually, agreed on the presence of 
significant lesions after viewing of the film. 
Thus, 14, 15, 12 and 14 patients underwent repeti-
tive atrial pacing stress tests after intervals of 15, 
30, 45 and 60 minutes respectively. Baseline clini-
cal and angiographic criteria, presented in Table I, 
were comparable in all groups. 
Procedures 
Patients were studied at approximately the same 
time in the morning after an overnight fast, 
without premedication. All procedures were 
carried out under local anaesthesia with 1% lido-
caine. First, left and right coronary angiography 
was performed with non-ionic contrast material 
using the Seldinger technique. When inclusion 
criteria were met, a no 7 Fr Millar pigtail micro-
tipmanometer or a no 7 Fr Cordis pigtail catheter 
was introduced into the left ventricle through an 
arterial introducer system (Desilet) in a femoral 
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Table I: Baseline clinical and angiographic criteria. 
Sex (M/F) 
Age (X± SEM/range) 
:previous infarct (n) 
Positive X-ECG (Jl.) 
Medication (n) 
nitrates 
beta-blockers 
calcium antagonists 
Coronary angiography (n) 
(>70% diameter stenosis) 
1-vessel 
2-vessel 
3-vessel 
LV wall motion abnormality (n) 
LV ejection fraction(%) 
LVEDV (mlfm2) 
t5min 
Interval 
11/3 
56±1.5 
(45-65) 
9 
8 
5 
11 
5 
4 
5 
5 
6 
52±4.9 
77±7.0 
30min 
Interval 
15/0 
57±1.9 
(46-66) 
6 
11 
11 
11 
11 
5 
8 
3 
8 
59±2.1 
70±6.0 
45min 60min 
Interval Interval 
11/1 14/0 
56±2.1 58±1.5 
(45-67) (46-68) 
8 7 
9 10 
5 7 
8 10 
9 9 
4 3 
3 7 
5 v 
9 7 
56±4.0 55±3.7 
70±6.2 72±7.2 
Abbreviations: EDV =End Diastolic Volume; F =Female; LV= Left Ventricular; M =Male; 
min = minutes; n = number 
artery. Next, a no 7 Fr thermodilution pacing 
catheter (Wilton Webster Laboratories) or a no 7 
Fr Zucker bipolar pacing catheter was advanced 
from an antecubital vein into the midportion of the 
coronary sinus, such that the proximal thermistor 
or pacing electrode was at least 3 em beyond the 
orifice of the coronary sinus. Particular care was 
taken to ensure a stable catheter position, which 
also allowed for sufficient amounts of blood to be 
collected over relatively short periods. Absence of 
reflux from the right atrium was confirmed by 
bolus injections of saline at room temperature. 
Catheter positions were then recorded on video 
disc to allow rechecking during the study. 
Hemodynamic and electrocardiographic 
measurements and calculations 
After instrumentation, fluid-filled catheters were 
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calibrated using Statham or Bentley pressure trans-
ducers. Zero reference level was set at midchest. 
Micromanometer pressures were balanced to zero 
and superimposed on the conventional pressure 
curve. During the study, all pressures, the first 
derivative of left ventricular (LV) pressure, coro-
nary sinus flow and 3 ECG leads were continuous-
ly recorded on paper at the appropriate paperspeed, 
using a CGR cath lab system. 
Concomitantly, hemodynamic variables, including 
LV systolic and end diastolic pressures, LV pres-
sure-derived contractility and relaxation para-
meters (peak positive and negative LV dP/dt, 
VCE40 and Vmllx) were determined on-line with a 
Mennen cath lao system. 
In a beat-to-beat analysis the system averages 15 
to 20 consecutive beats to level out respiratory 
variations. Representative curves may be chosen 
for further analysis by the operator. 
ST-segment changes were assessed in leads I, ll 
and V5 from 3-5 consecutive beats, at 80 msec 
after the J point using a calibrated magnifying lens. 
Lactate determination 
For lactate determination, simultaneous sampling 
from the coronary sinus and left ventricle was 
carried out. Exactly 1 m1 of blood was quickly 
transferred into tubes containing 2 m1 of icecold 
0.6 M HC104, mixed thoroughly and kept on ice. 
Collecting tubes were colour-coded to obviate 
mistakes in the transfer proces during fast 
repetitive sampling. Immediately after the study, 
samples were weighed and centrifuged at 2000xg 
for 20 minutes and the supernatant frozen for 
subsequent determination. The lactate assay was 
carried out in triplicate. Technique and standard 
deviation of the assay in our laboratory has been 
reported(2). 
Scoring of anginal pain 
Before the start of each study, patients were 
requested to indicate the moment, when they 
experienced the beginning of chest discomfort. 
Next, they were asked to score anginal pain, 
according to a modified Borg scale, during each 
test and to indicate the time of disappearance after 
each test. 
Study protocol 
Studies were carried out at least 40 minutes after 
coronary angiography and 20 minutes after instru-
mentation. Multiple control determinations of all 
hemodynamic and electrocardiographic variables 
were performed and on -line registrations checked 
for baseline variations. Blood sampling for lactate 
was carried out in duplicate. Next, the first atrial 
pacing stress test was performed with increments 
in heart rate of 10 beats per 2 minutes until the 
occurrence of significant anginal pain, defined as 
the level of pain at which the patient would usually 
rest or take nitroglycerin. Other endpoints for 
pacing included atrioventricular block or a maxi-
mum paced heart of 170 beats/minute. At fixed 
intervals during pacing, e.g. halfway between the 
100, 120, 140 and 160 beats/minute period, 
hemodynamic and electrocardiographic variables 
were reassessed and blood collected for lactate. All 
parameters were determined at maximal pacing 
rates just before cessation of pacing, with sub-
sequent reassessment of all variables at 15 seconds 
and at 1 and 2 minutes post-pacing. This was fol-
lowed by a predetermined stabilization period of 
15, 30, 45 or 60 minutes. Next, control deter-
minations conform the first atrial pacing stress test 
were carried out, followed by a second test, which 
was identical in design to the first atrial pacing 
stress test. Care was taken that measurements 
during this second test were carried out at exactly 
the same intervals as during the first test and that 
duration of the tests and maximal pacing rates 
were identical. 
Statistical analysis 
Baseline variables in the 4 study groups were 
compared using an analysis of variance. Within 
groups, changes from control during each pacing 
test and changes in variables during and after 
pacing between both tests were evaluated, using a 
two-tailed t-test for paired observations. A 
p value <0.05 was regarded as significant. All 
variables are presented as average (X) and one 
standard error of the mean (SEM). 
RESULTS 
Baseline period before the first atrial pacing 
stress test 
None of the patients had objective or subjective 
signs of myocardial ischemia at baseline before the 
first pacing stress test. However, after analysis of 
lactate data, 8 patients proved to have lactate 
production values at baseline varying from -90% 
to -1%. Of these, 2, 3, 2 and 1 patients belonged to 
the 15-, 30-, 45- and 60-minute interval group, 
resp. Hemodynamic variables and electrocardio-
graphic criteria, i.e. ST-segments, were com-
parable between the 4 groups. Moreover, average 
lactate extraction values did not differ at baseline. 
Baseline period before the second atrial pacing 
stress test 
At baseline before the second pacing stress test, 
angina was still present in one patient in the 
15-minute group. In the other patients, angina had 
usually subsided within the first minutes after the 
first test. Hemodynamic variables and ST -seg-
ments were comparable between the 4 groups at 
control before the second pacing test (Tables ll and 
III). In contrast, myocardial lactate extraction was 
significantly higher in the 30- and 60-minute 
groups, compared with the 15- and 45-minute pa-
tients. Ten patients had lactate production at base-
line. Of these, 5 were in the 15-minute group and 
none in the 60-minute group. Within groups, 
baseline hemodynamic variables of both pacing 
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Table ll: Hemodynamic changes during repetitive ischemic episodes with varying intervals. 
Control 120/min MAX 15"P-P l'P-P 2'P-P 
15 MIN INTERVAL 
HR (beats/min) 
PI 68±3.0 121±1.4"' 135±5.3"' 66±5.0 66±3.7 62±3.6 
PIT 72±3.6 120± 1.1"' 132±4.8"' 71±4.6 70±5.2 66± 1.8 
DP (HRxLVSPxl0-3} 
PI 8.9±0.90 17.3±1.77"' 17.6±1.17"' 10.4±1.36 9.6±0.92 8.9±1.33 
PIT 10.0±0.77 17.7±1.97"' 16.9± 1.40"' 9.3±1.45 10.3±0.65 8.0±0.42 
L VEDP (mmHg) 
PI 14±1.4 12±2.2 16±2.6 19±2.1 17±1.5 17±2.2 
PIT 15± 1.8 10±2.0 15±2.5 19±3.4 17±2.6 15±1.5 
LV dp/dt pos (mmHg.sec-1) 
PI 1578±132 1979±262 2128±219"' 1801±193 1723±118 1580±144 
PIT 1740±232 1945±450 1975±232 1682±173 1584±109 1451±79 
Vmax (sec-1) 
PI 46.7±3.5 56±4.8 67±6.5"' 45.2±3.6 46.7±2.4 44.6±2.1 
PIT 45.7±2.1 54±5.9 54±3.9 42.2±3.4 43.5±2.7 49.0±3.8 
30 MIN INTERVAL 
HR (beats/min) 
PI 76±3.0 122±0.9"' 126±5.6"' 75±5.1 74±3.3 73±3.9 
PIT 72±3.6 122±0.9"' 127±3.7"' 71±4.4 73±4.4 78±6.7 
DP (HRxLVSPx10""3) 
PI 11.6±0.6 18.4±0.8·• 19.0± 1.3"' 12.4±1.2 11.7±0.8 11.3±0.9 
PIT 10.1±0.6 17.9± 1.1"' 18.7±1.4"' 10.9±1.2 10.2±1.1 11.0± 1.4 
LVEDP(mmHg) 
PI 15±1.2 11±1.9* 14±2.7 18±3.1 17±2.3 17± 1.9 
PIT 14±1.6 6±1.4* 11±2.0 16±2.1 14±2.1 13±2.1 
LV dp/dt pos (mmHg.sec-1) 
PI 1988±166 2597±246* 2991±330"' 2258±281 2148±296t 2310±320 
PIT 1753±238 2010±116 2244±203 1741±237 1657±97 1772±156 
Vmax (sec-1) 
PI 53.3±4.8 75±7.1*t 73±8.2"'t 63±8.6t 54±6.1 57±7.6 
PIT 48.1±2.9 57±3.3 56±4.4 43±4.6 46± 1.8 53±5.5 
Abbreviations: DP = double product; HR = heart rate; LVEDP = left ventricular end diastolic pressure; LVSP = left ventricular 
systolic pressure; MAX = maximal pacing rates; min = minute(s); PI = atrial pacing stress test I; P II = atrial pacing stress test 
II; P-P =post-pacing; sec = seconds; ' = minutes; " = seconds. 
Allvalues-;±SEM; *p<.05vs control; t p<.05 P Ivs P II. 
tests were also comparable with the exception of 
contractility parameters in the 60-minute group, 
which had improved at control before the second 
test compared to the first one. Within each group, 
electrocardiographic parameters and arterial and 
coronary venous lactate values were also similar at 
baseline before both pacing tests. 
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Reproducibility of hemodynamic variables 
during pacing (Table IT, lla) 
By design, maximal heart rates were identical 
during both atrial pacing stress tests within each 
group. As left ventricular systolic pressures did not 
change during either test in each group, the double 
Table Ila: Hemodynamic changes during repetitive ischemic episodes with varying intervals. 
Control 120/min MAX 15"P-P l'P-P 2'P-P 
45 MIN lNTERV AL 
HR (beats/min) 
PI 74±2.7 120±1.1 .. 131±4.5 .. 77±4.3 77±4.8 74±3.6 
Pll 74±3.1 121±0.8 .. 134±4.5 .. 79±4.3 82±5.3 80±6.9 
DP (BRxLVSPxl0-3) 
PI 11.1±0.8 17.5±1.2 .. 19.2±0.9 .. 11.9±1.7 11.9±0.9 11.8± 1.5 
Pll 10.4±0.9 16.3±0.9 .. 18.3± 1.2 .. 11.9±1.0 11.7±1.3 10.6±2.8 
LVEDP (mmHg) 
PI 14±1.5 10±1.6 14±3.3 18±4.4 19±3.2 13±3.4 
Pll 13±1.4 7±1.2 .. 11±2.1 16±2.8 14±3.1 13± 1.8 
LV dp/dt pos (mmHg.sec-1) 
PI 1554±108 2120±123 .. 1964±99 .. 1554±213 1596±93 1778±100 
Pll 1701±209 2117±410 2250±221 .. 1891±313 2033±272 1949±228 
Vmax (sec-1) 
PI 46±2.6 55±3.0 .. 56±5.2 .. 51±3.4 44±3.9 49±6.3 
Pll 47±3.8 58±6.0 60±5.3 .. 53±4.4 48±6.9 50±3.0 
60 MIN INTERVAL 
HR (beats/min) 
PI 72±3.2 119±0.8* 137±4.3 .. 79±5.2 73±3.2 74±3.7 
Pll 75±4.0 120±0.7" 135±4.6'' 76±4.9 74±4.1 78±4.5 
DP (BRxL VSPx1o-3) 
PI 11.3±0.7 17.8±0.8 .. 19.6±1.0 .. 11.8±1.4 11.3±0.9 11.6±0.8 
Pll 11.5±0.6 18.3±0.9 .. 19.5±1.1 .. 12.3±1.3 11.6±1.0 12.1±0.9 
LVEDP (mmHg) 
PI 13±1.2 7±1.0" 9±1.0 .. 20±2.1 .. 13±1.4 13±1.6 
Pll 14±1.4 7±1.2 .. 9±0.9 .. 19±2.6 .. 13± 1.8 11±1.9 
LV dp/dtpos (mmHg.sec-1) 
PI 1738±122 2015±156 2394±183" 2120± 163" 1916±151" 1805±84 
Pll 1662±105 1978±174 2442±177 .. 2195±178" 2018±190 .. 1755±107 
Vmax (sec-1) 
PI 51±3.0 60±2.7 .. 65±3.1 .. 55±4.3 51±3.6 50±2.5 
Pll 49±2.1 59±3.1" 65±3.0 .. 56±3.7 52±4.0 50±1.7 
Abbreviations: DP = double product; HR = heart rate; LVEDP = left ventricular end diastolic pressure; LVSP = left ventricular 
systolic pressure; MAX =maximal pacing rates; min = minute(s); PI = atrial pacing stress test I; P II = atrial pacing stress test 
II; P-P =post-pacing; sec = seconds; ' =minutes; " = seconds. 
All values -;±SEM; *p<.05 vs contro~· t p<.05 P Ivs P II. 
product, an index of myocardial oxygen demand, 
inceased similarly during both tests. Maximal 
heart rates and the double product were also 
comparable between groups during both pacing 
tests. In contrast, pacing-induced alterations in 
contractility varied considerably within patient 
groups. Following the 15-minute interval, all 
indices improved significantly during the first 
pacing test, but no longer during the second. 
Likewise, with an interval of 30 minutes all but 
one contractility indices did not improve either 
during the second test. In contrast, following a 
60-minute interval the improvement in 
contractility was reproducible during both tests 
and persisted for 1 minute after pacing. Only the 
45-minute group did not show consistent 
improvement of contractility during either test. 
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ANGINA 
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c::JANGINA l!lli) NO ANGINA 
~LESS ANGINA -MORE ANGINA 
PACE TEST I PACE TEST II 
Fig. 1: Anginal complaints during the first and 
second pacing stress test. fVhereas during the first 
test angina occurs in nearly all patients, this was 
clearly less or absent during the second pacing 
test, irrespective of the interval between pacing. 
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Fig. 2: Average values of ST-segment depression 
during repetitive pacing tests with variable inter-
vals. Changes are not reproducible following 
intervals of 15 and 30 minutes. In contrast, 
values are comparable during maximal pacing 
rates (MAX) after intervals of 45 minutes 
upwards. Min= minutes; P-P =post-pacing. 
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Reproducibility of indices of myocardial 
ischemia during pacing. 
Angina 
During the first test, pacing-induced anginal 
symptoms did occur in all patients except for 2 
patients in the 45-minute group. However, during 
the second test, pacing-induced angina proved not 
to be reproducible in neither group (Fig. 1). 
Table ill: Reproducibility of electrocardiographic changes during successive ischemic periods 
with different intervals - ST-segment depression. 
Control 120/min MAX 15" P-P 1' P-P 2'P-P 
15 MIN INTERVAL 
PI -.04±.01 -.05±.03 -.10±.04 -.06±.03 -.03±.02 -.03±.03 
PII -.03±.02 -.03±.03 -.09±.03* -.03±.02 -.02±.02 -.03±.02 
30 MIN INTERVAL 
PI -.04±.01 -.09±.03 -.22±.05"'t -.04±.02 -.01±.01 
.0 ±.01 
.00±.01 
.01±.01 PII -.04±.01 -.08±.02 -.14±.05"' -.04±.03 
45 MIN. INTERVAL 
PI -.07±.02 -.16±.04"' -.24±.04* -.21±.06'' -.1 ±.05 -.09±.06 
PII -.06±.02 -.10±.03'' -.24±.04 -.16±.03* -.16±.02"' -.15±.03"' 
60 MIN. INTERVAL 
PI -.03±.02 -.05±.02 -.17±.04* -.10±.03" -.09±.02" -.08±.03 
PII -.03±.02 -.04±.02 -.16±.04"' -.10±.04"' -.08±.02" -.06±.02 
Abbreviations: MAX = maximal heart rates; min = minutes; P-P = post-pacing; P I = atrial pacing stress test I; P II = atrial 
pacing stress test II; ' =minutes; " =seconds. 
all values x ± SEM; * p<.05 vs control; t p<.05 P Ivs P II. 
In general, patients had significantly less angina, 
which started later and was of shorter duration. In 
the groups with 30-, 45- or 60-minute intervals, 
angina was either absent or less in 50% of patients 
and in 35% of patients in the 15-minute group 
during the second pacing test. Also, 3 patients 
experienced more angina during the second pacing 
test, 1 in the 45- and 2 in the 60-minute group. 
ST-segment changes (Table III) 
Ischemic electrocardiographic changes were not 
uniformly reproducible either. In the 15-minute 
group, significant changes only occurred during 
the second test but not during the first one. In 
contrast, ST -segment depressions were signifi-
cantly less during the second test, compared to the 
first, in the 30-minute group (Fig. 2). Average 
values for ST-segment depressions were only 
comparable with intervals as long as 45 and 60 
minutes. Even so, individual values for maximal 
ST-segment alterations varied considerably in all 
groups, although this was less after 60 minutes as 
shown in figure 3. 
Left ventricular end diastolic pressure 
(Table II) 
Left ventricular end diastolic pressure did not 
change in the 30- and 45-minute groups during 
either test. An ischemia-induced rise in left ventri-
cular filling pressure was only observed in the 15-
and 60-minute interval groups, but in both situa-
tions only after the first test. Individual values 
varied significantly also (Fig.4). 
Lactate (Table IV) 
Arterial lactate values remained unchanged during 
and after pacing in all groups (Fig. 5). Arterial 
lactate levels were also similar during both pacing 
tests, irrespective of pacing intervals. Coronary 
venous lactate levels increased significantly during 
the first test in all patient groups. In the second 
test, levels were similar to those during the first 
one, following the 45- and 60-minute period. 
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Fig. 3: Individual ST-SEGMENT ST-segment mV --- ----------
changes during 
two successive 
pacing stress tests ~ (I and II resp.) 
following intervals 
of 15, 30, 45 and 
60 minutes ('). 
There is a marked 
individual ~ variability with intervals of 45 minutes or less, but a somewhat .. more ~ homogeneous ~ response after 60 ~-minutes. 0 
15' 30' 45' 60' 
II II II II 
LVEDP 
40 
mmHg 
Fig. 4: Individual 
30 
values for post-
pacing left 
ventricular end 
diastolic pressure 
20 
during two 
successive pacing 
~ stress tests, I 5, 30, 45 and 60 minutes 10 apart. Irrespective of the interval between tests, pressures, measured 
0 
immediately after 
15' 30' 45' 60' pacing, vary 
II II II II considerably. 
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Table IV: Reproducibility of myocardial lactate metabolism during successive ischemic periods. 
Control 120/min MAX 15" P-P 1'P-P 2'P-P 
15 MIN INTERVAL 
art. lactate (mmol/1): 
PI 0.63±0.04 0.60±0.03 0.62±0.04 0.59±0.04 0.60±0.05 0.60±0.06 
Pll 0.57±0.04 0.61±0.04 0.61±0.05 0.63±0.04 0.64±0.05 0.63±0.07 
cor. ven. lactate (mmol/1): 
PI 0.54±0.04 0.61±0.06 0.82±0.07+t 0.88±0.09+t 0.77±0.09+ 0.67±0.05* 
Pll 0.54±0.04 0.56±0.06 0.63±0.04" 0.77±0.05" 0.66±0.05" 0.57±0.06 
lactate extraction(%): 
PI 13±4.7 -9±11.3 -17±6.5"t -53±13.1"t -23±10.1*t -18±13"t 
PII 6±3.4 12±5.6 -1±4.8 -25±9.4" -6±6.9* 3±9.2 
30 MIN INTERVAL 
art. lactate (nunol/1): 
PI 0.54±0.05 0.51±0.07 0.54±0.06 0.52±0.07 0.54±0.07 0.54±0.07 
Pll 0.54±0.05 0.53±0.05 0.53±0.05 0.49±0.06 0.54±0.06 0.53±0.06 
cor. ven. lactate (mmol/1): 
PI 0.47±0.06 0.52±0.07 0.72±0.10* 0.74±0.09" 0.59±0.07 0.52±0.06 
Pll 0.43±0.06 0.53±0.09 0.58±0.08* 0.62±0.08" 0.61±0.11 0.55±0.09 
lactate extraction(%): 
PI 12±8.3 -3±11.1 -33±13"t -55±15"t -18±9.2" 1±8.3 
Pll 21±4.8 -8±9.1* -8±8.8* -23±14" -9±11'~ 0.5±8.2 
45 MIN INTERVAL 
art. lactate (mmol/1): 
PI 0.63±0.06 0.60±0.05 0.66±0.06 0.64±0.04 0.66±0.06 0.65±0.05 
Pll 0.65±0.05 0.62±0.06 0.67±0.09 0.67±0.09 0.73±0.11 0.73±0.10 
cor. ven. lactate (mmol/1): 
PI 0.59±0.06 0.64±0.07 0.88±0.16'' 1.03±0.17" 0.94±0.16·~ 0.77±0.12 
PII 0.61±0.07 0.66±0.06 0.87±0.15* 1.07±0.18" 0.96±0.15* 0.75±0.16 
lactate extraction(%): 
PI 11±3.7 -8±5.7* -22±10.3* -49± 13.1" -31±12.3 -12± 11.4 
Pll 8±3.5 -10±2.5" -23±6.9" -57±17.3" -38± 16.1" -4±7.7 
60 MIN INTERVAL 
art. lactate (nm10lll): 
PI 0.76±0.11 0.73±0.14 0.80±0.12 0.81±0.12 0.84±0.13 0.82±0.12 
Pll 0.84±0.14 0.78±0.15 0.79±0.13 0.80±0.12 0.84±0.12 0.75±0.11 
cor. ven. lactate (mmol/1): 
PI 0.61±0.11 0.64±0.13 0.77±0.14" 0.85±0.14" 0.96±0.16* 0.67±0.12 
Pll 0.60±0.11 0.63±0.12 0.77±0.14" 0.87±0.15" 0.89±0.15* 0.63±0.11 
lactate extraction(%): 
PI 21±3.8 16±3.9 6±4.3'~ -22± 15" -15±13.1 -6±7.1'~ 
Pll 28±4.1 17±4.0 3±6.1" -20±13.1" -4± 12.6·~ -9±7.3·~ 
Abbreviations: art. = arterial; cor. ven. = coronary venous; MAX = maximal heart rates; MIN = minutes; P-P =post-pacing; P 
I = atrial pacing stress test I; P II = atrial pacing stress test II. 
Allvaluesx ± SEM; *p<.05vs control; t p<.05 P lvs P II. 
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Fig. 5: Arterial and coronary venous lactate levels 
during and after 2 successive pacing stress tests 
with different intervals. Whereas arterial levels 
do not change during pacing and are reproduc-
ible, coronary venous levels increase significantly 
with maximal levels at 15 seconds(") or 1 minute 
(')post-pacing (p-p). Following intervals of 15 
and 30 minutes coronary venous levels rise sig-
nificantly less during the second test. In contrast, 
they are comparable after 45 and 60 minutes. 
MAX = maximal pacing rates. 
Values are x±SEM. 
In contrast, coronary venous lactate levels increas-
ed significantly less during the second test after 15 
or 30 minutes (Fig. 5). Consequently, in the latter 
groups, the values for myocardial lactate produc-
tion were also significantly less during the second 
pacing test, compared to the first one (Fig. 6). 
Alternatively, the arterial - coronary venous lacta-
te difference and the lactate production values were 
comparable with intervals as great as 45 and 60 
minutes. Individual lactate production values were 
also significantly less in the 15- and 30-minute 
groups during the second pacing test, compared to 
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the first one (Fig. 7). However, they were gener-
ally comparable in the 45- and 60-minute groups. 
Although some fluctuations were still present, 
only 2 patients in the 45-minute and one in the 60-
minute group had .::_10% less lactate production 
during the second test. 
DISCUSSION 
Besides general indices of ischemia, such as angina 
or ST-segment changes, metabolic markers, in 
particular myocardial lactate production, are 
preferentially used in the invasive assessment of 
pharmacological interventions. Also, in these 
circumstances, atrial pacing has been the stress test 
of preference. However, despite a large volume of 
published material concerning such intervention 
studies, information on the reproducibility of 
lactate changes during repetitive periods of ische-
mia is scarce, fragmentary and inconclusive. 
Consequently, studies have either not been 
controlled or have referred to "historical" controls, 
often derived from the results of different labora-
tories. The present study addresses the question Qf 
reproducibility, not only of lactate, but also of 
symptomatic, electrocardiographic and hemo-
dynamic sequelae of ischemia, in a prospective, 
randomized fashion. It investigates various inter-
vals between stress tests over a period, which 
would appear acceptable in ethical and logistical 
terms, in adequate numbers of patients. 
Our study clearly indicates that, after relative short 
intervals of 15 to 30 minutes, changes in myocar-
dial lactate metabolism are not reproducible with 
significantly less lactate production during the se-
cond test. However, after 45 and 60 minutes, 
excellent reproducibility is achieved without 
significant individual variability. In contrast, 
whereas average values for ST -segment changes 
were comparable after intervals as long as 45 
minutes, individual variability was still consider-
able at this point of time, but disappeared after a 
60-minute interval between pacing periods. Like-
wise, contractility parameters were only compa-
rable after 60 minutes had elapsed, whereas left 
ventricular filling pressure either did not change or 
show marked individual variability. Moreover, 
angina was clearly not reproducible, irrespective 
of pacing intervals. 
Usefulness of myocardial lactate production as 
marker of ischemia 
The usefulness of myocardial lactate metabolism as 
marker of ischemia during pacing-induced stress 
in humans has been questionedC13). When myocar 
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Fig 6: Average lactate extraction values during 
two successive pacing stress tests (I and II) with 
different intervals. Following intervals of 45-
and 60 minutes lactate production values are 
comparable. However, after shorter periods, i.e. 
15 and 30 minutes, lactate production is 
significantly less during the second pacing test. 
Max = maximum pacing rates; min = minutes; 
p-p =post-pacing . 
dial lactate production, rather than a change in 
extraction is considered necessary to objectively 
indicate myocardial ischemiaC14,15), the sensitivity 
of this criterion does indeed appear low as well as 
variable, ranging from 35% to 69% during pacing-
induced stress in humansC4,l6-21>. However, from 
the same studies it would not appear that other 
objective criteria of ischemia, such as electrocar-
diographic changes or alterations in left ventricular 
filling pressure are superior in this respect. Also, it 
should be pointed out here, that in almost all 
investigations which have applied atrial pacing as 
stress, lactate measurements were carried out 
during maximal pacing and not thereafter. We and 
others have shown, that coronary venous lactate 
levels increase significantly when measured in the 
immediate post-pacing period(3,5)_ When assessed 
at this point of time, the sensitivity of lactate 
metabolism as indicator of ischemia improves 
significantly, compared with evaluations made at 
maximal pacing only. Also, in so doing, we have 
found that, regarding sensitivity, it becomes 
superior to other objective markers of myocardial 
ischemia (5). Thus, in considering the effect of 
pharmacological interventions, not only the 
reproducibility of lactate changes during, but also 
after pacing, should be taken into account. 
Reproducibility of myocardial lactate 
metabolism during repetitive episodes of 
pacing-induced ischemia 
In humans, ischemia-induced changes in myocar-
dial lactate metabolism are not reproducible when 
the interval between ischemic periods is 30 min-
utes or less. The results of our study indicate that 
ischemia-induced lactate production is significant-
ly diminished during the second stress test com-
pared with the first. Several explanations may 
apply. 
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Fig. 7: Individual values for lactate extraction during 2 successive pacing stress tests (I and II) with 
different intervals, measured at control, maximal rates (MAX) and at 15 seconds (")post-pacing (p-p). 
Individual values are significantly more positive during the second test following the 15- and 3D-
minute interval, indicative of less lactate production compared with the first test. In contrast, values 
are comparable with intervals of 45 minutes upwards, except for some fluctuations in the 60-minute 
interval group. 
Firstly, it could be argued, that ischemia was less 
during the second atrial pacing stress test and, 
hence, lactate production values reduced. This 
would seem unlikely in the event that myocardial 
oxygen demand was reproducible and other objec-
tive signs of ischemia did not follow a similar 
pattern. Thus, ST-segment depression was actual-
ly more pronounced during the second pacing test, 
following an interval of 15 minutes. Less ische-
mia, for instance due to persistent collateral flow 
after the first ischemic period is more likely to play 
a role after short intervals between successive 
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ischemic periods. Also, previous studies in the pig 
heart demonstrate significantly reduced lactate 
production during repetitive 30-minute ischemic 
periods separated by 35 minutes of reperfusionClO). 
In these experiments, coronary flow reductions 
were comparable during each ischemic period. 
Moreover, in this study, collateral blood supply 
was unlikely to have played a roleC22) after the 
relatively short ischemic periods. 
Alternatively, a reduction in myocardial lactate 
production during a second episode of ischemia 
following relatively short recovery periods, may 
be explained by insufficient repletion of intracel-
lular glycogen stores following the first ischemic 
period. Besides glucose uptake in the cardiocyte, 
which during ischemia depends critically on 
instantaneous coronary flow, glycogenolysis may 
provide for an additional substrate for glycolysis. 
The latter reserves are limited, however, and may 
be exhausted within several minutes during severe 
anoxia or ischemia(23). Still, depending on the 
regenerating potential following ischemia, which 
will be time-dependent, a limited availability of 
glycogen at the onset of the second ischemic 
episode cannot be discarded. 
A third and attractive mechanism to explain 
reduced lactate production following repetitive 
ischemic episodes with relatively short intervals, 
relates to a progressive inhibition of glycolysis in 
the course of ischemia. During early ischemia, 
glycolysis is predominantly regulated by the 
activity of phosphofructokinase<24,25). Inhibition 
of glycolysis during more prolonged periods of 
ischemia occurs at the level of glyceraldehyde-3-
P-dehydrogenase(26). Both enzymes are sensitive 
to pH changes and depend on the ratio A TP versus 
ADP and AMP(27)_ Sustained inhibition of glyco-
lysis after an ischemic episode may be the explana-
tion as to why myocardial lactate production 
values are not reproducible when only relatively 
short periods of recovery from ischemia are 
allowed. Persistent reductions in coronary flow 
and sustained release of cardiac nucleosides 
following a similar protocol of pacing and 
subsequent ischemia as in the present study, have 
been reported(2,28). Selwyn et al. (29) also have 
reported sustained reductions in myocardial perfu-
sion for as long as 20 minutes after stress testing. 
Hence, on-going residual coronary flow 
reductions and ischemia post-pacing may lead to 
persistent inhibitions of glycolysis and, subse-
quently, less lactate production during a second 
atrial pacing stress test. 
Apparently, a minimum interval of 45 minutes is 
needed to nullify the effects of persistent ischemia 
on glycolysis and/or replete glycogen stores. 
Reproducibility of lactate - comparison with 
other studies in humans 
As mentioned, few human studies are available on 
the reproducibility of myocardial lactate changes 
during (pacing-induced) ischemia. Of these, none 
examined the differential effect of varying 
intervals between stress tests. Also, studies were 
usually carried out in relatively small patient 
groups. These investigations do not provide 
consensus as to the optimal time frame between 
tests with respect to the reproducibility of myocar-
dial lactate production. Jackson and coworkers 
were the first to suggest good reproducibility after 
a 45-minute interval between pacing str~ 
tests(ll). However, their observations were based 
on placebo studies in 5 patients, 3 of whom did not 
produce lactate. Several years later we confirmed 
their findings in a preliminary report concerning 
larger patient numbers and more frequent inter-
vals<30). Nevertheless, thus far there has been no 
agreement on individual reproducibility, not even 
after recovery periods of 45 minutes02,31). 
Likewise, whether average lactate production 
values are comparable following shorter periods 
between pacing tests has also been debated(4,9,32). 
Whereas Ihlen and coworkers<4) suggested that 
lactate extraction may be reproducible after a 
20-minute interval, this could not be confirmed in 
a recent study by Drobinski and coworkers(9). Our 
investigations strongly suggest that average lactate 
production values are not reproducible following 
recovery periods of 30 minutes or shorter, whereas 
individual values only become comparable follow-
ing intervals of 45 minutes upwards. The discrep-
ancy in results from different human studies may, 
to a certain extent, relate to different study proto-
cols. Although the pacing model, i.e. incremental 
versus continuous pacing at high rates, may not be 
important in this respect, the duration of pacing 
could affect the results. Thus, the study by Ihlen et 
al. suggests that very short pacing periods (20 
seconds per interval) may allow for lactate changes 
to be reproducible after relatively short intervals 
(20 minutes). In contrast, longer pacing periods 
and, hence, more extensive ischemia, result in a 
suppression of lactate production following similar 
recovery periods. However, the very short pacing 
period applied by these authors is not practical, 
particularly not when other sequelae of ischemia 
have to be determined. 
Usefulness and reproducibility of other 
objective markers of ischemia 
In the present study, other markers of ischemia 
were not very reproducible. Electrocardiographic 
changes, i.e. ST-segment depression, is usually 
considered the gold standard in the objective 
assessment of myocardial ischemia. However, its 
sensitivity during pacing-induced ischemia is not 
impressive(21). Although the occurrence of signifi-
cant pacing-induced ST-segment depression has 
been reported to vary between 52% and 
95%(4,16-21,33), in average, electrocardiographic 
abnormalities during pacing are found in 50% and 
60% of patients. Also, its specificity has been 
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questioned(21,34). We have recently shown that, 
during a similar pacing protocol as used in the 
present study, ST-segment depressions of _::0.1 
mV occur in 57% and 39% of patients without 
coronary artery disease or with only minimal 
lesions, resp<5). Moreover, in patients with sig-
nificant coronary artery disease, ST-segment 
changes were considerably less sensitive than 
myocardial lactate alterations. 
Little information is available on the reproducibil-
ity of ST-segment changes in the context of fast 
atrial pacing. Thadani et al reported good repro-
ducibility of average values after only 10-minute 
intervals, however, they did not provide data on 
individual values(19). In contrast, Lau and co-
workers found good individual reproducibility 
after short intervals; their study population was 
small, however(35). 
In the present study, we were unable to detect any 
reproducibility in group values for this parameter 
for recovery periods as long as 30 minutes, 
whereas reasonable individual comparability was 
only attained after 60 minutes. Together with the 
relative lack of sensitivity, this suggests in our 
opinion that electrocardiographic changes are not 
as useful as a criterion whereby to judge the anti-
ischemic efficacy of interventions during pacing as 
alterations in myocardial lactate metabolism. 
Similarly, changes in left ventricular end diastolic 
pressure are not as useful as lactate in this context. 
Aagin, reported sensitivity mai vary but on the 
whole appears relatively low(S, 1). This potential 
marker of ischemia is also not reproducible. 
Thadani et al. observed less increase following a 
second pacing test after an interval of 20 min-
utesC19). In the present study we confirmed this but 
also showed, that average values were still less 
following the second pacing test when the recov-
ery period was at least 60 minutes. Furthermore, 
individual values varied considerably. Hence, 
changes in left ventricular filling pressure should 
not be taken into account when assessing the effect 
of interventions unless control comparisons are 
used. 
Reproducibility of angina 
Angina is often used as the main endpoint to assess 
the effect of pharmacological interventions during 
pacing. Either a reduction in the level of pain or 
lengthening of the time to reproducible angina 
during a second pacing test is taken to provide 
proof for the efficacy of the intervention. Our 
study clearly indicates that this is not justified. A 
considerable number of patients had less angina 
despite the absence of any intervention. Couse-
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quently, a lengthening of the time to comparable 
anginal pain as during the first test was present. 
Although this lack in reproducibility was slightly 
less after the shortest recovery period (15 minutes) 
there was no significant difference compared to the 
other intervals. The percentage of patients, who 
did not develop a similar level of angina during the 
second test after 15 minutes, compares well with 
values from other studies following comparable 
recovery periods, which vary from 20-43%(12,19). 
That angina is even less reproducible following 
longer intervals has not been reported yet. Jackson 
et al. suggested that it was comparable after a 
45-minute interval(10). However, these observa-
tions are derived from a study of only 5 patients. 
In view of our findings, we do not recommend 
angina to be used as criterion to delineate the 
efficacy of therapeutic interventions. 
Limitations of the study 
An important limitation of this study is, that coro-
nary flow was only measured in a small number of 
patients and not coincidental with the other meas-
urements. Thus, it is not possible to examine the 
effect of varying recovery periods during succes-
sive pacing tests on coronary flow. Also, no 
consistent information is available on the repro-
ducibility of cardiac lactate uptake. Comparable 
average values for coronary flow have been re-
ported following an interval of 45 minutes(12) with 
moderate individual varations in the range of 10-
20%. Preliminary data from our laboratory also 
indicate, that both average and individual values 
are comparable with an interval of 60 minutes 
(unpublished observations). Thus, it may be 
anticipated, that with the longer intervals between 
pacing, myocardial lactate uptake and release 
values may have been equally comparable in our 
study. 
Secondly, in this study only one metabolite was 
studied, lactate. The overall assessment of the 
myocardial metabolism during ischemia could 
have been improved by measuring additonal meta-
bolites. Using pacing as stress test, it has been 
shown, that free fatty acids are not reproducible 
after intervals varying between 20 and 45 
minutes(9,31,32). In contrast, amino acid and citrate 
fluxes may be more reproducible after recovery 
periods of 45 minutes<12J. Comparable increases in 
coronary venous hypoxanthine levels have also 
been demonstrated following successive coronary 
occlusions during angioplastyC36). However, as it 
is not proven yet that any of these metabolites are 
better indicators of ischemia than lactate, further 
studies should be carried out to justify the addition 
of these, in part elaborate, procedures. 
Implications 
Our data indicate that the occurrence and degree of 
ischemia should not be asssessed during successive 
atrial pacing stress tests with relatively short inter-
vals, i.e. of 30 minutes or less, at least not when 
myocardial lactate metabolism is considered the 
main criterion. However, intervals of 45 minutes 
or more between the end of the first and the onset 
of the second pacing test are sufficient to establish 
reproducibility of this metabolite. As more than 
10% reduction in lactate production only occurred 
in very few patients during the second test after 
these intervals, a greater effect following interven-
tions could be taken to assess individual respon-
siveness. With respect to ischemia-induced 
electrocardiographic changes, our studies suggest a 
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Chapter Vll: 
REGIONAL CORONARY FLOW CHANGES DURING ISCHEMIA AND 
RELATION WITH METABOLIC ALTERATIONS. 
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VISUALIZATION OF MYOCARDIAL BLOOD-FLOW CHANGES WITH 
INTRACORONARY 81mKr 
W.J. REMME, P.H. COX, X.H. KRAUSS, H.P.A.C.M. KRUYSSEN, 
C.J. STORM, D.C. van HOOGENHUYZEN 
INTRODUCTION 
The decision to undertake agressive therapy of a coronary 
artery lesion, be it PTCA or surgery, depends entirely on the 
functional significance of the particular coronary artery 
stenosis present. Although more factors than the stenosis 
resistance alone determine the outcome of myocardial ischemia 
(see chapter 1, this volume), this can be expected to occur 
in high-grade lesions (>70% diameter stenosis). In smaller 
lesions, however, the determination of regional myocardial 
blood-flow may be necessary to justify a therapeutic decision. 
Noninvasive myocardial perfusion studies with 201 Tl can 
be of particular value in single· vessel lesions. In multi-
vessel disease the sensitivity to delineate the smaller lesion 
may be less and overlapping of the various coronary flowbeds 
may prohibit the assessment of the exact localization of 
diminished myocardial perfusion. 
Myocardial blood-flow studies in the intact subject can 
either be performed by the thermodilution method (1,2), inert 
gas washout ~echniques (3,4) or precordial mapping of radio-
nuclides (5-9). In the thermodilution and inert gas washout 
techniques the coronary sinus has to be catheterized, which 
makes it an invasive procedure, allbeit of the right side of 
the heart. Although these methods allow for accurate measure-
ments, even at high flowrates (4-10) an essential drawback is 
the fact that only overall left ventricular f~ow is measured. 
This limits its value in CAD which is essentially a regional 
disease. A recent modification in the thermodilution tech-
nique now allows for 2 areas of the left ventricular outflow 
to be measured (11,12). However, the specific measurement of 
coronary flow through the smaller subregions of the left ven-
tricle is not possible. In addition the obligatory positioning 
of the catheter in the mid coronary sinus to prevent atrial 
reflux interference with the measurements, usually precludes 
proper sampling from postero-lateral regions. 
Labelled microspheres of approximately 15~ in diameter 
reflect transmural distribution of myocardial blood-flow very 
well as has been demonstrated in animal stuJies (13,14). 
Studies in man were carried out during heartcatheterization 
with macroaggregated albumin, usually employing a dual 
isotope technique. These investigations performed at rest and 
after some form of stress did show the technique to be quite 
reliable and safe (15-18) .Obviously its potential use in 
humans is however limited to only a few investigations per 
patient. 
Inert radioactive gases administered either directly into 
the coronary circulation or non-selectively in the aortic 
root have been used for the precordial mapping of coronary 
blood-flow. Of these 133xe has had the widest application 
(5-9). During catheterization the gas is injected in solution 
as a bolus into the coronary artery and the regional wash-out 
curves are measured. Several successive studies with a minimal 
interval of 6-8 min can be performed (6). It has been claimed 
that quantitative measurements of regional coronary blood-flow 
can be made. To what extent this really is possible, when 
measuring essentially 3-dimensional blood-flow changes in a 
2-dimensional way is questionable. This criticism however, 
applies to any kind of precordial mapping technique. Other 
potential difficulties with the 133xe method is a (small) 
percentage of recirculation (± 5%) and its affinity for fat 
(tissue participation coeeficient(~) in myocardium assumedly 
0,72 versus~in fat tissue of 8 (19)),which can give background 
accumulation during repetitive studies. Finally its relatively 
low energy spectrum (gamma rays of 81 keV 37%) facilitates 
Compton scatter. 
Several years ago a Krypton isotope, 81 mKr, was intro-
duced (20-22), which allowed the continuous measurement of 
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regional myocardial blood-flow changes (23-26). In this chapter 
our experiences with the continuous intracoronary administra-
tion of 81 ~r will be discussed. 
Characteristics of 81mKr 
81
mKr is formed by isometric transition from unstable 81 Rb 
to stable 81 Kr, emitting 190 keV gamma rays (65% abundance). 
The isotope is chemically and biologically inert and has a 
very short physical halflife of 13.6 sec. After intracoronary 
administration it diffuses readily through the capillary 
membranes and equilibrates rapidly with the extracellular 
myocardial fluid. 
During continuous and constant administration 81 mKr is 
distributed in relation to regional coronary blood-flow. 
Stabilization between local supply and decay of the isotope 
is reached within 30-60 sec after the commencement of intra-
coronary administration. Any change in 81 mKr distribution 
hereafter depends on its regional supply rate and hence on 
local myocardial blood-flow. When 81 ~r is continuously 
administered at a constant rate alterations in local myocardial 
blood-flow can be measured as the percentage change in 81mKr 
distribution in relation to the control situation. Due to its 
very short physical halflife 81 mKr is not measurable in the 
venous effluent in the right atrium. This together with its 
190 keV radiation spectrum ensures imaging with a negligable 
background. 
81
mKr production. During our studies 81 mKr was eluted 
from a sterile, pyrogen-free 81 Rb/ 81~r generator. 81 Rb is 
formed during proton bombardment of natural Krypton gas, which 
results in a 81 Rb production rate of 3 mCi/~ A.h.; over 95% 
of which is recovered in aqueous solution (27). The 81 Rb; 81 mKr 
generator was calibrated to deliver 20-25 mCi at the time of 
the study. The unstable 81 Rb decays to 81 mKr, which emits 
190 keV gamma rays (65% abundance). Elution of the generator 
81m 
with 5% glucose yields a solution containing only Kr. Even 
at high perfusion rates of 25 ml/min only a negligeable 
break-through of 81 Rb occurs. 
The eluate is then passed through a sterile ~illepore 
filter into the coronary artery catheter. Optimal perfusion 
rates from the generator in order to achieve sufficient and 
. 81m 81 
constant bulld-up of Kr on the Rb column are in between 
12-15 ml/min. In our studies a constant perfusion rate with 
5% glucose of 13,3 ml/min was achieved with the use of a 
persistaltic infusion pump, resulting in 15 mCi total radio-
activity per min with a 20 mCi generator. 
Instrumentation. Contrary to studies with 133xe, where 
multicrystal cameras were preferable due to their fast count 
rate possibilities, the single crystal camera is better for 
the 81 mKr studies described in this chapter. Very fast count 
rates as can be realized with multiple crystal cameras (up to 
200.000 - 500.000 counts per sec) are unnecessary in view of 
the limited production of 81mKr by the generator even at 
a higher calibration (up to 35 mCi) • On the other hand the 
better spatial resolution of the single crystal camera enables 
flow changes to be determined in relatively small areas of 
the left ventricle, which is less optimal with the multicrystal 
camera due to its poor pictorial resolution. Count rates are 
improved using a ~-inch crystal instead of the !-inch crystal 
gamma cameras currently used for nuclear cardiology purposes. 
In these studies we have tried out both crystal sizes. 
Total counts over the heart/min averaged ± 250.000 for 
the ~ inch crystal gamma camera (General electric porta 
camera) and ± 180.000 for the ! inch (Siemens LEM portable 
camera) using similar data processing techniques. Data given 
in this chapter are obtained with the ~-inch crystal gamma 
camera, connected on line to a Medical Data· Systems - A2 
computer and energy detection set on 190 keV ± 20%. Throughout 
the study imaging was visualized both on a persistence scope 
and on a monitor connected to the computer. 
Images were acquired in 15 sec frames with the camera in 
45° LAO position. In some studies an additional investigation 
was carried out in the 30° right inferior oblique position (RIO) 
to achieve optimal separation between the marginal branches 
of the left circumflex coronary artery. 
-173~ 
-174-
Changes in 81 ~r distribution were measured in various 
regions of interest. over the left ventricle, including both 
normal regions and areas with CAD, over the ascending aorta, 
total left heart and background regions, including the right 
atrium. Areas of interest were constructed using an electronic 
lightpen on the visual display unit. 
Movement artefacts during the study were avoided and care 
was taken that successive regions of interest did not move 
out of their originally constructed areas. Further calcula-
tions were made of both total counts per area as well as of 
total counts per pixel per area. In order to correct for 
possible fluctuations in 81 mKr delivery counts per area per 
frame were always correlated with and given as percentages 
of simultaneous total counts over the left heart. 
Patient studies: Methodology and materials. Studies were 
carried out in patients with suspected or confirmed coronary 
artery disease in whom catheterization was believed necessary 
either to confirm the diagnosis or to investigate the possibil-
ity of angioplasty or by-pass surgery. 
Patients were studied without premedication after an 
overnight fast because of concomittant metabolic investiga-
tions. 
Using the Seldinger technique introducer systems were 
inserted in the right femoral artery and in the right brachial 
vein. This allowed the positioning of a 7F Judkins or Amplatz 
left coronary artery catheter in the ostium of the left 
coronary artery and a 7F Zucker bipolar pacing catheter in the 
mid-coronary sinus for pacing purposes and sampling of 
coronary venous blood. The length of the left coronary main 
stem and the position of the catheter tip in it were then 
examined in the 30° RIO position. Next, possible selective 
injections in one of the branches of the left coronary artery 
were studied by both slow and rapid manual injection of 
contrast material in the 45° LAO and 30° RIO positions and 
registered on videotape for continuous replay. When the 
possibility of streaming was present different catheters and 
catheter sizes were tried. Finally, any fluctuation in 81 mKr 
Cor.sinus(CSC 
catheter ,..-~"""' ''-, 
' / ""· \ 
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Fig. 1. Schematic representation of the study design. 81ffiKr is eluted 
in 5% glucose from the 81Rbj811l1Kr generator and infused directly into 
the left coronary artery. At the bottom of the figure nonnal 811l1Kr 
distribution over the LAD and RCX area is shown in a'patient without 
coronary artery disease. LAD = left anterior descending artery. 
RCX = left circumflex artery. 
distribution over the left ventricle was excluded during a 
10 min control period before initiation of the study. 
When the possibility of streaming still existed or in the 
case of a short mainstem either a super-selective perfusion 
was carried out in the coronary branch of interest or the 
patient was excluded from the study altogether. A schematic 
representation of the investigational set-up and normal 81 mKr 
distribution at rest is given in fig 1. A stabilization 
period of 20 min was allowed before initation of a stress 
test by way of incremental atrial pacing. During this test the 
heart rate was increased by 10 beats every 2 min until either 
anginal pain and/or atrio-ventricular block occurred. Through-
out the study precordial imaging was carried out in successive 
15 sec frames. Results are given for the control situations, 
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LEFT CORONARY ARTERY 
450 LAO 
81 m Kr DISTRIBUTION DURING CONTROL 
450 LAO 
Fig. 2. 81Ill£<r distribution at rest in a patient with a 100% LAD occlusion 
(see arrow). There is diminished 81nt.Kr perfusion over the distal LAD area 
and normal distribution over the RCX and proximal LAD region. LAD = left 
anterior descending artery. RCX = left circumflex artery. 
at ·100, 120, 140, 160 and 180 beats/min and during anginal 
pain or atrio-ventricular block, followed by determinations 
15 sec, 1, 2 and 5 min after pacing. Onset and progression 
of anginal pain was correlated with 81 mKr distribution changes 
in the simultaneous 15 sec imaging frames. 
Results 
In 2 patients a selective infusion in the diseased branch 
of the left coronary artery was carried out because of a short 
mainstem. 
One patient had to be excluded due to a possible streaming 
artefact. 
81
mKr distribution changes in patients with normal coronary 
arteries. In 4 patients no significant coronary artery disease 
81m was present (CAD <50%) • In these patients distribution 
over the left ventricle was normal during the control period 
and did not change during and after atrial pacing. 
81 ~r distribution changes in patients with CAD. In 16 
patients with >50% CAD 12 areas with ~90% and 6 areas with 
CONTROL 
LEFT CORONARY ARTERY 
450 LAO 
ANGINA PECTORIS 
130 B/MIN 
Fig. 3a 
5 MIN P-P 
Fig. 3a. Absent 81ITKr distribution in the RCX region at rest and during 
pacing in a patient who was catheterized twice within one week. Within 
this period a 99% RCX stenosis had progressed to a total occlusion 
without anterograde collaterals. Halfway the LAD a 50-70% stenosis is 
present, which however does not result in any change in 81Il1Kr distribu-
tion in this area during pacing. LAD = left anterior descending artery. 
RCX = left circumflex artery. 
70-90% were present. Wallmotion abnormalities during left 
ventriculography at rest (30° RAO and 45° LAO projections) 
were observed in 9 patients: 8 in >90% and 1 in 70-90% left 
CAD areas, varying from hypo- to dyskinesia. Anterograde 
collaterals were present in 7 areas: in 6 with ~90% and 1 with 
a 70-90% stenosis. 
81 ~r distribution at rest. During the 10 min control 
period the 81 ~r distribution pattern remained stable with 
only small fluctuations (<5%). 81 mKr perfusion was normal in 
most areas. In only 5 an obviously diminished, however un-
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CONTROL 
RIGHT CORONARY ARTERY 
450 LAO 
ANGINA PECTORIS 
130 B/MIN 
Fig. 3b 
5 MIN P-P 
Fig. 3b. 81 ITI<r perfusion of the right coronary artery in the same 
.patient. During the interval between the two catheterizations a retro-
grade collateral circulation to the RCX area has developed. 81Ill.Kr 
perfusion is now shown to improve markedly in the RCX area during 
atrial pacing. 
changed distribution was observed, all in ~90% left CAD 
regions. In 4 of these anterograde collaterals were present 
with decreased, however measurable radioactivity (fig 2). In 
1 patient, who was reinvestigated within 1 week after a 
previous catheterization in order to perform a Krypton study, 
a 99% left marginal branch had closed without signs of a 
recent infarction. However also without the formation of 
anterograde collaterals (fig. 3a). No 81 ~r perfusion of the 
marginal area occurred, either at rest and during pacing. 
Retrograde collaterals from the right coronary artery had 
developed in between the 2 successive catheterizations with 
I 
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Table 1. 81 rrxr distribution changes during and after pacing in patients with >70% L-eAD 
Lesion: control 100 b/min 120 b/min 
* * >90% 100% 86 ± 6 77 ± 7 
N = 12 
70-90% 100% 92 ± 4.6 87 ± 3.9 
N = 6 
* * nonnal 100% 112 ± 3.7 118 ± 3 
areas 
Abbreviations: L-eAD = left coronary artery disease 
b/min = beats/minute 
AP = anginal pain 
~-P = post-pacing• 
= p <0,05 vs control 
* 
+ = p <0,001 (AP >90% vs AP 70-90%) 
AP 15 sec P-P 1 min P-P 
-
+* 74 ± 6+ * 67 ± 6.3 83 ± 6.2 
* * * 80 ± 5.6 80 ± 3,6 88 ± 6.5 
* * * 125 ± 5.6 120 ± 3.9 118 ± 5.7 
5 min P-P 
* 84 ± 6.8 
* 90 ± 4.7 
110±5.1 
I 
...... 
00 
0 
I 
40 
L-E, 
% 
20 
CONTROL 1008/MIN ANGINA PECTORIS 
120 8/MIN 
15SEC P-P 5 MIN P-P 
01-----~~~----------~ 
,----- I T 
CONTROL 1008/MIN ANGINAPECTORIS 15SECP-P 5MINP-P 
120 8/MIN 
Fig. 4. Typical example of early and progressive decrease of 81ffiJ<r distribution in a 90% stenosis area (LAD) • 
There is simultaneous increase in the normal RCX region. Changes occur before anginal pain and in this case, 
toegether with lactacte production and have not returned to control values 5 min a~ter cessation of pacing. 
P-P= post pacing. B/min= beats/min. SEC= sec. RCX= left circumflex artery. LAD= left anterior descending artery. 
CONTROL 
LEFT CORONARY ARTERY 
450 LAO 
1108/MIN 
Fig. 5a 
ANGINA PECTORIS 
130 B/MIN 
Fig. Sa. 4S0 LAD view of 81Ir1Kr distribution at rest and during pacing in 
a patient with proximal 90% lesions in the LAD (closed arrow, Sa) and 
obtuse rrarginal artery (open arrow Sb). During angina pectoris there is 
diminished 81InKr distribution over the LAD area, which however is not 
so evident in the obtuse rrarginal region, presunE]:)ly due to norma). perfusion 
of postero-lateral branches which in this view are partially overlying 
the diseased coronary artery. 
some retrograde filling at rest; which however improved during 
the atrial pacing stress test (fig 3b). In none of the patients 
was the diminished 81 ~r distribution at rest accompanied by 
signs of myocardial ischemia, such as anginal pain, ECG 
changes or myocardial lactate production. However, abnormal 
wall motion at rest was found in all and documented old myo-
cardial infarcts in 3 patients. 
81 ~r distribution during pacing (table 1). During atrial 
pacing 81 ~r distribution decreased in all >70% left-CAD 
areas with simultaneous increases in the normal areas. In the 
~90% lesions this fall in 81 ~r perfusion developed at an 
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CONTROL 
LEFT CORONARY ARTERY 
3QD RIO 
ANGINA PECTORIS 
130 B/MIN 
Fig. 5b 
2 MIN P-P 
Fig. Sb. During a second atrial pacing stress test imaging was performed 
in the 30° RIO position. The obtuse marginal artery is in this view 
separated from the postero-lateral branches and a 81ITKr perfusion defect 
is nON clearly visible in this area during pacing (a=ows). 81ITKr distribu-
tion is still abnormal 2 min after pacing in both obtuse marginal and LAD 
regions. 
early stage and was progressive to the end of pacing. 
An example is given in fig 4. In this patient with a 
proximal 90% stenosis of the LAD artery 81 mKr perfusion 
diminished at an early stage before the development of anginal 
pain, however, together with lactate production. During anginal 
pain an impressive shift in 81 mKr distribution from the diseased 
t th 1 . h" . d f 81 ~-0 e norma area lS seen. T lS progresslve ecrease o Kr 
perfusion of early onset was found in all ~90% lesions. In the 
70 90% · h · 81 mK d" t "b t" 11 - stenosls group a c ange ln r lS rl u lon usua y 
only occurred halfway or towards the end of pacing. 
Further,the magnitude of the changes differ between the 
2 groups with significantly lower 81mKr perfusion during anginal 
pain, 67 ± 6.3% of control in the >90% lesions as compared to 
a decrease to 80 ± 5.6% in the 70-90% stenosis group (p<0.001). 
The fact that 81 ~r changes are found in all >70% areas and 
not in the <50% lesions indicates its possible use to discrim-
inate between significant and non-significant CAD. 
81 ~r distribution changes after pacing. In our studies 
usually late return to the control situation was found long 
after general signs of ischemia had subsided. Given the fact 
that the overall myocardial blood-flow is back to normal with-
in the first 1-2 min after pacing, this implies an absolute 
flow reduction in the ischemic area. As can be seen from 
table 1 this flow reduction lasted more than 5 min and in some 
patients was still found to exist as long as 15 min after 
pacing. In only 6 of the 18 areas with >70% CAD did 81 mKr 
distribution return to normal within 5 min after pacing. An 
explanation for this unexpected long-lasting flow reduction 
after atrial pacing induced ischemia is difficult to give. 
Prolonged post-stenotic vasodilatation with lowering of peri-
pheral perfusion pressure may result in an increase in stenotic 
resistance and a reduction in regional flow (28). A continuing 
adenosine release from the ischemic area is likely in view of 
the fact that myocardial venous hypoxanthine levels are still 
increased 5 min after pacing in analogue studies (29). Region-
al myocardial blood-flow which is still abnormal 15 min after 
pacing is possibly the reason for a non-reproducible lactate 
pattern during repetitive atrial pacing stress tests with this 
interval (30). 
Repetitive 81 mKr distribution imaging in various positions. 
81~~ imaging in our studies was always started in the 45° LAO 
position, separating the LAD and RCX regions. In addition 
perfusion studies of the right coronary artery were performed 
from this angle. This than allows a clear view of the right 
coronary perfusion areas in the infero-apical and postero-
lateral regions (fig 3) without the problems of overprojection 
of the left coronary artery blood-supply in these areas. In 
single vessel lesions and in most of the patients with multi-
vessel disease one left coronary artery in the 45° LAO view 
study was usually sufficient to obtain all the information 
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needed. However, in some instances a second study was necessary 
from a different imaging angle in order to separate the branches 
of the left circumflex artery. The 30° right inferior oblique 
position was chosen for this purpose separating the various 
marginal branches of this artery. The second study was performed 
after a 30 min interval. An example is given in fig 5. This 
patient had both a >90% stenosis of the LAD and of the obtuse 
marginal branch. During atrial pacing in the 45° LAO projection 
there is an obvious decrease of 81 ~r distribution over the 
LAD area, however, not so apparent over the RCX area (fig Sa) 
Due to overprojection of the normal postero-lateral branch 
over the stenotic obtuse marginal artery a decrease in 81 ~r 
perfusion in the latter could be compensated by hyperemia and 
an increase in 81 ~r activity in the normal postero-lateral 
area. 
The functional significance of the obtuse marginal stenosis 
is now demonstrated in the second study with the gamma camera 
in the 30° RIO position (fig Sb). The marginal branches and their 
perfusion area are now separated and diminished 81 mKr distrubu-
tion is clearly seen in the peripheral obtuse marginal region, 
as well as in the LAD area. 
S l . . 81mK . f . l . e ectlve lntra-coronary r ln uslon versus nonse ectlve 
administration. Due to its very short half-life 81 mKr must be 
administered either directly into the coronary artery (select-
ive) or in the immediate vicinity of the coronary artery ostia 
(non-selective). Though the possibility of a streaming arte-
fact with the intracoronary method, imposes an important theo-
retical drawback to the procedure its occurence is in our 
experience easily recognizable and preventable. 
In the great majority of patients this type of study can 
be carried out without streaming artefacts after selection of 
the appropriate type of catheter. Also a change in catheter-
tip position during pacing and fast heart rates, giving rise to 
a more superselective infusion and hence a distribution arte-
fact, is unlikely in view of the fact that in most patients 
81~r distribution did not return to the control situation 
immediately after cessation of pacing, which would be expected 
in case of artefacts. The consistent observation of a decreased 
Fig. 6. Direct intracoronary administration of 81ffiKr (left image) 
corrpared with an infusion of the same amount into the aortic sinuses 
(right image) • The difference in activity over the heart is obvious. 
Also, perfusion of the right coronary bed can be seen (closed arrow), 
which may overlap in the infero-apical region. The same problem may 
oc= in the RCX area by counts from the descending aorta (open arrow) 
during intra-aortic administration. RCX = left circumflex artery. 
81ITKr perfusion pattern during episodes of spontaneous anginal 
pain and normal resting heart rates found in the same areas 
as during pacing induced ischemia is also a strong argument 
against streaming artefacts (data not given in this chapter) 
In our experience the selective intracoronary infusion 
of 81 ~r provided acceptable information about the functional 
significance of the coronary artery disease present. 
On the other hand we were unable to obtain reliable data 
when applying nonselective methods of administration of 81 mKr 
in the aortic root and/or aortic sinuses both with "normal" 
or specially designed catheters. 
Invariably the total amount of counts over the heart was 
far too low to allow proper statistical analysis. This is not 
surprising taking into consideration the relatively small 
portion of cardiac output which enters the coronary circula-
tion. Even using special catheters, designed for delivery of 
81
mKr directly in the coronary sinuses, the total amount of 
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of radioactivity over the left ventricle is proportionally 
small compared with the direct intracoronary administration. 
An example of the best nonselective 81 mKr imaging we were 
able to manage is shown in fig 6 as well as an intracoronary 
study in the same patient. The difference in activity is obvious. 
Also demonstrated is the obligate simultaneous perfusion of 
the right coronary artery with overprojection in the infero-
apical region. Both this overprojection and the relatively 
high background activity of the descending aorta, usually 
underlying the circumflex area present problems defining 81 mKr 
perfusion changes in these regions. Problems were not encounter-
ed with the direct intracoronary administration. 
Clinical implications 
As the investigation is necessarily invasive it is not 
suitable for use as a routine procedure. However, valuable 
information can be derived from this kind of study especially 
with reference to the functional significance of the various 
lesions in multivessel disease. This information is not always 
available from conventional, noninvasive techniques. 
Due to the short half-life of 81 mKr a multitude of succes-
sive studies can be performed in the same patient without 
extra exposure to radiation other than that necessary for the 
instantaneous study. The effect of repetitive stress tests and 
pharmaceutical intervention on regional myocardial blood-flow 
and myocardial ischemia can be evaluated. Further, the localiza-
tion of perfusion disturbances during spontaneous anginal 
attacks or ergonovine-induced coronary spasm can be investigated 
as well as the influences of vaso-active drugs in these situa-
tions. Presumably the most important reason however, to subject 
the patient to this kind of investigation will be the situation 
where a moderate coronary artery lesion of 50-70% exists and 
the decision whether to perform surgery or angioplasty is 
debatable. The clinical significance of this stenosis will be 
adequately demonstrated during an atrial pacing stress test 
'th t' 't d' 't t' f 81 mK Wl con lnuous ln racoronary a mlnls ra lOn o r. 
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Continuous Determination of Regional Myocardial 
Blood Flow with lntracoronary Krypton-81 m 
in Coronary Artery Disease 
WILLEM J. REMME, MD, X. HANNO KRAUSS, MD, 
DIEDERIK C.A. VAN HOOGENHUYZE, MD, PETER H. COX, PhD, 
COCK J. STORM, MD, and DICK A. KRUYSSEN, MD 
Pacing-induced changes in regional coronary flow 
were studied continuously with krypton-81 m by in-
tracoronary infusion in 25 patients: 21 with 50% or 
greater diameter narrowing of 1 or more left coro-
nary arteries (group I) and 4 with less than 50% 
diameter reduction of a left coronary artery (group 
II). No changes occurred in group II. In group I, 
krypton-81 m perfusion decreased progressively in 
all areas with more than 70% diameter narrowing, 
with a simultaneous increase in normal regions. At 
the end of pacing during angina, krypton-81 m per-
fusion was reduced to 81 ± 4% of control in areas 
with 71 to 90% diameter reduction (n = 8) and to 
69 ± 6% in areas with more than 90% diameter 
narrowing (n = 15). In contrast, in regions with 50 
to 70% diameter reduction changes were variable 
(decrease in 4 regions, increase in 2 and an un-
Regional changes in myocardial blood flow during 
ischemia have been studied in humans with various 
scintigraphic techniques. After the introduction of the 
rubidium-31/krypton-31m generator,1-4 it was subse-
quently shown in animal experiments that krypton-31m 
also had the potential to indicate regional myocardial 
flow changes. 5-7 SelWYD et al8•9 were the first to dem-
onstrate coronary flow reductions in areas with a sig-
nificant coronary stenosis in humans, with krypton-31m 
administered continuously into the aortic sinuses. The 
relation between the magnitude of regional coronary 
flow changes and degree of coronary artery stenosis, 
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changed distribution in 1 region). Krypton-81m 
perfusion decreased early, before general signs of 
ischemia in areas with more than 90% diameter 
reduction, whereas this decrease occurred later in 
regions with 71 to 90% diameter narrowing, con-
currently with ST -segment changes but before an-
ginal pain. Although all signs of ischemia had dis-
appeared between 2 and 5 minutes after pacing, 
changes in krypton-81 m distribution persisted in 
most areas for 5 to 15 minutes after pacing. It is 
concluded that the functional significance of coro-
nary arterial narrowing can be assessed with a 
continuous intracoronary infusion of krypton-81 m. 
Changes in regional distribution persisted after 
cessation of pacing-induced ischemia, indicating an 
ongoing decrease in regional myocardial blood flow. 
(Am J Cardiol1985;56:445-451) 
however, was not studied. Also, although the radionu-
clide is used more optimally during continuous intra-
coronary infusion, such studies in humans have not been 
reported, apart from preliminary data from our labo-
ratory.lO,ll This study investigates the applicability of 
this technique and the relation between regional myo-
cardial blood flow changes during ischemia and the 
degree of coronary artery stenosis. 
Methods 
All patients gave informed consent. Studies were conducted 
in patients with either documented signs of myocardial 
ischemia (positive results with bicycle ergometry test or pos-
itive results on thallium scintigraphy), a previous myocardial 
infarction or persistent angina-like complaints without ob-
jective signs of ischemia. 
Catheterization procedures: Catheterization was per-
formed after an overnight fast without premedication using 
the Seldinger technique. Studies were carried out before 
routine coronary and left heart angiography. After 5,000 IU 
of heparin and 250 mg of Aspegic® (acetylsalicylic acid) were 
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given intravenously, a No. 7Fr Judkins or Amplatz left cor-
onary artery catheter was positioned in the left coronary 
artery. 
The occurrence of selective injections in 1 of the branches 
of the left coronary artery was then determined during slow 
and rapid manual contrast injections in both the 30° right 
inferior oblique and 45° left anterior oblique position. All 
angiographic information was stored on videotape to enable 
rechecking of the catheter-tip position during the study. 
After catheterization the coronary angiograms were ana-
lyzed by 2 independent cardiologists, experienced in reporting 
more than 700 angiograms annually. If there was disagree-
ment, a quantitative determination was carried out.12 Sig-
nificant left coronary artery disease (CAD) was taken to be 
present with a diameter reduction of 50% or greater in 1 or 
more left coronary arteries. The left coronary artery lesions 
were separated into 5 categories: normal (0 to 20% diameter 
reduction), insignificant left CAD (20 to 49% diameter nar-
rowing), 50 to 70%, 71 to 90%, and more than 90% diameter 
reduction, respectively. Patients with left main disease or 
collateral supply from the right coronary artery were excluded 
from the study. Concomitant right CAD was accepted only if 
it did not interfere with left coronary flow. 
Scintigraphic procedures: During the study krypton-81m 
was continuously eluted in 5% glucose from a sterile, pyro-
gen-free rubidium-81/krypton-81m perfusion generator, 
calibrated to deliver 20 mCi_l3 The eluate was then passed 
through a 200-nm membrane fllter and continuously infused 
into the left coronary artery at a constant rate of 800 ml/hour. 
After a 20-minute stabilization period, precordial scanning 
was started in the 45° left anterior oblique position using a 
%-inch crystal General Electric Portacamera connected on 
line with a Medical Data System A2 computer. Energy de-
tection was set on 190 ke V ± 20%. Images were acquired over 
15-second periods and krypton-81m distribution changes 
measured in the various regions of interest, including areas 
with normal coronary arteries, regions with significant left 
CAD (50% or greater diameter reduction), total heart, as-
cending aorta and background areas. Regions of interest were 
constructed using an electronic lightpen on a visual display 
unit. Movement artifacts were avoided and care was taken 
that successive regions of interest did not differ from the 
originally constructed areas. Calculations were made of total 
CONTROL 
15 SEC POST-PACING 
FIGURE 1. Selective infusion of krypton-81m in the left circumflex 
artery, which has a 71 to 90% diameter reduction (arrow). During 
pacing, krypton-81 m perfusion decreases clearly in the poststenotic 
area before angina occurs with a simultaneous increase in the pre-
stenotic region. 
counts per area and changes in krypton-81m distribution 
expressed as percentages of control. Fluctuations in kryp-
ton-81m supply to the left myocardium were accounted for 
by dividing total counts per region by total counts over the 
heart per time frame. When areas with coronary lesions were 
superimposed, a second study in the 30° right inferior oblique 
position was performed after 30 minutes. 
Electrocardiographic measurements: Leads I, II and V 5 
were continuously monitored for determination of heart r>;1te 
and ST -segment changes. 
Study protocol: Approximately 60 seconds after initiation 
of the infusion, an equilibrium was reached in the regions 
studied. During the following 10-minute control period, 
krypton-81m distribution was continuously monitored and 
the distribution pattern measured during several15-second 
periods. With the occurrence of streaming, i.e., distribution 
changes of more than 5%, the catheter was either repositioned 
or replaced, or a superselective perfusion of the coronary 
branch of interest was carried out. When this was unsuccessful 
the study was terminated. 
After the control period, atrial pacing was carried out with 
increments of 10 beats/min until angina, atrioventricular block 
or a maximal pacing heart rate of 170 beats/min occurred. 
Krypton-81m distribution was monitored continuously during 
the pacing period and until5 minutes after pacing. However, 
in most patients repeated studies were carried out and 
monitoring usually was performed until 15 minutes after 
pacing. 
Statistical analysis was performed using the Student t test 
for unpaired and paired values. All values are expressed as 
mean ± 1 standard error of the mean. 
Results 
In 3 patients, streaming artifacts occurred during the 
control period. One patient was excluded. In the other 
2 patients, a superselective infusion was carried out in 
a stenosed coronary artery branch. In both studies, a 
normal area and an area of stenosis were present, which 
allowed for satisfactory information about krypton-81m 
distribution changes during pacing (Fig. 1). 
Complete studies were performed in 25 patients, 21 
men and 4 women, aged 36 to 66 years (mean 54), either 
with significant left CAD (50% or greater stenosis, n = 
21, group I) or no left CAD (less than 50% stenosis, n = 
4, group II). Patient data and angiographic findings are 
listed in Table I. In group I, 15 areas with more than 
90%, 8 with 71 to 90% and 7 with 50 to 70% diameter 
reduction of a left coronary artery were present. Ten 
patients had electrocardiographic signs of an old myo-
cardial infarction. In another 5 patients, the left ven-
triculogram showed wall motion abnormalities at rest 
in areas corresponding with significant left CAD. In 3 
patients, an inferior myocardial infarction with a 100% 
occlusion of the right coronary artery and collateral 
supply from the left coronary artery were present. 
Krypton-Slm distribution at rest: Krypton-81m 
distribution was stable throughout the control period 
with a count rate of 250,000 to 300,000 counts/min. 
Total counts over the heart and aorta showed minor 
fluctuations (less than 5%), and background counts were 
negligible. The distribution pattern over the left heart 
was normal in 17 patients in group I and all patients in 
group II (Table I). Although none of the other 4 patients 
in group I had signs of myocardial ischemia, a stable 
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TABLE I Clinical and Angiographic Data and Krypton-81m Distribution at Rest 
Angiographic Findings 
Left Ventricular 
Coronary % Diameter Reduction Krypton-81 m 
Age(yr) Healed Wall Distribution 
PI & Sex AP Ml LAD LC Right Collat. EF(%) Motion at Rest 
Group 1: Left Coronary Artery Disease'-50% or Greater Diameter Reduction (n = 21) 
1 49F + 0 0 71-90 0 0 60 N N 
2 53M + 0 0 71-90 0 0 66 N N 
3 58M + Post >90 100 0 +LC 45 Post Ak/ Ant Hyp JLAD, ~LC 
4 50M 0 Ant 100 0 0 +LAD 47 Ant Dys LAD 
5 60F + 0 >90 50-70 0 0 62 N N 
6 61M + 0 71-90 71-90 0 +LC 58 N N 
7 64M + 0 >90 0 0 +LAD 51 Ant Hyp N 
8 53M + Ant 100 71-90 0 +LAD 62 Ant Hyp ~LAD 
9 47F + 0 0 100 0 +LC 64 Post Hyp N 
10 41M + 0 >90 >90 >90 0 59 Ant Hyp N 
11 58M + 0 71-90 71-90 0 0 77 N N 
12 59M + Ant >90 0 <50 0 51 Ant Hyp N 
13 37M + Ant 71-90 0 <50 0 56 Ant Hyp N 
14 40M 0 Ant >90 50-70 0 0 74 Ant Hyp N 
15 62M + 0 >90 50-70 71-90 0 63 N N 
16 51M + Ant >90 >90 >90 +LC 42 Ant Hyp/lnf Ak N 
17 63F + 0 50-70 0 0 0 80 N N 
18 59M + 0 >90 0 <50 0 62 Ant Hyp N 
19 57M + 0 50-70 0 0 0 62 N N 
20 66M + 0 50-70 0 0 0 85 N N 
21 61M + Post 50-70 100 0 0 45 Post Hyp Absent LC 
Group II: Left Coronary Artery Disease'-Less than 50% Diameter Reduction (n = 4) 
22 60M + Post <50 0 100 +Right 72 N N 
23 49M + 0 <so 0 0 0 74 N N 
24 48M + 0 <50 0 0 0 70 N N 
25 36M 0 Post <50 0 100 +Right 53 Post Hyp N 
• Diameter reduction or 1 or more left coronary arteries. 
Ant = anterior; Ak = akinesia; AP = preexisting angina pectoris or anginalike symptoms; Coli at. = collateral filling from left coronary artery; Dys = dyskinesia; EF = ejection 
fraction; Hyp = hypokin~sla; lnf = inferior; LAD = left anterior descending artery; LC = left circumflex artery; Ml = myocardial infarction; N = normal; Post = posterior; + 
= present; 0 = absent; j, = decrease. 
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TABLE II Krypton-81m Distribution Changes During and After Pacing {% of Control) 
Pacing Periods 
Areas with 
LCAD 100 beats/min 120 beats/min AP 15 sec P-P 1 min P-P 5 min P-P 
>90% (n = 15) 81 ± 4* 77 ± 7.5* 69 ± 6* 79 ± 6* 81 ± 7* 84±4* 
71-90% (n = 8) 97±2 87 ± 4* 81 ± 4* 81 ± 3* 83 ± 5.5* 87 ± 2* 
Normal (n = 21) 110 ± 3* 116 ± 3* 132 ± 7* 121 ± 7* 119 ± 7* 113 ± s· 
• p <0.05 vs control values. 
AP = anginal pain; LCAD = left coronary artery disease; P-P = postpacing. 
pattern of decreased krypton-31m distribution was 
found in 5 areas with more than 90% diameter reduc-
tion, of which 4 corresponded with documented old 
myocardial infarctions. 
Pacing study period: Maximal paced heart rates 
were similar in both groups (137 ± 4 beats/min in group 
I and 132 ± 3 beats/min in group II). In 19 patients in 
group I and in all patients in group II, pacing was dis-
continued because of chest pain. It was was first noted 
at a mean heart rate of 122 ± 4 beats/min in group I and 
at 114 ± 10 beats/min in group II (difference not sig-
nificant), and lasted for 2.2 ± 0.47 minutes after pacing 
in the group with left CAD and for 2.5 ± 0.65 mirmtes 
in group II (difference not significant). Significant 
ST -segment changes occurred in 13 patients in group 
I, but the ST segment returned to baseline values be-
tween 2 and 5 minutes after pacing in all but 2 areas. In 
group II, ST-segment changes occurred in 2 patients 
with a 100% occlusion of the right coronary artery. 
Krypton-31m distribution during and after 
pacing: Background activity remained unchanged 
during pacing, and significant reflux of krypton-31m in 
the aorta did not occur. In some patients administration 
of total krypton-31m decreased slightly during the study 
period with a decrease in total counts over the heart and 
the aorta of ±5%. 
Areas with less than 50% diameter reduction: In 
group II patients, krypton-31m distribution did not 
change in the normal areas or in the regions with less 
than 50% diameter narrowing of a left coronary artery, 
although small fluctuations (less than 5% of control) 
were observed. 
Areas with more than 90% left coronary artery 
disease: In areas with more than 90% diameter nar-
rowing a continuous decrease in krypton-31m perfusion 
was found, starting early after the onset of pacing, be-
fore angina or ST -segment changes. An example is 
shown in Figure 2. Mean values of distribution changes 
in areas with more than 90% diameter reduction are 
listed in Table II, as well as the measured values over 
normal areas. The temporal relation with the occurrence 
of angina and ST -segment changes is displayed in Fig-
ure 3. At 100 beats/min, krypton-31m perfusion de-
creased to 31 ± 4% of control (p <0.05 vs control), 
gradually decreasing thereafter to 69 ± 6% of control at 
the end of pacing during anginal pain. This progressive 
decline in krypton-31m distribution of early onset 
during pacing was found in 12 areas with more than 90% 
diameter narrowing. In 2 other regions, a late decrease 
in perfusion was observed toward the end of pacing 
(Table III). A late increase in krypton-31m perfusion 
during pacing was observed in an area with 100% oc-
FIGURE 2. Krypton-81m distribution changes in a patient with a proximal (more than 90%) diameter reduction in the left anterior descending artery 
(arrow). At rest there is equal perfusion of both normal and abnormal areas (A). During pacing a progressive decrease in krypton-81m perfusion 
of the poststenotic area is observed with significant changes already at 100 and 120 beats/min (B and C), before the occurrence of ST -segment 
changes (140 beats/min, D) and angina (160 beats/min, E). No change 15 seconds after pacing (F), and, thereafter, a very slow return to the control 
situation, which is still not reached 15 minutes after pacing (G, 8 minutes after pacing; H, 15 minutes after pacing). 
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TABLE Ill Number of Areas with Krypton-81m Distribution Changes During and After Pacing 
Krypton-81 m Distribution 
During Pacing After Pacing 
Return to Control 
Areas with Normal Early Late Early Late 
LCAD Unchanged Decrease Decrease Increase Unchanged (<Smin) (>Smin) 
>90% (n = 15) 0 12 2 
71-90% (n = 8) 0 4 4 
50-70% (n = 7) 1 2 2 
<SO% (n =4) 4 0 0 
LCAD = left coronary artery disease. 
elusion and anterograde collaterals with diminished 
krypton-31m uptake at rest. In the other areas with 
diminished krypton-31m distribution at rest, perfusion 
decreased even more during pacing with a late return 
to the control situation after pacing (Fig. 4). 
Although krypton-31m perfusion had increased 
slightly 15 seconds after pacing, it was still diminished 
5 minutes after pacing. In some patients, krypton-31m 
distribution was still abnormal, even 15 minutes after 
pacing. In only 4 of the 15 areas with more than 90% 
diameter reduction did krypton-31m distribution nor-
malize within the 5-minute period after pacing. 
Left coronary artery disease (71 to 90% stenosis): 
Krypton-31m perfusion decreased in all regions with 71 
to 90% diameter narrowing of a left coronary artery 
during pacing. Changes occurred later than in the group 
with more than 90% diameter reduction (Table II), in 
some areas only halfway or toward the end of pacing. 
However, a significant decrease to 37 ± 4% of control (p 
<0.05 vs control) was found at 120 beats/min. During 
anginal pain, krypton-31m distribution had further 
tOO 8/MIN 120 B/MIN AP 
o-o NORMAL AREA 
---·71-90% 
o--D>90% 
15 SEC P·P t MIN P-P 5 MIN P-P 
FIGURE 3. Mean values of krypton-81 m distribution changes in areas 
with 71 to 90% and more than 90% diameter reductions and in normal 
regions. Temporal relation with the occurrence of angina and ST-seg-
ment changes is seen. Krypton-81m perfusion is significantly reduced 
already at 100 beats/min in areas with more than 90% diameter nar-
rowing before signs of ischemia. In regions with 71 to 90% diameter 
reduction this occurs later, at 120 beats/min, concurrently with ST-
segment changes, but before angina. Krypton-81m distribution is still 
reduced 5 minutes after pacing, in areas with both 71 to 90% and more 
than 90% diameter reduction. N.S. = not significant; P-P = post-
pacing. 
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decreased to 31 ± 4%, remained unchanged 15 seconds 
after pacing and thereafter slowly increased to 37 ± 2% 
of control 5 minutes after pacing (p <0.05 vs control 
[Fig. 3]). At this period krypton-31m perfusion was still 
diminished in 6 areas (Table III). 
Left coronary artery disease (50 to 70% stenosis): 
The response to pacing was variable in areas with 50 to 
70% diameter reduction (Table III). In 4 patients with 
a 1-vessellesion, krypton-31m perfusion diminished 
during pacing in 3 and remained unchanged in 1 patient. 
In the multivessel group either a decrease (1 patient) or 
an increase (2 patients) was found. 
Discussion 
Krypton-31m is a biologically and chemically inert 
radionuclide with a 13-second half-life, which is short 
in relation to myocardial transit time. This implies that 
during continuous administration the process of equi-
librium is affected only in a very small percentage by 
tracer washout and that background counts are negli-
gible. In eluted form, krypton-31m is soluble in plasma 
and diffuses freely through capillary membranes.14 
During continuous administration into the coronary 
140 BEATS/MIN 180 BEATS/MIN 
1 MIN POST-PACING 5 MIN POST-PACING 
FIGURE 4. Krypton-81m distribution in a patient with a proximal 100% 
occlusion of the left anterior descending artery, anterograde collaterals 
and anterior and septal dyskinesia. At rest, krypton-81 m perfusion is 
already diminished over the peripheral area of the left anterior de-
scending artery (arrow) and becomes almost nonexistent during pacing, 
although angina does not occur. Krypton-81m distribution does not 
return to control 5 minutes after pacing. 
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arterial system, the radionuclide will readily equilibrate 
itself in the myocardial vascular and extravascular 
compartments,l5 and a stable distribution pattern is 
obtained approximately 60 seconds after the onset of 
administration. 
Sources of misinformation: During intracoronary 
administration, streaming may occur because of im-
proper mixing of the radionuclide with blood in the left 
mainstem, which results in an uneven and usually un-
stable distribution pattern. This phenomenon was ob-
served in 3 patients in this study during the control 
period. In another 5 areas, krypton-31m perfusion was 
abnormal and was reduced as well during control; 
however, these abnormalities in perfusion were stable 
and only found in regions with more than 90% diameter 
reduction, corresponding with an old myocardial infarct 
or with an abnormal left ventriculogram. They were 
classified as true decreases in myocardial blood flow. 
Another possible source of false information could be 
a change in catheter-tip position caused by the fast 
movements of the heart during pacing. An immediate 
return to the control position after pacing with a prompt 
normalization of the krypton-31m distribution pattern 
would then be expected. This only happened in 1 pa-
tient. In most patients krypton-31m distribution nor-
malized only late after pacing, which makes this hy-
pothesis very unlikely. 
Krypton-81m distribution changes in relation to 
the degree of left coronary artery disease: Abnormal 
krypton-31m distribution was found at rest or during 
pacing in all areas with more than 70% diameter nar-
rowing, and in none of those with less than 50% diameter 
reduction. This finding signifies the usefulness of the 
radionuclide as an indicator of coronary flow changes 
when given through the intracoronary route. The fact 
that distribution changes occur early in severe CAD 
(more than 90% diameter reduction), but later with 
moderate lesions (71 to 90% diameter narrowing), also 
suggests that the remaining vasodilatory reserve ca-
pacity is detected adequately with this technique. 
Although coronary diameter reductions of 50 to 70% 
are generally believed to be significant, krypton-31m 
distribution changes were variable in areas with 50 to 
70% diameter narrowing. In 3 of the 7 regions krypton-
31m perfusion either remained unchanged (1-vessel 
CAD) or increased (multivessel CAD) during pacing, 
indicating an intact vasodilatory reserve capacity. Al-
though these findings suggest that the functional sig-
nificance of a 50 to 70% diameter reduction can be as-
sessed correctly with this technique, more observations 
are needed to reach definite conclusions as to its use-
fulness. 
Krypton-81m distribution changes after pacing: 
A persistent decrease in krypton-31m perfusion was 
found in 17 of 23 areas with more than 70% diameter 
narrowing lasting more than 5 minutes after pacing. To 
our knowledge, this finding has not been described in 
comparable studies of pacing-induced changes in 
myocardial blood flow. Changes are reported to nor-
malize without specification of the time required or to 
return to control values within a few minutes after 
pacing.9 The pathophysiologic characteristics under-
lying the long-lasting reductions in regional krypton-
31m perfusion after pacing are difficult to understand. 
Because total left coronary flow returns to control values 
within 2 minutes after pacing,16 the implication is that 
a persistent reduction occurs in regional flow. A possible 
explanation could be persistent poststenotic vasodila-
tion due to continuous adenosine release in the ischemic 
areas after pacing. This could lead to a decrease in 
perfusion pressure and an increase in stenosis resis-
tanceP which then may result in a continuous redis-
tribution of krypton-31m from the area of stenosis to 
normal, low resistance areas. Previous observations that 
coronary sinus hypoxanthine levels are elevated 5 
minutes after pacing in patients with angina,l8 strongly 
suggest this continuous adenosine release to occur. 
Persistent changes in krypton-31m activity may occur 
also as a result of dyskinesia and local wall thinning in 
the ischemic area. However, because ischemic wall 
motion abnormalities are reported to normalize with-
in 5 minutes after pacing,19 this seems rather unlikely. 
Comparison with other imaging techniques: In 
the present study, a decrease in krypton-31m perfusion 
was found in all areas with more than 70% coronary di-
ameter reduction. This finding indicates that the 
method has a greater sensitivity for detecting func-
tionally significant lesions than noninvasive methods 
like quantitative thallium-201 planar or tomographic 
imaging.20•21 It also compares favorably with myocardial 
imaging, using labeled macroaggregated albumen by 
intracoronary injection. Although with this technique, 
perfusion abnormalities were observed in 37 of 39 pa-
tients with significant CAD, imaging defects did not 
occur in all of the areas with more than 70% diameter 
'reduction.22 Precordi3J mapping with xenon-133 re-
sulted in a near complete separation between func-
tionally significant and insignificant coronary lesions.23 
Some of the characteristics of xenon-133 (e.g., low-
energy spectrum, some recirculation and affinity for 
fat tissue) and the time needed for the determination 
of washout curves24•25 are limiting factors, particularly 
in repeated studies with short intervals in the same 
patient. 
Digital coronary angiography provides a new, alter-
native technique for the evaluation of coronary flow 
reserve by measuring myocardial contrast appearance 
time. With this technique, an abnormal transit time and 
thus, presumably, a decrease in regional flow can be 
detected in areas with significant CAD.26 Changes are 
also found, however, with 30 to 40% diameter reduc-
tions, which do not agree with our results. Whether this 
means that digital coronary angiography has a greater 
sensitivity in the estimation of coronary flow reserve has 
to be investigated further in comparative studies, which 
includes the determination of ischemia as well. 
Selwyn et alB originally reported on the use of kryp-
ton-31m, given nonselectively in the aortic root with a 
specially designed catheter. Although regional perfusion 
abnormalities were found in practically all patients with 
significant CAD, various areas with more than 70% di-
ameter narrowing were not described as abnormal in 
patients with multivessel disease.9 This difference with 
our results may be attributable to a somewhat slower 
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·perfusion of an otherwise similar generator. Combined 
with the relatively low influx of the radionuclide into 
. the coronary system, when administered into the aortic 
sinuses, this may have resulted in a significant lower 
precordial count rate. Also, their studies do not clarify 
whether all significant coronary lesions or only scin-
tigraphically abnormal areas were studied. 
Limitations of the technique: Contrary to other 
:precordial mapping techniques, 9•23 only distributional 
changes and not coronary flow changes in absolute 
quantities can be measured when intracoronary infusion 
of a constant amount of radionuclide is given. Whether 
the observed changes really represent a regional de-
crease in coronary blood flow is impossible to know. A 
redistribution of radioactivity from areas with limited 
vasodilatory reserve and diminished increase in flow 
during pacing to normal areas can result in the observed 
changes in krypton-31m perfusion as well. 
In 7 of the 25 patients, spontaneous anginal attacks 
occurred, usually late after the first pacing stress test-a 
large percentage in our experience. This result could 
be due to the relatively long periods of continuous, 
low-speed intracoronary infusions. Intermittent ad-
ministration, alternating with flushing of the cath-
eters, should therefore be considered in subsequent 
studies. 
Clinical implications: The intracoronary adminis-
tration of krypton-31m ensures the delivery of sufficient 
radioactivity to measure distribution changes at short 
time intervals. This is important in situations in which 
myocardial blood flow varies continuously, e.g., during 
pacing or administration of vasoactive agents. Its short 
half-life ensures selective imaging of the target organ 
without background activity, whereas radiation of the 
patient is limited to the investigation period only. The 
major drawback of the technique is that it is invasive 
and depends on proper mixing with blood in the left 
coronary mainstem. It is our opinion that during a 
10-minute observation period before pacing, improper 
distributional changes and streaming artifacts can be 
recognized and corrected. Changes thereafter, during 
pacing, reflect real alterations in myocardial blood flow, 
whether this is a true decrease or only an impaired in-
crease in flow compared with normal regions. This 
technique may enable the clinician to better understand 
the functional significance of the lesion and may facil-
itate a proper decision on the right therapy, especially 
in areas with 50 to 70% coronary diameter reduction. 
Finally, the observation in this study of perservering, 
long-lasting perfusion abnormalities after pacing em-
phasizes the importance of a sufficiently long interval 
between repetitive atrial pacing stress tests in order to 
obtain reproducible pacing-induced myocardial 
ischemia. 27 
Acknowledgment: We gratefully acknowledge the expert 
technical assistance of An Maas, Elma van der Giessen, Joke 
van Vliet, Marianne van der Brink, Renny Noordhoek, Peter 
van der Kemp, Michael Pillay and Jan van Overeem, and are 
-196-
indebted to Margo Speelman and Karin van Peursen for 
· preparing the manuscript . 
References 
1. Jones T, Clark JC. A cyclotron produced rubidium-81/krypton-81m gen-
erator and its uses in gamma camera studies (abstr). Br J Radiol 1969; 
42:237. 
2. Yano Y, Anger HO. Ultrashort-lived radioisotopes for visualizing blood 
vessels and organs. J Nucl Med 1968;9:2-6. 
3. Clark JC, Horlock PL, Watson lA. Krypton-81m generators. Radiochemical 
and Radioanalytical Letters 1976;25:245-248. 
4. Kaplan E, Mayron L W. Evaluation of perfusion with the rubidium-81 /kryp-
ton-81m generator. Semin Nucl Med 1976;6:163-190. 
5. Kaplan E, Mayron LW, Friedman AM, Glndler JE, Frazln L, Moran JM, Loeb 
H, Gunnar RM. Definition of myocardial perfusion by continuous infusion 
of krypton-81m. Am J Cardiol1976;37:878-884. 
6. Turner JH, Selwyn AP, Jones T, Evans TR, Raphael MJ, Lavender JP. 
Continuous imaging of regional myocardial blood flow in dogs using kryp-
ton-81m. Cardiovasc Res 1976;10:398-404. 
7. Selwyn AP, Jones T, Turner JH, Pratt T, Clark J, Lavender P. Continuous 
assessment of regional myocardial perfusion in dogs using krypton-81 m. 
Circ Res 1978;42:771-777. 
8. Selwyn AP, Steiner R, Kivlsaari A, Fox KM. Forse G. Krypton-81 m in the 
physiologic assessment of coronary artery stenosis in man. Am J Cardiel 
1979;43:547-553. 
9. Selwyn AP, Forse G, Fox KM, Jonathan A, Steiner R. Patterns of disturbed 
myocardial perfusion in patients with coronary artery disease. Circulation 
1981;64:83-90. 
10. Remme WJ, Cox PH, Krauss XH. Continuous myocardial blood flow dis-
tribution imaging in man with krypton-81m intracoronary (abstr). Am J Cardiel 
1982;49:979. 
11. Remme WJ, Kruyssen HA, Cox P, Krauss XH. Assessment of functionally 
significant coronary artery IJisease during continuous intracoronary ad-
ministration of krypton-81m (abstr). Eur Heart J 1983;4:suppl E:32. 
12. KoolJman CJ, Reiber JHC, Gerbrands JJ, Schuurblers JCH, Slager CJ, 
den Boer A, Serruys PW. Computer-aided quantitation of the severity of 
coronary obstructions from single view cineangiograms. First IEEE Comp. 
Doc. Int. Symp. on Medical Imaging and Image Interpretation, IEEE Cat. no. 
82 CH1804-4;1982:59-64. 
13. Guillaum M, Czlchisz R, Richard P, Fagard E. Krypton-81m generator for 
ventilation and perfusion. Dosimetry, routine production. methodology for 
medical applications. Bull Soc Sci Lieges 1983;52:214-281. 
14. Kety SS. The theory and applications of the exchange of inert gas at the 
lungs and tissues. Pharmacal Rev 1951;3:1-41. 
15. Kaplan E, Mayron LW, Bames WE, ColombeHi LG, Friedman AM, Glndler 
JE. Continuous radionuclide generation. II. Scintigraphic definition of cap-
illary exchange by rapid decay of 81mKr and its applications. J Nucl Med 
1974;15:874-879. 
16. Remme WJ, van Hoogenhuyze DCA, Krauss XH, Hofman A, Kruyssen 
HACM, Storm CJ. Acute hemodynamic and anti-ischemic effects of intra-
venous amiodarone. Am J Cardiol 1985;5:639-644. 
17. Schwartz JS, Carlyle PF, Cohn JN. Decline in blood flow in stenotic cor-
onary arteries during increased myocardial energetic demand in response 
to pacing-induced tachycardia. Am Heart J 1981;101:435-440. 
18. Remme WJ, de Jong JW, Verdouw PD. Effects of pacing-induced myo-
cardial ischemia on hypoxanthine efflux from the human heart. Am J Cardiol 
1977;40:55-62. 
19. Hecht HS, Chew CY, Burnam M, Schnugg SJ, Hopkins JM, Singh BN. 
Radionuclide ejection fraction and regional wall motion during atrial pacing 
in stable angina pectoris: comparison with metabolic and hemodynamic 
parameters. Am HeartJ 1981;101:726-733. 
20. Berger BC, Watson DO, Taylor GJ, Craddock GB, Martin RP, Teates CD, 
Beller GA. Quantitative Thallium-20 1 exercise scintigraphy for detection 
of coronary artery disease. J Nucl Med 1981 ;22:585-593. 
21. Bateman T, Garcia E, Maddahl J, Rozanski A, Pantaleo N, Stanlloff H, 
Freeman M, Waxman A. Berman D. Clinical evaluation of seven-pinhole 
tomography for the detection and localization of coronary artery disease: 
comparison with planar imaging using quantitative analysis of myocardial 
thallium-201 distribution and washout after exercise. Am Heart J 1983; 
106:263-271. 
22. RHchle JL, HamiHon GW, Gould KL, Allen D, Kennedy JW, Hamrnennelsler 
KE. Myocardial imaging with indium-113m and technetiurn-99m macro-
23. ~~Y~,rn'~~. ~~~~i~F~fct~~~~~~;;:~~5~~:rt~8~H,Idoine J, collin R. 
Regional myocardial blood flow during hyperemia induced by contrast agent 
in patients with coronary artery disease. Am J Cardiol1976;38:416-421. 
24. Maser! A, L' Abbate A, Pesola A, Mlchelassl C, Marzilli M, DeNes M. Re-
gional myocardial perfusion in patients with atherosclerotic coronary artery 
disease at rest and during angina pectoris induced by tachycardia. Circu-
lation 1977;55:423-433. 
25. camon PJ. Measll'ement of regional myocardial perfusion by intracoronary 
Injection of xenon-133. In: Berman OS, Mason DT, eds. Clinical Nuclear 
Cardiology. New York: Grune & Stratton, 1981; 119-143. 
26. Vogel R, Le Free M, Bates S, O'Nelli W, Foster R, Kirlin P, Smith D, PIH 
B. Application of digital techniques to selective coronary arteriography: 
use of myocardial contrast appearance time to measure coronary flow 
reserve. Am Heart J 1984;107:153-164. 
27. Remme WJ, van Hoogenhuyze DCA, Storm CJ, Kruyssen HA, Krauss XH. 
Lactate extraction pattern during repeated ischemia in the human heart 
(abstr). J Mol Cell Cardiol1982;13:suppl 1:76. 
VTI.3. 
Temporal Relation of Changes in Regional Coronary Flow and Myocardial 
Lactate and Nucleoside Metabolism During Pacing-Induced Ischemia. 
W.J. Remme, R. van den Berg, M. Mantel, P.H. Cox, D.CA. van Hoogenhuyze, 
X.H. Krauss, C.J. Storm, DA.C.M. Kruyssen. 
Cardiology Department, Zuiderziekenhuis, 
and Sticares Foundation, 
Rotterdam. 
AmJCardiol1986; 58:1188-1194 
-197-
Temporal Relation of Changes in Regional Coronary 
Flow and Myocardial Lactate and Nucleoside 
Metabolism During Pacing-Induced Ischemia 
WILLEM J. REMME, MD, RIA VAN DEN BERG, MART MANTEL, PhD, 
PETER H. COX, PhD, DIEDERIK C.A. VAN HOOGENHUYZE, MD, 
X. HANNO KRAUSS, MD, COK J. STORM, MD, and DICK A.C.M. KRUYSSEN, MD 
The temporal relation between myocardial lactate 
and hypoxanthine metabolism and regional changes 
in krypton-81m perfusion during pacing-induced is-
chemia was studied in 17 patients with coronary ar-
tery disease (CAD). During incremental atrial pac-
ing, lactate production and hypoxanthine release 
occurred early and simultaneously, accompanied by 
ST -segment changes, but before angina and only 
few minutes after a significant (17%) reduction in 
krypton-81 m perfusion in areas with more than 
90% luminal diameter reduction. During maximal 
pacing heart rates, krypton-81m distribution de-
creased to 68 ± 7% of control in areas with more 
than 90% diameter reduction and to 80 ± 4% in 
70 to 90% reduction (both p <0.05 vs control). 
Maximal lactate production occurred 15 seconds af-
ter pacing (extraction -'15 ± 7% vs 16 ± 2% 
during control, p <0.05) and peak hypoxanthine re-
lease 1 minute after pacing ( 1::.. arteriovenous 
-2.64 ± 0.8 J.LM vs 0.08 ± 0.21 f.LM during con-
trol, p <0.05). Krypton-81m perfusion decreased in 
In humans, regional coronary flow changes are ob-
served at an early stage during incremental atrial pac-
ing, in areas with significant coronary artery disease 
(CAD) before general signs of ischemia, such as angi-
na, electrocardiographic changes or hemodynamic ab-
normalities occur.H Changes in myocardial lactate 
metabolism have been used for decades to indicate 
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20 of the 21 CAD areas. Angina, ST-segment 
changes, hemodynamic alterations and lactate pro-
duction occurred in 15, 14, 9 and 15 patients, re-
spectively. In contrast, hypoxanthine release was 
found in all cases. After pacing, lactate production 
and all general indexes of ischemia persisted for 
only 2 to 3 minutes. In contrast, krypton-81m perfu-
sion was still significantly reduced 5 minutes after 
pacing and was only accompanied by hypoxanthine 
release (1::.. arteriovenous -1.41 ± 0.6 J.LM, p 
<0.05 vs control). Therefore, although lactate pro-
duction and hypoxanthine release occur early and 
simultaneously during pacing-induced ischemia, 
closely following coronary flow changes in high-ste-
notic areas, hypoxanthine appears to be more sen-
sitive and consistent as indicator of ischemia. Per-
sistant reductions in krypton-81m perfusion and 
hypoxanthine release strongly suggest prolonged is-
chemia after cessation of pacing. 
(Am J Cardiol 1986;58:1188-1194) 
myocardial ischemia during pacing-induced stress in 
humans,5·6 and compared with angina or ST-segment 
changes, myocardial lactate production appears to be a 
better indicator when assessed at the appropriate time, 
e.g., 15 seconds after pacing.7 Myocardial ischemia 
also causes a significant release of nucleosides and 
oxypurines from the heart8-16-in humans predom-
inantly of hypoxanthine.14·16·17 Although results of 
animal and human studies suggest that lactate produc-
tion precedes nucleoside release during ische-
mia,11·14·18 the temporal relation between these meta-
bolic changes and alterations in regional coronary 
flow in man is unknown. Also, the relative sensitivity 
of both metabolites as indicators of myocardial ische-
mia in humans is controversial.14-16 We investigated 
the incidence of lactate production and hypoxanthine 
1188 
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release in humans during pacing-induced ischemia 
and the temporal relation of these metabolic changes 
to alterations in regional coronary flow. 
Methods 
Patients: Seventeen patients (14 men, 3 women), 
aged 37 to 64 years (mean 53), were included after they 
gave informed consent. Only patients with exercise-
induced myocardial ischemia or previous myocardial 
infarction were studied. Cardiac medication was with-
held 24 hours before study and none of the patients 
received drugs that can influence nucleoside metabo-
lism, e.g., dipyridamole. Studies were performed with-
out premedication after an overnight fast and carried 
out before routine coronary and left ventricular angi-
ography, using the Seldinger technique. Immediately 
before the study, 5,000 IU of heparin and 250 mg of 
acetylsalicylic acid were administered intravenously. 
A No. 7Fr Zucker bipolar pacing catheter was ad-
vanced from a brachial vein into the mid portion of the 
coronary sinus, such that its position was stable and 
blood could be drawn easily from the coronary sinus. 
Its position was established by way of a coronary ve-
nous angiogram, using 3 ml of Renografin 76®. Next, a 
No. 7Fr Swan Ganz thermodilution catheter was ad-
vanced from a femoral vein into a pulmonary artery 
for the recording of pulmonary wedge pressure. Final-
ly, a No. 7Fr Amplatz or Judkins left coronary artery 
catheter was positioned in the ostium of the left coro-
nary artery via a Desilet® introducer system in a femo-
ral artery. The sidearm of the Desilet system was used 
to sample arterial blood for lactate and hypoxanthine 
determinations and to record arterial pressures. After 
positioning of the coronary artery catheter, slow and 
rapid manual contrast injections were recorded in dif-
ferent views to determine whether selective injections 
in 1 of the branches of the left coronary artery oc-
curred. All angiographic information was stored on 
videotape to allow rechecking of the various of cathe-
ter positions throughout the study. After catheteriza-
tion, coronary angiograms were analyzed by 2 inde-
pendent cardiologists. Diameter reductions of more 
FIGURE 1. Top, schematic representation of intra-
coronary krypton-81m perfusion. Bottom, sequen-
tial imaging during incremental atrial pacing in a 
patient with normal coronary arteries. Studies 
were performed in the 45 ° left anterior oblique 
(LAO) position. CS =coronary sinus; LAD = left 
anterior descending coronary artery; LCX = left 
circumflex coronary artery. 
than 70"7o in 1 or more left coronary arteries were 
considered to indicate significant left CAD. This steno-
sis group was separated in 2 categories: patients with 
70 to 90% and and those with more than 90% diameter 
reduction. A coronary artery was considered normal if 
0 to 25% diameter reduction was present. Areas with 
25 to 70% diameter reduction were not included in the 
study. Concomitant right CAD was not an exclusion 
criterion if it did not interfere with left coronary flow. 
Patients with left main disease or collateral supply 
from the right coronary artery were excluded from the 
study. 
Scintigraphic procedures (Fig. 1): Scintigraphic 
procedures have been described elsewhere.4 Briefly, 
a sterile, pyrogen-free rubidium-31/krypton-31m per-
fusion generator was used, calibrated to deliver 20 
mCi, perfused with glucose 5% at a rate of 300 ml/hour 
with the eluate administered continuously into the left 
coronary artery. Planar imaging was performed in the 
45° left anterior oblique position during 15-second ac-
quisition periods, using a General Electric Portacam-
era®, connected on line with a Medical Data System A 2 
computer with energy detection set at 190 ± 20% ke V. 
In this study, krypton-31m distribution changes were 
measured in areas with significant CAD, regions with 
normal coronary arteries, total heart and background 
areas. Calculations were made of total counts per area, 
divided by total counts over the heart per time frame to 
account for possible fluctuations in krypton-31m sup-
ply to the heart. Changes in krypton-31m distribution 
were expressed as a percentage of control. 
Metabolic determinations: Blood (1 ml) was sam-
pled simultaneously from the coronary sinus and fem-
oral artery, transferred directly into precooled tubes 
containing 2 ml of ice-cold 0.6 M HC104, mixed thor-
oughly and kept on ice. Immediately after the study, 
the samples were weighed and centrifuged for 20 min-
utes at a speed of 2,000 X g and the supernatant frozen 
for the assay of hypoxanthine. Lactate was immediate-
ly determined in triplicate by the enzymatic technique 
as described by Guttman and Wahlefeld.19 The stan-
dard deviation of the determination in our laborato-
81RbfB1mKr 
GENERATOR 
CONTROL LAO 45' 120 BEATS/MIN 150 BEATS/MIN 
END PACING 
5MIN POST-
PACING 
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TABLE I Clinical and Anglographlc Data 
Angiographic Data 
Coronary % Diameter Reduction 
pt AP Previous Ml LAD LC RCA Collat LVEF (%) Wall Motion 
+ 0 70-90 70-90 0 70 N 
2 + 0 >90 <70 0 0 62 N 
3 + 0 >so 0 0 +LAD 49 Ant hk 
4 + Ant >90 >90 >so +LC 42 Ant hk/inf ak 
5 + Post >so >90 0 0 66 N 
+ 0 0 100 0 +LC 64 Post hk 
7 + 0 70-90 70-90 0 0 68 N 
8 + Ant 70-90 0 <70 0 54 Ant hk 
9 + Ant >90 <70 0 0 61 Ant hk 
10 + 0 0 70-90 0 0 60 N 
11 + 0 >90 >90 >so 0 59 Ant hk 
12 0 Ant 100 0 0 +LAD 47 Ant dk 
13 + Post >90 100 0 +LC 45 Post ak/ant hk 
14 + Post <70 100 0 0 45 Post hk 
15 + 0 70-90 0 0 0 57 N 
16 + 0 >90 0 0 0 50 Ant hk 
17 + Ant 100 70-90 0 +LAD 62 Ant hk 
ak = akinesia; ant = anterior; AP = preexisting angina pectoris or angina-like symptoms; collat = collateral 
filling from left coronary artery; dk = dyskinesia; EF = ejection fraction; hk = hypokinesia; inf = inferior; LAD 
= left anterior descending artery; LC = left circumflex artery; LV = left ventricular; Ml = myocardial infarction; 
n = normal; post = posterior; RCA = right coronary artery; + = present; 0 = absent. 
ry is 0.012 mmol/liter. Hypoxanthine was assayed 
by dual-column high-pressure liquid chromatography 
(first column: t<-Bondapak-C-18 [Waters Assoc.], re-
versed phase, and second column: Nucleosil-10 SA 
[Chrompack]l, using a Valco CV-6-UH Pa-N-60 valve 
as described by van Gennip et aP0 and 0.0025 M 
KH2P04 (pH 2.9) as mobile phase. Hypoxanthine was 
determined by UV detection (A. = 254 nm). The stan-
dard deviation of the determination is 0.2 t<M/liter. 
Electrocardiographic measurements: Leads I, II 
and V5 were monitored throughout the study. ST-seg-
ment changes were measured 0.03 second after the J 
point in 5 consecutive beats at a paper speed of 100 
mm/s. 
Study protocol: A stabilization period of 15 minutes 
was allowed after instrumentation. Thus, at least 30 
minutes was allowed between the last coronary angio-
gram and baseline measurements. Next, krypton-31m 
perfusion was monitored during one 10-minute obser-
vation period. The procedures to detect and correct for 
streaming artifacts are described in detail elsewhere.4 
Only patients in whom the baseline krypton-31m dis-
tribution pattern was stable entered the study. Multi-
ple control hemodynamic, metabolic and scintigraphic 
determinations were then made. Subsequently, atrial 
pacing was carried out with increments in heart rate of 
10 beats every 2 minutes until limiting angina or atrio-
ventricular block occurred or a maximal heart rate of 
170 beats/min was reached. All measurements were 
repeated during pacing at prefixed heart rates (100, 
120, 140, 160 and 170 beats/min), during angina or 
block, followed by determinations at 15 seconds and 1, 
2 and 5 minutes after pacing. 
Statistical analysis was performed using the Stu-
dent t test for paired values. All values are expressed 
as mean ± standard error of the mean. 
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Results 
Patient data and angiographic findings are listed in 
Table I. Fifteen patients had exercise-induced angina 
pectoris and 7 had electrocardiographic signs of an old 
myocardial infarction, all corresponding to areas of 
angiographically visible regional left ventricular wall 
motion disturbances. In another 5 areas hypokinesia or 
akinesia was present distal to a high-grade coronary 
artery lesion without electrocardiographic signs of in-
farction. All patients had more than 70o/o diameter 
reductions of 1 or more major branches of the left 
coronary artery, considered to be within the sampling 
area of the coronary sinus catheter; 14 areas with more 
than 90o/o and 9 with 70 to 90% diameter reductions. In 
3 patients right CAD was present as well, without col-
lateral supply from the left coronary artery. 
Control period: During the control period no clini-
cal signs of myocardial ischemia were found. Lactate 
metabolism was normal in all patients. However, sta-
ble, persistent reductions in krypton-81m distribution 
were found in 4 areas, all in regions with a left ven-
tricular wall motion abnormality, 3 of which corre-
sponded with an old myocardial infarct. Two patients 
with diminished krypton-31m distribution at rest pro-
duced hypoxanthine during the control period, with-
out other signs of ischemia or lactate production 
(Fig. 2). 
Pacing period: During pacing, 15 patients had angi-
na and 14 significant (more than 0.1 mV) ST-segment 
changes. Angina started at 131 ± 6 beats/min and ST-
segment changes (0.12 ± 0.04 mV, p <0.05 vs control) 
(Fig. 3) at 120 beats/min. 
Krypton-31m perfusion during pacing: A progres-
sive decrease in krypton-31m perfusion occurred in 22 
of the 23 regions with more than 70% stenosis. In areas 
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TABLE II Changes in Regional Coronary Flow and Myocardial Metabolism During and After Atrial Pacing 
Pacing Periods 
Control iOO beats/min i20 beats/min AP iS Sec P-P 1 Min P-P 5 Min P-P 
Blm Kr distribution (%) 
>90% areas (n = i4) iOO 83 ± 4.5' 77 ± 6' 68 ± r 78 ± 6' s; ± 6' 78 ± 5· 
70-90% areas (n = 9) iOO 96 ± 2 83 ± 3.5' 80 ± 4' 79 ± 3.5' 83 ± 4' 87 ± 3 
Lactate (mmol/liter) 
A 0.68 ± 0.04 0.72 ± 0.06 0.69 ± 0.06 0.69 ± 0.06 0.73 ± 0.06 0,7i ± 0.06 0.75 ± 0.07 
v 0.60 ± 0.04 0.65 ± 0.07 0.70 ± 0.08 o.74 ± o.o8· o.ss ± o. ;o· 0.72 ± o.o8· 0.65±0.ii 
Extraction (%) i6 ± 2 8±4 -i ± 5 -6 ± s· -i5±7' -3±7' i2 ± 5 
[(A-VIA) X iOO%] 
Hypoxanthine (,umol/liter) 
A i.69'± O.i i.58 ± 0.16 1.58 ± 0.15 i.67 ± O.ii i.84 :j: O.i8 i.86 ± O.i6 i.54 ± 0.2 
v i.64 ± O.i6 i.73 ± 0.2 2.62 ± 0.5. 3.73 ± 0.76' 5.52 ± ;.s8· 5.96 ± i.53' 2.96 ± 0.57' 
A-V difference 0.05 ± O.i7 0.45 ± 0.42 i.26 ± 0.42' 1.49 ± 0.4i' 2.i9 ± o.s· 2.64 ± 0.77' i.4i ± 0.57' 
• p <0.05 vs control; all values mean ± standard error of the mean. 
A = arterial; AP = maximal paced heart rates; P-P = postpacing; V = venous. 
with more than 90o/o stenosis, krypton·81m perfusion 
diminished early to 83 ± 4.5% of control (p <0,05), at 
100 beats/min, before angina or ST-segment changes, 
whereas in areas with 70 to 90% stenosis a significant 
reduction to 83 ± 3.5% of control was observed later, at 
120 beats/min, together with ST-segment changes but 
before the onset of angina (Fig. 3). During maximal 
heart rates (137 ± 5 beats/min) krypton-81m perfusion 
had further decreased to 68 ± 7% of control in areas 
with more than 90% CAD and to 80 ± 4% of control in 
70 to 90% regions [both p <0.05 vs control) [Table II). 
Metabolic changes during pacing: Arterial hypo-
xanthine and lactate levels remained unchanged 
CONTROL 
.I ·10 1-25 
·50 
0 
• 
CONTROL 
120 B/MIN 
I 
I 
120 B/MIN 
I 
I 
ANGINA 
END PACING 
(140 B/MIN) 
throughout the study [Table II). Coronary sinus hypo-
xanthine and lactate values progressively increased 
during pacing. Both were significantly elevated at 120 
beats/min, which resulted in simultaneous lactate pro-
duction and hypoxanthine release at this period [lac-
tate extraction -1 ± 5% vs 16 ± 2% [control) and 
difference in arteriovenous hypoxanthine -1.26 ± 
0.42 ,uM/liter vs 0.08 ± 0.17 ,uM [control) [both p <0.05). 
Thus, changes in lactate and nucleoside metabolism 
were only preceded by krypton-31m distribution 
changes in areas of severe [more than 90%) narrowing 
[Fig. 3). During maximal pacing rates, lactate produc-
tion increased to -6 ± 5% and the difference in arte-
END PACING (140 8/M!N) 
I 
I 
1 MIN P·P 
5 MIN P·P 
I 
I 
5 MIN P-P 
FIGURE 2. Krypton-81 m perfusion and metabolic changes In a patient with a 99% proximal stenosis In the left anterior descending coronary 
artery (LAD) (open arrow) and a 100% occlusion of the left circumflex artery (LC) (closed arrow) with anterograde collaterals and 
electrocardiographic signs of an old lateral infarction. At rest, there is decreased krypton-81m perfusion In the LAD and LC areas and 
significant hypoxanthine release, without other signs of ischemia. During pacing, krypton-81m perfusion decreases even more In both 
areas, accompanied by progressive metabolic changes, which persist 5 minutes after pacing (P-P), together with reduced krypton-81m 
perfusion to the LAD region, but despite an increase in (collateral) supply to the LC area. 
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riovenous hypoxanthine levels to -1,49 ± 0,41 f.LM/ 
liter. 
Postpacing period: Immediately after pacing pul-
monary capillary wedge pressures increased to 22 ± 3 
mm Hg (p <0.05 vs 13 ± 1 mm Hg at control), but only 
in 9 patients. Pressures had normalized already 1 min-
ute after pacing. Angina lasted for 2.2 ± 0.5 minutes 
after pacing and abnormal ST-segment changes for 2.3 
± 0.3 minutes. 
Krypton-31m distribution after pacing: In areas 
with more than 90o/o stenosis, krypton-31m perfusion 
increased slightly but significantly between the period 
of maximal pacing heart rates and after 1 minute post-
pacing, whereas no changes in occurred areas with 70 
to 90% stenosis during this period. At 5 minutes after 
pacing, krypton-31m distribution was still significantly 
reduced (73 ± 5%) in areas with more than 90% steno-
15 
~ 
sis (p <0.05 vs control) but no longer in areas with 70 to 
90% stenosis (37 ± 3o/o, difference not significant vs 
control). 
Metabolic changes after pacing: Maximal release 
of both metabolites occurred 'after pacing. Lactate pro-
duction values were highest 15 seconds after pacing 
(lactate extraction -15 ± 7%, p <0.05 vs control) and 
maximal hypoxanthine release occurred 1 minute af-
ter pacing (.t. arteriovenous -2.64 ± 0.3 f.LM/liter, p 
<0.01 vs control). Lactate production occurred in 15 
patients, whereas significant hypoxanthine release (.t. 
arteriovenous more than -0.4 JLM/liter) was observed 
in all17 patients. Changes in lactate metabolism were 
brief and had disappeared 2 minutes after pacing. In 
contrast, significant hypoxanthine release was still 
present 5 minutes after pacing (.t. arteriovenous -1.4 ± 
0.6 JLM/liter, p <0.05 vs control). An example of persis-
~lOOtE~-~-=-~---~~~------------------------------------------
0 N.S. -- * ~ ---·------.i. _____ -:J*~==-===4~----Q 
75 
•-- -•70-90<11> stenosm orens 
(n~9) 
B _--~=""'-:1 -----.,. -----,---------------, -,..-----------, ---, 
~~ 
~~ ·3 
I"-
!'·'~ n· . r~-r=~=-----Ln-'------'-0--L.--------'------'---'-__L_----LO-'---=rs 
" ~ 0.1 
FIGURE 3. Temporal relation of krypton-81m distribution changes, myocardial lactate production and hypoxanthine release and general 
indexes of ischemia during and after incremental atrial pacing (P-P). Although lactate and hypoxanthine are produced early and 
simultaneously, only preceded by krypton-81m perfusion changes in areas with more than 90% stenosis, maximal lactate production and 
hypoxanthine release occur at 15 seconds and 1 minute after pacing, respectively, irrespective of krypton-81m distribution changes. After 
pacing, both a reduction in krypton-81m perfusion (in areas with more than 90% stenosis) and hypoxanthine release persist, indicating 
ongoing flow reduction and ischemia. N.S. = not significant. 
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tent reduction in poststenotic krypton-81m perfusion 
and ongoing hypoxanthine release is shown in Figure 
4. 
Discussion 
Changes in myocardial metabolism and coronary 
flow during pacing: In the present study a close tem-
poral relation was found between changes in postste-
notic regional coronary flow and myocardial metabo-
lism during pacing-induced ischemia. This, to our 
knowledge, has not been investigated in humans, per-
haps because in humans repetitive measurements of 
regional coronary flow changes at short intervals are 
difficult to carry out. We recently described a tech-
nique using intracoronary krypton-81m that permits 
continuous determination of changes in regional coro-
nary flow pattern.3.4 In the previous studies,3.4 a pro-
gressive decrease in krypton-81m distribution was 
seen in areas with more than 70o/o CAD. These 
changes occurred well before the onset of angina, sug-
gesting that angina is a late phenomenon in ischemia. 
Although angina is usually considered the standard for 
ischemia, changes in lactate metabolism, particularly 
when measured 15 seconds after pacing-induced 
stress, are more sensitive as a marker of myocardial 
ischemia? Whether this also implies that lactate pro-
duction in humans is an early event after coronary 
flow reduction and onset of ischemia is unknown. 
Changes in myocardial lactate and nucleoside metab-
olism during ischemia and the temporal relation with 
coronary flow reductions have been studied exten-
sively in animal experiments. Although myocardial 
adenine nucleoside accumulation and release from 
the heart occurs soon after the onset of coronary flow 
reduction, the results of some studies indicate that 
myocardial lactate production is an earlier event dur-
z 
ing ischemia than adenine nucleotide breakdown and 
that lactate efflux from the heart precedes myocardial 
nucleoside release.11•18 In a previous study in humans, 
we reported that during pacing-induced ischemia lac-
tate production also occurs early, before hypoxanthine 
release.14 In the latter study significant hypoxanthine 
changes were only found after angina had developed, 
whereas in the present investigation hypoxanthine re-
lease occurred early, simultaneously with lactate pro-
duction, and before the onset of angina. This apparent 
discrepancy may be explained by the fact that in the 
early study an enzymatic method was used, which did 
not differentiate between xanthine and hypoxanthine. 
Small but significant early elevations in hypoxanthine 
may have therefore remained unnoticed in the (hypo-
xanthine] xanthine pool. With the present method the 
hypoxanthine and xanthine peaks are measured sep-
arately. The value of this method has already been 
reported,16•20 and although several adaptations were 
incorporated in our own assay technique, it is compa-
rable to the method of Harmsen et aP6 Of the different 
nucleosides, only hypoxanthine could be measured in 
adequate amounts. Because of high activity of adeno-
sine deaminase and nucleoside phosphorylase and 
subsequent fast turnover of adenosine and inosine to 
hypoxanthine in humans, these intermediate metabo-
lites of nucleoside metabolism could only be detected 
in amounts too small to make them useful for diagnos-
tic purposes (unpublished data]. This is in accordance 
with the results of our previous study14 and the work of 
other investigators.16 
Validity of hypoxanthine and lactate as ma .... kers 
of ischemia in humans: The present investigation sug-
gests that hypoxanthine is a more sensitive indicator of 
ischemia than lactate, for a variety of reasons. First, 
although changes in coronary flow occurred in all pa-
I,::Jf--____LD_L__ _________ ------; ________ __LD_L___ 
:s "40 
CONTROL 100 8/MlN END PACING 15SECP-P 
(120 8/MINl 
• I 
5 MIN P-P 
h~j i:§~ 
(L 
s: -2 
0 
I 
CONTROL 100 8/MIN 
I 
ANGINA 
END PACING 
(120 8/MIN) 
I I 
15SEC P-P 5 MIN P-P 
FIGURE 4. Typical changes in krypton-81 m distribution, lactate and hypoxanthine metabolism in a patient with a proximal 90% stenosis of 
the left anterior descending artery (LAD). Early during pacing, krypton-81m distribution decreases over the LAD area, together with lactate 
and hypoxanthine release, but before angina. After pacing (P-P), both the krypton-81m perfusion defect and hypoxanthine release persist, 
indicating ongoing (silent) ischemia despite normalization of lactate metabolism. 
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tients, myocardial lactate production was only ob-
served in 15. In contrast, significant hypoxanthine re-
lease occurred in all17 patients. Second, whereas the 
arterial levels of both metabolites did not change dur-
ing the study, the percent increase in coronary venous 
hypoxanthine levels greatly exceeded the concomitant 
alterations in coronary venous lactate levels, both dur, 
ing and after pacing. Finally, in 2 of the 4 patients with 
diminished krypton-31m perfusion during control 
conditions, and thus, presumably, a reduction in re-
gional coronary flow, hypoxanthine release was the 
only indication of ischemia at rest. 
Changes in myocardial metabolism and coronary 
flow after pacing: At least 5 minutes after pacing, 
krypton-31m perfusion was still reduced in areas with 
more than 90o/o stenosis. We previously reported this 
observation.M At that time after pacing, all general 
indexes of ischemia, such as angina and electrocardio-
graphic and hemodynamic changes, were no longer 
present for several minutes at least. 
Likewise, lactate metabolism had normalized be-
tween 1 and 2 minutes after pacing. In contrast, signifi-
cant amounts of hypoxanthine were still released 5 
minutes after pacing, suggesting ongoing (silent) myo-
cardial ischemia, despite normalization of myocardial 
oxygen demand after pacing. This indicates that at this 
stage other factors are involved, which maintain ische-
mia after pacing-induced stress. The ongoing hypo-
xanthine release after pacing supports the hypothesis 
that persistent changes in coronary flow after pacing 
may be caused by continuing adenosine production in 
the poststenotic area.4 Prolonged ischemia or reduc-
tions in regional coronary flow after stress testing were 
reported by Selwyn and et al,21 who observed abnor-
mal rubidium-32 uptake persisting for as long as 20 
minutes after stress testing in some of their patients. 
Whether this was caused by a continuous reduction in 
regional flow or by a persistent reduction in cellular 
uptake of rubidium-32 is unclear. Although our data 
suggest persistent reductions in coronary flow in the 
postpacing period, more extensive studies are needed 
to evaluate the duration of coronary flow reductions 
after stress testing. 
Clinical implications: Our data suggest that hypo-
xanthine is more sensitive as a marker of ischemia 
than either lactate, angina or ST -segment changes. In 
contrast to lactate, it is still released during longer peri-
ods of ischemia. Hypoxanthine, therefore, should be 
a valuable indicator of longer lasting periods of 
ischemia in humans and may be useful to validate 
interventions during the early phase of infarction. The 
observation in this study of persistent perfusion abnor-
malities and ischemia after pacing emphasizes the ne-
cessity of sufficiently long intervals between repetitive 
atrial pacing stress tests to allow for reproducibility of 
pacing-induced ischemia.zz 
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Chapter Vlll: 
ASSESSMENT OF THE ACUTE ANTIISCHEMIC PROPERTIES OF 
VASOACTIVE COMPOUNDS IN MAN FOCUSING ON METABOLISM. 
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Acute Hemodynamic and Antiischemic Effects 
of Intravenous Amiodarone 
WILLEM J. REMME, MD, DIEDERIK C.A. VAN HOOGENHUYZE, MD, 
X. HANNO KRAUSS, MD, ALBERT HOFMAN, PhD, 
DICK A.C.M. KRUYSSEN, MD, and COCK J. STORM, MD 
The acute hemodynamic and antiischemic proper-
ties of amiodarone were investigated in 16 patients 
with more than 70% diameter reduction of a left 
coronary artery. Two successive atrial pacing stress 
tests (APST I and II) were performed, with an in-
terval of 40 minutes in between, and amiodarone, 
5 mg/kg/5 min, was infused 30 minutes after APST 
I. Hemodynamic changes during amiodarone ad-
ministration consisted of a 20% decrease in left 
ventricular (LV) systolic pressure, a 13% decrease 
in systemic vascular resistance and an 18% de-
crease in stroke work. Coronary vascular resistance 
was reduced 19% and coronary sinus flow in-
creased 23%. Despite a secondary 14% increase 
in heart rate, contractility decreased 21%, ac-
companied by a 45% increase in LV end-diastolic 
pressure, which persisted until APST II. Although 
most hemodynamic changes were observed only 
Amiodarone, widely used as an antiarrhythmic agent, 
was originally introduced as an antianginal compound,1 
primarily because of its hemodynamic properties, which 
indicate that it has the potential to reduce myocardial 
ischemia. In the intact animal it reduces vascular re-
sistance and after load, and increases coronary flow as 
a result of its smooth-muscle relaxing properties,2-5 
while, in addition to its negative chronotropic activity, 
it reduces contractility as well at the higher dose levels.6 
Thus, the myocardial oxygen supply/demand ratio is 
favorably altered and myocardial oxygen consumption 
reduced. Although the results of the various animal 
studies are similar, the hemodynamic changes by the 
same intravenous dose in humans varies from study to 
From the Department of Cardiology, Zuiderziekenhuis, Rotterdam, The 
Netherlands. This study was supported in part by a grant of the Sticares 
Foundation. Rotterdam, The Netherlands. Manuscript received Sep-
tember 12, 1984; revised manuscript received November 30, 1984, 
accepted December 4, 1984. 
Address for reprints: Will em J. Remme, MD, Department of Cardi-
ology, Zuiderziekenhuis. Groene Hilledijk 315, 3075 EA Rotterdam, The 
Netherlands. 
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during the infusion, contractility and LV systolic 
pressure were still diminished at the beginning of 
APST II and remained so during pacing, resulting in 
a reduction in myocardial oxygen demand compared 
to APST I. Although overall myocardial oxygen 
consumption and coronary flow were equal during 
both pacing tests, amiodarone significantly reduced 
pacing-induced myocardial ischemia. Lactate me-
tabolism remained normal during APST II (lactate 
extraction 12 ± 3% vs -28 ± 8% (APST I) at 
maximal pacing rates [p < 0.05]), while ST-segment 
depression, LV end-diastolic pressure postpacing 
and angina were also significantly reduced during 
APST II. Thus, in humans, intravenous amiodarone 
reduces vascular resistance and contractility and 
inhibits pacing-induced myocardial ischemia, pre-
sumably by reducing myocardial oxygen demand. 
(Am J Cardiol1985;55:639-644) 
study.7-9 In addition, the effect of these hemodynamic 
changes on myocardial ischemia in humans has not been 
investigated. In this study, the instantaneous cardio-
vascular actions of amiodarone in patients with coro-
nary artery disease, as well as the effects on pacing-
induced myocardial ischemia, were investigated. 
Methods 
Patients: We studied 16 patients (15 men and 1 woman), 
aged 42 to 67 years (mean 53) with stable, exercise-induced 
angina pectoris and objective signs of ischemia during stress 
testing. All cardiac medication except short-lasting nitro-
glycerin was withheld 48 to 72 hours before the study. Cath-
eterization was performed without premedication for the 
patient and after an overnight fast. To participate, a stenosis 
of more than 70% in the left anterior descending artery, the 
left circumflex artery or proximal marginal branches had to 
be present, thus ensuring that venous blood from the stenotic 
area was collected by the coronary sinus catheter. Three pa-
tients had 1-vessel, 9 had 2-vessel and 4 had 3-vessel disease. 
Left ventricular (LV) ejection fraction was slightly decreased 
(47 ± 4%) and LV end-diastolic volume index was normal (81 
± 8 ml/m2 ) (Table I). 
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TABLE I Patient Characteristics 
% Diameter Reduction 
Pt Age (yr) & Sex Previous Ml LVEDV (mlfm2) LVEF (%) LAD LC RCA 
1 57M 0 94 61 80 90 0 
2 58F 0 61 63 80 90 + 100 0 
3 54M lnf 97 22 70 0 100 
4 53M lnf 37 70 90 0 100 
5 59M lnf 150 38 70 80 90 
6 67M Ant 76 35 100 100 0 
7 51M lnf 74 34 70 + 90 0 100 
8 42M 0 46 51 80 0 100 
9 56M 0 89 25 99 90 100 
10 55M 0 42 50 80 + 90 90 60 
11 50M lnf 89 44 0 80 90 
12 47M 0 80 60 100 0 70 
13 50M Ant 48 49 80 90 99 
14 53M Ant 115 23 100 0 0 
15 50M Ant 67 67 100 70 + 90 0 
16 57M 0 81 51 90 0 0 
Mean 53± 2 78± 7 46± 4 
±SEM 
Ant = anterior; lnf = inferior; LAD = left anterior descending coronary artery; LC = left circumflex artery; L VEDV = left ventricular end-diastolic 
volume; LVEF = left ventricular ejection fraction; Ml = myocardial infarction; RCA = right coronary artery; SEM = standard error of the mean. 
Catheterization procedures: After routine left and .right 
coronary arteriography was carried out using the Seldinger 
technique, a No. 7Fr Millar micromanometer catheter was 
positioned in the left ventricle using a Desilet system in the 
femoral artery. The side arm of this Desilet system was used 
to record aortic pressures. A No. 7Fr Swan Ganz catheter was 
advanced through a femoral vein with its tip in a pulmonary 
artery and its proximal lumen in the right atrium. Then, a 
thermodilution pacing catheter (Wilton Webster Laboratory) 
was placed with its tip in the mid portion of the coronary sinus, 
such that its position was stable and blood could be drawn 
from the coronary sinus quickly enough to allow a rapid se-
quence of blood samples to be collected. 
Measurements: After positioning, the catheters were cal-
ibrated using a 0 reference level set at mid chest. The micro-
manometer pressures were balanced to 0 and calibrated with 
the fluid-filled system. Recordings of pressures and LV dP/dt 
were made on paper in the appropriate pressure ranges, using 
a CGR 1000 Cath Lab system. Cardiac output was measured 
by the thermodilution technique. All pressures and pres-
sure-derived contractility indexes (LV peak dP/dt pos, dP/ 
dt/P at 40 mm Hg (VCE40) and Vmax total pressure) as well 
as cardiac output were determined online by a Mennen-
Cathlab computer system. Calculations were made from 12 
consecutive beats. Coronary sinus blood flow was determined 
with the continuous infusion thermodilution method as 
originally described by Ganz et aJ. 10 Thirty to 35 ml of glucose 
5% at room temperature was infused over 30 seconds into the 
coronary sinus. During the infusion both the mean and pul-
satile flow were recorded simultaneously and measurements 
were made during midrespiration after the mean flow curve 
had stabilized. The external thermistor was always well inside 
the coronary sinus ostium to prevent atrial reflux interfering 
with the flow measurements. This was confirmed by a bolus 
injection of saline solution into the right atrium. A coronary 
venous angiogram using 3 ml of Renografin 76" was recorded 
on a video disk to allow rechecking of the position of the 
catheter tip during the investigation. 
Metabolic and electrocardiographic measurements: 
Simultaneous sampling of 2 ml of blood for lactate essay was 
performed from the coronary sinus and left ventricle which 
was then directly transferred into tubes containing 2 ml of 
ice-cold 8% HC104, thoroughly mixed and kept on ice. After 
centrifugion, lactate was determined as described by Guttman 
and Wahlefeld. 11 Venous and arterial 0 2 saturation values 
were measured using an American Optical oximeter. 
ThToughout the studies leads I, II and V 5 were continuously 
monitored, and ST-segment changes, 0.08 second after the 
,J point, measured in 5 consecutive beats at a paper speed of 
50mm/s. 
Calculations: From the measured values, the following 
calculations were made: coronary vascular resistance (mean 
arterial pressure/coronary sinus blood flow); myocardial 0 2 
consumption or uptake (difference in arterial and coronary 
sinus Oz content X coronary sinus blood flow); modified 
tension-time index or double product, an index of myo-
cardial 0 2 demand (heart rate X LV systolic pressure). Sys-
temic vascular resistance, derived as 80 (arterial mean pres-
sure - atrial mean pressure)/cardiac output; pulmonic vas-
cular resistance. derived as 80 (pulmonary mean pressure -
LV mean diastolic pressure)/cardiac output: stroke work 
index was expressed as stroke index (mean aortic pressure -
LV end-diastolic pressure) X 0.0136. Myocardial lactate ex-
traction (%), derived as 100 (arteriocoronary sinus/arterial 
lactate concentration). 
Study protocol: After positioning of the catheters, a sta-
bilization period of at least 15 minutes was allowed to reach 
a minimum interval of 30 minutes between coronary angiog-
raphy and the study. Multiple control determinations of all 
variables were then made to ensure a stable baseline. Then, 
the first atrial pacing stress test (APST I) was carried out with 
increments in heart rate of 10 beats/2 minutes until angina, 
atrioventricular block or a maximal heart rate of 170 beats/ 
min. All variables were again determined at prefixed heart 
rates during pacing (e.g., at 100, 120, 140 and 160 beats/min), 
during angina or block, followed by measurements 15 seconds, 
1. 2 and 5 minutes after pacing. After a 25-minute stabilization 
period after APST I, control measurements were carried out 
and at 30 minutes after APST I, amiodarone (5 mg/kg body 
weight) was infused over 5 minutes. All determinations were 
repeated at 1, 3 and 5 minutes after the onset of amiodarone 
administration, followed by measurements 5 minutes after 
the infusion. A second atrial pacing stress test (APST II) was 
carried out in an identical fashion as APST I. To ensure 
identical pacing heart rates. the patients received 0.5 mg at-
ropine before each APST. 
Statistical analysis: Our data-analytic approach was 2-
fold. First, the measurements during and after amiodarone 
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TABLE II Systemic Hemodynamic Changes During Amiodarone Administration 
During Amiodarone Infusion 
5 min After 
Control 1 min 3min 5 min Infusion 
HR (beats/min) 78 ± 4 84 ± 4.5' 89 ± 4* 87 ± 4* 77 ± 3 
LVSP (mm Hg) 141 ± 6 123 ± 6* 113±4' 118 ± 5' 128 ± 5' 
MAP(mm Hg) 103 ± 4 96 ± 3* 87±3' 92 ± 3* 99 ± 3 
CO (liters/min) 4.8 ± 0.3 4.9 ± 0.2 
SVR (dynes s cm-5) 1,698 ± 76 1,475±84' 
Sl (mllbeat!m2) 31 ± 2 30 ± 2 
SWI (g/mfm2) 39 ± 3 32 ± 3' 
LV peak dP/dt pos (mm Hg s-1) 1,789±61 1,609 ± 109 1,543 ± 120* 1,419 ± 100* 1,355 ± n· 
Vmax(s-1) 49 ± 3 46 ± 2 49 ± 3 44 ± 2' 40 ± 3' 
VCE 40 (s- 1) 34± 2 32 ± 2 32 ± 3 28 ± 2' 27 ± 2* 
L VE[)P (mm Hg) 11±1 10 ± 1 12± 1 15 ± 2* 16 ± 2' 
PAS ;mmHg) 25 ± 1 26 ± 2 31 ± 2 32 ± 2' 32 ± 1* 
PAD (mm Hg) 13 ± 1 14± 1 17 ± 1' 17 ± 1' 17 ± 1' 
PVR (dynes s cm-5) 202 ± 16 220 ± 14 
• p <0.05 vs control. 
CO = cardiac output; HR = heart rate; LVEDP = left ventricular. end-diastolic pressure; LVSP = left ventricular systolic pressure; MAP = mean 
aortic pressure; PAD= diastolic pulmonary artery pressure; PAS·= systolic pulmonary artery pressure; PVR =pulmonary vascular resistance; 
Sl = stroke index; SVR = systemic vascular resistance; SWI = stroke work index. 
TABLE Ill Coronary Hemodynamic Changes During Amiodarone Administration 
During Amiodarone Infusion 
5 min After 
Control 1 min 3min 5 min Infusion 
CSBF (mllmin) 127 ± 11 146 ± 13* 153± 13* 152 ± 15' 139 ± 13 
CVR (mm Hg/ml/min) 0.9 ± 0.1 0.7 ± o.o5· o.6 ± o.o5· o.7 ± o.o5· 0.8 ± 0.1 
t,A-CS 0 2 content (vol%) 7.2 ± 0.3 6.5 ± 0.4- 5.4 ± 0.4' s.a ± o.s· 7.2 ± 0.4 
MV02 (mllmin) 9.1 ± 0.9 ·9.3 ± 0.9 8.1 ± 1 8.3 ± 0.8 9.5 ± 1 
TTl (HR X L VSP X 1 o-s) 10.4 ± 0.5 10.1 ± 0.4 9.9 ± 0.5 10.1 ± 0.5 102 ± 0.6 
• p <0.05 vs. control. 
A =arterial; CS =.coronary sinus; CSBF = coronary sinus blood flow; CVR = coronary vascular resistance; HR = heart rate; LVSP = left ventricular 
systolic pressure; MV02 = myocardial oxygen consumption; Til = modified tension-time index or double product. 
administration were compared with baseline (control) value. 
A t test for paired observations with 11 degrees of freedom was 
used, as the objective of this analysis was to test differences 
with the baseline observation. A 2-tailed p value <0.05 was 
considered significant. 
Second, comparisons of measurements during atrial pacing 
before and after amiodarone administration were made, again 
using at test for paired observations, with a 2-tailed p value 
<0.05 indicating a significant difference from 0. All values are 
expressed as mean ± standard error of the mean. 
Results 
Systemic hemodynamic changes during ami-
odarone infusion: The systemic hemodynamic effects 
of amiodarone are given in Table II. During the infusion 
an immediate decrease in LV systolic and aortic pres-
sures was observed with a maximal decrease of 20% and 
16% during the third minute of amiodarone adminis-
tration. LV systolic pressure was still reduced 5 minutes 
after the infusion. At the end of the infusion systemic 
vascular resistance and stroke work index had decreased 
l:Wo and 18% from their control values (p <0.05), while 
cardiac output and stroke index remained unchanged. 
Heart rate increased immediately, with a 14% increase 
at the third minute of infusion (p <0.05 vs control). 
These changes lasted a short time and had returned to 
baseline levels 5 minutes after amiodarone adminis-
tration. In contrast to the early and short-lasting in-
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crease in heart rate, a significant decrease in contrac-
tility occurred later during the infusion, which was 
longer lasting with a maximal reduction 5 minutes after 
amiodarone (Vmax 18% and VCE40 21% vs control). 
Concomitant with these changes in contractility, LV 
end-diastolic pressure increased significantly, from 11 
± 1 mm Hg (control) to 15 ± 2 mm Hg at the end of the 
infusion and to 16 ± 2 mm Hg 5 minutes after ami-
odarone administration. Sy~tolic and diastolic pulmo-
nary pressure increased from 25 ± 1 and 13 ± 1 mm Hg 
before amiodarone to 32 ± 1 and 17 ± 1 mm Hg 5 min-
utes after amiodarone administration (p <0.05). Pul-
monary vascular resistance did not change. 
Coronary hemodynamic changes during ami-
odarone (Table Ill): Coronary vascular resistance 
decreased immediately during amiodarone adminis-
tration, with a maximal change of 19% (p <0.05). Cor-
onary sinus blood flow increased significantly with a 
maximal 23% increase during the third minute. These 
changes were short-lasting and only found during am-
iodarone adminis1ration. Although during the same 
period the difference in arterial and coronary sinus 0 2 
content diminished by 27% (p <0.05 vs control), myo-
cardial oxygen consumption remained unchanged, as 
did myocardial oxygen demand. 
Effects of amiodarone on hemodynamics during 
atrial pacing stress tests (Table IV): During both 
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TABLE IV Effects of Amiodarone on Hemodynamics During Atrial Pacing Stress Test 
Control 100 beats/min 120 beats/min AP 1 min P-P 2 min P-P 5 min P-P 
LVSP (mm Hg) I 145 ± 5 142± 5 139 ± 7 146± 8 149 ± 7 149 ± 8 137 ± 6 
II 128 ± 5· 131 ± 5• 126 ± 5• 129 ± 5• 137± 5• 136 ± 6. 129 ± 6. 
Til (X 10-3 ) I 11.6 ± 0.6 14.3 ± 0.5 17 ± 0.8 20.7 ± 1.0 11.4±0.7 11.6 ± 0.8 10 ± 0.4 
II 10.2 ± 0.6• 13.2 ± o.5· 15 ± 0.6· 17.5 ± 0.9· 10.6 ± 0.6 10.4 ± 0.6· 10.2 ± 0.6 
LV dP/dt pas I 1,788 ± 93 1,904 ± 91 2,066 ± 165 2,099 ± 132 1,828 ± 121 1,821 ± 117 1,594 ± 94 
(mm Hg s-1) II 1,355 ± n· 1,323 ±52. 1,547 ± 72. 1,675 ± 124. 1,605 ± 126. 1,423 ± 68. 1,478 ± 70 
VCE40 (s- 1) I 35 ± 2 38 ± 2 39 ± 2 42 ± 2 35 ± 2 33± 2 31 ± 1.5 
II 26± 2. 26 ± 1. 32 ± 2. 35 ± 3• 31 ± 2.5· 29 ± 2. 29 ± 1.5 
CSBF (ml/min) I 137 ± 11 152 ± 15 159 ± 14 178 ± 15 152 ± 12 135 ± 13 131 ± 10 
II 139 ± 13 144± 13 158 ± 16 164± 13 146± 15 135 ± 14 144 ± 16 
CVR (mm Hg/ml/min) I 0.83 ± 0.06 0.71 ± 0.08 0.72 ± 0.05 0.68 ± 0.07 0.7 ± 0.04 0.81 ± 0.08 0.8 ± 0.05 
II 0.78 ± 0.06 0.77 ± 0.07 0.73 ± 0.08 0.68 ± 0.05 0.81 ± 0.07 0.79 ± 0.07 0.83 ± 0.08 
MV02 (ml/min) I 9.8 ± 0.9 10.7 ± 1.1 11.5 ± 1.1 12.2 ± 1.2 9.1 ± 0.9 9 ± 0.9 
II 9.5 ± 1 9.9 ± 1 10.9 ± 1.1 11.7 ± 0.8 9.2± 1.4 9.4 ± 1 
• p <0.05 APST I (before amiodarone) vs APST II (after amiodarone). 
AP = end of pacing due to angina or block; CSBF = coronary sinus blood flow; CVR = coronary vascular resistance; LVSP = left ventricular 
systolic pressure; P-P = post-pacing; Til =tension-time index; I =first atrial pacing stress test; II =second APST. 
APSTs maximal heart rates were comparable: 144 ± 6 
beats/min during APST I and 141 ± 6 beats/min during 
APST II. The tension-time index, however, was sig-
nificantly diminished throughout APST II because of 
a reduction in LV systolic pressure. Contractility, al-
ready diminished after amiodarone administration, 
remained significantly decreased during APST II. The 
reduction in tension-time index and contractility and, 
thus, in myocardial oxygen demand, did not result in 
significant changes in coronary sinus blood flow, coro-
nary vascular resistance or overall myocardial oxygen 
consumption. 
Effects of amiodarone on pacing-induced ische-
mia: Amiodarone clearly inhibited the development and 
extent of myocardial ischemia. During APST I myo-
cardial lactate production was already evident at 120 
beats/min before angina, increasing to -28 ± 8% at the 
end of pacing and to a maximal value of -41 ± 18% 15 
seconds after pacing (Fig. 1). In contrast, during APST 
II after amiodarone administration mean lactate ex-
traction values remained positive, although in a few 
patients some lactate production was found immedi-
ately after pacing. Individual lactate production values 
were, however, always less during APST II than during 
Lactate 
extraction 
40 (":~'""""') --~~,, 
C 1 DO/min 120/min AP 15 sec P·P 1' P-P 2' P-P 5' P-P 
FIGURE 1. Lactate extraction pattern during atrial pacing stress test 
(APST) before and after amiodarone administration. During the first 
stress test (APST 1), before amiodarone, lactate production is present 
at 120 beats/min and increases to a peak value of -41 ± i 8.4% 15 
seconds after pacing. During the second test (APST II), after amiodar-
one, there is a significant improvement in metabolism with lactate 
extraction values throughout the atrial pacing stress test. AP = maximal 
pacing rate; P-P = postpacing. •p <0.05. 
APST I. In addition, ST-segment changes were signif-
icantly less during APST II (0.17 ± 0.04 vs 0.26 ± 0.04 
m V during APST I) (Fig. 2). Also, there was less eleva-
tion in LV end -diastolic pressure immediately after 
pacing during APST II (17 ± 2 vs 22 ± 1.8 mm Hg dur-
ing APST I, p <0.05) (Fig. 3). 
Finally, 14 patients complained of angina during 
APST I; during APST II, symptoms were absent in 8 
patients, less severe in 4 and similar in 4. 
Adverse effects: Amiodarone was generally well 
tolerated. Some patients experienced a warm feeling 
and facial flushing. In 2 patients (nos. 6 and 13), lactate 
production occurred during the last minute of infusion 
and 5 minutes after infusion, accompanied by ST-
segment changes and a short-lasting period of angina 
in patient 6. 
Discussion 
Amiodarone, a benzofuran derivate, was shown in this 
study to have important hemodynamic and anti-
ischemic properties in humans when given intrave-
nously. These acute hemodynamic changes consist of 
an immediate reduction in systemic and coronary vas-
cular resistance, a decrease in LV systolic and aortic 
pressures and in cardiac work, an increase in coronary 
blood flow and a reduction in the difference in arterial 
and coronary sinus 02 content. Although a short-lasting 
increase in heart rate is observed, a later, but longer-
lasting reduction in contractility occurs with an eleva-
tion of LV filling pressure. 
C 100/ 120/ AP 15 sec 1' P-P 2' P-P 5' P-P 
min min P-P 
FIGURE 2. ST -segment depression values during pacing before and 
after amiodarone administration. There is significantly less ST-segment 
depression during the second atrial pacing stress test (APST II), after 
amiodarone. AP = maximal pacing rate; P-P = postpacing. • p 
<0.05. 
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These cardiovascular effects compare well with he-
modynamic changes in the intact animaP-6 Some dif-
ferences exist, however. In the animal studies, the 
vasodilating effect is more prominent in the coronary 
than in the systemic vasculature, with major changes 
in coronary resistance and flow and only a moderate 
decrease in systemic resistance and afterload.4,5,12 In the 
present study, the magnitude of changes in afterload 
and coronary blood flow were comparable. 
Also, as amiodarone has negative chronotropic ac-
tions, heart rate has been reported to decrease in animal 
studies, in contrast to our study results, in which an 
increase was found, presumably secondary to the de-
crease in afterload. This also suggests that in humans, 
the vasodilating effect on the systemic vasculature is 
more important than in the intact animal model. 
However, one must be cautious with this deduction 
because the hemodynamic changes in man are a con-
sequence of the combined effects of amiodarone and its 
solvent, Tween 80, whereas in the animal studies pure 
amiodarone is used. 
The acute hemodynamic effects of intravenous ami-
odarone in humans have been studied by other inves-
tigators using an identical dose.7-9 The rate of admin-
istration, however, varied from 1 to 4 minutes. Also, 
various types of patients, as well as normal persons, were 
studied. Although this may explain the dissimilarity in 
the results of some of these studies, in 2 of these inves-
tigations the same rate of infusion was used in the same 
type of patients. Still, opposing hemodynamic effects 
were reported.7.9 
This apparent dissimilarity was one of the reasons for 
conducting the present investigation. Only patients with 
coronary artery disease were studied and dose and rate 
of administration chosen on purpose, as this regimen, 
followed by a 1,500-mg infusion over 24 hours, was ef-
fective in patients with ventricular tachycardias (un-
published observation). 
Patients with a diminished LV ejection fraction were 
not excluded from the study, because in clinical practice 
patients receiving amiodarone for acute ischemia are 
likely to have a diminished ventricular function as well. 
Theoretically, in these patients the reduction in con-
tractility and increase in LV filling pressure during the 
amiodarone bolus infusion may induce a deterioration 
of LV function and an aggrevation instead of an im-
provement of myocardial ischemia. In this study this 
was only observed in 1 out of 6 patients with a LV 
ejection fraction less than 40%, indicating that ami-
odarone may be given safely even to patients with di-
minished ventricular function. Whether this still holds 
true under less stable circumstances, i.e., ischemia or 
infarction, must be further investigated. 
The hemodynamic changes observed in this study 
could be partially caused by the solvent Tween 80. 
Sicart et al8 compared the hemodynamic effects of 
amiodarone with solvent and pure Tween 80. They 
concluded that the early vasodilation and reduction in 
afterload observed during amiodarone administration 
were primarily caused by Tween 80 and the later effects, 
i.e., changes in contractility and LV end-diastolic 
pressure, by amiodarone itself. The hemodynamic 
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changes induced by Tween 80 only last a few minutes 
and almost certainly will have disappeared at the onset 
of APST II in this study. 
The antiischemic properties of amiodarone in 
man: Amiodarone was originally introduced as an 
antianginal agent and was clinically effective in patients 
with angina pectoris.13- 16 It was reported recently to 
limit infarct size in the dog_l? In patients with variant 
angina pectoris, amiodarone had beneficial effects.lS 
Apart from a preliminary report from our laboratory, 
its antiischemic properties during acute episodes of 
pacing-induced myocardial ischemia have not been 
reported, nor have the hemodynamic actions involved.19 
In this study, amiodarone clearly inhibited the occur-
rence and extent of pacing-induced (regional) myo-
cardial ischemia, although it did not affect overall 
myocardial 0 2 consumption during atrial pacing. These 
antiischemic properties were demonstrated in particular 
by normalization of myocardial lactate metabolism after 
amiodarone treatment. Myocardial lactate production, 
in our experience, is a sensitive indicator of ischemia 
when assessed immediately (15 seconds) after pacing. 
Although the classic indexes of myocardial ischemia 
(i.e., angina, ST -changes and LV end -diastolic pressure 
after pacing) are reproducible at shorter pacing inter-
vals, an interval of at least 30 minutes between succes-
sive pacing tests is needed for a reproducible lactate 
production pattern.20 A 40-minute period between the 
2 pacing stress tests was therefore chosen in this study 
and no placebo-controlled patients were used. The an-
tiischemic effects of amiodarone were, apart from the 
reduction of anaerobic glycolysis, emphasized as well 
by a significant reduction in angina, ST -segment de-
pression and abnormal LV end -diastolic pressure ele-
vation during APST II. Our study results indicate that 
a reduction of tension-time index and contractility, and 
thus myocardial 0 2 demand, is a major factor in this 
antiischemic action. During pacing, after amiodarone, 
the reduction of coronary vascular resistance had al-
ready disappeared and overall coronary flow was similar 
during both pacing stress tests. This makes an increase 
in regional flow in the ischemic area less likely. However, 
as we did not measure regional flow in this study, this 
must remain an assumption. 
25 LVEDP 
mmHg 
20 
15 
10 
C 1 00/ 120/ AP 15 sec 1' P-P 2' P-P 5' P-P 
min min P-P 
FIGURE 3. Left ventricular en<kliastolic pressure (LVEDP) values during 
and after atrial pacing stress test (APST), before and after amiodarone 
administration. L VEDP immediately after pacing ( 15 sec P-P) is signif-
icantly less elevated after amiodarone. AP = maximal pacing rate; P-P 
= postpacing. • p <o.os. 
644 HEMODYNAMIC AND ANTJISCHEMIC EFFECTS 
When an infusion of amiodarone is added to the bolus 
injection, a longer-lasting increase in coronary blood 
flow may result, yielding an increase in regional oxygen 
delivery. Combined with the reduction in myocardial 
0 2 demand, this will further diminish ischemia, pro-
vided LV filling pressure remains within the normal 
range. It may be anticipated that such an approach will 
benefit the acutely ischemic patient. Especially in the 
patient with infarction who has ventricular dysrhyth-
mias as well, intravenous amiodarone may be considered 
the treatment of choice. 
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Dose related coronary and systemic haemodynamic 
effects of intravenous bepridil in patients with coronary 
artery disease 
W. J. REMME*, D. C. A. VAN HooGENHUYZE*, X. H. KRAuss*, A. HoFMANt, C. J. STORM* AND 
H. A. C. M. KRUYSSEN* 
*Department of Cardiology, Zuiderziekenhuis, Rotterdam and t Department of Epidemiology, Erasmus 
University, Rotterdam, The Netherlands 
KEY WORDS: Bepridi1, calcium-blocking drug, coronary artery disease. 
The acute coronary and systemic haemodynamic effects of intravenous bepridil were investigated in 27 patients 
with coronary artery disease; 13 (group 1) received 2 mg kg- 1 and 14 (group 2) 4 mg kg- 1 over 5 min. An 
immediate systemic and coronary vasodilation occurred in both groups during and immediately after the 
infusion. Changes were dose-related with a maximal decrease in left ventricular (LV) systolic pressure of 11% 
(group 1) and 18% (group 2), in mean aortic pressure of 11% (group 1) and 19% (group 2), and in coronary 
resistance of23% (group 1) and41% (group 2). Coronary flow increased by 17% (group 1) and47% (group 
2) (all changes significantly different from control (C) values and between groups). Cardiac output, measured 
immediately after bepridil, was unaltered, although in group 2 stroke volume index increased ( 14%) and 
systemic resistance decreased (16%), both P<0·05 vs C. In group 2, heart rate (HR) and contractility 
initially increased (8% and 10%, respectively, P<0·05 vs C), secondary to the greater fall in afterload, 
followed by a significant reduction at 5 and 10 min after bepridil (9% and 10%, respectively), accompanied by 
a 36% increase in LV enddiastolic pressure ( P<0·05 vs C). No such changes were observed in group 1, apart 
from a simultaneous decrease in HR (9%, P<0·05 vs C). Thus, in humans, a dose-related, biphasic haemo-
dynamic pattern is observed with intravenous bepridil, consisting of an acute, short-lasting vasodilation, 
followed by late negative chronotropic and inotropic effects, which, with long term bepridil administration, may 
be beneficial during myocardial ischaemia. 
Introduction 
Bepridil hydrochloride is a new, long-acting com-
pound with both antiischaemic and antiarrhythmic 
properties[I-IOJ_ Although it is primarily regarded as 
a calcium-channel blocking agent[I 1l, it also affects 
the fast sodium channel[I2l. A competitive inhi-
bition of calcium-dependent calmodulin has been 
described as well[13l. In tissue preparations and in 
the perfused heart model, it induces systemic and 
coronary arterial vasodilation[14l and has negative 
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inotropic and chronotropic properties[IIJ_ In the 
intact cardiovascular system, however, these direct 
effects of the drug may be attenuated or even 
counteracted by reflex mechanisms, the resulting 
haemodynamic profile predominantly depending 
on dose and rate of administration. Until recently 
only minor systemic and coronary haemodynamic 
effects ofbepridil have been reported in humans, in 
a dose which caused significant electrophysiologic 
changes[15J. However, as measurements were per-
formed only after bepridil administration, some 
of its direct haemodynamic properties may have 
remained unnoticed. In another 2 studies the sys-
temic haemodynamic changes during intravenous 
administration of low dosages of bepridil in 
humans have been investigated[16•17l. The acute 
coronary and systemic cardiovascular properties of 
bepridil in dose regimens that result in antiischemic 
effects in humans have not been reported yet, apart 
from some preliminary communications[1•2•18l. The 
present study, therefore, was performed to compare 
© 1987 The European Society of Cardiology 
the direct and secondary coronary and systemic 
haemodynamic effects of some of these dose regi-
mens in patients with coronary artery disease in 
order to define the optimal dose in terms of safety 
and of haemodynamic changes, which may be 
relevant to its antiischaemic properties. 
Methods 
PATIENT POPULATION 
Twenty-seven patients were studied, 23 men and 
4 women, aged 32 to 62 years (mean 49), with stable 
exercise-induced angina pectoris and objective 
signs of myocardial ischaemia during stress testing. 
Only patients with >50% coronary diameter 
reductions, without any other form ofheart disease, 
participated in the study. Patients with a recent 
infarction (less than 3 months old), hypertension, 
evidence of congestive heart failure (New York 
Heart Association functional class III and IV) or 
conduction disturbances were excluded. Beta-
blocking agents, calcium blocking drugs and long-
acting nitrates were withheld 48-72 hours prior to 
the study. Short-acting nitroglycerin was allowed 
untill2 hours before the investigation. None of the 
patients studied received other vasodilating drugs, 
digitalis or diuretics. After the nature of the investi-
gation and of the compound and the extra time 
needed for the study were explained, all patients 
gave their consent on the day previous to the investi-
gation. 
Catheterization procedures 
Catheterizations were carried out without pre-
medication after an overnight fast. The study 
protocol was preceded by left and right coronary 
arteriography via the Seldinger technique and a 
routine atrial pacing stress test. Next, a no. 7 F 
thermodilution pacing catheter (Wilton Webster 
Laboratory) was advanced into the midportion of 
the coronary sinus via a branchial vein and a 7 F 
Millar micromanometer catheter positioned in the 
left ventricle via a Desilet introducer system in the 
femoral artery. The side-arm of this Desilet system 
was used to record aortic pressures. Finally, a 
no. 7 F Swan Ganz thermodilution catheter was 
advanced with its tip in a pulmonary artery and its 
proximal lumen in the right atrium via a femoral 
vein. 
MEASUREMENTS 
After positioning, the catheters were calibrated 
using a zero reference level set at mid-chest. The 
micromanometer pressure was balanced to zero and 
calibrated with the fluid-filled system. Recordings 
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of all pressures and of the first derivative of left 
ventricular (LV) pressure (LV dpjdt), were made on 
paper in the appropriate pressure ranges, using a 
CGR 1000 Cath Lab System. Cardiac output (CO) 
was measured in triplicate by the thermodilution 
technique. All pressures and pressure-derived 
contractility and relaxation indices (LV peak dpjdt 
positive and negative, dpjdt/P at 40 mmHg 
(VCE40) and Vmax total pressure) as well as 
cardiac output were determined on-line by a 
Mennen Cath Lab Computer System. Calculations 
were made from 12 consecutive beats. Coronary 
sinus blood flow (CSBF) was determined with 
the continuous infusion thermodilution method. 
Approximately 30-35 ml of glucose 5% at room 
temperature was infused over 30 seconds into the 
coronary sinus. During the infusion, both the mean 
and pulsatile flow were recorded simultaneously and 
measurements were made during mid-respiration 
after the mean flow curve had stabilized. The 
external thermistor was always well inside the 
coronary sinus ostium to prevent atrial reflux inter-
fering with the flow measurements. This was con-
firmed by a bolus injection of saline in the right 
atrium. A coronary venous angiogram, using 3 ml 
of Renografin 76®, was recorded on a video disc to 
allow re-checking of the position of the catheter tip 
during the investigation. 
METABOLIC AND ELECTROCARDIOGRAPHIC 
MEASUREMENTS 
Coronary venous and arterial 0 2 saturation 
values were measured using an American Optical 
Oxymeter. Throughout the study, leads I, II and V 5 
were continuously monitored for determination of 
heart rate and the PQ, QRS and QT interval. 
Measurements were performed at a paper speed of 
1 00 mm s- 1 . The QT c interval was determined 
according to Bazett's formula. 
CALCULATIONS 
From the measured values, the following calcu-
lations were made: coronary vascular resistance by 
dividing mean arterial pressure by coronary sinus 
blood flow; myocardial 0 2 consumption by multi-
plying the difference in arterial and coronary sinus 
0 2 content by coronary sinus blood flow; modified 
tension time index or double product, an index of 
myocardial 0 2 demand, by multiplying heart rate 
by LV systolic pressure. Systemic vascular resistance 
was derived as 80 x (arterial mean pressure- atrial 
mean pressure)jcardiac output and pulmonary 
vascular resistance as 80 x (pulmonary mean 
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pressure- LV mean diastolic pressure )/cardiac Tablel General patient data and angiographicfindings 
output; stroke work index was expressed as stroke 
index (mean aortic pressure- LV end diastolic 
pressure) x 0.0136. 
STUDY PROTOCOL 
After instrumentation, a period of 30 min was 
allowed for stabilization. The studies were therefore 
initiated at least 60 min after angiography. Multiple 
control determinations of all variables were then 
made over a period of20 min to ensure stable base-
line values for all parameters. Next, 2 mg kg- 1 
(group I, 13 patients) or 4mgkg- 1 (group 2, 14 
patients) bepridil was administered over a period of 
5 min. All variables were again determined at 2, 4, 6, 
I 0, 15 and 30 min after the onset ofthe infusion, with 
the exception of cardiac output, which could not be 
measured during bepridil administration, since the 
proximal lumen of the Swan Ganz catheter was used 
for drug infusion. This route of administration was 
chosen as the long-term, infusion of bepridil in 
a peripheral vein may induce thrombophlebitis 
(unpublished observation). 
DATA-ANALYSIS 
Our approach to data analysis was twofold. 
Firstly, electrocardiographic and haemodynamic 
changes during and after bepridil infusion were 
expressed as percentages of baseline values. 
A t-test for paired observations was used, as the 
objective of this analysis was to test differences from 
the baseline observations. A two-tailed P-value 
< 0·05 was considered significant. 
Secondly, baseline values and mean percent 
changes were compared between the two patient 
groups using a t-test for unpaired observations. All 
values are expressed as means± I standard error of 
the mean (SEM). 
Results 
General patient data and baseline angiographic 
findings are listed in Table 1. Although in the 
high-dose group, multivessel disease was more 
frequent than in group I, baseline left ventricular 
angiographic data were not different. 
ELECTROCARDIOGRAPIDC CHANGES DURING AND 
AFTER BEPRIDIL ADMINISTRATION 
The baseline values of the QT and QT c interval 
were different between both groups. [397 ± 11 ms 
and 447 ± 10 ms, respectively (group 1) and 
365 ± 10 ms and 408 ± 8 ms, respectively (group 2) 
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Group 1 Group2 
Bepridil Bepridil 
2mgkg- 1 4mgkg- 1 
(5min)- 1 (5min)- 1 
Patients (N) 13 14 
Sex(M/F) 9/4 14/0 
Age (yrs) mean 47±2·3 52±2·4 
range 36±62 32-60 
Old Myocardial infarct 5 6 
CAD: !-vessel 8 5 
2-vessel 1 5 
3-vessel 4 4 
LVEF(%) 52±4 57±3 
LVEDV(mlm- 2 ) 75±7 69±4 
LV wall motion 
abnormalities (N) 12 13 
CAD- coronary artery disease (>50% diameter reduction) 
LVEDV- left ventricular end diastolic volume index 
L VEF- left ventricular ejection fraction 
(P < 0·05, group 1 vs group 2)]. Both the values 
for the PQ and QRS interval were comparable. 
Immediately after the onset of bepridil adminis-
tration a significant lengthening of the QT and QTc 
interval occurred in both groups compared with 
control, which lasted until the end of the investi-
gation (Table 2). Changes were dose-related with a 
maximal lengthening of the QTc interval of 10% 
(group I) and of 18% (group 2), 4 min after onset of 
bepridil administration. The percent changes were, 
however, only significantly different between both 
groups, at a later stage, at 5 and 10 min after the 
infusion. 
SYSTEMIC HAEMODYNAMIC CHANGES DURING AND 
AFTER BEPRIDIL 
The systemic haemodynamic changes during and 
after bepridil administration are given in Table 3 
and in Figs 1 and 2. All baseline values were 
comparable. In both groups, an immediate, but 
brief decrease in aortic pressures (Fig. 1) and in LV 
systolic pressure occurred, only observed during 
and· I min after bepridil administration. These 
changes were dose-dependent and significantly 
different between the 2 groups. At the end of the 
infusion period a maximal reduction in LV systolic 
pressure of II% (group I) and of 18% (group 2) 
and in mean aortic pressure of II% (group I) and of 
19% (group 2) were present (all values P<0·05 vs 
control). Systemic vascular resistance decreased 
only in the high-dose group from 1423 ± 116 dynes s 
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Table 2 Electrocardiographic changes during and after bepridil administration 
Minutes after onset ofbepridil administration 
Variable Control During bepridil infusion After bepridil infusion 
2min 4min 6min !Omin 15min 30min 
PQ-interval (ms) Group I 156±8 160±7 160±6 163±7 162±7 160±6 162±6 
Group2 164±6 167±6 171±6 171 ±6 174±6 170±6 169±7 
QRS-interval (ms) Group I 90±6 93±6 96±7 93±6 90±6 90±6 90±6 
Group2 76±5 72±7 74±4 74±4 79±3 76±7 73±7 
QT-interval (ms) Group I 397 ±II 399± 11 418±15t 429± lit 435±1lt 436±1lt 422±14t 
Group2 365± lOt 408±10t 422±10t 434± lOt 441 ± 12*t 436± 11 *t 423± 12t 
QT0-interval (ms) Group I 447± 10 473±8t 490±10t 484±9t 476±8t 473±10t 474± lOt 
Group 2 408±8t 477±6t 483±7t 478±8t 470± IO*t 468±9*t 462±8t 
* P < 0·05 group·! vs group 2 (percent change from baseline values); t P < 0·05 vs control; tP < 0·05 group I vs group 2 (baseline 
values). 
150 
*t . ' "ll"t *t 
Group I--. 
Group 2 cr---o 
50 * P<0·05 vs control 
t P<0·05 group I vs group 2 
c 2 4 6 10 15 30 
Time (min) 
Figure 1 Effect ofbepridil, 2 mg kg- 1 (5 min)- 1 (13 patients, group I) and 
4mgkg- 1 (5min)- 1 (14 patients, group 2), on systolic, diastolic and mean 
aortic pressure (SAP, DAP and MAP, resp.). Values are mean± SEM. 
em-s (control) to 1196± 103 dynes s em-s, 1 min 
after bepridil (P<0·05). No changes were observed 
in the low-dose group. Heart rate increased by 8% 
in the 4 mg kg - 1 group at the beginning of the infu-
sion (P<0·05 vs control), however, it decreased 
gradually thereafter, with a significant 9% reduction 
10 and 15 min after the onset ofbepridil admimins-
tration. In the 2 mg kg- 1 group heart rate did 
not change during the infusion, but decreased by a 
similar percentage as in the high dose group, also at 
10 and 15 min after onset of the infusion. No con-
tractility changes occurred in the low dose group. In 
contrast, in the high-dose patients, a significant 
initial increase in contractility (1 0%) was observed, 
together with the increase in heart rate. This 
was followed by a longer lasting significant 10% 
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0 Table 3 Systemic haemodynamic changes during and after bepridil administration 
'""' I 
Minutes after onset ofbepridil administration ~ 
:--. 
Variable Control During bepridil infusion After bepridil infusion ~ 
"" ~
2min 4min 6min 10min 15min 30min ~ 
"" 0 
...... 
HR (beats min- 1 ) Group 1 78±3·5 84±4 82±4 77±3 71±3* 72±3* 75±3 I ~ 
Group2 76±4 83±3* 79±3 74±3 70±3* 70±3* 73±2·5 
LVSP(mmHg) Group 1 131±6 118±5* 117±5·5* 120±6* 129±7 126±5·5 124±6 
Group2 132±4 112±3*t 108±2·5*t 116±3*t 134±4 134±4 132±4 
L VEDP (mmHg) Group 1 13±2 12±1·5 13±1·5 14±2 14±2 14±2 12±2 
Group2 11±1 11±1 14± 1-5* 15±2* 15±2* 14±2* 11±2 
LV dp/dt pos (mmHg s- 1) Group 1 1577± 101 1709± 172 1569± 130 1543± 123 1527 ± 113 1477±97 1506± 104 
Group2 1686±100 1654±92 1569± 130 1529± 106*t 1529±95*t 1563 ± 104* 1634±96 
VCE40(s- 1) Group 1 34±2·5 36±2·5 33±2 32±2 32±2 31±3 34±3 
Group2 34±1 36±1* 33±1·5 31±2 30±1·5* 31±1·5* 32±1 
VmaxTP(s- 1) Group 1 48±3 52±3 50±3 46±5 47±3 45±3 49±3·5 
Group2 50±1 55±2·5* 51 ±2·5 48±2·5 45±2* 46±2* 48±2 
LV dpfdt neg (mgHg s- 1) Group 1 1701±123 1746±150 1605±137 1617±131 1706±140 1653± 129 1737 ± 139 
Group2 1861 ± 159 1589± 163*t 1508± 148*t 1483 ± 107*t 1685± 150 1847±184 1782± 165 
CO (lmin- 1) Group 1 6·1±0·5 - 5·8±0·4 5·5±0·3 5·7±0·35 5·9±0·5 
Group2 5·5±0·3 6·0±0·4 5·6±0·45 5·5±0·4 5·7±0·3 
SVI (ml beaC 1 m- 2) Group 1 41±3 39±2 41±2 42±2·5 41±2 
Group2 39±2 - - 43±2*t 42±3 40±3 41±2 
SWI(gmm- 2) Group 1 50±4 41±4 43±5 47±4 44±6 
Group2 46±3 41±4 54±6 50±6 47±3 
SVR (dynes s em - 5) Group 1 1281 ± 108 - 1190±99 1395±149 1326± 114 1315±112 
Group2 1423± 116 - 1196± 103*t 1471±178 1444± 168 1417± 140 
PAS(mmHg) Group 1 27±3 25±2 28±2·5 28±2 27±3 27±3 27±4 
Group2 24±2 27±2 28±2 29±2·5 29±3 27±2 26± 1·5 
PAD(mmHg) Group 1 12±2 12±1 13 ± 1·5 13±1 13±1·5 13± 1 13±2 
Group2 10±1 11± 1 12±1 12± 1 12±1 11± 1 10± 1 
PAM(mmHg) Group 1 17±2 16±1 18±2 18±1·5 17±2 17±1 18± 1 
Group2 15± 1 17±1 18±1 19± 1·5 17±2 18± 1 17±1 
PVR (dynes s em - 5) Group 1 238±32 259±35 259±32 254±28 242±38 
Group2 216±15 - 257±22 262±35 260±26 242±14 
CO-cardiac output; L VEDP -left ventricular end diastolic pressure; L VSP -left ventricular systolic pressure; HR- heart rate; PAD- pulmonary artery diastolic 
pressure; PAM- pulmonary artery mean pressure; PAS- pulmonary artery systolic pressure; PVR- pulmonary vascular resistance; SVI- stroke volume index; SVR-
systemic vascular resistance; SWI- stroke work index. * P < 0·05 vs control, t P <.0·05 Group 1 vs Group 2 (percent change from baseline values). 
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Figure 2 Temporal relation between changes in heart rate (HR), contractility 
(LV dpjdt, V max' LV P dp/dt negative and left ventricular end diastolic pressure 
(LVEDP) in the4mgkg- 1 group (see text). Values aremean±SEM. *P<0·05 vs 
control. 
decrease after bepridil administration, whereas 
positive LV dp/dt was already reduced toward 
the end of the infusion period, from 1861 ± 
159 mmHg s - 1 (control) to 1508± 148 mmHg s- 1, 
4 min after onset of bepridil (P < 0·05) (Fig. 2). At 
the same time, the peak negative value of LV dpjdt 
diminished by 20% in group 2 (P < 0·05), but did 
not change in group 1. Concomitant with these 
reductions in contractility and, possibly, in relax-
ation, LV end diastolic pressure increased signifi-
cantly by 36%, from 11 ± 1 mmHg (control) to 
15 ± 2 mmHg (1 min after bepridil infusion), a rise 
in LV filling pressure, which lasted for 10 min after 
the infusion. In the 2 mg kg- 1 group, LV filling 
pressure did not change. Although cardiac output, 
which was first measured 1 min after the infusion, 
remained unaltered in both groups, stroke volume 
index increased by 14% in group 2, immediately 
after the infusion (P<0·05). Stroke work index, 
however, did not alter. Pulmonary artery pressures 
and pulmonary vascular resistance remained 
unchanged in both groups. 
CORONARY HAEMODYNAMIC CHANGES DURING AND 
AFTER BEPRIDIL ADMINISTRATION (TABLE IV) 
Baseline coronary haemodynamic variables were 
comparable in both groups, except for the values of 
myocardial 0 2 consumption and ofthe difference in 
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Table 4 Coronary haemodynamic changes during and after bepridil administration 
Minutes after onset ofbepridil administration 
Variable Control During bepridil infusion After bepridil infusion 
2min 4min 6min 10min 15min 30min 
CSBF (ml min_,) Group I 121 ±7 135±9 142±10t 136±9 117±8 121±8 118±9 
Group 2 113±8 164± 15*t 166± 14*t 137± 14 133±15 115±14 121±14 
CVR(mmHgml- 1 min- 1) Group 1 0·83±0·07 0·69±0·05t 0·65±0·06t 0·76±0·07 0·91±0·10 0·83±0·08 0·90±0·09 
Group 2 0·90±0·08 0·59±0·11*t 0·53±0·07*t 0· 70 ± 0·07*t 0·89±0·12 0·98±0·11 0·91 ±0·12 
A-CS 0 2 content (vo1 %) Group 1 6·8±0·3 6·3±0·3 6·4±0·3 7·1±0·3 7·5±0-4 7·4±0·3 7·0±0·3 
Group2 9·1 ±o-7t 6·9±0·93*t 6·7±0·7*t 8·2±0·9 9·2±0·6 9·2±0·7 9·6±0·8 
MV02 (ml min- 1) Group 1 8·1±0·5 8·7±0·7 9·3±0·7 9·5±0·7 9·1±0·7 9·1±0·7 8·5±0·7 
Group2 10·2±0·8t 10·5±1·1 10·4±1·2 10·5±1·2 11·7±1·4 10·4±1·2 11·0± 1·3 
TTl Group 1 10·2±0·7 9·9±0·7 9·7±0·8 9·2±0·6 9·2±0·8 9·1±0·6 9·3±0·6 
(HRxLVSP x 10- 3) Group2 10·1±0·7 9·4±0·6 8·6±0·5t 8·6±0·5t 9·4±% 9·7±0·6 9·4±0·5 
A- arterial; CS- coronary sinus; CSBF- coronary sinus blood flow; CVR- coronary vascular resistance; MV02 =myocardial oxygen consumption; TTl- tension 
time index or double product: *P<0·05 group 1vs group 2 (percent change from baseline values; tP<0·05vscontrol; tP<0·05 group I vs group II (baseline values). 
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Figure 3 Percent changes in coronary sinus flow (CSBF) and coronary 
vascular resistance (CVR) from baseline values in both groups during and 
after bepridil administration. Values are mean± SEM. 
arterial and coronary sinus 0 2 content, which were 
higher in group 2 (26% and 34%, resp., P<0·05 vs 
group 1 ). Bepridil induced coronary vasodilation, 
simultaneously with the systemic vascular changes. 
A dose-related reduction in coronary vascular resist-
ance immediately followed the onset of bepridil 
administration with a maximal decrease of23% in 
group 1 and of 41% in group 2 (both P<0·05 vs 
control). These changes were brief. In the low-dose 
group they were only observed during the infusion-
period, whereas in group 2 a significant reduction in 
coronary resistance was still present 1 min after 
bepridil administration. Changes in coronary flow 
were dose-related as well. A maximal increase of 
47% occurred in the high-dose group, from 
113 ± 8 ml min - 1 (control) to 166± 14 ml min - 1 
4 min after onset ofbepridil (P<0·05). In contrast, 
at the same time coronary flow only rose by 17% 
in group 1, from 121±7mlml- 1 to 142± 
10 ml min- 1 ; an increase which was just signifi-
cantly different from the control value. The percent 
changes in coronary resistance and flow from their 
respective control values were significantly different 
between the 2 groups as well (Fig. 3). Although 
during the infusion period, the difference in arterial 
and coronary sinus 0 2 content diminished by 26% 
in the 4 mg kg- 1 group (P < 0·05 vs control), myo-
cardial oxygen consumption remained unchanged, 
despite a significant 15% reduction in tension time 
index, an index of myocardial oxygen demand. In 
the low-dose group no changes were observed in 
coronary sinus 0 2 content, neither in myocardial 
0 2 consumption nor demand. 
ADVERSE EFFECTS 
Bepridil was well tolerated. None of the patients 
developed symptomatic hypotension, bradycardia 
or clinical signs of heart failure. The only side-
effect, which was observed in a few patients in 
groups 2, was a short period of a generalised feeling 
of warmth and of facial flushing during the infusion 
period. 
Discussion 
The acute anti-ischaemic and antiarrhythmic 
properties of intravenous bepridil in humans have 
been reported by various investigators[l·2•6•8- 101. In 
these studies, bepridil was always administered as a 
bolus infusion of2 or 3 mg kg - 1 over a few minutes. 
At a comparable dose and rate of administration, 
the compound has marked coronary and systemic 
-223-
138 W. J. Remme et al. 
haemodynamic effects in animal experimentsl19- 21 l. 
In humans, the immediate cardiovascular actions of 
these dose regimens have not been reported yet, 
apart from some preliminary communicationsD·2•18l. 
In one early publication, the haemodynamic effects 
of bepridil were compared with other calcium-
blocking agentsl22l. However, as in this study 
all patients received concomitant beta-blocking 
therapy, the haemodynamic changes observed do 
not necessarily reflect the cardiovascular profile of 
bepridil. This investigation therefore is the first to 
examine the haemodynamic effects of intravenous 
bepridil in humans in dosages that should be 
relevant to its acute antiischemic properties. 
DOSE-RELATIONSIDP OF HAEMODYNAMIC AND 
ELECTROCARDIOGRAPIDC CHANGES 
The hemodynamic changes during bepridil 
administration were clearly dose-related, both in 
magnitude and direction. During the low-dose 
administration only a moderate reduction in 
systemic and coronary resistance occurred with a 
small decrease in LV systolic and aortic pressures 
and a moderate increase in coronary flow. In 
contrast, when 4 mg kg- 1 was administered, a 47% 
increase in coronary flow and an equivalent reduc-
tion in coronary resistance was observed, despite a 
greater reduction in aortic diastolic pressure. 
The inotropic changes during and after bepridil 
were clearly dose-related as well, whereas the 
chronotropic effects were not. Although an initial 
rise in heart rate occurred in the high-dose group, 
this, presumably, was a reflex mechanism secondary 
to the greater decrease in afterload and not a direct 
effect ofbepridil. The concomitant initial increase in 
contractility also can be explained by a temporary 
increase in sympathetic tone. Although the reduc-
tion in afterload was maximal at the end of the 
infusion, both heart rate and contractility decreased 
already during the later stages of bepridil adminis-
tration, indicating that the intrinsic myocardial 
effects of the drug were in operation at the time 
of the infusion. Judging by the reduction in the 
velocity parameters alone, a significant decrease in 
contractility occurred in the high-dose group, how-
ever, only at a later stage, 5 min after termination of 
bepridil administration, at a time that afterload had 
already normalized. When on the other hand the 
early decrease in positive LV dp/dt is taken into 
account as well, it may be argued that, besides 
changes in this parameter, caused by the decrease in 
afterload, a reduction in contractility was already 
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present at the end of the infusion period, which then 
also explains the significant increase in LV filling 
pressure at the end of bepridil administration. 
This increase in LV filling pressure might be 
explained as well, though, by the reduction in 
negative LV dp/dt at this time, which indicates a 
decrease in relaxation. Changes in relaxation have 
been reported with nifedipine in humansl23l. How-
ever, as in our study the decrease in negative LV 
dpjdt coincided with the fall in LV systolic pressure 
(Fig. 2), it may also have been a pressure-dependent 
phenomenon, and not necessarily an indication of a 
decrease in relaxation alone. 
The reductions in heart rate observed after 
bepridil administration were similar in both groups 
at a time that the peripheral vasodilating effects of 
bepridil were no longer present. The other electro-
physiologic changes, however, e.g. the lengthening 
of the QT and QTc interval, were clearly dose-
dependent. They also persisted throughout the 
entire investigation in both groups, in contrast 
with the short-term vascular and the intermediate 
inotropic effects of bepridil. These differences in 
duration of action between electrophysiological and 
haemodynamic effects reflect the complex cellular 
activity of bepridil. In the high-dose group, 
coronary venous 0 2 content increased significantly 
during bepridil administration, whereas no changes 
occurred in the low-dose group. In animal exper-
iments, both an increase in coronary venous 0 2 
content and a reduction in myocardial 0 2 con-
sumption has been describedl20•21 l. In our study, 
myocardial 0 2 consumption did not decrease, 
however, despite a reduction in the double product, 
whereas contractility was unchanged at this point 
of the infusion. An explanation for the fact that 
bepridil did not reduce myocardial 0 2 consumption 
may be the increase in LV enddiastolic pressure and 
therefore presumably, in diastolic wallstress. 
BIPHASIC HAEMODYNAMIC PATTERN OF BEPRIDIL 
The haemodynamic actions of bepridil in this 
investigation can be divided into 2 phases: an 
immediate and short-lasting coronary and systemic 
vasodilation followed by late negative inotropic and 
chronotropic effects. This dual mode of action has 
been observed in animal experiments as welll19.2°l. In 
these studies an immediate, shortlasting reduction 
in vascular resistance and a persistant bradycardia 
were reported, both with high and low doses of 
bepridil. Negative inotropic effects, however, only 
occurred at the higher dose level[l9l, which is in 
agreement with our results. In the study by 
Marshall and Muirl20l, a negative inotropic effect 
was not observed, though, despite the adminis-
tration of5 mg kg- 1 ofbepridil. However, as in their 
study haemodynamic changes were only measured 
immediately and 20 min after bepridil adminis-
tration, intermediate alterations in contractility 
may have remained unnoticed. 
CLINICAL IMPLICATIONS 
The minor haemodynamic effects observed with 
the 2 mg kg- 1 dose, indicate that with this dose 
regimen a substantial anti-ischemic effect is not to be 
expected. On the other hand, the negative inotropic 
changes and, particularly, the elevation ofL V filling 
pressure, which occur with the4 mg kg- 1 dose, may 
be hazardous when administered to patients with an 
already jeopardized myocardial function. It follows, 
that a 3 mg kg- 1 dose, preferably infused over 
5 min, may be more suitable, provided that the bolus 
infusion is followed by long-term administration 
ofbepridil, in order to maintain the vascular effects 
of the drug. Although the haemodynamic effects 
of such a dose regimen should be tested first 
before making definite statements about its clinical 
efficacy, it may be anticipated, that patients with 
unstable angina or an acute myocardial infarction 
will benefit from the antiischemic properties of 
bepridil during a similar dose regimen. 
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Acute Hemodynamic and Antiischemic Properties 
of Intravenous Bepridil in Coronary Artery 
Disease 
Willem J. Remme, MD, Dick A.C.M. Kruyssen, MD, Diederik C.A. Van Hoogenhuyze, MD, 
Bert Hofman, PhD, X. Hanno Krauss, MD, and Cok J. Storm, MD 
The acute hemodynamic and antiischemic effects of 
intravenous bepridil (3 mg/kg/5 minutes followed 
by 1 mg/kg!bour) were studied in 19 patients with 
coronary artery disease under basal conditions and 
during 2 identical pacing stress tests 30 minutes 
before (pace test I) and 15 minutes after (pace test 
II) onset of infusion. Bepridil immediately decreased 
coronary and systemic vascular resistance (26 and 
17%, respectively). This resulted in a 19 and 21% 
reduction in left ventricular systolic and mean aor-
tic pressures and a 15% increase in coronary flow 
and stroke index (p <0.05 vs control for each). 
These vasodilating effects were short lasting, per-
sisting for 5 minutes after the bolus infusion, fol-
lowed by significant reductions in heart rate (15%) 
and contractility (10%) and a temporary 46% in-
crease in left ventricular filling pressure. During 
both pace tests heart rate, contractility, coronary 
flow and myocardial 0 2 consumption were compa-
rable. In contrast, bepridil prevented the significant 
increase in systemic resistance and mean aortic 
pressure observed during pace test I (11 and 15%, 
respectively). Subsequently, myocardial 0 2 demand 
was significantly less during pacing after bepridil, 
due to an 11% reduction in left ventricular systolic 
pressure (p <0.05 vs control and pacing test II vs 
1). This resulted in marked antiischemic effects: 
normalization of lactate extraction and reduction in 
ST-segment depression (-14 ± 7 vs 3 ± 6% and 
0.2 ± 0.02 vs 0.13 ± 0.02 mV, respectively, pace 
test I vs II, p <0.05), and in less or no angina in 18 
patients. Thus, intravenous bepridil significantly re-
duces acute myocardial ischemia during pacing-in-
duced stress, predominantly through its systemic 
vasodilating effects and subsequent reduction in 
myocardial 0 2 demand. 
(Am J Cardiol 1989;63:670-675) 
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Bepridil hydrochloride is a novel compound with a complex pharmacologic profile, consisting of slow calcium- and fast sodium-channel blocking prop-
erties, I-3 and a dose-related inhibitory effect on cal-
cium-dependent vascular calmodulin.4 These cellular 
properties provide for systemic and coronary vasodilata-
tion together with negative inotropic and chronotropic 
activity in vitro, 1.5 which may indicate a potential 
toward antiischemic effects in vivo. In humans, bepridil 
given orally reduces exercise-induced ischemia6- 8 and 
compares favorably to other antianginal compounds.9•10 
Its antiischemic efficacy during intravenous administra-
tion has not yet been described. We investigated the po-
tential antiischemic properties and underlying hemo-
dynamic effects of bepridil administered in dosages, 
which, in a previous study, were identified as optimal in 
terms of hemodynamic activity and safety. 11 
METHODS 
Patients: After approval of the protocol by the Insti-
tutional Ethical Review Board and informed consent, 
19 patients with exercise-induced angina or an old myo-
cardial infarct and objective signs of ischemia during 
stress testing participated. There were 18 men and 1 
woman, aged 38 to 68 years (mean 57). Patients with 
unstable angina, valvular heart disease, hypertension or 
heart failure were excluded. Cardiovascular therapy 
was withheld 48 to 72 hours before the investigation, 
but short-acting nitroglycerin was allowed until 6 hours 
before the study. To participate, a diameter reduction of 
2:70% in at least I proximal branch of the left coronary 
artery had to be present. Catheterization was performed 
without premedication after an overnight fast. Individu-
al clinical and catheterization data are listed in Table I. 
Catheterization procedures: After routine coronary 
angiography, a 7Fr thermodilution pacing catheter 
(Webster Laboratories) was advanced from a brachial 
vein into the mid portion of the coronary sinus, such that 
its position was stable, no interference by atrial reflux 
occurred and blood could be drawn quickly enough to 
allow for fast repetitive sampling. The catheter's posi-
tion was identified radiographically by injecting 3-ml 
iopamidol and the data were stored on video disc to al-
low rechecking during the study. Next, a 7Fr thermodi-
lution catheter was positioned with its tip in a pulmo-
nary artery via a femoral vein and a 7Fr Millar micro-
manometer catheter advanced into the left ventricle 
TABLE I Patient Characteristics 
Percent Diameter Reduction of 
Coronary Artery 
Age (yrs). LVEDV 
Pt Sex Previous Ml LVEF(%) (ml/m2) LAD LC Right 
1 49.M 0 50 88 100 
2 68,M Inferior 41 78 90 90 
3 62,M 0 53 68 99 80 90 
4 57, M Anterior 52 40 99 70 
5 47, M 0 42 73 100 90 100 
6 64,M Anterior 38 88 70 70 
7 59. M Inferior 43 66 70 100 
8 54,M Anterior 22 47 70 90 
9 54. M Inferior 38 60 90 90 99 
10 59,M Anterior 40 70 50 100 100 
11 61, M 0 41 65 70 100 70+ 100 
12 47, M Anterior 60 82 100 99 80 
13 55, M Inferior 52 49 100 100 
14 66,M Anterior 46 96 99 70 100 
15 66,M Inferior 51 59 99 99 
16 63,M Anterior 27 99 90 70 
17 60, M Anterior 53 59 100 70 100 
18 38,M 0 60 70 99 99 
19 57. F 0 68 105 70 
Mean ±SEM 58± 1.8 47 ±2.7 73 ± 4.5 
LAD -left anterior descending; LC"" lett circumflex; LVEDV -left ventricular end-diastolic volume; LVEF left ventncular ejection fraction: MI myocardial infarction: SEM- stan-
dard error of the mean. 
from the right femoral artery via a Desilet introducer 
system. Arterial pressures were recorded through the 
side arm of this system. 
Hemodynamic, metabolic and electrocardiographic 
measurements: All fluid-filled catheters were calibrat-
ed using a 0 reference level set at midchest. Right atrial, 
femoral and pulmonary artery pressures were measured 
using Bentley transducers. The micromanometer pres-
sure was balanced to 0 and superimposed on the con-
ventional pressure tracing. All pressures and left ven-
tricular dP / dt were recorded at different paper speeds, 
e.g., 10, 25 and 100 mmjs, using a CGR 1000 Cathlab 
system. Cardiac output was measured in triplicate by 
the thermodilution technique. Throughout the study, 
pressures, pressure-derived contractility indexes and 
cardiac output were determined on-line by a Mennen 
Cathlab computer system. Coronary sinus flow was cal-
culated by the method of Ganz et aJ. 12 Both pulsatile 
and mean coronary flow were measured during a con-
tinuous infusion of 30 to 35 ml of 5% glucose at room 
temperature over 30 seconds by motor-driven infusion 
pump. Electrocardiographic leads I, II and V 5 were con-
tinuously monitored for heart rate. ST-segment changes 
were measured in 5 consecutive beats, 0.06 second after 
the J point, at a paper speed of 100 mmjs using a cali-
brated magnifying lense. 0 2 saturation levels were mea-
sured with an American Optical oximeter. The tech-
nique used for collecting blood samples for lactate and 
the sensitivity of its determination have been reported. 13 
Calculated variables: Derived hemodynamic vari-
ables (stroke index, stroke work, systemic, pulmonary 
and coronary resistances, myocardial 0 2 consumption 
and the double product, an index of myocardial 0 2 de-
mand) were calculated using standard formulas. 14 Myo-
cardiallactate extraction (%) was calculated as 100 X 
(arterial - coronary sinus/arterial lactate concentra-
tion). 
Study protocol: Multiple control determinations of 
all variables were performed 20 and 40 minutes after 
instrumentation and coronary angiography, respective-
ly, to ensure stable baseline values without residual ef-
fects of the contrast material. A first atrial pacing stress 
test (pace I) was then carried out with 10 beats/2 min 
increase in heart rate until moderate to severe angina, 
atrioventricular block or a maximum rate of 170 beats/ 
min occurred. At fixed intervals (1 00, 120, 140 and 160 
beats/min), during maximal pacing rates and at 15 sec-
onds, l, 2 and 5 minutes after pacing all variables were 
again determined. Thirty minutes were allowed for sta-
bilization after pace I, followed by multiple control 
measurements. Next, bepridil, 3 mgjkg over 5 minutes, 
was administered, followed by a continuous infusion at 
a rate of I mgjkgjhour until the end of the study. Vari-
ables were reexamined I, 3, 5, 10 and 15 minutes after 
onset of bepridil administration, followed immediately 
by a second pacing test (pace II), identical to pace I. 
Cardiac output was measured before and 5 minutes af-
ter each pacing test and before and 5 and 15 minutes 
after onset of bepridil administration. Patients received 
0.5 mg atropin before each pace test to ensure reproduc-
ibility of pacing. Bepridil plasma levels were determined 
at I, 3, 5, 10, 15, 25, 35 and 45 minutes after onset of 
drug infusion and during maximal pacing rates. 
Statistical analysis: Values are expressed as mean± 
1 standard error of the mean. Each patient served as his 
own control. Measurements during bepridil infusion be-
fore pacing were compared with control values, using a 
t test for paired observations with 19 degrees of free-
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TABLE II Systemic Hemodynamic Changes During Bepridil Administration 
During Bepridil Infusion Before Pacing 
Control 1 minute 3 minutes 5 minutes 10 minutes 15 minutes 
HR (beats/min) 81 ±2 86± 2* 84±3 79 ±2 69± 2* 72±2* 
LVSP(mm Hg) 143±6 128± 5* 116 ± 3* 119 ± 4* 140± 5 143± 6 
MAP(mm Hg) 108± 5 93±4* 85 ±4* 87 ±4* 102 ± 4* 105±6 
CO (liters/min) 5.5 ± 0.3 - - 5.8±0.2 - 5.4± 0.3 
SVR (dynes. s. cm-5) 1.554 ± 140 - - 1,284± 90* - 1.444 ± 112 
Sl (mljbeatsjm2) 35 ± 2 - - 39±2 - 41 ±2* 
SWI (gjmjm2) 46 ± 1.4 - - 43 ± 2.1 - 46 ± 1.8 
LV peakdP jdt pos(mm Hg·s-1) 1,628 ± 71 1,571 ± 81 1,525 ±59 1.470 ±55* 1,440 ±57* 1.477 ±52* 
Vmax (s-1) 48±2 50± 3 51± 2 48±2 43 ±2* 45±2 
VCE40 (s-1) 35 ± 2 35.5 ± 2 35±2 32.5± 2 31 ±2* 31 ± 1* 
LV peak dP /dt neg(mm Hg·s-1) 1.762 ± 69 1,674± 83 1,464± 67* 1,511 ± 70* 1.639 ± 65* 1.668± 71 
LVEDP (mm Hg) 10± 1 10± 1 13 ± 1* 15± 2* 14± 1* 12± 1 
PAS(mm Hg) 25±2 25± 2 27 ± 2* 29 ± 1.5* 26 ± 1 28±2 
PAD(mm Hg) 11 ± 1 11 ± 1 12± 1 12± 1 11 ±3 11 ± 5 
PVR (dynes . s. cm-5) 185 ± 76 - - 146 ± 102 - 156 ± 82 
* o <0.05 vs control. Cb = card1ac output; HR =heart rate; LVEDP""' left ventricular end-diastolic pressure; LVSP =left ventricular systolic pressure; MAP= mean aortic pressure; PAD= diastolic pul-
mcnary artery pressure; PAS= systolic pulmonary artery pressure; PVR =pulmonary vascular resistance; Sl =stroke index; SVR =systemic vascular resistance; SWJ =stroke work 
index. 
TABLE Ill Coronary Hemodynamic Changes During Bepridil Administration 
During Bepridil Infusion Before Pacing 
Control 1 minute 3 minutes 5 minutes 10 minutes 15 minutes 
CSBF (mljmin) 151 ±8 165± 9 169 ± 11 173 ± 10* 155±9 153 ± 10.5 
CVR (mm Hgjml/mln) 0.75 ± 0.06 0.6 ± 0.05* 0.5 ± 0.04* 0.5 ± 0.04* 0.7 ± 0.07 0.7 ± 0.06 
::. A-CS 0 2 content (vol %) 6.8 ± 0.25 5.7 ± 0.3* 5.5 ± 0.3* 5.7 ± 0.3* 6.7 ± 0.3 7.1 ± 0.3 
MV02 (mljmin) 10.4± 0.8 9.5 ± 0.9 9.55 ± 0.6 9.9 ± 1.0 10.45 ± 0.65 10.3 ±0.8 
Til (HR X LVSP X lQ-3) 11.5 ± 0.55 10.8± 0.5 9.8± 0.4'' 9.4 ± 1.0* 9.8 ± 0.4* 10.2 ± 0.5* 
"' p <0.05 vs control. 
A"" arterial; CS""' coro~ary sinus; CSBF"" coronary sinu~ blood flow: CVR =coronary vascular resistance; HR = heart rate; LVSP =left ventricular systolic pressure; MV02.., myo-
cardial oxygen consumption; Til = mod1fied tens1on-time mdex or double product. 
TABLE IV Effects of Bepridil on Hemodynamics During Atrial Pacing 
100 120 
Control beats/min beats/min MAX 1 min P-P 2min P-P 5 min P-P 
LVSP(mm Hg) 148±6 148± 6 143± 6 148± 6 158±8 155± 6 153 ± 6 
143 ± 6 135 ± 5* 129 ± 3* 131 ± 6* 138± 6* 136±4.5* 140± 6* 
n1 ex w-3 ) 10.2 ± 0.5 14.8 ± 0.6 17.4±0.7 21.5 ± 0.7 12.9 ± 0.7 12.35 ± 0.7 12.6 ± 0.7 
10.2 ± 0.5 13.1 ± 0.4* 14.3±0.4* 19.0 ± 0.7* 12.5±0.5 11.9 ± 0.5 12.2±0.5 
Vmax (s-1) 45±2 55± 2.2 59± 2.8 58±3.3 49±2.6 53± 2.5 51± 3.1 
45 ± 1.9 50± 2.2 53± 2.4 58±2.5 52±2.8 52± 2.3 51± 2.8 
CSBF (ml/min) 144 ± 11 188 ± 17 210 ± 20 229 ± 16 - 193 ± 21 185 ± 16 
153± 10.5 166 ± 11 175±10.5 220 ± 18 - 162 ± 12 161 ± 11 
CVR (mm Hgjmljmin) 0.76±0.05 0.65±0.22 0.59±0.23 0.56 ± 0.05 - 0.62±0.22 0.66 ± 0.05 
II 0.71 ±0.06 0.69±0.25 0.65±0.22 0.55 ± 0.05 - 0.69±0.23 0.675 ± 0.05 
MV02 (mljmin) I 9.8 ± 1.0 12.7 ±2.05 14.75 ± 1.8 15.7 ± 1.5 - 12.1 ± 1.4 12.8± 1.6 
II 10.3 ± 0.8 12.0 ± 1.2 13.3 ± 2.1 15.0 ± 1.5 - 10.3 ± 1.0 11.1 ± 0.9 
• p <0.05, I (before bepridil) vs I! (after bepridil). 
CSBF = coronary sinus blood flow; CVR = coronary vascular resistance; LVSP = left ventricular systolic pressure; I =first atrial pacing stress test; 11 =second atrial pacing stress 
test MAX= max1mal pacing rates: MV02 = myocardial oxygen consumption; P-P =after pacing; Til =tension-time index. 
dam, as the object of this analysis was to test differences 
with the baseline observation. A t test for paired obser-
vations was also used for measurements during both 
pacing tests before and during bepridil. A 2-tailed p val-
ue <0.05 was considered significant. 
RESULTS 
Systemic hemodynamic changes during bepridil ad-
ministration before pacing: Bepridil immediately re-
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duced left ventricular systolic and mean aortic pressures 
(19 and 21% respectively, at 3 minutes of bepridil ad-
ministration) (Table II). These changes were short last-
ing; they were only observed during the first 5 to 10 
minutes of the infusion. Likewise, systemic vascular re-
sistance also decreased (17% vs control, p <0.05), but 
only at 5 minutes of bepridil. Heart rate initially in-
cr~ased significantly but thereafter gradually decreased 
by 15% at 10 minutes of bepridil administration (p 
<0.05 vs control). The velocity parameters decreased 
simultaneously with a significant 10% reduction at 10 
and 15 minutes after onset of bepridil. In contrast, left 
ventricular dP j dt was already diminished at 5 minutes 
of bepridil administration, closely following the reduc-
tion in arterial pressures. This early change in contrac-
tility was accompanied by a significant 46% increase in 
left ventricular end-diastolic pressure. Cardiac output 
remained unaltered, but stroke index steadily improved 
with a significant 15% increase at 15 minutes. 
Coronary hemodynamic changes during bepridil 
administration before pacing: Coronary blood flow in-
creased immediately with a maximum increase of 15% 
after 5 minutes of bepridil, accompanied by a 26% re-
duction in coronary resistance (both p <0.05 vs control) 
(Table III). These changes were short lasting, and only 
observed during the bolus infusion. Myocardial 02 con-
sumption did not change, despite a significant 19% re-
duction in the difference in arterial and coronary venous 
0 2 content during the bolus infusion and a persistent 
15% reduction in the double product (p <0.05 vs con-
trol). 
Effects of bepridil on hemodynamics during and af-
ter pacing: Maximal heart rates were similar during 
both pacing tests (145 ± 4 and 146 ± 4 beats/min 
[pace I and II, respectively]) (Table IV). In contrast, 
throughout pace II, left ventricular systolic pressure and 
the double product were significantly less (11 and 12%, 
respectively) compared with pace I. Mean arterial pres-
sure also was significantly less during pace II (106 ± 4 
vs 120 ± 6 mm Hg [pace I] during maximal rates). 
Moreover, whereas systemic resistance increased during 
pace I from 1,394 ± 129 (control) to 1,553 ± 150 
dynes · s · cm-5 (5 minutes after pacing, p <0.05), it 
tended to decrease during pacing with bepridil ( 1,444 ± 
112 [control] vs 1,399 ± Ill dynes· s · cm-5 [5 min-
utes after pacing]). Changes in contractility and in cor-
40 Lactate (art-ven x 100%1 
extraction art 
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·20 
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C 100/ 1201 MAX 15 sec 1 mm 2 mm 5 m1n 
p-p p-p p-p p-p 
FIGURE 1. Changes in lactate extraction during pacing before 
(APST I) and during bepridil administration (APST II). Lactate 
production, present during APST I at maximal pacing rates 
(MAX) and during the first minute after pacing (p-p ), is signifi-
cantly less during APST II. Art = arterial; ven = venous. 
onary flow and resistance were comparable during both 
pacing tests. Myocardial 0 2 consumption was also simi-
lar despite the significant reduction in myocardial 02 
demand during pace II. 
Effects of bepridil on pacing-induced myocardial is-
chemia: Bepridil clearly reduced myocardial ischemia, 
evidenced by normalization of lactate metabolism dur-
ing pace II, compared with pace I (Figure 1). Further-
more, at 15 seconds after pacing, lactate extraction was 
-57 ± 16% during pace test I, compared with only -9 
± 9% during pacing with bepridil (p <0.05). Moreover, 
during pace II there was less ST-segment depression 
than during pace I (-0.13 ± 0.02 vs -0.20 ± 0.02 mV, 
respectively, p <0.05, Figure 2). Left ventricular end-
diastolic pressure was significantly reduced (23 ± 2 
[pace I] vs 15 ± 1 mm Hg [pace II], 15 seconds after 
pacing, Figure 2). Finally, whereas all patients had se-
vere angina during pace I, I 0 had no angina, 8 had less 
0.3 
ST-segment 
mV 0.2 
0.1 
LVEDP 
mmHg 20 
* 
* 
= APST I 
- APST II 
FIGURE 2. Effect of pacing without and with bepridil (APST I 
and APST II, respectively) on ST-segment changes and left 
ventricular end-diastolic pressure (LVEDP). Both ST-segment 
depression and L VEDP are significantly reduced during 
maximal pacing rates (MAX) and 15 seconds after pacing 
(p-p). C = control. 
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FIGURE 3. Bepridil plasma levels during the bolus infusion, 3 
mg/kg, given over the first 5 minutes and during the following 
maintenance infusion of 1 mg/kg;bour. MAX = maximal pac-
ing rates; ' = minute. 
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angina and only 1 patient had similar angina during 
pacing with bepridil. 
Plasma bepridil levels: High plasma levels were ob-
served immediately after onset of administration (Fig-
ure 3), with maximal values at 3 minutes (12,456 ± 920 
ngjml). Following the bolus infusion they decreased 
abruptly and subsequently stabilized at 7.5 minutes of 
bepridil, thereafter fluctuating around the 2,500-ng/ml 
level. As the average duration of pacing during both 
tests was 15.3 ± 0.6 minutes, bepridil plasma levels had 
been stable for approximately 20 to 23 minutes at the 
end of pace I I. 
Adverse effects: Bepridil was well tolerated. No side 
effects were reported. However, in patient no. 13, left 
ventricular end-diastolic pressure increased from 15 
(control) to 38 mm Hg (5 minutes of bepridil) and in 
patient no. I 0 lactate production was observed immedi-
ately after the bolus administration. Both instances 
were asymptomatic. 
DISCUSSION 
Bepridil, a compound with predominant calcium-an-
tagonistic properties, is known to reduce exercise-in-
duced ischemia and to alleviate angina after oral ad-
ministration.6-10 The present study is the first to demon-
strate that it also has important antiischemic properties 
during intravenous administration, predominantly due 
to a marked reduction in myocardial oxygen demand 
during pacing-induced stress. This antiischemic effect 
was achieved at dosages that were well tolerated and 
did not result in proarrhythmic or untoward hemody-
namic effects, despite a reduced left ventricular function 
at baseline in most patients. 
Hemodynamic effects of bepridil before pacing: 
Bepridil induced early but short lasting vasodilatation, 
which led to a reduction in systemic and coronary resis-
tance, a decrease in left ventricular systolic and aortic 
pressures and, despite the simultaneous reduction in 
coronary perfusion pressure and myocardial 0 2 de-
mand, a significant increase in coronary flow. 
We had previously observed that 5-minute bolus in-
fusions of 2 and 4 mgjkg bepridil result in dose-re-
lated coronary and systemic arterial vasodilating effects, 
which cnly occur during the infusion period. 11 The 
present dosage scheme-a maintenance infusion in ad-
dition to the bolus administration-was designed to 
achieve sustained systemic and, particularly, coronary 
vasodilatation. This was obviously not successful, be-
cause in the present study vasodilatation only persisted 
for 10 minutes after onset of infusion. This early but 
short lasting vasodilatation was followed by negative 
inotropic and chronotropic effects, comparable to our 
previous results with a 4 mgjkg bolus infusion. 11 Cer-
tain differences do, however, exist. In the present study, 
the negative inotropic effects of bepridil were shorter 
lasting and the improvement in left ventricular pump 
function was more sustained. This indicates a more opti-
mal balance between negative inotropic and vasodilator 
properties of bepridil with the present dosage scheme. 
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This scheme also compares favorably with the dosages 
used in other studies with intravenous bepridil in hu-
mans.15-17 In most of these studies, which all used a 
relatively slow infusion rate of 2 to 4 mgjkg over 15 
minutes, a reduction in contractility, an increase in left 
ventricular filling pressure and either an unchanged or 
diminished left ventricular pump function was observed. 
In only 1 study did cardiac output increase transiently 
after the administration of 3 mgjkg over 15 minutes. 17 
Hemodynamic and antiischemic effects during pac-
ing: Bepridil significantly reduced myocardial ischemia, 
indicated in particular by the reduction in myocardial 
lactate production during and immediately after pacing. 
Moreover, the significant reduction in angina, ST-seg-
ment changes and increase in left ventricular filling 
pressure during pace II also underline its antiischemic 
properties. 
This antiischemic effect of bepridil is most likely due 
to a reduction in myocardial 0 2 demand during pacing, 
comparable to the effects of other calcium antagonists 
in similar investigations. 18-20 Although bepridil initially 
increased coronary flow during the bolus infusion before 
pacing, these changes were no longer apparent during 
the subsequent pacing test. An increase in myocardial 
0 2 supply therefore appears less likely as a mechanism 
to explain its antiischemic effects. However, as the coro-
nary sinus thermodilution technique only measures 
overall left ventricular function and not regional perfu-
sion, this assumption cannot be verified. Theoretically, 
because bepridil reduces left ventricular diastolic pres-
sure during pacing, this may have resulted in improved 
perfusion of the poststenotic subendocardial area. 
During both pacing tests, heart rates were identical 
by design and contractility changes were similar. Thus, 
bepridil's predominant mode of action during pacing 
appears to be a decrease in myocardial oxygen demand, 
due to a reduction in left ventricular systolic pressure. 
Moreover, it prevented the increase in arterial pressure 
and systemic resistance observed during the first pace 
test. We recently reported systemic neurohumoral acti-
vation and subsequent vasoconstriction during pacing-
induced ischemia.21 It may be postulated that the latter 
is prevented by arterial vasodilators such as bepridil. 
Thus, intravenous bepridil significantly reduces ische-
mia and is well tolerated. Its potential usefulness in un-
stable angina and infarction should be further investi-
gated. 
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Acute antiischaemic properties of high dosages of 
intravenous diltiazem in humans in relation to its 
coronary and systemic haemodynamic effects 
w. J. REMME*, D. c. A. VAN HOOGENHUYZE*, A. HOFMANt, c. J. STORM*, X. H. KRAUSS* AND 
H. A. c. M. KRUYSSEN* 
*Department of Cardiology, Zuiderziekenhuis, Rotterdam and t Department of Epidemiology, 
Erasmus University, Rotterdam, The Netherlands 
KEY WORDS: Intravenous diltiazem, haemodynamics, pacing-induced ischaemia. 
The antiischaemic properties of intravenous diltiazem in recommended therapeutic doses are disputed. In 
17 patients with coronary artery disease the systemic and coronary haemodynamic effects of diltiazem 
were assessed during a high-dose infusion (0·4 mg kg~ 1 per 5 min ,followed by 0·4 mg kg~ 1 per 10 min). In 
addition, its potential antiischaemic properties were investigated during identical pacing stress tests, 30 
minutes before ( P 1 ) and immediately after diltiazem administration ( P 2 ). Diltiazem reduced left ventricular 
systolic pressure from 133±5 to 116 ±5 mmHg (P< 0·005, .X±SEM) ,persisting until after P2 • It decreased 
systemic and coronary resistance by 32% (P < 0·00 1) and 29% (P < 0·005), respectively, with a sustained 
increase in cardiac output from 5·9 ± 0·4 to 7·3 ± 0·61 min~ 1 (P < 0·01), but a brie/20% rise in coronary flow 
(P < 0·05), after the bolus infusion only. Heart rate, contractility, left ventricular filling pressure and myo-
cardial 0 2 consumption remained unchanged. Despite high plasma levels (673 ± 81jlg 1~ 1 ) diltiazem was well 
tolerated. During identical maximal pacing rates diltiazem considerably reduced myocardial 0 2 demand 
(double product: 16·3 ± 0·8 ( P 2 ) vs 21·1 ± 1·1 ( P 1 ), P < 0·005), due to an 18% decrease in left ventricular 
systolic pressure, resulting in diminished coronary flow and myocardial 0 2 consumption during P 2 ( 14% and 
15%, respectively, P < 0·05 vs P 1 ). Diltiazem also significantly reduced pacing-induced ischaemia, indicated 
by normalization of myocardial lactate extraction ( 1 ± 8% ( P 2 ) vs -41 ± 12% ( P 1 ), P < 0·05), and left 
ventricular filling pressure (13±2 (P2 ) vs 27±3mmHg (P 1 ), P<0·01), less ST-segment depression 
(0·12±0·01 (P2 ) vs 0·24±0·02mV (P1 ), P<0·01) and improved contractility (Vmax 59±5 (P2 ) vs 
48 ± 3 s ~ 1 ( P 1 ), P < 0·05). Angina was absent or less in 15 patients during pacing after diltiazem. Thus, 
diltiazem, in high dosages, induces continuing systemic but short lasting coronary vasodilation, improves pump 
function without negative chronotropic and inotropic effects and has pronounced antiischaemic properties, 
predominantly due to diminished myocardial 0 2 demand. 
Introduction 
The antianginal efficacy of orally administered 
diltiazem has been reported in a multitude of 
studies[I-SJ_ In contrast, the potential antiischaemic 
effects of diltiazem, when given intravenously, are 
less well established. Moreover, the results of the 
few studies reported, in which the effect of intra-
Submitted for publication on 29 December 1986 and in revised form 9 
Aprill987. 
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venous diltiazem on either pacing- or exercise-
induced stress was investigated, are conflicting 
with regard to antiischaemic efficacy and effect on 
coronary haemodynamicsr9- 12l. This may be 
explained by the difference in dosages used in 
these investigations, which ranged from 18 to 
35 jlg kg~ 1 min~ 1 . In this dose-range coronary 
flow is not affected by diltiazemr9•11 - 16l. As the 
systemic, and particularly, the coronary effects of 
diltiazem are dose-dependent[13l and as, in humans, 
a dose-dependent increase in coronary flow has 
been demonstrated with other calcium-entry 
blocking agents as wellr17•18l, it may be antici-
pated that with higher dosages the antiischaemic 
properties of diltiazem become more manifest, 
© 1987 The European Society of Cardiology 
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predominantly because of improved myocardial 
oxygen supply. The present study therefore investi-
gated the acute and systemic haemodynamic effects 
of relatively high dosages of intravenous diltiazem 
in patients with coronary artery disease, the safety 
of such a drug regimen, and the subsequent anti-
ischaemic properties of the compound during 
pacing induced stress. 
Methods 
PATIENTS 
The protocol was approved by the human studies 
committee of the Zuiderziekenhuis. Seventeen 
patients (16 men and 1 woman) were studied after 
informed consent was obtained. All patients had 
stable, exercise-induced angina pectoris and/or a 
documented old myocardial infarction, whereas 11 
patients had objective signs of ischaemia during 
stress testing (Table 1). The mean age was 54 years 
(range 39 to 67). Thirteen patients had documented 
myocardial infarctions (9 anterior and 8 inferior). 
All cardiac medication was tailed off 48-72 hours 
Table I Clinical and angiographic data 
Age 
Patient (years) Previous E AP LVEDV 
Sex 
MI rgo (m1m- 2 ) 
46M ant 0 + 107 
2 39M 0 + + 46 
3 60F 0 + + 62 
4 64M ant/inf + + 147 
5 58M 0 + + 36 
6 40M ant 0 0 71 
7 51M inf 0 + 86 
8 52M inf + + 
9 SSM antjinf + + 125 
10 63M inf 0 + 61 
11 SSM inf + + 80 
12 62M antjinf + + 134 
13 61M ant + + 52 
14 62M 0 + + 62 
15 47M ant 0 0 70 
16 67M ant + + 72 
17 44M ant/inf 0 + 56 
Mean±SEM 54±2·1 79±8·1 
before the study, apart from shortacting nitro-
glycerin which was allowed until 8 hours before the 
investigation. Only patients with a ?: 70% diameter 
reduction in one or more branches of the left coron-
ary artery within the sampling area of the coronary 
sinus catheter participated. Nine patients had 1-
vessel, three had 2-vessel and five had 3-vessel 
coronary artery disease. Overall left ventricular 
ejection fraction was slightly decreased (47±4%), 
but left ventricular end diastolic volume index was 
normal (79 ± 8 ml m- 2). 
CATHETERIZATION PROCEDURES 
Catheterization was performed without premedi-
cation after an overnight fast using the Seldinger 
technique. After routine left and right coronary 
arteriography with non-ionic contrast medium 
(lopamidol), a 7 Fr Wilton-Webster thermodilu-
tion pacing catheter was advanced from a brachial 
vein into the mid portion of the coronary sinus and 
positioned such that blood could be drawn quickly 
enough to allow a rapid sequence of blood samples 
to be collected. The stability of the catheter tip 
Coronary angiogram 
LVEF (% luminal narrowing) 
(%) 
LAD LCX RCA 
38 100 50 0 
51 80 90 0 
67 99 0 0 
34 100 100 80 
56 70 0 0 
23 99 0 0 
42 0 99 0 
0 90 0 
25 100 99 99 
51 70 70 70+ 100 
47 90 0 100 
22 100 90 100 
64 100 0 0 
50 100 100 0 
54 100 0 0 
68 90 0 50 
61 99 90 70 
47±3-8 
AP=exercise induced angina, ant=anterior, ergo=positive bicycle ergometry test; inf=inferior; 
LAD= left anterior descending artery; LCX= left circumflex artery; L VEDV =left ventricular end 
diastolic volume; L VEF =left ventricular ejection fraction; MI =myocardial infarction; RCA= right 
coronary artery; SEM =standard error of the mean; + =present; 0 =absent;~= no data. 
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was checked and the possibility of atrial reflux in-
vestigated by a bolus injection of saline solution 
into the right atrium. A coronary venous angio-
gram, using 4 ml of iopamidol was recorded on 
video disk to allow rechecking of the position of the 
catheter tip during the study. Next, a 7 Fr Millar 
micromanometer catheter or an 8 Fr Honeywell 
pigtail angiographic micromanometer catheter was 
positioned in the left ventricle via a Desilet system in 
the right femoral artery. The side-arm of this Desilet 
system was used to record arterial pressures. 
Finally, a 7 Fr Swan Ganz thermodilution catheter 
was advanced from a femoral vein with its tip in a 
pulmonary artery and its proximal lumen in the 
right atrium. 
MEASUREMENTS 
All fluid filled catheters were calibrated using a 
zero reference level set at midchest. The micro-
manometer pressures were balanced to zero and 
superimposed on the conventional pressure trac-
ings. All pressures and the first derivative of left 
ventricular pressure (LV dp/dt) were recorded on 
paper in the appropriate pressure ranges at different 
paper speeds, e.g. 25, I 00 and 250 mm s- 1 , using a 
CGR 1000 Cath Lab system. Cardiac output was 
measured with the thermodilution method and 
recorded on paper at a speed of 10 mm s - 1. All 
pressures, pressure-derived indices of contractility 
(LV peak dp/dtpositive, dp/dt/P at40 mmHg (VCE 
40), V max total pressure) as well as cardiac output 
were determined on-line by a Mennen Cath Lab 
Computer system and calculations made from 12 
consecutive beats. The system allows for inter-
action with the computer before final calculations 
are made by showing representative tracings and 
measuring points before each determination. 
Coronary sinus blood flow was determined with 
the thermodilution techique during a continuous 
30 second infusion of 30-35 ml of glucose 5% at 
room temperature into the coronary sinusf19l. 
Both the mean and pulsatile flow were recorded 
continuously. Calculations were made during mid-
respiration after the mean flow curve had stabilized, 
towards the end of the infusion period. At the end of 
the investigation, the pressure curves from the 
femoral artery were compared with a simultaneous 
recording from the aortic root by the microman-
ometer catheter. Throughout the study, leads I, II 
and V 5 were continuously monitored and recorded 
at a paper speed of IOOmm s- 1 for the determi-
nation of heart rate and/or ST-segment changes. 
The ST-segment was measured in 5 consecutive 
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beats, 0·08 s after the J point, using a calibrated 
magnifying lens. 
METABOLIC MEASUREMENTS 
One ml of blood was collected simultaneously 
from the left ventricle and coronary sinus for lactate 
assay, transferred directly into precooled tubes 
containing I ml of icecold 8% HCL0 1 , mixed 
thoroughly and kept on ice during the study. After 
the investigation, lactate was determined in tripli-
cate using an enzymatic method, described by 
Guttman and Whalefe]df20l. Standard deviation 
of the determination in our laboratory is 
0·012 mmoll- 1 . Venous and arterial 0 2 saturation 
values are measured using an American Optical 
Oxymeter. 
CALCULATIONS 
Derived haemodynamic values (stroke volume 
index; stroke work index; systemic, pulmonary and 
coronary vascular resistance; myocardial 0 2 con-
sumption and the double product (DP), an index 
of myocardial 02 demand) were calculated using 
standard formulasf21 l. 
Myocardial lactate extraction(%) was calculated 
as 
L -L 
_A __ csx 100% L , 
A 
where LA and Lcs are the arterial and coronary 
sinus lactate levels, respectively. 
STUDY PROTOCOL 
A stabilization period of 20 min was allowed 
after positioning of the catheters in order to reach 
a minimum interval of 40 min between the last cor-
onary angiogram and the study. Multiple control 
determinations of all variables, except cardiac out-
put, were then made to ensure stable baseline 
values, which were then followed by the first atrial 
pacing stress test (APST I). During pacing, heart 
rate was elevated with increments of 10 beats per 
2 min until either angina pectoris was present to a 
similar degree as would discontinue physical exer-
cise in normal life, atrioventricular block occurred, 
or a maximal pacing heart rate of 170 beats min- 1 
was reached. All variables were re-evaluated at pre-
fixed intervals during pacing, e.g. at 100, 120, 140, 
160 beats min-\ during maximal pacing heart 
rates, followed by measurements 15 s, I, 2 and 5 min 
after pacing. The degree of angina during pacing 
was assessed using a scoring system ranging from 0 
968 W. J. Remme et a!. 
(no angina) to 10 (severe angina). After a 30 minute 
stabilization period after pacing, multiple control 
measurements were again determined. Diltiazem 
was thereupon administered intravenously by a 
motor driven infusion pump in a dose of 
0·4 mg kg- 1 over 5 min, followed by 0·4 mg kg- 1 
over 10 min. Repeat measurements of all variables 
were carried out 1, 3, 5, 10 and 15 min after the onset 
of the infusion. Cardiac output measurements were 
made at baseline before the infusion, followed by 
repeat determinations at 5 and 15 min after onset of 
diltiazem administration. Immediately after the 
infusion a second atrial pacing stress test (APST II) 
was carried out, identical to APST I. To ensure 
similar pacing heart rates during both pacing stress 
tests, all patients received 0·5 mg atropine before 
each APST. Blood sampling for diltiazem assay was 
carried out at control before diltiazem infusion, at 5 
and 15 minutes after onset of diltiazem adminis-
tration and in some patients at maximal pacing 
heart rates during APST II. 
STATISTICAL ANALYSIS 
Measurements during diltiazem administration 
were compared with baseline (control) values. A t 
test for paired observations with 16 degrees of 
freedom was used, as the object of this analysis was 
to test differences with the baseline observation. In 
a separate analysis a linear regression model was 
used to study the effect measures in relation to the 
plasma levels of diltiazem. A 2-tailed P value < 0·05 
was considered significant. The comparisons of 
measurements during atrial pacing before and after 
diltiazem were also made using a t test for paired 
observations, with a 2-tailed P value < 0·05 indi-
cating significant differences from zero. Data are 
presented as mean values ± 1 standard error of the 
mean. 
Results 
SYSTEMIC HAEMODYNAMIC CHANGES DURING 
DILTIAZEM INFUSION (TABLE 2) 
Initially, no changes occurred. However, 3 min 
after the onset of diltiazem administration both left 
ventricular systolic pressure and aortic pressures 
decreased significantly. A reduction, which per-
sisted throughout the infusion period with a maxi-
mal decrease in left ventricular systolic pressure 
of 13% at the end of the infusion period, 
from 133 ± 5·5 mmHg (control) to 116 ± 5·5 mmHg 
( 15 min diltiazem infusion, P < 0·005) and a similar 
maximal reduction in mean aortic pressure, 5 and 
10 min after the onset of the diltiazem infusion 
Table 2 Systemic haemodynamic changes during diltia=em administration 
Time after onset of diltiazem infusion 
Haemodynamic variables baseline (0-4 mg kg-
1 per 5 min, followed by 0·4 mg kg- 1 per I 0 min) 
HR (beats/min) 
LVSP(mmHg) 
LVEDP(mmHg) 
MAP(mmHg) 
CO (!/min) 
SVR (dynes s em-s) 
SI (mljbeatjm2 ) 
SWI(gmm2 ) 
LV peak dp/dt pos (mmHg.s -J) 
V max(S- 1) 
PAS(mmHg) 
PAD(mmHg) 
PAM(mmHg) 
PVR (dynes s em- 5) 
84±4 
133±5 
13±2 
102±3 
5·9±0·4 
1343± 104 
37±3 
45±4 
1487±86 
45±3 
28±3 
13±2 
18±2 
166 ±32 
1 min 3min 
85±4 
130±6 
13±2 
99±3 
1504±92 
47±3 
25±2 
12±1 
16±2 
87±4 
121 ±6*t 
13±2 
92±3·5** 
1523±107 
48±3 
28±3 
14±2 
19±2 
5min 
86±3 
117 ±5** 
14±2 
88±3** 
7·3 ±0·6*t 
944±85tt 
45±3*t 
44±4 
1493 ± 101 
49±3 
26±2 
13±1 
17±1 
149±31 
*P<0·05; tP<0·025; *tP<O·Ol; **P<0·005; ttP<O·OO! vsbaseline. Values aremean±SEM. 
lOmin 15min 
81±3 79±3 
117±5** 116±5** 
14,5±2 14±2 
88±4** 89±3** 
6·8±0-4t 
908±9Itt 
43±3t 
44±4 
1489± 106 1434± 102 
48±3 46±2 
27±2 31±4 
13±1 16±2 
17±1 21±2·5 
148±28 
CO= cardiac output; HR =heart rate; L VEDP =left ventricular end diastolic pressure; L VSP =left ventricular systolic press-
ure; MAP= mean aortic pressure; min= minute; PAD= pulmonary artery diastolic pressure; PAM= pulmonary artery mean 
pressure; PAS= pulmonary artery systolic pressure; PVR =pulmonary vascular resistance; s =seconds; SI =stroke index; 
SVR =systemic vascular resistance; SWI =stroke work index. 
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from 102±3mmHg (control) to 88±3mmHg 
(5 min ·diltiazem, P < 0·005). Systemic vascular 
resistance decreased from 1343 ± 104 dynes s em- 5 
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(control) to 944±85 dynes s cm- 5 at 5min 
(P<0·001), and to 908 ± 91 dynes s em - 5 at 15 min-
utes after the onset of diltiazem infusion 
(P<0·001), a reduction of 32%. Cardiac output 
concomitantly increased by 24% from 5·9 ± 
0-41 min-! (control) to 7·3 ±0·61 min-! (5 min 
diltiazem, P<0·001) and was still elevated by 15% 
at the end of the infusion. Heart rate, contractility 
indices and left ventricular end diastolic pressure 
remained unaltered. Pulmonary artery pressures 
ahd pulmonary vascular resistance did not change 
either. 
CORONARY HAEMODYNAMIC CHANGES DURING 
DILTIAZEM ADMINISTRATION (TABLE 3) 
04 mg kg- 1 ( 5 min-1) 0·4 mg kg- 1 ( 10 min- 1 ) 
A significant reduction in coronary vascular re-
sistance was first observed 3 min after the beginning 
of the infusion with a maximal decrease of 29% at 
5 min of diltiazem (0·56 ± 0·05 mmHg ml- 1 min -I 
vs 0· 79 ± 0·08 mmHg ml- 1 min- 1 (control), P < 
0·0025). Although, in contrast to the persisting 
changes in systemic vascular resistance, coronary 
resistance increased thereafter (Fig. 1 ), it was still 
significantly reduced at the end of the infusion. 
Despite the reduction in aortic pressures, coronary 
sinus flow increased by 20%, from 138 ± 
15mlmin- 1 (control) to 166± 17m! min~ 1 (5 min 
diltiazem), P<0·05. This increase in flow occurred 
late, however, and was short-lasting, being 
observed for only 5 and 10 min after the onset of 
diltiazem administration (Fig. 2). Myocardial 
oxygen extraction decreased significantly between 3 
and 15 min of the infusion period with a maximal 
reduction of 21% at 5 min of diltiazem infusion 
[difference between arterial and coronary sinus 0 2 
Figure I Temporal relation between systemic and coronary 
vascular effects of diltiazem. At the end of the infusion the 
decrease in systemic vascular resistance persists, whereas 
changes in coronary vascular resistance have already returned 
towards baseline values. At this time cardiac output is still 
increased, in contrast to coronary flow. (C =control; CO= 
cardiac output; CSBF =coronary sinus flow; CVR = coron-
ary vascular resistance; min= minute; SVR =systemic vascu-
lar resistance; * P < 0·05 vs C). 
Table 3 Coronary haemodynamic changes during diltiazem administration 
Time after onset of diltiazem infusion 
Haemodynamic variables Baseline (0-4 mg kg-
1 per 5 min, followed by 0·4 mg kg- 1 I 0 min) 
!min 3min 5min !Omin 15min 
CSBF (ml min- 1 ) 138±15 142±3 152±16 166±17* 160±17* !51± 15 
CVR (mmHg ml- 1 min- 1) 0·79±0·08 0·73±0·07 0·62±0·07* 0·56±0·05*t 0·50±0·08** 0·71±0·07* 
.6A-CS 0 2 content (vol %) 7-0±0-4 6·9±0·3 6·3±0·4** 5·6±0·4** 5·8±0-4** 5·9 ±0-4** 
MV0 2 (mlmin- 1) 9·8± 1·1 9·8±1·0 9·7± 1·1 8·8±0·9 9·2±0·8 8·9±0·9 
DP (HR x LVSP x w- 3) 10·9±0·5 11±0·6 10-4±0·5 9·9±0·5* 9-4±0·5* 9·1 ±0·6* 
* P<0·05; *tP<0·01; ** P<0·005 vs.baseline. Values are mean ±SEM. 
A= arterial; CS =coronary sinus; CSBF =coronary sinus blood flow; CVR =coronary vascular resistance; MV02 = myocar-
dial oxygen consumption; DP=modified tension-time index or double product; other abbreviations as in Table 2. 
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Figure 2 Effect of diltiazem on myocardial lactate balance 
during pacing. During the first atrial pacing stress test (APST 
I) before diltiazem, lactate production is present during maxi-
mal pacing heart rates (AP) and the first minute after pacing. 
After diltiazem, during and after the second atrial pacing test 
(APST II) average lactate extraction values remain positive, 
indicating a significant reduction in ischaemia (art =arterial; 
C =control; p-p =post-pacing; ven =coronary venous 
*P<0·05 vsC). 
content: 5·55 ±0-42 vol% vs 7·0 ± 0·45 vol% (con-
trol), P < 0·005]. Myocardial oxygen consumption 
did not change though, despite a 17% reduction 
in myocardial oxygen demand at the end of the 
infusion period [DP: 9·1 ± 0· 7 at 15 min diltiazem vs 
10·9±0·5 (control), P<0·05]. 
EFFECTS OF DILTIAZEM ON CORONARY AND SYSTEMIC 
HAEMODYNAMICS DURING PACING (TABLE 4) 
Maximal pacing heart rates were comparable 
during both pacing stress tests: 153 ± 5 beats min- 1 
(APST I) and 150 ± 5 beats min- 1 (APST II). 
Myocardial oxygen demand (DP), however, was 
significantly diminished during and after APST 
II, because of a persisting 18% reduction in left 
ventricular systolic pressure during pacing after 
diltiazem (P<0·01 vs APST I). This resulted in 
a reduction in myocardial oxygen consump-
tion (ll·l ± 1-4 ml min -I (APST II) vs 14· 7 ± 
1·6 ml min -I (APST I), P < 0·005) and less increase 
in coronary sinus flow (187 ± 16 ml min -I (APST 
II) vs 217 ± 19 ml min- 1 (APST I), P < 0·05) during 
maximal pacing heart rates. Contractility on the 
other hand, had improved during pacing after 
diltiazem. At the end of APST II V max was 59± 
4·9s- 1 vs 48±3·2s- 1 at the end of APST I 
(P<O·OS). 
EFFECTS OF DILT!AZEM ON PACING-INDUCED 
ISCHAEMIA 
Myocardial lactate production, present during 
APST I, was absent during pacing after diltiazem. 
Whereas the arterial lactate levels did not change 
throughout the entire investigation and lactate 
extraction was normal during the control periods 
before both stress tests, coronary venous lactate 
levels rose significantly during APST I. This 
resulted in lactate production during maximal 
pacing heart rates (- 16 ± 4%) and in the first 
minute after pacing ( -41 ± 12%, 15 s post-pacing). 
In contrast, during APST II after diltiazem, the 
mean lactate extraction values remained positive 
(Fig. 2). Although some patients still produced lac-
tate during the second pacing test, the individual 
values were significantly less than the correspond-
ing values during the first test in all but one patient 
(Fig. 3). The antiischaemic properties of diltiazem 
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Figure 3 Individual lactate extraction values 15 seconds 
after the control pacing stress test (APST I) and 15 seconds 
after pacing with diltiazem (APST II). There is a significant 
reduction of lactate production values or a return towards 
normal lactate extraction in all but one patient, who pro-
duced lactate during APST I (art=arterial; ven=coronary 
venous* P<0·05 APST I vs II). 
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Figure 4 Significant reduction by diltiazem of ST-segment 
changes and left ventricular end diastolic pressure (L VEDP) 
during the second pacing test (APST II) compared to the 
control test (APST I). These differences in ST-segment 
changes are already present at 120 beats min_, before angina 
and persist, as well as the difference in L VEDP, until 5 min-
utes post-pacing (p-p) (AP=maximal pacing heart rates; 
C =control; * P < 0·05 APST I vs II). 
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were emphasized as well by a reduction in ST-
segment depression during and after APST II 
[0·12±0·01 mV vs 0·24±0·02mV (APST 1), 
P < 0·05] and by normalization of left ventricular 
~nd diastolic pressure immediately after pacing 
[13±2 mmHg (APST II) vs 27±2·8 mmHg (APST 
1), P < 0·0 1 (Fig. 4)]. Moreover, whereas angina was 
present in all patients during APST I, it was absent 
in 7, less severe in 8 and similar in only 2 patients 
during pacing after diltiazem. 
PLASMA DIL TIAZEM LEVELS 
Plasma diltiazem levels were high during the 
infusion period as would be expected. After 
the initial infusion rate, at 5 min the mean 
concentration was 673 ± 8lJ1g 1- 1 , declining to 
445 ± 73 Jlmg 1- 1 at the end of the infusion. There 
was no significant correlation between individual 
plasma levels and percent changes in haemo-
dynamic parameters. In the last 5 patients to be 
studied, ~iltiazem plasma levels were also deter-
mined during maximal pacing heart rates during 
APST II, 13 ± 1·8 min after the end of the infusion 
period. The average diltiazem level at this time of 
the study had declined to 193 ± 23 Jlg 1- 1 . 
Table 4 Effec/s of diliia::em on coronary and syslemic haemodynamics during pacing 
During pacing After pacing 
Haemodynamic variables baseline 
100 beats min_, 120 beats min-t MAX I min p-p 5 minp-p 
LVSP(mmHg) 
APSTI 137±6 132±9 131 ±5 136±6 141±6 136±6 
APST II 116±5·5* 117±5* 112±4* 111±5* 114±6* 117±5* 
DP(x10- 3) 
APSTI 10·2±0·5 13-0±0·6 15·7±0·5 21·1±1·1 11·7±0·9 11·6±0·6 
APST II 9·1±0·7 11·6 ±0·5*t 1H±0·5*t 16·3±0·8** 10·5±0·6 10·5±0·5 
LV dpjdt pos (mmHg s- 1) 
APSTI 1466±75 1542± 125 1693±88 1849±104 1602± 170 1534±82 
APST II 1434± 102 1540±86 1547±92 1704±133 1527 ± 89 1508 ± 93 
V max (S- 1) 
APSTI 42±2 46±2 51±3 48±3 44±4 45±3 
APST II 46±2·5 52±3 54±3 59±5* 52±4 50±3 
CSBF (ml min- 1) 
APSTI 147±15 148± 13 191±24 217±19 159± 15 147±15 
APST II 151±15 135± 13 166±17 187±16* 135±13 146± 13 
CVR(mmHgm1- 1 min- 1) 
APSTI 0·68±0·06 0·70±0·06 0·57±0·06 0·58±0·05 0·75±0·07 0·73±0·05 
APSTII 0·73±0·07 0·72±0·07 0·67±0·07 0·59±0·05 0·71±0·07 0·66±0·06 
MV0 2 (m1min- 1) 
APSTI 10·9±1·2 10·0± 1·6 12·8±1·7 14·7±1·6 10·3±1·2 10·6±1·3 
APST II 8·9±0·9 9·0± 1·3 11·1 ± 1-4 12·5± 1·1* 9·2± 1·3 9-6±1·1 
*P<0·05; *tP<O·Ol; **P<0-005, APST I vs APST II. Values aremean+SEM. 
MAX= maximal heart rates; APST =atrial pacing stress test; p-p =post-pacing; other abbreviations as in Tables 2 and 3. 
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ADVERSE EFFECTS 
Diltiazem was well tolerated. Side-effects were 
not observed. In one patient (no. 9) left ven-
tricular systolic pressure temporarily decreased 
from 103 mmHg to 78 mmHg halfway through the 
infusion, however, without signs of ischaemia. 
Discussion 
ACUTE HAEMODYNAMIC EFFECTS OF DILTIAZEM 
In this study, diltiazem, administered intra-
venously at relatively high dosages, induced 
pronounced systemic and coronary vasodilating 
effects, which resulted in a reduction in afterload, 
improvement ofleft ventricular pump function and 
an increase in coronary flow. Whereas with lower 
dosages, ranging from 18 to 3 5 J..Lg kg- 1 min- 1 , 
an improvement in cardiac output is observed as 
well, coronary blood flow does not increase in 
humansl9•11 l. Although coronary vascular resist-
ance is significantly reduced with these lower 
dosagesl11 · 12.1 6l this effect apparently is not sufficient 
to offset the impact of systemic vasodilation on 
coronary perfusion pressure in a situation where 
myocardial oxygen demand is reduced as well. 
Clearly, higher dosages of diltiazem, as used in the 
present study (53 J..Lg kg- 1 min - 1) are needed to 
induce a significant rise in coronary flow. Apart 
from these quantitative differences, the effects of dil-
tiazem on systemic versus coronary vascular beds 
differ in duration as well. Whereas, in t.he present 
study, coronary vascular changes already returned 
towards baseline values during the infusion period, 
the systemic vascular effects were definitely longer 
lasting. Systemic vascular resistance was still 
decreasing at the end of the infusion period, 
whereas the reduction in left ventricular systemic 
and aortic pressures persisted until at least 5 min 
after the second atrial pacing stress test. In contrast, 
the increase in coronary flow was shortlasting, 
only being observed halfway through the infusion 
period. 
Despite the pronounceCl reduction in afterload, 
reflex positive chronotropic or inotropic effects, 
caused by baroreceptor-mediated sympathetic 
stimulation, did not occur. A secondary increase 
in heart rate is commonly found in patients with 
coronary artery disease during intravenous admin-
istration of calcium-entry blocking agents, par-
ticularly with the dihydropyridine derivatives 
nifedipinel22·23l, nicardipinel24•25l and nisoldipinel26l 
as well as with bepridill17•18l. In contrast, no such 
changes are reported with verapamil, presumably 
because of its pronounced negative chronotropic 
and inotropic effects, which offset the increase in 
sympathetic drive during afterload reductionl27.28l. 
In animal experiments the acute administration of 
diltiazem in dosages, which produce hypotension, 
does not result in changes in contractility and only 
leads to a modest increase in heart ratel29l, whereas, 
in humans, diltiazem at lower dose levels has been 
reported to decrease heart ratel30l. The absence of 
a secondary increase in heart rate and contractility in 
our patients therefore seems best explained by the 
intrinsic negative chronotropic and inotropic 
properties of diltiazem. 
EFFECTS ON HAEMODYNAMICS DURING PACING 
The predominant haemodynamic effects of dil-
tiazem during pacing consisted of a decrease in 
left ventricular systolic and aortic pressure, thereby 
reducing the double product and myocardial oxy-
gen demand. Diltiazem did not result in an ad-
ditional increase in coronary sinus flow during 
pacing. In contrast, coronary sinus flow was sig-
nificantly reduced during pacing after diltiazem, 
compared with the first pacing test. Thus, it seems 
unlikely that the higher dosages used in the present 
study result in an improvement of myocardial 
oxygen supply to the ischaemic regions. This is 
an assumption that cannot be verified, however, as 
the thermodilution technique does not measure 
regional post-stenotic coronary flow. Theoretically, 
the reduction in coronary sinus flow, could have 
been the result of a reduction in oxygen demand in 
the normal myocardial areas alone. Moreover, even 
with an overall reduction in coronary flow, the 
decrease in left ventricular filling pressure and dias-
tolic wall tension during pacing after diltiazem may 
in fact improve subendocardial post-stenotic flow. 
Even so, the significant reduction in myocardial 
oxygen demand in the present study is sufficient to 
explain the antiischaemic properties observed. A 
similar mechanism for the reduction in pacing-
induced ischaemia has been reported for other 
calcium-entry blocking agentsl31 - 34l and for other 
vasoactive drugs, such as amiodaronel35l. In these 
studies coronary flow did not increase during pac-
ing after drug administration or was reported to 
decreasel32l. Only felodipine induced a greater 
increase in coronary flow during atrial pacingl36l. 
This suggests that, like diltiazem, these agents affect 
pacing-induced ischaemia predominantly by a 
reduction in myocardial oxygen demand, rather 
than an increase in oxygen supply. 
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EFFECT OF OIL TIAZEM ON PACING-INDUCED ISCHAEMIA 
The antiischaemic properties of diltiazem were 
clearly demonstrated by a reduction or absence 
of classic symptoms of ischaemia, e.g. angina, ST-
segment changes and alterations in left ventricular 
filling pressure after pacing. More importantly, it 
was also demonstrated by normalization of lactate 
metabolism during pacing after diltiazem. Myocar-
dial lactate production is reproducible, provided a 
minimum interval of 45 minutes between atrial 
pacing stress tests is adhered to[37l. The significant 
reduction in lactate production observed during the 
second atrial pacing stress test underlines the anti-
ischaemic properties of diltiazem. Moreover, con-
tractility, measured by the velocity parameters 
(VCE40, V maJ, which are less load-dependent than 
conventional pressure-derived indices[38l, actually 
increased during pacing after diltiazem. Together 
with the reduction in left ventricular filling pressure 
this suggests an improvement in left ventricular 
systolic function, alone or in combination with an 
increase in left ventricular compliance, due to the 
reduction of ischaemia. 
PLASMA OIL TIAZEM LEVELS 
Despite the very high plasma diltiazem levels no 
untoward haemodynamic or clinical effects were 
observed. In one patient a drastic fall in blood 
pressure occurred. However, in this case diltiazem 
plasma levels were not unduly high. Conversely, 
in patients with markedly elevated plasma levels, 
haemodynamic changes were not different from the 
other patients. Thus, no correlation was present 
between diltiazem plasma levels and cardiovascular 
effects of the drug. Although in the present study a 
pronounced antiischaemic effect was observed, the 
limited number of diltiazem plasma levels during 
maximal pacing heart rates preclude any sensible 
correlation between therapeutic effects and plasma 
levels of diltiazem. 
CLINICAL IMPLICATIONS 
The present study indicates that diltiazem, 
known to have antianginal properties when given 
orally, also has pronounced antiischaemic proper-
ties during intravenous administration, provided 
that rather high dosages are given. As this dose 
regimen is well tolerated, even by patients with 
markedly diminished left ventricular function[39l, 
it would appear that diltiazem in these dosages 
may be given safely to patients with acutely com-
promised ventricular function due to acute ischae-
mia and/or infarction. Although, at present, it is 
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uncertain whether calcium-entry blocking agents 
can limit infarct size, it may be anticipated that 
the reduction in myocardial oxygen demand during 
diltiazem administration leads to a reduction of 
accompanying ischaemia. Moreover, diltiazem in 
these circumstances may improve ventricular pump 
function, both by a direct unloading effect on the 
ventricle as well as by its antiischaemic properties. 
The results of the present study therefore indicate 
that diltiazem, given intravenously, should benefit 
the acutely ischaemic patient and that further 
studies are warranted in patients with acute myo-
cardial ischaemia and/or infarction to elucidate 
further its potential as an antiischaemic agent under 
these circumstances. 
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SUMMARY 
Acute hemodynamic effects and tolerability of 
intravenous amiodarone, 5 mg/kg administered 
over 5 minutes, were compared in patients with 
coronary artery disease and either a normal (left 
ventricular (LV) ejection fraction .::_45%, n=lO, 
gr. N) or impaired LV function (ejection fraction 
<45%, n=9, gr. L). 
Amiodarone acutely reduced systemic vascular 
resistance and LV and aortic pressures in both 
groups [13%, 18% and 13%, resp., (gr. N) and 
15%, 17% and 15%, resp.(gr. L)]. Heart rate 
initially increased (18%, gr. Land 10%, gr. N), but 
followed by a late 6% decrease, in gr. N only, and 
by a progressive reduction in contractility (Vmax) 
together with a rise in LV end diastolic pressure 
[19 and 38%, resp. (N) and 17% and 58%, resp. 
(L)], all values p<0.05 vs control. Coronary flow 
increased significantly with 20% (gr. N) and 31% 
(gr. L), but only during amiodarone adminis-
tration, accompanied by a 26% and 25% reduction 
in myocardial oxygen extraction in groups N and L 
resp. Stroke work decreased in both groups [20% 
(gr. N) and 19% (gr. L), p <.05 vs control]. In 
contrast, cardiac output only improved (10%) in 
patients with impaired ventricular function. Sig-
nificant side effects did not occur. Thus, relatively 
high dosages of intravenous amiodarone are well 
tolerated and improve cardiac pump function in 
patients with an impaired, but not with a normal 
cardiac ftmction. However, the tendency to 
increase LV end diastolic pressures cautions for 
careful monitoring in patients in whom preexisting 
LV filling pressure may be elevated. 
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INTRODUCTION 
Acute myocardial ischemia and/or infarction and 
subsequent cellular instability may result in serious 
ventricular dysrhythmias, requiring immediate 
antiarrhythmic therapy. As ventricular function 
frequently is decreased as a result of ischemia, 
contractility changes as a result of antiarrhythmic 
therapy(!) may be contraindicated in this situation. 
To achieve therapeutic drug levels quickly, rela-
tively high dosages of the antiarrhythmic have to 
be administered intravenously. This may lead to a 
further deterioration of cardiac pump function as a 
result of dose-related negative inotropic proper-
ties. In this respect, it has been suggested that 
amiodarone, given orally, compares favourably to 
other antiarrhythmics, having little or no negative 
inotropic effects on the one hand and peripheral 
vasodilating properties on the other(l). This may 
be different during intravenous administration. 
Animal studies uniformly indicate that, besides 
coronary and systemic effects and negative 
inotropic properties, intravenous amiodarone also 
results in a dose-dependent reduction in contrac-
tility and subsequent increase in left ventricular 
filling pressures(2-6). Although the hemodynamic 
profile of intravenous amiodarone in humans may 
vary considerably, despite identical dosagesC7-10), 
a clear reduction of contractility has been demon-
strated in two studies in patients with a normal 
preexisting left ventricular functionClO,ll). In 
contrast, although some studies suggest a pre-
dominant cardiodepressant effect in patients with 
ventricular dysfunction<12,l3) the systemic and 
coronary hemodynamic effects of amiodarone are 
only incompletely evaluated in this patient group 
and not compared with those with a normal 
ventricular function. The present study compares 
the hemodynamic effects and tolerability of a 
loading dose of intravenous amiodarone, which in 
earlier studies was reported effective against 
ventricular arrhythmias04,15), in patients with 
diminished versus normal ventricular function. 
METHODS 
Patients 
After informed consent, 19 patients, 18 men and 1 
woman, mean age 53±1.4 yrs, range 42-67, 
entered into the study. To ensure a homogeneous 
study group, only patients with stable exercise-
induced angina and objective signs of ischemia 
during exercise testing and/or a documented old 
myocardial infarction were studied. Patients with 
systemic hypo- or hypertension, a recent myocar-
dial infarction (less than 3 months ago), conduc-
tion disturbances, bradycardia or signs of conges-
tive heart failure were excluded. Cardiac therapy 
was tailed off 48-72 hours before the investigation 
with the exception of short-acting nitroglycerin, 
which was permitted up to 12 hours before the 
study. None of the patients had previously receiv-
ed antiarrhythmic therapy. To participate, sig-
nificant coronary artery disease ~70% diameter 
stenosis of one or more epicardial coronary 
arteries) had to be present. Based on the ventricular 
ejection fraction, angiographically determined, 
patients were separated into those with a normal 
left ventricular function (ejection fraction ~45%, 
group N, n=10) and those with an impaired left 
ventricular function (ejection fraction <45%, group 
L, n=9). Clinical characteristics and angiographic 
data of patients in both groups are given in Table I. 
Groups were comparable with respect to sex, age 
and number of coronary artery lesions. By design, 
left ventricular ejection fraction was significantly 
different [57±2% (group N) versus 31±3% (group 
L)]. Likewise, left ventricular end diastolic 
volumes were different [64±6 mlfm2 (group N) 
versus 95±9 ml/m2 (group L), p<0.05] whereas the 
number of previous infarcts was greater in patients 
with diminished left ventricular function. 
Catheterization procedures and 
instrumentation 
Studies were carried out during left and right heart 
catheterization in the morning, after an overnight 
fast and without premedication. First, left and 
right coronary angiography was performed using 
the Seldinger technique, to ensure eligibility for 
the study. Then, a nr. 7 Fr balloon-tipped triple 
lumen thermodilution catheter was positioned in 
the pulmonary artery via a Desilet system in the 
right femoral vein. Next a nr. 7 Fr Millar microtip 
manometer catheter was introduced into the left 
ventricle through a Desilet introducer system in the 
femoral artery, the side arm of which was used to 
record arterial pressures. Finally, a nr. 7 Fr ther-
modilution pacing catheter was inserted in the 
coronary sinus through a brachial vein positioned 
such that the proximal thermistor was at least 2 em 
beyond the orifice of the coronary sinus and its 
position stable. The absence of atrial reflux was 
confirmed by a bolus injection of saline into the 
right atrium. The position of the catheters was 
subsequently recorded on video-disc to allow 
rechecking during the investigation. 
Measurements and calculations 
After calibration of the fluid- filled catheters with a 
zero reference level set at midchest, the micro-
manometer pressure was balanced to zero and 
superimposed on the conventional pressure 
tracings. Pressure and flow signals and the first 
derivative of left ventricular pressures (LV dp/dt) 
were recorded on paper using a CGR 1000 cathlab 
system. Cardiac output was measured on -line by a 
Mennen cathlab computer system. Also, by way of 
this system, pressures and pressure-derived 
contractility indices were determined on -line from 
12 to 15 consecutive beats. Coronary sinus blood 
flow was measured during a continuous 30 second 
infusion of 30 to 35 ml of glucose 5% at room 
temperature, using the method of Ganz et al(l6). 
Both the mean and phasic flow were recorded and 
calculations made from the mean flow curve. At 
the end of the study the pressure curves from the 
femoral artery were compared with a simultaneous 
recording from the aortic route by the 
micromanometer catheter, to compensate for any 
difference between proximal and distal arterial 
pressures. Arterial and coronary venous oxygen 
saturation values were measured using an 
American optical oxymeter. 
Hemodynamic measurements 
Hemodynamic measurements included mean and 
phasic systemic arterial, pulmonary arterial and 
right atrial pressures (mmHg), left ventricular 
peak systolic and mean and end diastolic pressures 
(mmHg), pressure derived contractility indices 
[left ventricular dp/dt (mmHg.sec-1) and Vmax 
total pressure (sec-1)]. Thermodilution cardiac 
output was determined in triplicate. From the 
measured hemodynamic parameters the following 
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Table 1: Baseline clinical and angiographic characteristics. 
Gr.N Gr.L 
(ejection fraction .::_45%) (ejection fraction <45%) 
Sex 9 male/1 female 
Age 52±1.6(42-58 yrs) 
Previous myocardial infarction 3 
Coronary angio: 
(.::.70% diameter stenosis) 
1- vessel 2 
2- vessel 5 
3- vessel 3 
Left ventricular ejection 57±2 
fraction% 
Left ventricular end diastolic 64±6 
volume (ml/m2) 
t p<0.05 group L vs group N. Values are :X± SEM 
variables were calculated according to previously 
described formulasC17): coronary vascular resis-
tance (CVR, mmHg/ml/min), s~stemic vascular 
resistance (SVRi dynes.sec.cm- ), stroke index 
(SI, mllbeat/m ), stroke work index (SWI, 
g/m/m2), myocardial oxygen extraction 
(~A -CS02 , vol %), myocardial oxygen consump-
tion (MV02, ml/min). 
Studyprotocol 
Approximately 30 to 45 minutes after the last 
coronary angiogram and 15 to 20 minutes after 
instrumentation, multiple control measurements of 
all hemodynamic variables were carried out to 
ensure stable baseline values. Thereafter, amio-
darone was infused, 5 mg/kg over 5 minutes. 
Repeated measurements of all variables were 
performed at 1, 3, 5 and 10 minutes after onset of 
amiodarone administration. Due to the rapid 
sequence of measurements, cardiac output deter-
minations were only carried out at 7.5 minutes 
after the beginning of drug infusion. 
Statistical analysis 
In each group, measurements made during amio-
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9 male 
55±2.8 (43-67 yrs) 
7 
2 
5 
2 
31±3t 
95±9t 
darone administration were compared with base-
line values before administration, using a t test for 
paired observations. A two tailed p value <.05 was 
considered significant. Differences in hemodyna-
mic values between groups were compared using a 
t test for unpaired observations with a two tailed p 
value <.05 considered significant. 
RESULTS 
Baseline hemodynamic values. 
At baseline, hemodynamic variables were 
comparable between the two groups, except for 
contractility parameters which were significantly 
lower in group L. 
Systemic hemodynamic effects of amiodarone 
in normal versus depressed ventricular function 
(Table II) 
Immediately following the onset of amiodarone 
infusion, left ventricular systolic and mean aortic 
pressures decreased with 18% and 13% resp. in 
group Nand with 17% and 15% resp. in group L. 
This reduction in pressures was of short duration. 
Already after 5 minutes following amiodarone 
Table IT: Systemic hemodynamic changes during amiodarone administration. 
After onset of amiodarone infusion 
control I min 3min 5~in IO min 
HR (beats/min) group N 83±5.8 89.5±6.7 92±5.9" 91±5.9" 78±5.5" 
group L 78±4.1 82±4.3 92±4.4" 87±4.8" 81±3.0 
LVSP(mmHg) groupN 139±5.1 125±7.0 114±3.2" 119±3.7" 127±4.2 
groupL 136±1.4 127±9.3 113±8.0" 121±9.9" 137±9.9 
MAP(mmHg) groupN 105.5±4.0 99.0±2.4 92±3.3" 95±3.2" 105±2.3 
groupL 97±5.5 88±3.5"t 83±2.9" 88±4.8" 91±5.2t 
SVR groupN 1780±104 1551±951* 
(dynes.s.cm-5) group L 1730±108 1469±1191" 
CO (!/min) group N 4.9±0.4 5.1±0.31 
group L 4.5±0.2 4.9±0.31" 
SVI (ml/beat/m2) groupN 31.3±2.6 29.7±1.41 
group L 31.2±2.2 30.5±2.71 
SWI (g.m.m2) groupN 41.1±4.0 32.6±1.61" 
group L 35.7±2.7 29.1±2.61'' 
LV peak dP/?t pos group N 1867±142 1838±157 1832±211 1643±162" 1500±126* (mmHg.sec- ) group L 1492±114 1450±127 1521±170 1361±111" 1272±86" 
Vmax (sec-1) groupN 56.4±4.0 54.5±3.7 58.9±6.6 50.4±4.1" 45.6±4" 
group L 42.l±L6t 42.4±L9t 45.4±3.4 40.8±2.5" 34.7±1.1"t 
VCE40 (sec-1) groupN 38.4±3.1 39.1±3.3 39.1±4.8 33.4±3.2" 30.3±2.9" 
group L 28.3±1.4t 28.4±L8t 30.4±2.7t 26.7±1.9"t 23.3±0.7"t 
LVEDP (mmHg) group N 10±1.7 10±1.6 11±1.7 12±2.1 13±2.3" 
group L 12±1.5 10±1.5" 13±2.0 11±2.3" 19±2.7* 
PAM(mmHg) group N 16.5±0.9 18±1.1 21±1.4" 21±1.7" 21±1.3" 
group L 18±1.0 18±1.7 21±1.3" 22±1.0" 23±1.1" 
PVR group N 113±27 137±77 (dynes. s.cm-5) group L 111±35 80±46 
Abbreviations: CO = cardiac output; HR = heart rate; LVEDP = left ventricular end diastolic pressure; LVSP = left ventricular 
systolic pressure; MAP = mean aortic pressure; min = minute(s); PAM = mean pulmonary artery pressure; PAS = systolic 
pulmonary artery pressure; PVR =pulmonary vascular resistance; SI = stroke index; SVI = stroke volume index; SVR = systemic 
vascular resistance; SW1 = stroke work index. All values means ± standard error of the mean. 
* p<.05 vs control t p<.05 group L vs group N 
administration, pressures had returned to control 
values in both groups (Fig. 1). Amiodarone equal-
ly reduced systemic vascular resistance in both 
patient groups, 13% in group N and 15% in group 
L. Cardiac output remained unchanged in patients 
with a normal baseline left ventricular function. In 
contrast, in patients with a depressed left ventricu-
lar function, a significant 9% increase in cardiac 
output was observed (Fig. 1). However, stroke 
volume did not change, due to a significant 18% 
rise in heart rate, which started early after onset of 
drug administration and persisted until the end of 
the infusion (Fig. 2). In group N, heart rate also 
increased, but to a lesser extent (11% versus 
control, p<0.05), followed by a late reduction, 5 
minutes after amiodarone. Left ventricular stroke 
work decreased with 21% in group Nand with 18% 
in group L (both p<0.05 versus control). 
Amiodarone significantly reduced contractility in 
both groups, which started already during the 
infusion, despite the concomitant increase in heart 
rates. Changes in left ventricular dp/dt and V ma15. 
were progressive, with a maximal reduction or 
20% and 19% in group Nand of 15% and 18% in 
group L., 5 min after the end of amiodarone 
administration (Fig. 2). In group L, left ventricular 
end diastolic pressure initially decreased with 15%. 
However, subsequently it increased in both 
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Fig. 1: Acute, but shortlasting effects of intra-
venous amiodarone on systemic vascular resis-
tance (SVR), left ventricular systolic pressure 
(LVSP) and mean aortic pressure (MAP), compar-
able in both groups. 
Amiodarone improved cardiac output (CO) in 
patients with impaired ventricular function at 
base level (group L, closed symbols), but not in 
patients with a normal ventricular function (group 
N, open symbols). 
S1 =stroke index; ef =ejection fraction. 
groups, parallel to the changes in contractility, 
from 10 mmHg (control) to 13 mmHg (5 min after 
amiodarone) in group N and from 12 mmHg 
(control) to 19 mmHg (5 min after amiodarone) in 
group L (Fig. 2). 
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Coronary hemodynamic effects of amiodarone 
in patients with normal versus diminished 
ventricular function (Table ill) 
A significant but similar reduction in coronary 
vascular resistance was observed in both groups, 
again only during amiodarone infusion, with a 
Fig. 2: Effects of amiodarone on heart rate (HR), 
contractility indices (LV dpldt, Vmax) and left 
ventricular end diastolic pressure (LVEDP). 
Amiodarone induced significant 11% and 18% 
increases in heart rate early after drug adminis-
tration in groups N (open symbols) and L (closed 
symbols) resp., followed by a late reduction in 
patients with normal ventricular function at base-
line. Progressive, but similar reductions in 
contractility are observed in both groups, accom-
panied by a late 30% and 55% increase in LVEDP 
in groups N (open symbols) and L (closed 
symbols) resp. ef = ejection frastion. 
HR 
b/min 
LV dp/dt 
pos. 
mmHgs·1 
LVEDP 
mmHg 
19 pts with CAD 
D-O ef > 45% (n = 1 0) x ± SEM 
•-• ef < 45% (n = 9) * p < .05 vs. C 
t p < .05 L vs. N 
90 
80 
70 
1900~ 1700 
1500 
1300 
60 
50 
40 
30 
20 
15 
10 
~-----------~L 
l·// I N 
. 
* 
AMIODARONE 5 mg/kg 
c 1' 3' 5' 10' 
Table ill: Coronary hemodynamic changes during amiodarone administration. 
After onset of amiodarone infusion 
control I min 3min 5min IOmin 
CSBF (ml/min) groupN 135±8.7 151±12.6* 162± 15.0* 149±9.3 136±9.9 
group L 134±19.6 162±21.6* 167±21.3* 176±27.7'' 157±15.5 
CVR (mmHg/ml/min) groupN 0.79±0.06 0.69±0.05 0.60±0.05* 0.65±0.03'1' 0.79±0.05 
groupL 0.83±0.10 0.60±0.07* 0.58±0.09* 0.60±0.09* 0.67±0.08 
flA-CS02 content groupN 12.0±0.7 11.0±0.7* 8.9±0.8* 9.1±0.8* 11.3±0.8 (vo1%) group L 11.8±0.7 10.3±0.7* 8.8±0.9* 9.9±1.1* 11.1± 1.1 
MV02 (ml/min) groupN 16.9±1.7 16.8±2.0 14.8±2.5 13.8±1.7"' 15.5± 1.6 groupL 15.6±2.1 15.9±1.6 13.6±1.1 15.8± 1.4 16.6±2.2 
TTl (HRxLVSPx10-3) groupN 11.3±0.6 10.8±0.7 10.5±0.7 10.8±0.7 9.9±0.8* 
group L 10.6±1.1 10.3±0.7 10.4±0.9 10.5±1.0 11.1±0.8 
Abbreviations: A = arterial; CS = coronary sinus; CSBF = coronary sinus blood flow; CVR = coronary vascular resistance; HR 
= heart rate; LVSP = Left ventricular systolic pressure; min = minute{s); MV02 = myocardial oxygen consumption; IT! = 
modified tension-time index or double product. ALL values mean ± standard error of the mean. 
* p<.05vs control 
maximum decrease of 24% (group N) and of 30% 
(group L). Despite the concomitant reduction in 
coronary perfusion pressure, coronary flow 
increased during this period (20% in group N and 
31% in group L, both p<0.05 versus control). 
These coronary hemodynamic changes were 
accompanied by a significant reduction in myocar-
dial oxygen extraction of 26% and 25% in group N 
and L, resp. In contrast, myocardial 02 consump-
tion did not change appreciably in group L. In 
group N a moderate 18% decrease in MV02 was 
observed at the end of amiodarone infusion 
(p<0.05 versus control). Again, these changes in 
myocardial energetics were of short duration, only 
observed during amiodarone administration. 
Adverse effects 
Amiodarone was relatively well tolerated in both 
groups. Shortlasting periods of facial flushing 
were reported in a few patients during the last 
minutes of amiodarone administration. 
DISCUSSION 
The aim of this study was to compare the acute 
hemodynamic effects and tolerability of a relative-
ly high intravenous dose of amiodarone in patients 
with normal versus diminished pre-existing 
cardiac function. Serious ventricular dysrhythmias 
are prone to occur during acute myocardial ische-
mia and/or infarction. As it is not uncommon in 
this situation, that myocardial function is depres-
sed as well, subsequent aggressive antiarrhythmic 
therapy may further compromise the latter. The 
intrinsic negative inotropic effects of antiarrhyth-
mic compounds generally are dose-related. Like-
wise, a progressive reduction in contractility has 
been reported with incremental dose-levels of 
intravenous amiodarone in open-chest anesthetized 
dogs(6). However, as its systemic vasodilating 
properties are equally dose-related, progressive 
unloading of the left ventricle with higher dosages 
of amiodarone may outbalance these negative ino-
tropic effects. Thus far, the systemic and coronary 
hemodynamic profile of high dosages of intrave-
nous amiodarone, such as administered in the 
present study, has not been systematically inves-
tigated in patients with pre-existing ventricular 
dysfunction or compared with those in patients 
with normal ventricular function. The present 
dose, 5 mg/kg amiodarone, was chosen, as 
previous studies has suggested that this dose, 
administered over 5-15 minutes, alone or followed 
by a maintenance infusion of 1000-1500 mg/24 
hours, may result in acute antiarrhythmic 
effects(14,15,18,19). 
Acute hemodynamic profile of intravenous 
amiodarone in normal versus diminished 
ventricular function 
The present study indicates that a high dose of 
intravenous amiodarone, given over a relatively 
short period, does not further compromise cardiac 
pump function. If anything, it improves it in 
patients with pre-existing ventricular dysfunction, 
but not in patients with a normal cardiac function 
at baseline. 
The hemodynamic profile of intravenous 
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Fig. 3: Significant similar reductions in coronary 
vascular resistance (CVR) in both groups, result-
ing in a 20% and 31% increase in coronary flow 
(CSBF) in groups N (open symbols) and L (closed 
symbols) resp. 
Simultaneously, myocardial oxygen extraction· 
(~-CS 02 content) decreases in both groups, 
accompanied by an 18% decrease in myocardial 
oxygen consumption (MV02Y in group N (open 
symbols). ef = ejection fraction 
amiodarone is biphasic. First, immediate but 
shortlasting systemic and coronary vasodilating 
effects are observed during the infusion period, 
accompanied by an increase in heart rate. Some-
what later, starting from the end of amiodarone 
administration, progressive negative inotropic and 
chronotropic effects become apparent. As these 
different hemodynamic effects did overlap at the 
time cardiac output measurements were perform-
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ed, the progressive reduction in contractility and 
hence in myocardial function may still have been 
offset by the unloading effects of amiodarone on 
the left ventricle. The biphasic hemodynamic pro-
file of amiodarone also suggests, that the improve-
ment in cardiac output will be more pronounced 
during amiodarone administration when systemic 
vasodilatation is maximal. On the other hand, the 
progressive reduction in contractility may eventu-
ally result in a significant depression of cardiac 
output. 
As in the present study cardiac output measure-
ments were only performed before and at 7.5 
minutes after amiodarone administration, it is 
unfortunate that these assumptions cannot be veri-
fled. The improvement of cardiac pumping perfor-
mance in patients with ventricular dysfunction 
during amiodarone related predominantly to the 
pronounced increase in heart rate. Hence, stroke 
volume did not change significantly. There is a 
suggestion though, that the effect on stroke volume 
by amiodarone, nevertheless, may be different 
between both patient groups. Although the reduc-
tion in systemic vascular resistance and left ventri-
cular systolic pressure were similar, it stands to 
reason that amiodarone induces a greater decrease 
in ventricular wall stress, in patients with enlarged 
hearts, e.g. in group Lin our study. This, in itself, 
may improve systolic performance. Moreover, in 
these patients, with ischemic cardiomyopathy, 
amiodarone theoretically could result in a reduc-
tion in (silent) ischemia and in improved ven-
tricular performance due to its effects on wall 
stress and, subsequently, on myocardial oxygen 
demand and subendocardial flow. In this respect, 
our data, which indicate more pronounced effects 
on coronary vascular resistance and coronary flow 
in patients with ventricular dysfunction, may sup-
port this theory. However, as none of our patients 
showed any sign of ischemia, this mechanism 
remains a very hypothetical one. 
Comparison with oral amiodarone in left 
ventricular dysfunction 
Oral amiodarone generally is well tolerated in 
patients with left ventricular dysfunction(11,20,21). 
As such, it compares favourably with other antiar-
rhythmic agents(l). Although it has been suggested 
that oral amiodarone is better tolerated than the 
intravenous formulation(19), such a comparison is 
hazardous, as the clinical conditions where either 
form of therapy is contemplated, will be different. 
Following institution of oral therapy, it takes 
several days for antiarrhythmic efficacy to devel-
op(23,24). The intravenous formulation therefore is 
obligatory for direct antiarrhythmic efficacy. Con-
sequently, it is administered to patients in highly 
unstable conditions with arrhythmias following 
acute cardiovascular disorders, such as ischemia or 
infarction and, possibly, in addition to other 
antiarrhythmic agents. That hemodynamic de-
rangements, i.e. hypotension and cardiogenic 
shock, have been reported<15,25) comes as no sur-
prise. Exacerbations of heart failure have also been 
reported with oral amiodarone(26,27). The propen-
sity to develop negative effects on ventricular 
function following intravenous amiodarone, may 
depend on the rapidity of administration, however. 
Comparison with different infusion rates in 
ventricular dysfunction 
Theoretically, as the negative inotropic effects of 
amiodarone are dose-related, a slower rate of 
administration might prevent untoward effects on 
cardiac pump function. Schwartz .and co-
workers(l2) administered 5 mg/kg amiodarone 
intravenously over 20 minutes to 18 patients with 
coronary artery disease, 9 with an ejection fraction 
~30%, and 9 with an ejection fraction <30%. 
Apparently, at this slow rate of administration, 
amiodarone does induce vasodilating effects. 
Systemic vascular resistance and arterial pressures 
in their study did not change. ln contrast, cardiac 
output was clearly depressed during the first 10 
minutes after infusion, particularly in patients with 
a low ejection fraction at baseline. Simultaneously, 
there was a decrease in stroke volume in these 
patients. These results do not indicate that a slow 
infusion rate of amiodarone will improve hemo-
dynamic profile. On the other hand, the significant 
increase in left ventricular filling pressure, observ-
ed in our patients with pre-existing ventricular 
dysfunction, was not observed by Schwartz et 
al. (12). 
Hemodynamic effects of Tween 80 
Commercially available amiodarone is dissolved in 
Tween 80. The hemodynamic effects reported in 
this trial may, at least in part, result from cardio-
vascular actions of the solvent. It has been sug-
gested, that besides vasodilating effects, Tween 80 
may also result in negative inotropic properties(28). 
Sicart and co-workers<8) compared the hemo-
dynamic effects of 10 mg/kg amiodarone, dis-
solved in Tween 80 with an equivalent amount of 
the solvent alone. In their study, Tween 80 alone 
did not result in negative inotropic effects, but 
induced a moderate reduction in systemic vascular 
resistance. In combination with amiodarone, how-
ever, the effect on systemic vascular resistance was 
clearly more pronounced and resulted in a second-
ary increase in heart rate, not observed with 
Tween 80 alone. Hence, to a certain extent, Tween 
80 augments the initial vasodilating effects of 
amiodarone, but does not further affect its cardio-
vascular profile. 
Side effects 
Side effects consisted of facial flushing during the 
period of amiodarone administration, but in 
accordance with the shortlasting vasodilating 
effects of amiodarone, were shortlived and well 
tolerated. Also, the reduction in blood pressure in 
our supine patients was well tolerated. 
Clinical implications 
The results from this study indicate that a relative-
ly high intravenous dose of amiodarone has no 
negative effects on cardiac pump function and is 
generally well tolerated. Although, as a result of 
its systemic vasodilating effects, aortic pressures 
decrease, these changes are moderate and do not 
lead to clinically significant reductions in coronary 
perfusion pressure. In contrast, coronary flow 
improves in both patient groups. Moreover, as a 
result of systemic vasodilatation, cardiac pump 
function even improves, although only in patients 
with ventricular dysfunction. 
Hence, a bolus administration of 5 mg/kg Amio-
darone, administered in 5 minutes, should be 
considered safe in patient with a diminished 
ventricular function as a result of ischemia or 
infarction, particularly as the compound, at this 
dose level, bas clear antiischemic effects(28). Only 
in patients with elevated ventricular filling pres-
sure before drug treatment or in patients with 
clinical signs of heart failure, a more cautious 
approach is advisable, in view of the observed 
increase in left ventricular end diastolic pressure in 
our patients with ventricular dysfunction. In the 
latter situation, hemodynamic monitoring is advis-
able to titrate the optimal rate of administration of 
intravenous amiodarone. 
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Abstract. 
Antiischemic efficacy, hemodynamic profile and 
safety of high-dose intravenous diltiazem, 0.4 
mg/kg/5 min followed by 0.4 mg/kg/10 min, were 
compared in normotensive patients with coronary 
artery disease, 11 (Gr. A) with normal and 12 (Gr. 
B) with impaired ventricular function (ejection 
fraction ~45%) during 2 identical pacing stress 
tests, 30 minutes before (APST I) and immediately 
following diltiazem administration (APST II). 
Diltiazem was well tolerated despite high peak 
plasma levels, 869±152 j.lg/1 (Gr. A) and 926±169 
J.l g/1 (Gr. B). It immediately reduced systemic 
vascular resistance, left ventricular systolic and 
mean arterial pressures [27%, 15% and 13%, resp. 
(Gr. A) and 32%, 14% and 17%, resp. (Gr. B), 
p<0.05 vs control]. Although cardiac output 
improved with 19% (Gr. A) and 27% (Gr. B), the 
increase in stroke index was significantly greater 
and more prolonged in Gr. B. Also, whereas 
diltiazem did not affect heart rate or contractility in 
either group, left ventricular end diastolic pressure 
increased significantly by 33% in Gr. A, but not in 
Gr. B. Moreover, whereas diltiazem equally 
reduced coronary resistance in both groups and 
improved coronary flow by 26% (Gr. A) and by 
17% (Gr. B), resp., myocardial 0 2 extraction only 
decreased in Gr. B (24%, p<0.05 vs control). 
During APST II, myocardial 0 2 demand was 26% (Gr. A) and 19% (Gr. B) less, compared to APST I 
(p<0.05), Although this resulted in less angina and 
ST -segment depression in both groups, 
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antiischemic efficacy of diltiazem was more 
pronounced in patients with impaired ventricular 
function. During pacing with diltiazem, 
myocardial lactate metabolism normalized in Gr. B 
but not in Gr. A. Moreover, velocity parameters 
improved more during APST II in Gr. B. The rise 
in left ventricular pressure following pacing also 
was reduced to a greater extent in Gr. B than in Gr. 
A. Thus, high-dose intravenous diltiazem is well 
tolerated and improves left ventricular pump 
function, particularly in patients with preexisting 
ventricular dysfunction. Its more pronounced anti-
ischemic effects in the latter group may suggest 
particular clinical usefulness when ventricular 
function is impaired. 
INTRODUCTION 
The antianginal efficacy of oral diltiazem is, 
reportedly, dose-related and improves with 
increments in dosageCl ,2). Whereas variable anti-
ischemic effects are observed with relatively low 
doses of intravenous diltiazem ranging from 18 to 
35 j.lg.kg-1, high-dose intravenous administration 
(i.e. 53 J.l fkg-1 results in clear-cut antiischemic 
properties< -7). Moreover, in humans, coronary 
flow improves only when such high intravenous 
dosages are administered<7-12). Thus, in clinical 
situations where increases in coronary vascular 
tone and a reduction in coronary flow are likely to 
be present, e.g. myocardial ischemia at rest or, 
possibly, the acute phase of myocardial infarction, 
a high, rather than a low dose administration of 
diltiazem may be preferable. 
Several studies have shown that diltiazem may 
limit myocardial injury during prolonged periods 
of ischemia or during the acute phase of myocar-
dial infarction, even when administered after the 
event bas occurredC13,l4). Moreover, animal 
experiments indicate that during infarction and 
thrombolytic therapy, diltiazem further salvages 
myocardial tissue in addition to the effect of 
thrombolysis(lS). Thus, diltiazem may be useful in 
similar conditions in humans, providing it is given 
intravenously and in a sufficiently high dose to 
profit from its coronary vasodilating effect. 
However, in clinical situations such as myocardial 
infarction or prolonged ischemia at rest, where left 
ventricular function commonly is reduced, these 
high dosages of diltiazem may be contra-indicated 
because of the intrinsic negative inotropic 
properties of diltiazem, which, in vitro, are dose-
related(l6). In patients with chronic congestive 
heart failure, a relatively low dose intravenous 
administration of diltiazem is well tolerated(17). 
Conversely, in patients with a normal ventricular 
function, deflned as a left ventricular ejection 
fraction _::50%, high intravenous dosages do not 
negatively affect myocardial contractility or left 
ventricular pump function(7). No data are 
available, however, on the acute hemodynamic 
effects of the latter dose regimen in patients with a 
diminished left ventricular function. Moreover, it 
has not been established as to whether the 
antiischemic efficacy of high-dose intravenous 
diltiazem is preserved in these patients. The 
present study compares the acute systemic and 
coronary hemodynamic effects of high dosages of 
intravenous diltiazem in patients with a normal 
versus impaired left ventricular function, 
investigates the safety of such a drug regimen, and 
compares the antiischemic effects of diltiazem in 
these two patient groups during pacing-induced 
stress. 
METHODS 
Patients 
After approval of the study-protocol by the 
Human Studies Committee of the Zuiderzieken-
huis on February 8, 1985 and after informed 
consent was obtained, 23 patients participated in 
this study, 21 men and 2 women (mean age 54±2 
years, x±SEM). All patients were catheterized for 
stable, exercise-induced angina with objective 
signs of ischemia during exercise testing and/or a 
documented old myocardial infarction. Patients 
with systemic hypertension, valvular disease, a 
recent myocardial infarction (less than 2 months 
ago), conduction disturbances or signs of conges-
tive heart failure were not admitted to the study. 
Patients with unstable angina were not included, as 
such patients may deteriorate upon withdrawal of 
cardiac medication. Unstable angina was defined 
by the occurrence of recent episodes of angina, 
increased frequency and/or duration of episodes of 
angina during the last month or recent prolonged 
episodes of angina at rest (>20 minutes). Also, 
patients with angina, predominantly occurring at 
rest, and/or ECG-changes, suggestive of variant 
angina, were not included. All cardiac therapy was 
tailed off 48-72 hours before the study with the 
exception of short-acting nitroglycerin, which was 
permitted up to 6 hours before the investigation. 
Coumarin derivatives were withheld 72 hours pre-
study and anti-platelet drugs (e.g. aspirin) were 
stopped at least 10 days before the investigation. 
To participate, it was essential that a .::_70% 
diameter reduction in either the left anterior 
descending artery, the proximal left circumflex 
artery or a proximal marginal branch of the left 
coronary artery was present. On the day before the 
investigation the left ventricular ejection fraction 
was determined by multigated radionuclide 
angiography and patients were divided into those 
with a normal (ejection fraction >45%, group A, 
n=ll) and an impaired ventricular function 
(ejection fraction .::_45%, group B, n=12). Clinical 
characteristics and angiographic data are given in 
Table I. Both groups were comparable as to sex, 
age, exercise-inducible ischemia and number of 
diseased vessels. Previous infarcts, however, were 
more frequent in group B. In the latter group, left 
ventricular end diastolic volume was increased 
compared to group A [97±9 mlfm2 (group B) 
versus 59±5 ml/m (group A), p <0.05] and, by 
design, left ventricular ejection fraction reduced 
[35±2% (group B) versus 58±2% (group A), 
p <0.05]. 
Catheterization procedures 
Patients were catheterized in the morning after an 
overnight fast, without premedication. First, left 
and right coronary angiography was performed 
with non-ionic contrast material (Iopamidol) using 
the Seldinger technique. Next, a no 7 F 
thermodilution pacing catheter (Wilton Webster) 
was inserted in the coronary sinus through a 
brachial vein, such that the proximal thermistor 
was at least 2 em beyond the orifice of the 
coronary sinus, the catheter position stable and 
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Table I: Clinical characteristics and angiographic data. 
Gr. A Gr.B 
left ventricular 
ejection fraction >45% 
left ventricular 
ejection fraction .::_45% 
number of patients 11 12 
age (yr) 
male/female 
51±5 (range 39 to 67) 
10/1 
51±3 (range 40 to 66) 
11/1 
previous infarct (n) 
exercise-induced angina (n) 
positive ergometry test (n) 
coronary angiography 
(>70% stenosis) 
4 anterior I 3 inferior 7 anterior I 7 inferior 
1-vessel: 
2-vessel: 
3-vessel: 
LV ejection fraction(%) 
9 
8 
4 
3 
4 
58±2 
LV end diastolic volume 59±5.4 
(ml/m2) 
10 
7 
5 
2 
5 
35±2* 
97±8.8* 
Abbreviations: LV= left ventricular; n =number; yr =year. 
Values are mean± SEM; *p<.OS Gr. A vs B. 
that blood could be drawn quickly enough to allow 
for a rapid sequence of blood samples. The absence 
of atrial reflux was confirmed by a bolus injection 
of saline at room temperature into the right atrium. 
A no 7 F balloon-tipped, triple-lumen thermo-
dilution catheter was positioned in a pulmonary 
artery via a Desilet system in the right femoral 
vein. Care was taken, that the catheter tip was 
stable without baseline drift on the thermodilution 
signal. Finally, a no 7 or no 8 F Millar or Honey-
well pigtail angiographic micromanometer 
catheter was introduced into the left ventricle 
through a Desilet introducer system in a femoral 
artery. The side arm of this system was used to 
record arterial pressures. The position of the 
catheters was recorded on video disc to allow re-
checking or'tlieir respective positions during the 
study. 
Measurements 
Hemodynamic measurements included mean and 
-264-
phasic systemic arterial, pulmonary artery, and 
right atrial pressures, left ventricular (LV) peak 
systolic, mean and end diastolic pressures, LV 
pressure-derived contractility indices (LV peak 
dp/dt, dp/dt/P at 40 mmHg and V rna total pres-
sure), thermodilution cardiac output rm triplicate) 
and coronary sinus blood flow. All fluid filled 
catheters were calibrated, using Bentley trans-
ducers, with a zero reference level set at mid-
chest. The micromanometer pressures were balan-
ced to zero and superimposed on the conventional 
pressure tracings. After appropriate calibration, all 
pressure and flow signals and the first derivative of 
left ventricular pressure (LV dp/dt) were recorded 
on paper at different paperspeeds, using a CGR 
1000 cath lab system. Cardiac output was 
measured on -line by a Mennen cath lab computer 
system. This system also allows for the on -line 
determination of all pressures and pressure-
derived contractility indices, measured over 12 to 
15 consecutive beats. Coronary sinus blood flow 
was determined during a continuous 30-second 
PACING 
30 min 
t .... 
cc 100 120 MAX 15" 1' 2' 5' 
post-pacing 
c c 1' 3' 5' 10' 15' 100 120 MAX 15"1' 2' 5' 
post-pacing b/min b/min b/min b/min 
Fig 1: Schematic representation of study protocoL Diltiazem is administered over 15 minutes, 30 
minutes after and just before 2 identical atrial pacing stress tests (APST) I and II, resp. Hemodynamic 
and metabolic parameters are evaluated at prefixed intervals, designated by closed arrows. In addition, 
cardiac output is measured before and 5 and 15 minutes (') after onset of diltiazem administration 
(open arrows). blmin =beats/minute,- C =control; HR =heart rate; MAX= maximal pacing rates. 
infusion of 30-35 ml of glucose 5% at room 
temperature. Both the mean and phasic flow were 
recorded. Calculations were made from the mean 
flowcurve, according to the formula: coronary 
sinus blood flow (ml/min) = vl X [(Tb -Ti)/(Tb-
Tc )-1]xL08, where Tb is blood temperature 
before injection, Ti is temperature of injectate, Tq 
is temperature of mixture of coronary sinus blooa 
and injectate, and V1 the rate ofinjectate (ml/min). At the end of the study, the pressure curves from 
the femoral artery were compared with a simul-
taneous recording from the aortic root by the 
micromanometer catheter, to compensate for any 
difference between proximal and distal arterial 
pressures. 
Metabolic and electrocardiographic 
measurements 
Arterial and coronary venous blood was sampled 
simultaneously for the determination of oxygen 
and lactate. Oxygen saturation values were 
measured, using an American Optical Oxymeter. 
For the determination of lactate, 1 cc of whole 
blood was collected and immediately deproteinized 
in 1 cc ice-cold 8% HC104, vortexed and kept on 
ice until further assay. The procedures for lactate 
determination and the standard deviation of the 
assay in our laboratory have been previously 
published(lS,l9)_ Heart rate and ST-segment 
changes were determined from 100 mm/sec 
recordings of ECG leads I, II and V5. The ST-
segment was measured in 5 consecutive beats, 
0.08 second after the J point, using a calibrated 
magnifying lens. Plasma diltiazem levels were 
determined by high-performance liquid chromato-
graphy analysis. 
Calculations 
Coronary vascular resistance (mmHg/ml/min) was 
calculated as the difference between mean arterial 
pressure (mmHg) and LV mean diastolic pressure 
(mmHg), divided by coronary sinus blood flow 
(mllmin). ~stemic vascular resistance 
(dynes.sec.cm· ) was derived as [mean arterial 
pressure (mmHg) - mean right arterial pressure 
(mmHg)] x 80 I cardiac output (1/min). Stroke 
work index (g.m.m2) was calculated as stroke 
index (mllbeat/m2) x [mean arterial pressure 
(mmHg) - left ventricular end diastolic pressure 
(mmHg)] x 0.0136. Myocardial oxygen extraction 
(m102/ml) was calculated as arterial oxygen 
content (m102/ml) - coronary venous oxygen 
content (ml02/ml) and myocardial oxygen 
consumption (ml/min) as the product of myocar-
dial oxygen extraction (m102/ml) and coronary blood flow (ml/min). Percentage myocardial lac-
tate extraction was calculated as 100 x [arterial 
lactate content (mmol/1) - coronary venous lactate 
content (mmol/1) ]/arterial lactate content 
(mmol/1). Myocardial lactate uptake (mmol/min) 
was determined by multiplying the difference in 
arterial and coronary venous lactate content 
(mmol/ml) with coronary blood flow (ml/min). 
Study protocol 
At least 40 minutes after the last coronary angio-
gram and 20 minutes after instrumentation, multi-
pie control measurements of all variables, except 
cardiac output, were performed to ensure stable 
baseline values (Fig. 1). An atrial pacing stress test 
(APST I) then followed, during which heart rate 
was elevated with 10 beats/2 minutes until 
moderate to severe anginal pain or atrioventricular 
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block occurred, or a maximal heart rate of 170 
beats/ minute was reached. Repeated determina-
tions of all hemodynamic and metabolic variables 
were carried out at fixed intervals during pacing, 
e.g. halfway the 100 and 120 beats/minute period, 
and during maximal pacing rates (MAX), followed 
by measurements at 15 seconds, 1, 2, and 5 min-
utes after pacing. Coronary flow was measured 
during the last 30 seconds before pacing was inter-
rupted. Next, coronary flow measurements were 
performed immediately following the 2-minute 
post-pacing period. 
After the first pacing stress test, a 30-minute 
stabilization period was allowed before multiple 
control determinations of all hemodynamic and 
metabolic variables were again carried out. Next, 
diltiazem was administered intravenously (0.4 
mg!kg during 5 minutes, followed by 0.4 mg/kg 
during 10 minutes) and all measurements repeated 
at 1, 3, 5, 10 and 15 minutes after the onset of 
administration. Cardiac output was determined at 
baseline and at 5 and 15 minutes of diltiazem 
administration. Immediately following diltiazem 
infusion, a second atrial pacing stress test (APST 
IT) was carried out, identical to APST I. During 
APST II all variables were reassessed at similar 
time intervals as during APST I. Blood for dil-
tiazem assay was collected just before the infusion, 
and at 5 and 15 minutes of infusion and, in the last 
11 patients studied, also at the end of APST II, just 
before discontinuation of pacing. At the onset of 
each pacing stress test, patients received atropine 
(0.5 mg i. v.) to ensure identical maximal pacing 
heart rates, as the option of this part of the inves-
tigation was to study the antiischemic properties of 
the compound under identical pacing stress condi-
tions. 
Statistical analysis 
In each group, measurements made during dil-
tiazem administration were compared with base-
line values before infusion, using a t-test for 
paired observations. A 2-tailed p value <0.05 was 
considered significant. The same method was used 
to compare measurements during APST I and II 
within each group. Group differences in hemo-
dynamic and metabolic mean values before and 
during diltiazem administration and before, during 
and after both atrial pacing stress tests, were 
compared using at-test for unpaired observations. 
A 2-tailed p value <0.05 was considered signifi-
cant. In a separate analysis, a linear regression 
model was applied to investigate the difference 
between plasma levels of diltiazem and effect 
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measures within each group, whereas differences 
in diltiazem levels between both groups were 
compared with at-test for unpaired observations. 
RESULTS 
Systemic hemodynamic changes during 
diltiazem administration in patients with 
normal versus impaired baseline left 
ventricular function (Table ll) 
Diltiazem equally reduced systemic vascular re-
sistance in both groups (27%, group A and 32%, 
group B, both p<0.05 versus control), resulting in 
significant, similar decreases in left ventricular 
systolic pressure (15%, group A and 14%, group B) 
and in mean arterial pressure (13%, group A and 
17%, group B, fig 2). Pressure changes occurred 
gradually, starting at 3 minutes of diltiazem admi-
nistration, but persisting until the end of the study. 
Cardiac output improved significantly and consist-
ently, both in group A (19%) as well as in group B 
(27%). In contrast, in group A, stroke index was 
only increased temporarily, immediately after the 
bolus infusion, whereas in group B it remained 
elevated for the full duration of diltiazem adminis-
tration. Moreover, diltiazem induced a significant-
ly greater percent increase in stroke index in group 
B than in group A (32±3% versus 22±7%, resp., 
p<0.001). 
Neither heart rate nor the isovolumetric indices of 
contractility changed in either group. Although, in 
patients with an impaired left ventricular function, 
the velocity parameters were already significantly 
reduced at baseline, they did not further decline 
during diltiazem administration. Also, whereas 
during control, left ventricular end diastolic pres-
sure was significantly elevated in group B compa-
red with group A (15±2.6 mmHg versus 9±1.6 
mmHg, resp., p<0.05), it did not further increase 
during diltiazem administration in patients with 
impaired left ventricular function. In contrast, in 
group A, left ventricular filling pressure rose with 
33% towards the end of the infusion period (p 
<0.05 versus control). Pulmonary artery pressures 
and pulmonary vascular resistance did not change 
in either group. 
Coronary hemodynamic effects of diltiazem in 
normal versus impaired baseline left ven-
tricular function (Table ill) 
Baseline values of coronary sinus blood flow and 
coronary vascular resistance were significantly 
different in both groups [100±11 ml/min (group A) 
versus 155±17 ml/min (group B) and 1.2±0.17 
Table ll: Systemic hemodynamic changes during diltiazem administration in patients with 
normal vs impaired left ventricular function. 
minutes after onset of diltiazem infusion 
Control 1 3 5 10 15 
SVR (dynes.s.cm-5) 
GrA 1321±136 963±113* 986±107* 
GrB 1267±106 865±58* 931±68* 
LVSP(mmHg) 
GrA 137±5.5 129±4.8 120±5.1* 117±4.3" 118±4.2* 118±3.6* 
GrB 137±7.2 131±7.8 124±7.2* 118±6.5" 118±6.7* 119±7.7" 
MAP(mmHg) 
GrA 107±3.2 104±3.0 98±3.4" 93±3.8" 92±4.0* 92±3.0" 
GrB 103±4.4 100±5.3 89±4.1" 86±4.2" 88±4.9'' 91±4.1" 
CO (!/min) 
GrA 6.7±0.6 8.0±0.8" 7.4±0.6* 
GrB 6.2±0.4 7.9±0.6* 7.3±0.5'' 
SI (ml/beat/m2) 
GrA 44±3.8 49.4±4.7* 48.6±3.6 
GrB 36±2.8 46.2±3.6" 43.6±3.3'' 
SWI (g.m.m2) 
58±4.9t 55±4.4 54±4.9 GrA 
GrB 40±3.7 45±4.9 46±4.8 
HR (beats/min) 
86±5 85±5 80±5 77±5 GrA 81±5 85±5 
GrB 89±5 91±5 94±4 91±4 86±4 81±4 
LV peak d&/dtpos (mmHg-1) 
r A 1619±112 1674±122 1694±139 1676±127 1625±126 1576±104 
GrB 1459±81 1484±86 1526±87 1444±95 1468±89 1345±100 
VCE40 (sec-1) 33.9±2.8t 35.2±2.9t 35.9±2.7t 32.7±3.7f 34.2±2.3t 0.7±3.7t GrA 
GrB 28.2±1.5 29.1±1.8 29.8±1.8 29.0±1.8 28.2±2.1 26.8±2.0 
Vmax (sec-1) 
51±3.8t 53±4.3t 57±3.1t 57±2.8t 55±2.8t 54±2.4f GrA 
GrB 42±2.3 41±2.9 46±3.06 45±2.8 43±3.3 43±2.9 
LVEDP (mmHg) 
9±1.6t GrA 8±1.2 10±1.4 11±1.7 12±1.4'' 12±1,4'' 
GrB 15±2.6 14±2.9 13±2.4 15±2.6 17±2.8 16±2.8 
MPAP(mmHg) 
GrA 15±1.0 15±1.3 16±1.3 17±1.4 17±1.2 18± 1.2 
GrB 18±2.9 16±1.9 19±3.2 16± 1. 7 19±3.5 19±2.3 
PVR(mmHg) 
GrA 106±34 106±38 110±39 GrB 156±43 110±30 115±44 
Abbreviations: CO = cardiac output; HR = heart rate; LVEDP = left ventricular end diastolic pressure; LVSP = left 
ventricular systelic pressure; min = minutes; MAP = mean arterial pressure; MPAP =mean pulmonary artery pressure; 
PVR = pulmonary vascular resistance; sec = seconds; Sl = stroke index; SVR = systemic vascular resistance; SWl = stroke 
work index. 
"p<0.05 vs control; f p<0.05 Gr. A vs B. Values are mean± SEM. 
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Table ill: Coronary hemodynamic changes during diltiazem infusion in patients with normal 
vs impaired left ventricular function. 
minutes after onset of diltiazem infusion 
Control 1 3 5 10 15 
CSBF (ml/min) 
Gr. A 100±11f 108±12t 116±9t 126±11* 122±12t* 114±13 
Gr.B 155±17 154±16 175±20 173±21 182±22* 170±18 
CVR (mmHg/ml/min) 
Gr. A 1.20±0.17t 1.10±0.14f 0.87±0.07t* 0.76±0.07t* 0.82±0.12* 0.84±0.10 
Gr.B 0.74±0.07 0.69±0.07 0.58±0.06* 0.55±0.06* 0.57±0.07" 0.66±0.06* 
.b.A-CS 02 content (vol %) 
Gr. A 7.08±0.53 6.78±0.43 6.08±0.55 5.56±0.58 5.70±0.50 5.95±0.52 
Gr. B 6.60±0.34 6.36±0.34 5.52±0.39* 5.03±0.37" 5.17±0.45* 5.38±8.35* 
MV02 (ml/min) 
Gr. A 7.80±0.95t 8.19±1.15 7.52±0.74 7.50±0.83 7.24±0.88 7.99±0.97 
Gr.B 10.60±1.23 9.88±1.30 9.43±1.50 8.73±1.10 8.83±1.09 9.20±1.28 
DP (HRx LVSP x 10-3) 
Gr. A 10.97±0.69 10.89±0.72 9.64±0.60 9.27±0.61* 9.42±0.66* 9.07±0.66* 
Gr.B 10.60±1.23 9.88± 1.30 9.43±1.5 8.73±1.10* 8.83±1.09* 9.20±1.28* 
Abbreviations: CSBF = coronary sinus blood flow; CVR =coronary vascular resistance; .b.A-CS o2 content= difference 
in arterial and coronary sinus 0 2 content; DP =double product; MVOz =myocardial oxygen conswnption. 
*p<0.05vs control; t p<0.05 Gr. A vs B. Values are mean± SEM. 
mmHg/ml/min (group A) versus 0.74±0.07 
mmHg/ml/min (group B), resp., p<0.05]. 
However, subsequent changes during diltiazem 
infusion were similar. Coronary sinus flow 
increased by 26% (group A) and by 17% (group B), 
albeit only for a short period, between 5 and 10 
minutes of diltiazem infusion. Concomitantly, 
coronary vascular resistance decreased by 37% 
(group A) and by 26% (group B), at 5 minutes of 
diltiazem. The reduction in coronary vascular 
resistance persisted for the entire infusion period, 
but only in group B patients. Likewise, myocardial 
oxygen extraction only decreased in group B (24% 
compared with baseline values, p<0.05) despite 
similar reductions in the double product, an index 
of myocardial oxygen demand, and despite similar 
changes in coronary flow in both groups. This 
reduction in myocardial oxygen extraction also 
persisted for the entire infusion period. Myocardial 
oxygen consumption, although different at base-
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line [7.8±1.0 ml/min (group A) versus 10.6±1.2 
ml/min (group B), p<0.05], did not further change 
during diltiazem administration in either group. 
Systemic and coronary hemodynamic effects 
of diltiazem on hemodynamics during pacing 
(Tables IV and V) 
Baseline heart rates were similar during and after 
APST I and APST IT in both groups. Maximal 
pacing rates during APST I were 153±6 
beats/minute and 155±5 beats/minute for groups A 
and B, resp. By design, maximal pacing rates were 
also similar during APST I and IT in each group. In 
contrast, the double products were significantly, 
albeit equally, reduced in both groups during 
APST II, compared with APST I (by 26%, group 
A and by 19%, group B) due to similar reductions 
in left ventricular systolic pressure during pacing 
after diltiazem in both groups. Mean arterial pres-
Table IV: Effects of diltiazem on systemic hemodynamics during pacing. 
Control MAX lminp-p 5 min p-p 
HR (beats/minute) Gr.A APSTI 71±3 153±6* 80±6 80±6 
APSTll 77±5 151±6* 92±5 92±5 
Gr.B APSTI 80±4 155±5* 83±6 84±5 
APSTll 81±4 155±6* 87±5 88±6 
LVSP(mmHg) Gr.A APSTI 138±6 140±7.0 147±6 140±6.5 
APSTll 118±4# 119±5.0# 125±5# 121±5# 
Gr.B APSTI 143±8 141±7.5 150±8 143±7.5 
APSTll 119±8# 113±7.3# 120±6.3# 121±6.2# 
MAP(mmHg) Gr.A APSTI 102±3.5 116±3.9" 107±3.5'' 102±3.8 
APSTll 95±4.3 103±3.5f* 97±3 97±3.2 
Gr.B APSTI 102±5.9 113±6.7* 111±8.3'' 108±9 
APSTll 90±3.7 95±4 93±5.3 93±4.7"' 
LV dp/dt pos (mmHg.s-1) Gr. A APSTI 1536±98 2027±134* 1828±156'' 1674±99 
APSTll 576±104 1927±163" 1733±159'' 1602±136 
Gr.B APSTI 1426±66 1955±203* 1811±169* 1527±86 
APSTll 1345±100 1563±102" 1537±96*# 1445±97# 
Vmax (s-1) Gr.A APSTI 47±2 58±3'' 52±4"' 48±3 
APSTll 54±2 72±6" 57±3.5 56±3 
Gr.B APSTI 39±2t 43±3t 43±3 42±3 
APSTll 43±3t 52±3f''# 48±3# 47±3# 
Abbreviations: DP = double product; HR = heart rate; LVSP = left ventricular systolic pressure; MAP = mean arterial 
pressure; MAX =maximal pacing rates; p-p =post-pacing; 
*p<0.05vs control; t p<0.05 Gr. A vs B; # = p<.05 APSTivs 11. Values are mean± SEM. 
sures increased significantly during APST I by 
14% (group A) and by 11% (group B) at maximal 
pacing rates. During APST II, arterial pressures 
again increased in group A (12% versus control 
APST II, p<0.005) but no longer in group B. Also, 
changes in contractility during pacing before and 
after diltiazem were different in both groups. In 
group B velocity indices (V max) increased more 
during pacing after diltiazem than during the 
untreated, first pacing test [43±3 sec-1 (APST I) 
versus 51±3 sec-1 (APST II), p<0.05)]. In group 
A, on the other hand, isovolumetric indices of 
contractility did not further improve during APST 
II. Moreover, in group B, coronary flow increased 
less during pacing after diltiazem than during 
APST I [248±24 ml/min (APST I) versus 210±20 
ml/min (APST II), p<0.05]. Again, in group A, 
changes in coronary flow were siinilar during both 
pacing tests. 
Myocardial oxygen consumption was not signifi-
cantly different during APST I and II in both 
groups, although it tended to be less during pacing 
after diltiazem. In contrast, myocardial 
0 2 extraction (.6.A-CS 0 2 content) was signifi-
cantly greater during APST II than during APST I 
in group B (Table V). 
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Table V: Effect of diltiazem on coronary hemodynamics during pacing. 
Control MAX 1 min p-p 5 min p-p 
CSBF (rnl/min) Gr. A APSTI 123±10 181±16* 126±10 116±9 
APSTII 120±13 160±18* 116±9 116±9 
Gr. B APSTI 159±20 249±24*t 188±27t 163±21 
APSTII 174±20#t 210±20>1<# 162±26# 162±18t 
CVR (mmHg/rnl/min) Gr. A APSTI 0.89±0.08 0.69±0.07>1< 0.89±0.09 0.91±0.10 
APSTII 0.89±0.10 0.70±0.06+ 0.82±0.06 0.91±0.09 
Gr.B APSTI 0.70±0.07 0.48±0.05''f 0.64±0.09 0.70±0.09 
APSTII 0.56±0.07t# 0.48±0.05·•t 0.61±0.14 0.66±0.08* 
~A-CS o2 content (vol %) Gr. A APSTI 12.6±0.7 11.4±0.6 10.3±0.4 12.3±0.8 
APSTII 10.0±1.0# 10.8±0.8>1< 8.9±0.6# 10.4±0.6 
Gr. B APSTI 10.5±0.7t 10.0 ±0.5 9.7±0.4 10.2±0.5 
APSTII 8.3±0.4# 10.35±0.5>1< 9.4±0.4 9.8±0.6 
MV02 (rnl/min) Gr. A APSTI 15.9±2.2 20.4±2.4* 12.4±1.4 14.7±1.8 
APSTII 12.4±1.1# 17.3±1.8'' 10.6±1.7 12.3±1.4 
Gr. B APSTI 17.2±2.8 25.2±3.0* 19.4±3.5 16.6±3.0 
APSTII 14.3±2.0 21.7±2.2'' 14.5±3.5 15.9±2.6 
DP Gr. A APSTI 10.1±0.6 20.7±1.0'' 11.8±0.8'' 11.5±0.6 
APSTII 9.2±0.7 17.6±0.8*t 11.8±0.5* 11.3±0.5* 
Gr. B APSTI 11.3±0.5 22.2±1.3* 13.7±1.2'' 13.0±1.0* 
APSTII 9.4±0.9# 17.2±1.3*# 11.2±0.8* 10.9±0.7* 
Abbreviations: CSBF = coronary blood flow; CVR = coronary vascular resistance; ~A-CS 0 2 content =difference in 
arterial and coronary sinus oxygen content; DP = double product; MV02 =myocardial oxygen consumption; 
MAX =maximal pacing heart rate; min =minute; p-p =post-pacing; 
*p<0.05vs control; t p<0.05 Gr. A vs B; # = p<.05 APSTlvs ll. Values are mean± SEM. 
Antiischemic properties of diltiazem in 
patients with normal versus impaired left 
ventricular function 
Diltiazem had similar antianginal effects in group 
A and group B. During APST II, 10 patients in 
each group had less or no angina when compared 
with the first, untreated pacing test. Also, the 
reduction in ST-segment depression was identical 
in each group during pacing before and after dil-
tiazem (Fig. 2). In contrast, changes in myocardial 
lactate metabolism were different. Whereas 
control lactate extraction values before each APST 
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were similar and lactate production values during 
and after APST I comparable in groups A and B, 
lactate metabolism remained normal and un-
changed from baseline values during pacing after 
diltiazem in group B. (Fig. 3). In contrast, in 
group A, myocardial lactate extraction again 
changed to production during APST II, despite the 
administration of diltiazem. As a result, changes in 
myocardial lactate extraction were significantly 
ST-segment 
mV t p <.05 APST I vs APST II 
• 
c AP I APST J c API APST II 
Fig. 2: ST- segment changes during pacing before 
and after diltiazem in Gr. A (hatched bars) and 
Gr. B (open bars). Values are mean± SEM. 
APST = atrial pacing stress test; C = control; 
MAX = maximal pacing rates. 
Lactate 
extraction 
(art-ven x 1 00%) 
art 
30 
20 
-20 
-30 
-40 
-50 
c 
APST I 
* 
MAX 15'p-p 
* p< .05vs C 
+ p < .05 APST I vs APST II 
* 
APSTII 
c MAX 15'p-p 
Fig. 3: Effect of diltiazem on myocardial lactate 
extraction during pacing. During atrial pacing 
stress test (APST) I comparable lactate 
production is found in Gr. A (hatched bars) and 
Gr. B (open bars). In contrast, during APST II 
lactate extraction is preserved in Gr. B, 
significantly differentfromAPST I, but not in Gr. 
A. Values are mean± SEM. 
C = control; MAX = maximal pacing rates; ' = 
minute(s); p-p =post-pacing. 
different [lactate 15 seconds post-pacing: 
-6± 12% (group A) versus 7±5% (group B), 
p<0.05]. Moreover, in group B, the rise in left 
ventricular end diastolic pressure, measured at 15 
seconds post-pacing, was 18 mmHg less during 
APST II than during APST I, compared with a 
difference of 11 mmHg in group A (Fig. 4) . 
Plasma diltiazem levels 
Plasma diltiazem levels were comparable in groups 
A and B, with values of 869±152 J.Lg/1 and 
926±169 J.Lg/1, resp., at 5 minutes diltiazem, 
gradually decreasing to 339± 152 J.L g/1 and 
432±103 J.Lg/1, resp., at maximum pacing rates 
during APST II. There was no significant relation 
between individual plasma levels and percentage 
changes in hemodynamic parameters. 
Adverse effects 
No untoward clinical effects were observed. Myo-
cardial ischemia did not occur during diltiazem 
administration. Only one patient complained of a 
short period offacial flushing. 
DISCUSSION 
It has been suggested, that the usefulness of 
calcium-antagonists during prolonged periods of 
myocardial ischemia or during infarction, is 
restricted to their prophylactic use onlyC2°). 
However, some experimental data indicate, that 
intravenous diltiazem, when administered after the 
event, may still limit the degree of ischemia and 
protect the infarcting myocardium<13,14). More-
over, when administered just before thrombolysis, 
it enhances salvage of reperfused ischemic myo-
cardiumClS). Like all calcium antagonists, diltia-
zem could theoretically protect against ischemia-
induced myocardial injury through a number of 
actionsC20)_ However, the energy-sparing 
properties, resulting from its intrinsic hemo-
dynamic effects, e.g. the arterial vasodilating and 
negative inotropic properties of diltiazem, 
presumably are most important. The net result of 
the latter is a reduction in myocardial oxygen 
demand. In addition, through its coronary vaso-
dilating effects, it may augment the supply of 
oxygen and substrate to the myocardial area at 
risk. 
These intrinsic cardiovascular properties of dil-
tiazem are dose-related(6,21). Also, in humans, 
coronary vasodilatation and increments in 
coronary flow only become apparent when rela-
tively high dosages are used{3,S-ll)_ Thus, to 
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LVEDP 
mmHg 
30 
20 
10 
t 
+ p <.05 APST I vs APST II 
t p <.05 Gr A vs B 
t* 
* p<.05vs C 
t * t 
Fig. 4: Effect of diltiazem on left ventricular end 
diastolic pressure (LVEDP) in Gr. A (hatched 
bars) and Gr. B (open bars). 
Values are mean± SEM. 
APST = atrial pacing stress test; C = control; 
MAX= maximal pacing rates; ' = minute( s); p-p = 
post-pacing. 
achieve optimal antiischemic efficacy, not only 
through a reduction in myocardial oxygen demand 
by unloading of the left ventricle, but also by 
improving coronary flow and myocardial oxygen 
supply, a high dose rather than a low dose admin-
istration appears preferable. 
Alternatively, the intrinsic negative inotropic (and 
chronotropic) effects of diltiazem may be ampli-
fied when high dosages are givenC16). Consequent-
ly such administration of diltiazem could be hazar-
dous, particularly in clinical settings, where left 
ventricular function may be already depressed, 
e.g. during prolonged periods of myocardial 
ischemia or acute infarction. Thus, whereas diltia-
zem, at high dosages, may improve left ventricular 
function through its antiischemic properties, it 
may alternatively prove to be deleterious by its 
direct myocardial depressant effect. 
Systemic hemodynamic effects of high dose 
intravenous diltiazem in impaired versus 
normal ventricular function: 
In the present study, diltiazem, administered at a 
high infusion rate, was well tolerated, both by 
patients with a markedly impaired ventricular 
function and by patients with normal ventricles. In 
both groups it equally decreased systemic vascular 
resistance and caused a moderate but similar 
reduction in left ventricular systolic and aortic 
pressures, accompanied by an increase in cardiac 
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output. As, in each group, other systemic hemo-
dynamic variables did not change, at least not 
during the initial phase of the study, the latter most 
likely resulted from unloading effects on the left 
ventricle. 
The augmentation of left ventricular pump func-
tion was more pronounced in patients with an 
impaired left ventricular function at baseline. In 
this group, the increase in stroke index was sig-
nificantly greater and longer lasting than in 
patients with a normal left ventricular function. 
Given the fact, that the isovolumetric indices of 
contractility, heart rate and preload were not 
affected in neither group, this observation is not 
surprising. In this situation, comparable reductions 
in left ventricular systolic and arterial pressures by 
diltiazem should have a greater effect on systolic 
wall stress in patients with dilated, non-hypertro-
phied left ventricles (group B in this study), than in 
patients with normal-sized left ventricles (group 
A). Besides, although myocardial ischemia was 
not apparent before diltiazem administration, the 
subsequent greater reduction in myocardial oxygen 
demand in patients with enlarged left ventricles 
(group B) may also explain the greater impro-
vement of left ventricular function in this group. 
Augmentation of cardiac performance following 
intravenous diltiazem has been re~orted in patients 
with congestive heart failureC17, 2). The present 
study is the first to compare the effects of diltiazem 
in patients without clinical signs of heart failure, 
but with different degrees of left ventricular sys-
tolic (dys)function and to report an augmentation 
in cardiac performance in patients with asympto-
matic ventricular dysfunction. 
Despite the high dose used in our study, intrinsic 
negative chronotropic or inotropic properties of 
diltiazem, were not apparent. Neither heart rate 
nor contractility indices decreased during diltiazem 
administration in either group. 
The lack of negative chronotropic and inotropic 
effects in the present study presumably reflect a 
continuous interaction between the intrinsic hemo-
dynamic properties of diltiazem and baroreceptor-
dependent reflex mechanisms. This balance 
between primary and secondary cardiovascular 
effects is well-known with vasoactive compounds 
such as calcium-antagonistsC23). It not only 
depends on the type of calcium-antagonist and, 
subsequently, on the magnitude of vasodilator-
versus negative chronotropic and inotropic 
activity, but also on dosage and means of adminis-
tration. Intravenous diltiazem, at lower dosages 
than used in the present study, may decrease heart 
rateC24) and reduce contractilityC25). That contrac-
tility indices and heart rate did not change in the 
present study may suggest that the high dose 
evokes a secondary counteractive reflex mecha-
nism. However, statements concerning contractil-
ity changes should be made carefully in this study. 
The pressure-derived isovolumetric indices of 
contractility, used in the present study, are load-
dependent, albeit less pronounced where the 
velocity parameters, VCE40 and VJ;llax' are con-
cerned. Although the fact that velocity parameters 
did not change in the face of reduced arterial 
pressures does not suggest significantly diminished 
contractility, these parameters may underestimate 
this. The latter is suggested by the significant 
increase in left ventricular end diastolic pressure in 
group A. That in contrast left ventricular filling 
pressure did not change in group B most likely 
reflects a greater unloading effect of diltiazem in 
these patients with enlarged ventricles compared to 
group A. 
Coronary hemodynamic effects of diltiazem 
before pacing 
In this study, diltiazem induced a similar improve-
ment in coronary flow in both groups. Such 
increase in flow has been reported previously, 
using equivalent high dosages of diltiazem as in the 
present study(?). In contrast, with lower dose 
administrations, significant effects on coronary 
flow have not been observed(3,5,6,8-12,27). 
Myocardial oxygen extraction decreased only in 
patients with impaired left ventricular function. As 
this effect was still present at the end of diltiazem 
administration, when coronary flow had already 
normalized, changes in myocardial oxygen 
demand are most likely responsible. In view of 
similar changes in rate-pressure product in both 
groups, the difference in myocardial oxygen 
extraction is best explained by the increase in left 
ventricular filling pressure and hence, in diastolic 
wall stress in Gr. A. The latter may have offset the 
effect of ventricular unloading on myocardial 
oxygen demand in the latter group, but not in 
patients with impaired left ventricular function. 
Hemodynamic changes during pacing with 
diltiazem in impaired versus normal left 
ventricular function 
Diltiazem reduced left ventricular systolic 
pressures during pacing and, subsequently, the 
double product. This effect was similar in both 
patient groups. In contrast, the effect on mean 
arterial pressure was different. In Gr. A mean 
arterial pressure again increased during pacing 
after diltiazem, as they did during the first, 
untreated pacing test. However, in patients with 
impaired ventricular function, arterial pressures 
remained unchanged during pacing after diltiazem, 
in contrast to a significant elevation during the first 
pacing test. An increase in systemic vascular 
resistance and in arterial pressures during pacing-
induced ischemia has been reportedC28,29) and may 
be proportional to the degree of ischemiaC28). The 
different response to pacing after diltiazem on 
arterial pressures in both groups may reflect less 
ischemia in patients with impaired ventricular 
function. We have recently reported, that a differ-
ent calcium antagonist, bepridil, in a similar type 
study, prevented the increase in systemic resistance 
and in arterial pressures during pacing-induced 
stressC29). As it also reduced left ventricular sys-
tolic pressure, we hypothetized that its antiische-
mic effect was predominantly due to its systemic 
vasodilating effects. The data of the present study 
also suggest that the systemic vasodilating effect of 
diltiazem plays a key role in reducing pacing-
induced ischemia and that this effect is greater in 
patients with enlarged left ventricles. In contrast, 
its antiischemic effects apparently do not relate to 
an extra improvement of coronary flow during 
pacing. Coronary flow actuaiiy increased less 
during the second pacing test in Gr. B. Together 
with a significant reduction in myocardial oxygen 
extraction in this group, this reflects a greater 
reduction in pacing-induced oxygen demand after 
diltiazem in patients with an impaired ventricular 
function. Although a regional improvement of 
poststenotic subendocardial flow, undetected by 
the coronary sinus flow thermodilution technique, 
may still have occurred, particularly in this type of 
patients with enlarged left ventricles. It appears 
more likely that the greater reduction in wall stress 
following systemic vasodilation accounts for the 
difference in flow response and oxygen extraction 
during pacing. 
Antiischemic effects of diltiazem during 
pacing in impaired versus normal left 
ventricular function 
Diltiazem significantly reduced myocardial ische-
mia in both groups. It had similar effects on 
symptoms and on several objective signs of ische-
mia in patients with and without left ventricular 
dysfunction. However, there were indications, that 
the antiischemic effect of diltiazem was more 
pronounced in patients with impaired left 
ventricular function. Changes in myocardial lactate 
metabolism, identical in both groups during the 
first pacing-stress test, were significantly different 
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during pacing after diltiazem. In group A myocar-
dial lactate production reoccurred during APST II, 
but not in patients with an impaired left ventricular 
function. This indicates a more pronounced anti-
ischemic effect of diltiazem in the latter patient 
group. Even so, the increase in left ventricular end 
diastolic pressure also was less pronounced during 
pacing with diltiazem in patients with impaired 
versus normal ventricular function. Together with 
the better improvement of contractility in group B 
patients, this suggests that the antiischemic 
properties of high-dose diltiazem are more 
pronounced in patients with left ventricular dys-
function, at least during pacing-induced stress and 
ischemia. 
Plasma diltiazem levels 
Plasma diltiazem levels were comparable in both 
groups. Despite high initial values, hemodynamic 
deterioration was not observed in either patient 
group, and no untoward clinical effect or side-
effect was noted. Also, plasma diltiazem levels did 
not correlate with hemodynamic changes. More-
over, levels assessed just before discontinuation of 
pacing, were similar in both groups, indicating 
that the more pronounced antiischemic effects of 
diltiazem in group B patients did not relate to 
differences in plasma diltiazem levels. 
Limitations of the study 
Pacing was carried out after and not during diltia-
zem administration. Thus, a potential extra anti-
ischemic effect through drug-induced changes in 
coronary flow may have been missed. Moreover, 
diltiazem plasma levels during pacing were not in 
a steady state, but still declining. Optimally, the 
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Part 2 
Systemic and cardiac neurohumoral activation during acute myocardial 
ischemia in man. Rationale for converting enzyme inhibition in ischemia. 
A. Introduction and rationale for the studies. 
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INTRODUCTION 
Myocardial ischemia results in a complex chain of 
events, which is predominantly but not exclusively 
of cardiac origin. Apart from the metabolic alter-
ations mentioned in chapter I and their hemodyna-
mic sequelae, a large variety of other changes 
occur in the heart during ischemia, that are, as yet 
not touched upon. 
Free radicals. 
Oxygen-derived free radical formation, although 
directly linked to metabolism, has only been 
mentioned in passing. Although this phenomenon 
is generally considered in connection with reper-
fusion and reoxygenationCl), free radicals may also 
be generated from various sources during the acute 
phase of myocardial ischemiaC2). For instance, 
interruption of mitochondrial electron transport 
induces a shift from the normal tetravalent reduc-
tion of oxygen to water by cytochrome oxidase to 
univalent reduction and the formation of superoxi-
de radicals, in particular superoxide anionsC3-5). 
Alternative free radical production during ischemia 
may occur secondary to phospholipase activation 
and arachidonic acid accumulation, subsequently 
metabolized to endoperoxides, and to the conver-
sion of (hypo )xanthine by xanthine oxidase to 
urate, superoxide anion and hydroxyl peroxide. 
The latter enzyme is formed during ischemia by 
conversion from xanthine dehydrogenase, normal-
ly present and active during aerobic metabolismC6). 
Besides enhanced production of free radicals, 
ischemia is also characterized by a decline in its 
normal cellular scavengersC7). Accumulation of 
superoxide anion and hydroxyl peroxide may lead 
to production of the highly reactive hydroxyl radi-
cal, which subsequently forms additional toxic 
products, such as lipid radicals and lipid per-
oxides. As a result, (phospho )Iipases become acti-
vated and a detergent action of increased free fatty 
acids on membranes is observed(8). This leads to a 
destruction of the latter, to abnormalities in mem-
branal calcium kinetics and to cellular osmotic 
swelling. As, in the human heart, significant 
amounts of hypoxanthine are produced at an early 
stage of ischemiaC9,lO), it has been hypothesized 
that free radical production by way of the xanthine 
oxidase system may be an important mechanism 
during acute ischemia in man. However, in 
contrast to animal species such as the dog, but 
comparable to the situation in rabbit or pig hearts, 
the human heart does not produce xanthine oxi-
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daseC11,12). It is doubtful therefore, whether, 
during ischemia, the system really adds signifi-
cantly to oxygen derived free radical production in 
the human heart. 
Although recent observations during angioplasty 
suggested some urate release following ischemia 
and, hence, the presence of xanthine oxidoreduc-
tase in the human heartC13), it remains to be deter-
mined whether the xanthine oxidase form is really 
present during ischemia. 
Apart from the myocardium, the vascular endothe-
lium is also a target for free radical damage during 
ischemia. Besides enhanced permeability, free 
radicals may promote thrombogenicity, which, in 
part, depends on the interaction of the endothelial 
surface with blood elements, such as platelets. 
Platelets generate superoxide anionsC14), which, in 
tum, may promote their aggregation, further free 
radical release and, through serotonin production, 
may facilitate leucocyte adherence to the endothe-
liumC15). 
Leucocytes. 
Leucocytes may amplify ischemic injury through 
leucocyte entrapment in microvessels and sub-
sequent activation and release of potentially toxic 
materials, which may affect the vessels, blood 
constituents and the myocyteC16-19). Moreover, 
accumulation of leucocytes may occur in response 
to ischemia-induced chemotactic factors, such as 
leukotriene B4 or the cytokines, interleukin-1 and 
the tumor necrosis factorC20). Activation of leuco-
cytes also leads to oxygen-derived free radicals 
upon reoxygenationC2l), to release of vasoconstric-
tor substances (the pe~tide leukotrienes c4, D4 and 
E4 or 12-HETEC2 ) , and to oxydation of EDRFC23). 
Clearly, the potential to modulate leucocyte 
entrapment in the ischemic area, subsequent 
release of toxic substances and the pathophysio-
logic effects of the latter does seem an attractive 
issue, where the protection against ischemic myo-
cardial damage is concerned. Indeed, depletion of 
circulating neutrophils may significantly reduce 
the extent of ischemic injury of the heartC24). 
However, although pharmacological interventions 
with non-steroidal agents may induce beneficial 
effects in the stunned myocardium, not all 
NSAID's are effective in this respect. Moreover, 
some may even exacerbate myocardial ischemic 
injury and enhance scar thinning after 
infarction(25,26). The experimental design general-
ly applied in these studies makes it difficult to 
dissociate pure ischemia-related events from 
reperfusion damage, even after short periods of 
myocardial ischemiaC27). 
A different mechanism, potentially involved in 
myocardial ischemia, relates to vasoconstrictor 
leukotrienes, synthesized by activated leucocytes. 
The peptide leukotrienes LTC4 and LTD4, ad-
ministered intracoronary, induce coronary vaso-
constrictory effects(28}. Following leucocyte 
accumulation in the ischemic area, these lipooxy-
genase products might therefore result in local 
coronary vasoconstriction. However, a recent 
study was unable to find appreciable amounts· of 
these leukotrienes in the effluent from the ischemic 
myocardiumC29). The same authors reported, that 
changes in coronary vascular resistance were short 
lasting, only present for 2-4 minutes, despite 
ongoing leukotriene administration. In addition, 
some doubt has recently arisen concerning the 
potential enhancement of ischemia as a result of 
sustained coronary vasoconstrictor actions of 
peptide leukotrienes(30). 
Prostaglandins. 
Thus far, in this thesis, the effect of ischemia on 
prostaglandins has received limited attention. 
Theoretically, the combined effects of a reduced 
production of the endothelial vasodilator prostacy-
clin in the atherosclerotic endothelium and enhan-
ced formation of the potent vasoconstrictor throm-
boxane A2 from aggregating platelets on the 
abnormal endothelial surface, should significantly 
affect both origin and propagation of ischemia. 
Whereas, in the intact, endothelialized coronary 
circulation, thromboxane A?. does not behave as 
potent vasoconstrictor, possibly through modula-
tory effects of locally produced vasodilator mecha-
nisms, this is entirely different in diseased arteries. 
In models of critical coronary narrowing or endo-
thelial injury, thromboxane A2 results in cyclic blood flow reductions coupled to platelet aggre-
gation(31,32). Acetyl salicylic acid prevents this 
flow reductionC32). The major source of throm-
boxane A2 in ischemia is the aggregating platelet 
on the abnormal endothelial surface, although 
some production in different tissues, such as the 
vascular wall or the ischemic myocardium, cannot 
be excluded(33). Enhanced blood flow velocity 
may amplify this effect of platelet aggregation. 
Consequently, attention has been paid to the 
impact of eicosanoid metabolism using models of 
increased coronary blood flow velocity. 
Animal studies apartC34), several human studies 
have tried to establish the true significance of an 
abnormal production of the cyclooxygenase 
products during myocardial ischemia. Back in 
1977 Berger and coworkers reported increased 
release of prostaglandin F from the heart during 
pacing-induced ischemia(35). This was later 
followed by observations on enhanced throm-
boxane A2_ release as a result of vasospastic 
anginaC36,::>JJ and during pacing(38). However, 
reports on cardiac prostaglandin synthesis in man 
have been rather contradictory since, greatly due to 
the inherent difficulties of sampling platelet-
derived eicosanoids through long catheters. 
Whereas thromboxane production may be im£or-
tant in unstable angina or after thrombolysisC3 ,40), 
it is at present not quite clear whether pursuing this 
line of research in stable angina pectoris with the 
aim of finding alternative antiischemic thera-
pies(41,42) is really worthwhile. In this respect, our 
own preliminary results do not indicate that myo-
cardial ischemia induces platelet aggregation in the 
ischemic areaC43). Neither does it result in 
enhanced thromboxane release and/or diminished 
prostacyclin production. In contrast, we have 
found evidence for enhanced circulating throm-
boxane Az. levels in the course of pacing-induced 
ischemia m patients with simultaneous neuro-
humoral activation and systemic vasoconstriction 
(unpublished observations). 
Myocardial ischemia and neurohumoral 
activation. 
A different area and one which, at least in humans, 
has received little attention, is that which covers 
the interaction between myocardial ischemia on 
the one hand and peripheral and cardiac neuro-
humoral activation on the other. 
Whereas ample attention has been paid to occur-
rence and effects of sympathetic stimulation and 
activation of circulating neurohumoral systems in 
disease entities, such as heart failure or acute myo-
cardial infarction, very little is known of the inter-
action, if any, of myocardial ischemia and neuro-
hormones. 
Studies in animal models have demonstrated 
unequivocal evidence of profound cardiac sympa-
thetic stimulation in severe and, particularly, in 
prolonged episodes of myocardial ischemiaC44,45). 
These studies indicate, that cardiac catecholamine 
release, generally accepted as proof of sympathetic 
activity, does increase both as a function of the 
degree of ischemia, but also of time(44,46), sugges-
ting that a certain period of ischemia is needed 
before enhanced cardiac sympathetic tone becomes 
evident. 
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Iri fact, these data would indicate that short periods 
of myocardial ischemia, such as encountered 
during stress testing in humans, may be insuf-
ficient to induce cardiac catecholamine release as 
evidence of enhanced cardiac sympathetic tone. 
This may explain why the few investigations car-
ried out in man have never been able to detect an 
activated cardiac sympathetic tone during pacing-
induced myocardial ischemia(47,49)_ Also, it is not 
clear whether myocardial ischemia may affect sys-
temic neurohormones, mainly because the matter 
has not been given sufficient attention, neither in 
the animal model nor in man. Published data on 
the significance of neurohumoral changes in myo-
cardial ischemia relate predominantly to the topic 
of sudden death or arrhythmias in the context of 
ischemia and infarction and reflect studies on car-
diac sympathetic activity and/or catecholamine 
balance in animal models of ischemia(50,51). 
Certainly, the interaction of moderate, short 
lasting myocardial ischemia and peripheral neuro-
humoral mechanisms in man is incompletely 
understood. Studies have generally concentrated 
on angina pectoris rather than on the presence of 
objectivated myocardial ischemia(47-4g,52-54). No 
effort has been made to relate such changes, if 
present, with the degree of myocardial ischemia. 
Still, as in acute myocardial infarction cardiac 
dysfunction is directly related to the degree of 
peripheral neurohumoral activation, such a com-
parison would certainly make sense in ischemia. 
Moreover, studies in humans during ischemia have 
only considered changes in circulating catechol-
amines. Recent animal studies, however, do sug-
gest that other, albeit related, neurohumoral sys-
tems may also become significantly stimu-
lated(55,56) and may contribute to hemodynamic 
alterations, secondary to this neurohumoral activa-
tion. In particular, the renin-angiotensin system 
could be important in this respect. A coronary 
constrictive effect of angiotensin II has been sug-
gested(57). In contrast, arginine vasopressin does 
not seem to be involved in ischemia<57), whereas 
the role of ANF is as yet unclear. However, the 
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SUMMARY. Systemic neurohumoral activation is a com-
mon manifestation in congestive heart failure, irrespec-
tive of etiology, i.e., resulting from ischemic or other 
forms of cardiomyopathy. It is also a feature of acute 
myocardial infarction, particularly when accompanied 
by heart failure. However, whether systemic and/or 
cardiac neuroendocrine activation also occurs in other 
aspects of ischemic heart disease is, as yet, not fully 
established. Thus far, reports on neurohumoral changes 
during exercise-induced angina have been conflicting. 
In contrast, recent observations made during pacing-
induced ischemia would suggest significant elevations 
in circulating catecholamine and renin-angiotensin lev-
els. These neurohumoral changes, which are accom-
panied by systemic vasoconstriction, do not necessarily 
reflect the stress of anginal pain, but could also be the 
resut of ischemia-induced left ventricular dysfunction. 
In this model of pacing-induced ischemia, enalaprilat 
has been reported to prevent both myocardial ischemia 
and the rise in systemic catecholamines and angiotensin 
II, which may indicate a role for ACE inhibition in 
myocardial ischemia. Finally, preliminary data are pre-
sented that indicate neuroendocrine activation may be 
an early feature of ischemic cardiomyopathy, before the 
occurrence of heart failure symptoms. In resting, supine 
patients with ischemic heart diseasee, arterial angio-
tensin II levels were increased in asymptomatic patients 
with left ventricular dysfunction, as compared with 
patients with a normal cardiac function. Although the 
clinical significance of this observation is as yet unclear, 
it may be an additional argument for studying the 
usefulness of ACE inhibition in asymptomatic ischemic 
cardiomyopathy. 
KEY WORDS. ischemic cardiomyopathy, myocardial in-
farction, myocardial ischemia, catecholamines, renin-
angiotensin, ACE inhibition 
In certain aspects of ischemic heart disease, such as 
heart failure due to ischemic cardiomyopathy or acute 
myocardial infarction, neuroendocrine activation is 
well established. Generally it occurs as a result of 
cardiac dysfunction. As it may impose an additional 
burden on the already jeopardized ventricle through 
its vasoconstrictor effects, it has a significant impact 
on the ultimate cardiovascular profile and clinical 
condition of the patient. Althongh attention has been 
focused predominantly upon the sympathetic ner-
vous system and on circulating catecholamines, it has 
recently been realized that other systems are in-
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volved as well, which are both vasoconstrictor and 
va:::;odilator in nature, such as arginine vasopressin 
and circulating and local renin-angiotensin systems. 
Moreover, there are indications that neuroendocrine 
activation may also occur in other manifestations of 
ischemic heart disease. Before paying attention to 
neuroendocrine activation in heart failure or acute 
myocardial infarction, this article will also focus on 
neurohumoral changes in some of these other aspects, 
such as acute myocardial ischemia or ischemic cardio-
myopathy with left ventricular dysfunction, but with-
out concomitant heart failure. 
Congestive Heart Failure Due to 
Ischemic Cardiomyopathy 
Systemic neurohumoral activation is a well-known 
phenomenon in congestive heart failure, whether due 
to ischemic or other types of cardiomyopathy. During 
the more advanced stages of failure, both the pro~ 
gressive reduction in cardiac pump function, arterial 
blood pressure, and renal perfusion, as well as the 
subsequent administration of diuretics and vasodila-
tors, all result in an increase in sympathetic tone, 
circulating catecholamines, and arginine vasopressin 
and in activation of the renin-angiotensin system 
[1-4]. Available data suggest that the magnitude of 
this secondary neuroendocrine activation is pre-
sumably similar in heart failure due to ischemic heart 
disease or resulting from other forms of cardiomyo-
pathy [5]. Plasma levels of norepinephrine and dopa-
mine are usually elevated in heart failure [1, 2, 6], 
regardless of etiology. Individual levels vary widely, 
however, and, although in some studies a correlation 
with resting hemodynamic impairment has been 
Address for correspondence and reprint requests: WJ Remme, MD, 
Sticares, Weipoort 13, 3075 EA Rotterdam, The Netherlands 
suggested [5, 7], they do not really reflect the severity 
of heart failure [2, 5, 6]. Whereas systemic renin-
angiotensin levels are usually markedly elevated 
during the acute phase of cardiac decompensation, 
they are normal or only moderately increased in 
stable, chronic heart failure [3]. Moreover, sponta-
neous but important daily fluctuations in renin and 
aldosterone levels have been reported in heart failure 
patients [8]. Nevertheless, despite the apparent lack 
of correlation between the severity of heart failure 
symptoms and circulating neurohormones, elevated 
systemic catecholamine and renin-angiotensin levels 
appear to be negatively correlated with the prognosis 
ad vitam [9, 10]. 
Neurohumoral Activation in Acute 
Myocardial Infarction 
Acute myocardial infarction is another aspect of 
ischemic heart disease in which neuroendocrine acti-
vation is observed. It has qeen known for a long time 
that acute myocardial inf~rction leads to enhanced 
sympathetic nervous stimulation and significant ele-
vations in plasma and urinary catecholamine levels 
[11-13]. In addition, there is an increase in norepi-
nephrine release from the infarcted area with a 
gradual, but ultimately complete, loss of myocardial 
norepinephrine levels during the first 4 days after 
coronary occlusion [14]. Moreover, myocardiac nore-
pinephrine content also declines in noninfarcted 
regions, followed by only a very gradual return to 
control, a process that may continue up to 40 days 
after infarction. 
The rise in systemic and urinary catecholamines 
occurs very early, within 1 hour of the onset of 
symptoms [15], and appears to be related to the 
hemodynamic status of the patient and to the pres-
ence of ventricular dysfunction [16, 17]. Data from 
animal experiments suggests that during global 
ischemia there is a progressive overflow of norepi-
nephrine from the heart, which starts relatively late 
[18]. In contrast, early ischemia, i.e., of 10 minutes 
duration or less, does not result in significant changes 
in norepinephrine release [18, 19]. 
Systemic arginine vasopressin levels are also 
markedly elevated during acute myocardial infarc-
tion, in addition to the increase in circulating cate-
cholamine levels [20]. Again, changes are observed 
early after the onset of infarction. Although vaso-
pressin values are highest in patients with acute left 
ventricular failure, generally they appear to relate 
predominantly to the administration of opiates. 
Elevated plasma renin levels have been described 
in some patients with acute myocardial infarction, 
but only in those complicated by heart failure or by 
ventricular dysrhythmias [21, 22]. Recently, how-
ever, McAlpine and coworkers have indicated that 
the renin-angiotensin system may become activated 
in all patients with a myocardial infarction [20]. This 
generally occurred at a later stage during infarction, 
from 24 to 48 hours after the onset of symptoms, 
depending on the absence or presence ofleft ventricu-
lar failure. Although the authors indicated that the 
magnitude of the renin-angiotensin activation re-
lated predominantly to acute diuretic treatment in 
their study, renin-angiotensin levels also became 
elevated in patients without heart failure and not 
receiving diuretic therapy. These neurohumoral 
changes lasted for at least 10 days after infarction in 
patients who also developed heart failure symptoms. 
Unfortunately, no data are available on renin-angio-
tensin levels after this time. 
As beta blockade has the potential to reduce the 
detrimental effects of enhanced sympathetic stimula-
tion and increased catecholamine levels in acute 
myocardial infarction, this form of therapy has re-
ceived much attention. In contrast, the information 
available regarding the usefulness of ACE inhibition 
in this setting in humans is very limited. Data from 
animal studies indicate that this form of therapy may 
reduce ischemic injury and limit infarct size [23-25]. 
Up until now, the only information available on the 
effect of ACE inhibition in humans comes from 
studies carried out in myocardial infarctions that 
were complicated by left ventricular failure [26, 27]. 
The recent observation that the renin-angiotensin 
system is also activated in uncomplicated infarcts 
may indicate that the utility of ACE inhibition should 
also be studied in the latter circumstances to assess 
whether it may further improve both ventricular 
function and, ultimately, the prognosis, in addition to 
its late beneficial effect on the infarcted ventricle 
during long-term therapy [28, 29]. 
Neuroendocrine Activation in 
Ischemic Cardiomyopathy without 
Heart Failure 
Relatively little is known of neuroendocrine activa-
tion in other manifestations of ischemic heart disease 
than acute myocardial infarction or heart failure due 
to ischemic cardiomyopathy. Some years ago, Swed-
berg and coworkers studied resting plasma catechola-
mine levels and myocardial catecholamine balance in 
patients with angina pectoris without heart failure 
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and in subjects with chronic heart-failure symptoms 
[30]. Patients with angina and, presumably, a normal 
left ventricular function had normal arterial and 
coronary sinus norepinephrine levels that were sig-
nificantly different from the markedly elevated val-
ues found in heart failure patients (Figure 1A). No 
such differences were observed in epinephrine levels. 
Moreover, in contrast to the marked cardiac norepi-
nephrine release in heart-failure patients, cardiac 
norepinephrine efflux was not observed in anginal 
patients (Figure lB). 
At present it is unknown whether neurohumoral 
levels are still normal in patients with ischemic 
cardiomyopathy and left ventricular dysfunction but 
without heart failure symptoms. We have recently 
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Fig. 1. A. Plasma norepinephrine and epinephrine levels in 
patients with heart failure and in patients with angina pec-
toris without clinical signs of failure. In the latter group 
plasma catecholamine levels are normal. In contrast, norepi-
nephrine values are significantly elevated in heart failure pa-
tients. Adapted from Swedberg et al. [30] with permission. 
B. Myocardial catecholamine balance in heart failure pa-
tients and in patients with angina without signs of heart fail-
ure. In the latter patients, there is neither significant catecho-
lamine release nor uptake. In contrast, marked 
norepinephrine release is present in heart failure patients. 
Adapted from Swedberg et al. [30] with permission. 
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studied this question in 45 patients· with coronary 
artery disease, 28 with a normal left ventricular 
function, eight with left ventricular dysfunction but 
no clinical signs of heart failure, and nine patients 
with chronic, mild-to-moderate congestive heart fai-
lure. All cardiac therapy was stopped 24-72 hours 
before th~ .investigation. Only patients with con-
gestive hea~t failure received diuretics, which were 
withheld 24 hours before the study. Patients were 
fasting and had been supine for at least 1 1/2 hours 
before neurohumoral evaluation. Also, instrumenta-
tion was carried out at least 30 minutes before 
neurohumoral determinations. 
The ejection fraction and contractility parameters 
were reduced, and left ventricular volumes increased 
in both the asymptomatic patients with left ventricu-
lar dysfunction as well as in heart-failure patients 
(Table 1). However, left ventricular filling pressure 
and systemic resistance were still in the normal range 
and cardiac output only moderately diminished in 
asymptomatic patients with left ventricular dysfunc-
tion. 
In contrast, these parameters were clearly abnor-
mal in heart failure patients. Asymptomatic patients, 
therefore, appeared to do rather well, both hemody-
namically and clinically, despite their ventricular 
dysfunction. Nevertheless, there were some early 
neurohumoral changes in this group that were not 
observed in patients with a normal ventricular 
function. This early neuroendocrine activation in 
asymptomatic patients with left ventricular dysfunc-
Table 1. Resting hemodynamic values in patients with coronary 
artery disease with or without LV dysfunction and heart failure 
Normal LV Asympto- LV dysfunc-
function matic LV tion with 
dysfunction heart 
failure 
(n = 28) (n = 8) (n = 9) 
LV ejection fraction 64 ± 0.03 33 ± o.o5• 24 ± o.o3• 
(%) 
LV end-diastolic 65 ± 5 103 ± 15• 120 ± 14. 
volume 
(ml/min/m2) 
Cardiac output 6.2 ± 0.3 5.6 ± 0.5 4.0 ± 0.4 
(1/min) 
Vmax (sec·1) 56± 2 32 ± 3• 24 ± 2.5• 
LV end-diastolic 13 ± 1.5 15 ± 3 24 ± 3a,b 
pressure (mmHg) 
Systemic resistance 1380 ± 85 1497 ± 140 1880 ± 
(d.s.cm·5) 135a,b 
x ± SEM: •p < .05 vs. normal LV function; bp < .05 vs. 
asymptomatic LV dysfunction. LV= left ventricular. 
tion was not evidenced by sympathetic stimulation 
and increased catecholamine levels. Arterial norepi-
nephrine values were, in fact, only elevated in heart-
failure patients, whereas dopamine and epinephrine 
levels were comparable and normal in all patients. In 
contrast, arterial angiotensin II levels not only in-
creased in heart failure patients, but also in asymp-
tomatic patients with ventricular dysfunction (Figure 
2). 
The clinical significance of this early but still 
modest renin-angiotensin activation in asympto-
matic patients with chronic left ventricular dysfunc-
tion is as yet unclear. It apparently did not result in 
systemic vasoconstriction in these patients. Also, in 
view of a normal cardiac output and blood pressure 
and in the absence of diuretic treatment, it is not 
easily comprehended which signal initiates this 
neuroendocrine activation. Our observations were 
made in relatively small groups of patients, and data, 
for the moment, should be considered to be pre-
liminary. However, their potential significance 
c:::J NORMAL LV FUNCTION. n=28 
rzz:z1 LV DYSFUNCTION- CHF. n= 8 
- LV DYSFUNCTION- CHF INYHA CL 2·31. n = 9 * p 05 
ARTERIAL 
NOREPINEPHRINE 
(nmolil) 
* 
ARTERIAL 
ANGIOTENSIN II 
(pmoll) 
Fig. 2. Arterial norepinephrine (NE) angiotensin II (A II) lev-
els in patients with coronary artery disease and normal left 
ventricular (LV) function (LV ejection fraction " 45%, n = 28), 
LV dysfunction (LV ejection fraction s 45%, n = 8) without 
and with congestive heart failure (CHF, n = 9). Whereas nor-
epinephrine (NE) levels are only elevated in heart failure pa-
tients, A II values are also significantly different in patients 
with asymptomatic LV dysfunction compared with patients 
with normal LV function. 
should be further explored in a greater number of 
asymptomatic patients with ventricular dysfunction, 
whether or not of ischemic origin. That ACE inhibi-
tion may be useful in limiting ventricular dysfunction 
in the postinfarct period has already been strongly 
suggested [31, 32]. It may well be that its application 
should not be limited to this patient group only. 
Neurohumoral Activation During 
Acute Myocardial Ischemia 
Very little attention has been paid to neurohumoral 
activation as a result of myocardial ischemia, despite 
the fact that such activation is likely to occur sec-
ondary to the stress of anginal pain. In contrast to the 
observations in acute myocardial infarction, the few 
data available in stress- or pacing-induced ischemia 
do not indicate a significant rise in systemic or 
urinary catecholamine levels [33-35], at least not 
when compared with the neurohumoral changes 
found in normal individuals at comparable workloads 
and when only the mbre recent studies are taken into 
account, in which more sensitive and discriminating 
techniques for the assay of catecholamines were 
applied [36]. 
Although early studies did indicate increased cate-
cholamine levels during exercise-induced angina 
[12], more recent investigations could not corroborate 
these observations [33]. In contrast, Robertson and 
coworkers reported a rise in arterial and coronary 
venous norepinephrine and epinephrine levels, not 
during stress-induced ischemia, but as a late phe-
nomenon after spontaneous coronary spasm and 
anginal pain had developed [37]. Thus far, the effect 
of short periods of myocardial ischemia on systemic 
and/or transcardiac renin-angiotensin levels has not 
yet been evaluated in humans. Recent data from our 
laboratory indicate that during and for several mi-
nutes after (pacing-induced) ischemia, a significant 
elevation of systemic angiotensin II levels occurs 
without concomitant changes in coronary venous 
levels [38, 39]. No such changes are observed in 
patients with coronary artery disease in whom ische-
mia does not occur, despite identical alterations in the 
rate-pressure produce during pacing. Moreover, a 
significant increase in both the arterial and coronary 
venous norepinephrine values are found during 
ischemia (Figure 3), again without any such effect in 
nonischemic patients. These latter observations con-
trast with previous, similar-type studies in humans 
[34, 35], which may be due to differences in biochem-
ical techniques or in the study protocols used. In our 
study specific attention is paid to the direct post-
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Fig. 3. Changes in arterial and coronary venous norepineph-
rine and epinephrine levels during pacing-induced ischemia 
in patients with coronary artery disease. Compared with con-
trol values, arterial and coronary venous norepinephrine and 
arterial epinephrine levels increase significantly when meas-
ured during m=imal pacing rates and ischemia. 
pacing period with sequential sampling of blood 
during the first 2 minutes after pacing. Thus, the 
largest increase in norepinephrine and angiotensin II 
levels is observed at 1 minute postpacing and not 
during maximal rates before the cessation of pacing 
[39]. The clinical significance of these neurohumoral 
changes during ischemia relates presumably to the 
observation that, concomitantly and only in ischemic 
patients, arterial pressures become significantly in-
creased and that as late as 5 minutes after pacing 
systemic vascular resistance is still elevated. This 
systemic vasoconstriction beyond doubt is secondary 
to the increase in activation of circulating neuro-
hormones and poses an additional burden on the 
ischemic myocardium. 
Effect of Ischemia on Cardiac 
Norepinephrine Release 
Besides peripheral neurohumoral changes, ischemia-
induced alterations in cardiac catecholamine fluxes 
are also likely to occur. Since during myocardial 
ischemia and subsequent accumulation of various 
metabolites reuptake of norepinephrine by nerve 
endings in the heart may be inhibited, this could 
result in increased cardiac norepinephrine release. 
The latter, however, has not been consistently dem-
onstrated [34, 35]. 
Enhanced cardiac norepinephrine release is in-
variably present in animal models of infarction or 
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ischemia. However, for this to happen-ischemia has to 
persist for at least 10 minutes [20]. This, presumably, 
is why in human studies, where (pacing-induced) 
ischemia is usually present for only a few minutes, 
the expected increase in cardiac norepinephrine 
release has never been observed. In contrast, we have 
recently demonstrated that myocardial ischemia ac-
tually results in a short-lasting reversal of norepi-
nephrine release, which is commonly present at 
baseline, to uptake during the ischemic period [40]. 
This, however, is only observed in patients who also 
produce lactate during ischemia (Figure 4). As 
changes in cardiac norepinephrine balance do not 
occur in nonlactate producers or in nonischemic 
patients; this would suggest that norepinephrine 
release is only affected in the ischemic area. Richardt 
and coworkers have suggested that local adenosine 
production may inhibit cardiac noradrenaline release 
that is evoked by nerve stimulation during the very 
early phase of myocardial ischemia [ 41]. This would 
agree with both of our previous reports on sequential 
nucleoside production by the human heart in this 
model of pacing-induced ischemia [ 42, 43] and our 
recent observations on cardiac norepinephrine bal-
ance in this setting. 
Do Ischemia-Induced Neurohumoral 
Changes Only Result From Angina? 
A plausible way to explain neurohumoral changes 
during pacing-induced ischemia is to relate these 
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Fig. 4. Effect of ischemia on cardiac norepinephrine (NE) up-
take. In patients who during ischemia produce lactate, a sig-
nificant change from, cardiac NE release present during con-
trol to uptake during ischemia, is observed, which is absent 
in nonischemic patients. 
effects to the stress of pacing-induced anginal pain. 
We recently studied patients with symptomatic and 
asymptomatic ischemia, again with atrial pacing, and 
compared the results with a nonischemic group. It 
was clear from this study that neurohumoral activa-
tion was only present in patients who developed 
angina during pacing [ 44]. In contrast, no changes 
occurred in either nonischemic or silent ischemic 
patients. However, symptomatic and silent ischemic 
patients differed with respect to the absence or 
presence of angina, and, despite similar electro-
cardiographic changes, ischemia was clearly more 
severe in anginal than in asymptomatic patients. 
This suggests that the neurohumoral changes ob-
served in anginal patients may be the result of 
ischemia-induced ventricular dysfunction rather 
than being caused by angina alone. 
Therapeutic Implications of 
Ischemia-Induced Neurohumoral 
Activation During Ischemia 
The neuroendocrine changes caused by ischemia in 
our studies indicate that measures limiting this 
neurohumoral (over)activation and its effect on vas-
cular tone may be of therapeutic value. It is of interest 
that bepridil, a compound with predominant calcium-
entry blocking properties, effectively inhibits ische-
mia-induced vasoconstriction in the same type of 
study and patients [45]. As calcium antagonists 
indirectly attenuate postsynaptic alpha2-receptor-
mediated vasoconstriction [46], their usefulness as 
vasodilating agents may be particularly important 
during acute ischemia through these mechanisms. 
However, compounds that directly affect neurohu-
moral production may be of even greater value in this 
respect. Thus, it may be useful to evaluate agents 
that, through presynaptic D~-receptor modulation 
or angiotensin-II-receptor inhibition, may reduce 
norepinephrine release from nerve endings during 
myocardial ischemia. Likewise, ACE inhibitors may 
have antiischemic properties through a decrease in 
local and/or circulating angiotensin II and, sub-
sequently, less activation of this hormone during 
ischemia. Recently, attention has focused on the 
potential antiischemic and antianginal effects of ACE 
inhibition during exercise in normotensive patients 
with ischemic heart disease. Although in some stud-
ies a positive effect was shown [47-49], other in-
vestigations were unable to detect a significant 
antiischemic activity of ACE inhibitors during ex-
ercise-induced angina [50, 51]. We have recently 
demonstrated that enalaprilat reduces pacing-in-
duced ischemia, not through systemic hemodynamic 
effects, but presumably by limiting neurohumoral 
activation during ischemia [52]. The significance of 
the latter effect may be lost during the pronounced 
stimulation of circulating neurohormones that in-
variably occurs during exercise [53]. This could also 
explain the inconsistency of the antiischemic effects 
of ACE inhibition with exercise-induced stress. In 
contrast, in situations where ischemia is not exercise 
related, further exploration of the usefulness of ACE 
inhibition as an antiischemic therapy is certainly 
worthwhile. 
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ABSTRACT 
To identify the effect of short periods of myocar-
dial ischemia on systemic neurohormones and vas-
cular resistance, 32 untreated, resting, normoten-
sive patients with coronary artery disease under-
went incremental atrial pacing until angina. Arte-
rial and coronary venous lactate levels and arterial 
values of catecholamines and angiotensin II were 
determined at control, maximum pacing rates and 
at 1, 2, 5 and 30 minutes post-pacing. Based on 
pacing-induced ST segment depression ~1 mm) 
and/or myocardial lactate production, patients 
were selected as ischemic (I, n=25) or non-ische-
mic (NI, n=7). Baseline clinical, hemodynamic 
and angiographic data were comparable, except for 
more severe preexisting angina and coronary 
lesions in I. During pacing, chest pain was similar 
[78% (I) vs 72% (NI)] and hemodynamics compa-
rable, except for contractility, which did not 
improve, and left ventricular end diastolic pres-
sure, which increased significantly by 79% in I. 
Also, ischemia significantly increased arterial 
pressures and systemic resistance (13% and 11%, 
resp.) not observed in NI. Pacing did not affect 
neurohormones in NI. In contrast, in I arterial 
norepinephrine increased significantly from 
1.7±0.2 (control) to 2.6±0.3 (maximal pacing 
rates) and further to 3.0±0.4 nmol/1 (1 min post-
pacing). Concomitantly, angiotensin II levels rose 
from 6.2±1.4 (control) to 9.3±2.1 pmol/l (1 min 
post-pacing, p<0.05). Arterial epinephrine only 
increased during maximal rates (0.93±0.13 vs 
0.60±0.09 nmol/1 at control, p<0.05). Thus, 
pacing-induced myocardial ischemia activates 
circulating catecholamines and angiotensin II, 
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accompanied by systemic vasoconstriction. As the 
latter amplifies myocardial ischemia, modulation 
of this neuroendocrine stimulation may be of 
therapeutic value. 
INTRODUCTION 
In humans, systemic catecholamines and circulat-
ing renin-angiotensin levels become activated 
during acute myocardial infarction, depending on 
the degree of cardiac dysfunction 1-6). Whether 
myocardial ischemia also results in neuroendocrine 
activation, as a result of an acute, ischemia-in-
duced reduction in cardiac pump function, is less 
well defined. In humans, available data do not 
uniformly indicate significant changes in plasma or 
urinary catecholamines during exercise- or 
pacing-induced ischemiaC2,7-ll). Whereas an early 
study suggested increased catecholamine levels 
during exercise-induced angina(2), this could not 
be confirmed in a more recent investigation in 
which more sensitive and specific biochemical 
techniques were applied(?). Apart from these 
conflicting reports, it is unknown whether myo-
cardial ischemia affects the circulating renin-
angiotensin system. Furthermore, no data exist on 
the hemodynamic consequences of ischemia-
induced systemic neurohumoral activation in man. 
The present study investigates sequential changes 
in systemic neurohormones and hemodynamics 
during pacing-induced ischemia in normotensive 
patients with coronary artery disease and in similar 
patients, who did not develop ischemia during the 
test. 
MATERIALS AND METHODS 
Patient population: 
After the protocol was approved by the institu-
tional ethical review board and informed consent 
obtained, 32 patients, 29 men and 3 women, aver-
age age 57 years (range 37 to 69 years) were 
studied. Subjects were referred for coronary 
angiography for the evaluation of angina -like chest 
pain. Objective signs of ischemia or a previous 
myocardial infarction were not obligatory for 
inclusion, but patients had to be normotensive 
without symptoms of heart failure. Exclusion 
criteria included previous myocardial infarctions 
<1 month old, unstable angina, valvular heart 
disease, conduction disturbances or the use of 
diuretics. 
Cardiac therapy was withheld 36-72 hours pre-
study. Only short-acting nitroglycerin was allow-
ed until 6 hours before the investigation. Signifi-
cant coronary artery disease, defined as ?:..70% 
diameter narrowing, was present in 28 patients, 10 
with single-, 11 with double- and 7 with triple-
vessel disease. Objective signs of ischemia during 
pre-study ergometry testing ~0,1 mV ST-seg-
ment depression) were present in 22 patients, 
whereas 18 had .::_1 documented myocardial infarc-
tions. 
Catheterization procedures: 
Patients were studied at the same time in the 
morning after an overnight fast, without pre-
medication. After coronary angiography, using the 
Seldinger technique, an 8 Fr Sentron pigtail 
microtip manometer catheter was advanced into 
the left ventricle through a 9 Fr arterial Desilet 
introducer system in a femoral artery. The side-
arm of this system was used to measure arterial 
pressures. A 7 Fr triple-lumen thermodilution 
catheter was positioned with its tip in a pulmonary 
artery. Finally, a 7 Fr Zucker bipolar pacing 
catheter or 7 Fr thermodilution pacing catheter was 
advanced into the mid portion of the coronary 
sinus, such that the tip of the catheter was at least 3 
em beyond the orifice of the coronary sinus, its 
position stable and rapid blood sampling was 
ensured. The position of the catheters was sub-
sequently recorded on video-disc and frequently 
checked during the study. 
Measurements and calculations 
Fluid-filled catheters were calibrated, using 
Bentley transducers with a zero reference level set 
at mid chest. The micromanometer pressure was 
balanced to zero and superimposed on the conven-
tiona! pressure recording. All pressures, the first 
derivative of left ventricular pressure and the 
thermodilution-derived cardiac output signal were 
recorded on paper at different paper speeds, using 
a CGR 1000 cathlab system. Pressures and pres-
sure-derived contractility indices were measured 
on -line from 12 to 15 successive beats, using a 
Mennen Medical cath lab computer system. Like-
wise, cardiac output measurements were deter-
mined on -line. At the end of the study, the 
femoral arterial pressure curves were compared 
with simultaneous recordings from the ascending 
aorta by the Sentron catheter. 
Hemodynamic variables: 
Measured variables included left ventricular peak 
systolic and mean and end diastolic pressures 
(mmHg), pressure-derived contractility indices 
[left ventricular dP/dt (mmHg/sec) and Vmax 
(sec-1)], mean and phasic systemic and pulmonary 
arterial pressures (mmHg), mean right atrial pres-
sure (mmHg) and cardiac output (1/min). From 
these, systemic vascular resistance (dynes.s.cm-5), 
stroke index (ml/beat/m2) and stroke work index 
(g/mfm2) were calculated(l2). 
Electrocardiographic parameters: 
Leads I, II and V5 were monitored continuously to 
measure heart rate. ST -segments were determined 
at a paper speed of 100 mm/sec in 3 successive 
beats, 60 msec after the J -point of the QRS-
complex, using a calibrated magnifying lens. 
Metabolic and neurohumoral parameters: 
For the assay of lactate, 1 m1 of blood was with-
drawn simultaneously from the left ventricle and 
the coronary sinus in ice cold 8% HCL04 and 
analysed enzymaticallyC13). For the determination 
of catecholamines and angiotensin II, 6 m1 of 
blood was collected from the left ventricle in ice 
cold syringes. Of these, 3 ml were quickly trans-
ferred into precooled tubes containing 500 I!U 
heparin and 3 mg/ml glutathion for the catechol-
amine assay and 3 m1 into precooled tubes 
containing 4 mg EDTA and 0.06 mg 0-fenan-
trolin for the assessment of angiotensin II. Blood 
samples were then immediately centrifuged under 
cooled conditions at 3000 revs/min for 10 minutes 
and frozen at -20°C. Catecholamines: norepi-
nephrine, epinephrine and dopamine were deter-
mined by radioenzymatic assay, using high pres-
sure liquid chromatography to separate the radio-
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active productsC14). Angiotensin II was assessed by 
radioimmunoassayC15). 
Study protocol 
Repeated control measurements of all variables 
were carried out at approximately the same time in 
the morning, 1.5 to 2 hours after entering the 
catheterization laboratory, 20 minutes following 
instrumentation and at least 40 minutes after coro-
nary angiography. 
Throughout this period patients were supine. 
Subsequently, atrial pacing stress testing was 
performed with increments in heart rate of 10 
beats/2 minutes until significant angina -like pain, 
atrioventricular block or a maximum pacing rate of 
170 beats/minute. Significant angina -like pain was 
defined as the level of pain, at which the patient 
typically would rest or take nitroglycerin. 
All variables were redetermined at maximal pacing 
rates, just before cessation of pacing, followed by 
measurements at 1, 2, 5 and 30 minutes post-
pacing. In addition, left ventricular end diastolic 
Table 1: Baseline clinical an angiographic 
characteristics of ischemic and non-ischemic 
patients 
Sex 
Age (years) 
Positive X-ECG 
Previous Infarct 
Coronary angio 
(>70% stenosis) 
0-vessel 
1-vessel (LCA) 
2-vessel 
3-vessel 
Left ventricular 
ejection fraction 
Left ventricular 
end diastolic 
volume 
Ischemic 
(I, n=25) 
25Mil F 
55±1.8 
19 
15 
0 
7 
11 
7 
53±2.9 
63±4.3 
Non-ischemic 
(NI, n=7) 
5M/2F 
65±1.2 
3 
3 
4 
3 
0 
0 
51±6.3 
69±8.8 
Abbreviations: F = Female; LCA = Left Coronary Artery; 
M =Male; X-ECG =Exercise test. 
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pressure and lactate were measured at 10 and 15 
seconds post-pacing, resp. 
Due to the complexity of the study, cardiac output 
determinations were not carried out until 3-5 
minutes post-pacing. 
Statistical analysis 
Changes from baseline values were calculated for 
neurohormones in each patient. Statistical differ-
ences were assessed using a paired t-test with a p 
value less than 0.05 considered significant 
(2-sided). Baseline values for hemodynamic vari-
abies and changes from control during pacing were 
compared in patients, who during the test became 
ischemic and those who did not, using an unpaired 
Student t-test with a p value <0.05 to detect sig-
nificant differences. Values are given as averages 
(X) and standard errors of the mean (SEM). 
RESULTS 
Control period 
At baseline, none of the patients had clinical signs 
of ischemia. Values for norepinephrine and epi-
nephrine ranged between 0.7 and 3.15 nmol/1 and 
between 0.17 and 1.55 nmol/1, resp. Angiotensin 
II varied from <2 (in 2 patients) to 24 pmol/1. 
Pacing period 
Based on objective signs of ischemia during 
pacing, e.g. ST-segment depression of >1 mm 
and/or myocardial lactate production, patients 
were classified as ischemic (I, n=25) or non-
ischemic (NI, n=7). Pacing-induced chest pain 
was present in 20 patients in I and in 5 in NI. Both 
groups were comparable as to sex, age, number of 
previous myocardial infarcts, left ventricular vol-
umes and ejection fraction (Table I). In contrast, 
objective signs of ischemia during pre-study exer-
cise tests and significant coronary lesions were 
more prominent in I. 
Sequential hemodynamic changes during and 
after pacing 
Baseline hemodynamic variables were similar in 
both groups (Table II). Also, during pacing, maxi-
mal changes in heart rate, left ventricular systolic 
pressure and the double product were comparable, 
as well as pacing-induced alterations in coronary 
sinus flow, coronary resistance and myocardial 
oxygen extraction and consumption. In contrast, 
contractility indices (e.g. Vmax) did not change 
Table IT: hemodynamic variables at control and maximal pacing rates in ischemic vs 
non-ischemic patients. 
Group 
NI 
control 
maximal pacing 
10 seconds p-p 
control 
maximal pacing 
10 seconds p-p 
HR LVSP 
b/min mmHg 
85±3.5 148±6 
152±3.6t 143±7 
81±3.6 142±6 
147±7.lt 140±9 
LVEDP 
mmHg 
14±1.5 
15±1.9* 
25±2.9*t 
12±1.0 
7±0.7t 
13±1.4 
MAP 
mmHg 
112±3.9 
127±4.0t 
110±6.5 
115±8.2 
Vmax 
sec-1 
53±2.6 
57±2.8 
56±4.8 
71±6.6 
CBF 
ml/min 
109±8 
193±15 
122±14 
186±3lt 
DP 
bpm mmHgxlo-3 
12.2±8.6 
21.5±Llt 
11.5±0.6 
20.7±L8t 
Abbreviations: BPM = beats per minute; CBF=coronary venous blood flow; DP=double product; HR=heart rate; I= ischemic; 
LVEDP=left ventricular end diastolic pressure; LVSP=left ventricular systolic pressure; MAP=mean arterial pressure; Nl =non-
ischemic. p-p =post-pacing. *p<.05 group Ivs groupNI. t p<0.05vs control. 
during pacing in I, compared to a significant 27% 
improvement in NI (Fig. 1), whereas left 
ventricular end diastolic pressure was significantly 
elevated in I [25±3 versus 13±5 mmHg (NI) at 10 
seconds post-pacing]. In I, mean arterial pressure 
increased by 13% during maximal pacing, whereas 
systemic resistance was still elevated at 5 minutes 
post-pacing (1632±76 versus 1470±60 
dynes.s.cm-5 at control, p<0.05, Fig. 2). No such 
changes occurred in NI. 
Sequential electrocardiographic and metabolic 
changes during pacing 
By design, significant repolarization disturbances 
only occurred in I, persisting until2 minutes post-
pacing (Fig. 3). Pacing did not affect myocardial 
lactate metabolism in NI. In contrast, in I, myo-
cardial lactate extraction at control changed to 
production during maximal pacing rates and for 2 
minutes after pacing with a maximal value of 
-71±16% at 15 seconds post-pacing (Fig. 3). 
Effect of pacing-induced ischemia on systemic 
neurohormones 
Pacing did not affect arterial catecholamine or 
angiotensin II levels in NI (Table III). In contrast, 
significant neurohumoral changes were observed 
during myocardial ischemia. In I, arterial norepi-
nephrine increased from 1.7±0.2 (control) to 
2.6±0.3 (maximal pacing) and further to 3.0±0.4 
nmol/1 at 1 minute post-pacing, both p<0.05 
versus control (Fig. 4). Concomitantly, arterial 
angiotensin II levels rose significantly by 39%, 
from 6.2±1.4 (control) to 8.6±2.0 (maximal 
pacing) and to 9. 3±2.1 pmol/1 (1 minute after 
VMAx x ± SEM D---O I, n = 25 
sec·t t p < .05 Gr. I vs. Gr. Nl •----• Nl. n = 7 
100 t 
75 
_l __ 
.. -------- -----------.:t------l.------I--------.1 
50 
25 
10 t·----._1 ____ ---t-----!------1;'·-----r--------! 
~~--~--~--~~--~-7~ 
CONTROL MAX 1 0" p-p 1' P·P 2' p-p 5' p-p 30' p-p 
Fig. I: Effect of pacing- induced ischemia on 
contractility (Vmax) and left ventricular end 
diastolic pressure (LVEDP). Vmax significantly 
increases during maximal pacing rates (MAX) in 
non-ischemic patients (Gr NI), but not in the 
ischemic group (Gr /). In contrast, LVEDP is 
elevated in I, but not in NI, at 10 seconds (") 
post-pacing (p-p). ' = minute; C = control 
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x±SEM 
* p > .05 vs. Control 
c MAX c 5' p-p 
Fig. 2: Effect of pacing and ischemia on mean 
arterial pressure (MAP) and systemic vascular 
resistance (SVR). Both MAP and SVR increase 
significantly in patients, who become ischemic 
during pacing (!), but not in non-ischemic 
patients (Nl). ' = minute; C = control; MAX = 
maximal pacing rates; p-p =post-pacing 
pacing, Fig. 5). By contrast, epinephrine levels 
only increased during pacing [0.93±0.13 (maximal 
pacing) versus 0.60±0.09 nmol/1 (control), 
p<0.05, Fig. 6]. Norepinephrine and angiotensin II 
levels returned to baseline values between 2 and 5 
minutes post-pacing. Dopamine levels did not 
change. 
DISCUSSION 
Systemic neurohumoral activation frequently 
accompanies acute myocardial infarction, particu-
larly when complicated by cardiac pump fail-
ure(l-6), whereas, in animal models, long lasting, 
severe myocardial ischemia also increases neuro-
endocrine activation(l6). In contrast, it is not at all 
clear, whether short periods of moderate ischemia 
in man may equally affect peripheral neuro-
humoral systems. Thus far, data on catecholamine 
stimulation during exercise- or pacing-induced 
ischemia have been conflicting(2, 7-11, 17), whereas 
no information exists on other neurohormones in 
this context. The present study clearly demon-
strates that myocardial ischemia, induced by atrial 
pacing in the resting patient with coronary artery 
disease, results in significant activation of systemic 
catecholamines and the circulating renin-angio-
tensin system together with a significant increase 
in systemic vascular resistance and arterial pres-
sures. As it may be anticipated that afterload sub-
sequently increases, imposing an extra burden on 
the already ischemic myocardium, this systemic 
neurohumoral activation may be of clinical rele-
vance. 
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The effect of pacing-induced stress and of 
anginal pain on circulating neurohonnones 
Pacing per se does not significantly affect neuro-
hormones. In the present study, non-ischemic 
patients were paced to the same level as the ische-
mic patients with similar increases in myocardial 
oxygen demand and consumption. Nevertheless, 
arterial neurohumoral levels did not change sig-
nificantly, despite the fact that 72% of patients in 
Gr. NI complained of retrostemal pain during 
pacing. The latter indicates that angina is not a 
prerequisite for neurohumoral activation. Unfor-
tunately, this cannot be proven in our study, as 
very few ischemic patients were asymptomatic. 
However, other studies, carried out during 
pacing-induced stress, also did not observe sig-
nificant changes in systemic catechol-
amines(8,10,ll). In view of the elusive link between 
transient myocardial ischemia and angina(l8), 
neurohumoral activation most likely does not 
depend on the presence or absence of angina, but 
rather on myocardial ischemia and, possibly, on 
the severity hereof. 
.2 
0.1 
ST-segment depression 
mV 
* 
* 
* 
* 
- l,n=25 D Nl,n=7 
x± SEM 
* p > .05 vs. Control 
40 
Myocardial lactate extraction (%) 
20 
-20 
-40 
-60 
* * 
-80 
C MAX 15" p-p 1' p-p 2' p-p 5' p-p 30' p-p 
Fig. 3: Sequential changes in ST-segment and 
myocardial lactate extraction in ischemic patients 
(Gr I), persisting until 2 minutes (')post-pacing 
(p-p), but not in non-ischemic patients (Gr Nl). 
C = control; MAX = maximal pacing rates; " 
seconds 
Table ill: Effect of pacing on arterial neurohonnones in ischemic versus non-ischemic patients. 
c MAX 1' P-P 2' P-P 5' P-P 30' P-P 
NOREPINEPHRINE (nmol/1) 
Group! 1.7±0.2 2.6±0.3* 3.0±0.4* 2.4±0.3 2.4±0.3 2.1±0.2 
GroupNI 2.0±0.4 2.3±0.3 2.1±0.3 2.1±0.3 2.1±0.4 2.0±0.6 
EPINEPHRINE (nmol/1) 
Group I 0.60±0.09 0.93±0.13* 0.71±0.10 0.67±0.09 0.70±0.13 0.63±0.08 
GroupNI 0.54±0.09 0.62±0.10 0.57±0.13 0.61±0.13 0.58±0.14 0.66±0.19 
DOPAMINE (nmol/1) 
Group! 0.50±0.07 0.54±0.08 0.49±0.09 0.35±0.07 0.43±0.12 0.53±0.05 
GroupNI 0.35±0.08 0.33±0.08 0.21±0.07 0.24±0.08 0.36±0.08 0.40±0.08 
ANGIOTENSIN II (pmol/1) 
Group I 6.2±1.4 8.6±2.0* 9.3±2.1* 5.5±0.9 6.0±0.9 6.9±1.8 
GroupNI 5.0±1.5 4.9±1.4 4.7±1.4 4.3±1.4 4.4± 1.3 5.8±1.6 
Abbreviations: '=minute(s); C=control; !=ischemic; MAX=maximalpacing rates; Nl=non-ischemic; P-P=post-pacing 
*p<.05vs control 
Only few patients in Gr. I did not produce lactate, 
which implicates predominant anterior wall isch-
emia. Besides stimulation of mechanoreceptors in 
this area by hemodynamic or metabolic stimuli and 
subsequent excitation of the vasomotor centre in 
the medulla oblongataC18,19), a more pronounced 
reduction in cardiac pump function could also 
explain the enhanced sympathetic outflow in this 
study. 
Comparison with other studies of pacing- or 
exercise-induced ischemia 
Thus, the inconsistency in observations on neuro-
endocrine activation in the available patient studies 
may be explained by differences in degree of 
ischemia. Alternatively, they may be explained by 
differences in sensitivity and specificity of the 
biochemical analytical techniques available at the 
time of study. Nevertheless, several relatively 
recent investigations, all performed in a similar 
model of pacing-induced stress, have been equally 
inconsistent in their observations on neuroendo-
crine activation during ischemia(8,10,17)_ As study 
protocol, type of patients and the catecholamine 
assay techniques were basically comparable, the 
variability in study-results is difficult to explain. 
Our study differs from these investigations in two 
aspects. First, the objective in the present study 
was to analyze neurohumoral alterations during 
ischemia per se, irrespective of angina, but con-
firmed by objective signs of ischemia. Only 
Schwartz et al. (8) stipulated the presence of ob-
jective evidence for ischemia in their anginal 
patients. Secondly, the combined radioenzymatic 
assay and high pressure liquid chromatography 
technique may significantly improve the detection 
of small changes in catecholamine levels. More-
over, our study differs from previous investi-
gations in man, as it also investigated alterations in 
other neurohormones and concomitant hemody-
namic changes. 
Effect of pacing-induced ischemia on 
circulating angiotensin n levels 
In the present study, arterial angiotensin II levels 
increased significantly during pacing-induced Fig. 
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Fig 4. Effects of pacing and myocardial ischemia 
on arterial norepinehrine levels. In ischemic 
patients (Gr I) levels increase significantly from 
control to maximal pacing rates (MAX) and 
further, at I minute (') post-pacing (p-p). In 
contrast, in non-ischemic patients (Gr NI) pacing 
does not affect arterial norepinephrine levels. 
ischemia, but not during equivalent increments in 
heart rate in non-ischemic patients. Thus far, no 
data are available on the effect of ischemia on the 
circulating renin-angiotensin system. Recent ani-
mal studies indicate, however, that this system 
may indeed be influenced by myocardial 
ischemia(20,21). Ertl et al. demonstrated a signifi-
cant increase in arterial renin and, to a lesser 
extent, in arterial angiotensin II following 10 min-
utes of coronary occlusion in a canine modelCZO). 
Also, 30-second occlusions of the left anterior 
descending artery result in significant elevations of 
plasma renin and angiotensin II, whereas fast atrial 
pacing in the presence of a coronary artery stenosis 
induces a 50% increment in arterial reninC20,22). As 
this activation of the circulating renin-angiotensin 
system by ischemia was not modulated by beta-
adrenergic blockade, but prevented by 
nephrectomy, may be initiated by renin release 
from the kidney as a result of renal under-
perfusion, secondary to ischemia-induced left 
ventricular dysfunction. This, in turn, suggests 
that stimulation of the circulating renin-angio-
tensin system depends on the severity of myocar-
dial ischemia. 
Ischemia-induced neurohumoral activation 
may result in systemic vasoconstriction 
A significant increase in systemic vascular resist-
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ance and a rise in arterial pressures did occur 
during ischemia, but was not observed in non-
ischemic patients. As ischemia-induced cardiac 
dysfunction and the subsequent decrease in cardiac 
output primarily will result in a reduction of arte-
rial pressures, secondary counterregulatory forces 
must supervene. Whether the increase in systemic 
catecholamines and/or activation of the circulating 
renin-angiotensin system is causally involved can-
not be determined from our studies, as specific 
antagonists of these neurohumoral systems were 
not administered. Hence, the concomitant change 
in systemic resistance and neurohormones only 
suggests such an interrelationship, but could be 
coincidental. 
Clinical implications 
Our observations were made in the resting, supine 
patient and do not necessarily apply to the model 
of exercise-induced ischemia. Exercise by itself 
results in a marked increase in circulating neuro-
hormones, also in normal individualsC23). In con-
trast, in the resting patient, with stable and low 
baseline neurohumoral levels, subsequent activa-
tion during ischemia may be clinically significant. 
pmol/1 
10 
ANGIOTENSIN II o---o I, n = 2S 
•-----.. NI,n=7 
x±SEM 
* p >.OS vs. Control 
----1 r·-------r--------r---------r·--------r··· 
CONTROL MAX 1' p-p 2' p-p S' p-p 30' p-p 
Fig. 5: Effects of pacing and myocardial ischemia 
on arterial angiotensin II levels. In the ischemic 
group (Gr I) a 39% increase is observed, persis-
ting until I minute (') after pacing (p-p). Pacing 
per se does not affect angiotensin II in the non-
ischemic group (Gr NI). 
MAX = maximal pacing rates. 
Hence, in patients with ischemia at rest, e.g. 
unstable angina or the early phase of myocardial 
infarction, a similar or even more pronounced 
neuroendocrine activation than in our study, may 
be present with systemic, and possibly coronary 
nmolil 
1.0 
0.5 
EPINEPHRINE 
* 
o---o I, n = 25 
•----.. Nl, n = 7 
x±SEM 
* p > .05 vs. Control 
L---.-----r----.-----.----~~r-,-
CONTROL MAX 1' p-p 2' p-p 5' p-p 30' p-p 
Fig_ 6: Effects of pacing and myocardial ischemia 
on arterial epinephrine levels- A significant el-
evation occurs in ischemic (Gr 1), but not in non-
ischemic patients (Gr NI) and only at maximal 
pacing rates (MAX). '=minute; p-p=post-pacing. 
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ABSTRACT 
Systemic and cardiac neuroendocrine activation is 
prominent in myocardial infarction, depending on 
concomitant cardiac dysfunction. Its occurrence 
and clinical significance in myocardial ischemia is 
less well defined and was studied in 56 fasting, 
supine, untreated subjects with stable angina-like 
chest pain during incremental atrial pacing. 
Coronary venous and arterial neurohormones 
( catecholamines and angiotensin II) and lactate 
were determined at control, maximal pacing rates 
and at 1, 2, 5 and 30 minutes post-pacing (p-p). 
Based on objective signs of ischemia during 
pacing, patients were grouped as ischemic and 
non-ischemic (NI,n=ll). To facilitate identifi-
cation of neurohumoral changes in the ischemic 
myocardium, ischemic patients were then separa-
ted in lactate and non -lactate producers (LP and 
NLP, n=28 and n=17, resp.). Pacing-induced an-
gina occurred in 55%, 82% and 82% of NI, LP and 
NLP, resp. Baseline hemodynamic and neurohu-
moral values were comparable in all groups, as 
were pacing-induced changes in heart rate, double 
product and coronary hemodynamics. However, in 
LP, contractility and relaxation did not improve or 
deteriorate during pacing, left ventricular filling 
pressure rose significantly, whereas cardiac output 
was still significantly reduced (10%) and systemic 
resistance increased (23%) at 5 minutes p-p, in 
contrast to NI and NLP. As a result, arterial 
pressures were markedly elevated during and after 
pacing in LP. Pacing did not change dopamine 
levels in either group, neither did it affect other 
neurohormones in non-ischemic patients. In 
contrast, in LP, arterial norepinephrine increased 
from 1.9±0.2 nmol/1 (control) to 3.2±0.3 nmol/1 
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(1 minute p-p), persisting until 5 minutes p-p. In 
NLP, arterial norepinephrine only rose by 36% at 
the end of pacing. Likewise, increases in arterial 
and coronary venous epinephrine and in coronary 
venous norepinephrine were less in NLP than in 
LP. Moreover, arterial angiotensin II increased 
from 6.8±0.9 pmol/1 (control) to 9.3±1.58 pmol/1 
(1 minute p-p, p<0.05), but only in LP. Cardiac 
norepinephrine release at rest changed to uptake 
during pacing ( -0.05±0.02 nmol/min versus 
0.06±0.05 nmol/min, p<0.05) in LP, but not in 
NLP or NI. In contrast, epinephrine uptake in-
creased significantly in all ischemic patients, 
although more so in LP. Changes in cardiac cate-
cholamine uptake correlated with changes in res-
pective arterial levels in lactate producers. It is 
concluded that short periods of ischemia may 
induce significant activation of circulating 
catecholamines and renin-angiotensin levels, 
accompanied by systemic vasoconstrictory effects. 
Changes do not appear to relate to angina, but de-
pend on the severity of ischemia. Moreover, 
ischemia enhances cardiac epinephrine uptake and 
reverses basal norepinephrine release to uptake in 
the ischemic myocardium. 
INTRODUCTION. 
Systemic neuroendocrine activation is a consistent 
observation in heart failure, particularly prominent 
in advanced stages or during exacerbations of the 
syndromeCI,2). It is also well established in the 
acute phase of myocardial infarction, where 
circulating levels of catecholamines, renin -angio-
tensin and arginine-vasopressin appear to relate to 
the degree of left ventricular dysfunction<3-5). 
Whereas in animal models of severe, prolonged 
myocardial ischemia cardiac norepinephrine efflux 
increases, indicative of enhanced sympathetic sti-
mulation (6), the effect of myocardial ischemia on 
systemic and cardiac neurohormones in humans is 
less well understood. Although it may be 
anticipated that acute, ischemia-induced reduc-
tions in cardiac pump function may activate 
sympathetic tone, increase circulating 
catecholamines and, possibly, enhance renin-
angiotensin levels, there is unsufficient evidence in 
humans to suggest this. Available data in man do 
not show uniform changes in plasma or urinary 
catecholamines during exercise- or pacing-
induced ischemia (7-14). Neither is it clear whether, 
myocardial catecholamine balance is affected by 
myocardial ischemia (9,11,14). Animal studies 
indicate, that cardiac norepinephrine release is 
enhanced, when ischemia lasts for 10 minutes or 
more, but not during shorter periods(6). In 
humans, the effect of pacing-induced ischemia on 
cardiac norepinephrine release is not clear<9,11). 
Besides insufficient and/or inconsistent data on 
circulating or cardiac catecholamines in humans, 
information on the effect of ischemia on different, 
but related neurohormones, such as the circulating 
renin-angiotensin system, is practically non-
existent. However, animal data indicate the 
circulating renin-angiotensin system may borne 
activated following short episodes of artery 
occlusion(l5). Whether ischemia affects 
transcardiac angiotensin II fluxes is unknown 
though. 
In the present study, sequential changes in sys-
temic and transcardiac catecholamine and angio-
tensin II levels were investigated during pacing-
induced ischemia in normotensive patients with 
coronary artery disease without heart failure and 
compared with the effects of pacing in patients 
without ischemia. Secondly, the effect of these 
changes on coronary and systemic hemodynamics 
were studied. Thirdly, an attempt was made to 
compare transcardiac neurohumoral fluxes in 
ischemic versus non-ischemic myocardium. 
MATERIALS AND METHODS 
Patients. 
After approval of the study protocol by the insti-
tutional Ethical Review Committee and after 
informed consent was obtained, 56 patients, 4 
women and 52 men, age 54 years (varying from 31 
to 73 years) were studied. Subjects were selected 
at random from patients, referred for coronary 
angiography for the evaluation of stable angina 
pectoris with documented exercise-induced 
ischemia and/or a previous myocardial infarction 
as well as for angina-like chestpain without signs 
of myocardial ischemia. To be included in the 
study, patients had to be normotensive without 
signs or symptoms of congestive heart failure, 
valvular heart disease or conduction disturbances. 
A previous myocardial infarction had to be at least 
1 month old. Patients with unstable angina were 
not included as it was believed, that such patients 
might deteriorate upon withdrawal of cardiac 
medication. Unstable angina was defined by the 
occurrence of recent symptoms, increased 
frequency and/or duration of episodes of angina 
during the last month or recent prolonged episodes 
of angina at rest (20 minutes duration), despite 
medication. In contrast, patients with stable angina 
had to have an unchanged pattern of exercise-
induced symptoms; occasional, short lasting 
episodes of angina at rest were allowed. 
All cardiac therapy was withheld 36-72 hours pre-
study, depending on plasma halflives. Beta-
blocking agents were stopped between 48 and 72 
hours before the investigation. Only short-acting 
nitroglycerin was allowed until6 hours pre-study. 
Oral anticoagulants were stopped 2 to 3 days 
before the investigation. Anti-platelet therapy, 
e.g. aspirin, was withheld 10 days prior to the 
investigation. 
Fifty-six patients had significant coronary artery 
disease, defined as ~70% diameter narrowing of at 
least one epicardial coronary artery. Seventeen pa-
tients had single vessel disease. Of these, 14 
patients had either a lesion in the left anterior 
descending, a proximal stenosis of the left cir-
cumflex artery or a lesion in the proximal marginal 
branches of the left coronary artery. In 3 patients a 
significant stenosis in the right coronary artery was 
the only lesion present. Objective signs of myo-
cardial ischemia during exercise testing were 
present in 32 patients and a documented old 
myocardial infarction in 24 patients. In the latter 
group 9 patients had no demonstrable signs of 
ischemia during exercise. 
Catheterization procedures. 
All patients were studied in the fasting state, at the 
same time in the morning. Patients were not 
premedicated and local anaesthesia was achieved 
with 1% lidocaine. Before the study, coronary 
angiography was performed, using the Seldinger 
technique. Thereafter, a no 7 Fr Millar or 8 Fr 
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Fig. 1: Schematic representation of pacing study 
protocol (APST). At least 40 minutes after 
coronary angiography and 20 minutes after 
instrumentation, control measurements of 
hemodynamic (arrow) and neurohumoral (H) 
variables and lactate were made. Next, atrial 
pacing with increments in heart rate (HR) of 10 
beats per 2 minutes was carried out. Repeat 
hemodynamic and metabolic measurements were 
peiformed at fixed intervals, i.e. at 100 and 120 
beats/minute, at maximal heart rates (MAX) and 
at 15 seconds, 1, 2, 5 and 30 minutes (') after 
pacing (p-p). Neurohormones were reevaluated at 
MAX and at 1, 2, 5 and 30 min p-p. 
Sentron pigtail microtip manometer catheter was 
advanced to the left ventricle through an 8 or 9 Fr 
arterial Desilet introducer system in the right 
femoral artery, to record left ventricular pressures. 
The side-arm of the introducer system was used to 
record the arterial pressure curve. A no 7 Fr 
balloon-tipped triple-lumen thermodilution 
catheter (Edwards laboratory) was positioned in a 
pulmonary artery through an 8 Fr Desilet introdu-
cer system in the right femoral vein, to measure 
right atrial pressure and cardiac output. A no 7 Fr 
coronary sinus thermodilution and pacing catheter 
(Wilton Webster laboratories) was inserted in a 
right brachial vein and positioned in the coronary 
sinus, such that the proximal thermistor was at 
least 3 em beyond the orifice of the coronary sinus. 
Also, the catheter positions had to be stable and 
allow a rapid sequence of blood sampling. To 
improve sampling from the coronary sinus, a spe-
cially-devised catheter was used, the bol-end 
Wilton Webster thermodilution catheter [CCS-
7U-90B]. Contrary to the conventional end-hole 
coronary sinus catheter, the sampling orifice of the 
bol-end version usually stays well clear from the 
coronary sinus wall. Thus, sampling of relatively 
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large amounts of blood, e.g. 15-20 ml/minute, can 
be achieved throughout periods of at least 2 hours 
in approximately 90% of patients (personal expe-
rience in more than 250 patients). Absence of atrial 
reflux into the coronary sinus under the study 
conditions was confirmed by a bolus injection of 
10 ml of saline into the right atrium. After 
instrumentation, the position of the catheters was 
recorded on video disc to allow rechecking of their 
respective positions during the study. 
Hemodynamic and electrocardiographic 
measurements. 
The hemodynamic parameters in this study inclu-
ded left ventricular peak systolic, mean and end 
diastolic pressures, left ventricular pressure-
derived contractility (peak positive dP/dt, dP/dt/P 
at 40 mmHg and V max) and relaxation indices 
(peak negative dP/dt, Tau1 and Ta~), mean and phasic arterial pressures, nght atrial pressure and 
coronary sinus blood flow. Cardiac output 
measurements were performed in a limited number 
of patients. All fluid-filled catheters were 
calibrated, using Bentley transducers, with a zero 
reference level set at midchest. The micro-
manometer pressure was balanced to zero and 
superimposed on the conventional pressure tra-
cings. After appropriate calibration, all pressures, 
coronary flow, cardiac output and the first 
derivative of left ventricular pressure were 
recorded on paper, using a CGR 1000 cath lab 
system. They were also determined on -line by a 
Mennen cath lab computer system. Through this 
system, pressures and pressure-derived contrac-
tility indices were calculated in 15-20 consecutive 
beats, to average out respiratory variations. 
Contractility indices and peak negative dP/dt were 
calculated and displayed on -line. In contrast, the 
isovolumetric relaxation indices, Tau1 and Ta~, 
were measured off-line. 
Coronary sinus blood flow was determined during 
a continuous 30 second infusion of 30 m1 glucose 
at room temperature. Both the mean and phasic 
coronary flow were recorded. Calculations were 
made from the mean flow curve, according to the 
formula: coronary blood flow (mi/min) = Vi x 
[(Tb-Ti)(Tb-Tc5)-1] x 1.08, where Tb is blood 
temperature before injection, Ti temperature of 
injectate, T cs temperature of mixture of coronary 
sinus blood and injectates and Vi the rate of injec-
tion (ml/min). Coronary flow was determined 
with the patient holding his breath in mid-
respiration for the last 15 seconds of the recording. 
As the Mennen cath lab system displays 1-second 
measurements of coronary flow, it allows 
instantaneous estimation of the stability of 
coronary flow recordings. 
At the end of the study, the pressure curves from 
the femoral artery were compared with a simul-
taneous recording from the aortic root by the 
micromanometer catheter, to compensate for any 
difference between proximal and distal arterial 
pressures. 
Heart rate and ST-segment changes were deter-
mined from 100 mmlsec recordings of ECG leads 
I, II and V5. The ST-segment was measured in 3 to 
5 consecutive beats, 80 milliseconds after the J 
point, using a calibrated magnifying glass. 
Blood sample collection and assay of 
metabolites. 
Approximately 1 ml of blood was collected 
simultaneously from the left ventricle and coro-
nary sinus for the immediate determination of 
oxygen saturation values on an OSM -80 oxymeter 
(Waters Association). For lactate, simultaneous 
sampling from the left ventricle and the coronary 
sinus was carried out. Exactly 1 ml blood was 
quickly transferred into pre-cooled glass tubes, 
containing 2 ml of icecold 0.6 M HC104, mixed 
thoroughly and kept on ice. Immediately after the 
study, the samples were weighed and centrifuged 
for 20 minutes at a speed of 2,000 xg. Thereupon, 
the supernatant was frozen for subsequent assay of 
lactate, which was carried out in triplicate by the 
enzymatic technique as described by Guttman and 
Wahlefeld (16). The standard deviation of this 
determination in our laboratory, carried out in 
approximately 2.500 samples per year, is 0.012 
mmol/1 (17). To prevent mistaking arterial for 
venous blood samples or vice-versa during fast 
repetitive sampling procedures, blood was 
collected in colour-coded tubes. 
Neurohumoral measurements. 
In this study, the levels of angiotensin II and the 
catecholamines norepinephrine, epinephrine and 
dopamine were assessed by collecting a minimum 
of 6 ml of blood simultaneously from the left 
ventricle and coronary sinus in pre-cooled 
syringes. For the assay of angiotensin II, 3 ml was 
immediately transferred into ice-cold tubes 
containing 4 mg EDTA and 0.06 mg 0-fe-
nantroline. The remaining 3 ml was transferred 
into ice-cold tubes containing 500 I!U heparin and 
3 mglml gluthathion. Samples were immediately 
centrifuged at 3000 xg under coooled conditions 
and the supernatants frozen at -20° C. 
Catecholamines were determined by radio-
enzymatic assay and high-pressure liquid 
chromatography to separate the radio-active pro-
ducts, whereas an~iotensin II was assessed by 
radioimmunoassaycrs,19). 
Calculations. 
From the measured variables the following para-
meters were derived. Coronary vascular resistance 
(mmHglmllmin) was calculated as the difference 
between mean arterial pressure (mmHg) and left 
ventricular mean diastolic pressure (mmHg) 
divided by coronary sinus blood flow (mllmin). 
Systemic vascular resistance (dynes.sec.cm-5) was 
derived as [mean arterial pressure (mmHg) - mean 
right arterial pressure (mmHg) I cardiac output 
(1/min)] x 80. Stroke work index (g.m.m2) was 
calculated as stroke index (ml/beatlm2) x [mean 
arterial pressure (mmHg) - left ventricular end 
diastolic pressure (mmHg)] x 0.0136. Myocardial 
oxygen extraction (m1021ml) was calculated as 
arterial oxygen content (m1021ml) - coronary 
venous oxygen content (mlO~Iml), and myocardial 
oxygen consumption (mllmrn) as the product of 
myocardial oxygen extraction (m1021ml) and co-
ronary blood flow (mllmin). Percentage myo-
cardial lactate extraction was calculated as 100 x 
[arterial lactate content (mmol/1) - coronary 
venous lactate content (mmol/1)] I arterial lactate 
content (mmol/1). Myocardial lactate uptake 
(mmol!min) was determined by multiplying the 
difference in arterial and coronary venous lactate 
content (mmollml) with coronary blood flow 
(mllmin). 
Myocardial catecholamine and angiotensin II up-
take (nmollmin and pmol/min, resp.) were cal-
culated by multiplying the respective differences in 
arterial and coronary venous catecholamine 
(nmol!ml) or angiotensin II (pmol/ml) levels with 
the instantaneous coronary sinus blood flow (mll 
min). 
Study protocol. 
Patients were studied at least 45 to 60 minutes after 
the last coronary angiogram and 25 to 30 minutes 
after instrumentation. Hence, all studies were 
performed between 10.30 and 11.30 AM with the 
patient resting and supine for approximately 2 
hours. First, multiple control measurements of all 
hemodynamic variables were performed to ensure 
stable baseline values. Before control, arterial and 
coronary venous blood 
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Table 1: Baseline clinical and angiographic criteria. 
GrNI(n=ll) GrLP(n=28) GrNLP(n=17) 
Sex (male/female) 9/2 28/0 15/2 
Age (yrs) 49±3.1 55±1.7 54±2.4 
(range 31-66) (range 37-73) (range 36-71) 
Previous infarcts (ant/int) 4/1 8/4 2/5 
Positive exercise test 3 20 10 
Coronary angiography 
(2:70% diameter stenosis) 
0-vessel 4 0 0 
1-vessel (L/R) 3L/1R 7L/1R 4L/1R 
2-vessel 1 12 6 
3-vessel 2 9 5 
Left ventricular 
ejection fraction(%) 54±3.5 52±2.6 53±3.1 
Left ventricular 
end diastolic volume 
(rnl/m2) 74±6.7 69±4.8 67±3.7 
Abbreviations: ant/inf= anterior/inferior; LP =lactate producers; LIR =left/right; N = nwnber; NI =non-ischemic; 
NLP = non-lactate producers. All values x ±SEM. 
samples for metabolic and neurohumoral parame-
ters were collected, and repetitive coronary venous 
oxygen saturation values were carried out. Arterial 
and coronary venous blood samples were collected 
in duplicate. Then, an atrial pacing stress test was 
carried out, during which heart rate was elevated 
by 10 beats/2 minutes until anginal pain or 
atrioventricular block occurred or a maximal heart 
rate of 170 beats/minute was reached (Fig. 1). The 
patient always determined which level of anginal 
pain he or she would endure and, hence, the 
duration of the atrial pacing stress test. However, 
we tried to continue pacing until the severity of 
angina was at least comparable to that, at which 
the patient would normally discontinue exercise or 
take sublingual nitroglycerin. Repeated 
determinations of all hemodynamic and metabolic 
parameters were carried out at fixed intervals 
during pacing, e.g. midway the 100, 120, 140 and 
160 beats/minute period. During maximal heart 
rates, just before cessation cf pacing, all variables, 
including neurohormones, were reassessed, 
followed by repeated measurements of all varia-
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bles during the first, second and fifth minute after 
pacing. The sequence of blood sampling after 
pacing was such, that exactly at 15 seconds post-
pacing the collection of blood for lactate com-
menced. This was followed immediately by the 
collection of blood for neurohormones. This 
sequence was repeated during the second and fifth 
minute after pacing. Additional arterial and 
coronary venous blood samples for lactate were 
collected following the second minute after 
pacing. These will be referred to as the 2-minute 
post-pacing lactate samples. · 
After pacing, all hemodynamic variables were 
reassessed at the 1- , 2- and 5-minute post-pacing 
period, except for coronary flow, which was 
measured just preceding the 5-minute post-pacing 
period. In 39 patients variables were reassessed at 
30 minutes after pacing. 
During this interval patients had been resting 
without further instrumentation or investigational 
procedures. Throughout the entire study, 
approximately 60 ml of blood was collected for 
metabolic and neurohumoral assay. Although, 
Table II: Systemic hemodynamic variables during and after pacing. 
Control 120/min Max 1' P-P 5'P-P 30'P-P 
LYSPrrnillg 
136±4.5 130±4.0t 136±6.5 134±5.2 135±5.5 NI 138±6.6 
LP 153±5.3 147±6.3 149±6.0 162±6.6*t 153±5.3 144±7.1 
NLP 143±6.5 142±6.6 139±7.1 143±6.9 141±7.3 137±5.5 
DP (HRxLYSPxJ0-3) 
17±1.2 .. t 10±0.7 10±0.7 9±0.6 NI 10±0.7 15±0.9* 
LP 12±0.5 18±0.9 .. 22±0.9* 13±0.8 12±0.5 12±0.6 
NLP 11±0.7 17±0.9 .. 20±1.2* 11±1.0 11±0.9 10±0.5 
LYEDPrrnillg 
12±2.3 12±2.4 13±3.0 NI 13±2.3 9.6±2.4 7±1.4 .. 
LP 14±1.3 10.9±1.0 16±2.0t 18±2.1f 13±1.2 11±1.3 
NLP 13±0.9 8.9±0.9 7±1.0* 13±0.9 11±1.0 11±1.0 
MAPrrrnllg 
NI 101±2.8 105±4.2 103±4.8 104±5.3 102±3.6 100±1.6 
LP 111±3.2 119±4.1 .. 127±4.7* 124±4.2* 115±4.0 109±4.9 
NLP 106±4.9 112±5.4 117±5.3* 114±4.8 111±4.9 103±3.5 
LVdP/dt+rrrnllg.s-1 
1876±136* 1897±138* 1567±124 1547±92 1326±69 NI 1511±134 
LP 1779±80 2078±95 .. 2241±126* 1840±117 1796±65 1686±108 
NLP 1715±102 2229±175* 2363±125* 1740±130 1753±103 1720±106 
Ymaxs-1 
,, 
N1 45±3.5 62±6.9* 59±3.8* 44±3.8 45±3.6 41±2.7 
LP 50±2.6 57±3.0* 56±2.7 .. /1 51±2.9 49±2.5 49±13.3 
NLP 50±2.4 64±4.2* 68±3.5·• 52±2.7 50±2.4 51±2.5 
YCE s-1 
NI 40 30±2.6 42±4.8 .. 40±2.9 .. 30±2.4 30±2.2 27±1.7 
LP 35±1.7 40±2.0* 40±2.0 .. 11 34±1.9 34±1.6 33±2.2 
NLP 33±1.7 45±3.3* 47±2.4* 35±1.8 34±1.6 34 ±1.8 
LYdP/dt-trmH.g.s-1 
NI 1769±127 2032±200 1999±121* 1776±137 1958±147 1852±150 
LP 1914±86 2011±105 1971±118 1960±103 1980±100 1875±136 
NLP 1883±89 2081±117 2111±115·• 1963±125 1858±104 1788±74 
Tau1 msec NI 53±4.7 41±5.4 43±3.9* 52±4.9 56±7.2 56±5.9 
LP 50±4.5 47±4.3 47±4.7/1 51±4.9 51±4.8 50±7.0 
NLP 46±1.7 41±1.8* 39±2.2* 46±2.3 48±2.1 50± 1.4 
Tau2mst:c 
NI 42±3.9 38±6.8 42±4.7 43±4.1 41±4.2 43±4.2 
LP 44±4.7 50±7.2 55±5.5*11 48±5.1 44±5.2 38±4.0 
NLP 37±1.2 35±2.3 39±3.1 38±2.5 38±1.7 38± 1.5 
CO lim 
NI 5.0±0.4 4.8±0.4 4.7±0.5 
LP 5.9±0.3 5.3±0.3* 6.0±0.4 
NLP 5.4±0.3 4.9±0.2 5.7±0.5 
SYJmUbndZ 
NI 40±2.8 38±3.3 38±2.7 
LP 39±1.7 35±2.4 39±1.8 
NLP 39±1.9 36±2.2 41±3.8 
SYR d.s.cm-5 
NI 1545±114 1646±145 1684± 175 
LP 1723±132 2087±197* 1376±97 
NLP 1475±99 1670±158 1418±83 
PAMrrrnllg 
NI 17±1.7 17±2.6 18±2.1 16±1.6 16±1.6 16±1.8 
LP 17±0.8 17±0.8 24±1.3 .. 19±1.4 17±1.1 14±1.0 
NLP 17±0.9 17±1.3 21 ±1.3 .. 18±1.4 17±0.9 15 ±1.1 
Abbreviations: CO= cardiac output, DP =double product, LYEDP =left ventricular end diastolic pressure, LVSP =left 
ventricular systolic pressure, MAP =mean arterial pressure, Max =maximal pacing rates, min =minutes PAM =mean 
pulmonary artery pressure, P-P =post-pacing, SVI = stroke volume index, SYR = systemic vascular resistance. 
Allvaluesx ± SEM; *p<.05 vs control; f p<.05vs other groups;# p<.05 flAPSTversus other flAPST. 
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Table ill: Coronary hemodynamic variables during and after pacing. 
Control 120/min Max 5'P-P 30'P-P 
CSBFmllmin 
NI 137±15 143±25 202±32 149±15 144±25 
LP 117±12 149±14 205±19* 126±14 112±19 
NLP 122±16 144±17 175±24* 116±9 110±12 
CVRrrmllg/mllm 
NI 0.71±0.08 0.67±0.11 0.58±0.13 0.74±0.13 0.87±0.18 
LP 1.19±0.12t 1.00±0.13 0.73±0.06* 1.19±0.13 1.32±0.14 
NLP 0.90±0.10 0.95±0.10 0.75±0.09 0.95±1.01. 00±0.11 
fu-CS' 0 mllmin 
NI 214±0.6 12±1.0 ' 12±0.9 13±0.8 13±0.8 
LP 12±0.5 12±0.7 12±0.6 11±0.6 11±0.6 
NLP 12±0.7 13±0.7 12±0.7 12±0.7 13±0.8 
MVO mllmin 
NI 2 19±2.8t 17±4.2 23±4.9 20±2.7t 20±5.5 
LP 12± 1.1 15±1.7 22±2.0* 12±1.0 11±1.5 
NLP 14±1.6 17±2.5 21±2.5* 13±1.3 15±2.0 
Abbreviations: CSBF = coronary sinus blood flow; CYR = coronary vascular resistance; .6.A-CS 0 2 =myocardial oxygen 
extraction;_ Max= maximal pacing rates; min= minute; MV02 =myocardial oxygen conswnption; P-P =post-pacing. 
AU values x ± SEM; *p<.05 vs control; t p<.05 vs other groups. 
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Fig. 2.- Individual 
values and medians 
of arterial 
norepinephrine and 
epinephrine at 
baseline. Median 
values and range 
are similar in the 
non-ischemic 
group (NI) and in 
ischemic patients 
with (LP) or 
without lactate 
production (NLP). 
Values of patients 
with ischemia at 
rest (lactate 
production asterix) 
; ; are not different 
from non-ischemic 
patients. 
NLP 
Table IV: Arterial and coronary venous neurohonnones during and after pacing. 
Control Max 1'P-P 2'P-P 5'P-P 30'P-P 
Norepinephrine 
Arterial LP 1.9±0.18 2.8±0.26" 3.2±0.34" 2.7±0.2* 2.4±0.25 2.1±0.21 
NLP 1.6±0.19 2.1±0.28" 2.1±0.27" 2.2±0.26" 2.0±0.26 1.7±0.24 
NI 1.9±0.25 2.0±0.36 1.8±0.25 1.9±0.26 1.7±0.32 2.0±0.32 
Coronary LP 2.6±0.29t 3.0±0.36" 3.2±0.3" 2.8±0.32 3.1±0.48 2.7±0.3 
venous NLP 1.7±0.17 2.3±0.36 1.9±0.21 2.1±0.28 2.1±0.31 1.8±0.21 
NI 1.8±0.17 1.7±0.29 1.5±0.24 1.9±0.30 1.5±0.38 1.6±0.19 
Epinephrine 
Arterial LP 0.65±0.09 1.0±0.16* 0.8±0.1 0.7±0.09 0.9±0.14 0.7±0.14 
NLP 0.45±0.06 0.6±0.08* 0.5±0.07 0.5±0.06 0.6±0.09 0.5±0.09 
NI 0.4±0.08 0.4±0.07 0.3±0.05 0.4±0.08 0.3±0.09 0.3±0.03 
Coronary LP .45±0.07t 0.7±0.10* 0.65±0.10 0.5±0.09 0.6±0.11 0.5±0.10 
venous NLP 0.2±0.04 0.4±0.06* 0.3±0.06 0.25±0.04 0.3±0.04 0.3±0.07 
NI 0.2±0.05 0.4±0.15 0.2±0.05 0.2±0.06 0.2±0.06 0.2±0.03 
Dopamine 
Arterial LP 0.4±0.07 0.4±0.07 1.0±0.62 0.9±0.57 0.4±0.1 0.5±0.06 
NLP 0.2±0.04t 0.3±0.12 0.2±0.03 0.2±0.05 0.09±0.04 0.2±0.04 
NI 0.5±0.12 0.6±0.15 0.5±0.11 0.6±0.14 0.4±0.17 0.6±0.17 
Coronary LP 0.55±0.08 0.5±0.08 0.5±0.08 0.8±0.42 0.5±0.14 0.5±0.07 
venous NLP 0.2±0.04t 0.25±0.05 0.2±0.03 0.25±0.06 0.1±0.06 0.3±0.05 
NI 0.6±0.12 0.7±0.16 0.4±0.09 0.5±0.09 0.8±0.47 0.5±0.08 
Angiotensin II 
Arterial LP 6.8±0.93 9.1±1.57* 9.7±1.60" 8.5±1.13" 7.8±1.10'' 8.3±1.38 
NLP 5.8±0.84 5.7±0.84 5.7±0.81 5.4±0.99 5.9± 1.60 5.5±0.45 
N1 4.5±0.78 4.2±0.71 4.7±0.51 3.9±0.56 3.5±0.89 5.2±0.87 
Coronary LP 6.4±0.89 7.4±1.02 7.3±0.72 5.9±0.65 5.9±0.9 6.8± 1.2 
venous NLP 5.3±0.75 5.1±0.62 5.0±0.75 4.6±1.18 4.8±1.12 6.1±0.83 
NI 4.0±0.66 4.2±0.77 4.5±0.69 3.6±0.59 2.6±0.89 5.1±1.0 
Abbreviations: Max =maximal pacing rates; LP = Lactate producers; NI = non-ischemic patients; NLP = non-Lactate 
producers; P-P =post-pacing. All values x ± SEM; * p<.05 vs control; f p<.05 vs other groups. 
before each sample, catheters were emptied to ob-
viate the collection of residual saline and blood, 
the latter were always returned into the patient 
after sampling. 
Statistical analysis. 
Data are presented as mean and the standard error 
of the mean. The change in values between 
measurements during and after pacing and control 
were calculated. Group differences at control and 
for calculated changes were examined using a one-
way analysis of variance. Within groups compar-
isons with control values were evaluated using a 
two-tailed paired t-test. Coefficients of correl-
ation were calculated where appropriate. A p-
value of <.05 was regarded as significant. 
RESULTS 
Based on the occurrence of objective signs of myo-
cardial ischemia during pacing, e.g. myocardial 
lactate production and/or significant (>0.1 mV) 
ST-segment depression, patients were grouped as 
ischemic (45 patients) or non-ischemic (NI, 11 
patients). To facilitate identification of transcar-
diac neurohumoral changes in ischemic versus 
non-ischemic myocardium, the ischemic patients 
were subsequently divided into lactate- and non-
lactate producers (LP, n=28 and NLP, n= 17, 
resp.), the rationale being, that lactate production 
at least ensured that (part of the) coronary venous 
blood, collected during the study, represented the 
ischemic area. The presence of angina during 
pacing-induced stress was not considered as true 
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LACTATE 
EXTRACTION 
[%) 
ST-SEGMENT 
[mv) 
LVEDP 
[mmHg) 
CJ Nl n=11 
E1:1il LP n=28 
-NLP n=17 
* p < .05 vs. CONTROL 
t p < .05 vs. OTHER GROUPS 
*t 
Fig. 3: Metabolic, electrocardiographic and 
hemodynamic effects of pacing in non-ischemic 
patients (NI) and ischemic patients with (LP) and 
without myocardial lactate production (NLP). 
Although ST- segment changes were not different 
between LP and NLP, hemodynamic changes 
were. Left ventricular filling pressure (LVEDP) 
decreased during pacing in NLP and in NI, but 
remained unchanged in LP. Moreover, in the 
latter group LVEDP rose markedly after pacing, 
but not inNLP. Values are :X± SEM. 
representation of myocardial ischemia. Angina-
like symptoms occurred in 6 (55%), 14 (82%) and 
23 (82%) patients in groups NI, LP and NLP, 
respectively. 
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Clinical and angiographic characteristics of the 3 
groups are presented in Table I. Groups were 
comparable as to sex, age, number of old infarcts 
and left ventricular volumes and ejection fraction. 
In contrast, objective signs of ischemia during 
exercise occurred more often in groups LP and 
NLP than in group Nl. Alternatively, the severity 
of coronary artery disease was significantly less in 
group NI than in both ischemic groups. Of the 
non-ischemic patients, 4 had no significant coro-
nary lesions. In contrast, the 2 ischemic groups 
were similar with respect to the number of vessels 
diseased and the ratios of left versus right coronary 
artery lesions. 
Hemodynamic, metabolic and neurohumoral 
values at control. 
At baseline, none of the patients had clinical signs 
or symptoms of myocardial ischemia. However, 
retrospectively, 4 patients, all in group LP, had 
myocardial lactate production, indicative of 
asymptomatic myocardial ischemia before pacing. 
In none of these patients were significant 
electrocardiographic changes present, compared 
with the initial recordings upon entry in the 
catheterization laboratory. As a result, average 
myocardial lactate uptake was significantly 
reduced in group LP, compared with the other two 
groups. In contrast, myocardial lactate extraction 
values were not different between the three patient 
groups. 
Baseline hemodynamic values of the silent 
ischemic patients were not different from the other 
patients in group LP. Neither arterial nor coronary 
venous neurohumoral levels were outside the range 
of values in the other patient groups at control, 
although arterial norepinephrine and epinephrine 
values in 3 of the 4 asymptomatic patients were in 
the upper range (Fig. 2). 
Average values for systemic and coronary hemo-
dynamic variables were comparable between the 
three groups (Tables II and III). 
Only myocardial oxygen consumption was greater 
in group NI, whereas coronary vascular resistance 
was significantly higher in group LP, imespective 
of the 4 patients with lactate production at 
baseline. 
Also, the control values of most neurohormones 
did not differ between the groups (Table IV). Only 
coronary venous norepinephrine and epinephrine 
levels were higher in group LP, whereas arterial 
and coronary venous dopamine values were lower 
in group NLP. Again, the 4 patients with lactate 
production at baseline had no effect on the 
difference in coronary venous catecholamine levels 
between LP patients on the one hand and NI and 
NLP patients on the other. 
Metabolic and electrocardiographic changes 
during and after pacing. 
By design, only group LP had abnormal 
myocardial lactate metabolism with maximal 
production values at 15 seconds post-pacing 
(lactate extraction -76±15%, Fig. 3), persisting 
until between 2 and 5 minutes after the test. ST-
segment depression, however, was similar in both 
ischemic groups, 0.21±0.03 mV in LP and 
0.17±0.02 mV in NLP patients (Fig. 3), still being 
significantly abnormal during the second minute 
post-pacing. 
Coronary and systemic hemodynamic 
variables during and after pacing (Tables II 
and ill). 
Maximal pacing heart rates were comparable in 
both ischemic groups. In contrast, non-ischemic 
patients were paced to a lower heart rate (130±6.4 
beats/min) compared with groups LP and NLP 
(152±4.1 and 147±5.1 beats/min, resp., both 
p<0.05 versus Nl). As left ventricular pressures 
did not differ during pacing between groups, 
maximal values for the double product were 
likewise less in ischemic patients. However, when 
changes in heart rate and the double product 
between control and maximal pacing were 
compared, instead of maximal values, all groups 
were comparable. 
Also, maximal values of, as well as changes from 
control in coronary hemodynamic variables were 
similar between patient groups. 
In contrast, there were significant differences in 
pacing-induced changes in contractility and 
relaxation. Whereas all pressure-derived 
contractility and relaxation parameters improved 
markedly in groups NI and NLP, changes in 
lactate producers were minimal or non-existent 
(Table II). Vmax increased by 14±3.0 s-1 and by 
19±2.2 s-1 in NI and NLP, resp., compared with 
only 5.3±1.2 s-1 rise in group LP (p<0.01). Similar 
differences were present for VCE40 althQugh 
changes in the peak positive derivative of dP (dt 
were comparable. Moreover, whereas LV dP/dt 
negative and Tau1 shortened significantly in NI 
and NLP patients, this was less in LP. 
Furthermore, Tau2 lengthened markedly in lactate 
producers, but not in the other groups. 
These data indicate a marked disturbance in both 
contractility and relaxation, but only in patients 
who produced lactate during pacing. As a result, 
left ventricular end diastolic pressure (LVEDP) fell 
in NI and NLP during pacing, but remained 
unchanged in LP, whereas at 10 seconps after 
pacing, LVEDP increased significantly more in 
lactate producers than in non -lactate producers 
(Fig. 3). Similar differential results were obtained 
with mean pulmonary artery pressures. Also, 
cardiac output decreased significantly from 
5.9±0.35 1/min (control) to 5.3±0.37 1/min (5 min 
post-pacing) in group LP. Concomitantly, 
systemic vascular resistance increased by 21% in 
these patients. No such changes were observed in 
the other group~. Arterial pressures also increased 
significantly in both ischemic groups, however, 
more profoundly in group LP than in NLP (Fig. 
4). 
• p<0,05 vs CONTROL 
CONTROL 120 b/mln MAX 1 min p-p 2 min p-p 5 min p-p 
Fig. 4: Effect of pacing- induced ischemia on 
arterial pressures. In lactate producers (LP) a 
marked rise is observed in mean arterial pressure 
(MAP), starting at 120 beats/minute (min) and 
persisting until after 2 minutes post-pacing (p-p). 
In contrast, in non-lactate producers (NLP) a 
moderate increase occurs only at maximal pacing 
(MAX). Arterial pressures do not change in non-
ischemic patients. All values are :X ± SEM. 
Also, the rise in mean arterial pressure started 
earlier in LP patients, at 120 beats/minute, and 
persisted up to 2 minutes after pacing, whereas the 
increase in group NLP was only observed during 
maximal pacing rates. In contrast, arterial 
pressures did not change at all in non-ischemic 
patients. 
Neurohumoral changes during and after 
pacing. 
Both arterial and coronary venous neurohumoral 
levels remained unchanged during and after 
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NOREPINEPHRINE nmol/1 •p<.05vsCONTROL 
LP 
3 
2 
3 Nl 
n=11 
2 
L-~----r---~--~----~~ 
CONTROL MAX 1'p-p 2'p-p 5'p-p 30'p-p 
Fig. 5: Effect of pacing-induced ischemia on 
arterial (closed symbols) and coronary venous 
(open symbols) norepinephrine levels in non-
ischemic (NI), ischemic with (LP) and ischemic 
patients without lactate production (NLP). Pacing 
does not affect catecholamines in NI. In contrast, 
a significant increase in arterial and coronary 
venous levels is observed in LP at maximal pacing 
rates (MAX), persisting for several minutes after 
pacing (p-p). In NLP, only a moderate rise in 
norepinephrine levels is observed. 
pacing in the non-ischemic group. Furthermore, 
ischemia neither affected arterial nor coronary 
venous dopamine levels in groups LP and NLP. 
In contrast, arterial norepinephrine increased 
significantly from 1.91±0.18 nmol/1 at control to 
2.8±0.26 nmol/1 at the end of pacing with a further 
rise to 3.21±0.34 nmol/1 at 1 minute post-pacing 
in group LP, accompanied by equally significant, 
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albeit less pronounced increases in coronary 
venous norepinephrine levels. Thereafter, nor-
epinephrine values levelled off, remaining just not 
significant at 5 minutes post-pacing (Fig. 5). Both 
arterial and coronary sinus norepinephrine levels 
increased in non-lactate producers, but not as 
profound and consistent as in the LP group. 
Compared to a 68% increase in arterial 
norepinephrine in LP, this neurohormone rose 
with 36% in the NLP group. Moreover, 
Fig. 6: Effects of ischemia on epinephrine levels. 
In ischemic patients with lactate production (LP) 
both arterial (closed circles) and coronary venous 
(open squares) rise significantly during maximal 
pacing rates (MAX). In non-lactate producers 
(NLP) changes are in the same direction, but 
significantly less than in LP, whereas in non-
ischemic patients (NI) epinephrine does not 
change at all. All values are :X ± SEM. 
EPINEPHRINE nmol/1 * p < .05 vs CONTROL 
* 
LP 
n=28 
0,5 ~~~1r----~----~----r--r~~ * l. --1 
0 
NLP 
n=17 
* 
0,5 
--£---t;r___ * --""C'----"'2""----y----"f 
0 
.... ,,-_.._------.....__ __ 
'~----1C----~----~ 
0 ~ 
CONTROL MAX 1 'p-p 2'p-p 5'p-p 30'p-p 
whereas in the latter group coronary venous 
norepinephrine levels were elevated at maximal 
rates, they did fluctuate thereafter, in contrast to a 
sustained rise in the lactate production group. 
Epinephrine only changed during maximal pacing 
rates. Elevated arterial and coronary venous levels 
were found in both ischemic groups, again more so 
in lactate producers (Fig. 6). 
Arterial angiotensin II levels also increased, but 
only in lactate producers, from 6.78±0.93 pmol/1 
at control to 9.13±1.58 pmol/1 at maximal pacing 
rates and further to 9.7±1.68 pmol/1, 1 minute 
after pacing (both p<0.05 versus control). Values 
were still significantly elevated at 5 minutes post-
pacing (Fig. 7). Coronary venous levels did not 
change, neither did arterial nor coronary venous 
angiotensin II levels change in the ischemic group 
without lactate production or in non-ischemic 
patients. 
Neurohumoral changes did not correlate with 
lactate production values. However, a significant 
correlation was observed between changes in 
arterial norepinephrine and left ventricular end 
diastolic pressure in group LP (p<0.05). 
Cardiac neurohumoral balance during pacing 
and ischemia. 
Data on transcardiac neurohormones and coronary 
flow were available in 19 patients in group LP, in 
15 patients in group NLP and in 9 patients in 
groupNI. 
Catecholamines 
At control, transcardiac catecholamine fluxes were 
not statistically different between the three groups, 
although patients in groups LP and NLP showed a 
net release, and non-ischemic patients showed a 
net uptake pattern for norepinephrine (Table V). In 
contrast, transcardiac epinephrine and dopamine 
fluxes were similar in the three patient groups with 
uptake predominantly of the first neurohormone 
and release of the latter. Again, during and after 
pacing, no changes were found in cardiac 
dopamine balance. Likewise, myocardial fluxes of 
the other catecholamines remained unaltered in 
non-ischemic patients. In contrast, in lactate 
producers, net myocardial norepinephrine release, 
present at control, changed significantly to net 
uptake during maximal pacing rates (Fig. 8). No 
such changes occurred in non -lactate producers. 
However, the latter group showed a small but 
significant increase in epinephrine uptake during 
maximal pacing (Fig. 9). A significant increase in 
cardiac 
ANGIOTENSIN II pmolll * p < .05 vs CONTROL 
* 
11 LP * 
n=28 
10 
9 
8 
7 
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5 
9 NLP 
n=17 
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7 
6 
5 
4 
5 
4 
3 
2 ---,-----,----,-----,----.~~ 
CONTROL MAX 1'p-p 2'p-p 5'p-p 30'p-p 
Fig. 7: Arterial angiotensin II levels (closed 
symbols) increase significantly by 45% in lactate 
producers (LP) during maximal (MAX) and after 
pacing (p-p). Changes persist until5 minutes p-p. 
Coronary venous levels (open squares) do not 
change. Also, angiotensin II remains unaltered in 
non-ischemic patients (NI) and in ischemic 
patients without lactate production (NLP). 
epinephrine uptake also occurred in group LP and 
was more pronounced than in group NLP. 
Angiotensin II 
At rest, control average values for angiotensin II 
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uptake were positive in all groups (Table V). 
:However, individual values showed a large 
variation with relatively numerous patients 
producing angiotensin II from the heart. Pacing 
did not alter this pattern significantly, although 
lactate producers tended to have a greater angio-
tensin II uptake by the heart during pacing-
induced ischemia (Fig. 8). Also, changes in arte-
rial angiotensin II levels correlated significantly 
with cardiac uptake values during pacing (p<O.Ol). 
Hemodynamic, metabolic and neurohumoral 
variables after a 30-minute rest period 
Patients were re-evaluated following a 30 minute 
resting period after cessation of pacing. All meta-
bolic and electrocardiographic parameters were 
comparable to the respective control values in the 
three patient groups. Of the hemodynamic and 
neurohumoral variables, only arterial norepi-
nephrine and mean arterial pressure in group LP 
were different, significantly increased with respect 
to their baseline values. 
DISCUSSION 
The effect of myocardial ischemia on systemic and 
transcardiac neurohumoral levels in man has been 
disputed where catecholamines are concern-
ed(7-14), whereas the effect on other neurohumoral 
systems, such as the circulating renin-angiotensin, 
is unknown. 
Moreover, no attempts have yet been made to 
differentiate cardiac neurohumoral balances in 
ischemic versus non-ischemic myocardium, to 
relate changes in neurohormones with either 
systemic or coronary hemodynamic alterations 
during ischemia, or to estimate whether neuro-
hormones may be differentially affected by 
variable degrees of ischemia. 
Although the present study cannot claim to have 
addressed all of these arguments exhaustively, it 
provides several answers and clues to the com-
plicated issue of myocardial ischemia-induced 
neurohumoral activation. First, it is clearly shown 
that systemic catecholamines become stimulated 
during ischemia and that the level of activation 
may depend on the degree of ischemia. Secondly, 
the circulating renin-angiotensin system may 
become activated as well, depending on the 
severity of ischemia. Thirdly, these systemic 
neurohumoral changes do not appear to relate to 
pacing per se or to the presence of angina. 
However, they do result in an augmentation of 
systemic vascular resistance and of arterial 
-320-
pressures, again as a function of the level of 
ischemia. 
With respect to cardiac neurohumoral balance, 
ischemia results in a change of cardiac norepi-
nephrine release to uptake, but only in lactate 
producers, presumably reflecting alterations in the 
ischemic area. In contrast, epinephrine uptake is 
enhanced in all ischemic patients. Finally, whereas 
angiotensin II in this study was shown to be 
released from the heart at rest in a sizeable number 
of patients, both pacing and ischemia did not 
significantly affect the average uptake pattern. 
Furthermore, no significant alterations in the 
cardiac pattern of neurohumoral fluxes were 
observed in non-ischemic patients.Ischemia-
induced changes in systemic catecholamine levels: 
In our study arterial norepinephrine and 
epinephrine levels increased significantly in both 
ischemic groups during pacing-induced myocar-
dial ischemia. By contrast, this did not occur in 
non-ischemic patients, despite equivalent incre-
ments in heart rate. As such, this is the first study 
to show systemic catecholamine activation in 
patients with myocardial ischemia, not necessarily 
accompanied by angina. Previous investigations by 
different groups have nearly always been carried 
out in anginal patientsC9,1l-l3), thus making it 
fairly impossible to dissect the effect of stress, 
caused by angina from that of ischemia per se. 
Also, the presence of objective signs during 
ischemia was not stipulated in all studies (11,13,2<). 
The only study, which reported increased levels of 
norepinephrine and epinephrine during pacing in a 
well-defined patient population, did in fact include 
several patients without objective or subjective 
signs of ischemiaClO). 
Thus, reported changes in catecholamine levels 
may represent the occurrence of angina -like pain 
rather than of ischemia per se, which may be one 
of the reasons for the observed differences in 
results from previous studies. 
Is angina the cause for systemic neurohumoral 
stimulation during ischemia? 
Intuitively, angina pectoris and the inherent stress 
may be associated with enhanced sympathetic 
stimulation and elevated levels of circulating 
catecholamines. Also, blood pressure elevations, 
such as observed in the present study, have been 
reported during anginal painC21). However, the 
majority of studies, carried out during angina, do 
not support this assumptionC9,11,12,14). Although 
early studies reported a significant increase in 
plasma epinephrine and norepinephrine during 
Table V: Transcardiac neurohumoral changes during and after pacing. 
Control Max 2'P-P 5'P-P 30'P-P 
Norepinephrine 
nmol/min 
LP -0.051 ±0.024 0.062±0.054" -0.041 ±0.039 -0.072±0.024 -0.048±0.036 
NLP -0.019±0.018 -0.039±0.023 -0.011 ±0.027 -0.020±0.023 -0.020±0.018 
NI 0.031±0.023 0.060±0.061 0.022±0.058 0.044±0.021 0.053±0.035 
Epinephrine 
nmol/min 
LP 0.025±0.006 0.070±0.019" 0.023±0.011 0.032±0.011 0.037 ±0.013 
NLP 0.022±0.008 0.043 ±0.011 0.026±0.005 0.034±0.012 0.022±0.008 
NI 0.027±0.009 0.006±0.018 0.025±0.019 0.024±0.014 0.021±0.017 
Dopamine 
nmol/min 
LP -0.014±0.009 -0.014±0.015 -0.014±0.008 -0.010±0.008 -0.003 ±0.010 
NLP -0.011±0.006 0.004±0.011 0.006±0.010 0.001±0.008 -0.005±0.006 
NI -0.029±0.019 -0.007±0.043 0.029±0.016 -0.058±0.070 0.024±0.019 
Angiotensin ll 
pmol/min 
LP 0.045±0.040 0.357±0.162 0.151 ±0.050 -0.001 ±0.087 0.136±0.064 
NLP 0.052±0.04 0.071±0.054 0.101 ±0.064 0.098±0.080 -0.085±0.078 
NI 0.053±0.035 -0.005±0.026 -0.044±0.044 0.061 ±0.034 0.032±0.028 
Abbreviations: LP = lactate producers; Max =maximal pacing rates; Nl = non-ischemic patients; NLP = non-lactate 
producers; P-P =post-pacing; All values x ± SEM. * p <.05 vs control. 
exercise-induced angina(7,8), similar responses 
were also observed in normal individuals(8). 
Alternatively, whereas one of these studies report-
ed that exercise did not influence catecholamine 
levels in normal subjectsC7), later investigations in 
normal individuals have provided unequivocal 
evidence for the marked stimulation of circulating 
catecbolamines during exercise in normal 
persons(22,23). This suggests, that the value of 
early studies may be limited, presumably as the 
analytic techniques available were less sensitive 
and specific. Whether this argument also holds as 
explanation for the different results with respect to 
catecholamine changes during angina in more 
recent (pacing) studies is questionable, as all make 
use of a more advanced radioenzymatic assay tech-
nique(24) in one instance in combination with 
HPLC(14). Nevertheless, in four of these studies, 
no significant changes in norepinephrine nor epi-
nephrine levels were observed during 
angina(9,11,12,14). Only the study by Emmanuelson 
et al. reported a rise in circulating catecholamine 
levels(13). Our data too, do not support an 
important role for angina as the predominant 
causative factor in catecholamine activation during 
myocardial ischemia. In the first place, 6 out of the 
11 non-ischemic patients, in whom neurohumoral 
activation did not occur, bad very definite angina-
like complaints during the pacing test. Secondly, 
whereas the level and duration of catecholamine 
activation was different in lactate versus non -lac-
tate producers, the percentage of patients develop-
ing angina during pacing, was identical in both 
groups. Moreover, if angina is a major determi-
nant, it does not explain why nearly all studies, 
carried out in anginal patients only, have been 
negative in the neurohumoral response to pacing-
induced angina, whereas the present investigation 
does not necessarily concentrate on angina, but 
nevertheless indicates that ischemia does result in 
neurohumoral activation. One explanation for this 
difference in results may be, that in our study, the 
addition of HPLC separation of the radioactive 
products improved the sensitivity of the radio-
enzymatic assay for catecbolamines. In the only 
other study, where a similar technique was 
used(14) and in which arterial norepinephrine 
levels did not change, the pacing protocol was 
adapted to allow for long pacing periods without 
causing severe angina. As a result, maximum heart 
rates were relatively low and objective signs of 
ischemia only found in 9 out of 15 patients. In any 
case, the explanation given above does not alter the 
fact that other mechanisms than angina may be 
responsible for the effect of ischemia on neurohor-
mones, such as observed in our study. 
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Neurohumoral activation depends on the 
degree of ischemia. 
To explain neurohumoral activation in the sense of 
enhanced sympathetic stimulation and elevated 
circulating catecholamines in the absence of angina 
is no simple task. The concomitant increase in 
arterial pressures may reflect a cardiogenic 
hypertensive chemoreflex, described 
by James et al. (2.5-27), elicited by serotonin 
injection in the proximal part of the left coronary 
artery. A similar hypertensive response has been 
described followin~ bradykinin injection in the left 
coronary arteryC 8). How relevant these 
observations are to our study is unclear though. 
Few data are available on serotonin or bradykinin 
release from the heart during ischemia in man. In 
contrast, a preliminary study from our laboratory, 
carried out under identical circumstances as the 
present investigation, was 
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Fig. 8: Individual changes in cardiac norepinephrine balance and in epinephrine and angiotensin II 
uptake by the heart in ischemic patients with myocardial lactate production. During maximal pacing 
rates norepinephrine release, present at control, reverses to uptake. Also, epinephrine uptake increases 
significantly. In contrast, angiotensin II fluxes are too variable, although there is a tendency towards 
enhanced uptake. 
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unable to identify enhanced platelet aggregation in 
blood from the ischemic heart(29). 
Stimulation of mechanoreceptors with afferent 
nerves, that travel to the tractus solitarius in the 
medulla oblongate, has been implicated as expla-
nation for the tachycardia and systemic hyper-
tension, which may accompany anterior wall 
ischemia(30,31)_ Besides mechanical stimuli, lactate 
may activate (some of) these receptors with 
subsequent excitation of the vasomotor centre and 
efferent sympathetic impulse formation. Of 
importance is, that the majority of these receptors 
are in the anterior wall, which may, in part, 
explain the sympathetic stimulation, elevation of 
circulating catecholamines and blood pressure rise 
in the group with lactate production. By definition, 
ischemia in these patients must arise from the 
anterior, high septal or anterolateral wall of the 
heart. It does not explain why, however, in our 
study, patients without lactate production also had 
some degree of catecholamine stimulation and 
increase in blood pressure. Apart from the recep-
tors just mentioned, receptors with vagal C fiber 
afferent nerves are also present in the heart, pre-
dominantly in the inferoposterior part. Stimulation 
of these receptors, by changes in preload or 
volume, depresses the activity of the vasomotor 
centre in the medulla oblongata. This mechanism 
has been implicated as explanation for the vagal 
overactivity with hypotension observed in interior 
wall ischemia or infarction(31,32). If, in our 
patients without lactate production, ischemia had 
been confined to the inferoposterior or postero-
lateral wall, as the absence of lactate changes in the 
coronary venous effluent during ischemia may 
suggest, a reduction in blood pressure without 
elevated catecholamine levels was to be expected. 
This did not occur. Moreover, at the time that 
systemic catecholamine activation and increased 
arterial pressures were first observed in this group, 
at maximal pacing heart rates, left ventricular end 
diastolic pressure was reduced, which makes a 
significant increase in preload less probable. Thus, 
myocardial ischemia, exclusively located in the 
inferoposterior part of the heart, may not be the 
sole explanation. More likely, the non -lactate 
group, of which 88% has significant left coronary 
artery disease, had either predominant anterior 
wall ischemia comparable to lactate producers, but 
significantly less extensive, indicated by the 
absence of lactate production, or mixed ischemia 
of both anterior and inferior areas with relatively 
small ischemic regions in the sampling area of the 
coronary sinus catheter. In the latter instance, 
dilution with coronary venous effluent from non-
ischemic areas would make changes in lactate 
metabolism in the ischemic region undetectable. 
Either way, irrespective of electrocardiographic 
changes being similar in the two groups, the 
ischemic reponse would be far more pronounced in 
the lactate producers. This was suggested by 
marked depression of contractility and relaxation 
during pacing in the latter group. Moreover, in 
lactate producers, cardiac output was still 
significantly impaired, 5 minutes after pacing. In 
contrast, none of these changes occurred in the 
group without lactate production. Also, left 
ventricular end diastolic pressure increased 
significantly more in patients, who produced 
lactate during and immediately after pacing. 
The significant and prolonged reduction in cardiac 
pump function is most likely an important factor in 
the more pronounced neurohumoral activation 
during ischemia in this group, compared with the 
non -lactate producers. A reduction in cardiac 
output during the development of ischemia may 
reset arterial baroreceptors, stimulating the 
vasomotor centre in the medulla oblongata. 
Whether this results in a secondary overshoot, or 
mainly helps to amplify the stimulus for systemic 
vasoconstriction derived from sympathetic afferent 
nerves, is unknown. The pronounced reduction in 
myocardial function and cardiac output in lactate 
producers may also explain why a significant and 
sustained elevation of angiotensin II levels was 
observed in these patients, and not in the other 
ischemic group. 
Circulating angiotensin II levels and degree of 
myocardial ischemia. 
The present data suggest, that stimulation of the 
circulating renin-angiotensin system is directly 
related to the degree of myocardial ischemia and 
subsequent cardiac dysfunction. Our observations 
indicate, that such a stimulation only occurs when 
ischemia is sufficiently severe to reduce cardiac 
and stroke output and, possibly, diminish renal 
flow. Whereas no further data on ischemia-
induced alterations of the circulating renin-
angiotensin system exist in man, two recent studies 
in an ischemic dog model have suggested that the 
various components of the circulating renin-
angiotensin system, e.g. renin, angiotensin I and 
II, are subJect to changes as a result of 
ischemia(l5,3 ) . A significant elevation of arterial 
renin and angiotensin II levels is already observed 
after 30 seconds of coronary occlusion(34). 
Interestingly, these changes are absent in 
nephrectomized animals, but not affected by beta-
blockade<34). This underscores the importance of 
ischemia-induced ventricular dysfunction, rather 
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Fig. 9: Sequential alterations in cardiac neuro-
humoral balance. Changes in catecholamine bal-
ance in ischemic patients with (LP) and without 
lactate production (NLP), if present, only occur 
during maximal pacing rates (MAX) and return 
quickly to control values after pacing (p-p). 
Values are :X± SEM. NI =non-ischemic group. 
than a direct stimulatory effect through enhanced 
sympathetic stimulation and/or elevated circulating 
catecholamine levels. 
Cardiac neurohumoral balance at rest and 
during myocardial ischemia. 
Although, on average, angiotensin II was taken up 
by the heart at rest, a number of patients released 
the octapeptide. Recent data on gene expression of 
several components of the system, including renin 
and angiotensinogen, by the rodent heart<35) indi-
cate, that the heart has its own renin-angiotensin 
system. Also, there is evidence, that (part of) the 
system becomes activated during cardiac hyper-
trophy and myocardial infarction<36). Whether 
ischemia has similar effects is unknown, although 
our data do not support this concept. 
By contrast, ischemia did significantly affect car-
diac catecholamine balance. In patients with lactate 
production, the pattern of net cardiac nor-
epinephrine release, present at baseline, was 
reversed to net cardiac norepinephrine uptake. 
This was very consistent in patients in this group 
with marked ischemia, but short lasting (Fig. 9). 
Although data on the 2-minute post-pacing period 
are only present in a small number of patients, they 
indicate that, even after this short period, norepi-
nephrine balance was already returning to control 
values. 
As no such changes were found in ischemic 
patients without lactate production, the observed 
alterations in norepinephrine balance in lactate 
producers presumably reflect changes in norepi-
nephrine kinetics in the ischemic area. 
Whether ischemia results in diminished regional 
norepinephrine spillover or enhanced clearance 
cannot be deduced from our methods, but would 
have implied tracer techniques with long equili-
bration times<14,37). In animal experiments, myo-
cardial ischemia produces overflow of norepi-
nephrine(6). This is generally taken to reflect 
enhanced sympathetic activity, secondary to stress 
and anginal pain, as well as to enhanced autonomic 
reflexes, following stimulation of chemoreceptors 
and impaired hemodynamics(38)_ However, during 
short lasting periods of ischemia, comparable to 
patient study models of pacing-induced stress, 
norepin~hrine overflow is either minor(6) or 
absentC3 ,40). Thus far, patient studies have not 
been able to show net enhanced norepinephrine 
release from the heart (7,11,l4). The present study 
therefore is the first to indicate that during myo-
cardial ischemia net norepinephrine release is not 
only absent but that in addition, its usual release 
pattern is reversed to net uptake in the ischemic 
area .. The difference in results between our study 
and other investigations may relate to different 
sensitivities of the catecholamine assayC9,11) or to 
varying degrees of ischemia in the different 
studies. 
The change in net norepinephrine release to uptake 
during ischemia is not readily explained. Merely a 
reduction in efflux from the ischemic area as a 
result of diminished venous outflow is unlikely, in 
view of the increased coronary venous lactate 
levels. Enhanced neuronal re-uptake of norepi-
nephrine during ischemiaC41) could theoretically 
prevent the wash-out of norepinephrine, which 
has been shown to accumulate in the interstitial 
space in the ischemic m~ocardium, following 
sympathetic stimulation C4 ) . Whether the relat-
ively moderate rise in arterial catecholamine 
levels, found in our study, relates to the cardiac 
sympathetic stimulation at all, achieved under 
experimental conditionsC42), is doubtful, however. 
The change in circulating neurohormones certainly 
did not originate from the heart. Local norepi-
nephrine release from stimulated cardiac sympa-
thetic nerves (exocytotic release) is dependent on 
the presence of high-energy phosphates in the 
neuron C43). A decrease in norepinephrine release 
therefore may result from reduced availability of 
high-energy phosphates during ischemia. 
However, this process will take some time and 
cannot account for the early change, observed in 
our studies. More likely, presynaptic inhibition of 
exocytotic norepinephrine release by adenosine 
could be an important mechanism in addition to 
others, such as enhanced neuronal re-uptakeC44). 
Adenosine accumulation in the ischemic area has 
been well documented(45). Moreover, in a similar 
model as used in the present study, the human 
heart has been shown to release significant 
amounts of hypoxanthine early during pacing-
induced ischemiaC17,46), indicative of enhanced 
production of its precursor adenosine in the ische-
mic area. Thus, this mechanism, presynaptic 
modulation of norepinephrine release by adenosine 
through coupling to adenosine Al-receptors, may 
well be important during early myocardial ische-
mia. In addition to factors influencing production 
and metabolism of norepinephrine, enhanced 
binding to cardiac or vascular adrenergic receptors 
during ischemia may also be considered. 
In contrast to the specific changes in cardiac nor-
epinephrine balance, only occurring in severe 
ischemia with lactate production, enhanced epi-
nephrine uptake was observed in all ischemic 
patients, irrespective of the degree of ischemia. 
There was no significant difference in this respect 
between lactate and non -lactate producers. 
Enhanced extraction of epinephrine has been 
described in association with increased arterial 
epinephrine levels during relatively short periods 
of ischemia in a canine modelC40). In contrast, in 
human models with pacing-induced ischemia, 
significant changes in epinephrine uptake have not 
yet been detected(9,11). The fact, that in our study 
these changes were found, may relate to a different 
assay technique. More importantly, the fact, that 
changes were also detected in the coronary venous 
effluent from myocardial areas, which were 
presumably non-ischemic, may indicate that 
epinephrine uptake by the heart is an unspecific 
event, possibly reflecting attempts to improve 
function in normal and ischemic parts of the heart. 
Neurohumoral stimulation and hemodynamics 
in myocardial ischemia. 
The enhanced cardiac uptake of epinephrine in the 
non -lactate group may have attributed to the fact 
that the hemodynamic profile was identical in this 
group to non-ischemic patients, despite the 
presence of ischemia. In contrast, neither the 
increase in cardiac epinephrine uptake nor the 
reversal of net norepinephrine release to uptake, 
significantly counteracted the ischemia-induced 
impairment of contractility and relaxation, 
observed in lactate producers. 
Also, when the overall coronary sinus flow 
measurements are considered, there was no 
indication that enhanced norepinephrine uptake 
had any effect on coronary flow. If anything, 
coronary vascular resistance decreased more in 
lactate producers than in other groups. Several 
studies indicate that during progressive coronary 
flow reduction, cardiac sympathetic stimulation 
may reverse metabolic dilatation to alpha-
adrenergic vasoconstrictionC47-49). Also, human 
studies, conducted in identical circumstances as the 
present investigation, suggest a limitation of 
coronary flow increase or a decrease in the post-
stenotic area preceding the manifestation of 
ischemiaC17,50). Whether adrenergic mechanisms 
are involved in the latter phenomenon is unknown. 
In this study, neurohormones were only 
determined after ischemia was established. 
Moreover, the thermodilution flow technique does 
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not allow for a precise determination of regional, 
sequential changes in flow. It does not exclude the 
possibility that a local decrease in coronary flow 
did indeed occur, following the changes in cardiac 
norepinephrine balance in patients with severe 
ischemia. 
In contrast, our study clearly indicates that 
systemic vasoconstriction occurs concomitantly 
with the activation of systemic neurohormones. 
Elevated systolic arterial pressures during pacing-
induced ischemia have been reported before, but 
only in a limited number of patients with coronary 
artery disease and severe myocardial ischemiaCSl). 
When a rise in arterial pressures is taken to reflect 
enhanced systemic vasotone, ischemia-induced 
changes in catecholamines and in circulating 
angiotensin II levels could explain the latter. In the 
group without lactate production and moderate 
ischemia, the small increase in arterial pressures 
during maximal pacing rates was accompanied by 
a moderate rise in arterial catecholamines, but not 
in angiotensin II. Our data indicate that, depending 
on the severity of myocardial ischemia, the 
increase in systemic vascular resistance and arterial 
pressures may be sustained following ischemia and 
could be clinically important. Although we have 
no data on ventricular volumes during pacing-
induced ischemia, it is reasonable to assume that 
systolic wall stress will be elevated following the 
rise in arterial pressures. Subsequently, 
myocardial oxygen demand will increase, this may 
suggest a role for specific neurohumoral 
modulators, such as alpha-adrenergic antagonists 
and, possibly, converting enzyme inhibitorsCSS), 
during ischemia. 
Limitations of the study. 
By necessity, several assumptions have been made 
in this study, which may not be entirely correct. 
To differentiate coronary venous effluent from 
ischemic versus non-ischemic areas, a distinction 
was made between lactate and non -lactate 
producers. Here it was assumed, that the presence 
of myocardial lactate production values in the 
coronary venous effluent at least ensured, that 
blood was sampled from the ischemic area. The 
number of patients with myocardial lactate 
production may have been underestimated, though 
it stands to reason that in those patients, where the 
coronary effluent from the ischemic area was 
diluted to such an extent that lactate release was no 
longer detectable, the same was assumedly true for 
the neurohormones. Moreover, the distinction 
between lactate versus non -lactate producers 
served to differentiate between mild versus more 
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severe ischemic patients. Again, the absence of 
appreciable lactate release in the coronary venous 
effluent either indicates small ischemic areas in the 
sampling region of the coronary sinus catheter or 
predominant inferoposterior ischemia. In both 
instances the hemodynamic (and neurohumoral) 
consequences of ischemia are mitigated compared 
with conditions, where lactate production is 
clearly present. 
Theoretically, the lower absolute maximal pacing 
values in non-ischemic patients may limit the 
interpretation of the study. Ideally, pacing 
conditions should have been identical in the three 
groups. No data are present in humans, which 
suggest that elevating heart rate increases 
circulating catecholamines or activating cardiac 
sympathetic tone. In contrast, preliminary data 
from our laboratory indicate that fast atrial pacing 
to similar heart rates, which induces marked 
circulating neurohumoral activation in ischemic 
patients has no effect on these systems when 
ischemia is absentC53). Moroever, in the present 
study, the difference in heart rate between baseline 
and the end of pacing was comparable in all three 
groups. Therefore, the (absence of) changes in 
neurohormones in the non- ischemic group in this 
study has been taken to truly represent the absence 
of myocardial ischemia rather than the result of a 
mismatch between study populations. 
Implications. 
This study indicates that acute myocardial 
ischemia not only results in activation of systemic 
catecholamines and the circulating renin-
angiotensin system in man, but also in significant 
changes in cardiac catecholamine balance. 
Whereas the first is associated with a sustained 
increase in systemic vascular resistance, the 
second may influence post-stenotic coronary 
vasotone, although further detailed studies will 
have to be conducted to substantiate the latter 
hypothesis. Both mechanisms may significantly 
influence the severity of the ischemic attack, which 
originally provoked this neurohumoral response. 
Although the clinical importance of systemic and 
transcardiac neurohumoral changes, resulting from 
pacing-induced ischemia, have to be further 
specified, acute myocardial ischemia at rest, e.g. 
during unstable angina or the early phase of 
infarction, may well reflect this condition. The 
significance of specific therapy, focussing on 
modulation of these neurohumoral changes, such 
as alpha-adrenergic blockade, converting-enzyme 
inhibitors or renin-antagonists as an additional 
form of antiischemic therapy, should be further 
evaluated in these clinical settings. 
Our observation, that enalaprilat diminishes 
pacing- induced myocardial ischemia through a 
modulating effect on systemic neurohumoral 
activationC52) emphasizes the importance of these 
therapeutic modalities as antiischemic therapy. 
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Neurohumoral activation during acute myocardial 
ischaemia. Effects of ACE inhibition 
W. J. REMME, M. P. LooK, M. BooTSMA, H. A. C. M. KRUYSSEN, J. M. E. VERROSTTE, 
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Cardiovascular Research Foundation STICARES, Rotterdam, The Netherlands 
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ACE inhibition may be useful in several manifestations of ischaemic heart disease, such as heart 
failure due to ischaemic cardiomyopathy. Recent evidence suggests that these effects may also be 
present in normotensive patients with ischaemic heart disease without heart failure. Theoretically, 
converting-enzyme inhibition, through coronary and systemic vasodilating effects and negative 
inotropic properties, should have a favourable effect on the myocardial oxygen supply/demand ratio 
and, hence, affect the incidence and severity of myocardial ischaemia. It is doubtful, however, 
whether these cardiac and extracardiac properties of ACE inhibitors really underlie its potential 
antiischaemic effects, at least in the average patient with ischaemic heart disease without concomitant 
heart failure and hypertension. Recent animal and human studies indicate that converting-enzyme 
inhibitors may modulate myocardial ischaemia by reducing ischaemia-induced circulating neurohum-
oral activation. It has been shown that, depending on the severity of ischaemia, the circulating 
renin-angiotensin system may become activated together with an increase in circulating catecholamine 
levels. ACE inhibition suppresses this neuroendocrine stimulation during ischaemia and modulates 
subsequent systemic and, presumably, also coronary vasoconstriction. In addition to these effects on 
circulating neurohormones, ACE inhibition could affect myocardial ischaemia through a number of 
local actions, e.g. modulation of tissue (cardiac) angiotensin II formation and bradykinin 
breakdown, stimulation of prostaglandin synthesis and, in the use of sulphydryl compounds, by 
affecting EDRF formation. Whether ACE inhibitors have clear antiischaemic effects in all clinical 
conditions is uncertain. Their efficacy to limit exercise-induced ischaemia has been questioned. In 
contrast, pacing-induced ischaemia in patients at rest is clearly prevented by ACE inhibition. This 
differential effect may be related to a more pronounced difference in circulating neurohormones during 
exercise per se. It also suggests that ACE inhibitors may be particularly useful as (addirional) 
antiischaemic therapy in patients with angina at rest, e.g. unstable angina and the acute phase of 
myocardial infarction. 
Introduction 
The usefulness of ACE inhibition in heart 
failure and hypertension has been well 
established. Also, recent data indicate benefi-
cial effects of ACE inhibition on ventricular 
dilation and remodelling after myocardial 
infarctionlll. Moreover, animal studies strongly 
suggest that converting-enzyme inhibiton may 
limit the occurrence of ventricular dysrhythmias 
during sudden reperfusion following prolonged 
periods of ischaemia12- 51. 
There are a number of theoretical considera-
Correspondence: Willem J. Remme MD, Cardiovascular 
Research Foundation STICARES, Valkeniersweg 79, 
3075-AZ Rotterdam, The Netherlands. 
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tions which suggest that, besides these beneficial 
cardiovascular effects, ACE inhibitors may have 
direct antiischaemic properties as well. Thus far, 
however, converting-enzyme inhibitors have not 
been uniformly successful in reducing myocar-
dial ischaemia, despite their potential to reduce 
myocardial oxygen demand and to improve 
coronary flow. Following the rationale that 
converting-enzyme inhibition may have a 
beneficial effect on the myocardial oxygen 
supply/demand ratio through a reduction in pre-
and afterload, a negative inotropic effect and by 
way of coronary vasodilatation, a number of 
studies have been carried out in patients with 
ischaemic heart disease to prove the antiis-
chaemic and antianginal efficiency of ACE-
inhibition. Following high dosages of oral 
captopril, Daly and coworkers observed a small, 
but significant reduction in arterial pressures 
and in myocardial oxygen consumption in 
patients with anginal6l. As these effects were not 
accompanied by systemic or transcardiac neuro-
humoral changes, the authors speculated that 
the drug might have potential antianginal effects 
through a lack of reflex increase in myocardial 
sympathetic tone. A subsequent, placebo-
controlled study in the same patients did indeed 
show an improvement of exercise duration, but 
not of anginal threshold, and only in those 
patients in whom captopril decreased systolic 
blood pressure. However, the use of additional 
antianginal medication, including beta-blockers, 
as well as diuretics obviates a clear interpreta-
tion of the exact role of captopril as an 
antiischaemic agent in this study. Further studies 
in patients with angina pectoris, also carried out 
during exercise-induced stress, have not been 
able to clarify whether ACE-inhibitors have 
antiischaemic effects. Whereas a number of 
these investigations did indicate some antiis-
chaemic efficacy of the ACE inhibitor under 
studyl7- 11 l, others did notl12•13l. Moreover, antiis-
chaemic effects, when present, do not appear 
necessarily to relate to changes in systemic 
haemodynamics and myocardial oxygen 
consumptionl7- 9 l as suggested by Daly and 
coworkersl6l. One problem with interpreting the 
data is that most studies were uncontrolled and 
of relatively short duration. Recently, another 
mechanism has emerged, through which ACE 
inhibition may affect ischaemia in humans. 
During (pacing-induced) myocardial ischaemia a 
short-lasting, but significant systemic neuroen-
docrine activation has been demonstrated, 
accompanied by systemic vasoconstriction and a 
rise in arterial pressuresf14•15l As it is likely that 
the latter mechanism may amplify myocardial 
ischaemia, ACE inhibition, theoretically, could 
attenuate this by preventing the activation of 
circulating neurohormones. 
This article focuses on the potential antiis-
chaemic properties of ACE inhibition in relation 
to its effect on neuroendocrine stimulation 
during ischaemia. 
Neurohumoral activation in ischaenuc 
syndromes 
Significant neuroendocrine stimulation is 
commonly observed during acute myocardial 
infarction. Early following the onset of infarc-
tion, both plasma and urinary catecholamine 
levels are significantly elevatedP 6 •18l The mag-
nitude of these changes is directly related to 
acute alterations in cardiac function, with 
marked elevations prominent in patients with a 
low-output state or cardiogenic shockl19•20l. 
Likewise, circulating renin-angiotensin levels 
increase significantly during myocardial infarc-
tion complicated by acute failurel2 1J. These early 
neurohumoral changes during infarction ap-
parently relate to cardiac dysfunction and, 
therefore, are likely to be secondary to the 
subsequent reduction in cardiac output, blood 
pressure and tissue renal perfusion. Whether the 
stress of anginal pain, commonly present during 
the initial phase of infarction, exerts additional 
stimulatory effects on neurohormones is not 
clear. Likewise, it is uncertain, whether anginal 
pain has any effect on circulating neurohor-
mones during short periods of myocardial 
ischaemia per se without infarction. Studies 
carried out during exercise-induced stress, have 
demonstrated similar increases in circulating 
catecholamines in normal individuals and in 
patients with myocardial ischaemia and 
anginal22l. Also former investigations carried out 
during pacing-induced stress, which in itself does 
not affect circulating neuro-hormonesl14l, have 
not consistently indicated significant alterations 
in systemic catecholamine levels during anginal 
painl23-25 l. In contrast to the variable and 
conflicting effects of stress- or pacing-induced 
angina on neurohormones, a significant eleva-
tion of norepinephrine and epinephrine levels 
has been demonstrated during angina following 
spontaneous coronary artery spasml26l. Besides 
these conflicting observations on the relationship 
between anginal pain and circulating neurohor-
mones, it is also not clear whether ischaemia 
per se, not necessarily accompanied by 
anginal pain, affects systemic catecholamines. 
The few data available in humans do not 
indicate that ischaemia results in an extra 
activation of circulating catecholamines, 
at least not when compared with normal 
individuals subjected to identical stressl22l. 
Moreover, it is not known whether, in 
humans, myocardial ischaemia affects circulat-
ing renin-angiotensin levels, as this aspect 
has not yet received much attention at least 
not in subjects without hypertension or heart 
failure. 
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Systemic neurohormones in normotensive 
patients with coronary artery disease at rest 
and during pacing-induced stress 
Ertl and coworkers have demonstrated, that 
in canine models of myocardial ischaemia, 
arterial renin activity is significantly increased, 
following 15 min of coronary artery 
occlusiont27' 281 (Fig. 1). These effects were 
accompanied by changes in arterial angiotensin 
II, but not by increments in coronary venous 
renin-angiotensin levels. Interestingly, whereas 
beta-blockade did not blunt the activation of 
circulating renin-angiotensin, nephrectomy pre-
vented it completely. The authors also observed, 
that fast atrial pacing which, in the absence of a 
coronary artery narrowing, had no effect 
resulted in a 50% increase in arterial and 
coronary venous renin levels in the presence of a 
significant stenosis. 
Recently, we evaluated the response of the 
circulating renin-angiotensin system to myocar-
dial ischaemia in humans. To this purpose, 
normotensive patients with coronary artery 
disease referred for coronary angiography, were 
studied. Changes were compared with simul-
taneous effects of ischaemia on circulating 
catecholamines. At present, only limited data 
are available concerning the normal values of 
GOO 
400 
AnqloteM.II"' ll 
(pq ml-') 
ZOO Uotreated 
100 ~ 
50 
20 
Proprono~~~ 
3 mq kq 
!_.~~·~_! 
) Nephrectomy 
/~ 
Plcsmo-renl!'l OCIIVIIy 
(nq ml- 1 hr-1) 
Figure 1 Changes in plasma-renin activity (PRA) and 
angiotensin II concentrations during coronary artery 
occlusion (CAO) in open-chest, anaesthetized dogs. In 
untreated and propanolol pretreated animals arterial 
(filled symbols) PRA levels increase significantly. No 
such changes are observed in nephrectomized animals 
subjected to CAO. Arterial angiotensin II levels 
parallelled the effect of CAO on PRA levels, but changes 
were less significant, due to large scatter. (Reproduced 
from Ref 28, with permission.) 
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arterial angiotensin II, the hormone under 
study, in normotensive patients with coronary 
artery disease, without clinical signs of heart 
failure. Hence, we first compared resting 
circulating neurohumoral levels in these patients 
and in patients with ischaemic cardiomyopathy 
and (moderate) heart failure. A significant 
difference was observed in arterial norepi-
nephrine and angiotensin II levels, but not in 
arterial epinephrine and dopamine valuest29l 
(Fig. 2). Interestingly, when patients with 
coronary artery disease without heart failure 
were subsequently divided into patients with 
normal vs depressed left ventricular function, a 
difference was also observed in arterial an-
giotensin II levels between the two patient 
groups; a significantly higher arterial angiotensin 
II level was present in patients with impaired left 
ventricular function than in those with normal 
ventricular function. This early activation of the 
renin-angiotensin system apparently does not 
affect vasotone. In our study, systemic vascular 
resistance was comparable in patients with a 
normal and with an impaired left ventricular 
function without heart failuret291. 
-Pacing-induced stress does not affect systemic 
or coronary venous catecholamine and an-
giotensin II levels, at least not in normal 
individuals or in patients with coronary artery 
disease who do not become ischaemic during 
pacing[141 • In contrast, during pacing-induced 
ischaemia, a significant elevation in systemic 
angiotensin II is observedr3oJ. This observation 
compares well with the data from Ertl's studies 
on renin-angiotensin changes during coronary 
artery occlusion and subsequent fast atrial 
pacingt27•28l. The main difference is that, in our 
studies we did not observe a rise in coronary 
venous angiotensin II levels. Consequently, in 
our study, there was a tendency for angiotensin 
II to be taken up by the heart during the 
ischaemic period (Fig. 3). These changes were 
not significant, however, due to a wide 
variability of individual valuest3 '1. Nevertheless, 
our observation on cardiac angiotensin II 
balance does not support an enhanced angioten-
sin II release by the heart during ischaemia. 
Myocardial ischaemia also significantly 
increases circulating catecholamines in nor-
motensive patients with coronary artery disease. 
In our studies, an elevation of both arterial and 
coronary venous epinephrine levels was ob-
served druing myocardial ischaemia (Fig. 4). 
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Figure 2 Arterial catecholamines and angiotensin II (Ail) 
levels in patients with coronary artery disease and normal left 
ventricular (LV) function (LV ejection fraction ;:.45%, n = 28, 
D), LV dysfunction without (LV ejection fraction <45%, 
n = 8, fi!l) and with congestive heart failure (CHF, n = 9, 
NYHA Class 3, •). Epinephrine (E) and dopamine (D) levels 
are similar in all groups. Whereas norepinephrine (NE) levels 
are only elevated in heart failure patients, Ail values are also 
significantly different in patients with asymptomatic LV 
dysfunction compared with patients with normal LV function.* 
P < 0·05 vs control. (Adapted from Ref 29, with permission of 
the publishers). 
However, only during pacing itself and not 
following pacing-induced stress. In contrast, 
arterial and coronary venous norepinephrine 
levels were significantly elevated for a longer 
period, not only during pacing but also for 
several minutes thereafter['51 • The magnitude 
of this neuroendocrine activation during myo-
cardial ischaemia is variable and appears to 
relate to the severity of ischaemia and 
subsequent ventricular dysfunction[32' 331. Never-
theless, increased arterial pressures, due to 
enhanced systemic vasoconstriction, are a 
consistent finding during pacing-induced 
ischaemia['5 1. It is not illogical to assume a direct 
relationship between the observed changes in 
neurohormones and increased arterial pressures 
during pacing-induced myocardial ischaemia. 
Secondary to the effect of ischaemia on cardiac 
pump function, arterial pressures are not 
expected to increase, but rather decrease. Our 
findings, therefore, suggest counterregulatory 
forces. 
Furthermore, it is not illogical to assume that 
the increase in arterial pressures and afterload 
and, hence, in myocardial oxygen demand, will 
amplify the severity of myocardial ischaemia 
already present. Whether this additional form of 
myocardial ischaemia is substantial enough to 
warrant extra antiischaemic therapy in patients 
who are already ischaemic is, as yet, unknown. 
Reduction of myocardial ischaemia through 
inhibition of secondary neurohumoral 
stimulation. Wltich agent to choose? 
Theoretically, a number of options exist to 
affect myocardial ischaemia by reducing 
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Figure 3 Cardiac angiotensin II balance in normotensive 
patients with coronary artery disease without heart 
failure. Data are given during control (C) before atrial 
pacing and dming maximal pacing rates (max). Patients 
are divided into those who become ischaemic during 
atrial pacing with subsequent myocardial lactate produc-
tion (GR I+ L, n = 26, •-•) and those who do not (GR 
NI, n = 7, •-- -•). In GR NI cardiac angiotensin II 
balance remains unchanged whereas, in ischaemic 
patients, there is a tendency towards enhanced cardiac 
angiotensin II uptake. However, due to large individual 
variability, changes are not significant. Data are 
mean±SEM. 
ischaemia-induced neurohumoral overactivation 
and/or the accompanying systemic vasocon-
striction. Vasodilating agents in general may 
reduce the increase in arterial pressures 
following myocardial ischaemia and, hence, 
"!:._ 1·5 
0 
E 
1·0 
..s 0·5 
w 
0 
"!:._ 3·0 
0 2·0 E 
..s 1·0 w 
z 
0 M 2'p-p 
Figure 4 Effect of pacing-induced ischaemia on arterial 
catecholamine levels in normotensive patients with 
coronary artery disease with heart failure. A significant 
elevation in epinephrine (E) and norepinephrine (NE) is 
observed during maximum pacing rates (M), compared 
with control (C) levels. Changes in epinephrine are 
shortlasting, but the increase in norepinephrine persists 
for at least several minutes post -pacing (p-p). Data are 
mean± SEM * P < 0·05 vs control. (Reproduced from 
Ref 33, with permission of the publishers.) 
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attentuate ischaemia, without any effects on or 
related to neurohormones. Bepridil, a com-
pound with both fast sodium- and slow calcium-
channel blocking properties and calmodulin-
inhibiting effects, indeed prevents the ine;rease 
in systemic vascular resistance and arterial 
pressures following myocardial ischaemial341 • 
Whether this effect relates to vasodilation per 
se, to modulation of post-synaptic a 2 stimulation 
or primarily to the antiischaemic effects of 
bepridil, which mainly result from a reduction of 
myocardial oxygen demand, is unclear. The 
antiischaemic effects of calcium-antagonists, 
such as bepridil, are well established. As they 
affect vasoconstriction, induced by postsynaptic 
a2 stimulationl351 , this property is likely to be of 
additional importance during ischaemia-induced 
increments in circulating catecholamine levels. 
Alternatively, postsynaptic a 1-blocking 
agents, for similar reasons, could be useful 
during (pacing-induced) myocardial ischaemia. 
Supposedly, these agents should be particularly 
useful in preventing acreceptor-mediated 
coronary vasoconstriction during myocardial 
ischaemial361 • Unfortunately, no data are avail-
able on the effects of selective postsynaptic 
acblocking agents in this setting. In fact, only 
few data exist on the effects of a 1-adrenoceptor 
blockade on myocardial ischaemia and/ or 
angina pectoris. In patients with variant angina, 
prazosin does not prevent or reduce ischaemic 
attacksl371. In contrast, in patients with chronic, 
stable angina pectoris, indoramin, in addition to 
nitrates and beta-blockade, improves exercise 
duration and increases maximal oxygen con-
sumption during exercise without a change in 
the maximal double productl381 • Although in the 
latter study it has been suggested that the 
antiischaemic effect of the selective a 1 
adrenoceptor-blocker, indoramin, results from 
actions on peripheral arterioles, no evidence 
has been provided for an effect on neurohum-
oral (over)activation during exercise-induced 
ischaemia. 
Besides a-adrenoceptor blockade, converting-
enzyme inhibition may afford another approach 
to induce antiischaemic effects by modulating 
(the effects on) neurohumoral stimulation 
secondary to myocardial ischaemia. ACE 
inhibition, well-established in the treatment of 
congestive heart failure and hypertension, and 
now recognized as potentially useful in limiting 
post-myocardial dilatation and remodelling, 
thus far has not been uniformly considered as 
antiischaemic therapy. A few short-term studies 
in patients with ischaemic heart disease have 
recently been conducted with captopril, ena-
lapril, ramipril and cilazapril to establish 
whether these compounds have any antiis-
chaemic potential16- 131 • The outcome of these 
studies has been variable. A number have 
claimed success in this respectl6-ttJ; others have 
been unable to show any antiischaemic 
effectl12•131. All of these studies were carried out 
during exercise-induced stress. If limitation of 
ischaemia-induced neurohumoral activation is 
the primary mode of action through which ACE 
inhibition reduces myocardial ischaemia it may 
be argued that this phenomenon is probably of 
less importance in exercise- than in pacing-
induced ischaemia. Exercise results in a marked 
increase in circulating neurohormones, at least 
in catecholamines, even in normal individuals1221. 
The extra increase in circulating neurohormones 
by subsequent myocardial ischaemia may be 
small in comparison to the initial elevation 
following exercise alone and, hence, may not 
result in additional systemic (and coronary) 
vasoconstriction. In contrast, during pacing-
induced stress without ischaemia, with the 
individual under study resting, systemic 
catecholamine and renin-angiotensin levels do 
not change1141 • Here, the subsequent activation 
during ischaemia becomes clearly evident. It 
may be anticipated, therefore, that in patients 
with ischaemia at rest, e.g. with unstable angina 
or during the early phase of infarction, a similar 
or even more pronounced neuroendocrine 
activation is observed. 
Ischaemia-induced neurohumoral activation 
and the potential antiischaemic effects of ACE 
inhibition 
Converting-enzyme inhibition presumably 
affects ischaemia-induced sympathetic stimula-
tion and neuroendocrine activation in a rather 
complex way. Besides reducing circulating 
angiotensin II levels and increasing plasma renin 
and angiotensin I, ACE inhibition also modu-
lates the formation of local tissue angiotensin II. 
Endogenous renin-angiotensin systems are pre-
sent in many tissues, including the heart, and 
exert paracrine and autocrine influences on local 
tissue functionl39--421 . It has been postulated that 
these tissue renin-angiotensin systems are the 
primary site of action of ACE inhibitors. It is 
unknown, however, whether, during relatively 
short periods of ischaemia, these local tissue 
renin-angiotensin systems really are important 
and whether they become activated in these 
conditions. Cardiac angiotensin II may influence 
coronary vasotone and coronary flow. In the 
isolated ischaemic rat heart, angiotensin I and II 
administration negatively affects myocardial 
metabolism and high-energy phosphate content 
and amplifies reperfusion arrhythmiasl43 1. It is 
tempting, therefore, to speculate on changes in 
cardiac renin-angiotensin activation during is-
chaemia in man. Evidence for this does not 
exist, however. In contrast, it has been proposed 
that not the local systems, but rather the 
circulating renin-angiotensin system is involved 
in short-term control of cardiovascular 
regulation 1441 • The local tissue systems, on the 
other hand, would provide for a more tonic 
regulation of tissue function. Hence, unless 
regional changes in tissue renin-angiotensin 
activation during short periods of ischaemia are 
established for certain, it appears more sensible 
to consider only overall changes in circulatory 
renin-angiotensin activation during short periods 
of myocardial ischaemia. 
In this respect, preliminary data from our 
laboratory indicate, that ACE inhibition with 
intravenous enalaprilat, at dosages which reduce 
arterial ACE activity by 90%, abolishes the 
increase in angiotensin II levels, observed during 
pacing-induced stress1451. In addition to these 
effects on angiotensin II levels, enalaprilat also 
reduces catecholamine stimulation during 
ischaemia. 
The renin-angiotensin system affects 
sympathetic adrenergic activity through various 
central and peripheral actions. Angiotensin II 
facilitates norepinephrine release from vascular 
adrenergic nerve endings, limits neuronal 
reuptake of norepinephrine, promotes norepi-
nephrine biosynthesis in the adrenergic nerve 
terminal and stimulates central norepinephrine 
activity146A71 • Furthermore, it facilitates catechol-
amine release from the adrenal medulla and 
potentiates the activity of the sympathetic 
nervous system in general. Converting-enzyme 
inhibition has been shown to increase elevated 
circulating norepinephrine levds in severe 
hypertension and in heart failure. Probably 
more applicable to the topic discussed in this 
paper, Liang and Gavras have demonstrated 
that ACE-inhibition decreases norepinephrine 
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release in conscious dogs subjected to acute 
hypoxaemia1481. The reduction in catecholamine 
and renin-angiotensin activation during myocar-
dial ischaemia by enalaprilat, as shown by us, 
may be of clinical value. With its effect on 
neurohormones, enalaprilat abolished the rise 
in arterial pressures commonly observed during 
pacing-induced ischaemia. Hence, it may be 
postulated that enalaprilat also reduced myocar-
dial oxgyen demand in this setting of pacing-
induced ischaemia. The latter may be (one of) 
the mechanism(s) through which the compound 
exerted its antiischaemic properties in this 
study1451 • 
Other mechanisms through which ACE 
inhibition may affect myocardial ischaemia 
Besides its modulating effect on neurohumoral 
stimulation during ischaemia, ACE inhibition 
may limit the extent of myocardial ischaemia 
also through both cardiac and extracardiac 
pharmacologic effects, not necessarily related to 
changes in circulating neurohormones. Apart 
from the latter, converting-enzyme inhibition 
also modulates cardiovascular function through 
effects on local renin-angiotensin, prostaglandin 
synthesis, bradykinin degradation and possibly 
also on local norepinephrine release. In 
addition, ACE inhibitors which contain a 
sulphydryl-group may induce vasodilation thro-
ugh an effect on EDRF. The magnitude of these 
additional properties varies with each ACE-
inhibitor.. Moreover, these effects of ACE-
inhibitors in general will vary, depending on 
duration and magnitude of action, rate of 
perfusion and distribution of the drug in 
different tissues and as a result of different 
physico-chemical properties. Thus, the various 
ACE inhibitors will contribute differently to the 
cardiovascular pharmacological profile of 
converting-enzyme inhibition in general. Some 
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Figure 5 Systemic haemodynamic effects of ACE inhibition in 
normal subjects (open circles, n = 14) and patients with 
congestive heart failure (closed circles, n = 36). Values given 
indicate mean± standard deviation (S.D.). (Reproduced from 
Ref 50, with permission.) 
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of these pharmacological properties may in-
fluence the myocardial oxygen demand-supply 
balance and, hence, be instrumental in prevent-
ing or alleviating myocardial ischaemia. Arterial 
and venodilating effects and, subsequently, a 
reduction in afterload and preload may substan-
tially reduce myocardial oxygen demand. Like-
wise, coronary blood flow and myocardial 
oxygen supply may be augmented following 
converting-enzyme inhibition. Indeed, in heart 
failure patients, such systemic haemodynamic 
effects are clearly present. Also, in patients with 
dilated cardiomyopathy, coronary flow increases 
with ACE inhibition, given intracoronaryl491 , but 
not following intravenous or oral administration 
of converting-enzyme inhibitionl50"511 • However, 
it is doubtful whether vasodilating effects 
play a significant role in normotensive patients 
without heart failure. Faxon et al. reported no 
change in mean arterial, right atrial or left 
ventricular filling pressures in normal individuals 
following teprotidel501 (Fig. 5). Likewise, coro-
nary blood flow did not change in their study 
(Fig. 6). In contrast, Daly and coworkers 
observed a significant 11% reduction in arterial 
pressures in normotensive patients with coro-
nary artery disease without heart failure; 
however, only after high dosages of oral 
captopril (average 127 mg) were administeredl6l. 
This was accompanied by a significant reduction 
in myocardial oxygen consumption. It is 
questionable whether equivalent results are 
obtained with dosages of captopril, presently 
considered to be in the 'normal' rangel7 •8l. We 
have reported that in similar type patients, 
enalaprilat (1·25-1·5 mg intravenously) also did 
not induce significant haemodynamic effects 
although antiischaemic effects were clearly 
present'29 l. Moreover, coronary flow also did not 
change in this study. These observations do not 
support the hypothesis that the antiischaemic 
effects of ACE inhibitors depend on changes in 
the myocardial oxygen supply demand ratio. Of 
course, regional coronary vasodilation in the 
ischaemic areas through local effects on 
angiotensin, bradykinin or prostaglandins, can-
not be ruled out. In this respect, modulation of 
cardiac norepinephrine release and its effect on 
coronary vaostone during ischaemia certainly 
would seem an attractive hypothesis to explain, 
at least in part, the antiischaemic effects 
observed with ACE inhibition. 
In conclusion, animal and human data on the 
effect of ACE-inhibition on myocardial is-
chaemia do indeed indicate that these agents 
may have antiischaemic effects, at least in 
conditions where the patient is resting. These 
antiischaemic properties appear to relate to 
modulation of ischaemia-induced neurohumoral 
activation and subsequent systemic and possibly 
coronary vasoconstriction. Whether this effect 
also applies to different situations, such as 
exercise-induced stress, is unclear. It is also 
unclear, whether local tissue effects of ACE-
inhibitors are relevant during a short period of 
myocardial ischaemia. The latter aspect needs 
further clarification, particularly in view of the 
different effects of the various ACE inhibitors 
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Figure 6 The effects of angiotensin-converting enzyme 
inhibiton on coronary blood flow, coronary vascular resistance 
and rate-pressure product in normal individuals (0) and in 
patients with heart failure (e). In normal individuals ACE 
inhibition affects neither coronary flow nor myocardial oxygen 
demand (rate-pressure product). (Reproduced from Ref 50, 
with permission.) 
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on local (cardiac) tissue renin-angiotensin 
system. 
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ABSTRACT 
Myocardial ischemia may induce activation of the 
circulating renin-angiotensin system, besides cat-
echolamine stimulation. To investigate whether 
converting enzyme inhibition has the potential to 
limit acute myocardial ischemia in relation to 
modulation of neurohumoral activation, 12 fast-
ing, supine, normotensive patients with ischemic 
heart disease without heart failure symptoms 
underwent 2 identical incremental atrial pacing 
stress tests, 45 minutes before (APST I) and 15 
minutes after (APST II) 1.25-1.5 mg enalaprilat 
(E) i.v. Before, during and for 5 minutes after 
pacing (p-p), hemodynamic measurements and 
paired arterial and coronary venous samples for 
lactate and neurohormones ( catecholamines and 
angiotensin II) were carried out with additional 
determinations before and 5, 15 and 40 minutes 
after E. Arterial ACE activity and arterial and 
coronary venous angiotensin II decreased by 90%, 
46% and 38%, resp., 5 minutes after E with 
changes persisting thereafter. Hemodynamics 
remained unaltered before and after pacing. Only a 
moderate 10% reduction in mean arterial pressure, 
starting 15 minutes after E, and a similar, but later 
decrease in left ventricular systolic pressure were 
observed. Also, coronary and systemic hemodyna-
mics were not different during pacing before and 
after E, apart from a 12% improvement in relaxa-
tion. Nevertheless, E resulted in marked anti-
ischemic effects, indicated by significantly less 
lactate production during APST II (extraction 
-1±9% vs -35±20% during APST I), less ST-seg-
ment depression [ -0.14±0.03 mV (APST II) vs 
-0.21±0.03 mV (APST I), p<0.05] and a signifi-
cant reduction in left ventricular end diastolic 
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pressure immediately after pacing [15±3 mmHg 
(APST II) vs 25±3 mmHg (APST I)]. Also, angina 
was absent or less in 9 patients during APST II. 
Whereas during APST I arterial norepinephrine, 
epinephrine and angiotensin II increased by 93%, 
42% and 39%, resp., accompanied by a significant 
rise in arterial pressures, E abolished this neuro-
humoral and secondary hemodynamic response. 
Moreover, it prevented the change from net car-
diac norepinephrine release to net uptake, observed 
during the first, untreated test. It is concluded that 
enalaprilat may have significant modulating effects 
on myocardial ischemia at rest, apparently through 
inhibition of systemic neurohumoral activation 
during ischemia and subsequent vasoconstriction. 
As a result it may have important effects on after-
load. In addition, it may beneficially affect post-
stenotic coronary vascular tone by preventing net 
cardiac norepinephrine uptake during ischemia. 
The latter hypothesis should be further evaluated. 
INTRODUCTION 
Converting enzyme inhibition may theoretically be 
useful in the treatment of myocardial ischemia. 
Through systemic and coronary vasodilating 
effects and negative inotropic properties it may 
favourably affect the myocardial oxygen 
demand/supply ratio and, hence, the occurrence 
and extent of myocardial ischemia. Systemic vasa-
dilating properties are at the root of ACE-inhibit-
ing therapy in hypertension and heart failure, 
whereas coronary vasodilatation has been reported 
in dilated cardiomyopathy following enalaprilat 
administration(!). Whether converting enzyme 
inhibitors have similar cardiovascular actions in 
the average patient with coronary artery disease 
without hypertension or heart failure, is uncertain 
though. 
A different mechanism, which may be more 
relevant to the potential usefulness of ACE inhibi-
tion in this respect, relates to the observation that 
myocardial ischemia may induce significant 
neurohumoral activation. Recently, stimulation of 
systemic catecholamines and angiotensin II has 
been reported in humans during pacing-induced 
ischemia(Z). Moreover, in this situation, cardiac 
epinephrine uptake increases, whereas net cardiac 
norepinephrine release, present at rest, temporarily 
reverts to net uptake during ischemiaC3). As these 
neurohumoral changes are accompanied by sig-
nificant systemic vasoconstriction and an increase 
in afterload, they may be clinically relevant. Also, 
adrenergically-mediated coronary vasoconstriction 
in the ischemic area has been proposed in animal 
models of ischemiaC4). These neurohumoral 
changes therefore may add to the ischemic burden 
already imposed on the heart. 
Modulation of systemic and transcardiac neuro-
humoral activation could well be the primary 
mechanism through which ACE inhibitors may 
result in a reduction of myocardial ischemia(S). In 
addition, they may affect ischemia through several 
local (cardiac) actions, e.g. stimulation of prosta-
glandin synthesisC6), modulation of bradykinin 
breakdown(?) and, possibly, of local angiotensin II 
formationC8-10). Moreover, compounds which 
contain sulfhydryl groups may affect EDRF 
productionC11). 
Thus far, studies in ambulant patients with ische-
mic heart disease have been conflicting with res-
pect to limitation of exercise-induced 
ischemia(S,lZ-lS). Also, no data are available on the 
acute effects of ACE inhibition in patients with 
ischemia at rest. Likewise, it is not known 
whether antiischemic effects and neurohumoral 
actions of the compound under study are related. 
Consequently, whether neurohumoral effects of 
specific cardiovascular mechanisms of converting 
enzyme inhibition are responsible for its potential 
antiischemic activity, is also unknown. 
The present study examines the antiischemic effic-
acy of a non-sulfhydryl ACE inhibitor, enalapri-
lat, in normotensive patients with coronary artery 
disease at rest, in relation to its modulating effect 
on systemic and transcardiac neurohormones and 
to its systemic and coronary hemodynamic proper-
ties. 
MATERIALS AND METHODS 
Patients 
Twelve patients participated in the trial, after the 
study was approved by the institutional Ethical 
Review Board and after informed consent was 
obtained. They were selected from patients refer-
red for coronary angiography for the evaluation of 
stable angina pectoris and/or a previous myocar-
dial infarction. In either case documented exer-
cise-induced myocardial ischemia had to be 
present. To be selected patients had to be normo-
tensive without signs or symptoms of heart failure, 
renal insufficiency, valvular heart disease or con-
duction disturbances. Patients with unstable 
angina, defined by the occurrence of recent episo-
des of angina, angina at rest or an increase in 
frequency and/or duration of anginal episodes des-
pite medication, were excluded. Myocardial 
infarction had to be at least one month old. All 
cardiac therapy was withheld 24 to 72 hours before 
the investigation. Only short acting nitroglycerin 
was allowed until 6 hours pre-study. Patients on 
diuretic or ACE-inhibitor treatment were not 
included. Oral anticoagulation was stopped 2-3 
days before the study, whereas anti-platelet thera-
PY and NSAIDs were withheld at least 10 days 
prior to investigation. 
To participate it was essential that patients had at 
least one ~70% diameter narrowing in either the 
left anterior descending, a diagonal branch, the 
proximal part of the left circumflex or a proximal 
marginal branch. 
Patients received 1.25-1.5 mg enalaprilat 
(depending on body weight, < or > 75 kg, resp.), 
administered intravenously during 1 minute. This 
dose was chosen, following a dose-finding, which 
started with 0.625 mg in the first patient, sub-
sequently doubling this dose in each patient. As the 
third patient to be studied had a significant (> 30% 
reduction) in mean arterial pressure after 15 
minutes, the study dose was set on 1.25 mg. 
Clinical and angiographic characteristics are given 
in Table I. All patients were male. By design, all 
patients had exercise-induced ischemia. In 
addition, 8 patients had sustained one or more 
myocardial infarctions. Four patients had single 
vessel disease of the left anterior or proximal left 
circumflex artery. Two-vessel disease was present 
in 6 patients and 3-vessel in 2. Average values for 
left ventricular (LV) ejection fraction and end 
diastolic volumes were normal. 
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Table I: Patient characteristics 
Sex (male/female) 
Age (years) 
Number of old myocardial infarctions 
Coronary angiography 
(::70% diameter stenosis): 
1-vessel 
2-vessel 
3-vessel 
Left ventricular ejection fraction (%) 
Left ventricular end diastolic 
volume index (ml/m2) 
Catheterization procedures. 
Patients were studied at the same time in the mor-
ning between 10.00 and 12.30 a.m. All had been 
fasting since the previous night and had been supi-
ne for approximately 1.5 hours before the start of 
the study. None received premedication. All 
procedures were carried out under local anaes-
thesia with 1% lidocaine. 
First, left and right coronary angiography was 
performed with non-ionic contrast material, using 
the Seldinger technique. If the patient then met the 
inclusion criteria, instrumentation for the study 
was carried out. This included the positioning of a 
no 7 Fr thermodilution pacing catheter (Wilton 
Webster Laboratories) in the coronary sinus via a 
brachial vein, such that the proximal thermistor 
was at least 3 em beyond the ostium of the corona-
ry sinus. Moreover, care was taken that the posi-
tion of the catheter was stable but at the same time 
allowed for fast sampling of relatively large quan-
tities of blood. To improve the sampling pro-
cedure, a specially designed bol-end variety 
(CCS-7U -90B) was used. Thus, relatively large 
amounts of blood (15-20 cc/minute) could be col-
lected repetitively at short intervals throughout 
periods of at least 2 hours in nearly all patients. 
After positioning, the absence of reflux was 
confirmed by bolus injections of saline at room 
temperature in the right atrium at control and 
paced heart rates. Next, a no 7 Fr balloon-tipped 
triple-lumen thermodilution catheter was 
advanced into a pulmonary artery through a 
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12/0 
51± 2,2 
(range 42-68) 
8 
4 
6 
2 
54± 3.5 
74± 6.7 
femoral vein for the measurement of right atrial 
and pulmonary artery pressures and the determi-
nation of cardiac output. Again, care was taken 
that the catheter tip was stable without baseline 
drift on the thermodilution signal. Finally, a no 8 
Fr Sentron pigtail microtip manometer catheter 
was positioned in the left ventricle through a no 9 
Fr arterial Desilet introducer system in the right 
femoral artery. The side arm of this system was 
used to record the arterial pressure curve. 
The position of the catheters was recorded on 
video disc and regularly checked throughout the 
study. 
Hemodynamic and electrocardiographic 
measurements. 
After instrumentation, all fluid -filled catheters 
were calibrated, using Bentley transducers with a 
zero reference level, set at midchest. Next, the 
micromanometer pressure was balanced to zero 
and superimposed on the conventional left ven-
tricular pressure curve. After calibration pro-
cedures, all pressures, the first derivative of left 
ventricular pressure, cardiac output, coronary flow 
and 3 ECG leads (I, II and V s) were recorded on 
paper at different speeds, e.g. 25, 50 and 100 
mm/sec, using a CGR 1000 cath lab system. 
All hemodynamic parameters, including mean and 
phasic systemic arterial, pulmonary arterial and 
right atrial pressures, left ventricular (LV) pressure 
derived contractility and relaxation indices (LV 
peak dP/dt positive and negative, dP/dt/P at 40 
mmHg and V rna)(), cardiac output and coronary 
flow, were all oetermined on-line by a Mennen 
cath lab computer system. In calculating, the sys-
tem averages 15-20 consecutive beats to level out 
respiratory variations. In contrast, isovolumetric 
relaxation parameters, Tau, Tau1 and TaUz, were determined off-line. Coronary sinus blood flow 
was measured during a continuous 30-second 
infusion of 30 m1 glucose 5% at room temperature. 
Although both pulsatile and mean flow curves 
were recorded, calculations were made from the 
latter, according to the formula: coronary blood 
flow (ml/min) =vi X [(Tb-Ti)(Tb-Tcs)-1] X 1.08, 
where Tb is blood temperature before injection, Ti 
temperature of injectate, Tcs temperature of mix-
ture of coronary sinus blood and injectate and Vi 
the rate of injection (ml/min). 
Coronary flow was determined while the patient 
held his breath at mid-expiration for the last 15 
seconds of each recording. As the system displays 
consecutive 1-second measurements, it allows for 
proper estimation of the stability of coronary flow 
recordings. 
At the end of the study, the arterial pressure curve 
was compared with a simultaneous recording by 
the electrical catheter from the aortic root to com-
pensate for differences between proximal and dis-
tal systemic arterial pressures. Heart rate and ST-
segment changes were determined from 100 
mm/sec ECG recordings. The ST-segment was 
measured in 3 consecutive beats, at 80 msec after 
the J point, using a magnifying calibrated glass. 
Calculations. 
From the measured variables, the following para-
meters were derived. Coronary vascular resistance 
(mmHg/ml/min) was calculated as the difference 
between mean arterial pressure (mmHg) and left 
ventricular mean diastolic pressure (mmHg) divid-
ed by coronary sinus blood flow (ml/min). 
Systemic vascular resistance (dynes.sec.cm-5) was 
derived as [mean arterial pressure (mmHg) - mean 
right arterial pressure (mmHg) I cardiac output 
(1/min)] x 80. Stroke work index (g.m.m2) was 
calculated as stroke index (ml/beatfm2) x [mean 
arterial pressure (mmHg) - left ventricular end 
diastolic pressure (mmHg)] x 0.0136. Myocardial 
oxygen extraction (m102/ml) was calculated as 
arterial oxygen content (m102/ml) - coronary 
venous oxygen content (mlOzlml), and myocardial 
oxygen consumption (ml/mm) as the product of 
myocardial oxygen extraction (ml02/m1) and 
coronary blood flow (ml/min). Percentage myo-
cardia! lactate extraction was calculated as 100 x 
[arterial lactate content (mmol/1) - coronary 
venous lactate content (mmol/1)] I arterial lactate 
content (mmol/1). Myocardial lactate uptake 
(mmol/min) was determined by multiplying the 
difference in arterial and coronary venous lactate 
content (mmol/ml) with coronary blood flow 
(ml/min). 
Myocardial catecholamine and angiotensin II 
uptake (nmol/min and pmol/min, resp.) were cal-
culated by multiplying the respective differences in 
arterial and coronary venous catecholamine 
(nmol/ml) or angiotensin II (pmol/ ml) levels with 
the instantaneous coronary sinus blood flow 
(ml/min). 
Metabolic and neurohumoral determinations: 
Approximately 0.5 m1 of blood was collected 
simultaneously from the coronary sinus and left 
ventricle for the determination of 0 2 saturation on 
an OSM-80 oxymeter (Waters Associates). For 
lactate, exactly 1 cc of blood was collected simul-
taneously from the left ventricle and the coronary 
sinus, quickly transferred into tubes, containing 2 
cc of icecold 0.6 mol HC104, thoroughly mixed 
and kept on ice. After the study, the samples were 
weighed and centrifuged for 20 minutes at a speed 
of 2,000 xg. and the supernatant frozen for 
subsequent lactate assay. This was carried out in 
triplicate. The assay technique and standard 
deviation of the technique have been described(l9). 
For the determination of catecholamines and 
angiotensin II, 6 ml of blood was collected simul-
taneously from the left ventricle and coronary 
sinus in icecold syringes. Of these, 3 m1 was 
quickly transferred into precooled tubes, con-
taining 500 I/U heparin and 3 mg/ml gluthation for 
the catecholamine assay and the remaining 3 m1 
into pre-cooled tubes, containing 4 mg EDTA and 
0.06 mg 0-fenantroline for the assessment of 
angiotensin II. These samples were then immedia-
tely centrifuged under cooled conditions at 3,000 
rev/min for 10 minutes and stored at -20°C. 
Angiotensin II was determined by radioimmuno-
assay, as previously reported(20). Norepinephrine, 
epinephrine and dopamine were assessed by radio-
enzymatic assay, using high-pressure liquid chro-
matography, to separate the radio-active 
products<2f). 
For the determination of ACE, 3 m1 of blood was 
sampled from the left ventricle. ACE activity was 
determined by colorimetric assay(22). 
Scoring of anginal pain. 
Before the start of the study, the patients were 
asked to indicate the moment, when they 
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Fig. 1: Schematic representation of the study protocol. Identical incremental atrial pacing stress tests 
were carried out 45 minutes before (APST I) and 15 minutes after (APST II) enalaprilat (E) administra-
tion. Hemodynamic, metabolic and neurohumoral measurements were carried out at control (C) before 
pacing, during maximal pacing rates (MAX) and at 1 and 2 minutes post-pacing (P-P). In addition, all 
variables were determined before (CE) and 5, 15 and 40 minutes after E. 
experienced the beginning of anginal complaints. 
Moreover, during each pacing test they were asked 
to score the level of angina, according to a modi-
fied Borg scale. Also, patients were prompted to 
indicate the time of disappearance of angina after 
pacing. 
Study protocol (Fig. 1). 
Multiple control measurements of all hemo-
dynamic, metabolic and neurohumoral variables 
were carried out at approximately the same time in 
the morning, at least 40-50 minutes after coronary 
angiography and 20-30 minutes following instru-
mentation. Subsequently, the first, untreated atrial 
pacing stress test (APST I) was performed with 
increments in heart rate of 10 beats/2 minutes until 
a maximal pacing rate of 170 beats/minute, atrio-
ventricular block or significant anginal pain. The 
latter was defined as the level of pain, at which the 
patient typically would rest or take nitroglycerin. 
Hemodynamic, electrocardiographic and metabo-
lic parameters were assessed at fixed intervals 
during pacing, e.g. halfway the 100, 120 and 140 
beats/minute period, followed by repeat measure-
ments of all variables at maximal pacing rates, just 
before cessation of pacing. All variables were 
reassessed at 1 and 2 minutes after pacing. In 
addition, lactate sampling was carried out at 15 
seconds post-pacing and determination of left ven-
tricular end diastolic pressure at 10 seconds after 
pacing. In contrast, due to the complexity of the 
study at this point in time, cardiac output measure-
ments could only be carried out following the 2-
minute post-pacing sampling period in a limited 
number of patients. For similar reasons, coronary 
flow was only determined at 5 minutes after 
pacing and, in a limited number of patients, also at 
2 minutes post-pacing. Following the first pacing 
test, a 30-minute stabilization period was allowed 
before control determinations of all variables were 
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carried out. 
Next, enalaprilat was administered. Subsequently, 
all variables were redetermined at 5 and 15 
minutes following drug administration. 
This was followed by a second atrial pacing stress 
test (APST II), identical in design to the first 
pacing test, with all measurements performed at 
exactly the same intervals as during and after 
APST I. In addition, arterial blood was collected 
from the left ventricle for ACE assay before drug 
administration, at 5 and 15 minutes after enala-
prilat and at maximal pacing rates during APST II. 
Statistical analysis. 
The data analysis considered two parts of this 
study. First, measurements made following drug 
administration but before APST II and at 5 minutes 
after APST II were compared with baseline meas-
urements before enalaprilat administration. In this 
evaluation a t-test for paired observations was 
used with a 2-tailed p value <0.05 considered 
significant. Secondly, changes in the respective 
variables during pacing were compared between 
both tests using the same type of analysis. Values 
are given as averages ± 1 standard error of the 
mean. 
RESULTS 
Neurohumoral and hemodynamic effects of enala-
prilat before and after pacing. Control period: 
Neurohumoral levels were comparable at baseline 
before onset of APST I and at control before 
enalaprilat administration, 30 minutes after APST 
I (Table II). Likewise, hemodynamic and metabo-
lic variables were comparable between these 
periods (Table III). None of the patients had 
clinical signs of ischemia before drug administra-
tion or before any of the pacing tests. 
Table ll: Neurohumoral effects of enalaprilat before and after pacing. 
Minutes after enalaprilat administration 
C-APSTI CE 5min 15min 40min 
ACE(U/1) 
A 9.9 ±0.6 0.9 ±0.2* 0.9 ±0.2* 1.1 ±0.3* 
Angiotensin n {pmol!l) 
A 6.47±0.86 6.30±1.05 3.39±0.38* 3.39±0.39* 3.44±0.69* 
cs 6.27±1.10 5.48±0.72 3.42±0.43* 3.12±0.30 3.32±0.48* 
Norepinephrine (nmol/1) 
A 1.78±0.28 2.01±0.28 2.40±0.31 2.37±0.35 2.35±0.52 
cs 2.30±0.40 2.57±0.47 2.76±0.48 2.93±0.57 2.82±0.73 
Epinephrine (nmol/1) 
A 0.62±0.09 0.66±0.09 0.72±0.10 0.75±0.08 0.68±0.13 
cs 0.37±0.05 0.40±0.06 0.41±0.05 0.43±0.05 0.48±0.09 
Dopamine (nmol/1) 
A 0.35±0.08 0.40±0.06 0.42±0.09 0.40±0.07 0.39±0.12 
cs 0.51±0.07 0.53±0.08 0.53±0.08 0.51±0.08 0.57±0.14 
Abbreviations: A = arterial; C-APST I = control atrial pacing stress test I; CE = control before 
enalaprilat; CS = coronary sinus; min = minutes. :X ± SEM; * p<. 05 vs CE. 
Neurohumoral effects of enalaprilat before and 
after pacing (Table ll). 
ACE activity in arterial blood samples decreased 
quickly after enalaprilat administration from 
9.9±0.6 U/1 at control to 0.9±0.2 U/1, at 5 minutes 
post-drug. Thereafter, ACE-activity remained 
depressed at approximately the same level (Fig. 2). 
Simultaneously, arterial and coronary venous 
angiotensin n levels decreased by 46% and 38%, 
respectively (Fig. 2) without further changes 
during the remaining study period. Enalaprilat did 
not alter circulating catecholamine levels. 
Hemodynamic and metabolic effects of 
enalaprilat before and after pacing (Table ill). 
Enalaprilat did not affect myocardial lactate 
metabolism, myocardial oxygen extraction nor 
consumption before or after pacing. Also, the 
double product, an index of myocardial oxygen 
demand remained unchanged, despite a moderate, 
but significant 10% reduction in left ventricular 
systolic pressure, 40 minutes after drug 
administration (Fig. 3). A similar, although earlier 
decrease was observed in mean arterial pressure. 
Heart rate, contractility and relaxation parameters 
and left ventricular filling pressure remained 
unaltered. Also, enalaprilat did not affect cardiac 
output or systemic vascular resistance. Likewise, 
coronary flow and resistance did not change 
significantly, although the latter decreased by 16% 
at 15 minutes after drug administration (Fig. 3). 
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Fig. 2: Effect of enalaprilat (E) on arterial ACE 
activity and arterial and coronary venous 
angiotensin II levels. Already 5 minutes after E. 
ACE activity had decreased by 90%, accompanied 
by 46% and 38% reductions in arterial (open 
symbols) and coronary venous (closed symbols) 
angiotensin II levels, resp. Values are x ± SEM. 
CE = control before E; ' = minutes. 
Hemodynamic effects of enalaprilat during 
pacing (Table IV). 
By design, maximal pacing heart rates were 
similar during both pacing tests, 157±3.8 and 
157±4.06 beats/minute, APST I and IT, resp. As 
left ventricular systolic pressure did not change 
during pacing before or after enalaprilat, changes 
in the double product were likewise comparable. 
Moreover, pacing-induced alterations in contrac-
tility were identical during the first and second 
pace-test. 
In contrast, Tau1 shortened by 21% during APST II 
compared to an 11% reduction during APST I 
(p<0.05). Enalaprilat did not affect coronary 
hemodynamics during pacing, although 
myocardial oxygen consumption was 18% less 
during APST IT (ns). 
Finally, whereas mean aortic pressure significantly 
increased during APST I, this did not occur during 
pacing after enalaprilat (APST I vs IT p<0.05, 
Fig. 4). 
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Neurohumoral effects of enalaprilat during 
pacing (Table V). 
During APST I, arterial norepinephrine levels 
nearly doubled, increasing from 1. 78±0.28 mmol/1 
to 3.44±0.61 mmol/1, 1 minute post-pacing 
(p<0.05). Likewise, arterial epinephrine values 
increased significantly by 42% at maximal pacing 
rates. Moreover, arterial angiotensin II levels rose 
from 6.47±0.86 pmolll (control) to 9.0±1.65 
pmolll at 1 minute post-pacing (p<0.05). 
Dopamine levels did not change. Coronary venous 
values of all neurohormones remained unaltered. 
During APST II, after enalaprilat, the systemic 
neurohumoral activation, observed during the first 
pacing test, was abolished. Arterial values of nor-
epinephrine, epinephrine and angiotensin II did not 
increase anymore during APST IT (Fig. 5). As a 
result there was a significant difference between 
maximal neurohumoral activation during both 
pacing tests. Moreover, whereas during APST I, 
net cardiac norepinephrine release changed to 
uptake (Fig. 6), this was prevented by enalaprilat 
during the second test. 
LVSP 160j mmHg 
140 ~ 120 
MAP 110j mmHg 100 
90 * * * 
CBF 140~ ml/min 2  
100 
80 
mmHg/ml/min 
1.0 
CVR 1.5~ 
~~--T-~*--P~<_.o_s~v-s._c __ ~ 
c 1' 3' 5' 10' 15' 40' 
Fig. 3: Hemodynamic effects of enalaprilat (E) 
before and after pacing. E only resulted in a 
relatively late and moderate I 0% reduction in left 
ventricular systolic pressure (LVSP) and mean 
arterial pressure (MAP). Coronary flow (CSBF) 
was not affected, although coronary resistance 
(CVR) decreased by 16% (NI). Values are x ± 
SEM. CE = control before E; ' = minutes. 
Table ill: Hemodynamic and metabolic effects of enalaprilat before and after pacing. 
Minutes after enalaprilat administration 
C-APSTI CE 5min 15min 40min 
HR (beats/min) 78±4.0 81±3.6 80±4.5 82±3.98 82±4.2 
LVSP(mmHg) 147±8 143±7.7 138±8.5 136±6.8 127±5.4* 
L VEDP (mmHg) 12±1.0 10±1.2 11±1.5 10±1.19 11±1.35 
MAP(mmHg) 108±5.2 111±6.45 107±5.8 101±5.6* 98±3.2* 
PAM (mqillg) 16±0.9 15±1.0 14±1.04 13±0.78 15±1.1 
LV dP/dt pos (mmHg.s-1) 1798±106 1725±99 1735±111 1697±107 1568±97 
Vmax (sec-1) 51.2±3.1 49.7±3.3 52.6±3.9 51±3.8 47±3.2 
LV dP/dt neg (mmHg sec-1) 1890±111 1884±120 1764±122 1762±124 1608±78* 
Tau1 (msec) 44.6±1.7 45.7±1.5 46.7±2.6 46.7±1.39 48.8±2.27 
CO (l/min) 6.74±0.5 6.15±0.4 5.89±0.37 5.87±0.27 5.73±0.57 
SVR (dynes sec.cm-5) 1184±85 1345±100 1343±72 1285±72 1474±54 
CSBF (ml/min) 104±13 99±13 106±13 99±10 96±10 
CVR 1.23±0.19 1.29±0.15 1.13±0.12 1.08±0.10 1.18±0.59 
MV02 (ml/min) 12.2±1.53 11.3±4.2 11.6±1.54 11.1±1.41 10.5±1.05 
LE(%) 25±3.8 23±3.15 23±4.1 22±4.0 17±4.1 
Abbreviations: C-APST I = control atrial pacing stress test I; CE = control before enalaprilat; CO = 
cardiac output; CSBF =coronary sinus flow; CVR =coronary vascular resistance; HR =heart rate; LE 
= lactate extraction; LVEDP = left ventricular end diastolic pressure; LVSP = left ventricular systolic 
pressure; MAP = mean arterial pressure; min = minute; MV02 = myocardial oxygen consumpticm; PAM 
=pulmonary artery mean pressure; SVR = systemic vascular resistance. 
:X± SEM. * p<.OS vs CE. 
Likewise, the enhanced cardiac epinephrine 
uptake, observed during APST I, was not present 
during APST II. 
Antiischemic effects of enalaprilat. 
Enalaprilat significantly reduced myocardial 
ischemia. This was most prominently demonstrat-
ed by the marked decrease in myocardial lactate 
production during and immediately after pacing 
(Fig. 7). At maximal pacing rates, lactate extrac-
tion improved from -35±20% (APST I) to -1±9% 
(APST II) and from -60±19% to -22±17% (APST 
II) at 15 seconds post-pacing, both p<0.05. More-
over, during APST II there was significantly less 
ST-segment depression than during APST I, 
MAP 
mmHg 120 
110 
100 
* 
C MAX C MAX 
APST I APST II 
* p <.05 MAX vs. C 
t p <.05 APST I vs. II 
Fig. 4: Effect of pacing before and after enala-
prilat (E) on arterial pressures. Whereas mean 
arterial pressure (MAP) increased significantly 
during the first pacing test (APST I) at maximal 
pacing rates (MAX), this was prevented byE dur-
ing the second test (APST II). C = control. 
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Table IV: Hemodynamic effects of enalaprilat during pacing. 
Control Max lminP-P 2minP-P 
LVSP(mmHg) 
APSTI 147±8 144±7 154±9 155±9 
APSTII 136±7 134±8 140±7 134±6t 
DP(mmHg) 
APSTI 11.3±0.8 22.6±1.4* 12.3±1.2 12.3±0.9 
APSTII 11.1±0.7 21.2±1.4* 11.8±0.7 11.1±0.8 
LV dP/dt pos (mmHgsec-1) 
APSTI 1798±107 2339±196* 1930±134 1956±112 
APSTII 1697±107 2159±156* 1750±94 1734±110 
V max (sec-1) 
APSTI 51.2±3.1 60±3.2* 50±3.4 52±3.1 
APSTII 51±3.8 61±3.3* 50±3.6 50±1.9 
Tau1 (msec) 
APSTI 44±1.7 39±1.2* 51±2.31* 48±2.7 
APSTII 47±1.4 37±1.0*# 51±2.2 48±1.2 
CSBF (ml/min) 
APSTI 104±13 183±18* 105±13 
APSTII 99±10 157±17* 96±10 
CVR (mmHg/ml!min) 
APSTI 1.23±0.19 0.72±0.08* 1.33±0.26 
APSTII 1.08±0JO 0.74±0.07* 0.96±0.13 
MV02 (ml!min) 
APSTI 12.2±1.53 21.8±3.18* 10.9±1.33 
APSTII 11.3±1.4 17.9±1.79* 10.5±1.05 
Abbreviations: APST=atrial pacing stress test; CSBF=coronary blood flow; CVR=coronary vascular 
resistance; DP=double product; LVSP=left ventricular systolic pressure; Max=maximal pacing rates; 
min=minutes; P-P=post-pacing. :X± SEM * p<.05 vs control; t p<.05 APST I vs APST II; 
# p<.05 !::.APST I vs !::.APST II. 
whereas left ventricular end diastolic pressure was 
markedly reduced [25±2.6 mm.Hg (APST I) vs 
15±2.6 mm.Hg (APST II), p<0.05], 10 seconds 
after pacing (Fig. 8). 
Finally, angina, present in 11 of 12 patients during 
APST I, was absent or less in 9 patients during 
APSTIL 
Adverse effects. 
No side effects were noted with enalaprilat in the 
dosage used in this study; nor did any untoward 
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hemodynamic or metabolic change occur. Patients 
did not develop signs of ischemia following drug 
administration before pacing. 
DISCUSSION 
Although ACE inhibition supposedly may be use-
ful as antiischemic therapy based on several 
theoretical considerations which relate 
predominantly to its hemodynamic profile, its 
efficacy in this respect has not been convincingly 
demonstrated. Previous human studies have 
concentrated on exercise-induced ischemia and/or 
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Fig. 5 (left): Arterial neurohumoral changes 
during pacing before and after enalaprilat (APST 
I and II, resp.). During APST I norepinephrine 
levels increase significantly at maximal pacing 
rates (MAX) and at I minute post-pacing (J'P-P) 
and epinephrine levels at MAX. In contrast, 
during APST II changes in catecholamines are 
prevented by enalaprilat. Also, arterial 
angiotensin II, already reduced at baseline of 
APST II, increases significantly less during 
pacing after enalaprilat. Values are x ± SEM . 
t p < .05 APST I vs II 
,J, p < .05 Ll C APST I vs 
I L1 C APST II 
*p<.05vsc 
0.05 
0.025 
Fig. 6 (bottom): Effects of enalaprilat on cardiac 
neurohumoral balance during pacing. During the 
first pacing test, (APST I, open symbols), 
norepinephrine release reverses to uptake and 
epinephrine uptake increases during maximal 
pacing rates (MAX), both p<.05 vs control. Also, 
angiotensin II uptake tends to increase. In 
contrast, changes in cardiac neurohormones are 
absent during the second test (APST II, closed 
symbols) after enalaprilat. Values are x ± SEM. 
CARDIAC EPINEPHRINE 
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* 
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Table V: Arterial and coronary venous neurohonnones during pacing before and after enalaprilat 
Control Max lminP-P 2minP-P 
Norepinephrine, nmol/1 
APSTI A 1.78±0.28 2.77±0.49*# 3.44±0.61 *# 2.31±0.54 
cs 2.30±0.40 2.76±0.51 2.92±0.56 2.3 ±0.56 
APSTII A 2.37±0.35 2.57±0.34 2.90±0.39 2.68±0.47 
cs 2.93±0.58 3.29±0.57 2.98±0.61 3.06±0.74 
Epinephrine, nmol/1 
APSTI A 0.62±0.09 0.88±0.12* 0.71±0.14 0.63±0.11 
cs 0.37±0.05 0.58±0.08 0.47±0.07 0.40±0.07 
APSTII A 0.75±0.08 0.76±0.09 0.77±0.09 0.79±0.11 
cs 0.43±0.05 0.56±0.06 0.48±0.05 0.53±0.07 
Dopamine, nmol/1 
APSTI A 0.35±0.08 0.39±0.08 0.35±0.10 0.35±0.09 
cs 0.51±0.07 0.48±0.07 0.44±0.09 0.36±0.08 
APSTII A 0.40±0.07 0.37±0.07 0.47±0.11 0.35±0.13 
cs 0.51±0.08 0.48±0.09 0.62±0.07 0.57±0.10 
Angiotensin II, pmol/1 
APSTI A 6.47±0.86 7.38±1.37 9.00±1.65# 6.13±0.97 
cs 6.27±1.10 6.25±1.01 6.80±1.30 4.75±0.65 
APSTII A 3.39±0.39+ 3.44±0.45+ 3.91±0.60+ 3.52±0.39t 
cs 3.13±0.30 3.30±0.45 2.85±0.30 3.6 ±0.56 
Abbreviations: A = arterial; APST = atrial pacing stress test; CS= coronary sinus; max= maximal 
pacing; min = minutes; P- P =post-pacing. i ± SEM; * p<. 05 vs control; t p<. 05 APST I vs APST II; 
# p<.05 b..APST I vs b..APST II. 
angina and have not been able to clarify the issue 
as to whether converting enzyme inhibitors have 
antiischemic properties. Besides, no data are avail-
able concerning the effect of ACE inhibition on 
ischemia at rest. Neither is there any information, 
which indicates, that changes in coronary and sys-
temic hemodynamics and, hence, in the myocar-
dial oxygen supply/demand ratio as a result of 
ACE inhibition, are involved in its potential anti-
ischemic properties in man. In addition, it has not 
yet been investigated, whether ACE inhibitors 
may modulate ischemia-induced neurohumoral 
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activation, proposed as an alternative mechanism 
to limit myocardial ischemia. Consequently, the 
pharmacological basis for its potential antiischemic 
activity is still rather speculative. 
The present study is the first to address these items 
in the average type patients with ischemic heart 
disease, e.g. normotensive patients with stable, 
exercise-inducable ischemia and a normal left 
ventricular function. It demonstrates that the non-
sulfhydryl-containing ACE inhibitor enalaprilat 
has the potential to reduce (pacing-induced) myo-
cardial ischemia at rest and that these effects do not 
40 
20 
0 
-20 
-40 
-60 
-80 
MYOCARDIAL LACTATE EXTRACTION(%) 
* 
* 
C MAX 15" p-p 
APST I 
t P <.05 APST I vs. II 
* p <.05 MAX vs. C 
C MAX 15" p-p 
APST II 
Fig. 7: Antiischemic properties of enalaprilat as 
demonstrated by its effect on myocardial lactate 
metabolism. During pacing after enalaprilat 
(APST II) myocardial lactate production is 
significantly less than during the first test (APST 
!), both during maximal heart rates (MAX) and at 
15 seconds post-pacing (P-P). Values are x ± 
SEM. C = control. 
relate to overall coronary or systemic cardiovas-
cular actions of the drug. In contrast, the study 
strongly suggests that the antiischemic properties 
of enalaprilat relate to inhibition of ischemia-
induced systemic and transcardiac neurohumoral 
activation and subsequent reduction of systemic 
vasoconstriction. 
Rationale for the potential antiischemic 
activity of ACE inhibitors. 
Converting enzyme inhibition bas the potential to 
reduce myocardial oxygen demand and to improve 
coronary flow(1,3,5,2:5,24). Through balanced type 
vasodilating properties, it may diminish pre- and 
afterload. Together with the intrinsic negative 
inotropic activity and the potential coronary vasa-
dilating properties of ACE inhibition, this may 
beneficially affect the myocardial oxygen 
supply/demand ratio. Whether these cardiovas-
cular actions are the result of inhibition of local 
cardiac<25) and/or vascular<26) ACE activity, or of 
a modulation of circulating ACE, is still unclear. 
Other mechanisms, through which converting 
enzyme inhibitors may affect myocardial ischemia, 
include modulation of local bradykinin degrada-
tion<?) and improved synthesis of prostaglan-
dins(6). Moreover, converting enzyme inhibitors, 
which contain sulfhydryl groups, may induce 
vasodilatation through an effect on endothelium-
derived relaxing factor (EDRF). Also, recent data 
suggest that the latter may act as free radical 
scavengers(27 ,28). An additional and potentially 
important mechanism, through which ACE 
inhibition may affect myocardial ischemia, relates 
to the significant changes in systemic and transcar-
diac catecholamines and components of the renin-
angiotensin system, observed during the acute 
phase of myocardial iscbemia(2,3). Theoretically, 
by modulating this neurohumoral stimulation and 
the ensuing systemic and, possibly, coronary 
vasoconstriction, converting enzyme inhibitors 
may result in antiischemic effects. 
Fig. 8: Antiischemic properties of enalaprilat are 
indicated by the significant reduction in ST-
segment depression during the second test (APST 
II) after enalaprilat, compared with the first, 
untreated test (APST /). 
Moreover, left ventricular filling pressure 
(LVEDP) does not increase anymore at 10 
seconds (") post-pacing (P-P) in APST //, in 
contrast to a marked elevation following APST I. 
Values are x ± SEM. C = control. 
ST-SEGMENT 
DEPRESSION 
mV 
LVEDP 
mmHg 
0.3 
0.2 
0.1 
25 
* 
t. 
C MAX C MAX 
APST I APST II 
* 
t 
c 10" c 10" 
p-p p-p 
* p <.05 MAX vs. C 
t p <.05 APST I vs. II 
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Ischemia-induced neurohumoral activation and 
antiischemic properties of ACE inhibition. 
In the present study, myocardial ischemia induced 
significant changes in several circulating neuro-
hormones, e.g. in norepinephrine and epinephrine, 
whereas arterial angiotensin II levels rose by 39%. 
Concomitantly, arterial pressures increased. A 
similar activation of systemic catecholamines and 
of the circulating renin-angiotensin system has 
been previously reported by us(2,29). In an identi-
cal model and similar type patients it was shown, 
that pacing per se had no such effects in non-
ischemic patients. Also,these studies provided 
strong evidence that neurohumoral stimulation was 
not necessarily due to the stress of anginal pain. 
More likely, activation of the circulating catechol-
amines and, in particular, of the circulating renin-
angiotensin system, is directly related to the 
severity of ischemia(30,31). In addition, as in the 
present study, it was shown, that short periods of 
ischemia do not result in enhanced norepinephrine 
release from the heart but in temporarily increased 
net uptake, presumably in the ischemic area. Also, 
cardiac epinephrine uptake increases during ische-
mia. In contrast, no significant changes are found 
in the cardiac angiotensin II balance in normo-
tensive patients, although there is a tendency 
towards increased uptake(3). 
The clinical relevance of the observed changes in 
systemic neurohormones may relate to the con-
comitant increase in systemic vascular resist-
ance(29). In the present study the latter was reflect-
ed by a significant increase in arterial pressures 
during the ischemic event in the first, untreated 
pacing test. Unfortunately, the few data available 
on cardiac output after pacing in this study do not 
allow interpretation of changes in systemic resist-
ance. However, in a similar model as used in the 
present investigation, we have recently demon-
strated that both elevated arterial norepinephrine 
and angiotensin II levels and the increase in 
systemic vascular resistance may persist until at 
least 5 minutes after pacing, depending on the 
severity of ischemia(31). It stands to reason to 
assume, that the resultant increase in afterload will 
aggravate ischemia already present. As such, 
modulation of ischemia- induced neurohumoral 
activation and, hence, of systemic vasoconstric-
tion by specific neurohumoral antagonists may 
represent a novel, additional form of antiischemic 
therapy. In this respect, both alpha -1 and alpha-2 
adrenergic blocking drugs may prove useful. In 
fact, several calcium-antagonists have been 
demonstrated to reduce myocardial ischemia in a 
similar patient model as in the present study(32-35). 
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Besides alpha adrenergic blockade, converting 
enzyme inhibition may provide for an alternative 
approach to antiischemic therapy. Apart from their 
direct effect on circulating and local tissue angio-
tensin II formation, ACE inhibitors may also affect 
ischemia-induced catecholamine stimulation. The 
renin-angiotensin system(s) interacts with both 
central and peripheral sympathetic adrenergic 
activity. Thus, angiotensin II, besides stimulating 
adrenal catecholamine release, may promote 
central norepinephrine activity, facilitate norepi-
nephrine release from adrenergic nerve endings, 
limit the neuronal re-uptake of this catecholamine 
and stimulate norepinephrine synthesis in adren-
ergic nerve terminals. Converting enzyme 
inhibition, therefore, could limit myocardial 
ischemia not only through inhibition of angio-
tensin II stimulation but also by modulating sym-
pathetic activity during ischemia. 
In the present study, enalaprilat, during the second 
pacing test, prevented the increase in arterial 
catecholamine and angiotensin II levels observed 
during the first test before drug administration. 
Simultaneously, it prevented the significant 
increase in arterial pressures, also observed during 
the first stress test. Whether this implicates a 
decrease in wall stress during pacing with enal-
aprilat is impossible to say in the absence of 
information on ventricular volumes. However, the 
reduction in systemic vascular resistance, likely to 
have occurred during pacing with enalaprilat, sug-
gests that its antiischemic activity in this model 
may relate to such an effect on left ventricular wall 
stress. Whether this is the only mechanism 
involved in its antiischemic effect is uncertain. 
Of interest is that, whereas during the untreated 
pacing stress test net cardiac norepinephrine 
release changed to net uptake, this was prevented 
by enalaprilat. Also, the enhanced uptake of 
epinephrine during pacing without enalaprilat was 
absent during the second test after medication. 
Besides mechanisms, such as presynaptic inhibi-
tion of exocytotic norepinephrine release or en-
hanced neuronal re-uptake during ischemia, bind-
ing to cardiac and/or vascular adrenergic receptors 
may be considered to explain the change in cardiac 
norepinephrine balance during ischemia(31). Sev-
eral studies suggest an important role for alpha 
adrenergic coronary vasoconstriction in the post-
stenotic area during ischemia<4,36-38). Under 
experimental conditions of progressive coronary 
flow reduction, intracoronary norepinephrine ad-
ministration or cardiac sympathetic nerve stimula-
tion reverses (metaboli~ coronary vasodilatation 
to vasoconstriction(4,36, 9)_ The change from net 
norepinephrine release to uptake in the present 
study (Table VI) may reflect coronary vascular 
alpha adrenergic receptor occupation. In a previous 
study we have indicated, that enhanced net cardiac 
norepinephrine uptake during myocardial ischemia 
may be specific for the ischemic area(31). Also, in 
a similar model, post-stenotic coronary flow 
changes have been observed in humans, preceding 
metabolic and electrocardiographic indices of 
ischemiaC19). Although direct evidence is lacking, 
we speculate that post-stenotic alpha-adrenergic 
coronary vasoconstriction may also be a feature of 
pacing-induced ischemia. 
Whereas enalaprilat prevented the change from net 
cardiac norepinephrine release to uptake during 
pacing, it did not improve overall coronary flow. 
This does not necessarily implicate that the drug 
failed to restore coronary flow reserve in the post-
stenotic region. Simultaneous reduction of myo-
cardial oxygen demand, for instance by decreasing 
systemic vascular resistance, will result in less 
coronary flow increase in non-ischemic areas. 
Consequently, an improvement of post-stenotic 
flow may not become apparent with the thermo-
dilution method. Thus, apart from its effects on 
myocardial oxygen demand, enalaprilat' s anti-
ischemic properties may result from a modulatory 
effect on cardiac norepinephrine kinetics and sub-
sequent alpha adrenergically-induced coronary 
vasoconstriction in the post-stenotic region. 
Possible alternative mechanisms underlying the 
antiischemic effects of enalaprilat. 
In this study, emphasis has been on the modulatory 
effect of enalaprilat on ischemia-induced neuro-
humoral activation and concomitant vasoconstric-
tion. 
Antiischemic properties resulting from a reduction 
of myocardial oxygen demand by mechanisms 
other than an effect of the drug on afterload, as 
suggested above, are unlikely. Enalaprilat did not 
affect contractility or relaxation in our study. 
Although Foult et al. (1) reported a reduction in 
pressure-derived velocity parameters following 
intracoronary administration of enalaprilat in 
patients with dilated cardiomyopathy, no such 
changes were observed in our patients. Neither did 
isovolumic relaxation parameters change in our 
study. The decrease in the peak negative value of 
LV dP/dt at the end of the study followed the 
moderate reduction in left ventricular systolic 
pressure and is presumably secondary to this. 
An improvement of left ventricular distensibility 
has been proposed as one mechanism, through 
which ACE inhibitors may affect cardiac remodel-
ling. Preliminary data suggest improvement fol-
lowing intravenous ACE inhibition in patients 
with ventricular dysfunction (40). Whether these 
effects of converting enzyme inhibition pertain in 
Table VI: Cardiac neurohumoral balance during pacing before and after enalaprilat. 
Control Max 2 min P-P (n=5) 
Norepinephrine (nmol/min) 
APSTI -0.074±0.041 0.011±0.043* -0.061±0.037 
APSTII -0.092±0.048 -0.123±0.055t -0.054±0.077 
Epinephrine (nmol/min) 
APSTI 0.026±0.08 0.049±0.014* 0.023±0.010 
APSTII 0.029±0.07 0.028±0.010 0.046±0.026 
Dopamine (nmol/min) 
APSTI 0.031±0.039 -0.017±0.019 -0.008±0.007 
APSTII 
-0.009±0.007 -0.015±0.010 -0.030±0.021 
Angiotensin ll (pmol/min) 
APSTI -0.020±0.039 0.322±0.187 -0.019±0.084 
APSTII 0.038±0.022 -0.002±0.068 0.003±0.029 
Abbreviations: ~PST_= atrial pacing stress test; Max= maximal pacing rates; min= minutes; 
P-P = post-pacmg. x ± SEM; * p<.OS vs control; t p<.OS APST I vs APST II. n =number of patients. 
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patients with normal-sized, normally contracting 
ventricles, is not known. As in the present study 
no information is available on ventricular vol-
umes, extrapolation of our data to (absence of) 
changes in ventricular distensibility or wall stress 
is not possible. However, at the beginning of the 
pacing test, after enalaprilat, systemic vascular re-
sistance had not changed, whereas during pacing 
neither right nor left ventricular filling pressures 
differed from those during the first test. Although 
inconclusive, these data do not suggest that 
changes in preload or relaxation are important 
mechanisms in the antiischemic activity of ena-
laprilat in this model. In contrast, the significant 
reduction in left ventricular end diastolic pressure 
immediately after pacing is considered the result 
rather than the cause of decreased myocardial 
ischemia. 
Comparison to different models of ischemia. 
A number of short term studies have been carried 
out with several ACE inhibitors, including ena-
lapril, in patients with ischemic heart disease, with 
variable outcomeC5,12-18). Although antiischemic 
efficacy was claimed in most studies (5,12-16), 
several were unable to show any such effectC17,18)_ 
Apart from these conflicting results, interpretation 
of these investigations is complicated by the fact 
that several were conducted in patients who were 
either hypertensiveC5,13) or in whom the circu-
lating renin-angiotensin system was activated by 
diuretic pretreatmentC41). Moreover, apart from 
the latter study, the effect of ACE inhibition on 
neurohumoral activation as a mechanism for its 
potential antiischemic effects has not been con-
sidered in these studies. Yet, the observations in 
animal models on alpha-1 adrenergically-induced 
post-stenotic vasoconstriction during exercise and 
recent publications on exercise-induced coronary 
vasoconstriction during myocardial ischemia in 
manC42,43), suggest an antiischemic potential of 
ACE inhibitors through modulation of neuro-
humoral activation and subsequent coronary vaso-
constriction. In addition, enhanced renin-angio-
tensin stimulation, as observed in patients with 
more severe myocardial ischemia (31), may affect 
coronary reserveC41). Differential effects of con-
verting enzyme inhibitors on neurohumorally-
induced coronary vasoconstriction may explain the 
divergent effects on ischemia, observed thus far. 
Limitations of the study. 
Several limitations of the study have already been 
discussed, e.g. the absence of information on 
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regional coronary flow and ventricular volumes or 
cardiac output during pacing. Also, in this study 
no information is present on the reproducibility of 
neurohumoral stimulation during successive 
periods of pacing-induced ischemia. Preliminary 
data from a recent placebo comparison indicate, 
that both the changes in catecholamines and angio-
tensin II are reproducible when the interval 
between pacing tests is at least one hour, as in the 
present study (unpublished observations). 
Clini~l implications. 
This study provides evidence that ACE inhibitors 
may reduce myocardial ischemia, possibly through 
mechanisms which differ from those underlying 
currently available antiischemic therapy. Hence, 
ACE inhibitors may provide for an additional form 
of therapy. The question is whether this is true for 
all patients with ischemic heart disease and for all 
conditions under which ischemia presents itself. 
With respect to modulation of systemic neurohor-
mones and vasoconstriction, it is questionable 
whether this aspect of ACE inhibition is important 
during upright exercise; a situation where neuro-
hormones are already markedly elevated in the 
absence of ischemiaC44). 
Our current data indicate that the efficacy of con-
verting enzyme inhibitors may depend on acti-
vation of circulating and, possibly, of cardiac 
neurohormones. As this activation relates to the 
severity of myocardial ischemia it may well be that 
ACE inhibitors are particularly effective in supine 
patients with ischemia at rest, e.g. with unstable 
angina or during the initial phase of myocardial 
infarction. It may be anticipated that in these con-
ditions ischemia is more severe than in the present 
study and, consequently, ischemia-induced neuro-
humoral stimulation more pronounced. Our data 
therefore suggest that the clinical usefulness of 
enalaprilat should be further studied in these clini-
cal conditions. 
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SUMl\1ARY 
This thesis aims at defining the relevance and 
applicability of some metabolic aspects of acute 
myocardial ischemia to delineate occurrence and 
extent of the latter in man. Studies focus on myo-
cardial lactate metabolism and adenine nucleotide 
catabolism, correlate changes with other markers 
of ischemia and attempt to define a temporal 
relation with regional changes in coronary flow. 
Next, the acute antiischemic properties of different 
vasoactive compounds are outlined using these 
metabolites in a properly defined study model. 
Studies also attempt to differentiate the usefulness 
of various vasodilator compounds as antiischemic 
therapy in relation to the underlying cardiac 
function. 
In the second part of this thesis the impact of 
myocardial ischemia on systemic and cardiac neu-
rohormones, i.e. catecholamines and renin-angio-
tensin system(s), are discussed. 
The relation between degree of ischemia and neu-
rohumoral activation will be emphasized, potential 
subsequent systemic and coronary vasoconstrictor 
effects mentioned, and the usefulness of neurohu-
moral modulation, i.e. by converting enzyme 
inhibition in the treatment of myocardial ischemia 
indicated. 
PART 1: Myocardial metabolic changes during 
acute ischemia in man. Relation to coronary 
flow and potential for evaluating pharmaco-
logical interventions. 
Chapter/ 
Chapter I of this thesis serves as an introduction to 
the first theme of this thesis, i.e. the acute metabo-
lic alterations which occur during the early phase 
of myocardial ischemia. It addresses the normal 
regulation of cardiac metabolism, followed by a 
discussion of the derangements herein during 
ischemia. Particularly those aspects of cardiac 
metabolism which may be relevant for the detec-
tion of ischemia in man, are emphasized. 
The heart is a fast metabolizing organ, relying on a 
continuous supply of oxygen and substrates, such 
as free fatty acids, glucose or lactate, to provide 
for its energy production. After processing, these 
substrates to acetyl- Co A molecules, oxydation 
takes place in the citric acid cycle and energy in the 
form of ATP is formed during substrate -and 
respiratory chain -linked oxydative phosphoryla-
tion. 
Oxygen supply is central to this and oxydative 
phosphorylation will immediately slow down or 
halt when oxygen is not available anymore. 
Although the role of substrate supply soon 
becomes crucial, the presence of endogenous 
substrates, such as glycogen, will provide for fuel, 
at least for several minutes following the onset of 
ischemia. 
Lack of oxygen and substrates is one aspect of 
ischemia. Another is the accumulation of inter-
mediates which cannot be further processed, e.g. 
fatty acid amphiphiles of long-chain acyl CoA and 
acyl-carnitine, which may affect structure and 
function of various subcellular components, such 
as the sarcolemma, and of enzyme systems, 
leading to a derangement in contractile function, 
ionic changes and cell swelling. Besides a poten-
tially protective effect by specific fatty acid 
binding proteins, carnitine is also essential in 
reducing long-chain acylcarnitines and acyl CoA 
levels during ischemia. It limits their effect on 
various enzyme systems, such as pyruvate dehy-
drogenase or adenine nucleotide translocase, 
essential for ATP transfer out of the mitochon-
drion. 
During ischemia, cellular pH falls progressively, 
partly due to accumulation of reduced coenzymes, 
partly resulting from the activation of anaerobic 
glycolysis. Enhanced glycolytic flux and glyco-
genolysis occur early during the ischemic process 
and provide for 2 mol A TP per mol glucose. 
Although insufficient energy for cardiac contrac-
tion, this additional A TP supply may suffice for 
basic cellular functions. The endproduct of glyco-
lysis, pyruvate, cannot be further processed in the 
citric acid cycle and is transformed to lactate. 
Consequently, myocardial lactate production 
rather than the normal extraction pattern is 
encountered during the early phase of ischemia and 
serves as a specific marker of the latter process. It 
is also a sensitive indicator of relatively short 
periods of ischemia, as amply indicated in this 
thesis. During prolonged periods of ischemia its 
effectiveness becomes progressively less due to 
inhibition of glycolysis at the glyceraldehyde-3-
P-dehydrogenase and phosphofructokinase level. 
Besides lactate, adenine nucleoside release from 
the heart makes for another metabolic diagnostic 
tool in the diagnosis of ischemia. Consequently to 
the inability to resynthesize high-energy phos-
phates during ischemia, AMP and inorganic phos-
phate accumulate, followed by dephosphorylation 
of AMP to adenosine. This nucleoside modulates a 
variety of physiologic effects in different tissues, 
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including negative inotropic, dromotropic and 
chronotropic actions besides its well-known vasa-
dilating effect. From a diagnostic point of view, it 
is important that this nucleoside is able to pass the 
cell membrane after which it is quickly deamin-
ated to inosine and further to hypoxanthine. 
Nucleosides have proved to be significant indica-
tors of ischemia in animal models and in man, as 
outlined in this thesis. As a byproduct, inorganic 
phosphate release from the heart could be used to 
assess ischemia. Other potential markers, to be 
commented upon in later chapters, include blood 
gases, potassium and glucose. 
Finally, in chapter I attention is paid to the role of 
citrate and certain amino acids, such as alanine, 
aspartate and glutamate, in the control of glyco-
lysis by way of the malate-aspartate cycle. More-
over, they may reduce intracellular acidosis during 
ischemia and remove excess ammonia. Also, a 
change in the uptake-release pattern of citrate and 
of the amino acids may reflect the presence of 
ischemia. 
Chapter II 
The second introductory chapter concerns vascular 
control and regulation of coronary flow. 
Coronary resistance and flow continuously adjust 
to the instantaneous metabolic demand of the myo-
cardium. This autoregulatory process occurs at the 
microvascular level on a beat to beat basis and is 
governed by local metabolic factors, i. e. adeno-
sine, p02, pC02 and pH. In addition, coronary 
flow is under the influence of myogenic mecha-
nisms and of endothelium-dependent control. The 
endothelium produces several potent vasodilator-
and vasoconstrictor substances. Besides the endo-
thelium-derived relaxing factor(EDRF) or nitrous 
oxide, the endothelium-derived hyperpolarizing 
factor and prostanoids, such as prostacyclin or the 
the prostaglandins Fza and -Ez, the endothelium 
also forms endothelins, a family of peptides with 
long lasting, strong vasoconstrictor properties. 
EDRF is produced in the intact endothelium by a 
number of exogenous substances, including ace-
tylcholine, catecholamines, adenine nucleotides, 
thrombin and bradykinin through stimulation of 
specific endothelial receptors. Moreover, coronary 
flow per se may stimulate EDRF production. 
Apart from these endothelium-dependent proces-
ses, vasodilatation may be induced by direct 
stimulation of vascular smooth muscle cell guany-
late and adenylate cyclase systems, similar to the 
mechanism of action of EDRF. The vascular 
smooth muscle cell ultimately controls its own 
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contractile state and, hence, vasotone. In chapter II 
intracellular regulators and signal transduction 
through smooth muscle cell receptor modulation or 
by direct intracellular effects are discussed. 
Emphasis is on adrenergic vascular control in view 
of our observations of neurohumoral activation 
during ischemia. Several animal studies suggest an 
important role for a -adrenergic vasoconstriction 
during ischemia, presumably linked to a 2 - adre-
nergic stimulation. During coronary flow reduc-
tion, intracoronary norepinephrine or cardiac sym-
pathetic stimulation reverses metabolic dilatation 
to vasoconstriction. Superimposed on a significant 
coronary lesion even a small decrease in arterial 
lumen caused by such vasoconstrictory effects may 
lead to a severe reduction in coronary flow. In this 
respect, the abnormal vasodilator response in athe-
rosclerotic arterial segments, but also in hyper-
cholesterolemia without obvious sclerosis, is 
important. Ample evidence exists that stimuli 
which would otherwise induce vasodilatation, may 
actually lead to constriction under these circum-
stances. 
Also, impaired vasodilating prostaglandin synthe-
sis in atherosclerotic arteries leaves the effect of 
platelet-produced vasoconstnctmg prostanoids 
unopposed. In addition to mechanical factors, such 
as the Bernouilly effect on stenosis resistance, an 
abnormal regulation of vasomotor tone by mecha-
nisms such as outlined above, may significantly 
contribute to the syndrome of coronary insuf-
ficiency, initially detennined by the degree of 
coronary artery stenosis. Due to the variability of 
dynamic changes in vasomotor tone superimposed 
on a fixed arteriosclerotic lesion, different degrees 
of ischemia may be found in one individual in 
situations where myocardial oxygen demand is 
identical. Alternatively, a similar reduction in 
coronary perfusion may occur in the same indivi-
dual, but resulting from entirely different stimuli. 
An abnormal coronary vasomotor tone may indeed 
be present in the post-stenotic area during exercise 
or pacing-induced stress. Data on coronary flow 
distribution during pacing-induced ischemia in 
this thesis suggest that this abnormal vasomotor 
tone persists after evidence for ischemia has sub-
sided. Moreover, neurohumoral activation during 
ischemia indicates that adrenergic mechanisms 
may indeed be involved. 
Chapter III 
How useful are metabolic markers as indicators of 
ischemia and are they applicable in man? Chapter 
III concerns these questions. Specific changes in 
myocardial metabolism may be detected using 
various radionuclide methods or by way of mag-
netic resonance spectroscopy. Consequently, a 
number of non-invasive techniques have been 
developed to monitor these changes during ische-
mia with obvious advantages over invasive 
methods. However, a number of important limita-
tions of technical and economic nature (still) 
restrict their applicability. Most importantly, fast, 
sequential determinations of metabolic changes, a 
prerequisite for monitoring myocardial metabo-
lism during the early phase of ischemia, is 
generally not possible with these methods. The 
latter is less of a problem with available invasive 
techniques. Basically, these can be categorized in 
methods, which use catheter tip electrodes, tracer 
methods or techniques which rely on the bio-
chemical evaluation of metabolites in the coronary 
venous effluent. Catheter tip techniques allow for 
rapid and sensitive determination of specific meta-
bolic alterations. Its main limitation is that only 
one substrate is measured. In contrast, biochemical 
evaluation of metabolites, as used throughout this 
thesis, allows for a multitude of metabolites and 
other humoral substances to be measured simul-
taneously with coronary flow. Determinations can 
be fast, sequential and should allow for reproduc-
ible metabolic assessments, provided a number of 
technical requirements are adhered to. 
These are discussed at length in this chapter. In 
this context, the sensitivity and specificity of 
several metabolites as indicators of ischemia are 
considered as well as the optimal stress test for this 
particular kind of study. With respect to the latter, 
only two apply in man, i. e intermittent coronary 
occlusion during angioplasty and the atrial pacing 
stress test. The main disadvantage of the first, 
coronary occlusion, may be that strict adherence to 
the study protocol is not always possible on ethical 
grounds. The main disadvantage of the second may 
be that this form of stress, fast atrial pacing, does 
not necessarily reflect the pathophysiological con-
ditions under which the patient experiences his 
ischemic attack. On the other hand, the pacing 
stress test offers a number of advantages, exten-
sively discussed throughout this thesis, not 
encountered by other methods. 
As this thesis concentrates on the usefulness of 
lactate and hypoxanthine as markers of ischemia in 
man, available data from the literature are discus-
sed. In fact, it would appear that myocardiallacta-
te production, a certain tell- tale of ischemia and 
appreciated as such in animal studies, has a rela-
tively low sensitivity in man, in average ranging 
between 50 and 60%. In this chapter the possible 
reasons behind these rather disappointing figures 
are given and suggestions how to improve the 
assessment of lactate metabolism provided. These 
suggestions are tested in chapter V. Furthermore, 
the latter considers whether additional metabolites 
may improve the detection of ischemia besides 
lactate. Although it has been suggested that the 
amino acids alanine and glutamate may be more 
sensitive as means to assess ischemia, changes are 
relatively moderate compared with lactate. Like-
wise, it has been suggested that citrate release 
during ischemia may add to the detection of the 
latter, in conjunction with lactate. However, its 
specificity is uncertain and, at present, insufficient 
data are available to clarify the real significance of 
citrate as marker of ischemia. 
In contrast, cardiac nucleoside release from the 
heart provides for an alternative and potentially 
sensitive means to detect ischemia and one which 
is specific. In man, hypoxanthine is the nucleoside 
of choice. In fact, adenosine and inosine are hardly 
measurable in humans. Studies which have 
claimed the latter usually have raised questions 
concerning sampling techniques. Our experience 
with hypoxanthine release from the heart is 
discussed in chapters IV and VI. 
Finally, chapter III discusses available data on the 
reproducibility of metabolic markers, specifically 
of lactate, during successive periods of ischemia, 
or rather the lack of data in this respect. 
Despite widespread use of this metabolite to test 
the effectiveness of pharmacological interventions 
in ischemia, little is known of its reproducibility. 
Moreover, available data are conflicting with res-
pect to the recovery period between ischemic 
periods needed to provide for reproducible meta-
bolic changes. Furthermore, concerning the repro-
ducibility of other metabolites, no data are avail-
able in man. 
Chapter IV 
In this chapter our early experience with respect to 
adenine nucleoside kinetics in ischemia are discus-
sed. These investigations started off in an open-
chested, anesthetized pig model, in which the left 
anterior descending flow was reduced by 75% for a 
period of one hour. The porcine heart has several 
advantages compared with that of other species. 
One is that it is better comparable to the human 
situation, e. g. because of the absence of func-
tioning collaterals. In the coronary venous effluent 
directly draining the ischemic area, an early release 
of lactate and of the nucleosides inosine and hypo-
xanthine was found. Maximum changes in all 
metabolites occurred within the first 10 minutes of 
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ischemia, lactate preceding inosine only during the 
initial 2 minutes of occlusion. More importantly, 
coronary venous levels of both metabolites 
gradually declined towards the end of the ischemic 
period. In contrast, the rise in coronary venous 
hypoxanthine 1evels remained relatively constant, 
although maximal changes in the pig were 
markedly less than inosine. In contrast to the pro-
nounced lactate production and nucleoside release 
in this model, changes in other metabolites, such 
as potassium or inorganic phosphate, were moder-
ate. In view of the correlations between lactate 
and the nucleosides on the one hand and between 
each of these parameters and hemodynamic 
changes during ischemia on the other, it was con-
cluded that nucleosides, in particular inosine, were 
good markers of ischemia. This was further evalu-
ated in humans during incremental atrial pacing. 
Patients were divided in 2 groups depending on the 
occurrence of anginal pain, as was usual in those 
days. In a comparable protocol as described in 
more detail in chapter V, it was found that patients 
with angina who had all significant (>50%) coro-
nary disease, did produce significant amounts of 
hypoxanthine from the heart. Patients without 
angina, most of whom had no coronary disease, 
did not. Inosine was not detectable in either group. 
Of interest, average coronary hypoxanthine levels 
were still significantly elevated at 5 minutes after 
pacing. However, when a difference of >0. 4 
umol/1 was taken to indicate abnormal changes in 
hypoxanthine levels only 60% of patients with 
significant coronary lesion had ischemia-induced 
nucleoside release, compared to 80% with lactate 
production. Also, in this study, lactate production 
occurred at an earlier stage than hypoxanthine 
release. Although the latter did reflect what was 
observed in our animal studies, the observed 
difference in sensitivity between lactate and hypo-
xanthine might also relate to the nucleoside assay 
technique used at that time. 
Apart from the fact that in this study ischemia-
induced hypoxanthine release was shown for the 
first time in man, this investigation also provided 
clear evidence that other metabolites than lactate 
and nucleosides were not useful to identify ische-
mia in humans. Thus, no appreciable changes in 
coronary venous inorganic phosphate, glucose or 
blood gases were found, whereas potassium egress 
from the heart during pacing was very small and 
not specific. 
Chapter V 
Contrary to our first results presented in chapter 
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IV, most human investigations do not support the 
assumption that myocardial lactate production is a 
very useful indicator of ischemia. Percentages of 
patients with lactate production during pacing-
induced stress on average vary between 50 and 
60%. This lack of sensitivity not be true but reflect 
an under-estimation of its value particularly as the 
metabolite invariably was assessed at the wrong 
time during the procedure. Moreover, conclusions 
were generally based on small patient populations, 
in which angina wrongfully was taken to represent 
ischemia, and in which the location of coronary 
artery disease was not always taken into account. 
In a large prospective trial, described in chapter V, 
we compared patients with left-sided coronary 
artery disease with patients without or with mini-
mal coronary lesions, studying lactate metabolism 
not only during, but also in the post-pacing 
period. In so doing, it was found that in patients 
with significant coronary artery disease maximal 
changes were found between 15 and 30 seconds 
after pacing and not during maximal pacing rates. 
Furthermore, the number of patients with lactate 
production in the post-pacing period only, was 
significant. The procedure now identified myocar-
dial lactate production as a sensitive and specific 
marker of ischemia with the difference between 
lactate and non -lactate producers determined by 
maximal obtained heart rate and myocardial 
oxygen demand during pacing. As such it scored 
appreciably higher than other objective indicators 
of ischemia, such as electrocardiographic or 
hemodynamic changes. Moreover, lactate was 
more specific. In patients without significant coro-
nary lesions, myocardial lactate production was 
low, in contrast to changes in other objective 
variables as well as in angina, which proved to be 
rather unspecific. 
Chapter VI 
To be able to assess the effectiveness of interven-
tions in ischemia through changes in myocardial 
metabolism one must first address the issue of their 
reproducibility following repetitive periods of 
myocardial ischemia. In man this aspect has been 
given little attention. However, that it is an impor-
tant issue is clearly shown in chapter VI. 1, where 
the effect of two relatively severe ischemic epi-
sodes of 30 minutes each, separated by a recovery 
period of 35 minutes, on different metabolites in 
the pig heart is presented. The main finding here is 
that changes in both lactate and the nucleoside 
inosine are not reproducible and that ongoing ino-
sine production throughout the recovery period 
suggests persistent ischemia, 35 minutes after 
onset of reperfusion. The latter may serve to 
explain why lactate production is not similar 
during the second compared to the first ischemic 
period. It is not quite clear why, in the absence of 
data on myocardial nucleotide content, inosine is 
not reproducible. 
Although the study design does not allow a direct 
comparison with the pacing protocol used in 
patients, the results of this investigation certainly 
caution against the uncontrolled use of lactate or 
nucleosides in the assessment of repetitive episodes 
of ischemia. This aspect was further studied with 
respect to myocardial lactate metabolism in man. 
The reproducibility of lactate production, com-
pared with electrocardiographic and hemodynamic 
variables, was evaluated during repetitive atrial 
pacing stress tests with intervals varying from 15 
to 60 minutes. Following the shorter intervals, i. 
e. 15 and 30 minutes, lactate production was sig-
nificantly less during the second ischemic episode. 
In contrast, comparable values were found after 45 
or 60 minutes. Also, individual values were repro-
ducible, a few exceptions aside. Again, as with 
sensitivity or specificity, the reproducibility of 
lactate appeared better than that of other variables, 
such as the gold standard, ST segment depression. 
Also, angina was not at all reproducible, generally 
being significantly less during the second test. Our 
results led us to propose that pacing-induced 
ischemia should be allowed to recover for at least 
45 to 60 minutes before a second test is carried 
out. 
Chapter VII 
Our previous studies suggested that metabolic 
changes occurred early during pacing-induced 
ischemia in man. However, they did not provide 
for data on the temporal relation with changes in 
coronary flow. The latter necessitates a technique 
which allows for continuous monitoring of coro-
nary flow distribution over relatively long periods. 
Available methods generally are not suitable. 
Thus, a new technique was developed whereby 
myocardial flow changes were determined by 
precordial monitoring ofkrypton-81m distribution 
in the myocardium. 
To this purpose, this short-lived isotope (half-life 
13 seconds) was continuously infused in the left 
coronary artery and mapping performed in regions 
of interest during IS-second acquisition periods. 
Early reductions in coronary flow occurred in 
high-stenosis (>90%) areas preceding changes in 
70-90% regions by several minutes. Of 
importance, they also preceded lactate and hypo-
xanthine release from the heart by a similar period. 
Changes in krypton-81m distribution persisted 
after pacing. Long after angina, electro-
cardiographic, hemodynamic or metabolic (lactate) 
signs of ischemia bad disappeared, indicative of 
ongoing flow reduction up to 15 minutes after 
pacing. As cardiac hypoxanthine release, measured 
by a more sensitive assay technique than in our 
earlier investigations, did also persist for periods 
over and above 5 minutes post-pacing, this not 
only suggests sustained flow reductions, but also 
persistent ischemia. Moreover, the improved 
analysis of hypoxanthine in this study allowed us 
to show that nucleoside changes were as early as 
lactate production and that the sensitivity of this 
marker was as good as lactate in identifying 
ischemia. 
Furthermore, the studies with krypton-8lm 
provided evidence that a coronary artery diameter 
narrowing of 50 -70% not necessarily has to be 
significant in terms of flow reductions during 
pacing-induced stress. 
Chapters VI II and IX 
The issue as to whether metabolic markers, i.e. 
lactate, are really applicable and useful in assessing 
the acute antiischemic properties of different phar-
macological interventions in man, is addressed in 
chapters VIII and IX. 
To this purpose a number of vasoactive com-
pounds were tested in the model of repetitive atrial 
pacing stress tests, such as described previous 
chapters. Based on our experiences with respect to 
the reproducibility of metabolic, electrocardio-
graphic and hemodynamic indices, a minimum 
interval of one hour was chosen between tests (see 
chapter VI). Studies included investigations with 
amiodarone, bepridil and diltiazem. Although 
their pharmacological profiles are not identical, 
these agents share coronary and systemic vasodila-
ting properties besides intrinsic negative inotropic 
and chronotropic effects. However, which of these 
cardiovascular properties prevail depends on fac-
tors, such as dose as well as route and speed of 
administration. In general, high dose administra-
tion increases the systemic and, particularly, coro-
nary hemodynamic effects. Subsequently, second-
ary reflex mechanisms tend to counteract the nega-
tive chronotropic and inotropic properties of the 
compound. 
Part of our efforts was directed at defining dosage 
schemes, which would result in optimal cardio-
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vascular conditions for the type patient under 
study, i.e. the patient with acute myocardial ische-
mia at rest, e.g. with unstable angina or the initial 
phases of myocardial infarction. Here, marked 
bradycardia or reduced contractility is unwanted. 
Instead, vasodilating effects of the agent in ques-
tion should be such that cardiac pump function is 
preserved or may even improve together with an 
improvement of coronary blood flow. 
Thus, in each instance high-dose infusions were 
given with the result that for all compounds tested 
cardiac output and coronary flow increased, 
whereas negative chronotropic and inotropic 
effects were (temporarily) suppressed. In this 
respect, our observations in patients with signifi-
cantly impaired cardiac function are interesting. 
As shown in chapter IX, such patients actually 
improve better than patients with a normal cardiac 
function with regards to cardiac - and stroke 
output. More interesting, the acute antiischemic 
effects of the agents tested were definitely more 
pronounced in patients with an impaired ventri-
cular function at baseline. These observations are 
clinically relevant. Patients, hospitalized with 
severe ischemia at rest or an acute myocardial 
infarction generally have a significantly depressed 
cardiac function. Our studies indicate that rela-
tively high dosages of diltiazem, a calcium-anta-
gonist, or of bepridil, a calcium-antagonist with 
additional blocking effects of sarcolemmal sodium 
channels and calmodulin-inhibitory properties, 
should be administered instead of the low dosages, 
commonly considered "safe". In this respect, our 
data on the effect of amiodarone are relevant to the 
clinical situation where severe ventricular arrhyth-
mias tend to occur in situations where a markedly 
impaired cardiac function coincides with myocar-
dial ischemia. 
The antiischemic properties of diltiazem, bepridil 
and amiodarone were delineated by a significant 
reduction in lactate production during the second 
pacing test. Although in most studies ischemic 
electrocardiographic and hemodynamic changes 
were also less during pacing with these 
compounds, the determination of lactate metabo-
lism proved to be necessary to identify antiische-
mic efficacy in all events. Also, the magnitude of 
changes was generally greater for lactate than for 
ST-changes, which, in addition, indicates the use-
fulness of this marker of ischemia in this type of 
investigations. In our study model where the 
second stress test was started 15 minutes after the 
onset of drug administration, the antiischemic 
effects of all compounds tested appeared to relate 
to their sustained systemic vasodilating properties 
and the resulting reduction in myocardial oxygen 
-368-
demand. An improvement in coronary flow was 
not apparent anymore at that time. It may be 
argued that the significant antiischemic effects of 
these agents may be more pronounced when these 
drugs are administered when myocardial ischemia 
is already present. 
Although the possibity of a "steal-effect" in this 
condition ought to be considered, the potential of 
these agents to interfere with local coronary vaso-
constriction in the ischemic area, brought about by 
ischemia-induced neurohumoral changes, may be 
an important argument for the acute intravenous 
administration of these compounds in the dosages 
mentioned in this thesis. That such (additional ?) 
vasodilating effects, based on modulating neuro-
humorally-induced vasoconstriction, may occur, 
is suggested by the observation that both bepridil 
and diltiazem prevented the increase in systemic 
resistance and in arterial pressures during pacing-
induced ischemia. 
The neurohumoral aspects of acute myocardial 
ischemia and the possible relation to ischemia-
induced vasoconstriction is discussed in part 2 of 
this thesis. 
PART2 
Systemic and cardiac neurohumoral activation 
during acute myocardial ischemia in man. 
Rationale for converting enzyme inhibition in 
ischemia. 
Chapter X 
Myocardial ischemia results in a complex chain of 
events, only partially reflected by the metabolic 
changes discussed in this thesis. In this respect, 
free radical formation and the effect of ischemia on 
leucocytes, leukotrienes, platelets and pro§tanoids 
may be mentioned. In addition, the possibility that 
local or circulating neurohormones or related 
systems become activated during myocardial 
ischemia may be worthwhile to consider; particu-
larly, as such a stimulation could affect systemic or 
coronary vascular tone and, hence, the ischemic 
process. 
Neurohumoral activation is well known in condi-
tions such as the advanced stages of heart failure or 
myocardial infarction, particularly when accom-
panied by acute pump failure. Not only are cir-
culating catecholamines elevated in these situa-
tions, circulating arginine vasopressine and renin-
angiotensin levels as well as cardiac sympathetic 
tone may also become increased. Moreover, recent 
data suggest that several of these systems are 
alieady activated in patients with left ventricular 
dysfunction, however without the presence of 
heart failure symptoms. Whether, in humans, 
myocardial ischemia also results in neurohumoral 
activation is less well established. Several argu-
ments could be put forward for such an activation, 
i.e. the stress of anginal pain or acute, ischemia-
induced ventricular dysfunction. 
However, in contrast to markedly enhanced 
cardiac sympathetic activity during prolonged, 
severe ischemia in animal models, data on cir-
culating or cardiac catecholamine changes during 
short lasting ischemia in man are inconclusive. 
Futhermore, no information is available on altera-
tions in different systems, such as the renin-angio-
tensin system(s). That ischemia may affect the 
latter is indicated by several animal studies. 
Part 2 of this thesis relates to our studies on the 
effect of short periods of relatively moderate 
ischemia, such as results from pacing-induced 
stress, on several neurohumoral systems. These 
investigations focused on circulating and trans-
cardiac catecholamine and angiotensin II levels.As 
conditions as hypertension or heart failure may 
affect the results, patients were carefully selected 
to be normotensive, without heart failure symp-
toms and not on therapy or diet which could 
influence baseline neurohormones. 
Our studies clearly indicate that during and for 
several minutes after pacing-induced ischemia 
arterial norepinephrine and angiotensin II levels 
become significantly elevated. In addition, epi-
nephrine levels also increase, but only during the 
stress test. Moreover, net cardiac norepinephrine 
release, present at baseline, reverts to net uptake in 
the ischemic area during pacing, accompanied by 
increased cardiac epinephrine uptake. Our studies 
further suggest that the magnitude of neuro-
humoral activation depends on the severity of 
myocardial ischemia. In contrast, angina is not as 
clearly related to ischemia-induced neurohumoral 
stimulation. 
Concomitantly with the changes in neurohor-
mones, systemic vascular resistance and arterial 
pressures also increase significantly. Again, 
changes correlate with the severity of ischemia. 
Although no causal relationship with ischemia-
induced neurohumoral activation could be esta-
blished as specific antagonists were not admi-
nistered in these studies, their association is 
suggested by this correlation as well as by the 
temporal relationship. If so, neurohumoral activa-
tion during ischemia could very well be clinically 
relevant. An increase in ventricular wall stress 
secondary to the rise in arterial pressures undoubt-
edly will amplify the severity of ischemia already 
present. 
In addition, enhanced catecholamine uptake by the 
heart may result in adrenergically-induced 
coronary vasoconstriction. Although our data did 
not suggest that overall coronary flow decreased 
during ischemia, regional coronary vasoconstric-
tion in the post-stenotic area may still have occur-
red. That adrenergic modulation of coronary 
vascular resistance may occur during pacing-
induced ischemia is suggested by the observation 
that a high, but not a low dose of labetalol limits 
pacing-induced decrease in resistance, as descri-
bed in chapter III. Consequently, the high dose 
with the percentwise greater betablocking profile 
has less antiischemic efficacy than the low dose of 
labetalol despite a more pronounced reduction in 
myocardial oxygen demand with the high dose. 
This example illustrates that modulation of 
adrenergic alterations in coronary tone during 
ischemia may have therapeutic implications. In the 
next and last chapter of this thesis the potential 
clinical usefulness of specific neurohumoral 
modulators during ischemia is discussed. 
Chapter XI 
The observation that arterial angiotensin II levels 
increase during ischemia together with changes in 
catecholamines led us to investigate the anti-
ischemic potential of converting enzyme 
inhibition. 
A number of theoretical considerations suggest 
that ACE inhibitors may limit myocardial ische-
mia. Through a reduction in pre- and afterload and 
negative inotropic effects and by way of coronary 
vasodilatation, these agents may favourably affect 
the oxygen supply-demand ratio. These cardio-
vascular actions not only depend on inhibition of 
local or circulating angiotensin II formation, but 
also on their effects on bradykinin degradation, 
prostaglandin synthesis and their complex interac-
tion with sympathetic adrenergic activity. Further-
more, compounds with SH-groups may affect 
EDRF production. 
Taken together these properties should allow the 
ACE inhibitor act as an antiischemic agent. 
However, thus far experiences with chronic treat-
ment of stable, exercise-induced angina have been 
conflicting and generally disappointing. Several 
studies have claimed some positive results, others 
were definitely negative. The reason is not clear. It 
has been speculated that antiischemic activity in 
this situation only occurs when hemodynamic 
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effects in the sense of blood pressure lowering is 
present as well. However, this also bas been dis-
puted in later investigations. 
One problem with interpretating the data from 
these studies is that most of them were uncontrol-
led and of relatively short duration. In addition, 
information on the antiiscbemic effectiveness of 
ACE inhibitors in humans is lacking. 
In chapter XI we describe the acute antiiscbemic 
effects of enalaprilat, a non-sulfhydryl containing 
converting enzyme inhibitor in patients with 
pacing-induced myocardial ischemia at rest. As in 
our previous studies, discussed in chapter X, this 
condition was characterized by activation of 
circulating catecbolamines and of arterial angio-
tensin II levels together with a significant increase 
in arterial pressures during the first, untreated 
pacing test. In contrast, a second test, 15 minutes 
after enalaprilat, did not result in any form of 
neurohumoral activation, while arterial pressures 
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remained unchanged. Moreover, enalaprilat sig-
nificantly reduced myocardial ischemia, indicated 
by a marked reduction in myocardial lactate 
production. These antiiscbemic effects could not 
be explained by direct systemic or coronary hemo-
dynamic properties of the agent, but appeared to 
relate to a modulating effect on neurobormones 
and on arterial pressures. Thus, it bas the potential 
to reduce afterload and myocardial oxygen 
demand. In addition, as enalaprilat prevented net 
cardiac norepinephrine uptake during ischemia, a 
modulating effent on post-stenotic coronary vas-
cular tone cannot be excluded. The results of this 
study emphasize the potential significance of 
systemic and cardiac neurohumoral activation 
during ischemia and also the potential usefulness 
of specific neurohumoral modulators such as con-
verting enzyme inhibitors and alpha-adrenergic 
antagonists as an (additional) form of antiischemic 
therapy. 
SAMENV ATTING. 
Metabole aspecten van acute myocardischemie en 
toepasbaarheid van metabole parameters om voor-
komen en ernst van dit ziektebeeld bij de mens te 
kunnen vastleggen staan centraal in bet eerste deel 
van dit proefschrift. Hiertoe werden veranderingen 
in bet Iactaatmetabolisme en adenine-nucleotide 
afbraak in bet hart bestudeerd en vergeleken met 
bet effect van ischemic op andere metabole, hemo-
dynamische en elctrocardiografische parameters 
bestudeerd. Vervolgens werd de tijdsrelatie tot re-
gionale veranderingen in coronaire bloeddoorstro-
ming bepaald. Tenslotte werd bet acute anti-ische-
mische profiel van verschillende vaatverwijdende 
agentia bestudeerd, gebaseerd op de voordien 
gedefinieerde metabole aspecten van ischemic. 
Het tweede deel van bet proefschrift bespreekt bet 
effect van myocardischemie op systemische en 
cardiale neurohumorale activatie, in bet bijzonder 
bet effect op catecholamines en bet renine-angio-
tensine systeem. De relatie tussen de mate van 
ischemic en neurohumorale activatie en de relatie 
met gelijktijdige systemische en coronaire vaso-
constrictoire effecten wordt in bet tweede gedeelte 
van bet proefschrift bediscussieerd, evenals de 
mogelijke toepasbaarheid van specifieke neurohu-
morale modulatie, bijvoorbeeld door remming van 
bet angiotensine converterend enzyme. 
DEELI. 
Hoofdstuk /. 
Hoofdstuk I vormt een algemene introductie tot bet 
eerste thema van dit proefschrift betreffende de 
acute metabole veranderingen tijdens myocard-
ischemie. Achtereenvolgens worden in dit hoofd-
stuk de normale regulatiemechanismen van de 
stofwisseling in bet hart besproken, gevolgd door 
de veranderingen hierin tijdens ischemic. De 
continue wisselwerking tussen samentrekking en 
verslapping van bet hart maakt dat een constante 
toelevering van zuurstof en voedingsstoffen zoals 
vrije vetzuren, glucose en lactaat noodzakelijk is. 
Oxidatie van deze substraten vindt plaats in de 
citroenzuurcyclus, waarbij energie in de vorm van 
ATP-moleculen gevormd wordt tijdens diverse 
oxydatieve fosforyleringsprocessen. De laatste zijn 
gevoelig voor zuurstofaanbod. Tijdens ischemic en 
bet daarmee gepaard gaande gebrek aan zuurstof en 
voedingsstoffen neemt de fosforylering zeer snel 
af. Dit heeft tot gevolg dat intermediaire stofwis-
selingsprodukten, zoals acyl CoA en acyl-carnitine 
complexen, ophopen in de hartcel. Deze kunnen 
leiden tot verandering van structuur en functie van 
diverse subcellulaire componenten, zoals de cel-
membraan, en tevens enzyme systemen negatief 
beinvloeden, resulterend in veranderende celfunc-
tie, verstoorde ionenuitwisseling en celzwelling. 
Bovendien treedt bij ischemic een daling op van de 
cellulaire pH door ophoping van gereduceerde 
coenzymen en activatie van de anaerobe glycolyse. 
Dit laatste heeft tot direct gevolg dat laktaat in 
plaats van geextraheerd te worden door bet myo-
card wordt geproduceerd en reeds in een vroege 
fase van ischemic. Bovendien treedt bij ischemic 
een progressieve daling op van de cellulaire pH 
door accumulatie van gereduceerde coenzymen ten 
gevolge van activatie van de anaerobe glycolyse. 
Zoals blijkt uit dit proefschrift functioneert deze 
laatste verandering als een zeer gevoelige indicator 
voor bet ischemische proces, althans wanneer deze 
kort van duur is. Bij Ianger durende ischemic 
wordt de glycolyse progressief geremd op 
glyceraldehyde-3-P-dehydrogenase en fosfofruc-
tokinase niveau, met als direct gevolg dat de sensi-
viteit van lactaatproduktie als maat voor bet ische-
misch proces afneemt. 
Ret onvermogen tot vorming van hoog-energe-
tische fosfaten gedurende ischemic Ieidt tot stape-
ling van AMP en inorganisch fosfaat, gevolgd 
door defosforylering van AMP tot adenosine. Deze 
nucleoside beinvloedt een aantal cardiovasculaire 
functies en heeft een sterke vaatverwijdende wer-
king. Uit diagnostisch oogpunt is bet van belang 
dat adenosine de celmembraan kan passeren, 
waarna bet snel gedeamineerd wordt tot inosine en 
vervolgens tot hypoxanthine. Deze laatste nucleo-
siden zijn belangrijke metabole indicatoren van 
myocardischemie, zoals eveneens uit dit proef-
schrift blijkt. Tevens komt hier naar voren dat bij 
de mens andere metaboliten, zoals inorganisch 
fosfaat, kalium en glucose minder belangrijk zijn 
uit oogpunt van diagnostiek dan lactaat of de 
nucleosides, inosine en hypoxanthine. Daaren-
tegen zijn er aanwijzingen dat een veranderde 
kinetiek van sommige aminozuren en van citraat 
gedurende bet ischemisch proces gebruikt kan 
worden om de aanwezigheid hiervan te diagnos-
tiseren. 
Hoofdstuk II. 
Het tweede introductiehoofdstuk betreft regule-
ringsmechanismen van vasomotoriek, met name 
die van bet coronaire vaatnet. Coronaire vaatweer-
stand en doorbloeding worden continu gereguleerd 
op basis van de metabole behoefte van bet myocard 
op dat moment. Dit autoreguleringsproces vindt 
plaats op microvasculair niveau en wordt bepaald 
door locale metabole factoren, zoals adenosine, 
p02 en pH. Hiernaast wordt de coronairflow gere-
guleerd door zowel myogene als endotheel-afhan-
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kelijke controlemechanismen. Het endotheel pro-
duceert diverse krachtige vaatverwijdende stoffen, 
zoals de endotheel-afuankelijke relaxerende factor 
(EDRF), de endotheel-afuankelijke hyperpolarise-
rende factor en prostaglandines, zoals prostacy-
cline en prostaglandine F2a en -~. Daarnaast 
produceert bet endotheel krachtige vaatver-
nauwende stoffen, de endothelinen. Het kortwer-
kende EDRF wordt aileen gevormd in bet. intacte 
endotheel onder invloed van diverse circulerende 
agentia, zoals acetylcholine, doch ook onder 
invloed van de coronaire doorbloedingssnelheid, 
waarbij wandspanningsveranderingen en activatie 
van specifieke kaliumkanaaltjes een rol kunnen 
spelen. Het geproduceerde EDRF induceert vaat-
verwijding door activatie van bet guanylaat cyclase 
systeem in de gladde spiercel. Dit systeem en bet 
verwante adenylaat cyclase kunnen zowel direct 
gestimuleerd worden of na activatie van receptoren 
op de gladde spiercel zelf. Ten aanzien hiervan 
wordt in bet proefschrift de nadruk gelegd op 
adrenergisch vasculaire controle mechanismen, 
gezien onze bevindingen dat neurohumorale aciti-
vatie optreedt gedurende ischemie. Verscheidene 
studies suggereren dat a -adrenergisch geindu-
ceerde vasoconstrictie gedurende ischemie belang-
rijk kan zijn. Reeds een geringe vermindering van 
bet arteriele lumen op basis van deze of vergelijk-
bare mechanismen, doch gesuperponeerd op een 
reeds bestaande gefixeerde atherosclerotische 
laesie, kan leiden tot ernstige coronaire doorbloe-
dingsstoornissen. Recente bevindingen dat endo-
theel-afuankelijke vaatverwijding gestoord raakt 
niet aileen in atherosclerotische segmenten, doch 
ook tijdens hypercholesterolemie in normaal 
ogende coronairvaten, kunnen in dit verband 
belangrijk zijn. Niet aileen betreft bet hier een 
gestoorde EDRF productie, doch ook een vermin-
derde prostaglandine synthese, factoren die naast 
mechanische, zoals bet Bernouiily effect op de 
stenose-weerstand, in belangrijke mate kunnen 
bijdragen tot bet syndroom van coronairinsuffi-
cientie. Diverse studies, inclusief eigen bevindin-
gen vermeld in Hoofdstuk VII, suggereren dat 
abnormale vasomotoriek inderdaad aanwezig is in 
bet ischemische gebied gedurende inspanning of 
atriaal pacen en dat deze persisteert nadat ischemie 
niet meer aantoonbaar is. 
Hoofdstuk III. 
In hoofdstuk III wordt de praktische toepassing 
van bet gebruik van metabole indicatoren ter bepa-
ling van ischemie belicht. Veranderingen in hart-
stofwisseling kunnen ontdekt worden op een non-
invasieve wijze met gebruikmaking van diverse 
radio-isotopen of door middel van magnetische 
resonantie spectroscopie. Hoewel deze technieken 
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duidelijke voordelen hebben ten opzichte van 
invasieve methodieken, wordt de toepasbaarheid 
hiervan beperkt door diverse factoren van tech-
nische aard. Bovendien zijn snelle metabole veran-
deringen, belangrijk gedurende de vroege fase van 
ischemie, over bet algemeen niet vast te leggen 
met deze methoden. Dit laatste kan wei door 
middel van invasieve technieken, zoals daar zijn 
directe biochemische bepalingen van stofwisse-
lingsproducten in arterieel en coronair veneus 
bloed of metingen met behulp van specifieke elec-
troden in de bloedbaan. De laatste methode biedt 
de mogelijkheid tot snelle sequentiele metingen, 
doch is beperkt tot slechts een variabele. In tegen-
stelling tot bet voorafgaande biedt de directe bio-
chemische bepaling van metabolieten in bet bloed, 
een techniek die in dit proefschrift centraal staat, 
de mogelijkheid om diverse stofwisselingsproduc-
ten gelijktijdig met coronairflow-veranderingen te 
kunnen bepalen. In hoofdstuk III wordt de gevoe-
ligheid en specificiteit van verschiilende metaboli-
ten als indicatoren van ischemie besproken en aan-
dacht besteed aan de optimale stress test in dit 
kader. Ten aanzien van dit laatste zijn twee metho-
des bruikbaar; die, waarbij tijdens angioplasty 
intermitterende coronairafsluiting wordt toegepast 
en de atriale pacing stress test. Bij de eerste 
methode kan strikt navolgen van een studieproto-
col op ethische bezwaren stuiten. Een belangrijk 
nadeel van de tweede methode, de atrial pacing 
stress test, kan zijn dat deze niet altijd de condities 
nabootst die aanleiding geven tot ischemische aan-
vailen bij de patienten in bet dagelijks Ieven. Hier-
tegenover staat dat de atriale pacing stress test een 
aantal belangrijke voordelen biedt, met name 
wanneer bet metingen van hartstofwisseling en 
coronairdoorbloeding betreft. Dit proefschrift stelt 
bet nut van lactaat en hypoxanthine als indicatoren 
van ischemie bij de mens centraal. Hoofdstuk III 
bediscussieert de in de literatuur aanwezige gege-
vens ten aanzien hiervan. Het is opmerkelijk en 
tegelijkertijd teleurstellend dat in bet algemeen de 
gevoeligheid van lactaatproductie om myocard-
ischemie te diagnosticeren laag is, met een inci-
dentie varierend tussen 50% en 60% gedurende 
pacing. Deze matige sensitiviteit betreft waar-
schijnlijk een onderbelichting van de werkelijke 
rol van deze metaboliet ten gevolge van voor-
namelijk technische onvolkomenheden in de tot nu 
toe gepubliceerde patientenstudies. Hoe de gevoe-
ligheid van deze metabole maat voor ischemie te 
verbeteren, wordt aangegeven in de verdere 
hoofdstukken van dit proefschrift. Andere meta-
bolieten, zoals sommige aminozuren en citraat, 
blijken niet gevoeliger te zijn dan lactaat. De enige 
uitzondering hierop vormt mogelijk de nucleoside 
hypoxanthine. Daarentegen zijn adenosine en ino-
sine bij de mens niet of nauwelijks aantoonbaar. 
Indien metabole veranderingen gebruikt worden 
om de effectiviteit van farmacologische interven-
ties te testen, is bet een eerste noodzaak dat deze 
stofwisselingsstoornissen reproduceerbaar zijn 
tijdens intermitterende perioden van myocard-
ischemie. Ondanks bet veelvuldig gebruik van met 
name lactaat in dit verband, zijn er in de literatuur 
nauwelijks of geen gegevens ten aanzien hiervan. 
Ditzelfde geldt ook voor andere metabolieten. Dit 
aspect, de reproduceerbaarheid van cardiale stof-
wisselingsstoornissen tijdens ischemie, wordt aan 
de hand van onze bevindingen ten aanzien van 
nucleosiden- en lactaatveranderingen in hoofdstuk 
VI verder besproken. 
Hoofdstuk IV. 
Uit historische overwegingen worden in dit proef-
schrift eerst onze studies betreffende adenine 
nucleoside veranderingen tijdens ischemie bespro-
ken. De onderzoekingen hiemaar begonnen in een 
ischemisch varkensmodel, waarin de doorbloeding 
van de Ramus descendens anterior gereduceerd 
werd met 75% gedurende een uur. In dit model 
werd reeds in een vroege fase bet vrijkomen van 
lactaat en van de nucleosiden inosine en hypoxan-
thine uit ischemisch gebied gemeten. Maximale 
veranderingen vonden plaats gedurende de eerste 
10 minuten, waarbij lactaatproductie iets eerder 
optrad dan inosineverlies. Na de initiele 10 
minuten namen de spiegels van deze metabolieten 
in bet coronair-veneuze effluent geleidelijk af en 
benaderden de controle-situatie tegen bet einde 
van bet onderzoek. Daarentegen bleven de coro-
nair-veneuze hypoxanthine spiegels relatief 
constant verhoogd. Veranderingen in andere 
metabolieten, zoals kalium en inorganisch fosfaat, 
waren duidelijk minder uitgesproken dan die van 
lactaat, inosine en hypoxanthine. Vervolgens werd 
bet effect van myocardischemie op nucleoside-
verlies uit ischemisch gebied onderzocht bij 
patienten gedurende een atriale pacing stress test. 
In deze studie werden patienten onderverdeeld 
afhankelijk van bet optreden van angina pectoris 
gedurende de test. Hierbij bleek dat bij angineuze 
patienten een significante verhoging optrad van 
hypoxanthine in bet coronair-veneuze bloed, 
evenals van lactaat, doch niet van inosine, kalium, 
inorganisch fosfaat en glucose. Ook veranderingen 
in p02, pC02 en pH konden niet aangetoond 
worden in het coronair-veneuze effluent bij deze 
angineuze patienten. Hoewel bij de totale angi-
neuze groep de coronair-veneuze hypoxanthine 
spiegels significant stegen en verhoogd bleven tot 
minstens 5 minuten na pacing, bleek toch dat 
slechts bij 60% van de patienten significante veran-
deringen plaatsvonden, in tegenstelling tot een 
lactaatproduktie van 80% in deze studie. Dit 
laatste, een relatief hoge incidentie van lactaatpro-
duktie in deze studie, contrasteert met de getallen 
die in de meeste patientenstudies gerapporteerd 
worden en die, zoals vermeld, varieren tussen de 
50 en 60%. Deze getallen berusten echter op vrij 
kleine patientengroepen. Van meer belang is dat 
deze waamemingen gebaseerd zijn op metingen 
die aileen verricht werden tijdens de laatste test, in 
aile gevailen een atriale pacing stress test. 
H oofdstuk V. 
Hierin wordt een onderzoek beschreven bij ruim 
450 patienten, bij wie gedurende dezelfde testme-
tingen lactaatmetingen niet aileen werden verricht 
tijdens, doch met name in de directe periode na 
pacing. Uit deze studie blijkt heel duidelijk dat 
metingen verricht 15 tot 30 seconden na de atriale 
pacing stress test, de incidentie van geobjecti-
veerde lactaatproduktie significant doet toenemen 
van 60 tot 78%. Dit heeft tot gevolg dat lactaatpro-
duktie een gevoeliger parameter blijkt dan 
standaard-variabelen zoals ST-segment depressies 
en stijgingen in linker ventrikel einddiastolische 
druk. Daamaast blijkt lactaatproduktie sterk speci-
fiek. In patienten zonder of met slechts geringe 
coronairafwijkingen werd dit slechts 9-10% 
gevonden in tegensteiling tot aanzienlijk hogere 
percentages patienten in deze groepen met abnor-
male electrocardiografische of hemodynamische 
veranderingen tijdens de atriale pacing stress test. 
Hoofdstuk VI. 
Reproduceerbaarheid van metabole veranderingen 
tijdens ischemie is een eerste vereiste indien deze 
gebruikt worden ter identificatie van de effectivi-
teit van interventies. Dit komt heel duidelijk naar 
voren uit hoofdstuk VI, waarin bet effect van twee 
relatief emstige perioden van ischemie, 30 
minuten lang, gesepareerd door een herstelperiode 
van 35 minuten, op de diverse metaboliten in bet 
varkenshart wordt besproken. Hieruit blijkt duide-
lijk dat gedurende de tweede periode de mate van 
lactaat- en adenosineproduktie beduidend minder 
is dan gedurende de eerste. Bovendien blijkt uit bet 
onderzoek dat inosine-produktie persisteert 
gedurende de herstelperiode als uiting van blijven-
de ischemie, ondanks herstel van de coronairdoor-
bloeding. Dit laatste kan verklaren waarom de 
lactaatproductie minder is gedurende de tweede 
ischemische periode. Persisterende ischemie kan 
leiden tot een progressieve inhibitie van de anaero-
be glycolyse. Deze biggenstudie geeft in ieder 
geval duidelijk aan dat bet ongecontroleerd 
gebruik van metabolieten zoals lactaat of nucleosi-
den bij de beoordeling van herhaalde ischemische 
perioden gevaren met zich mee kan brengen. Dit 
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aspect werd vervolgens bestudeerd bij patienten 
met ischemisch hartlijden waarbij de reproduceer-
baarheid van lactaatproduktie, vergeleken met 
electrocardiografische en hemodynamische varia-
belen, werd geevalueerd tijdens herhaalde atriale 
pacing stress tests met wisselende intervallen, 
varierend van 15 tot 60 minuten. Deze studie geeft 
duidelijk aan dat angina en hemodymische para-
meters niet reproduceerbaar zijn onatbankelijk van 
de perioden tussen de belastingtests en dat een 
individuele reproduceerbaarheid van electrocardi-
ografische veranderingen pas gevonden wordt na 
een uur. Daarentegen blijkt de lactaatproduktie 
goed reproduceerbaar vanaf 45 minuten, doch 
significant minder tijdens de tweede belastingtest, 
met kortere intervallen van 15 en 30 minuten. 
Gebaseerd op deze bevindingen wordt voorgesteld 
het effect van interventies te toetsen met een inter-
val van ten minste 45 minuten tussen pacing tests 
indien lactaatproduktie als variabele wordt 
gebruikt. 
H oofdstuk VI I. 
Hoewel ooze vroegere studies reeds suggereerden 
dat metabole veranderingen vroeg optreden tijdens 
pacing-geinduceerde ischemie, waren er aanvan-
kelijk geen gegevens ten aanzien van de tijdsrelatie 
met coronaire doorbloedingsstoornissen. Dit laat-
ste aspect werd onderzocht door middel van een 
continue intracoronaire toediening van krypton-
81m, een isotoop met een zeer korte halfwaarde 
tijd, dat de mogelijkheid biedt tot voortdurende 
monitoring van regionale cardiale doorbloedings-
veranderingen. Bij deze techniek worden zeer 
vroege verminderingen in reperfusie gedetecteerd 
in gebieden met hooggradige coronairlaesies, eni-
ge minuten nadien gevolgd door veranderingen in 
gebieden met matig emstige vemauwingen, 
gelijktijdig met lactaatproduktie en hypoxanthine 
verlies. De meeste veranderingen in krypton- 81 m 
distributie waren van lange duur, persisterend tot 
minstens 5 a 15 minuten na staken van de pacing 
stress test en nadat de meeste ischemische parame-
ters waren genormaliseerd. Aileen hypoxanthine 
verlies uit het hart bleef gedurende relatief lange 
tijd na de test aanwezig, suggererend dat myocard-
ischemie persisteerde, simultaan met de eveneens 
persisterende coronaire doorbloedingsstoornissen. 
Hoo/dstuk VIII en IX. 
Zijn metabole veranderingen, zoals bijvoorbeeld 
lactaatproduktie gedurende ischemie, goede para-
meters om het effect van interventie te meten? Dit 
aspect wordt belicht in de hoofdstukken VIII en 
IX, waar het effect van verschillende vasoactieve 
stoffen op het ontstaan van pacing-geinduceerde 
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ischemie wordt besproken. In dit kader werden 
amiodarone, diltiazem en bepridil onderzocht bij 
patienten met een normale, doch ook, voor som-
mige agentia, bij patienten met een significant 
verminderde linker kamerfunctie. Ondanks het 
verschillend farmacologisch profiel resulteerden de 
drie farmaca in een duidelijk antiischemisch effect, 
zich uitend in een verminderde lactaatproduktie of 
zelfs een normalisering van het laktaatmetabo-
lisme, in een verminderde ST-segment depressie 
en een verminderde stijging van de linker 
einddiastolische druk na pacing. De antiischemi-
sche eigenschappen werden met name duidelijk bij 
patienten met een gestoorde ventrikelfunctie. 
Ondanks het feit dat vrij hoge doseringen werden 
toegediend, verbeterden met name deze patienten 
zowel wat betreft linker kamerfunctie als wat 
betreft de door pacing geinduceerde ischemie. Dit 
ondanks het feit dat de farmaca naast de vaatver-
wijdende werking tevens negatieve inotrope en 
chronotrope eigenschappen heben. Dit laatste werd 
echter overschaduwd door de sterke vaatverwij-
dende werking bij hoge doseringen van deze 
farmaca in onze studies. De drie studies zijn 
klinisch relevant in het Iicht van de vaak sterk 
verminderde linker kamerfunctie tijdens acute 
ischemie of tijdens de initiele fase van een 
myocardinfarct, situaties waar de acute toediening 
van de onderzochte farmaca belangrijk kan zijn. 
De antiischemische eigenschappen in deze drie 
studies berusten voomamelijk op een vermindering 
van de zuurstofbehoefte van het hart, teweegge-
bracht door de systemische vaatverwijdende 
werking van deze stoffen. Hoewel aanvankelijk 
een verbeterde coronairdoorbloeding optrad, was 
deze ten tijde van de atriale pacing stress test niet 
meer aanwezig. Dit kan betekenen dat de reeds 
aanwezige antiischemische eigenschappen kunnen 
worden versterkt indien deze middelen gegeven 
worden tijdens ischemische episoden. In dit 
verband kan de in dierproeven geobserveerde 
alpha-adrenerge vasoconstrictie van belang zijn. 
Farmaca zoals diltiazem en bepridil, met calcium-
antagonistische eigenschappen, interfereren 
hiermee, zoals ook wordt gesuggereerd in de 
huidige studies, waarbij de stijging in 
systeemvaatweerstand en arteriele bloeddruk, 
optredend tijdens ischemie, werd genivelleerd. 
Deze effecten ondersteunen tevens de bevindingen 
in deel II van dit proefschrift betreffende 
neurohumorale aspecten van myocardischemie en 
de mogelijke relatie tot vasoconstrictie. 
DEEL 2. 
Hoofdstuk X. 
Metabole veranderingen tijdens acute myocard-
ischemie is slechts een aspect van dit syndroom. 
Myocardischemie heeft hiemaast invloed op vrije 
radikalen vorming, op leucocyten, thrombocyten 
en daarmee verwante stoffen zoals leukotrienen en 
prostaglandines. Bovendien dient de mogelijkheid 
dat locale of circulerende neurohormonen of/en 
verwante systemen geactiveerd raken gedurende 
myocardischemie, in emstige overweging geno-
men te worden. Stimulering kan een systemisch of 
coronaire vasoconstrictoire Werking veroorzaken 
en daarmee het ischemisch proces verergeren. 
In tegenstelling tot aantoonbare neurohumorale 
activatie tijdens het gevorderde stadium van hart-
falen of gedurende een myocardinfarct, zijn er 
weinig gegevens beschikbaar ten aanzien van het 
effect van myocardischemie op de diverse neuro-
humorale systemen. Beschikbare informatie betreft 
uitsluitend circulerende en cardiale catechol-
amines. Roewel de tendens is dat activatie niet 
optreedt, zijn de meningen tot nu toe niet eenslui-
dend. Ret aspect van neurohumorale activatie 
gedurende kortdurende perioden van myocard-
ischemie bij patienten die aileen coronairlijden 
hebben zonder hypertensie of decompensatio 
cordis, heeft de laatste jaren onze bijzondere 
aandacht gehad. Met behulp van de atriale pacing 
stress test als model werd duidelijk aangetoond dat 
tijdens ischemie een significante stijging optreedt 
van arteriele norepinephrine en epinephrine spie-
gels met tegelijkertijd stimulering van het circule-
rend renine-angiotensine systeem, zich uitend in 
significante stijgingen van de arteriele angiotensine 
II -spiegels. Deze neurohumorale activatie is 
afhankelijk van de mate van ischemie en wordt niet 
duidelijk bepaald door de aanwezigheid van angina 
pectoris. Bovendien blijkt uit deze studies dat het 
normaal aanwezige netto verlies van norepi-
nephrine uit het hart verandert in netto opname 
gedurende de test in het ischemische gedeelte van 
het hart. Ret klinische belang van deze waame-
mingen lijkt gelegen in het feit dat er tegelijkertijd 
een significante toename is van de systemische 
vaatweerstand en de arteriele dmkken. Een causaal 
verband kon, bij afwezigheid van specifieke anta-
gonisten, in deze studies niet met zekerheid aange-
toond worden, doch lijkt aannemelijk in het Iicht 
van de aanwezige tijdscorrelatie; de neuro-
humorale- en vaatweerstands-veranderingen 
treden gelijktijdig op en persisteren tot 5 minuten 
na de test. Eveneens geldt voor beide een duide-
lijke relatie met de mate van ischemie. 
De toegenomen vaatweerstand beillvloedt onge-
twijfeld de wandspanning van de linker kamer en 
daarmee de zuurstofbehoefte van het myocard. Dit 
heeft tot gevolg dat de reeds aanwezige ischemie 
alleen maar versterkt wordt. Een verergering van 
ischemie kan eveneens optreden secundair aan 
coronair-vasoconstrictoire werkingen ten gevolge 
van de toegenomen catecholamine-opname in het 
ischemisch gedeelte van het hart. Dat adrenerge 
modulatie van de coronaire vaatweerstand kan 
optreden gedurende door pacing-geillduceerde 
ischemie wordt gesuggereerd door onze waame-
mingen dat een hoge dosering labetolol de normaal 
optredende afname in coronaire vaatweerstand 
tegengaat, in tegenstelling tot een lage dosering. 
Dit effect bemst waarschijnlijk op de relatief meer 
uitgesproken betablokkerende eigenschappen van 
de hogere dosering labetalol en resulteert in een 
vermindering van het antiischemische effect van 
deze stof in deze dosering, vergeleken met de lage 
dosering. Dit ondanks het feit dat met de hoge 
dosering labetalol de zuurstofbehoefte van het hart 
sterker wordt verminderd dan met een lage dose-
ring. Deze bevindingen, enerzijds de versterkte 
neurohumorale activatie tijdens ischemie en ander-
zijds de gelijktijdige systemische en mogelijk 
coronaire vasoconstrictie, suggereren dat interven-
ties, gericht op specifieke modulering van deze 
neurohumorale veranderingen, van therapeutisch 
belang kunnen zijn bij de behandeling van myo-
cardischemie. 
Hoofdstuk XI. 
In het laatste hoofdstuk van dit proefschrift wordt 
deze suggestie nader onderzocht. In het Iicht van 
de verhoogde arteriele angiotensine II-spiegels 
naast de catecholaminen-activatie tijdens acute 
myocardischemie werd een onderzoek uitgevoerd 
naar de mogelijke antiischemische eigenschappen 
van een angiotensine-converterende enzyme rem-
mer, enalaprilat. Behoudens een modulerend effect 
op neurohumorale activatie gedurende ischemie, 
zijn een aantal theoretische overwegingen aanwe-
zig, die het concept dat dergelijke middelen 
antiischemische eigenschappen kunnen bezitten, 
ondersteunen. Behoudens remming van circule-
rend en locaal angiotensine II-vorming beillvloe-
den deze middelen bradykinine afbraak, prosta-
glandine-synthese en sympathische adrenerge acti-
viteit. Op basis van intrinsiek hemodynamische 
eigenschappen zoals negatief inotrope effecten en 
systemische vaatverwijding, naast potentieel coro-
nair vaatverwijdende effecten is een gunstige 
beillvloeding van de verhouding myocardiale 
zuurstofbehoefte versus -voorziening te verwach-
ten. Desondanks zijn de bevindingen in patienten-
studies ten aanzien van antiangineuze eigenschap-
pen niet hoopgevend. Deze betreffen aile vrij 
kleine, merendeels ongecontroleerde studies in 
ambulante patienten met grotendeels geringe tot 
matige inspanningsgebonden angina pectoris. 
Roewel sommige van deze studies een zekere mate 
van antiischemische activiteit claimen van de 
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betreffende converterende enzymremmer, is bet 
totaalbeeld in deze niet hoopgevend. Onze eigen 
studie daarentegen Iaat een zeer duidelijk effect 
zien op pacing-ge"induceerde ischemie. De sntdie 
werd uitgevoerd tijdens twee identieke atriale 
pacing stress tests met een interval van een uur, 
waarbij enalaprilat werd toegediend 15 minuten 
voor de tweede stress test. In tegenstelling tot 
duidelijk aanwezige neurohumorale activatie en 
verhoogde arteriele drukken gedurende de eerste, 
onbehandelde test, waren deze totaal afwezig bij 
de tweede belastingstest na enalaprilat. Bovendien 
bleek enalaprilat een significante vermindering van 
de myocardischemie teweeg te brengen. De basis 
voor deze antiischemische eigenschappen, bij 
afwezigheid van veranderingen zowel in bet zuur-
stofaanbod als de zuurstofbehoefte van bet hart, 
kan alleen verklaard worden door de afwezige 
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neurohumorale activatie gedurende de tweede 
pacing stress test en de daarmee gepaard gaande 
normalisering van de arteriele drukken. Op deze 
manier werd indirect een vermindering van de 
zuurstofbehoefte van bet myocard bereikt. Boven-
dien bestaat de mogelijkheid, dat een Iocaal modu-
lerend effect op coronaire vaten in bet ischemische 
gebied bijdroeg aan de antiischemische werking 
van deze ACE-remmer, daar enalaprilat de 
versterkte norepinephrine-opname in bet ische-
mische gedeelte van bet hart eveneens tegenging. 
De resultaten van deze studie benadrukken bet 
belang van systemische en cardiale neurohumorale 
activatie gedurende ischemie en bet potentiele 
belang van specifiek neurohumoraal modulerende 
agentia, zoals ACE-remmers en alpha-adrenerge 
antagonisten bij de behandeling van myocard-
ischemie. 
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